

# 参考文献

## 第 1 章

1. Milligan ETC, Morgan CN. Surgical anatomy of the anal canal: with special reference to anorectal fistulae. *Lancet*. 1934;2(5804):1150–6.
2. Nivatvongs S, Stern HS, Fryd DS. The length of the anal canal. *Dis Colon Rectum*. 1981;24(8):600–1.
3. Morren GL, Beets-Tan RG, van Engelshoven JM. Anatomy of the anal canal and perianal structures as defined by phased-array magnetic resonance imaging. *Br J Surg*. 2001;88(11):1506–
4. Parks AG. Pathogenesis and treatment of fistula-in-ano. *Br Med J*. 1961;1(5224):463–9.
5. Lilius HG. Fistula-in-ano, an investigation of human foetal anal ducts and intramuscular glands and a clinical study of 150 patients. *Acta Chir Scand Suppl*. 1968;383:7–88.
6. Barleben A, Mills S. Anorectal anatomy and physiology. *Surg Clin North Am*. 2010;90(1):1–15. Table of Contents.
7. Sboarina A, et al. Shape and volume of internal anal sphincter showed by three-dimensional anorectal ultrasonography. *Eur J Radiol*. 2012;81(7):1479–82.
8. Haas PA, Fox Jr TA. The importance of the perianal connective tissue in the surgical anatomy and function of the anus. *Dis Colon Rectum*. 1977;20(4):303–13.
9. Treitz W. Ueber einen neuen Muskel am Duodenum des Menschen, uber elsatische Sehnen, und einige andere anatomische Verhältnisse. *Vierteljahrschrift Praktische Heilkunde (Prager)*. 1853;37:133–44.
10. Chang SC, Shih JJM, Shih JYM, Lee HHC. Review of Treitz's muscles and their implications in a hemorrhoidectomy and hemorrhoidopexy. *Fu-Jen J Med*. 2006;4(1):1–6.
11. Thomson WH. The nature of haemorrhoids. *Br J Surg*. 1975;62(7):542–52.
12. Goligher JC, Leacock AG, Brossy JJ. The surgical anatomy of the anal canal. *Br J Surg*. 1955;43(177):51–61.
13. Bollard RC, et al. Normal female anal sphincter: difficulties in interpretation explained. *Dis Colon Rectum*. 2002;45(2):171–5.
14. Hussain SM, Stoker J, Lameris JS. Anal sphincter complex: endoanal MR imaging of normal anatomy. *Radiology*. 1995;197(3):671–7.
15. Wunderlich M, Swash M. The overlapping innervation of the two sides of the external anal sphincter by the pudendal nerves. *J Neurol Sci*. 1983;59(1):97–109.
16. Mittal RK, et al. Purse-string morphology of external anal sphincter revealed by novel imaging techniques. *Am J Physiol Gastrointest Liver Physiol*. 2014;306(6):G505–14.
17. DeLancey JO, et al. Comparison of levator ani muscle defects and function in women with and without pelvic organ prolapse. *Obstet Gynecol*. 2007;109(2 Pt 1):295–302.
18. Shafik A. New concept of the anatomy of the anal sphincter mechanism and the physiology of defecation. II. Anatomy of the levator ani muscle with special reference to puborectalis. *Invest Urol*. 1975;13(3):175–82.

19. Betschart C, et al. Comparison of muscle fiber directions between different levator ani muscle subdivisions: in vivo MRI measurements in women. *Int Urogynecol J*. 2014;25(9):1263–8.
20. Levi AC, Borghi F, Garavoglia M. Development of the anal canal muscles. *Dis Colon Rectum*. 1991;34(3):262–6.
21. Grigorescu BA, et al. Innervation of the levator ani muscles: description of the nerve branches to the pubococcygeus, iliococcygeus, and puborectalis muscles. *Int Urogynecol J Pelvic Floor Dysfunct*. 2008;19(1):107–16.
22. Wallner C, et al. Evidence for the innervation of the puborectalis muscle by the levator ani nerve. *Neurogastroenterol Motil*. 2006;18(12):1121–2.
23. Shafik A. A new concept of the anatomy of the anal sphincter mechanism and the physiology of defecation. VIII. Levator hiatus and tunnel: anatomy and function. *Dis Colon Rectum*. 1979;22(8):539–49.
24. Andrew BP, et al. Enlargement of the levator hiatus in female pelvic organ prolapse: cause or effect? *Aust N Z J Obstet Gynaecol*. 2013;53(1):74–8.
25. DeLancey JO, et al. Comparison of the puborectal muscle on MRI in women with POP and levator ani defects with those with normal support and no defect. *Int Urogynecol J*. 2012;23(1):73–
26. Heald RJ, Moran BJ. Embryology and anatomy of the rectum. *Semin Surg Oncol*. 1998;15(2):66–71.
27. Najarian MM, et al. Determination of the peritoneal reflection using intraoperative proctoscopy. *Dis Colon Rectum*. 2004;47(12):2080–5.
28. Chapuis P, et al. Mobilization of the rectum: anatomic concepts and the bookshelf revisited. *Dis Colon Rectum*. 2002;45(1):1–8. discussion 8–9.
29. Heald RJ, Husband EM, Ryall RD. The mesorectum in rectal cancer surgery—the clue to pelvic recurrence? *Br J Surg*. 1982;69(10):613–6.
30. *Nomina Anatomica*. 6th ed. Singapore: Churchill Livingstone; 1989.
31. Quirke P, et al. Effect of the plane of surgery achieved on local recurrence in patients with operable rectal cancer: a prospective study using data from the MRC CR07 and NCIC-CTG CO16 randomised clinical trial. *Lancet*. 2009;373(9666):821–8.
32. Church JM, Raudkivi PJ, Hill GL. The surgical anatomy of the rectum—a review with particular relevance to the hazards of rectal mobilisation. *Int J Colorectal Dis*. 1987;2(3):158–66.
33. Sato K, Sato T. The vascular and neuronal composition of the lateral ligament of the rectum and the rectosacral fascia. *Surg Radiol Anat*. 1991;13(1):17–22.
34. Crapp AR, Cuthbertson AM. William Waldeyer and the rectosacral fascia. *Surg Gynecol Obstet*. 1974;138(2):252–6.
35. Gordon PH, Nivatvongs S. Principles and practice of surgery for the colon, rectum, and anus. 3rd ed. New York, NY: Informa Healthcare USA, Inc.; 2007.
36. Lindsey I, et al. Anatomy of Denonvilliers' fascia and pelvic nerves, impotence, and implications for the colorectal surgeon. *Br J Surg*. 2000;87(10):1288–99.
37. Richardson AC. The rectovaginal septum revisited: its relationship to rectocele and its importance in rectocele repair. *Clin Obstet Gynecol*. 1993;36(4):976–83.
38. Corman ML. Classic articles in colonic and rectal surgery. A method of performing abdominoperineal excision for carcinoma of the rectum and of the terminal portion of the pelvic colon: by W. Ernest Miles, 1869–1947. *Dis Colon Rectum*. 1980;23(3):202–5.
39. Heald RJ, Ryall RD. Recurrence and survival after total mesorectal excision for rectal cancer. *Lancet*. 1986;1(8496):1479–82.

40. Nano M, et al. Contribution to the surgical anatomy of the ligaments of the rectum. *Dis Colon Rectum*. 2000;43(11):1592–7. discussion 1597–8.
41. Lin M, et al. The anatomy of lateral ligament of the rectum and its role in total mesorectal excision. *World J Surg*. 2010;34(3):594–8.
42. Abramson DJ. The valves of Houston in adults. *Am J Surg*. 1978;136(3):334–6.
43. Llauger J, et al. The normal and pathologic ischiorectal fossa at CT and MR imaging. *Radiographics*. 1998;18(1):61–82. quiz 146.
44. Courtney H. The posterior subsphincteric space; its relation to posterior horseshoe fistula. *Surg Gynecol Obstet*. 1949;89(2):222–6.
45. Michaels NA, Siddharth P, Kornblith PL, Park WW. The variant blood supply to the small and large intestines: its importance in regional resections. A new anatomic study based on four hundred dissections with a complete review of the literature. *J Int Coll Surg*. 1963;39:127–70.
46. Schuurman JP, Go PM, Bleys RL. Anatomical branches of the superior rectal artery in the distal rectum. *Colorectal Dis*. 2009;11(9):967–71.
47. Ayoub SF. Arterial supply to the human rectum. *Acta Anat (Basel)*. 1978;100(3):317–27.
48. Fraser ID, et al. Longitudinal muscle of muscularis externa in human and nonhuman primate colon. *Arch Surg*. 1981;116(1):61–3.
49. Guyton AC. Textbook of medical physiology. Philadelphia, PA: WB Saunders; 1986.
50. O’Beirne J, editor. New views of the process of defecation and their application to the pathology and treatment of diseases of the stomach, bowels and other organs. Dublin: Hodges and Smith; 1833.
51. Hyrtl J. Handbuch der topographischen anatomie und ihrer praktisch medicinisch-chirurgischen anwendungen. II. Band. 4th ed. Wien: Braumüller; 1860.
52. Mayo WJ. A study of the rectosigmoid. *Surg Gynecol Obstet*. 1917;25:616–21.
53. Cantlie J. The sigmoid flexure in health and disease. *J Trop Med Hyg*. 1915;18:1–7.
54. Otis WJ. Some observations on the structure of the rectum. *J Anat Physiol*. 1898;32:59–63.
55. Balli R. The sphincters of the colon. *Radiology*. 1939;33:372–6.
56. Shafik A, et al. Rectosigmoid junction: anatomical, histological, and radiological studies with special reference to a sphincteric function. *Int J Colorectal Dis*. 1999;14(4–5):237–44.
57. Sonneland J, Anson BJ, Beaton LE. Surgical anatomy of the arterial supply to the colon from the superior mesenteric artery based upon a study of 600 specimens. *Surg Gynecol Obstet*. 1958;106(4):385–98.
58. Steward JA, Rankin FW. Blood supply of the large intestine. Its surgical considerations. *Arch Surg*. 1933;26:843–91.
59. Griffiths JD. Surgical anatomy of the blood supply of the distal colon. *Ann R Coll Surg Engl*. 1956;19(4):241–56.
60. Haller A. The large intestine. In: Cullen W, editor. First lines of physiology. A reprint of the 1786 edition, Sources of science, vol. 32. New York, NY: Johnson; 1966. p. 139–40.
61. Drummond H. Some points relating to the surgical anatomy of the arterial supply of the large intestine. *Proc R Soc Med*. 1913;7:185–93.
62. Drummond H. The arterial supply of the rectum and pelvic colon. *Br J Surg*. 1914;1:677–85.
63. Meyers CB. Griffiths’ point: critical anastomosis at the splenic flexure. *Am J Roentgenol*. 1976;126:77.
64. Watanabe J, et al. Evaluation of the intestinal blood flow near the rectosigmoid junction using the indocyanine green fluorescence method in a colorectal cancer surgery. *Int J Colorectal Dis*.

2015;30(3):329–35.

65. Skandalakis JE, Gray SW, Ricketts R. The colon and rectum. In: Skandalakis JE, Gray SW, editors. *Embryology for surgeons. The embryological basis for the treatment of congenital anomalies*. Baltimore, MD: Williams & Wilkins; 1994. p. 242–81.
66. Nobles VP. The development of the human anal canal. *J Anat*. 1984;138:575.
67. McPherson AG, Trapnell JE, Airth GR. Duplication of the colon. *Br J Surg*. 1969;56(2):138–42.
68. Benson CD. Surgical implications of Meckel's diverticulum. In: Ravitch MM, Welch KJ, Benson CD, editors. *Pediatric surgery*. Chicago, IL: Year Book Medical Publishers; 1979. p. 955.
69. Zani A, et al. Incidentally detected Meckel diverticulum: to resect or not to resect? *Ann Surg*. 2008;247(2):276–81.
70. Park JJ, et al. Meckel diverticulum: the Mayo Clinic experience with 1476 patients (1950–2002). *Ann Surg*. 2005;241(3):529–33.
71. Fomolo JL. Congenital lesions: intussusception and volvulus. In: Zuidema GD, editor. *Shackelford's surgery of the alimentary tract*. Philadelphia, PA: WB Saunders; 1991. p. 45–51.
72. Louw JH. Investigations into the etiology of congenital atresia of the colon. *Dis Colon Rectum*. 1964;7:471–8.
73. Duhamel B. From the mermaid to anal imperforation: The syndrome of caudal regression. *Arch Dis Child*. 1961;36(186):152–5.
74. Moore TC, Lawrence EA. Congenital malformations of the rectum and anus. II. Associated anomalies encountered in a series of 120 cases. *Surg Gynecol Obstet*. 1952;95(3):281–8.
75. Brown SS, Schoen AH. Congenital anorectal stricture. *J Pediatr*. 1950;36(6):746–51.

## 第 2 章

1. Szmulowicz U, Hull T. Colonic physiology. In: Beck DE, Roberts P, Saclarides T, Senagore A, Stamos M, Wexner SD, editors. *The ASCRS textbook of colon and rectal surgery*. 2nd ed. New York: Springer Science + Business media LLC; 2011. p. 23.
2. Kunzelmann K, Mall M. Electrolyte transport in the mammalian colon: mechanisms and implications for disease. *Physiol Rev*. 2002;82(1):245–89.
3. Sellers RS, Morton D. The colon: from banal to brilliant. *Toxicol Pathol*. 2014;42(1):67–81.
4. Fry R, Mahmoud N, Maron D, Bleier J. Chapter 52: Colon and rectum. In: Townsend C, Beauchamp R, Evers B, Mattox K, editors. *Sabiston textbook of surgery*. 19th ed. Philadelphia: Elsevier Saunders; 2012. p. 1294.
5. Booth RE, Johnson JP, Stockand JD. Aldosterone. *Adv Physiol Educ*. 2002;26(1–4):8–20.
6. Pouokam E, Steidle J, Diener M. Regulation of colonic ion transport by gasotransmitters. *Biol Pharm Bull*. 2011;34(6):789–93.
7. Canani RB, Costanzo MD, Leone L, Pedata M, Meli R, Calignano A. Potential beneficial effects of butyrate in intestinal and extraintestinal diseases. *World J Gastroenterol*. 2011;17(12):1519–28.
8. Leonel AJ, Alvarez-Leite JJ. Butyrate: implications for intestinal function. *Curr Opin Clin Nutr Metab Care*. 2012;15(5):474–9.
9. Hussain ZH, Everhart K, Lacy BE. Treatment of chronic constipation: prescription medications and surgical therapies. *Gastroenterol Hepatol*. 2015;11(2):104.
10. Chey WD, Kurlander J, Eswaran S. Irritable bowel syndrome: a clinical review. *JAMA*. 2015;313(9):949–58.

11. Sarna SK. Colonic motor activity. *Surg Clin North Am.* 1993;73(6):1201–23.
12. Furness JB, Callaghan BP, Rivera LR, Cho HJ. The enteric nervous system and gastrointestinal innervation: integrated local and central control. *Adv Exp Med Biol.* 2014;817:39–71.
13. Sarna SK. Physiology and pathophysiology of colonic motor activity (2). *Dig Dis Sci.* 1991;36(7):998–1018.
14. Furness JB. The enteric nervous system: normal functions and enteric neuropathies. *Neurogastroenterol Motil.* 2008;20 Suppl 1:32–8.
15. Gershon MD. Nerves, reflexes, and the enteric nervous system: pathogenesis of the irritable bowel syndrome. *J Clin Gastroenterol.* 2005;39(5 Suppl 3):S184–93.
16. Straub RH, Wiest R, Strauch UG, Harle P, Scholmerich J. The role of the sympathetic nervous system in intestinal inflammation. *Gut.* 2006;55(11):1640–9.
17. Gudsoorkar VS, Quigley EM. Colorectal sensation and motility. *Curr Opin Gastroenterol.* 2014;30(1):75–83.
18. Quigley EM. What we have learned about colonic motility: normal and disturbed. *Curr Opin Gastroenterol.* 2010;26(1):53–60.
19. Brookes SJ, Dinning PG, Gladman MA. Neuroanatomy and physiology of colorectal function and defaecation: from basic science to human clinical studies. *Neurogastroenterol Motil.* 2009;21 Suppl 2:9–19.
20. Huizinga JD, Chen JH. Interstitial cells of Cajal: update on basic and clinical science. *Curr Gastroenterol Rep.* 2014;16(1):363.
21. Bassotti G, de Roberto G, Castellani D, Sediari L, Morelli A. Normal aspects of colorectal motility and abnormalities in slow transit constipation. *World J Gastroenterol.* 2005;11(18):2691–6.
22. Camilleri M, Bharucha AE, di Lorenzo C, Hasler WL, Prather CM, Rao SS, et al. American Neurogastroenterology and Motility Society consensus statement on intraluminal measurement of gastrointestinal and colonic motility in clinical practice. *Neurogastroenterol Motil.* 2008;20(12):1269–82.
23. Dinning PG, Smith TK, Scott SM. Pathophysiology of colonic causes of chronic constipation. *Neurogastroenterol Motil.* 2009;21 Suppl 2:20–30.
24. Bassotti G, Crowell MD, Whitehead WE. Contractile activity of the human colon: lessons from 24 hour studies. *Gut.* 1993;34(1):129–33.
25. Dinning PG, Fuentealba SE, Kennedy ML, Lubowski DZ, Cook IJ. Sacral nerve stimulation induces pan-colonic propagating pressure waves and increases defecation frequency in patients with slow-transit constipation. *Colorectal Dis.* 2007;9(2):123–32.

## 第 3 章

1. Jorge JMN, Habr-Gama A. Anatomy and embryology of the colon rectum and anus. In: Wolff BG, Fleshman JW, Beck DE, Pemberton JH, Wexner SD, editors. *The ASCRS textbook of colon and rectal surgery.* New York, NY: Springer; 2007. p. 1–11.
2. Bollard RC, Gardiner A, Lindow S, Phillips K, Duthie GS. Normal female anal sphincter: difficulties in interpretation explained. *Dis Colon Rectum.* 2002;45:171–5.
3. Gordon PH. Anatomy and physiology of the anorectum. In: Fazio VW, Church JM, Delaney CP, editors. *Current therapy in colon and rectal surgery.* 2nd ed. Philadelphia, PA: Elsevier Mosby; 2005. p. 1–4.

4. Milligan ETC, Morgan CN, Jones LE, Officer R. Surgical anatomy of the anal canal and the operative treatment of haemorrhoids. *Dis Colon Rectum*. 1985;28:620–8.
5. Morgan CN. The surgical anatomy of the anal canal and rectum. *Postgrad Med J*. 1936;12:287–314.
6. Taylor I, Duthie HL, Amallwud R, et al. Large bowel myoelectrical activity in man. *Gut*. 1975;16:808–14.
7. Gordon PH. Anorectal anatomy and physiology. *Gastroenterol Clin North Am*. 2001;30:1–13.
8. Gowers WR. The automatic action of the sphincter ani. *Proc R Soc Lond*. 1877;26:77–84.
9. Cornes H, Bartolo DCC, Stirra T. Changes in anal canal sensation after childbirth. *Br J Surg*. 1991;78:74–7.
10. Miller R, Bartolo DCC, Cervero F, Mortenson NJ. Differences in anal sensation in continent and incontinent patients with perineal descent. *Int J Colorectal Dis*. 1989;4:45–9.
11. Keighley MRB. Abdominal mucosectomy reduces the incidence of soiling and sphincter damage after restorative proctocolectomy and J-pouch. *Dis Colon Rectum*. 1987;39:386–90.
12. Stelzner F. The morphological principles of anorectal continence. In: Rickham PP, Hecker WSH, Prevot J, editors. *Anorectal malformations and associated diseases*, Progress in pediatric surgery series, vol. 9. Munich: Urban & Schwarzenberg; 1976. p. 1–6.
13. Kaiser AM, Ortega AE. Anorectal anatomy. *Surg Clin North Am*. 2002;82:1125–38.
14. Duthie HL, Gairns FW. Sensory nerve-endings and sensation in the anal region of man. *Br J Surg*. 1960;206:585–95.
15. Sangwan YP, Solla JA. Internal anal sphincter: advances and insights. *Dis Colon Rectum*. 1998;41:1297–311.
16. Palit S, Lunniss PJ, Scott SM. The physiology of human defecation. *Dig Dis Sci*. 2012;57:1445–64.
17. Bajwa A, Emmanuel A. The physiology of continence and evacuation. *Best Pract Res Clin Gastroenterol*. 2009;23:477–85.
18. Brookes SJ, Dinning PG, Gladman MA. Neuroanatomy and physiology of colorectal function and defaecation: from basic science to human clinical studies. *Neurogastroenterol Motil*. 2009;21 Suppl 2:9–19.
19. Gurjar SV, Jones OM. Physiology: evacuation, pelvic floor and continence mechanisms. *Surgery*. 2011;29(8):358–61.
20. Lubowski DZ, Meagher AP, Smart AC, et al. Scintigraphic assessment of colonic function during defecation. *Int J Colorectal Dis*. 1995;10:91–3.
21. Brading AF, Ramalingam T. Mechanisms controlling normal defecation and the potential effects of spinal cord injury. In: Weaver LC, Polosa C, editors. *Progress in brain research* 2006; vol 152:p. 345–358 (Chapter 23).
22. Broens PMA, Penninckx FM, Ochoa JB. Fecal continence revisited: the anal external sphincter continence reflex. *Dis Colon Rectum*. 2013;56:1273–81.
23. Lynn PA, Olsson C, Zagorodnyuk V, et al. Rectal intraganglionic laminar endings are transduction sites of extrinsic mechanoreceptors in the guinea pig rectum. *Gastroenterology*. 2003;125:589–601.
24. Lynn PA, Blackshaw LA. In vitro recordings of afferent fibres with receptive fields in the serosa, muscle and mucosa of rat colon. *J Physiol*. 1999;518(Pt 1):271–82.
25. Tanagho EA, Schmidt RA. Electrical stimulation in the clinical management of the neurogenic

bladder. *J Urol*. 1988;140:1331–9.

26. Ganio E, Luc AR, Clerico G, Trompetto M. Sacral nerve stimulation for treatment of fecal incontinence: a novel approach for intractable fecal incontinence. *Dis Colon Rectum*. 2001;44:619–29.

27. Malouf AJ, Wiesel PH, Nicholls T, Nicholls RJ, Kamm MA. Sacral nerve stimulation for idiopathic slow transit constipation. *Gastroenterol Clin North Am*. 2001;118:4448–9.

28. Carrington EV et al. A systematic review of sacral nerve stimulation mechanisms in the treatment of fecal incontinence and constipation. *Neurogastroenterol Motil*. 2014;26(9):1222–37.

29. Thumas TO, Dudding TC, et al. A systemic review of posterior tibial nerve stimulation for faecal incontinence. *Colorectal Dis*. 2012;15:519–26.

30. Ebert E. Gastrointestinal involvement in spinal cord injury: a clinical perspective. *J Gastrointestin Liver Dis*. 2012;21(1):75–82.

31. Lynch AC, Frizelle FA. Colorectal motility and defecation after spinal cord injury in humans. In: Weaver LC, Polosa C, editors. *Progress in brain research* 2006;vol 152:193–203 (Chapter 23).

32. Nout YS, Leedy GM, Beattie MS, Bresnahan JS. Alterations in eliminative and sexual reflexes after spinal cord injury: defecatory function and development of spasticity in pelvic floor musculature. In: Weaver LC, Polosa C, editors. *Progress in brain research* 2006;vol 152:359–273 (Chapter 23).

33. Preziosi G, Raptis DA, Raeburn A, Panicker J, Emmanuel A. Autonomic rectal dysfunction in patients with multiple sclerosis and bowel symptoms is secondary to spinal cord disease. *Dis Colon Rectum*. 2014;57:514–21.

34. Valle's M, Mearin F. Pathophysiology of bowel dysfunction in patients with motor incomplete spinal cord injury: comparison with patients with motor complete spinal cord injury. *Dis Colon Rectum*. 2009;52:1589–97.

35. Bharucha AE, Rao SSC. An update on anorectal disorders for gastroenterologists. *Gastroenterology*. 2014;146:37–45.

36. Bharucha AE, Wald A, Enck P, Rao S. Functional anorectal disorders. *Gastroenterology*. 2006;130:1510–8.

37. Van Ginkel R, Reitsma JB, Buller HA, et al. Childhood constipation: longitudinal follow-up beyond puberty. *Gastroenterology*. 2003;125:67–72.

38. Rao SSC, Tuteja AK, Vellema T, et al. Dyssynergic defecation: demographics, symptoms, stool patterns and quality of life. *J Clin Gastroenterol*. 2004;38:680–5.

39. Rao SS, Welcher KD, Leistikow JS. Obstructive defecation: a failure of rectoanal coordination. *Am J Gastroenterol*. 1998;93:1042–50.

40. Andromanakos N, Skandalakis P, Troupis T, Filippou D. Constipation of anorectal outlet obstruction: pathophysiology, evaluation and management. *J Gastroenterol Hepatol*. 2006;21:638–46.

41. Felt-Bersma RJ, Tiersma ES, Cuesta MA. Rectal prolapse, rectal intussusception, rectocele, solitary rectal ulcer syndrome, and enterocele. *Gastroenterol Clin North Am*. 2008;37:645–68.

42. Atkin GK, Suliman A, Vaizey CJ. Patient characteristics and treatment outcome in functional anorectal pain. *Dis Colon Rectum*. 2011;54:870–5.

43. Hull M, Cort MM. Evaluation of the levator ani and pelvic wall muscles in levator ani syndrome. *Urol Nus*. 2009;29(4):225.

44. Eckardt VF, Dodt O, Kanzler G, Bernhard G. Anorectal function and morphology in patients

- with sporadic proctalgia fugax. *Dis Colon Rectum*. 2004;39:755–62.
45. Shin GH, Toto EL, Schey R. Pregnancy and postpartum bowel changes: constipation and fecal incontinence. *Am J Gastroenterol*. 2015;110:521–9.
  46. Chiloire M, Darconza G, Piccioli E, et al. Gastric emptying and orocecal transit time in pregnancy. *J Gastroenterol*. 2001;36:538–43.
  47. Oetting G, Franz HB. Mapping of androgen, estrogen and progesterone receptors in the anal continence organ. *Eur J Obstet Gynecol Reprod Biol*. 1998;77:785–95.
  48. Shultz SJ, Wideman L, Montgomery MM, et al. Changes in serum collagen markers, IGF-I, and knee joint laxity across the menstrual cycle. *J Orthop Res*. 2012;30:1405–12.
  49. Parks AG, Swash M. Denervation of the anal sphincter causing idiopathic anorectal incontinence. *J R Coll Surg Edinb*. 1979;24:94–6.
  50. Bharucha AE, Fletcher JG, Melton III LJ, et al. Obstetric trauma, pelvic floor injury and fecal incontinence: a population-based case–control study. *Am J Gastroenterol*. 2012;107:902–11.
  51. Dudding TC, Vaizey CJ, Kamm MJ. Obstetric anal sphincter injury incidence, risk factors, and management. *Ann Surg*. 2008;247(2):224–37.
  52. Pretlove SJ, Thompson PJ, Tooze-Hobson PM, et al. Does the mode of delivery predispose women to anal incontinence in the first year postpartum? A comparative systematic review. *BJOG*. 2008;115:421–34.

## 第 4 章

1. Ashburn J, Church J. Open sesame revisited. *Am J Gastroenterol*. 2013;108(1):143. doi: 10.1038/ajg.2012.382.
2. Farmer KC, Church JM. Open sesame: tips for traversing the anal canal. *Dis Colon Rectum*. 1992;35(11):1092–3.
3. Nivatvongs S, Fryd DS. How far does the proctosigmoidoscope reach? A prospective study of 1000 patients. *N Engl J Med*. 1980;303(7):380–2.
4. Gibertson VA. Proctosigmoidoscopy and polypectomy in reducing the incidence of rectal cancer. *Cancer*. 1974;34(3 suppl):936–9.
5. Nelson RL, Abcarian H, Prasad ML. Iatrogenic perforation of the colon and rectum. *Dis Colon Rectum*. 1982;25(4):305–8.
6. Christensen AF, Nyhuus B, Nielsen MB, Christensen H. Three-dimensional anal endosonography may improve diagnostic confidence of detecting damage to the anal sphincter complex. *Br J Radiol*. 2005;78(928):308–11.
7. Xhaja X, Church J. The use of ancillary techniques to aid colonoscope insertion. *Surg Endosc*. 2014;28(6):1936–9.
8. Kann BR, Margolin DA, Brill SA, et al. The importance of colonoscopy in colorectal surgeons' practices: results of a survey. *Dis Colon Rectum*. 2006;49(11):1763–7.
9. Juillerat P, et al. EPAGE II. Presentation of methodology, general results and analysis of complications. *Endoscopy*. 2009;41:240–6.
10. Gimeno-García AZ, Quintero E. Colonoscopy appropriateness: really needed or a waste of time? *World J Gastrointest Endosc*. 2015;7(2):94–101.
11. Chan TH, Goh KL. Appropriateness of colonoscopy using the ASGE guidelines: experience in



a large Asian hospital. *Chin J Dig Dis*. 2006;7(1):24–32.

12. Suriani R, Rizzetto M, Mazzucco D, et al. Appropriateness of colonoscopy in a digestive endoscopy unit: a prospective study using ASGE guidelines. *J Eval Clin Pract*. 2009;15(1):41–5.

13. Gimeno García AZ, González Y, Quintero E, et al. Clinical validation of the European Panel on the Appropriateness of Gastrointestinal Endoscopy (EPAGE) II criteria in an open-access unit: a prospective study. *Endoscopy*. 2012;44(1):32–7.

14. Petruzzello L, Hassan C, Alvaro D, et al. Appropriateness of the indication for colonoscopy: is the endoscopist the ‘gold standard’? *J Clin Gastroenterol*. 2012;46(7):590–4.

15. Eskeland SL, Dalén E, Sponheim J, et al. European panel on the appropriateness of gastrointestinal endoscopy II guidelines help in selecting and prioritizing patients referred to colonoscopy—a quality control study. *Scand J Gastroenterol*. 2014;49(4):492–500.

16. Zuccaro G. Treatment and referral guidelines in gastroenterology. *Gastroenterol Clin North Am*. 1997;26:845–57.

17. Cappell MS, Ghandi D, Huh C. A study of the safety and clinical efficacy of flexible sigmoidoscopy and colonoscopy after recent colonic surgery in 52 patients. *Am J Gastroenterol*. 1995;90:1130–4.

18. Froelich F, Wietlisbach V, Gonvers JJ, et al. Impact of colonic cleansing on quality and diagnostic yield of colonoscopy: the European Panel of Appropriateness of Gastrointestinal Endoscopy European multicenter study. *Gastrointest Endosc*. 2005;61(3):378–84.

19. Kao D, Lalor E, Sandha G, et al. A randomized controlled trial of four precolonoscopy bowel cleansing regimens. *Can J Gastroenterol*. 2011;25(12):657–62.

20. Markowitz GS, Stokes MB, Radhakrishnan J, et al. Acute phosphate nephropathy following oral sodium phosphate bowel purgative: an underrecognized cause of chronic renal failure. *J Am Soc Nephrol*. 2005;16:3389–96.

21. Markowitz GS, Perazella MA. Acute phosphate nephropathy. *Kidney Int*. 2009;76:1027–34.

22. Cohen LB. Advances in bowel preparation for colonoscopy. *Gastrointest Endosc Clin N Am*. 2015;25(2):183–97.

23. Brunelli SM, Lewis JD, Gupta M, et al. Risk of kidney injury following oral phosphosoda bowel preparations. *J Am Soc Nephrol*. 2007;18:3199–205.

24. Hookey LC, Depew WT, Vanner SJ. A prospective randomized trial comparing low-dose oral sodium phosphate plus stimulant laxatives with large volume polyethylene glycol solution for colon cleansing. *Am J Gastroenterol*. 2004;99(11):2217–22.

25. Gurudu SR, Ramirez FC, Harrison ME, et al. Increased adenoma detection rate with system-wide implementation of a split-dose preparation for colonoscopy. *Gastrointest Endosc*. 2012;76(3):603–8.e1.

26. Kilgore TW, Abdinoor AA, Szary NM, et al. Bowel preparation with split-dose polyethylene glycol before colonoscopy: a meta-analysis of randomized controlled trials. *Gastrointest Endosc*. 2011;73(6):1240–5.

27. Enestvedt BK, Tofani C, Laine LA, et al. 4-Liter split-dose polyethylene glycol is superior to other bowel preparations, based on systematic review and meta-analysis. *Clin Gastroenterol Hepatol*. 2012;10(11):1225–31.

28. Abuksis G, Mor M, Segal N, et al. A patient education program is cost-effective for preventing failure of endoscopic procedures in a gastroenterology department. *Am J Gastroenterol*. 2001;96(6):1786–90.

29. Johnson DA, Barkun AN, Cohen LB, et al. Optimizing adequacy of bowel cleansing for colonoscopy: recommendations from the US multi-society task force on colorectal cancer. *Gastroenterology*. 2014;147(4):903–24.
30. Aronchick CA, Lipshutz WH, Wright SH, et al. A novel tableted purgative for colonoscopic preparation: efficacy and safety comparisons with Colyte and Fleet Phospho-Soda. *Gastrointest Endosc*. 2000;52:346–52.
31. Rostom A, Jolicoeur E. Validation of a new scale for the assessment of bowel preparation quality. *Gastrointest Endosc*. 2004;59(4):482–6.
32. Calderwood AH, Schroy PC, Lieberman DA, et al. Boston Bowel Preparation Scale scores provide a standardized definition of adequate for describing bowel cleanliness. *Gastrointest Endosc*. 2014;80(2):269–76.
33. Gerard DP, Foster DB, Raiser MW, et al. Validation of a new bowel preparation scale for measuring colon cleansing for colonoscopy: the Chicago bowel preparation scale. *Clin Transl Gastroenterol*. 2013;4:e43.
34. Clark BT, Rustagi T, Laine L. What level of bowel prep quality requires early repeat colonoscopy: systematic review and meta-analysis of the impact of preparation quality on adenoma detection rate. *Am J Gastroenterol*. 2014;109(11):1714–23.
35. Chokshi RV, Hovis CE, Hollander T, et al. Prevalence of missed adenomas in patients with inadequate bowel preparation on screening colonoscopy. *Gastrointest Endosc*. 2012;75(6):1197–203.
36. Poon CM, Lee DW, Mak SK, et al. Two liters of polyethylene glycol-electrolyte lavage solution versus sodium phosphate as bowel cleansing regimen for colonoscopy: a prospective randomized controlled trial. *Endoscopy*. 2002;34(7):560–3.
37. Barclay RL. Esophagogastroduodenoscopy-assisted bowel preparation for colonoscopy. *World J Gastrointest Endosc*. 2013;5(3):95–101.
38. Patanè S. Is there a need for bacterial endocarditis prophylaxis in patients undergoing gastrointestinal endoscopy? *J Cardiovasc Transl Res*. 2014;7(3):372–4.
39. Wilson W, Taubert KA, Gewitz M, et al. Prevention of infective endocarditis: guidelines from the American Heart Association: a guideline from the American Heart Association Rheumatic Fever, Endocarditis, and Kawasaki Disease Committee, Council on Cardiovascular Disease in the Young, and the Council on Clinical Cardiology, Council on Cardiovascular Surgery and Anesthesia, and the Quality of Care and Outcomes Research Interdisciplinary Working Group. *Circulation*. 2007;116:1736–54.
40. Duval X, Delahaye F, Alla F, et al. Temporal trends in infective endocarditis in the context of prophylaxis guideline modifications: three successive population-based surveys. *J Am Coll Cardiol*. 2012;59(22):1968–76.
41. Dayer MJ, Jones S, Prendergast B, et al. Incidence of infective endocarditis in England, 2000–13: a secular trend, interrupted time-series analysis. *Lancet*. 2014. doi: 10.1016/S0140-6736(14)62007-9.
42. Banerjee S, Shen B, Baron TH, et al. Antibiotic prophylaxis for GI endoscopy. *Gastrointest Endosc*. 2008;67:791–8.
43. Zuckerman MJ, Hirota WK, Adler DG, et al. ASGE guideline: the management of low-molecular-weight heparin and nonaspirin antiplatelet agents for endoscopic procedures. *Gastrointest Endosc*. 2005;61:189–94.

44. Khashab MA, Chithadi KV, Acosta RD, et al. Antibiotic prophylaxis for GI endoscopy. *Gastrointest Endosc.* 2015;81(1):81–9.
45. Piraino B, Bernardini J, Brown E, et al. ISPD position statement on reducing the risks of peritoneal dialysis-related infections. *Perit Dial Int.* 2011;31:614–30.
46. Meyer GW, Artis AL. Antibiotic prophylaxis for orthopedic prostheses and GI procedures: report of a survey. *Am J Gastroenterol.* 1997;92:989–91.
47. Anderson MA, Ben-Menachem T, Gan SI, et al. Management of antithrombotic agents for endoscopic procedures. *Gastrointest Endosc.* 2009;70:1060.
48. Fujimoto K, Fujishiro M, Kato M, et al. Guidelines for gastroenterological endoscopy in patients undergoing antithrombotic treatment. *Dig Endosc.* 2014;26:1–14.
49. Ridolfi TJ, Valente MA, Church JM. Achieving a complete colonic evaluation with incomplete colonoscopy is worth the effort. *Dis Colon Rectum.* 2014;57:383–7.
50. Baxter NN, Goldwasser MA, Paszat LF, Saskin R, Urbach DR, Rabeneck L. Association of colonoscopy and death from colorectal cancer. *Ann Intern Med.* 2009;150:1–8.
51. Church JM. Complete colonoscopy: how often? And if not, why not? *Am J Gastroenterol.* 1994;89:556–60.
52. Rizek R, Paszat LF, Stukel TA, Saskin R, Li C, Rabeneck L. Rates of complete colonic evaluation after incomplete colonoscopy and their associated factors: a population-based study. *Med Care.* 2009;47:48–52.
53. Kao KT, Tam M, Sekhon H, Wijeratne R, Haigh PI, Abbas MA. Should barium enema be the next step following an incomplete colonoscopy? *Int J Colorectal Dis.* 2010;25:1353–7.
54. Toma J, Paszat LF, Gunraj N, Rabeneck L. Rates of new or missed colorectal cancer after barium enema and their risk factors: a population-based study. *Am J Gastroenterol.* 2008;103:142–8.
55. Baron JP, Hirota TH, Waring WK, et al. Guidelines for conscious sedation and monitoring during gastrointestinal endoscopy. *Gastrointest Endosc.* 2003;58(3):317.
56. Lee DW, Li AC, Ko CW, et al. Use of a variable-stiffness colonoscope decreases the dose of patient-controlled sedation during colonoscopy: a randomized comparison of 3 colonoscopes. *Gastrointest Endosc.* 2007;65(3):424–9.
57. Faulx AL, Vela S, Das A, et al. The changing landscape of practice patterns regarding unsedated endoscopy and propofol use: a national Web survey. *Gastrointest Endosc.* 2005;62(1):9–15.
58. Porostocky P, Chiba N, Colacino P, et al. A survey of sedation practices for colonoscopy in Canada. *Can J Gastroenterol.* 2011;25(5):255–60.
59. Loberg M, Furholm S, Hoff I, et al. Nitrous oxide for analgesia in colonoscopy without sedation. *Gastrointest Endosc.* 2011;74(6):1347–53.
60. Aboumarzouk OM, Agarwal T, Syed Nong Chek SA et al. Nitrous oxide for colonoscopy. *Cochrane Database Syst Rev* 2011;(8):CD008506.
61. Tuncali B, Pekcan YO, Celebi A, et al. Addition of low-dose ketamine to midazolam-fentanyl-propofol-based sedation for colonoscopy: a randomized, double-blind, controlled trial. *J Clin Anesth.* 2015;27:301–6.
62. Childers RE, Williams JL, Sonnenberg A. Practice patterns of sedation for colonoscopy. *Gastrointest Endosc.* 2015;82(3):503–11.
63. Singh H, Poluha W, Cheung M et al. Propofol for sedation during colonoscopy. *Cochrane Database Syst Rev* 2008;(4):CD006268.
64. Wang D, Chen C, Chen J, et al. The use of propofol as a sedative agent in gastrointestinal

endoscopy: a meta-analysis. *PLoS One*. 2013;8(1):e53311.

65. Bright E, Roseveare C, Dalgleish D, et al. Patient-controlled sedation for colonoscopy: a randomized trial comparing patient-controlled administration of propofol and alfentanil with physician-administered midazolam and pethidine. *Endoscopy*. 2003;35(8):683–7.

66. Ulmer BJ, Hansen JJ, Overley CA, et al. Propofol versus midazolam/fentanyl for outpatient colonoscopy: administration by nurses supervised by endoscopists. *Clin Gastroenterol Hepatol*. 2003;1(6):425–32.

67. Church JM. Colonoscopy. In: Church JM, editor. *Endoscopy of the colon, rectum, and anus*. New York: Igaku-Shoin; 1995. p. 99–135.

68. Cirocco WC, Rusin LC. The reliability of cecal landmarks during colonoscopy. *Surg Endosc*. 1993;7(1):33–6.

69. Iacopini G, Frontespezi S, Vitale MA, et al. Routine ileoscopy at colonoscopy: a prospective evaluation of learning curve and skill-keeping line. *Gastrointest Endosc*. 2006;63(2):250–6.

70. Ten Cate EM, Wong LA, Groff WL, et al. Post-surgical surveillance of locally advanced ileal carcinoids found by routine ileal intubation during screening colonoscopy: a case series. *J Med Case Rep*. 2014;8:444.

71. Kennedy G, Larson D, Wolff B, et al. Routine ileal intubation during screening colonoscopy: a useful maneuver? *Surg Endosc*. 2008;22(12):2606–8.

72. Uraoka T, Kato J, Kuriyama M, et al. CO<sub>2</sub> insufflation for potentially difficult colonoscopies: efficacy when used by less experienced colonoscopists. *World J Gastroenterol*. 2009;15(41):5186–92.

73. Chen PJ, Li CH, Huang TY, et al. Carbon dioxide insufflation does not reduce pain scores during colonoscope insertion in unsedated patients: a randomized, controlled trial. *Gastrointest Endosc*. 2013;77(1):79–89.

74. Leung FW. Water-aided colonoscopy. *Gastroenterol Clin North Am*. 2013;42(3):507–19.

75. Church JM. Warm water irrigation for dealing with spasm during colonoscopy: simple, inexpensive, and effective. *Gastrointest Endosc*. 2002;56(5):672–4.

76. Miroslav V, Klemen M. Warm water immersion vs. standard air insufflation for colonoscopy: comparison of two techniques. *Hepatogastroenterology*. 2014;61(136):2209–11.

77. Asai S, Fujimoto N, Tanoue K, et al. Water immersion colonoscopy facilitates straight passage of the colonoscope through the sigmoid colon without loop formation: randomized controlled trial. *Dig Endosc*. 2015;27(3):345–53.

78. Rabenstein T, Radaelli F, Zolk O. Warm water infusion colonoscopy: a review and meta-analysis. *Endoscopy*. 2012;44(10):940–51.

79. Garborg K, Kaminski MF, Lindenburger W, et al. Water exchange versus carbon dioxide insufflation in unsedated colonoscopy: a multicenter randomized controlled trial. *Endoscopy*. 2015;47(3):192–9.

80. Bartel MJ, Picco MF, Wallace MB. Chromocolonoscopy. *Gastrointest Endosc Clin N Am*. 2015;25(2):243–60.

81. Huneburg R, Lammert F, Rabe C, et al. Chromocolonoscopy detects more adenomas than white light colonoscopy or narrow band imaging colonoscopy in hereditary nonpolyposis colorectal cancer screening. *Endoscopy*. 2009;41(4):316–22.

82. Kahi CJ, Anderson JC, Waxman I, et al. High-definition chromocolonoscopy vs. high-definition white light colonoscopy for average-risk colorectal cancer screening. *Am J Gastroenterol*.

2010;105(6):1301–7.

83. Pellise M, Fernandez-Esparrach G, Cardenas A, et al. Impact of wide-angle, high-definition endoscopy in the diagnosis of colorectal neoplasia: a randomized controlled trial. *Gastroenterology*. 2008;135(4):1062–8.

84. Singh R, Mei SC, Sethi S. Advanced endoscopic imaging in Barrett's oesophagus: a review on current practice. *World J Gastroenterol*. 2011;17(38):4271–6.

85. Rastogi A, Early DS, Gupta N, et al. Randomized, controlled trial of standard-definition white-light, high-definition white-light, and narrow-band imaging colonoscopy for the detection of colon polyps and prediction of polyp histology. *Gastrointest Endosc*. 2011;74(3):593–602.

86. Rastogi A, Keighley J, Singh V, et al. High accuracy of narrow band imaging without magnification for the real-time characterization of polyp histology and its comparison with high-definition white light colonoscopy: a prospective study. *Am J Gastroenterol*. 2009;104(10):2422–30.

87. Gralnek IM, Segol O, Suissa A, et al. A prospective cohort study evaluating a novel colonoscopy platform featuring full-spectrum endoscopy. *Endoscopy*. 2013;45(9):697–702.

88. Gralnek IM, Siersema PD, Halpern Z, et al. Standard forward-viewing colonoscopy versus full-spectrum endoscopy: an international, multicentre, randomised, tandem colonoscopy trial. *Lancet Oncol*. 2014;15(3):353–60.

89. Hanson JM, Atkin WS, Cunliffe WJ, et al. Rectal retroflexion: an essential part of lower gastrointestinal endoscopic examination. *Dis Colon Rectum*. 2001;44(11):1706–8.

90. Cutler AF, Pop A. Fifteen years later: colonoscopic retroflexion revisited. *Am J Gastroenterol*. 1999;94(6):1537–8.

91. Saad A, Rex DK. Routine rectal retroflexion during colonoscopy has a low yield for neoplasia. *World J Gastroenterol*. 2008;14(42):6503–5.

92. Quallick MR, Brown WR. Rectal perforation during colonoscopic retroflexion: a large, prospective experience in an academic center. *Gastrointest Endosc*. 2009;69(4):960–3.

93. Rex DK, Vemulapalli KC. Retroflexion in colonoscopy: why? where? when? how? what value? *Gastroenterology*. 2013;144(5):882–3.

94. Kushnir VM, Oh YS, Hollander T, et al. Impact of retroflexion vs. second forward view examination of the right colon on adenoma detection: a comparison study. *Am J Gastroenterol*. 2015;110(3):415–22.

95. Chandran S, Parker F, Vaughan R, et al. Right-sided adenoma detection with retroflexion versus forward-view colonoscopy. *Gastrointest Endosc*. 2015;81(3):608–13.

96. Niv Y, Gershtansky Y, Kenett RS, et al. Complications in colonoscopy: analysis of 7-year physician-reported adverse events. *Eur J Gastroenterol Hepatol*. 2011;23(6):492–8.

97. Chan AO, Lee LN, Chan AC, Ho WN, Chan QW, Lau S, Chan JW. Predictive factors for colonoscopy complications. *Hong Kong Med J*. 2015;21(1):23–9.

98. Stock C, Ihle P, Sieg A, et al. Adverse events requiring hospitalization within 30 days after outpatient screening and nonscreening colonoscopies. *Gastrointest Endosc*. 2013;77(3):419–29.

99. Ko CW, Riffle S, Michaels L, et al. Serious complications within 30 days of screening and surveillance colonoscopy are uncommon. *Clin Gastroenterol Hepatol*. 2010;8(2):166–73.

100. Castro G, Azrak MF, Seeff LC, Royalty J. Outpatient colonoscopy complications in the CDC's Colorectal Cancer Screening Demonstration Program: a prospective analysis. *Cancer*. 2013;119 Suppl 15:2849–54.

101. Levin TR, Zhao W, Conell C, et al. Complications of colonoscopy in an integrated health care delivery system. *Ann Intern Med.* 2006;145(12):880–6.
102. Nelson DB, McQuaid KR, Bond JH, et al. Procedural success and complications of large-scale screening colonoscopy. *Gastrointest Endosc.* 2002;55(3):307–14.
103. Alam M, Schuman BM, Duvernoy WF, et al. Continuous electrocardiographic monitoring during colonoscopy. *Gastrointest Endosc.* 1976;22:203.
104. Herman LL, Kurtz RC, McKee KJ, et al. Risk factors associated with vasovagal reactions during colonoscopy. *Gastrointest Endosc.* 1993;39(3):388–91.
105. Da Silva RM. Syncope: epidemiology, etiology, and prognosis. *Front Physiol.* 2014;5:471.
106. Davison ET, Levine M, Meyerowitz R. Ventricular fibrillation during colonoscopy: case report and review of the literature. *Am J Gastroenterol.* 1985;80:690–3.
107. Ugajin T, Miyatani H, Momomura S, et al. Ventricular fibrillation during colonoscopy: a case report—colonoscopy in high-risk patients should be performed with ECG monitoring. *Intern Med.* 2008;47(7):609–12.
108. Gupta SC, Gopalswamy N, Sarkar A, et al. Cardiac arrhythmias and electrocardiographic changes during upper and lower gastrointestinal endoscopy. *Mil Med.* 1990;155(1):9–11.
109. Eckardt VF, Kanzler G, Schmitt T, Eckardt AJ, Bernhard G. Complications and adverse effects of colonoscopy with selective sedation. *Gastrointest Endosc.* 1999;49(5):560–5.
110. Ristikankare M, Julkunen R, Mattila M, et al. Conscious sedation and cardiorespiratory safety during colonoscopy. *Gastrointest Endosc.* 2000;52(1):48–54.
111. Day LW, Kwon A, Inadomi JM, Walter LC, Somsouk M. Adverse events in older patients undergoing colonoscopy: a systematic review and meta-analysis. *Gastrointest Endosc.* 2011;74(4):885–96.
112. Cena M, Gomez J, Alyousef T, et al. Safety of endoscopic procedures after acute myocardial infarction: a systematic review. *Cardiol J.* 2012;19(5):447–52.
113. Cappell MS. Safety and efficacy of colonoscopy after myocardial infarction: an analysis of 100 study patients and 100 control patients at two tertiary cardiac referral hospitals. *Gastrointest Endosc.* 2004;60(6):901–9.
114. Lois F. An unusual cause of regurgitation during colonoscopy. *Acta Anaesthesiol Belg.* 2009;60(3):195–7.
115. Webb T. Pneumothorax and pneumomediastinum during colonoscopy. *Anaesth Intensive Care.* 1998;26:302–4.
116. Marwan K, Farmer KC, Varley C, Chapple KS. Pneumothorax, pneumomediastinum, pneumoperitoneum, pneumoretroperitoneum and subcutaneous emphysema following diagnostic colonoscopy. *Ann R Coll Surg Engl.* 2007;89(5):W20–1.
117. Koltun WA, Collier JA. Incarceration of colonoscope in an inguinal hernia. “Pulley” technique of removal. *Dis Colon Rectum.* 1991;3:191–3.
118. Leisser A, Delpre G, Kadish U. Colonoscope incarceration: an avoidable event. *Gastrointest Endosc.* 1990;36(6):637–8.
119. Singla S, Keller D, Thirunavukarasu P, et al. Splenic injury during colonoscopy—a complication that warrants urgent attention. *J Gastrointest Surg.* 2012;16(6):1225–34.
120. Kamath AS, Iqbal CW, Sarr MG, et al. Colonoscopic splenic injuries: incidence and management. *J Gastrointest Surg.* 2009;13(12):2136–40.
121. Michetti CP, Smeltzer E, Fakhry SM. Splenic injury due to colonoscopy: analysis of the world

literature, a new case report, and recommendations for management. *Am Surg.* 2010;76(11):1198–204.

122. Ahmed A, Eller PM, Schiffman FJ. Splenic rupture: an unusual complication of colonoscopy. *Am J Gastroenterol.* 1997;92:2101–4.

123. Petersen CR, Adamsen S, Gocht-Jensen P, et al. Splenic injury after colonoscopy. *Endoscopy.* 2008;40(1):76–9.

124. Stein DF, Myaing M, Guillaume C. Splenic rupture after colonoscopy treated by splenic artery embolization. *Gastrointest Endosc.* 2002;55:946–89.

125. Shi X, Shan Y, Yu E, et al. Lower rate of colonoscopic perforation: 110,785 patients of colonoscopy performed by colorectal surgeons in a large teaching hospital in China. *Surg Endosc.* 2014;28(8):2309–16.

126. Rathgeber SW, Wick TM. Colonoscopy completion and complication rates in a community gastroenterology practice. *Gastrointest Endosc.* 2006;64(4):556–62.

127. Buisson A, Chevaux JB, Hudziak H, et al. Colonoscopic perforations in inflammatory bowel disease: a retrospective study in a French referral centre. *Dig Liver Dis.* 2013;45(7):569–72.

128. Araujo SE, Seid VE, Caravatto PP, Dumarco R. Incidence and management of colonoscopic colon perforations: 10 years' experience. *Hepatogastroenterology.* 2009;56(96):1633–6.

129. Polter DE. Risk of colon perforation during colonoscopy at Baylor University Medical Center. *Proc (Bayl Univ Med Cent).* 2015;28(1):3–6.

130. Damore LJ, Rantis PC, Vernava AM, Longo WE. Colonoscopic perforations. Etiology, diagnosis, and management. *Dis Colon Rectum.* 1996;39(11):1308–14.

131. Korman LY, Overholt BF, Box T, Winker CK. Perforation during colonoscopy in endoscopic ambulatory surgical centers. *Gastrointest Endosc.* 2003;58(4):554–7.

132. Luning TH, Keemers-Gels ME, Barendregt WB, et al. Colonoscopic perforations: a review of 30,366 patients. *Surg Endosc.* 2007;21(6):994–7.

133. Foliente RL, Chang AC, Youssef AI, et al. Endoscopic cecal perforation: mechanisms of injury. *Am J Gastroenterol.* 1996;91:705–8.

134. Orsoni P, Berdah S, Verrier C, et al. Colonic perforation due to colonoscopy: a retrospective study of 48 cases. *Endoscopy.* 1997;29(3):160–4.

135. Avgerinos DV, Llaguna OH, Lo AY, Leitman IM. Evolving management of colonoscopic perforations. *J Gastrointest Surg.* 2008;12(10):1783–9.

136. Trecca A, Gaj F, Gagliardi G. Our experience with endoscopic repair of large colonoscopic perforations and review of the literature. *Tech Coloproctol.* 2008;12(4):315–21.

137. Magdeburg R, Collet P, Post S, et al. Endoclipping of iatrogenic colonic perforation to avoid surgery. *Surg Endosc.* 2008;22:1500–4.

138. Yang DH, Byeon JS, Lee KH, et al. Is endoscopic closure with clips effective for both diagnostic and therapeutic colonoscopy-associated bowel perforation? *Surg Endosc.* 2010;24(5):1177–85.

139. Kim HW. What is different between postpolypectomy fever and postpolypectomy coagulation syndrome? *Clin Endosc.* 2014;47(3):205–6.

140. Cha JM, Lim KS, Lee SH, et al. Clinical outcomes and risk factors of post-polypectomy coagulation syndrome: a multicenter, retrospective, case-control study. *Endoscopy.* 2013;45(3):202–7.

141. Lee SH, Kim KJ, Yang DH, et al. Postpolypectomy fever, a rare adverse event of polypectomy:

- nested case-control study. *Clin Endosc.* 2014;47(3):236–41.
142. Rabeneck L, Paszat LF, Hilsden RJ, et al. Bleeding and perforation after outpatient colonoscopy and their risk factors in usual clinical practice. *Gastroenterology.* 2008;135:1899–906.
143. Wayne JD. Management of complications of colonoscopic polypectomy. *Gastroenterologist.* 1993;1(2):158–64.
144. Rosen L, Bub DS, Reed JF, Nastase SA. Hemorrhage following colonoscopic polypectomy. *Dis Colon Rectum.* 1993;36(12):1126–31.
145. Sawhney MS, Salfiti N, Nelson DB, et al. Risk factors for severe delayed postpolypectomy bleeding. *Endoscopy.* 2008;40(2):115–9.
146. Heldwein W, Dollhopf M, Rösch T, et al. The Munich Polypectomy Study (MUPS): prospective analysis of complications and risk factors in 4000 colonic snare polypectomies. *Endoscopy.* 2005;37:1116–22.
147. Kim HS, Kim TI, Kim WH, et al. Risk factors for immediate postpolypectomy bleeding of the colon: a multicenter study. *Am J Gastroenterol.* 2006;101(6):1333–41.
148. Wu XR, Church JM, Jarrar A, et al. Risk factors for delayed postpolypectomy bleeding: how to minimize your patients' risk. *Int J Colorectal Dis.* 2013;28(8):1127–34.
149. Watabe H, Yamaji Y, Okamoto M, et al. Risk assessment for delayed hemorrhagic complication of colonic polypectomy: polyp-related factors and patient related factors. *Gastrointest Endosc.* 2006;64:73–8.
150. Hui AJ, Wong RM, Ching JY, et al. Risk of colonoscopic polypectomy bleeding with anticoagulants and antiplatelet agents: analysis of 1657 cases. *Gastrointest Endosc.* 2004;59:44–8.
151. Moon HS, Park SW, Kim DH, et al. Only the size of resected polyps is an independent risk factor for delayed postpolypectomy hemorrhage: a 10-year single-center case-control study. *Ann Coloproctol.* 2014;30(4):182–5.
152. Buddingh KT, Herngreen T, Haringsma J, et al. Location in the right hemi-colon is an independent risk factor for delayed post-polypectomy hemorrhage: a multi-center case-control study. *Am J Gastroenterol.* 2011;106(6):1119–24.
153. Choung BS, Kim SH, Ahn DS, et al. Incidence and risk factors of delayed postpolypectomy bleeding: a retrospective cohort study. *J Clin Gastroenterol.* 2014;48(9):784–9.
154. Dobrowolski S, Dobosz M, Babicki A, et al. Blood supply of colorectal polyps correlates with risk of bleeding after colonoscopic polypectomy. *Gastrointest Endosc.* 2006;63(7):1004–9.
155. Sorbi D, Norton I, Conio M, et al. Postpolypectomy lower GI bleeding: descriptive analysis. *Gastrointest Endosc.* 2000;51:690–6.
156. Rossetti A, Buchs NC, Breguet R, et al. Transarterial embolization in acute colonic bleeding: review of 11 years of experience and long-term results. *Int J Colorectal Dis.* 2012;28:777–82.
157. Liaquat H, Rohn E, Rex DK. Prophylactic clip closure reduced the risk of delayed postpolypectomy hemorrhage: experience in 277 clipped large sessile or flat colorectal lesions and 247 control lesions. *Gastrointest Endosc.* 2013;77(3):401–7.
158. Katsinelos P, Fasoulas K, Chatzimavroudis G, et al. Prophylactic clip application before endoscopic resection of large pedunculated colorectal polyps in patients receiving anticoagulation or antiplatelet medications. *Surg Laparosc Endosc Percutan Tech.* 2012;22(5):e254–8.
159. Cheung RJ, Ortiz D, DiMarino AJ. GI endoscopic reprocessing practices in the United States. *Gastrointest Endosc.* 1999;50(3):362–8.
160. Muscarella LF. Inconsistencies in endoscope-reprocessing and infection-control guidelines: the



- importance of endoscope drying. *Am J Gastroenterol*. 2006;101(9):2147–54.
161. Spach DH, Silverstein FE, Stamm WE. Transmission of infection by gastrointestinal endoscopy and bronchoscopy. *Ann Intern Med*. 1993;118(2):117–28.
162. Kovaleva J, Peters FT, van der Mei HC, Degener JE. Transmission of infection by flexible gastrointestinal endoscopy and bronchoscopy. *Clin Microbiol Rev*. 2013;26(2):231–54.
163. Kola A, Piening B, Pape UF, et al. An outbreak of carbapenem-resistant OXA-48—producing *Klebsiella pneumoniae* associated to duodenoscopy. *Antimicrob Resist Infect Control*. 2015;4:8.
164. Lee SH, Chung IK, Kim SJ, et al. An adequate level of training for technical competence in screening and diagnostic colonoscopy: a prospective multicenter evaluation of the learning curve. *Gastrointest Endosc*. 2008;67(4):683–9.
165. Spier BJ, Benson M, Pfau PR, et al. Colonoscopy training in gastroenterology fellowships: determining competence. *Gastrointest Endosc*. 2010;71(2):319–24.
166. Peters SL, Hasan AG, Jacobson NB, Austin GL. Level of fellowship training increases adenoma detection rates. *Clin Gastroenterol Hepatol*. 2010;8(5):439–42.
167. Klare P, Ascher S, Wagenpfeil S, et al. Trainee colonoscopists fulfil quality standards for the detection of adenomatous polyps. *BMC Med Educ*. 2015;15(1):312.
168. Leyden JE, Doherty GA, Hanley A, et al. Quality of colonoscopy performance among gastroenterology and surgical trainees: a need for common training standards for all trainees? *Endoscopy*. 2011;43(11):935–40.
169. Williams MR, Crossett JR, Cleveland EM, et al. Equivalence in colonoscopy results between gastroenterologists and general surgery residents following an endoscopy simulation curriculum. *J Surg Educ*. 2015;72(4):654–7.
170. Cohen J, Cohen SA, Vora KC, et al. Multicenter, randomized, controlled trial of virtual-reality simulator training in acquisition of competency in colonoscopy. *Gastrointest Endosc*. 2006;64:361–8.
171. Sedlack RE, Kolars JC. Computer simulator training enhances the competency of gastroenterology fellows at colonoscopy: results of a pilot study. *Am J Gastroenterol*. 2004;99:33–7.
172. Jirapinyo P, Imaeda AB, Thompson CC. Endoscopic training in gastroenterology fellowship: adherence to core curriculum guidelines. *Surg Endosc*. 2015;24:4110–4.
173. Jirapinyo P, Thompson CC. Current status of endoscopic simulation in gastroenterology fellowship training programs. *Surg Endosc*. 2015;29(7):1913–9.
174. Lieberman D, Nadel M, Smith RA, et al. Standardized colonoscopy reporting and data system: report of the Quality Assurance Task Group of the National Colorectal Cancer Roundtable. *Gastrointest Endosc*. 2007;65(6):757–66.
175. Singh H, Kaita L, Taylor G, et al. Practice and documentation of performance of colonoscopy in a central Canadian health region. *Can J Gastroenterol Hepatol*. 2014;28(4):185–90.
176. Beaulieu D, Barkun A, Martel M. Quality audit of colonoscopy reports amongst patients screened or surveilled for colorectal neoplasia. *World J Gastroenterol*. 2012;18(27):3551–7.
177. Robertson DJ, Lawrence LB, Shaheen NJ, et al. Quality of colonoscopy reporting: a process of care study. *Am J Gastroenterol*. 2002;97(10):2651–6.
178. De Jonge V, Sint Nicolaas J, Cahen DL, et al. Quality evaluation of colonoscopy reporting and colonoscopy performance in daily clinical practice. *Gastrointest Endosc*. 2012;75(1):98–106.
179. Bourikas LA, Tsiamoulos ZP, Haycock A, et al. How we can measure quality in colonoscopy?

- World J Gastrointest Endosc. 2013;5(10):468–75.
180. Ketwaroo GA, Sawhney MS. Quality measures and quality improvements in colonoscopy. *Curr Opin Gastroenterol*. 2015;31(1):56–61.
181. Hale MF, Sidhu R, McAlindon ME. Capsule endoscopy: current practice and future directions. *World J Gastroenterol*. 2014;20(24):7752–9.
182. Hoedemaker RA, Westerhof J, Weersma RK, et al. Non-small-bowel abnormalities identified during small bowel capsule endoscopy. *World J Gastroenterol*. 2014;20(14):4025–9.
183. Goenka MK, Majumder S, Goenka U. Capsule endoscopy: present status and future expectation. *World J Gastroenterol*. 2014;20(29):10024–37.
184. O'Donnell S, Qasim A, Ryan BM, et al. The role of capsule endoscopy in small bowel Crohn's disease. *J Crohns Colitis*. 2009;3(4):282–6.
185. Long MD, Barnes E, Isaacs K, et al. Impact of capsule endoscopy on management of inflammatory bowel disease: a single tertiary care center experience. *Inflamm Bowel Dis*. 2011;17(9):1855–62.
186. Dionisio PM, Gurudu SR, Leighton JA, et al. Capsule endoscopy has a significantly higher diagnostic yield in patients with suspected and established small-bowel Crohn's disease: a meta-analysis. *Am J Gastroenterol*. 2010;105(6):1240–8.
187. Triester SL, Leighton JA, Leontiadis GI, et al. A meta-analysis of the yield of capsule endoscopy compared to other diagnostic modalities in patients with obscure gastrointestinal bleeding. *Am J Gastroenterol*. 2005;100(11):2407–18.
188. Zagorowicz ES, Pietrzak AM, Wronska E, et al. Small bowel tumors detected and missed during capsule endoscopy: single center experience. *World J Gastroenterol*. 2013;19(47):9043–8.
189. Van Gossum A. Wireless capsule endoscopy of the large intestine: a review with future projections. *Curr Opin Gastroenterol*. 2014;30(5):472–6.

## 第 5 章

1. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2015. *CA Cancer J Clin*. 2015;65(1):5–29.
2. Edwards BK, Ward E, Kohler BA, et al. Annual report to the nation on the status of cancer, 1975–2006, featuring colorectal cancer trends and impact of interventions (risk factors, screening, and treatment) to reduce future rates. *Cancer*. 2010;116(3):544–73.
3. Centers for Disease Control and Prevention. National Center for Health Statistics. National health interview surveys 2000, 2013. public use data files. Updated 2014.
4. Zauber AG, Winawer SJ, O'Brien MJ, et al. Colonoscopic polypectomy and long-term prevention of colorectal-cancer deaths. *N Engl J Med*. 2012;366(8):687–96.
5. Baker SL, Miller RA, Creighton A, Aguilar PS. Effect of 6-minute colonoscopy withdrawal time policy on polyp detection rate in a community hospital. *Gastroenterol Nurs*. 2015;38(2):96–9.
6. Baxter NN, Sutradhar R, Forbes SS, Paszat LF, Saskin R, Rabeneck L. Analysis of administrative data finds endoscopist quality measures associated with postcolonoscopy colorectal cancer. *Gastroenterology*. 2011;140(1):65–72.
7. Lieberman DA, Weiss DG, Bond JH, Ahnen DJ, Garewal H, Chejfec G. Use of colonoscopy to screen asymptomatic adults for colorectal cancer. veterans affairs cooperative study group 380. *N Engl J Med*. 2000;343(3):162–8.

8. Rathgaber SW, Wick TM. Colonoscopy completion and complication rates in a community gastroenterology practice. *Gastrointest Endosc.* 2006;64(4):556–62.
9. Rex DK, Bond JH, Winawer S, et al. Quality in the technical performance of colonoscopy and the continuous quality improvement process for colonoscopy: recommendations of the U.S. multi-society task force on colorectal cancer. *Am J Gastroenterol.* 2002;97(6):1296–308.
10. Barclay RL, Vicari JJ, Doughty AS, Johanson JF, Greenlaw RL. Colonoscopic withdrawal times and adenoma detection during screening colonoscopy. *N Engl J Med.* 2006;355(24):2533–41.
11. Corley DA, Jensen CD, Marks AR, et al. Adenoma detection rate and risk of colorectal cancer and death. *N Engl J Med.* 2014;370(14):1298–306.
12. Rex DK, Schoenfeld PS, Cohen J, et al. Quality indicators for colonoscopy. *Gastrointest Endosc.* 2015;81(1):31–53.
13. Chapuis PH, Dent OF, Goulston KJ. Clinical accuracy in the diagnosis of small polyps using the flexible fiberoptic sigmoidoscope. *Dis Colon Rectum.* 1982;25(7):669–72.
14. Neale AV, Demers RY, Budev H, Scott RO. Physician accuracy in diagnosing colorectal polyps. *Dis Colon Rectum.* 1987;30(4):247–50.
15. Bujanda L, Cosme A, Gil I, Arenas-Mirave JJ. Malignant colorectal polyps. *World J Gastroenterol.* 2010;16(25):3103–11.
16. Molatore S, Ranzani GN. Genetics of colorectal polyps. *Tech Coloproctol.* 2004;8 Suppl 2:s240–2.
17. Gschwantler M, Kriwanek S, Langner E, et al. High-grade dysplasia and invasive carcinoma in colorectal adenomas: a multivariate analysis of the impact of adenoma and patient characteristics. *Eur J Gastroenterol Hepatol.* 2002;14(2):183–8.
18. Kulling D, Christ AD, Karaaslan N, Fried M, Bauerfeind P. Is histological investigation of polyps always necessary? *Endoscopy.* 2001;33(5):428–32.
19. Church J. Polyp treatment. In: *Endoscopy of the colon, rectum and anus.* 1st ed. Japan: Igaku-Shoin; 1995. p. 156–78.
20. Lee SW, Garrett KA, Shin JH, Trencheva K, Sonoda T, Milsom JW. Dynamic article: long-term outcomes of patients undergoing combined endolaparoscopic surgery for benign colon polyps. *Dis Colon Rectum.* 2013;56(7):869–73.
21. Din S, Ball AJ, Taylor E, Rutter M, Riley SA, Johal S. Polypectomy practices of sub-centimeter polyps in the English Bowel Cancer Screening Programme. *Surg Endosc.* 2015; 29(11): 3224–3230.
22. Singh N, Harrison M, Rex DK. A survey of colonoscopic polypectomy practices among clinical gastroenterologists. *Gastrointest Endosc.* 2004;60(3):414–8.
23. Kedia P, Waye JD. Colon polypectomy: a review of routine and advanced techniques. *J Clin Gastroenterol.* 2013;47(8):657–65.
24. Rex DK. Preventing colorectal cancer and cancer mortality with colonoscopy: What we know and what we don't know. *Endoscopy.* 2010;42(4):320–3.
25. Woods A, Sanowski RA, Wadas DD, Manne RK, Friess SW. Eradication of diminutive polyps: a prospective evaluation of bipolar coagulation versus conventional biopsy removal. *Gastrointest Endosc.* 1989;35(6):536–40.
26. Efthymiou M, Taylor AC, Desmond PV, Allen PB, Chen RY. Biopsy forceps is inadequate for the resection of diminutive polyps. *Endoscopy.* 2011;43(4):312–6.
27. Liu S, Ho SB, Krinsky ML. Quality of polyp resection during colonoscopy: are we achieving polyp clearance? *Dig Dis Sci.* 2012;57(7):1786–91.

28. Draganov PV, Chang MN, Alkhasawneh A, et al. Randomized, controlled trial of standard, large-capacity versus jumbo biopsy forceps for polypectomy of small, sessile, colorectal polyps. *Gastrointest Endosc.* 2012;75(1):118–26.
29. Williams CB. Small polyps: the virtues and the dangers of hot biopsy. *Gastrointest Endosc.* 1991;37(3):394–5.
30. Monkemuller KE, Fry LC, Jones BH, Wells C, Mikolaenko I, Eloubeidi M. Histological quality of polyps resected using the cold versus hot biopsy technique. *Endoscopy.* 2004;36(5):432–6.
31. Vanagunas A, Jacob P, Vakil N. Adequacy of “hot biopsy” for the treatment of diminutive polyps: a prospective randomized trial. *Am J Gastroenterol.* 1989;84(4):383–5.
32. Savides TJ, See JA, Jensen DM, Jutabha R, Machicado GA, Hirabayashi K. Randomized controlled study of injury in the canine right colon from simultaneous biopsy and coagulation with different hot biopsy forceps. *Gastrointest Endosc.* 1995;42(6):573–8.
33. Peluso F, Goldner F. Follow-up of hot biopsy forceps treatment of diminutive colonic polyps. *Gastrointest Endosc.* 1991;37(6):604–6.
34. Gilbert DA, DiMarino AJ, Jensen DM, et al. Status evaluation: hot biopsy forceps. American society for gastrointestinal endoscopy. technology assessment committee. *Gastrointest Endosc.* 1992;38(6):753–6.
35. Riley S. Colonoscopic polypectomy and endoscopic mucosal resection: A practical guide. <http://www.bsg.org.uk/clinical-guidance/endoscopy/colonoscopic-polypectomy-and-endoscopic-mucosal-resection-a-practical-guide.html>. Updated 2008. Accessed 5 June 2015.
36. Kim JS, Lee BI, Choi H, et al. Cold snare polypectomy versus cold forceps polypectomy for diminutive and small colorectal polyps: A randomized controlled trial. *Gastrointest Endosc.* 2015;81(3):741–7.
37. Hewett DG. Colonoscopic polypectomy: current techniques and controversies. *Gastroenterol Clin North Am.* 2013;42(3):443–58.
38. Paspatis GA, Tribonias G, Konstantinidis K, et al. A prospective randomized comparison of cold vs hot snare polypectomy in the occurrence of postpolypectomy bleeding in small colonic polyps. *Colorectal Dis.* 2011;13(10):e345–8.
39. Lee CK, Shim JJ, Jang JY. Cold snare polypectomy vs. cold forceps polypectomy using double-biopsy technique for removal of diminutive colorectal polyps: a prospective randomized study. *Am J Gastroenterol.* 2013;108(10):1593–600.
40. Ichise Y, Horiuchi A, Nakayama Y, Tanaka N. Prospective randomized comparison of cold snare polypectomy and conventional polypectomy for small colorectal polyps. *Digestion.* 2011;84(1):78–81.
41. Van Gossum A, Cozzoli A, Adler M, Taton G, Cremer M. Colonoscopic snare polypectomy: Analysis of 1485 resections comparing two types of current. *Gastrointest Endosc.* 1992;38(4):472–5.
42. Repici A, Pellicano R, Strangio G, Danese S, Fagoonee S, Malesci A. Endoscopic mucosal resection for early colorectal neoplasia: pathologic basis, procedures, and outcomes. *Dis Colon Rectum.* 2009;52(8):1502–15.
43. Conio M, Bianchi S, Repici A, Ruggeri C, Fisher DA, Filiberti R. Cap-assisted endoscopic mucosal resection for colorectal polyps. *Dis Colon Rectum.* 2010;53(6):919–27.
44. Moss A, Bourke MJ, Williams SJ, et al. Endoscopic mucosal resection outcomes and prediction of submucosal cancer from advanced colonic mucosal neoplasia. *Gastroenterology.*

2011;140(7):1909–18.

45. Moss A, Williams SJ, Hourigan LF, et al. Long-term adenoma recurrence following wide-field endoscopic mucosal resection (WF-EMR) for advanced colonic mucosal neoplasia is infrequent: results and risk factors in 1000 cases from the Australian colonic EMR (ACE) study. *Gut*. 2015;64(1):57–65.
46. Luigiano C, Consolo P, Scaffidi MG, et al. Endoscopic mucosal resection for large and giant sessile and flat colorectal polyps: a single-center experience with long-term follow-up. *Endoscopy*. 2009;41(10):829–35.
47. Buchner AM, Guarner-Argente C, Ginsberg GG. Outcomes of EMR of defiant colorectal lesions directed to an endoscopy referral center. *Gastrointest Endosc*. 2012;76(2):255–63.
48. Steele SR, Johnson EK, Champagne B, et al. Endoscopy and polyps—diagnostic and therapeutic advances in management. *World J Gastroenterol*. 2013;19(27):4277–88.
49. Japanese Gastric Cancer Association. Japanese gastric cancer treatment guidelines 2010 (ver.3). *Gastric Cancer*. 2011;14:113–23.
50. Gotoda T, Ho KY, Soetikno R, Kaltenbach T, Draganov P. Gastric ESD: current status and future directions of devices and training. *Gastrointest Endosc Clin N Am*. 2014;24(2):213–33.
51. Draganov PV, Gotoda T, Chavalitdharmong D, Wallace MB. Techniques of endoscopic submucosal dissection: application for the western endoscopist? *Gastrointest Endosc*. 2013;78(5):677–88.
52. Ono S, Fujishiro M, Koike K. Endoscopic submucosal dissection for superficial esophageal neoplasms. *World J Gastrointest Endosc*. 2012;4(5):162–6.
53. Oda I, Suzuki H, Nonaka S, Yoshinaga S. Complications of gastric endoscopic submucosal dissection. *Dig Endosc*. 2013;25 Suppl 1:71–8.
54. Tanaka S, Kashida H, Saito Y, et al. JGES guidelines for colorectal endoscopic submucosal dissection/endoscopic mucosal resection. *Dig Endosc*. 2015;27(4):417–34.
55. Deprez PH, Bergman JJ, Meisner S, et al. Current practice with endoscopic submucosal dissection in Europe: position statement from a panel of experts. *Endoscopy*. 2010;42(10):853–8.
56. Bhatt A, Abe S, Kumaravel A, Vargo J, Saito Y. Indications and techniques for endoscopic submucosal dissection. *Am J Gastroenterol*. 2015.
57. Huai ZY, Feng Xian W, Chang Jiang L, Xi Chen W. Submucosal injection solution for endoscopic resection in gastrointestinal tract: a traditional and network meta-analysis. *Gastroenterol Res Pract*. 2015;2015:702768.
58. Probst A, Golger D, Anthuber M, Markl B, Messmann H. Endoscopic submucosal dissection in large sessile lesions of the rectosigmoid: learning curve in a European center. *Endoscopy*. 2012;44(7):660–7.
59. Hotta K, Oyama T, Shinohara T, et al. Learning curve for endoscopic submucosal dissection of large colorectal tumors. *Dig Endosc*. 2010;22(4):302–6.
60. Saito Y, Uraoka T, Yamaguchi Y, et al. A prospective, multicenter study of 1111 colorectal endoscopic submucosal dissections (with video). *Gastrointest Endosc*. 2010;72(6):1217–25.
61. Kobayashi N, Yoshitake N, Hirahara Y, et al. Matched case-control study comparing endoscopic submucosal dissection and endoscopic mucosal resection for colorectal tumors. *J Gastroenterol Hepatol*. 2012;27(4):728–33.
62. Steele SR, Brown TA, Rush RM, Martin MJ. Laparoscopic vs open colectomy for colon cancer: results from a large nationwide population-based analysis. *J Gastrointest Surg*. 2008;12(3):583–91.

63. Beck DE, Karulf RE. Laparoscopic-assisted full-thickness endoscopic polypectomy. *Dis Colon Rectum*. 1993;36(7):693–5.
64. Franklin Jr ME, Diaz-E JA, Abrego D, Parra-Davila E, Glass JL. Laparoscopic-assisted colonoscopic polypectomy: the Texas Endosurgery Institute experience. *Dis Colon Rectum*. 2000;43(9):1246–9.
65. Wilhelm D, von Delius S, Weber L, et al. Combined laparoscopic-endoscopic resections of colorectal polyps: 10-year experience and follow-up. *Surg Endosc*. 2009;23(4):688–93.
66. Ommer A, Limmer J, Mollenberg H, Peitgen K, Albrecht KH, Walz MK. Laparoscopic-assisted colonoscopic polypectomy—indications and results. *Zentralbl Chir*. 2003;128(3):195–8.
67. Franklin Jr ME, Leyva-Alvizo A, Abrego-Medina D, et al. Laparoscopically monitored colonoscopic polypectomy: an established form of endoluminal therapy for colorectal polyps. *Surg Endosc*. 2007;21(9):1650–3.
68. Winter H, Lang RA, Spelsberg FW, Jauch KW, Huttl TP. Laparoscopic colonoscopic rendezvous procedures for the treatment of polyps and early stage carcinomas of the colon. *Int J Colorectal Dis*. 2007;22(11):1377–81.
69. Lee SW, Garrett KA, Shin JH, Trencheva K, Sonoda T, Milsom JW. Dynamic article: long-term outcomes of patients undergoing combined endolaparoscopic surgery for benign colon polyps. *Dis Colon Rectum*. 2013;56(7):869–73.
70. Yan J, Trencheva K, Lee SW, Sonoda T, Shukla P, Milsom JW. Treatment for right colon polyps not removable using standard colonoscopy: combined laparoscopic-colonoscopy approach. *Dis Colon Rectum*. 2011;54(6):753–8.
71. Franklin Jr ME, Portillo G. Laparoscopic monitored colonoscopic polypectomy: long-term follow-up. *World J Surg*. 2009;33(6):1306–9.

## 第 6 章

1. Reilly DF, McNeely MJ, Doerner D, Greenberg DL, Staiger TO, Geist MJ, et al. Self-reported exercise tolerance and the risk of serious perioperative complications. *Arch Intern Med*. 1999;159(18):2185–92.
2. American Society of Anesthesiologists. Practice advisory for the perioperative management of patients with cardiac implantable electronic devices: pacemakers and implantable cardioverter-defibrillators: an updated report by the american society of anesthesiologists task force on perioperative management of patients with cardiac implantable electronic devices. *Anesthesiology*. 2011;114(2):247–61.
3. Kaplan EB, Sheiner LB, Boeckmann AJ, Roizen MF, Beal SL, Cohen SN, et al. The usefulness of preoperative laboratory screening. *JAMA*. 1985;253(24):3576–81.
4. Smetana GW, Macpherson DS. The case against routine preoperative laboratory testing. *Med Clin North Am*. 2003;87(1):7–40.
5. Peterson P, Hayes TE, Arkin CF, Bovill EG, Fairweather RB, Rock Jr WA, et al. The preoperative bleeding time test lacks clinical benefit: College of American Pathologists' and American Society of Clinical Pathologists' position article. *Arch Surg*. 1998;133(2):134–9.
6. Lee TH, Marcantonio ER, Mangione CM, Thomas EJ, Polanczyk CA, Cook EF, et al. Derivation and prospective validation of a simple index for prediction of cardiac risk of major noncardiac

surgery. *Circulation*. 1999;100(10):1043–9.

7. Mathew A, Devereaux PJ, O'Hare A, Tonelli M, Thiessen-Philbrook H, Nevis IF, et al. Chronic kidney disease and postoperative mortality: a systematic review and meta-analysis. *Kidney Int*. 2008;73(9):1069–81.

8. Grek S, Gravenstein N, Morey TE, Rice MJ. A cost-effective screening method for preoperative hyperglycemia. *Anesth Analg*. 2009;109(5):1622–4.

9. Bouvet C, Lubbeke A, Bandi C, Pagani L, Stern R, Hoffmeyer P, et al. Is there any benefit in pre-operative urinary analysis before elective total joint replacement? *Bone Joint J*. 2014;96-b(3):390–4.

10. Apfelbaum JL, Connis RT, Nickinovich DG, Pasternak LR, Arens JF, Caplan RA, et al. Practice advisory for preanesthesia evaluation: an updated report by the American Society of Anesthesiologists Task Force on Preanesthesia Evaluation. *Anesthesiology*. 2012;116(3):522–38.

11. Fleisher LA, Fleischmann KE, Auerbach AD, Barnason SA, Beckman JA, Bozkurt B, et al. 2014 ACC/AHA guideline on perioperative cardiovascular evaluation and management of patients undergoing noncardiac surgery: executive summary: a report of the American College of Cardiology/American Heart Association Task Force on practice guidelines. Developed in collaboration with the American College of Surgeons, American Society of Anesthesiologists, American Society of Echocardiography, American Society of Nuclear Cardiology, Heart Rhythm Society, Society for Cardiovascular Angiography and Interventions, Society of Cardiovascular Anesthesiologists, and Society of Vascular Medicine Endorsed by the Society of Hospital Medicine. *Journal of nuclear cardiology : official publication of the American Society of Nuclear Cardiology*. 2015;22(1):162–215.

12. Smetana GW, Lawrence VA, Cornell JE. Preoperative pulmonary risk stratification for noncardiothoracic surgery: systematic review for the American College of Physicians. *Ann Intern Med*. 2006;144(8):581–95.

13. Poirier P, Alpert MA, Fleisher LA, Thompson PD, Sugerman HJ, Burke LE, et al. Cardiovascular evaluation and management of severely obese patients undergoing surgery: a science advisory from the American Heart Association. *Circulation*. 2009;120(1):86–95.

14. Archer C, Levy AR, McGregor M. Value of routine preoperative chest x-rays: a meta-analysis. *Can J Anaesth*. 1993;40(11):1022–7.

15. Devereaux PJ, Xavier D, Pogue J, Guyatt G, Sigamani A, Garutti I, et al. Characteristics and short-term prognosis of perioperative myocardial infarction in patients undergoing noncardiac surgery: a cohort study. *Ann Intern Med*. 2011;154(8):523–8.

16. Girish M, Trayner Jr E, Dammann O, Pinto-Plata V, Celli B. Symptom-limited stair climbing as a predictor of postoperative cardiopulmonary complications after high-risk surgery. *Chest*. 2001;120(4):1147–51.

17. Bilimoria KY, Liu Y, Paruch JL, Zhou L, Kmieciak TE, Ko CY, et al. Development and evaluation of the universal ACS NSQIP surgical risk calculator: a decision aid and informed consent tool for patients and surgeons. *J Am Coll Surg*. 2013;217(5):833–42.e1-3.

18. Devereaux PJ, Yang H, Yusuf S, Guyatt G, Leslie K, Villar JC, et al. Effects of extended-release metoprolol succinate in patients undergoing non-cardiac surgery (POISE trial): a randomised controlled trial. *Lancet*. 2008;371(9627):1839–47.

19. Wijeyesundera DN, Duncan D, Nkonde-Price C, Virani SS, Washam JB, Fleischmann KE, et al. Perioperative beta blockade in noncardiac surgery: a systematic review for the 2014 ACC/AHA

guideline on perioperative cardiovascular evaluation and management of patients undergoing noncardiac surgery: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. *Circulation*. 2014;130(24):2246–64.

20. Bouri S, Shun-Shin MJ, Cole GD, Mayet J, Francis DP. Meta-analysis of secure randomised controlled trials of beta-blockade to prevent perioperative death in non-cardiac surgery. *Heart*. 2014;100(6):456–64.

21. Kumar R, McKinney WP, Raj G, Heudebert GR, Heller HJ, Koetting M, et al. Adverse cardiac events after surgery: assessing risk in a veteran population. *J Gen Intern Med*. 2001;16(8):507–18.

22. Singla S, Sachdeva R, Uretsky BF. The risk of adverse cardiac and bleeding events following noncardiac surgery relative to antiplatelet therapy in patients with prior percutaneous coronary intervention. *J Am Coll Cardiol*. 2012;60(20):2005–16.

23. Dweck MR, Cruden NL. Noncardiac surgery in patients with coronary artery stents. *Arch Intern Med*. 2012;172(14):1054–5.

24. Savonitto S, D'Urbano M, Caracciolo M, Barlocco F, Mariani G, Nichelatti M, et al. Urgent surgery in patients with a recently implanted coronary drug-eluting stent: a phase II study of “bridging” antiplatelet therapy with tirofiban during temporary withdrawal of clopidogrel. *Br J Anaesth*. 2010;104(3):285–91.

25. Stein M, Cassara EL. Preoperative pulmonary evaluation and therapy for surgery patients. *JAMA*. 1970;211(5):787–90.

26. Singh M, Liao P, Kobah S, Wijesundera DN, Shapiro C, Chung F. Proportion of surgical patients with undiagnosed obstructive sleep apnoea. *Br J Anaesth*. 2013;110(4):629–36.

27. Kaw R, Chung F, Pasupuleti V, Mehta J, Gay PC, Hernandez AV. Meta-analysis of the association between obstructive sleep apnoea and postoperative outcome. *Br J Anaesth*. 2012;109(6):897–906.

28. Chung F, Elsaid H. Screening for obstructive sleep apnea before surgery: why is it important? *Curr Opin Anaesthesiol*. 2009;22(3):405–11.

29. Chung F, Subramanyam R, Liao P, Sasaki E, Shapiro C, Sun Y. High STOP-Bang score indicates a high probability of obstructive sleep apnoea. *Br J Anaesth*. 2012;108(5):768–75.

30. Liao P, Luo Q, Elsaid H, Kang W, Shapiro CM, Chung F. Perioperative auto-titrated continuous positive airway pressure treatment in surgical patients with obstructive sleep apnea: a randomized controlled trial. *Anesthesiology*. 2013;119(4):837–47.

31. Kannel WB, McGee DL. Diabetes and cardiovascular risk factors: the Framingham study. *Circulation*. 1979;59(1):8–13.

32. Halkos ME, Puskas JD, Lattouf OM, Kilgo P, Kerendi F, Song HK, et al. Elevated preoperative hemoglobin A1c level is predictive of adverse events after coronary artery bypass surgery. *J Thorac Cardiovasc Surg*. 2008;136(3):631–40.

33. Pezzarossa A, Taddei F, Cimicchi MC, Rossini E, Contini S, Bonora E, et al. Perioperative management of diabetic subjects. Subcutaneous versus intravenous insulin administration during glucose-potassium infusion. *Diabetes Care*. 1988;11(1):52–8.

34. Flegal KM, Carroll MD, Kit BK, Ogden CL. Prevalence of obesity and trends in the distribution of body mass index among US adults, 1999–2010. *JAMA*. 2012;307(5):491–7.

35. Mullen JT, Moorman DW, Davenport DL. The obesity paradox: body mass index and outcomes in patients undergoing nonbariatric general surgery. *Ann Surg*. 2009;250(1):166–72.

36. Dindo D, Muller MK, Weber M, Clavien PA. Obesity in general elective surgery. *Lancet*.



2003;361(9374):2032–5.

37. Mariani L, Lo Vullo S, Bozzetti F. Weight loss in cancer patients: a plea for a better awareness of the issue. *Support Care Cancer*. 2012;20(2):301–9.

38. Mullen JL, Gertner MH, Buzby GP, Goodhart GL, Rosato EF. Implications of malnutrition in the surgical patient. *Arch Surg*. 1979;114(2):121–5.

39. Sorensen J, Kondrup J, Prokopowicz J, Schiesser M, Krahenbuhl L, Meier R, et al. EuroOOPS: an international, multicentre study to implement nutritional risk screening and evaluate clinical outcome. *Clin Nutr*. 2008;27(3):340–9.

40. Schwegler I, von Holzen A, Gutzwiller JP, Schlumpf R, Muhlebach S, Stanga Z. Nutritional risk is a clinical predictor of postoperative mortality and morbidity in surgery for colorectal cancer. *Br J Surg*. 2010;97(1):92–7.

41. Panis Y, Maggiori L, Caranhac G, Bretagnol F, Vicaud E. Mortality after colorectal cancer surgery: a French survey of more than 84,000 patients. *Ann Surg*. 2011;254(5):738–43. discussion 43–4.

42. Wu GH, Liu ZH, Wu ZH, Wu ZG. Perioperative artificial nutrition in malnourished gastrointestinal cancer patients. *World J Gastroenterol*. 2006;12(15):2441–4.

43. Baker JP, Detsky AS, Wesson DE, Wolman SL, Stewart S, Whitewell J, et al. Nutritional assessment: a comparison of clinical judgement and objective measurements. *N Engl J Med*. 1982;306(16):969–72.

44. Doweiko JP, Nompleggi DJ. The role of albumin in human physiology and pathophysiology, Part III: Albumin and disease states. *JPEN J Parenter Enteral Nutr*. 1991;15(4):476–83.

45. Burden S, Todd C, Hill J, Lal S. Pre-operative nutrition support in patients undergoing gastrointestinal surgery. *Cochrane Database Syst Rev*. 2012;11:Cd008879.

46. Bootun R. Effects of immunosuppressive therapy on wound healing. *Int Wound J*. 2013;10(1):98–104.

47. Dean PG, Lund WJ, Larson TS, Prieto M, Nyberg SL, Ishitani MB, et al. Wound-healing complications after kidney transplantation: a prospective, randomized comparison of sirolimus and tacrolimus. *Transplantation*. 2004;77(10):1555–61.

48. Narrow WE, Rae DS, Robins LN, Regier DA. Revised prevalence estimates of mental disorders in the United States: using a clinical significance criterion to reconcile 2 surveys' estimates. *Arch Gen Psychiatry*. 2002;59(2):115–23.

49. Kraemer KL, Conigliaro J, Saitz R. Managing alcohol withdrawal in the elderly. *Drugs Aging*. 1999;14(6):409–25.

50. Pihkala H, Sandlund M. Parenthood and opioid dependence. *Subst Abuse Rehabil*. 2015;6:33–40.

51. Bradley KA, Rubinsky AD, Sun H, Bryson CL, Bishop MJ, Blough DK, et al. Alcohol screening and risk of postoperative complications in male VA patients undergoing major non-cardiac surgery. *J Gen Intern Med*. 2011;26(2):162–9.

52. Rubinsky AD, Sun H, Blough DK, Maynard C, Bryson CL, Harris AH, et al. AUDIT-C alcohol screening results and postoperative inpatient health care use. *J Am Coll Surg*. 2012;214(3):296–305.e1.

53. Bush K, Kivlahan DR, McDonell MB, Fihn SD, Bradley KA. The AUDIT alcohol consumption questions (AUDIT-C): an effective brief screening test for problem drinking. Ambulatory Care Quality Improvement Project (ACQUIP). Alcohol Use Disorders Identification Test. *Arch Intern*

Med. 1998;158(16):1789–95.

54. Tonnesen H, Rosenberg J, Nielsen HJ, Rasmussen V, Hauge C, Pedersen IK, et al. Effect of preoperative abstinence on poor postoperative outcome in alcohol misusers: randomised controlled trial. *BMJ*. 1999;318(7194):1311–6.

55. Tonnesen H, Nielsen PR, Lauritzen JB, Moller AM. Smoking and alcohol intervention before surgery: evidence for best practice. *Br J Anaesth*. 2009;102(3):297–306.

56. Gronkjaer M, Eliassen M, Skov-Ettrup LS, Tolstrup JS, Christiansen AH, Mikkelsen SS, et al. Preoperative smoking status and postoperative complications: a systematic review and meta-analysis. *Ann Surg*. 2014;259(1):52–71.

57. Jung KH, Kim SM, Choi MG, Lee JH, Noh JH, Sohn TS, et al. Preoperative smoking cessation can reduce postoperative complications in gastric cancer surgery. *Gastric Cancer*. 2015;18:683–90.

58. Frenk SM, Porter KS, Paulozzi LJ. Prescription opioid analgesic use among adults: United States, 1999–2012. *NCHS data brief*. 2015;189:1–8.

59. Vadivelu N, Mitra S, Kaye AD, Urman RD. Perioperative analgesia and challenges in the drug-addicted and drug-dependent patient. *Best Pract Res Clin Anaesthesiol*. 2014;28(1):91–101.

60. Douketis JD, Spyropoulos AC, Spencer FA, Mayr M, Jaffer AK, Eckman MH, et al. Perioperative management of antithrombotic therapy: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. *Chest*. 2012;141(2 Suppl):e326S–50S.

61. Levy JH, Tanaka KA, Dietrich W. Perioperative hemostatic management of patients treated with vitamin K antagonists. *Anesthesiology*. 2008;109(5):918–26.

62. Colvin BT, Barrowcliffe TW. The British Society for Haematology Guidelines on the use and monitoring of heparin 1992: second revision. *BCSH Haemostasis and Thrombosis Task Force. J Clin Pathol*. 1993;46(2):97–103.

63. Bernardi E, Piccioli A, Oliboni G, Zuin R, Girolami A, Prandoni P. Nomograms for the administration of unfractionated heparin in the initial treatment of acute thromboembolism--an overview. *Thromb Haemost*. 2000;84(1):22–6.

64. Maniscalco P, Caforio M, Imberti D, Porcellini G, Benedetti R. Apixaban versus enoxaparin in elective major orthopedic surgery: a clinical review. *Clin Appl Thromb Hemost*. 2015;21(2):115–9.

65. Antolovic D, Reissfelder C, Rakow A, Contin P, Rahbari NN, Buchler MW, et al. A randomised controlled trial to evaluate and optimize the use of antiplatelet agents in the perioperative management in patients undergoing general and abdominal surgery--the APAP trial (ISRCTN45810007). *BMC Surg*. 2011;11:7.

66. Mantz J, Samama CM, Tubach F, Devereaux PJ, Collet JP, Albaladejo P, et al. Impact of preoperative maintenance or interruption of aspirin on thrombotic and bleeding events after elective non-cardiac surgery: the multicentre, randomized, blinded, placebo-controlled, STRATAGEM trial. *Br J Anaesth*. 2011;107(6):899–910.

67. Sahebally SM, Healy D, Coffey JC, Walsh SR. Should patients taking aspirin for secondary prevention continue or discontinue the medication prior to elective, abdominal surgery? Best evidence topic (BET). *Int J Surg*. 2014;12(5):16–21.

68. Wolf AM, Pucci MJ, Gabale SD, McIntyre CA, Irizarry AM, Kennedy EP, et al. Safety of perioperative aspirin therapy in pancreatic operations. *Surgery*. 2014;155(1):39–46.

69. Wang AS, Armstrong EJ, Armstrong AW. Corticosteroids and wound healing: clinical considerations in the perioperative period. *Am J Surg*. 2013;206(3):410–7.

70. Post S, Betzler M, von Ditzfurth B, Schurmann G, Kuppers P, Herfarth C. Risks of intestinal anastomoses in Crohn's disease. *Ann Surg.* 1991;213(1):37–42.
71. Sliker JC, Komen N, Mannaerts GH, Karsten TM, Willemsen P, Murawska M, et al. Long-term and perioperative corticosteroids in anastomotic leakage: a prospective study of 259 left-sided colorectal anastomoses. *Arch Surg.* 2012;147(5):447–52.
72. Eriksen TF, Lassen CB, Gogenur I. Treatment with corticosteroids and the risk of anastomotic leakage following lower gastrointestinal surgery: a literature survey. *Colorectal Dis.* 2014;16(5):O154–60.
73. Ismael H, Horst M, Farooq M, Jordon J, Patton JH, Rubinfeld IS. Adverse effects of preoperative steroid use on surgical outcomes. *Am J Surg.* 2011;201(3):305–8. discussion 8–9.
74. El-Hussuna A, Andersen J, Bisgaard T, Jess P, Henriksen M, Oehlenschläger J, et al. Biologic treatment or immunomodulation is not associated with postoperative anastomotic complications in abdominal surgery for Crohn's disease. *Scand J Gastroenterol.* 2012;47(6):662–8.
75. Krane MK, Allaix ME, Zoccali M, Umanskiy K, Rubin MA, Villa A, et al. Preoperative infliximab therapy does not increase morbidity and mortality after laparoscopic resection for inflammatory bowel disease. *Dis Colon Rectum.* 2013;56(4):449–57.
76. Ali T, Yun L, Rubin DT. Risk of post-operative complications associated with anti-TNF therapy in inflammatory bowel disease. *World J Gastroenterol.* 2012;18(3):197–204.
77. Lujan JJ, Nemeth ZH, Barratt-Stopper PA, Bustami R, Koshenkov VP, Rolandelli RH. Factors influencing the outcome of intestinal anastomosis. *Am Surg.* 2011;77(9):1169–75.
78. Kabbinnar F, Hurwitz HI, Fehrenbacher L, Meropol NJ, Novotny WF, Lieberman G, et al. Phase II, randomized trial comparing bevacizumab plus fluorouracil (FU)/leucovorin (LV) with FU/LV alone in patients with metastatic colorectal cancer. *J Clin Oncol.* 2003;21(1):60–5.
79. Kabbinnar FF, Schulz J, McCleod M, Patel T, Hamm JT, Hecht JR, et al. Addition of bevacizumab to bolus fluorouracil and leucovorin in first-line metastatic colorectal cancer: results of a randomized phase II trial. *J Clin Oncol.* 2005;23(16):3697–705.
80. Hurwitz H, Fehrenbacher L, Novotny W, Cartwright T, Hainsworth J, Heim W, et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. *N Engl J Med.* 2004;350(23):2335–42.
81. Yoshioka Y, Uehara K, Ebata T, Yokoyama Y, Mitsuma A, Ando Y, et al. Postoperative complications following neoadjuvant bevacizumab treatment for advanced colorectal cancer. *Surg Today.* 2014;44(7):1300–6.
82. Deshaies I, Malka D, Soria JC, Massard C, Bahleda R, Elias D. Antiangiogenic agents and late anastomotic complications. *J Surg Oncol.* 2010;101(2):180–3.
83. Eveno C, le Maignan C, Soyer P, Camus M, Barranger E, Pocard M. Late anastomotic colonic dehiscence due to antiangiogenic treatment, a specific drug-class complication requiring specific treatment: an example of pazopanib complication. *Clin Res Hepatol Gastroenterol.* 2011;35(2):135–9.
84. Chung F, Yegneswaran B, Liao P, et al. STOP questionnaire: a tool to screen patients for obstructive sleep apnea. *Anesthesiology.* 2008;108:812–21.
85. Devereaux PJ, Goldman L, Cook DJ, Gilbert K, Leslie K, Guyatt GH. Perioperative cardiac events in patients undergoing noncardiac surgery: a review of the magnitude of the problem, the pathophysiology of the events and methods to estimate and communicate risk. *CMAJ.* 2005;173(6):627–34.

## 第 7 章

1. Adamina M, Kehlet H, Tomlinson GA, Senagore AJ, Delaney CP. Enhanced recovery pathways optimize health outcomes and resource utilization: a meta-analysis of randomized controlled trials in colorectal surgery. *Surgery*. 2011;149(6):830–40.
2. Asgeirsson T, Jrebi N, Feo L, Kerwel T, Luchtefeld M, Senagore AJ. Incremental cost of complications in colectomy: a warranty guided approach to surgical quality improvement. *Am J Surg*. 2014;207(3):422–6. discussion 5–6.
3. Chestovich PJ, Lin AY, Yoo J. Fast-track pathways in colorectal surgery. *Surg Clin North Am*. 2013;93(1):21–32.
4. Senagore AJ, Delaney CP. A critical analysis of laparoscopic colectomy at a single institution: lessons learned after 1000 cases. *Am J Surg*. 2006;191(3):377–80.
5. Senagore AJ, Stulberg JJ, Byrnes J, Delaney CP. A national comparison of laparoscopic vs. open colectomy using the National Surgical Quality Improvement Project data. *Dis Colon Rectum*. 2009;52(2):183–6.
6. Bosio RM, Smith BM, Aybar PS, Senagore AJ. Implementation of laparoscopic colectomy with fast-track care in an academic medical center: benefits of a fully ascended learning curve and specialty expertise. *Am J Surg*. 2007;193(3):413–5. discussion 5–6.
7. Delaney CP, Chang E, Senagore AJ, Broder M. Clinical outcomes and resource utilization associated with laparoscopic and open colectomy using a large national database. *Ann Surg*. 2008;247(5):819–24.
8. Delaney CP, Kiran RP, Senagore AJ, Brady K, Fazio VW. Case-matched comparison of clinical and financial outcome after laparoscopic or open colorectal surgery. *Ann Surg*. 2003;238(1):67–72.
9. Delaney CP, Senagore AJ, Gerkin TM, Beard TL, Zingaro WM, Tomaszewski KJ, et al. Association of surgical care practices with length of stay and use of clinical protocols after elective bowel resection: results of a national survey. *Am J Surg*. 2010;199(3):299–304. discussion 304.
10. Keller DS, Lawrence JK, Nobel T, Delaney CP. Optimizing cost and short-term outcomes for elderly patients in laparoscopic colonic surgery. *Surg Endosc*. 2013;27(12):4463–8.
11. Lawrence JK, Keller DS, Samia H, Ermlich B, Brady KM, Nobel T, et al. Discharge within 24 to 72 hours of colorectal surgery is associated with low readmission rates when using enhanced recovery pathways. *J Am Coll Surg*. 2013;216(3):390–4.
12. Rossi G, Vaccarezza H, Vaccaro CA, Mentz RE, Im V, Alvarez A, et al. Two-day hospital stay after laparoscopic colorectal surgery under an enhanced recovery after surgery (ERAS) pathway. *World J Surg*. 2013;37(10):2483–9.
13. Bloomstone JA, Loftus T, Hutchison R. ERAS: enhancing recovery one evidence-based step at a time. *Anesth Analg*. 2015;120(1):256.
14. Bona S, Molteni M, Rosati R, Elmore U, Bagnoli P, Monzani R, et al. Introducing an enhanced recovery after surgery program in colorectal surgery: a single center experience. *World J Gastroenterol*. 2014;20(46):17578–87.
15. Delaney CP, Zutshi M, Senagore AJ, Remzi FH, Hammel J, Fazio VW. Prospective, randomized, controlled trial between a pathway of controlled rehabilitation with early ambulation and diet and traditional postoperative care after laparotomy and intestinal resection. *Dis Colon Rectum*.

2003;46(7):851–9.

16. Eglinton TW. The era of ERAS: a new standard of perioperative care. *N Z Med J*. 2013;126(1369):6–7.

17. Feldman LS, Delaney CP. Laparoscopy plus enhanced recovery: optimizing the benefits of MIS through SAGES ‘SMART’ program. *Surg Endosc*. 2014;28(5):1403–6.

18. Gignoux B, Pasquer A, Vulliez A, Lanz T. Outpatient colectomy within an enhanced recovery program. *J Visc Surg*. 2015;152(1):11–5.

19. ERAS Compliance Group. The impact of enhanced recovery protocol compliance on elective colorectal cancer resection: results from an international registry. *Ann Surg*. 2015;261(6):1153–9.

20. Kariv Y, Delaney CP, Casillas S, Hammel J, Nocero J, Bast J, et al. Long-term outcome after laparoscopic and open surgery for rectal prolapse: a case-control study. *Surg Endosc*. 2006;20(1):35–42.

21. Kariv Y, Delaney CP, Senagore AJ, Manilich EA, Hammel JP, Church JM, et al. Clinical outcomes and cost analysis of a “fast track” postoperative care pathway for ileal pouch-anal anastomosis: a case control study. *Dis Colon Rectum*. 2007;50(2):137–46.

22. Ljungqvist O. ERAS—enhanced recovery after surgery: moving evidence-based perioperative care to practice. *JPEN J Parenter Enteral Nutr*. 2014;38(5):559–66.

23. Lohsiriwat V. Enhanced recovery after surgery vs conventional care in emergency colorectal surgery. *World J Gastroenterol*. 2014;20(38):13950–5.

24. Noel JK, Fahrbach K, Estok R, Cella C, Frame D, Linz H, et al. Minimally invasive colorectal resection outcomes: short-term comparison with open procedures. *J Am Coll Surg*. 2007;204(2):291–307.

25. Oda Y, Kakinohana M. Introduction of ERAS((R)) program into clinical practice: from preoperative management to postoperative evaluation: opening remarks. *J Anesth*. 2014;28(1):141–2.

26. Patel SS, Patel MS, Mahanti S, Ortega A, Ault GT, Kaiser AM, et al. Laparoscopic versus open colon resections in California: a cross-sectional analysis. *Am Surg*. 2012;78(10):1063–5.

27. Pokala N, Delaney CP, Senagore AJ, Brady KM, Fazio VW. Laparoscopic vs open total colectomy: a case-matched comparative study. *Surg Endosc*. 2005;19(4):531–5.

28. Rona K, Choi J, Sigle G, Kidd S, Ault G, Senagore AJ. Enhanced recovery protocol: implementation at a county institution with limited resources. *Am Surg*. 2012;78(10):1041–4.

29. Senagore AJ, Madbouly KM, Fazio VW, Duepre HJ, Brady KM, Delaney CP. Advantages of laparoscopic colectomy in older patients. *Arch Surg*. 2003;138(3):252–6.

30. Spanjersberg WR, van Sambeek JD, Bremers A, Rosman C, van Laarhoven CJ. Systematic review and meta-analysis for laparoscopic versus open colon surgery with or without an ERAS programme. *Surg Endosc*. 2015;29:3443–53.

31. Steele SR, Bleier J, Champagne B, Hassan I, Russ A, Senagore AJ, et al. Improving outcomes and cost-effectiveness of colorectal surgery. *J Gastrointest Surg*. 2014;18(11):1944–56.

32. Zutshi M, Delaney CP, Senagore AJ, Fazio VW. Shorter hospital stay associated with fastrack postoperative care pathways and laparoscopic intestinal resection are not associated with increased physical activity. *Colorectal Dis*. 2004;6(6):477–80.

33. Zutshi M, Delaney CP, Senagore AJ, Mekhail N, Lewis B, Connor JT, et al. Randomized controlled trial comparing the controlled rehabilitation with early ambulation and diet pathway versus the controlled rehabilitation with early ambulation and diet with preemptive epidural

- anesthesia/analgesia after laparotomy and intestinal resection. *Am J Surg*. 2005;189(3):268–72.
34. Delaney CP, Fazio VW, Remzi FH, Hammel J, Church JM, Hull TL, et al. Prospective, age-related analysis of surgical results, functional outcome, and quality of life after ileal pouch-anal anastomosis. *Ann Surg*. 2003;238(2):221–8.
  35. Gillissen F, Ament SM, Maessen JM, Dejong CH, Dirksen CD, van der Weijden T, et al. Sustainability of an enhanced recovery after surgery program (ERAS) in colonic surgery. *World J Surg*. 2015;39(2):526–33.
  36. Hoffman RL, Bartlett EK, Ko C, Mahmoud N, Karakousis GC, Kelz RR. Early discharge and readmission after colorectal resection. *J Surg Res*. 2014;190(2):579–86.
  37. Kehlet H. Enhanced Recovery After Surgery (ERAS): good for now, but what about the future? *Can J Anaesth*. 2015;62(2):99–104.
  38. Keller DS, Bankwitz B, Woconish D, Champagne BJ, Reynolds Jr HL, Stein SL, et al. Predicting who will fail early discharge after laparoscopic colorectal surgery with an established enhanced recovery pathway. *Surg Endosc*. 2014;28(1):74–9.
  39. Keller DS, Delaney CP. Current evidence in gastrointestinal surgery: natural orifice transluminal endoscopic surgery (NOTES). *J Gastrointest Surg*. 2013;17(10):1857–62.
  40. Keller DS, Khorgami Z, Swendseid B, Khan S, Delaney CP. Identifying causes for high readmission rates after stoma reversal. *Surg Endosc*. 2014;28(4):1263–8.
  41. Kiran RP, Delaney CP, Senagore AJ, Steel M, Garafalo T, Fazio VW. Outcomes and prediction of hospital readmission after intestinal surgery. *J Am Coll Surg*. 2004;198(6):877–83.
  42. Zhuang CL, Ye XZ, Zhang XD, Chen BC, Yu Z. Enhanced recovery after surgery programs versus traditional care for colorectal surgery: a meta-analysis of randomized controlled trials. *Dis Colon Rectum*. 2013;56(5):667–78.
  43. Thiele RH, Rea KM, Turrentine FE, Friel CM, Hassinger TE, Goudreau BJ, et al. Standardization of care: impact of an enhanced recovery protocol on length of stay, complications, and direct costs after colorectal surgery. *J Am Coll Surg*. 2015;220(4):430–43.
  44. Fearon KC, Ljungqvist O, Von Meyenfeldt M, Revhaug A, Dejong CH, Lassen K, et al. Enhanced recovery after surgery: a consensus review of clinical care for patients undergoing colonic resection. *Clin Nutr*. 2005;24(3):466–77.
  45. Kehlet H, Buchler MW, Beart Jr RW, Billingham RP, Williamson R. Care after colonic operation—is it evidence-based? Results from a multinational survey in Europe and the United States. *J Am Coll Surg*. 2006;202(1):45–54.
  46. Lassen K, Hannemann P, Ljungqvist O, Fearon K, Dejong CH, von Meyenfeldt MF, et al. Patterns in current perioperative practice: survey of colorectal surgeons in five northern European countries. *BMJ*. 2005;330(7505):1420–1.
  47. Cabana MD, Rand CS, Powe NR, Wu AW, Wilson MH, Abboud PA, et al. Why don't physicians follow clinical practice guidelines? A framework for improvement. *JAMA*. 1999;282(15):1458–65.
  48. Kehlet H, Wilmore DW. Evidence-based surgical care and the evolution of fast-track surgery. *Ann Surg*. 2008;248(2):189–98.
  49. Kahokehr A, Sammour T, Zargar-Shoshtari K, Thompson L, Hill AG. Implementation of ERAS and how to overcome the barriers. *Int J Surg*. 2009;7(1):16–9.
  50. Sammour T, Zargar-Shoshtari K, Bhat A, Kahokehr A, Hill AG. A programme of Enhanced Recovery After Surgery (ERAS) is a cost-effective intervention in elective colonic surgery. *N Z Med J*. 2010;123(1319):61–70.

51. Srinivasa S, Sammour T, Kahokehr A, Hill AG. Enhanced Recovery After Surgery (ERAS) protocols must be considered when determining optimal perioperative care in colorectal surgery. *Ann Surg*. 2010;252(2):409. author reply 409–10.
52. Henry A, Stopfkuchen-Evans M, Wolf L, Bader A, Goldberg J, Kelley R, et al. Implementation of an Eras pathway in an Academic Medical Center: measurement of compliance and results. *Dis Colon Rectum*. 2015;58(5), E220.
53. Miller T, Ernst FR, Krukas MR, Gan T. Level of compliance with the Enhanced Recovery after Surgery (Eras) protocol and postoperative outcomes. *Anesth Analg*. 2013;116:100.
54. Patel A, Marimuthu K, Mathew G. Enhanced recovery after surgery (ERAS) card: a simple intervention to improve junior doctor compliance. *Br J Surg*. 2011;98:131–2.
55. Stein SL. Perioperative management. *Clin Colon Rectal Surg*. 2013;26(3):137–8.
56. Eriksson LI, Sandin R. Fasting guidelines in different countries. *Acta Anaesthesiol Scand*. 1996;40(8 Pt 2):971–4.
57. Smith I, Kranke P, Murat I, Smith A, O’Sullivan G, Soreide E, et al. Perioperative fasting in adults and children: guidelines from the European Society of Anaesthesiology. *Eur J Anaesthesiol*. 2011;28(8):556–69.
58. Soreide E, Eriksson LI, Hirlekar G, Eriksson H, Henneberg SW, Sandin R, et al. Pre-operative fasting guidelines: an update. *Acta Anaesthesiol Scand*. 2005;49(8):1041–7.
59. Khoo CK, Vickery CJ, Forsyth N, Vinall NS, Eyre-Brook IA. A prospective randomized controlled trial of multimodal perioperative management protocol in patients undergoing elective colorectal resection for cancer. *Ann Surg*. 2007;245(6):867–72.
60. Gustafsson UO, Scott MJ, Schwenk W, Demartines N, Roulin D, Francis N, et al. Guidelines for perioperative care in elective colonic surgery: Enhanced Recovery After Surgery (ERAS((R))) Society recommendations. *World J Surg*. 2013;37(2):259–84.
61. Lohsiriwat V. The influence of preoperative nutritional status on the outcomes of an enhanced recovery after surgery (ERAS) programme for colorectal cancer surgery. *Tech Coloproctol*. 2014;18(11):1075–80.
62. Kehlet H. Multimodal approach to control postoperative pathophysiology and rehabilitation. *Br J Anaesth*. 1997;78(5):606–17.
63. Waitzberg DL, Saito H, Plank LD, Jamieson GG, Jagannath P, Hwang TL, et al. Postsurgical infections are reduced with specialized nutrition support. *World J Surg*. 2006;30(8):1592–604.
64. Keller DS, Bankwitz B, Nobel T, Delaney CP. Using frailty to predict who will fail early discharge after laparoscopic colorectal surgery with an established recovery pathway. *Dis Colon Rectum*. 2014;57(3):337–42.
65. Kulminski AM, Ukraintseva SV, Culminskaya IV, Arbeev KG, Land KC, Akushevich L, et al. Cumulative deficits and physiological indices as predictors of mortality and long life. *J Gerontol A Biol Sci Med Sci*. 2008;63(10):1053–9.
66. Farhat JS, Velanovich V, Falvo AJ, Horst HM, Swartz A, Patton Jr JH, et al. Are the frail destined to fail? Frailty index as predictor of surgical morbidity and mortality in the elderly. *J Trauma Acute Care Surg*. 2012;72(6):1526–30. discussion 30–1.
67. Hausel J, Nygren J, Lagerkranser M, Hellstrom PM, Hammarqvist F, Almstrom C, et al. A carbohydrate-rich drink reduces preoperative discomfort in elective surgery patients. *Anesth Analg*. 2001;93(5):1344–50.
68. Svanfeldt M, Thorell A, Hausel J, Soop M, Nygren J, Ljungqvist O. Effect of “preoperative”

oral carbohydrate treatment on insulin action—a randomised cross-over unblinded study in healthy subjects. *Clin Nutr.* 2005;24(5):815–21.

69. Svanfeldt M, Thorell A, Hausel J, Soop M, Rooyackers O, Nygren J, et al. Randomized clinical trial of the effect of preoperative oral carbohydrate treatment on postoperative whole-body protein and glucose kinetics. *Br J Surg.* 2007;94(11):1342–50.

70. Noblett SE, Watson DS, Huong H, Davison B, Hainsworth PJ, Horgan AF. Pre-operative oral carbohydrate loading in colorectal surgery: a randomized controlled trial. *Colorectal Dis.* 2006;8(7):563–9.

71. Contant CM, Hop WC, van't Sant HP, Oostvogel HJ, Smeets HJ, Stassen LP, et al. Mechanical bowel preparation for elective colorectal surgery: a multicentre randomised trial. *Lancet.* 2007;370(9605):2112–7.

72. Slim K, Vicaut E, Launay-Savary MV, Contant C, Chipponi J. Updated systematic review and meta-analysis of randomized clinical trials on the role of mechanical bowel preparation before colorectal surgery. *Ann Surg.* 2009;249(2):203–9.

73. Van't Sant HP, Weidema WF, Hop WC, Lange JF, Contant CM. Evaluation of morbidity and mortality after anastomotic leakage following elective colorectal surgery in patients treated with or without mechanical bowel preparation. *Am J Surg.* 2011;202(3):321–4.

74. Van't Sant HP, Weidema WF, Hop WC, Oostvogel HJ, Contant CM. The influence of mechanical bowel preparation in elective lower colorectal surgery. *Ann Surg.* 2010;251(1):59–63.

75. Guenaga KF, Matos D, Wille-Jorgensen P. Mechanical bowel preparation for elective colorectal surgery. *Cochrane Database Syst Rev.* 2011;9, CD001544.

76. Jung B, Pahlman L, Nystrom PO, Nilsson E, Mechanical Bowel Preparation Study Group. Multicentre randomized clinical trial of mechanical bowel preparation in elective colonic resection. *Br J Surg.* 2007;94(6):689–95.

77. Collin A, Jung B, Nilsson E, Pahlman L, Folkesson J. Impact of mechanical bowel preparation on survival after colonic cancer resection. *Br J Surg.* 2014;101(12):1594–600.

78. Van't Sant HP, Kamman A, Hop WC, van der Heijden M, Lange JF, Contant CM. The influence of mechanical bowel preparation on long-term survival in patients surgically treated for colorectal cancer. *Am J Surg.* 2015;210(1):106–10.

79. Morris MS, Graham LA, Chu DI, Cannon JA, Hawn MT. Oral antibiotic bowel preparation significantly reduces surgical site infection rates and readmission rates in elective colorectal surgery. *Ann Surg.* 2015;261(6):1034–40.

80. Nelson RL, Gladman E, Barbateskovic M. Antimicrobial prophylaxis for colorectal surgery. *Cochrane Database Syst Rev.* 2014;5, CD001181.

81. Nelson RL, Glenny AM, Song F. Antimicrobial prophylaxis for colorectal surgery. *Cochrane Database Syst Rev.* 2009;1, CD001181.

82. Roos D, Dijkman LM, Tijssen JG, Gouma DJ, Gerhards MF, Oudemans-van Straaten HM. Systematic review of perioperative selective decontamination of the digestive tract in elective gastrointestinal surgery. *Br J Surg.* 2013;100(12):1579–88.

83. Song F, Glenny AM. Antimicrobial prophylaxis in colorectal surgery: a systematic review of randomized controlled trials. *Br J Surg.* 1998;85(9):1232–41.

84. Bakker N, Cakir H, Doodeman HJ, Houdijk AP. Eight years of experience with Enhanced Recovery After Surgery in patients with colon cancer: impact of measures to improve adherence. *Surgery.* 2015;157(6):1130–6.



85. Senagore AJ, Brannigan A, Kiran RP, Brady K, Delaney CP. Diagnosis-related group assignment in laparoscopic and open colectomy: financial implications for payer and provider. *Dis Colon Rectum*. 2005;48(5):1016–20.
86. Delaney CP, Fazio VW, Senagore AJ, Robinson B, Halverson AL, Remzi FH. ‘Fast track’ postoperative management protocol for patients with high co-morbidity undergoing complex abdominal and pelvic colorectal surgery. *Br J Surg*. 2001;88(11):1533–8.
87. Tekkis PP, Senagore AJ, Delaney CP. Conversion rates in laparoscopic colorectal surgery: a predictive model with 1253 patients. *Surg Endosc*. 2005;19(1):47–54.
88. Bleier JI, Aarons CB. Perioperative fluid restriction. *Clin Colon Rectal Surg*. 2013;26(3):197–202.
89. Abraham-Nordling M, Hjern F, Pollack J, Prytz M, Borg T, Kressner U. Randomized clinical trial of fluid restriction in colorectal surgery. *Br J Surg*. 2012;99(2):186–91.
90. Boersema GS, van der Laan L, Wijsman JH. A close look at postoperative fluid management and electrolyte disorders after gastrointestinal surgery in a teaching hospital where patients are treated according to the ERAS protocol. *Surg Today*. 2014;44(11):2052–7.
91. Boland MR, Noorani A, Varty K, Coffey JC, Agha R, Walsh SR. Perioperative fluid restriction in major abdominal surgery: systematic review and meta-analysis of randomized, clinical trials. *World J Surg*. 2013;37(6):1193–202.
92. MacKay G. Randomized clinical trial of the effect of postoperative intravenous fluid restriction on recovery after elective colorectal surgery (Br J Surg 2006;93:1469–1474). *Br J Surg*. 2007;94(3):383.
93. MacKay G, Ihedioha U, McConnachie A, Serpell M, Molloy RG, Fearon KC, et al. Intravenous fluid and sodium restriction has no effect on recovery from colorectal surgery: an observer blinded randomized clinical trial. *Br J Surg*. 2006;93(7):901–2.
94. Miller TE, Roche AM, Mythen M. Fluid management and goal-directed therapy as an adjunct to Enhanced Recovery After Surgery (ERAS). *Can J Anaesth*. 2015;62(2):158–68.
95. Morera FJ. Randomized clinical trial of the effect of postoperative intravenous fluid restriction on recovery after elective colorectal surgery (Br J Surg 2006;93:1469–1474). *Br J Surg*. 2007;94(3):382–3.
96. Phan TD, An V, D’Souza B, Rattray MJ, Johnston MJ, Cowie BS. A randomised controlled trial of fluid restriction compared to oesophageal Doppler-guided goal-directed fluid therapy in elective major colorectal surgery within an Enhanced Recovery After Surgery program. *Anaesth Intensive Care*. 2014;42(6):752–60.
97. Tornero-Campello G. Randomized clinical trial of the effect of postoperative intravenous fluid restriction on recovery after elective colorectal surgery (Br J Surg 2006;93:1469–1474). *Br J Surg*. 2007;94(3):382.
98. Senagore AJ, Emery T, Luchtefeld M, Kim D, Dujovny N, Hoedema R. Fluid management for laparoscopic colectomy: a prospective, randomized assessment of goal-directed administration of balanced salt solution or hetastarch coupled with an enhanced recovery program. *Dis Colon Rectum*. 2009;52(12):1935–40.
99. American Society of Anesthesiologists Task Force on Acute Pain Management. Practice guidelines for acute pain management in the perioperative setting: an updated report by the American Society of Anesthesiologists Task Force on Acute Pain Management. *Anesthesiology*. 2012;116(2):248–73.

100. Garimella V, Cellini C. Postoperative pain control. *Clin Colon Rectal Surg.* 2013;26(3):191–6.
101. Ong CK, Lirk P, Seymour RA, Jenkins BJ. The efficacy of preemptive analgesia for acute postoperative pain management: a meta-analysis. *Anesth Analg.* 2005;100(3):757–73. table of contents.
102. Parikh HG, Dash SK, Upasani CB. Study of the effect of oral gabapentin used as preemptive analgesia to attenuate post-operative pain in patients undergoing abdominal surgery under general anesthesia. *Saudi J Anaesth.* 2010;4(3):137–41.
103. Siddiqui NT, Fischer H, Guerina L, Friedman Z. Effect of a preoperative gabapentin on postoperative analgesia in patients with inflammatory bowel disease following major bowel surgery: a randomized, placebo-controlled trial. *Pain Pract.* 2014;14(2):132–9.
104. Tirault M, Foucan L, Debaene B, Frasca D, Lebrun T, Bernard JC, et al. Gabapentin premedication: assessment of preoperative anxiolysis and postoperative patient satisfaction. *Acta Anaesthesiol Belg.* 2010;61(4):203–9.
105. Adachi YU, Nishino J, Suzuki K, Obata Y, Doi M, Sato S. Preemptive analgesia by preoperative administration of nonsteroidal anti-inflammatory drugs. *J Anesth.* 2007;21(2):294.
106. Mezei M, Hahn O, Penzes I. Preemptive analgesia—preoperative diclofenac sodium for postoperative analgesia in general surgery. *Magy Seb.* 2002;55(5):313–7.
107. Favuzza J, Brady K, Delaney CP. Transversus abdominis plane blocks and enhanced recovery pathways: making the 23-h hospital stay a realistic goal after laparoscopic colorectal surgery. *Surg Endosc.* 2013;27(7):2481–6.
108. Keller DS, Ermlich BO, Delaney CP. Demonstrating the benefits of transversus abdominis plane blocks on patient outcomes in laparoscopic colorectal surgery: review of 200 consecutive cases. *J Am Coll Surg.* 2014;219(6):1143–8.
109. Keller DS, Ermlich BO, Schiltz N, Champagne BJ, Reynolds Jr HL, Stein SL, et al. The effect of transversus abdominis plane blocks on postoperative pain in laparoscopic colorectal surgery: a prospective, randomized, double-blind trial. *Dis Colon Rectum.* 2014;57(11):1290–7.
110. Hubner M, Blanc C, Roulin D, Winiker M, Gander S, Demartines N. Randomized clinical trial on epidural versus patient-controlled analgesia for laparoscopic colorectal surgery within an enhanced recovery pathway. *Ann Surg.* 2015;261(4):648–53.
111. Hubner M, Schafer M, Demartines N, Muller S, Maurer K, Baulig W, et al. Impact of restrictive intravenous fluid replacement and combined epidural analgesia on perioperative volume balance and renal function within a Fast Track program. *J Surg Res.* 2012;173(1):68–74.
112. Kaminski JP, Pai A, Ailabouni L, Park JJ, Marecik SJ, Prasad LM, et al. Role of epidural and patient-controlled analgesia in site-specific laparoscopic colorectal surgery. *JSLS.* 2014;18(4).
113. Khan SA, Khokhar HA, Nasr AR, Carton E, El-Masry S. Effect of epidural analgesia on bowel function in laparoscopic colorectal surgery: a systematic review and meta-analysis. *Surg Endosc.* 2013;27(7):2581–91.
114. Marret E, Remy C, Bonnet F, Postoperative Pain Forum Group. Meta-analysis of epidural analgesia versus parenteral opioid analgesia after colorectal surgery. *Br J Surg.* 2007;94(6):665–73.
115. Zingg U, Miskovic D, Hamel CT, Erni L, Oertli D, Metzger U. Influence of thoracic epidural analgesia on postoperative pain relief and ileus after laparoscopic colorectal resection: benefit with epidural analgesia. *Surg Endosc.* 2009;23(2):276–82.
116. Levy BF, Scott MJ, Fawcett W, Fry C, Rockall TA. Randomized clinical trial of epidural, spinal or patient-controlled analgesia for patients undergoing laparoscopic colorectal surgery. *Br J Surg.*

2011;98(8):1068–78.

117. Douketis JD. Perioperative management of antithrombotic therapy: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians evidence-based clinical practice guidelines. *Chest*. 2012;141, e326S. Erratum in *Chest*. 2012;141(4):1129.

118. Rasmussen MS, Jorgensen LN, Wille-Jorgensen P. Prolonged thromboprophylaxis with low molecular weight heparin for abdominal or pelvic surgery. *Cochrane Database Syst Rev*. 2009;1, CD004318.

119. Fleming FJ. Operative approach and venous thromboembolism in colorectal surgery: casual or causal association? *Dis Colon Rectum*. 2011;54(12):1463–4.

120. Fleming FJ, Kim MJ, Salloum RM, Young KC, Monson JR. How much do we need to worry about venous thromboembolism after hospital discharge? A study of colorectal surgery patients using the National Surgical Quality Improvement Program database. *Dis Colon Rectum*. 2010;53(10):1355–60.

121. Pai A, Hurtuk MG, Park JJ, Marecik SJ, Prasad LM. A randomized study on 1-week versus 4-week prophylaxis for venous thromboembolism after laparoscopic surgery for colorectal cancer. *Ann Surg*. 2014 Sep 10. [Epub ahead of print].

122. Ng WQ, Neill J. Evidence for early oral feeding of patients after elective open colorectal surgery: a literature review. *J Clin Nurs*. 2006;15(6):696–709.

123. Lewis SJ, Andersen HK, Thomas S. Early enteral nutrition within 24 h of intestinal surgery versus later commencement of feeding: a systematic review and meta-analysis. *J Gastrointest Surg*. 2009;13(3):569–75.

124. Henriksen MG, Hansen HV, Hesselov I. Early oral nutrition after elective colorectal surgery: influence of balanced analgesia and enforced mobilization. *Nutrition*. 2002;18(3):263–7.

125. Henriksen MG, Jensen MB, Hansen HV, Jespersen TW, Hesselov I. Enforced mobilization, early oral feeding, and balanced analgesia improve convalescence after colorectal surgery. *Nutrition*. 2002;18(2):147–52.

126. Zhuang CL, Ye XZ, Zhang CJ, Dong QT, Chen BC, Yu Z. Early versus traditional postoperative oral feeding in patients undergoing elective colorectal surgery: a meta-analysis of randomized clinical trials. *Digest Surg*. 2013;30(3):225–32.

127. Asgeirsson T, El-Badawi KI, Mahmood A, Barletta J, Luchtefeld M, Senagore AJ. Postoperative ileus: it costs more than you expect. *J Am Coll Surg*. 2010;210(2):228–31.

128. Barletta JF, Asgeirsson T, Senagore AJ. Influence of intravenous opioid dose on postoperative ileus. *Ann Pharmacother*. 2011;45(7–8):916–23.

129. Barletta JF, Senagore AJ. Reducing the burden of postoperative ileus: evaluating and implementing an evidence-based strategy. *World J Surg*. 2014;38(8):1966–77.

130. Bungard TJ, Kale-Pradhan PB. Prokinetic agents for the treatment of postoperative ileus in adults: a review of the literature. *Pharmacotherapy*. 1999;19(4):416–23.

131. Harms BA, Heise CP. Pharmacologic management of postoperative ileus: the next chapter in GI surgery. *Ann Surg*. 2007;245(3):364–5.

132. Person B, Wexner SD. The management of postoperative ileus. *Curr Probl Surg*. 2006;43(1):6–65.

133. Stewart D, Waxman K. Management of postoperative ileus. *Am J Ther*. 2007;14(6):561–6.

134. Barletta JF, Asgeirsson T, El-Badawi KI, Senagore AJ. Introduction of alvimopan into an enhanced recovery protocol for colectomy offers benefit in open but not laparoscopic colectomy. *J*

Laparoendosc Adv Surg Tech A. 2011;21(10):887–91.

135. Bell TJ, Poston SA, Kraft MD, Senagore AJ, Delaney CP, Techner L. Economic analysis of alvimopan in North American phase III efficacy trials. *Am J Health Syst Pharm*. 2009;66(15):1362–8.

136. Bell TJ, Poston SA, Kraft MD, Senagore AJ, Techner L. Economic analysis of alvimopan—a clarification and commentary. *Pharmacotherapy*. 2013;33(5):e81–2.

137. Delaney CP, Wolff BG, Viscusi ER, Senagore AJ, Fort JG, Du W, et al. Alvimopan, for postoperative ileus following bowel resection: a pooled analysis of phase III studies. *Ann Surg*. 2007;245(3):355–63.

138. Leslie JB. Alvimopan for the management of postoperative ileus. *Ann Pharmacother*. 2005;39(9):1502–10.

139. Ludwig K, Viscusi ER, Wolff BG, Delaney CP, Senagore A, Techner L. Alvimopan for the management of postoperative ileus after bowel resection: characterization of clinical benefit by pooled responder analysis. *World J Surg*. 2010;34(9):2185–90.

140. Senagore AJ, Bauer JJ, Du W, Techner L. Alvimopan accelerates gastrointestinal recovery after bowel resection regardless of age, gender, race, or concomitant medication use. *Surgery*. 2007;142(4):478–86.

141. Simorov A, Thompson J, Oleynikov D. Alvimopan reduces length of stay and costs in patients undergoing segmental colonic resections: results from multicenter national administrative database. *Am J Surg*. 2014;208(6):919–25.

142. Wiriyaosol S, Kongdan Y, Euanorasetr C, Wacharachaisurapol N, Lertsithichai P. Randomized controlled trial of bisacodyl suppository versus placebo for postoperative ileus after elective colectomy for colon cancer. *Asian J Surg*. 2007;30(3):167–72.

143. Zingg U, Miskovic D, Pasternak I, Meyer P, Hamel CT, Metzger U. Effect of bisacodyl on postoperative bowel motility in elective colorectal surgery: a prospective, randomized trial. *Int J Colorectal Dis*. 2008;23(12):1175–83.

144. Keller D, Stein SL. Facilitating return of bowel function after colorectal surgery: alvimopan and gum chewing. *Clin Colon Rectal Surg*. 2013;26(3):186–90.

145. Purkayastha S, Tilney HS, Darzi AW, Tekkis PP. Meta-analysis of randomized studies evaluating chewing gum to enhance postoperative recovery following colectomy. *Arch Surg*. 2008;143(8):788–93.

146. Hocevar BJ, Robinson B, Gray M. Does chewing gum shorten the duration of postoperative ileus in patients undergoing abdominal surgery and creation of a stoma? *J Wound Ostomy Continence Nurs*. 2010;37(2):140–6.

147. Chan MK, Law WL. Use of chewing gum in reducing postoperative ileus after elective colorectal resection: a systematic review. *Dis Colon Rectum*. 2007;50(12):2149–57.

148. Nelson RL. A systematic review of prophylactic nasogastric suction after abdominal surgery. *Dis Colon Rectum*. 2004;47(4):640.

149. Nelson R, Tse B, Edwards S. Systematic review of prophylactic nasogastric decompression after abdominal operations. *Br J Surg*. 2005;92(6):673–80.

150. Rao W, Zhang X, Zhang J, Yan R, Hu Z, Wang Q. The role of nasogastric tube in decompression after elective colon and rectum surgery: a meta-analysis. *Int J Colorectal Dis*. 2011;26(4):423–9.

151. O'Brien DP, Senagore A, Merlino J, Brady K, Delaney C. Predictors and outcome of readmission after laparoscopic intestinal surgery. *World J Surg*. 2007;31(12):2430–5.

152. Keller DS, Chien HL, Hashemi L, Senagore AJ, Delaney CP. The HARM score: a novel, easy measure to evaluate quality and outcomes in colorectal surgery. *Ann Surg.* 2014;259(6):1119–25.
153. Wind J, Polle SW, Fung Kon Jin PH, Dejong CH, von Meyenfeldt MF, Ubbink DT, Gouma DJ, Bemelman WA, Laparoscopy and/or Fast Track Multimodal Management Versus Standard Care (LAFA) Study Group; Enhanced Recovery after Surgery (ERAS) Group. Systematic review of enhanced recovery programmes in colonic surgery. *Br J Surg.* 2006;93(7):800–9.
154. Vlug MS, Wind J, van der Zaag E, Ubbink DT, Cense HA, Bemelman WA. Systematic review of laparoscopic vs open colonic surgery within an enhanced recovery programme. *Colorectal Dis.* 2009;11(4):335–43.
155. Bradshaw BG, Liu SS, Thirlby RC. Standardized perioperative care protocols and reduced length of stay after colon surgery. *J Am Coll Surg.* 1998;186(5):501–6.
156. Raue W, Haase O, Junghans T, et al. ‘Fast-track’ multimodal rehabilitation program improves outcome after laparoscopic sigmoidectomy: a controlled prospective evaluation. *Surg Endosc.* 2004;18(10):1463–8.
157. Basse L, Raskov HH, Hjort Jakobsen D, Sonne E, Billesbolle P, Hendel HW, et al. Accelerated postoperative recovery programme after colonic resection improves physical performance, pulmonary function and body composition. *Br J Surg.* 2002;89:446–53.
158. Anderson AD, McNaught CE, MacFie J, Tring I, Barker P, Mitchell CJ. Randomized clinical trial of multimodal optimization and standard perioperative surgical care. *Br J Surg.* 2003;90:1497–504.
159. Gatt M, Anderson AD, Reddy BS, Hayward-Sampson P, Tring IC, MacFie J. Randomized clinical trial of multimodal optimization of surgical care in patients undergoing major colonic resection. *Br J Surg.* 2005;92:1354–62.
160. Serclová Z, Dytrych P, Marvan J, Nová K, Hankeová Z, Ryska O, Slégrová Z, Buresová L, Trávníčková L, Antos F. Fast-track in open intestinal surgery: prospective randomized study (Clinical Trials Gov Identifier no. NCT00123456). *Clin Nutr.* 2009;28(6):618–24.
161. Muller S, Zalunardo MP, et al. A fast-track program reduces complications and length of hospital stay after open colonic surgery. *Gastroenterology.* 2009;136:842–7.

## 第 8 章

1. Dahlke AR, Merkow RP, Chung JW, et al. Comparison of postoperative complication risk prediction approaches based on factors known preoperatively to surgeons versus patients. *Surgery.* 2014;156(1):39–45.
2. Sherman SK, Hrabe JE, Charlton ME, Cromwell JW, Byrn JC. Development of an improved risk calculator for complications in proctectomy. *J Gastrointest Surg.* 2014;18(5):986–94.
3. Fischer JP, Wes AM, Tuggle CT, Serletti JM, Wu LC. Risk analysis and stratification of surgical morbidity after immediate breast reconstruction. *J Am Coll Surg.* 2013;217(5):780–7.
4. Nelson MT, Greenblatt DY, Soma G, Rajimanickam V, Greenberg CC, Kent KC. Preoperative factors predict mortality after major lower-extremity amputation. *Surgery.* 2012;152(4):685–94. discussion 694–6.
5. Greenblatt DY, Kelly KJ, Rajamanickam V, et al. Preoperative factors predict perioperative morbidity and mortality after pancreaticoduodenectomy. *Ann Surg Oncol.* 2011;18(8):2126–35.

6. Davenport DL, Henderson WG, Khuri SF, Mentzer Jr RM. Preoperative risk factors and surgical complexity are more predictive of costs than postoperative complications: a case study using the National Surgical Quality Improvement Program (NSQIP) database. *Ann Surg.* 2005;242(4):463–8. discussion 468–71.
7. New ACS NSQIP Surgical Risk Calculator offers personalized estimates of surgical complications. *Bull Am Coll Surg.* 2013;98(10):72–3.
8. Bilimoria KY, Liu Y, Paruch JL, et al. Development and evaluation of the universal ACS NSQIP surgical risk calculator: a decision aid and informed consent tool for patients and surgeons. *J Am Coll Surg.* 2013;217(5):833–42 e831–33.
9. Schwarze ML, Brasel KJ, Mosenthal AC. Beyond 30-day mortality: aligning surgical quality with outcomes that patients value. *JAMA Surg.* 2014;149(7):631–2.
10. Paruch JL, Ko CY, Bilimoria KY. An opportunity to improve informed consent and shared decision making: the role of the ACS NSQIP Surgical Risk Calculator in oncology. *Ann Surg Oncol.* 2014;21(1):5–7.
11. Cologne KG, Keller DS, Liwanag L, Devaraj B, Senagore AJ. Use of the American College of Surgeons NSQIP Surgical Risk Calculator for laparoscopic colectomy: how good is it and how can we improve it? *J Am Coll Surg.* 2015;220(3):281–6.
12. Ehlenbach CC, Tevis SE, Kennedy GD, Oltmann SC. Preoperative impairment is associated with a higher postdischarge level of care. *J Surg Res.* 2015;193(1):1–6.
13. Robinson TN, Wu DS, Pointer LF, Dunn CL, Moss M. Preoperative cognitive dysfunction is related to adverse postoperative outcomes in the elderly. *J Am Coll Surg.* 2012;215(1):12–7. discussion 17–8.
14. Bouillon K, Kivimaki M, Hamer M, et al. Measures of frailty in population-based studies: an overview. *BMC Geriatr.* 2013;13:64.
15. Fried LP, Tangen CM, Walston J, et al. Frailty in older adults: evidence for a phenotype. *J Gerontol A Biol Sci Med Sci.* 2001;56(3):M146–56.
16. Robinson TN, Wallace JI, Wu DS, et al. Accumulated frailty characteristics predict postoperative discharge institutionalization in the geriatric patient. *J Am Coll Surg.* 2011;213(1):37–42. discussion 42–4.
17. Robinson TN, Wu DS, Pointer L, Dunn CL, Cleveland Jr JC, Moss M. Simple frailty score predicts postoperative complications across surgical specialties. *Am J Surg.* 2013;206(4):544–50.
18. Chow WB, Rosenthal RA, Merkow RP, Ko CY, Esnaola NF. Optimal preoperative assessment of the geriatric surgical patient: a best practices guideline from the American College of Surgeons National Surgical Quality Improvement Program and the American Geriatrics Society. *J Am Coll Surg.* 2012;215(4):453–66.
19. Mavros MN, Athanasiou S, Gkegkes ID, Polyzos KA, Peppas G, Falagas ME. Do psychological variables affect early surgical recovery? *PLoS One.* 2011;6(5):e20306.
20. Okkonen E, Vanhanen H. Family support, living alone, and subjective health of a patient in connection with a coronary artery bypass surgery. *Heart Lung.* 2006;35(4):234–44.
21. Kulik JA, Mahler HI. Social support and recovery from surgery. *Health Psychol.* 1989;8(2):221–38.
22. Mitchinson AR, Kim HM, Geisser M, Rosenberg JM, Hinshaw DB. Social connectedness and patient recovery after major operations. *J Am Coll Surg.* 2008;206(2):292–300.
23. Ferry M, Sidobre B, Lambertin A, Barberger-Gateau P. The SOLINUT study: analysis of the

interaction between nutrition and loneliness in persons aged over 70 years. *J Nutr Health Aging*. 2005;9(4):261–8.

24. Jacobs M, Verdeja JC, Goldstein HS. Minimally invasive colon resection (laparoscopic colectomy). *Surg Laparosc Endosc*. 1991;1(3):144–50.

25. Wexner SD, Cohen SM, Johansen OB, Nogueras JJ, Jagelman DG. Laparoscopic colorectal surgery: a prospective assessment and current perspective. *Br J Surg*. 1993;80(12):1602–5.

26. Wexner SD, Johansen OB, Nogueras JJ, Jagelman DG. Laparoscopic total abdominal colectomy. A prospective trial. *Dis Colon Rectum*. 1992;35(7):651–5.

27. Beck DE, Opelka FG, Bailey HR, Rauh SM, Pashos CL. Incidence of small-bowel obstruction and adhesiolysis after open colorectal and general surgery. *Dis Colon Rectum*. 1999;42(2):241–8.

28. Ten Broek RP, Issa Y, van Santbrink EJ, et al. Burden of adhesions in abdominal and pelvic surgery: systematic review and met-analysis. *BMJ*. 2013;347:f5588.

29. Duepre HJ, Senagore AJ, Delaney CP, Fazio VW. Does means of access affect the incidence of small bowel obstruction and ventral hernia after bowel resection? Laparoscopy versus laparotomy. *J Am Coll Surg*. 2003;197(2):177–81.

30. Dolejs S, Kennedy G, Heise CP. Small bowel obstruction following restorative proctocolectomy: affected by a laparoscopic approach? *J Surg Res*. 2011;170(2):202–8.

31. Clinical Outcomes of Surgical Therapy Study Group. A comparison of laparoscopically assisted and open colectomy for colon cancer. *N Engl J Med*. 2004;350(20):2050–9.

32. Guillo PJ, Quirke P, Thorpe H, et al. Short-term endpoints of conventional versus laparoscopic-assisted surgery in patients with colorectal cancer (MRC CLASICC trial): multicentre, randomised controlled trial. *Lancet*. 2005;365(9472):1718–26.

33. Yang W, Zilov A, Soewondo P, Bech OM, Sekkal F, Home PD. Observational studies: going beyond the boundaries of randomized controlled trials. *Diabetes Res Clin Pract*. 2010;88 Suppl 1:S3–9.

34. Kennedy GD, Heise C, Rajamanickam V, Harms B, Foley EF. Laparoscopy decreases postoperative complication rates after abdominal colectomy: results from the national surgical quality improvement program. *Ann Surg*. 2009;249(4):596–601.

35. Bilimoria KY, Bentrem DJ, Merkow RP, et al. Laparoscopic-assisted vs. open colectomy for cancer: comparison of short-term outcomes from 121 hospitals. *J Gastrointest Surg*. 2008;12(11):2001–9.

36. Bilimoria KY, Bentrem DJ, Nelson H, et al. Use and outcomes of laparoscopic-assisted colectomy for cancer in the United States. *Arch Surg*. 2008;143(9):832–9. discussion 839–40.

37. Wilson MZ, Hollenbeak CS, Stewart DB. Laparoscopic colectomy is associated with a lower incidence of postoperative complications than open colectomy: a propensity score-matched cohort analysis. *Colorectal Dis*. 2014;16(5):382–9.

38. Speicher PJ, Englum BR, Jiang B, Pietrobon R, Mantyh CR, Migaly J. The impact of laparoscopic versus open approach on reoperation rate after segmental colectomy: a propensity analysis. *J Gastrointest Surg*. 2014;18(2):378–84.

39. Causey MW, Stoddard D, Johnson EK, et al. Laparoscopy impacts outcomes favorably following colectomy for ulcerative colitis: a critical analysis of the ACS-NSQIP database. *Surg Endosc*. 2013;27(2):603–9.

40. Aimaq R, Akopian G, Kaufman HS. Surgical site infection rates in laparoscopic versus open colorectal surgery. *Am Surg*. 2011;77(10):1290–4.

41. Stefanou AJ, Reickert CA, Velanovich V, Falvo A, Rubinfeld I. Laparoscopic colectomy significantly decreases length of stay compared with open operation. *Surg Endosc.* 2012;26(1):144–8.
42. Kiran RP, El-Gazzaz GH, Vogel JD, Remzi FH. Laparoscopic approach significantly reduces surgical site infections after colorectal surgery: data from national surgical quality improvement program. *J Am Coll Surg.* 2010;211(2):232–8.
43. Silber JH, Williams SV, Krakauer H, Schwartz JS. Hospital and patient characteristics associated with death after surgery. A study of adverse occurrence and failure to rescue. *Med Care.* 1992;30(7):615–29.
44. Ghaferi AA, Osborne NH, Birkmeyer JD, Dimick JB. Hospital characteristics associated with failure to rescue from complications after pancreatectomy. *J Am Coll Surg.* 2010;211(3):325–30.
45. Ghaferi AA, Birkmeyer JD, Dimick JB. Complications, failure to rescue, and mortality with major inpatient surgery in medicare patients. *Ann Surg.* 2009;250(6):1029–34.
46. Ghaferi AA, Birkmeyer JD, Dimick JB. Variation in hospital mortality associated with inpatient surgery. *N Engl J Med.* 2009;361(14):1368–75.
47. AHRQ Patient Safety Indicators, Technical Specifications, PSI#15 Accidental Puncture or Laceration. Provider-Level Indicator. Version 4.1. 2009: 1–2. Available at: <http://www.qualityindicators.ahrq.gov/Downloads/Modules/PSI/V41/TechSpecs/PSI%2015%20Accidental%20Puncture%20or%20Laceration.pdf>
48. Kaafarani HM, Borzecki AM, Itani KM, et al. Validity of selected Patient Safety Indicators: opportunities and concerns. *J Am Coll Surg.* 2011;212(6):924–34.
49. Kin C, Snyder K, Kiran RP, Remzi FH, Vogel JD. Accidental puncture or laceration in colorectal surgery: a quality indicator or a complexity measure? *Dis Colon Rectum.* 2013;56(2):219–25.
50. Gu J, Stocchi L, Remzi F, Kiran RP. Factors associated with postoperative morbidity, reoperation and readmission rates after laparoscopic total abdominal colectomy for ulcerative colitis. *Colorectal Dis.* 2013;15(9):1123–9.
51. Sun RC, Button AM, Smith BJ, Leblond RF, Howe JR, Mezhir JJ. A comprehensive assessment of transfusion in elective pancreatectomy: risk factors and complications. *J Gastrointest Surg.* 2013;17(4):627–35.
52. Greenblatt DY, Rajamanickam V, Mell MW. Predictors of surgical site infection after open lower extremity revascularization. *J Vasc Surg.* 2011;54(2):433–9.
53. Greenblatt DY, Rajamanickam V, Pugely AJ, Heise CP, Foley EF, Kennedy GD. Short-term outcomes after laparoscopic-assisted proctectomy for rectal cancer: results from the ACS NSQIP. *J Am Coll Surg.* 2011;212(5):844–54.
54. Halabi WJ, Jafari MD, Nguyen VQ, et al. Blood transfusions in colorectal cancer surgery: incidence, outcomes, and predictive factors: an American College of Surgeons National Surgical Quality Improvement Program analysis. *Am J Surg.* 2013;206(6):1024–32. discussion 1032–3.
55. Meraney AM, Samee AA, Gill IS. Vascular and bowel complications during retroperitoneal laparoscopic surgery. *J Urol.* 2002;168(5):1941–4.
56. Bhoyrul S, Vierra MA, Nezhat CR, Krummel TM, Way LW. Trocar injuries in laparoscopic surgery. *J Am Coll Surg.* 2001;192(6):677–83.
57. Larobina M, Nottle P. Complete evidence regarding major vascular injuries during laparoscopic access. *Surg Laparosc Endosc Percutan Tech.* 2005;15(3):119–23.
58. Tou S, Malik AI, Wexner SD, Nelson RL. Energy source instruments for laparoscopic colectomy.



Cochrane Database Syst Rev. 2011;5, CD007886.

59. Adamina M, Champagne BJ, Hoffman L, Ermlich MB, Delaney CP. Randomized clinical trial comparing the cost and effectiveness of bipolar vessel sealers versus clips and vascular staplers for laparoscopic colorectal resection. *Br J Surg*. 2011;98(12):1703–12.
60. Marcello PW, Roberts PL, Rusin LC, Holubkov R, Schoetz DJ. Vascular pedicle ligation techniques during laparoscopic colectomy. A prospective randomized trial. *Surg Endosc*. 2006;20(2):263–9.
61. Halabi WJ, Jafari MD, Nguyen VQ, et al. Ureteral injuries in colorectal surgery: an analysis of trends, outcomes, and risk factors over a 10-year period in the United States. *Dis Colon Rectum*. 2014;57(2):179–86.
62. Palaniappa NC, Telem DA, Ranasinghe NE, Divino CM. Incidence of iatrogenic ureteral injury after laparoscopic colectomy. *Arch Surg*. 2012;147(3):267–71.
63. Larach SW, Patankar SK, Ferrara A, Williamson PR, Perozo SE, Lord AS. Complications of laparoscopic colorectal surgery. Analysis and comparison of early vs. latter experience. *Dis Colon Rectum*. 1997;40(5):592–6.
64. Delacroix SE, Winters JC. Urinary tract injuries: recognition and management. *Clin Colon Rectal Surg*. 2010;23(2):104–12.
65. Speicher PJ, Goldsmith ZG, Nussbaum DP, Turley RS, Peterson AC, Mantyh CR. Ureteral stenting in laparoscopic colorectal surgery. *J Surg Res*. 2014;190(1):98–103.
66. Delacroix SE, Winters JC. Bladder reconstruction and diversion during colorectal surgery. *Clin Colon Rectal Surg*. 2010;23(2):113–8.
67. Kashefi C, Messer K, Barden R, Sexton C, Parsons JK. Incidence and prevention of iatrogenic urethral injuries. *J Urol*. 2008;179(6):2254–7. discussion 2257–8.
68. Rivera R, Barboglio PG, Hellinger M, Gousse AE. Staging rectourinary fistulas to guide surgical treatment. *J Urol*. 2007;177(2):586–8.
69. Spahn M, Vergho D, Riedmiller H. Iatrogenic recto-urethral fistula: perineal repair and buccal mucosa interposition. *BJU Int*. 2009;103(2):242–6.
70. Fengler SA, Abcarian H. The York Mason approach to repair of iatrogenic rectourinary fistulae. *Am J Surg*. 1997;173(3):213–7.
71. Dreznik Z, Alper D, Vishne TH, Ramadan E. Rectal flap advancement—a simple and effective approach for the treatment of rectourethral fistula. *Colorectal Dis*. 2003;5(1):53–5.
72. Visser BC, McAninch JW, Welton ML. Rectourethral fistulae: the perineal approach. *J Am Coll Surg*. 2002;195(1):138–43.
73. Culkin DJ, Ramsey CE. Urethrorectal fistula: transanal, transsphincteric approach with locally based pedicle interposition flaps. *J Urol*. 2003;169(6):2181–3.
74. Bruce RG, El-Galley RE, Galloway NT. Use of rectus abdominis muscle flap for the treatment of complex and refractory urethrovaginal fistulas. *J Urol*. 2000;163(4):1212–5.
75. Wexner SD, Ruiz DE, Genua J, Noguera JJ, Weiss EG, Zmora O. Gracilis muscle interposition for the treatment of rectourethral, rectovaginal, and pouch-vaginal fistulas: results in 53 patients. *Ann Surg*. 2008;248(1):39–43.
76. Remzi FH, El Gazzaz G, Kiran RP, Kirat HT, Fazio VW. Outcomes following Turnbull-Cutait abdominoperineal pull-through compared with coloanal anastomosis. *Br J Surg*. 2009;96(4):424–9.
77. Lobo DN, Bostock KA, Neal KR, Perkins AC, Rowlands BJ, Allison SP. Effect of salt and water balance on recovery of gastrointestinal function after elective colonic resection: a randomised

- controlled trial. *Lancet*. 2002;359(9320):1812–8.
78. Muller S, Zalunardo MP, Hubner M, Clavien PA, Demartines N. A fast-track program reduces complications and length of hospital stay after open colonic surgery. *Gastroenterology*. 2009;136(3):842–7.
79. Adamina M, Senagore AJ, Delaney CP, Kehlet H. A systematic review of economic evaluations of enhanced recovery pathways for colorectal surgery. *Ann Surg*. 2015;261(5):e138.
80. Adamina M, Kehlet H, Tomlinson GA, Senagore AJ, Delaney CP. Enhanced recovery pathways optimize health outcomes and resource utilization: a meta-analysis of randomized controlled trials in colorectal surgery. *Surgery*. 2011;149(6):830–40.
81. Senagore AJ, Emery T, Luchtefeld M, Kim D, Dujovny N, Hoedema R. Fluid management for laparoscopic colectomy: a prospective, randomized assessment of goal-directed administration of balanced salt solution or hetastarch coupled with an enhanced recovery program. *Dis Colon Rectum*. 2009;52(12):1935–40.
82. Allen SJ. Fluid therapy and outcome: balance is best. *J Extra Corpor Technol*. 2014;46(1):28–32.
83. MacKay G, Fearon K, McConnachie A, Serpell MG, Molloy RG, O'Dwyer PJ. Randomized clinical trial of the effect of postoperative intravenous fluid restriction on recovery after elective colorectal surgery. *Br J Surg*. 2006;93(12):1469–74.
84. Dumville JC, Gray TA, Walter CJ, Sharp CA, Page T. Dressings for the prevention of surgical site infection. *Cochrane Database Syst Rev*. 2014;9, CD003091.
85. Horch RE. Incisional negative pressure wound therapy for high-risk wounds. *J Wound Care*. 2015;24(Suppl 4b):21–8.
86. Anglim B, O'Connor H, Daly S. Prevena, negative pressure wound therapy applied to closed Pfannenstiel incisions at time of caesarean section in patients deemed at high risk for wound infection. *J Obstet Gynaecol*. 2014;10:1–4.
87. Scalise A, Tartaglione C, Bolletta E, et al. The enhanced healing of a high-risk, clean, sutured surgical incision by prophylactic negative pressure wound therapy as delivered by Prevena Customizable: cosmetic and therapeutic results. *Int Wound J*. 2015;12(2):218–23.
88. Towfigh S, Clarke T, Yacoub W, et al. Significant reduction of wound infections with daily probing of contaminated wounds: a prospective randomized clinical trial. *Arch Surg*. 2011;146(4):448–52.
89. Leaper DJ, Tanner J, Kiernan M, Assadian O, Edmiston Jr CE. Surgical site infection: poor compliance with guidelines and care bundles. *Int Wound J*. 2015;12(3):357–62.
90. Van der Slegt J, van der Laan L, Veen EJ, Hendriks Y, Romme J, Kluytmans J. Implementation of a bundle of care to reduce surgical site infections in patients undergoing vascular surgery. *PLoS One*. 2013;8(8):e71566.
91. Johnson B, Starks I, Bancroft G, Roberts PJ. The effect of care bundle development on surgical site infection after hemiarthroplasty: an 8-year review. *J Trauma Acute Care Surg*. 2012;72(5):1375–9.
92. Cima R, Dankbar E, Lovely J, et al. Colorectal surgery surgical site infection reduction program: a national surgical quality improvement program—driven multidisciplinary single-institution experience. *J Am Coll Surg*. 2013;216(1):23–33.
93. Crolla RM, van der Laan L, Veen EJ, Hendriks Y, van Schendel C, Kluytmans J. Reduction of surgical site infections after implementation of a bundle of care. *PLoS One*. 2012;7(9):e44599.

94. Regenbogen SE, Read TE, Roberts PL, Marcello PW, Schoetz DJ, Ricciardi R. Urinary tract infection after colon and rectal resections: more common than predicted by risk-adjustment models. *J Am Coll Surg*. 2011;213(6):784–92.
95. Pronovost PJ, Goeschel CA, Wachter RM. The wisdom and justice of not paying for “preventable complications”. *JAMA*. 2008;299(18):2197–9.
96. Saint S, Meddings JA, Calfee D, Kowalski CP, Krein SL. Catheter-associated urinary tract infection and the Medicare rule changes. *Ann Intern Med*. 2009;150(12):877–84.
97. Centers for Medicare and Medicaid Services (CMS), HHS. Medicare program; hospital inpatient prospective payment systems for acute care hospitals and the long-term care hospital prospective payment system and fiscal year 2015 rates; quality reporting requirements for specific providers; reasonable compensation equivalents for physician services in excluded hospitals and certain teaching hospitals; provider administrative appeals and judicial review; enforcement provisions for organ transplant centers; and electronic health record (EHR) incentive program. Final rule. *Fed Regist*. 2014;79(163):49853–50536.
98. Purvis S, Gion T, Kennedy G, et al. Catheter-associated urinary tract infection: a successful prevention effort employing a multipronged initiative at an academic medical center. *J Nurs Care Qual*. 2014;29(2):141–8.
99. Lo E, Nicolle LE, Coffin SE, et al. Strategies to prevent catheter-associated urinary tract infections in acute care hospitals: 2014 update. *Infect Control Hosp Epidemiol*. 2014;35(5):464–79.
100. Nicolle LE, Bradley S, Colgan R, Rice JC, Schaeffer A, Hooton TM. Infectious Diseases Society of America guidelines for the diagnosis and treatment of asymptomatic bacteriuria in adults. *Clin Infect Dis*. 2005;40(5):643–54.
101. Tambyah PA, Maki DG. Catheter-associated urinary tract infection is rarely symptomatic: a prospective study of 1,497 catheterized patients. *Arch Intern Med*. 2000;160(5):678–82.
102. Kwaan MR, Lee JT, Rothenberger DA, Melton GB, Madoff RD. Early removal of urinary catheters after rectal surgery is associated with increased urinary retention. *Dis Colon Rectum*. 2015;58(4):401–5.
103. Wu AK, Auerbach AD, Aaronson DS. National incidence and outcomes of postoperative urinary retention in the Surgical Care Improvement Project. *Am J Surg*. 2012;204(2):167–71.
104. Coyle D, Joyce KM, Garvin JT, et al. Early post-operative removal of urethral catheter in patients undergoing colorectal surgery with epidural analgesia—a prospective pilot clinical study. *Int J Surg*. 2015;16(Pt A):94–8.
105. Kennedy GD, Tevis SE, Kent KC. Is there a relationship between patient satisfaction and favorable outcomes? *Ann Surg*. 2014;260(4):592–8. discussion 598–600.
106. Katz J, Jackson M, Kavanagh BP, Sandler AN. Acute pain after thoracic surgery predicts long-term post-thoracotomy pain. *Clin J Pain*. 1996;12(1):50–5.
107. Lynch EP, Lazor MA, Gellis JE, Orav J, Goldman L, Marcantonio ER. The impact of postoperative pain on the development of postoperative delirium. *Anesth Analg*. 1998;86(4):781–5.
108. Benyamin R, Trescot AM, Datta S, et al. Opioid complications and side effects. *Pain Physician*. 2008;11(2 Suppl):S105–20.
109. Werawatganon T, Charuluxanun S. Patient controlled intravenous opioid analgesia versus continuous epidural analgesia for pain after intra-abdominal surgery. *Cochrane Database Syst Rev*. 2005;1, CD004088.
110. Rudin A, Flisberg P, Johansson J, Walther B, Lundberg CJ. Thoracic epidural analgesia or

intravenous morphine analgesia after thoracoabdominal esophagectomy: a prospective follow-up of 201 patients. *J Cardiothorac Vasc Anesth*. 2005;19(3):350–7.

111. Senagore AJ, Delaney CP, Mekhail N, Dugan A, Fazio VW. Randomized clinical trial comparing epidural anaesthesia and patient-controlled analgesia after laparoscopic segmental colectomy. *Br J Surg*. 2003;90(10):1195–9.

112. Morimoto H, Cullen JJ, Messick Jr JM, Kelly KA. Epidural analgesia shortens postoperative ileus after ileal pouch-anal canal anastomosis. *Am J Surg*. 1995;169(1):79–82. discussion 82–3.

113. Scott AM, Starling JR, Ruscher AE, DeLessio ST, Harms BA. Thoracic versus lumbar epidural anesthesia's effect on pain control and ileus resolution after restorative proctocolectomy. *Surgery*. 1996;120(4):688–95. discussion 695–7.

114. Weeks JC, Nelson H, Gelber S, Sargent D, Schroeder G. Short-term quality-of-life outcomes following laparoscopic-assisted colectomy vs open colectomy for colon cancer: a randomized trial. *JAMA*. 2002;287(3):321–8.

115. Liu H, Hu X, Duan X, Wu J. Thoracic epidural analgesia (TEA) vs. patient controlled analgesia (PCA) in laparoscopic colectomy: a meta-analysis. *Hepatogastroenterology*. 2014;61(133):1213–9.

116. Levy BF, Tilney HS, Dowson HM, Rockall TA. A systematic review of postoperative analgesia following laparoscopic colorectal surgery. *Colorectal Dis*. 2010;12(1):5–15.

117. Kuruba R, Fayard N, Snyder D. Epidural analgesia and laparoscopic technique do not reduce incidence of prolonged ileus in elective colon resections. *Am J Surg*. 2012;204(5):613–8.

118. Day A, Smith R, Jourdan I, Fawcett W, Scott M, Rockall T. Retrospective analysis of the effect of postoperative analgesia on survival in patients after laparoscopic resection of colorectal cancer. *Br J Anaesth*. 2012;109(2):185–90.

119. Keller DS, Stulberg JJ, Lawrence JK, Delaney CP. Process control to measure process improvement in colorectal surgery: modifications to an established enhanced recovery pathway. *Dis Colon Rectum*. 2014;57(2):194–200.

120. Favuzza J, Brady K, Delaney CP. Transversus abdominis plane blocks and enhanced recovery pathways: making the 23-h hospital stay a realistic goal after laparoscopic colorectal surgery. *Surg Endosc*. 2013;27(7):2481–6.

121. Kiran RP, Ahmed Ali U, Coffey JC, Vogel JD, Pokala N, Fazio VW. Impact of resident participation in surgical operations on postoperative outcomes: National Surgical Quality Improvement Program. *Ann Surg*. 2012;256(3):469–75.

122. Castleberry AW, Clary BM, Migaly J, et al. Resident education in the era of patient safety: a nationwide analysis of outcomes and complications in resident-assisted oncologic surgery. *Ann Surg Oncol*. 2013;20(12):3715–24.

123. Davis Jr SS, Husain FA, Lin E, Nandipati KC, Perez S, Sweeney JF. Resident participation in index laparoscopic general surgical cases: impact of the learning environment on surgical outcomes. *J Am Coll Surg*. 2013;216(1):96–104.

124. Gorgun E, Benlice C, Corrao E, et al. Outcomes associated with resident involvement in laparoscopic colorectal surgery suggest a need for earlier and more intensive resident training. *Surgery*. 2014;156(4):825–32.

125. Englesbe MJ, Pelletier SJ, Magee JC, et al. Seasonal variation in surgical outcomes as measured by the American College of Surgeons-National Surgical Quality Improvement Program (ACS-NSQIP). *Ann Surg*. 2007;246(3):456–62. discussion 463–5.

126. Gopaldas RR, Overbey DM, Dao TK, Markley JG. The impact of academic calendar cycle on

coronary artery bypass outcomes: a comparison of teaching and non-teaching hospitals. *J Cardiothorac Surg*. 2013;8:191.

127. Birkmeyer JD, Stukel TA, Siewers AE, Goodney PP, Wennberg DE, Lucas FL. Surgeon volume and operative mortality in the United States. *N Engl J Med*. 2003;349(22):2117–27.

128. Birkmeyer JD, Siewers AE, Finlayson EV, et al. Hospital volume and surgical mortality in the United States. *N Engl J Med*. 2002;346(15):1128–37.

129. Sutton JM, Wima K, Wilson GC, et al. Factors associated with 30-day readmission after restorative proctocolectomy with IPAA: a national study. *Dis Colon Rectum*. 2014;57(12):1371–8.

130. Leonard D, Penninckx F, Kartheuser A, Laenen A, Van Eycken E. Effect of hospital volume on quality of care and outcome after rectal cancer surgery. *Br J Surg*. 2014;101(11):1475–82.

131. Osler M, Iversen LH, Borglykke A, et al. Hospital variation in 30-day mortality after colorectal cancer surgery in Denmark: the contribution of hospital volume and patient characteristics. *Ann Surg*. 2011;253(4):733–8.

132. Finks JF, Osborne NH, Birkmeyer JD. Trends in hospital volume and operative mortality for high-risk surgery. *N Engl J Med*. 2011;364(22):2128–37.

133. Drolet S, MacLean AR, Myers RP, Shaheen AA, Dixon E, Buie WD. Elective resection of colon cancer by high-volume surgeons is associated with decreased morbidity and mortality. *J Gastrointest Surg*. 2011;15(4):541–50.

134. Kirchhoff P, Clavien PA, Hahnloser D. Complications in colorectal surgery: risk factors and preventive strategies. *Patient Saf Surg*. 2010;4(1):5.

135. Kuwabara K, Matsuda S, Fushimi K, Ishikawa KB, Horiguchi H, Fujimori K. Impact of hospital case volume on the quality of laparoscopic colectomy in Japan. *J Gastrointest Surg*. 2009;13(9):1619–26.

136. Reames BN, Ghaferi AA, Birkmeyer JD, Dimick JB. Hospital volume and operative mortality in the modern era. *Ann Surg*. 2014;260(2):244–51.

137. Zhan C, Miller MR. Excess length of stay, charges, and mortality attributable to medical injuries during hospitalization. *JAMA*. 2003;290(14):1868–74.

138. Dimick JB, Chen SL, Taheri PA, Henderson WG, Khuri SF, Campbell DA. Hospital costs associated with surgical complications: a report from the private-sector National Surgical Quality Improvement Program. *J Am Coll Surg*. 2004;199(4):531–7.

139. Tang R, Chen HH, Wang YL, et al. Risk factors for surgical site infection after elective resection of the colon and rectum: a single-center prospective study of 2,809 consecutive patients. *Ann Surg*. 2001;234(2):181–9.

140. Anderson DJ, Kirkland KB, Kaye KS, et al. Underresourced hospital infection control and prevention programs: penny wise, pound foolish? *Infect Control Hosp Epidemiol*. 2007;28(7):767–73.

141. Gibson A, Tevis S, Kennedy G. Readmission after delayed diagnosis of surgical site infection: a focus on prevention using the American College of Surgeons National Surgical Quality Improvement Program. *Am J Surg*. 2014;207(6):832–9.

142. Flegal KM, Kit BK, Orpana H, Graubard BI. Association of all-cause mortality with overweight and obesity using standard body mass index categories: a systematic review and meta-analysis. *JAMA*. 2013;309(1):71–82.

143. Amri R, Bordeianou LG, Sylla P, Berger DL. Obesity, outcomes and quality of care: body mass index increases the risk of wound-related complications in colon cancer surgery. *Am J Surg*.

2014;207(1):17–23.

144. Dindo D, Muller MK, Weber M, Clavien PA. Obesity in general elective surgery. *Lancet*. 2003;361(9374):2032–5.

145. Makino T, Shukla PJ, Rubino F, Milsom JW. The impact of obesity on perioperative outcomes after laparoscopic colorectal resection. *Ann Surg*. 2012;255(2):228–36.

146. Hourigan JS. Impact of obesity on surgical site infection in colon and rectal surgery. *Clin Colon Rectal Surg*. 2011;24(4):283–90.

147. Gervaz P, Bandiera-Clerc C, Buchs NC, et al. Scoring system to predict the risk of surgical-site infection after colorectal resection. *Br J Surg*. 2012;99(4):589–95.

148. Merkow RP, Bilimoria KY, McCarter MD, Bentrem DJ. Effect of body mass index on short-term outcomes after colectomy for cancer. *J Am Coll Surg*. 2009;208(1):53–61.

149. Kartheuser AH, Leonard DF, Penninckx F, et al. Waist circumference and waist/hip ratio are better predictive risk factors for mortality and morbidity after colorectal surgery than body mass index and body surface area. *Ann Surg*. 2013;258(5):722–30.

150. Dionigi G, Rovera F, Boni L, et al. The impact of perioperative blood transfusion on clinical outcomes in colorectal surgery. *Surg Oncol*. 2007;16 Suppl 1:S177–82.

151. Benoist S. [Perioperative transfusion in colorectal surgery]. *Ann Chir*. 2005;130(6–7):365–73.

152. Tartter PI. The association of perioperative blood transfusion with colorectal cancer recurrence. *Ann Surg*. 1992;216(6):633–8.

153. Guenaga KF, Matos D, Castro AA, Atallah AN, Wille-Jørgensen P. Mechanical bowel preparation for elective colorectal surgery. *Cochrane Database Syst Rev*. 2005;1, CD001544.

154. Guenaga KK, Matos D, Wille-Jørgensen P. Mechanical bowel preparation for elective colorectal surgery. *Cochrane Database Syst Rev*. 2009;1, CD001544.

155. Slim K, Vicaut E, Launay-Savary MV, Contant C, Chipponi J. Updated systematic review and meta-analysis of randomized clinical trials on the role of mechanical bowel preparation before colorectal surgery. *Ann Surg*. 2009;249(2):203–9.

156. Cannon JA, Altom LK, Deierhoi RJ, et al. Preoperative oral antibiotics reduce surgical site infection following elective colorectal resections. *Dis Colon Rectum*. 2012;55(11):1160–6.

157. Darouiche RO, Wall MJ, Itani KM, et al. Chlorhexidine-alcohol versus povidone-iodine for surgical-site antisepsis. *N Engl J Med*. 2010;362(1):18–26.

158. Swenson BR, Hedrick TL, Metzger R, Bonatti H, Pruett TL, Sawyer RG. Effects of preoperative skin preparation on postoperative wound infection rates: a prospective study of 3 skin preparation protocols. *Infect Control Hosp Epidemiol*. 2009;30(10):964–71.

159. Redick EL. Applying FOCUS-PDCA to solve clinical problems. *Dimens Crit Care Nurs*. 1999;18(6):30–4.

160. Gerard JC, Arnold FL. Performance improvement with a hybrid FOCUS-PDCA methodology. *Jt Comm J Qual Improv*. 1996;22(10):660–72.

161. Plsek PE. Tutorial: quality improvement project models. *Qual Manag Health Care*. 1993;1(2):69–81.

162. Reid K, Pockney P, Draganic B, Smith SR. Barrier wound protection decreases surgical site infection in open elective colorectal surgery: a randomized clinical trial. *Dis Colon Rectum*. 2010;53(10):1374–80.

163. Edwards JP, Ho AL, Tee MC, Dixon E, Ball CG. Wound protectors reduce surgical site infection: a meta-analysis of randomized controlled trials. *Ann Surg*. 2012;256(1):53–9.

164. Murray BW, Huerta S, Dineen S, Anthony T. Surgical site infection in colorectal surgery: a review of the nonpharmacologic tools of prevention. *J Am Coll Surg*. 2010;211(6):812–22.
165. Belda FJ, Aguilera L, García de la Asunción J, et al. Supplemental perioperative oxygen and the risk of surgical wound infection: a randomized controlled trial. *JAMA*. 2005;294(16):2035–42.
166. Greif R, Akça O, Horn EP, Kurz A, Sessler DI, Group OR. Supplemental perioperative oxygen to reduce the incidence of surgical-wound infection. *N Engl J Med*. 2000;342(3):161–7.
167. Pryor KO, Fahey TJ, Lien CA, Goldstein PA. Surgical site infection and the routine use of perioperative hyperoxia in a general surgical population: a randomized controlled trial. *JAMA*. 2004;291(1):79–87.
168. Meyhoff CS, Wetterslev J, Jorgensen LN, et al. Effect of high perioperative oxygen fraction on surgical site infection and pulmonary complications after abdominal surgery: the PROXI randomized clinical trial. *JAMA*. 2009;302(14):1543–50.
169. Kurz A, Sessler DI, Lenhardt R. Perioperative normothermia to reduce the incidence of surgical-wound infection and shorten hospitalization. Study of Wound Infection and Temperature Group. *N Engl J Med*. 1996;334(19):1209–15.
170. Melling AC, Ali B, Scott EM, Leaper DJ. Effects of preoperative warming on the incidence of wound infection after clean surgery: a randomised controlled trial. *Lancet*. 2001;358(9285):876–80.
171. Israelsson LA, Jonsson T, Knutsson A. Suture technique and wound healing in midline laparotomy incisions. *Eur J Surg*. 1996;162(8):605–9.
172. Millbourn D, Cengiz Y, Israelsson LA. Effect of stitch length on wound complications after closure of midline incisions: a randomized controlled trial. *Arch Surg*. 2009;144(11):1056–9.
173. Reid K, Pockney P, Pollitt T, Draganic B, Smith SR. Randomized clinical trial of short-term outcomes following purse-string versus conventional closure of ileostomy wounds. *Br J Surg*. 2010;97(10):1511–7.
174. Sajid MS, Bhatti MI, Miles WF. Systematic review and meta-analysis of published randomized controlled trials comparing purse-string vs conventional linear closure of the wound following ileostomy (stoma) closure. *Gastroenterol Rep (Oxf)*. 2014;3(2):156–61.
175. Waits SA, Fritze D, Banerjee M, et al. Developing an argument for bundled interventions to reduce surgical site infection in colorectal surgery. *Surgery*. 2014;155(4):602–6.
176. Stevens DL, Bisno AL, Chambers HF, et al. Practice guidelines for the diagnosis and management of skin and soft tissue infections: 2014 update by the Infectious Diseases Society of America. *Clin Infect Dis*. 2014;59(2):e10–52.
177. Stevens DL, Bisno AL, Chambers HF, et al. Practice guidelines for the diagnosis and management of skin and soft tissue infections: 2014 update by the infectious diseases society of America. *Clin Infect Dis*. 2014;59(2):147–59.
178. Nichols RL, Florman S. Clinical presentations of soft-tissue infections and surgical site infections. *Clin Infect Dis*. 2001;33 Suppl 2:S84–93.
179. Russ AJ, Obma KL, Rajamanickam V, et al. Laparoscopy improves short-term outcomes after surgery for diverticular disease. *Gastroenterology*. 2010;138(7):2267–274, 2274.e2261.
180. Buchberg B, Masoomi H, Lusby K, et al. Incidence and risk factors of venous thromboembolism in colorectal surgery: does laparoscopy impart an advantage? *Arch Surg*. 2011;146(6):739–43.
181. Anderson Jr FA, Wheeler HB, Goldberg RJ, et al. A population-based perspective of the hospital incidence and case-fatality rates of deep vein thrombosis and pulmonary embolism. The

- Worcester DVT Study. *Arch Intern Med*. 1991;151(5):933–8.
182. Shapiro R, Vogel JD, Kiran RP. Risk of postoperative venous thromboembolism after laparoscopic and open colorectal surgery: an additional benefit of the minimally invasive approach? *Dis Colon Rectum*. 2011;54(12):1496–502.
183. Moghadamyeghaneh Z, Hanna MH, Carmichael JC, Nguyen NT, Stamos MJ. A nationwide analysis of postoperative deep vein thrombosis and pulmonary embolism in colon and rectal surgery. *J Gastrointest Surg*. 2014;18(12):2169–77.
184. Vedovati MC, Becattini C, Rondelli F, et al. A randomized study on 1-week versus 4-week prophylaxis for venous thromboembolism after laparoscopic surgery for colorectal cancer. *Ann Surg*. 2014;259(4):665–9.
185. Kennedy GD, Rajamanickam V, O'Connor ES, et al. Optimizing surgical care of colon cancer in the older adult population. *Ann Surg*. 2011;253(3):508–14.
186. McDonald KM, Romano PS, University of California San Francisco-Stanford Evidence-Based Practice Center, United States. Agency for Healthcare Research and Quality. Measures of patient safety based on hospital administrative data—the patient safety indicators. Rockville, MD: U.S. Dept. of Health and Human Services, Public Health Service, Agency for Healthcare Research and Quality; 2002.
187. Sheetz KH, Waits SA, Krell RW, Campbell Jr DA, Englesbe MJ, Ghaferi AA. Improving mortality following emergent surgery in older patients requires focus on complication rescue. *Ann Surg*. 2013;258(4):614–7. discussion 617–8.
188. Chaudhri S, Maruthachalam K, Kaiser A, Robson W, Pickard RS, Horgan AF. Successful voiding after trial without catheter is not synonymous with recovery of bladder function after colorectal surgery. *Dis Colon Rectum*. 2006;49(7):1066–70.
189. Delacroix SE, Winters JC. Voiding dysfunction after pelvic colorectal surgery. *Clin Colon Rectal Surg*. 2010;23(2):119–27.
190. Waljee A, Waljee J, Morris AM, Higgins PD. Threefold increased risk of infertility: a meta-analysis of infertility after ileal pouch anal anastomosis in ulcerative colitis. *Gut*. 2006;55(11):1575–80.
191. Cornish JA, Tan E, Teare J, et al. The effect of restorative proctocolectomy on sexual function, urinary function, fertility, pregnancy and delivery: a systematic review. *Dis Colon Rectum*. 2007;50(8):1128–38.
192. Nieuwenhuis MH, Douma KF, Bleiker EM, Bemelman WA, Aaronson NK, Vasen HF. Female fertility after colorectal surgery for familial adenomatous polyposis: a nationwide cross-sectional study. *Ann Surg*. 2010;252(2):341–4.
193. Juul T, Ahlberg M, Biondo S, et al. Low anterior resection syndrome and quality of life: an international multicenter study. *Dis Colon Rectum*. 2014;57(5):585–91.
194. How P, Stelzner S, Branagan G, et al. Comparative quality of life in patients following abdominoperineal excision and low anterior resection for low rectal cancer. *Dis Colon Rectum*. 2012;55(4):400–6.
195. Pachler J, Wille-Jørgensen P. Quality of life after rectal resection for cancer, with or without permanent colostomy. *Cochrane Database Syst Rev*. 2012;12, CD004323.
196. Bryant CL, Lunniss PJ, Knowles CH, Thaha MA, Chan CL. Anterior resection syndrome. *Lancet Oncol*. 2012;13(9):e403–8.
197. Emmertsen KJ, Laurberg S. Bowel dysfunction after treatment for rectal cancer. *Acta Oncol*.



2008;47(6):994–1003.

198. Juul T, Ahlberg M, Biondo S, et al. International validation of the low anterior resection syndrome score. *Ann Surg.* 2014;259(4):728–34.

199. Emmertsen KJ, Laurberg S. Low anterior resection syndrome score: development and validation of a symptom-based scoring system for bowel dysfunction after low anterior resection for rectal cancer. *Ann Surg.* 2012;255(5):922–8.

200. Marijnen CA, van de Velde CJ, Putter H, et al. Impact of short-term preoperative radiotherapy on health-related quality of life and sexual functioning in primary rectal cancer: report of a multicenter randomized trial. *J Clin Oncol.* 2005;23(9):1847–58.

201. Stephens RJ, Thompson LC, Quirke P, et al. Impact of short-course preoperative radiotherapy for rectal cancer on patients' quality of life: data from the Medical Research Council CR07/National Cancer Institute of Canada Clinical Trials Group C016 randomized clinical trial. *J Clin Oncol.* 2010;28(27):4233–9.

202. Tevis SE, Kohlnhofer BM, Stringfield S, et al. Postoperative complications in patients with rectal cancer are associated with delays in chemotherapy that lead to worse disease-free and overall survival. *Dis Colon Rectum.* 2013;56(12):1339–48.

203. Hendren S, Birkmeyer JD, Yin H, Banerjee M, Sonnenday C, Morris AM. Surgical complications are associated with omission of chemotherapy for stage III colorectal cancer. *Dis Colon Rectum.* 2010;53(12):1587–93.

## 第 9 章

1. Moran BJ. Stapling instruments for intestinal anastomosis in colorectal surgery. *Br J Surg.* 1996;83(7):902–9.

2. Ceraldi CM, et al. Comparison of continuous single layer polypropylene anastomosis with double layer and stapled anastomoses in elective colon resections. *Am Surg.* 1993;59(3):168–71.

3. Everett WG. A comparison of one layer and two layer techniques for colorectal anastomosis. *Br J Surg.* 1975;62(2):135–40.

4. Fielding LP, et al. Anastomotic integrity after operations for large-bowel cancer: a multicentre study. *Br Med J.* 1980;281(6237):411–4.

5. Reichel K, Rauner P, Guthy E. Clinical and experimental evaluation of single and double layer entero anastomosis. *Chirurg Gastroenterol.* 1975;9:461–7.

6. Slieker JC, et al. Systematic review of the technique of colorectal anastomosis. *JAMA Surg.* 2013;148(2):190–201.

7. Andersen E, Sondenaa K, Holter J. A comparative study of polydioxanone (PDS) and polyglactin 910 (Vicryl) in colonic anastomoses in rats. *Int J Colorectal Dis.* 1989;4(4):251–4.

8. Foresman PA, Edlich RF, Rodeheaver GT. The effect of new monofilament absorbable sutures on the healing of musculoaponeurotic incisions, gastrostomies, and colonic anastomoses. *Arch Surg.* 1989;124(6):708–10.

9. Bubrick MP, et al. Prospective, randomized trial of the biofragmentable anastomosis ring. The BAR Investigational Group. *Am J Surg.* 1991;161(1):136–42. discussion 142–3.

10. Corman ML, et al. Comparison of the Valtrac biofragmentable anastomosis ring with conventional suture and stapled anastomosis in colon surgery. Results of a prospective, randomized

clinical trial. *Dis Colon Rectum*. 1989;32(3):183–7.

11. Hardy Jr TG, et al. A biofragmentable ring for sutureless bowel anastomosis. An experimental study. *Dis Colon Rectum*. 1985;28(7):484–90.

12. Pahlman L, et al. Randomized trial of a biofragmentable bowel anastomosis ring in high-risk colonic resection. *Br J Surg*. 1997;84(9):1291–4.

13. Seow-Choen F, Eu KW. Circular staplers versus the biofragmentable ring for colorectal anastomosis: a prospective randomized study. *Br J Surg*. 1994;81(12):1790–1.

14. Thiede A, et al. Overview on compression anastomoses: biofragmentable anastomosis ring multicenter prospective trial of 1666 anastomoses. *World J Surg*. 1998;22(1):78–86. discussion 87.

15. Kim HR, et al. Early surgical outcomes of NiTi endoluminal compression anastomotic clip (NiTi CAC 30) use in patients with gastrointestinal malignancy. *J Laparoendosc Adv Surg Tech A*. 2012;22(5):472–8.

16. D’Hoore A, et al. COMPRES: a prospective postmarketing evaluation of the compression anastomosis ring CAR 27()/ColonRing(). *Colorectal Dis*. 2015;17(6):522–9.

17. Masoomi H, et al. Compression anastomosis ring device in colorectal anastomosis: a review of 1,180 patients. *Am J Surg*. 2013;205(4):447–51.

18. Jafari MD, et al. Perfusion assessment in laparoscopic left-sided/anterior resection (PILLAR II): a multi-institutional study. *J Am Coll Surg*. 2015;220(1):82–92.e1.

19. Jesus EC et al. Prophylactic anastomotic drainage for colorectal surgery. *Cochrane Database Syst Rev* 2004; (4): CD002100.

20. Urbach DR, Kennedy ED, Cohen MM. Colon and rectal anastomoses do not require routine drainage: a systematic review and meta-analysis. *Ann Surg*. 1999;229(2):174–80.

21. Merad F, et al. Is prophylactic pelvic drainage useful after elective rectal or anal anastomosis? A multicenter controlled randomized trial. French Association for Surgical Research. *Surgery*. 1999;125(5):529–35.

22. Rondelli F, et al. To drain or not to drain extraperitoneal colorectal anastomosis? A systematic review and meta-analysis. *Colorectal Dis*. 2014;16(2):O35–42.

23. Cabot JC, et al. Long-term consequences of not closing the mesenteric defect after laparoscopic right colectomy. *Dis Colon Rectum*. 2010;53(3):289–92.

24. Causey MW, Oguntoye M, Steele SR. Incidence of complications following colectomy with mesenteric closure versus no mesenteric closure: does it really matter? *J Surg Res*. 2011;171(2):571–5.

25. Rullier E, et al. Risk factors for anastomotic leakage after resection of rectal cancer. *Br J Surg*. 1998;85(3):355–8.

26. Bertelsen CA, et al. Anastomotic leakage after anterior resection for rectal cancer: risk factors. *Colorectal Dis*. 2010;12(1):37–43.

27. Platell C, Barwood N, Makin G. Clinical utility of a de-functioning loop ileostomy. *ANZ J Surg*. 2005;75(3):147–51.

28. Chow A, et al. The morbidity surrounding reversal of defunctioning ileostomies: a systematic review of 48 studies including 6,107 cases. *Int J Colorectal Dis*. 2009;24(6):711–23.

29. Pokorny H, et al. Predictors for complications after loop stoma closure in patients with rectal cancer. *World J Surg*. 2006;30(8):1488–93.

30. Chen TA. Loop ileostomy or loop colostomy: which one is better for fecal diversion? *Int J Colorectal Dis*. 2012;27(1):131–2.

31. Nurkin S, et al. The role of faecal diversion in low rectal cancer: a review of 1791 patients having rectal resection with anastomosis for cancer, with and without a proximal stoma. *Colorectal Dis.* 2013;15(6):e309–16.
32. Tan WS, et al. Meta-analysis of defunctioning stomas in low anterior resection for rectal cancer. *Br J Surg.* 2009;96(5):462–72.
33. Shiomi A, et al. Effects of a diverting stoma on symptomatic anastomotic leakage after low anterior resection for rectal cancer: a propensity score matching analysis of 1,014 consecutive patients. *J Am Coll Surg.* 2015;220(2):186–94.
34. Chude GG, et al. Defunctioning loop ileostomy with low anterior resection for distal rectal cancer: should we make an ileostomy as a routine procedure? A prospective randomized study. *Hepatogastroenterology.* 2008;55(86–87):1562–7.
35. Matthiessen P, et al. Defunctioning stoma reduces symptomatic anastomotic leakage after low anterior resection of the rectum for cancer: a randomized multicenter trial. *Ann Surg.* 2007;246(2):207–14.
36. Ulrich AB, et al. Diverting stoma after low anterior resection: more arguments in favor. *Dis Colon Rectum.* 2009;52(3):412–8.
37. Guenaga KF et al. Ileostomy or colostomy for temporary decompression of colorectal anastomosis. *Cochrane Database Syst Rev* 2007; (1): CD004647.
38. Goulder F. Bowel anastomoses: the theory, the practice and the evidence base. *World J Gastrointest Surg.* 2012;4(9):208–13.
39. Leung TT, et al. Comparison of stapled versus handsewn loop ileostomy closure: a meta-analysis. *J Gastrointest Surg.* 2008;12(5):939–44.
40. Choy PY et al. Stapled versus handsewn methods for ileocolic anastomoses. *Cochrane Database Syst Rev* 2011; (9): CD004320.
41. Liu Z, et al. Ileocolonic anastomosis after right hemicolectomy for colon cancer: functional end-to-end or end-to-side? *World J Surg Oncol.* 2014;12:306.
42. Carnuccio P, Jimeno J, Pares D. Laparoscopic right colectomy: a systematic review and meta-analysis of observational studies comparing two types of anastomosis. *Tech Coloproctol.* 2014;18(1):5–12.
43. Tarta C, Bishawi M, Bergamaschi R. Intracorporeal ileocolic anastomosis: a review. *Tech Coloproctol.* 2013;17(5):479–85.
44. Hallbook O, et al. Randomized comparison of straight and colonic J pouch anastomosis after low anterior resection. *Ann Surg.* 1996;224(1):58–65.
45. Hida J, et al. Indications for colonic J-pouch reconstruction after anterior resection for rectal cancer: determining the optimum level of anastomosis. *Dis Colon Rectum.* 1998;41(5):558–63.
46. Neutzling CB et al. Stapled versus handsewn methods for colorectal anastomosis surgery. *Cochrane Database Syst Rev* 2012; (2): CD003144.
47. Baker JW. Low end to side rectosigmoid anastomosis; description of technique. *Arch Surg.* 1950;61(1):143–57.
48. Bryant CL, et al. Anterior resection syndrome. *Lancet Oncol.* 2012;13(9):e403–8.
49. Bloemen JG, et al. Long-term quality of life in patients with rectal cancer: association with severe postoperative complications and presence of a stoma. *Dis Colon Rectum.* 2009;52(7):1251–8.
50. Lange MM, van de Velde CJ. Faecal and urinary incontinence after multimodality treatment of

rectal cancer. PLoS Med. 2008;5(10):e202.

51. Keighley MR, Matheson D. Functional results of rectal excision and endo-anal anastomosis. Br J Surg. 1980;67(10):757–61.

52. Lazorthes F, et al. Resection of the rectum with construction of a colonic reservoir and colo-anal anastomosis for carcinoma of the rectum. Br J Surg. 1986;73(2):136–8.

53. Parc R, et al. Resection and colo-anal anastomosis with colonic reservoir for rectal carcinoma. Br J Surg. 1986;73(2):139–41.

54. Dehni N, et al. Long-term functional outcome after low anterior resection: comparison of low colorectal anastomosis and colonic J-pouch-anal anastomosis. Dis Colon Rectum. 1998;41(7):817–22. discussion 822–3.

55. Joo JS, et al. Long-term functional evaluation of straight coloanal anastomosis and colonic J-pouch: is the functional superiority of colonic J-pouch sustained? Dis Colon Rectum. 1998;41(6):740–6.

56. Kusunoki M, et al. Function after anoabdominal rectal resection and colonic J pouch--anal anastomosis. Br J Surg. 1991;78(12):1434–8.

57. Lazorthes F, et al. Late clinical outcome in a randomized prospective comparison of colonic J pouch and straight coloanal anastomosis. Br J Surg. 1997;84(10):1449–51.

58. Ortiz H, et al. Coloanal anastomosis: are functional results better with a pouch? Dis Colon Rectum. 1995;38(4):375–7.

59. Seow-Choen F, Goh HS. Prospective randomized trial comparing J colonic pouch-anal anastomosis and straight coloanal reconstruction. Br J Surg. 1995;82(5):608–10.

60. Portier G, Platonoff I, Lazorthes F. Long-term functional results after straight or colonic J-pouch coloanal anastomosis. Recent Results Cancer Res. 2005;165:191–5.

61. Hida J, et al. Long-term functional changes after low anterior resection for rectal cancer compared between a colonic J-pouch and a straight anastomosis. Hepatogastroenterology. 2007;54(74):407–13.

62. Harris GJ, Lavery IC, Fazio VW. Function of a colonic J pouch continues to improve with time. Br J Surg. 2001;88(12):1623–7.

63. Brown CJ, Fenech DS, McLeod RS. Reconstructive techniques after rectal resection for rectal cancer. Cochrane Database Syst Rev 2008; (2): CD006040.

64. Hida J, et al. Functional outcome after low anterior resection with low anastomosis for rectal cancer using the colonic J-pouch. Prospective randomized study for determination of optimum pouch size. Dis Colon Rectum. 1996;39(9):986–91.

65. Lazorthes F, et al. Prospective, randomized study comparing clinical results between small and large colonic J-pouch following coloanal anastomosis. Dis Colon Rectum. 1997;40(12):1409–13.

66. Hallbook O, Sjudahl R. Anastomotic leakage and functional outcome after anterior resection of the rectum. Br J Surg. 1996;83(1):60–2.

67. Hallbook O, Johansson K, Sjudahl R. Laser Doppler blood flow measurement in rectal resection for carcinoma--comparison between the straight and colonic J pouch reconstruction. Br J Surg. 1996;83(3):389–92.

68. Ramirez JM, et al. Colonic J-pouch rectal reconstruction--is it really a neorectum? Dis Colon Rectum. 1996;39(11):1286–8.

69. Hida J, et al. Comparison of long-term functional results of colonic J-pouch and straight anastomosis after low anterior resection for rectal cancer: a five-year follow-up. Dis Colon Rectum.

2004;47(10):1578–85.

70. Furst A, et al. Colonic J-pouch vs. colectomy following resection of distal rectal cancer: early results of a prospective, randomized, pilot study. *Dis Colon Rectum*. 2003;46(9):1161–6.

71. Fazio VW, et al. A randomized multicenter trial to compare long-term functional outcome, quality of life, and complications of surgical procedures for low rectal cancers. *Ann Surg*. 2007;246(3):481–8. discussion 488–90.

72. Z'Graggen K, et al. A new surgical concept for rectal replacement after low anterior resection: the transverse colectomy pouch. *Ann Surg*. 2001;234(6):780–5. discussion 785–7.

73. Ho YH, et al. Comparison of J-pouch and colectomy pouch for low rectal cancers: a randomized, controlled trial investigating functional results and comparative anastomotic leak rates. *Ann Surg*. 2002;236(1):49–55.

74. Pimentel JM, et al. Transverse colectomy pouch and colonic J-pouch for rectal cancer--a comparative study. *Colorectal Dis*. 2003;5(5):465–70.

75. Huber FT, Herter B, Siewert JR. Colonic pouch vs. side-to-end anastomosis in low anterior resection. *Dis Colon Rectum*. 1999;42(7):896–902.

76. Machado M, et al. Similar outcome after colonic pouch and side-to-end anastomosis in low anterior resection for rectal cancer: a prospective randomized trial. *Ann Surg*. 2003;238(2):214–20.

77. Machado M, et al. Functional and physiologic assessment of the colonic reservoir or side-to-end anastomosis after low anterior resection for rectal cancer: a two-year follow-up. *Dis Colon Rectum*. 2005;48(1):29–36.

78. Ho YH, Tan M, Seow-Choen F. Prospective randomized controlled study of clinical function and anorectal physiology after low anterior resection: comparison of straight and colonic J pouch anastomoses. *Br J Surg*. 1996;83(7):978–80.

79. Furst A, et al. Neorectal reservoir is not the functional principle of the colonic J-pouch: the volume of a short colonic J-pouch does not differ from a straight coloanal anastomosis. *Dis Colon Rectum*. 2002;45(5):660–7.

80. Ho YH, et al. Small colonic J-pouch improves colonic retention of liquids – randomized, controlled trial with scintigraphy. *Dis Colon Rectum*. 2002;45(1):76–82.

81. Baik SH, et al. Hand-sewn coloanal anastomosis for distal rectal cancer: long-term clinical outcomes. *J Gastrointest Surg*. 2005;9(6):775–80.

82. Laurent A, et al. Colonic J-pouch-anal anastomosis for rectal cancer: a prospective, randomized study comparing handsewn vs. stapled anastomosis. *Dis Colon Rectum*. 2005;48(4):729–34.

83. Smith S, et al. The efficacy of intraoperative methylene blue enemas to assess the integrity of a colonic anastomosis. *BMC Surg*. 2007;7:15.

84. Beard JD, et al. Intraoperative air testing of colorectal anastomoses: a prospective, randomized trial. *Br J Surg*. 1990;77(10):1095–7.

85. Davies AH, et al. Intra-operative air testing: an audit on rectal anastomosis. *Ann R Coll Surg Engl*. 1988;70(6):345–7.

86. Kwon S, et al. Routine leak testing in colorectal surgery in the Surgical Care and Outcomes Assessment Program. *Arch Surg*. 2012;147(4):345–51.

87. Ricciardi R, et al. Anastomotic leak testing after colorectal resection: what are the data? *Arch Surg*. 2009;144(5):407–11. discussion 411–2.

88. Hanna MH, Vinci A, Pigazzi A. Diverting ileostomy in colorectal surgery: when is it necessary? *Langenbecks Arch Surg*. 2015;400(2):145–52.

89. Kamal T, et al. Should anastomotic assessment with flexible sigmoidoscopy be routine following laparoscopic restorative left colorectal resection? *Colorectal Dis.* 2015;17:160.
90. Li VK, et al. Use of routine intraoperative endoscopy in elective laparoscopic colorectal surgery: can it further avoid anastomotic failure? *Surg Endosc.* 2009;23(11):2459–65.
91. Rombeau JL, Collins JP, Turnbull Jr RB. Left-sided colectomy with retroileal colorectal anastomosis. *Arch Surg.* 1978;113(8):1004–5.
92. Deloyers L. Suspension of the right colon permits without exception preservation of the anal sphincter after extensive colectomy of the transverse and left colon (including rectum). *Technic - indications- immediate and late results.* *Lyon Chir.* 1964;60:404–13.

## 第 10 章

1. Hyman NH. Managing anastomotic leaks from intestinal anastomoses. *Surgeon.* 2009;7(1):31–5.
2. Marinatou A, Theodoropoulos GE, Karanika S, et al. Do anastomotic leaks impair postoperative health-related quality of life after rectal cancer surgery? A case-matched study. *Dis Colon Rectum.* 2014;57(2):181–7.
3. Makela JT, Kiviniemi H, Laitinen S. Risk factors for anastomotic leakage after left-sided colorectal resection with rectal anastomosis. *Dis Colon Rectum.* 2003;46(5):653–60.
4. Vignali A, Fazio VW, Lavery IC. Factors associated with the occurrence of leaks in stapled rectal anastomoses. A review of 1014 patients. *J Am Coll Surg.* 1997;185:105–13.
5. Van Geldare D, Fa-Si-Oen P, Noach LA, et al. Complications after colorectal surgery without mechanical bowel preparation. *J Am Coll Surg.* 2002;194:40–7.
6. Eckman C, Kujath P, Schiedeck THK, et al. Anastomotic leakage following low anterior resection: results of a standardized diagnostic and therapeutic approach. *Int J Colorectal Dis.* 2004;19:128–33.
7. Griffen FD, Knight CD, Whitaker JM, et al. The double stapling technique for low anterior resection: results, modifications, and observations. *Ann Surg.* 1990;211:745–52.
8. Yuh Yeh C, Changchien CR, Wang JY, et al. Pelvic drainage and other risk factors for leakage after elective anterior resection in rectal cancer patients. *Ann Surg.* 2005;241:9–13.
9. Karanjia ND, Corder AP, Bearn P, et al. Leakage from stapled low anastomosis after total mesorectal excision for carcinoma of the rectum. *Br J Surg.* 1994;81:1224–6.
10. Law WL, Chu KW. Anterior resection for rectal cancer with mesorectal excision. *Ann Surg.* 2004;240:260–8.
11. Ali UA, Martin ST, Rao AD, Kiran R. Impact of preoperative immunosuppressive agents on postoperative outcomes in Crohn's disease. *Dis Colon Rectum.* 2014;57(5):663–74.
12. Nachiappan S, Askari A, Currie A, Kennedy R, Faiz O. Intraoperative assessment of colorectal anastomotic integrity: a systematic review. *Surg Endosc.* 2014;24:2513–30.
13. Golub R, Golub RW, Cantu R, Stein HD. A multi-variate analysis of factors contributing to leakage of intestinal anastomosis. *J Am Coll Surg.* 1997;184:364–72.
14. Mileski WJ, Joehl RJ, Rege V, Nahrwold DL. Treatment of anastomotic leakage following low anterior colon resection. *Arch Surg.* 1988;123:968–71.
15. Hansen O, Schwenk W, Huckle HP, Sock W. Colorectal stapled anastomoses. Experiences and results. *Dis Colon Rectum.* 1996;39:30–5.
16. Jex RK, Van Hcerden JA, Wolff BG, et al. Gastrointestinal anastomoses. Factors affecting early

complications. *Ann Surg.* 1987;206:138–41.

17. Max W, Sweeny WB, Bailey HR, et al. Results of 1000 single layer continuous polypropylene intestinal anastomoses. *Am J Surg.* 1991;162:461–7.

18. Heald RJ, Leicester RJ. The low stapled anastomosis. *Br J Surg.* 1981;68:333–7.

19. Marijnen CA, Kapiteijn E, van de Velde CJ, et al. Acute side effects and complications after short term preoperative radiotherapy combined with total mesorectal excision in primary rectal cancer. *J Clin Oncol.* 2002;20:817–25.

20. Schrock TR, Deveney CW, Dunphy JE. Factors contributing to leak of colonic anastomosis. *Ann Surg.* 1973;177:513–8.

21. Branagan G, Finnis D. Prognosis after anastomotic leak in colorectal surgery. *Dis Colon Rectum.* 2005;48:1021–6.

22. Bruce J, Krukowski ZH, Al-Khairi G, et al. Systematic review of the definition and measurement of anastomotic leak after gastrointestinal surgery. *Br J Surg.* 2001;88:1157–68.

23. Caulfield H, Hyman N. Anastomotic leak after low anterior resection. *JAMA Surg.* 2013;148(2):177–82.

24. Docherty JG, McGregor JR, Akyol AM, et al. Comparison of manually constructed and stapled anastomoses in colorectal surgery. West of Scotland and Highland Anastomosis Study Group. *Ann Surg.* 1995;221:176–84.

25. Blumetti J, Chaudhry V, Clintron JR, et al. Management of anastomotic leak: lessons learned from a large colon and rectal surgery training program. *World J Surg.* 2014;38(4):985–91.

26. Fingerhut A, Hay JM, Elhadad A, et al. Supraperitoneal colorectal anastomosis: hand sewn versus circular staples - a controlled clinical trial. French Associations for Surgical Research. *Surgery.* 1995;118:479–85.

27. Bokey EL, Chapuis PH, Fung C, et al. Postoperative morbidity and mortality following resection of the colon and rectum for cancer. *Dis Colon Rectum.* 1995;38:480–7.

28. Alves A, Panis Y, Trancart D, et al. Factors associated with clinically significant anastomotic leakage after large bowel resection: multivariate analysis of 707 patients. *World J Surg.* 2002;26:499–502.

29. Biondo S, Pares D, Kreisler E, et al. Anastomotic dehiscence after resection and primary anastomosis in left-sided colonic emergencies. *Dis Colon Rectum.* 2005;48:2272–80.

30. Sarkissian H, Hyman N, Osler T. Postoperative fluid collections after colon resection: the utility of clinical assessment. *Am J Surg.* 2013;206:551–4.

31. Lim M, Akhtar S, Sasapu K, et al. Clinical and subclinical leaks after low colorectal anastomosis: a clinical and radiologic study. *Dis Colon Rectum.* 2006;49:1611–9.

32. Nesbakken A, Nygaard K, Lunde OC. Outcome and late functional results after anastomotic leakage following mesorectal excision for rectal cancer. *Br J Surg.* 2001;88:400–4.

33. Walker KG, Bell SW, Rickard MJ, et al. Anastomotic leakage is predictive of diminished survival after potentially curative resection for colorectal cancer. *Ann Surg.* 2004;240:255–9.

34. Law WL, Choi HK, Lee YM, et al. Anastomotic leakage is associated with poor long-term outcome in patients after curative colorectal resection for malignancy. *J Gastrointest Surg.* 2007;11:8–15.

35. Den Dulk M, Marijnen CAM, Collette L, Putter H, Pahlman L, Folkesson J, Bosset J-F, Rödel C, Bujko K, van de Velde CJH. Multicentre analysis of oncological and survival outcomes following anastomotic leakage after rectal cancer surgery. *Br J Surg.* 2009;96:1066–75.

36. Mirnezami A, Mirnezami R, Chandrakumaran K, et al. Increased local reoccurrence and reduced survival from colorectal cancer following anastomotic leak: systematic review and meta-analysis. *Ann Surg.* 2011;253(5):890–9.
37. Hyman NH, Osler T, Cataldo P, Burns EH, Shackford SR. Anastomotic leaks after bowel reconstruction: what does peer review teach us about the relationship between postoperative mortality? *J Am Coll Surg.* 2009;208(1):48–52.
38. Kang CY, Halabi WJ, Chaudhry OO, Nguyen V, Pigazzi A, Carmichael JC, Mills S, Stamos MJ. Risk factors for anastomotic leakage after anterior resection for rectal cancer. *JAMA Surg.* 2013;148:65–71.
39. Richards CH, Campbell V, Ho C, Hayes J, Elliot T, Thompson-Fawcett M. Smoking is a major risk factor for anastomotic leak in patients undergoing low anterior resection. *Colorectal Dis.* 2012;14:628–33.
40. Telem DA, Chin EH, Nguyen SQ, Divino CM. Risk factors for anastomotic leak following colorectal surgery: a case-control study. *Arch Surg.* 2010;145:371–6.
41. Rullier E, Laurent C, Garrelon JL, et al. Risk factors for anastomotic leakage after resection of rectal cancer. *Br J Surg.* 1997;185:355–8.
42. Lipska M, Bissett IP, Parry BR, et al. Anastomotic leakage after lower gastrointestinal anastomosis: men are at high risk. *ANZ J Surg.* 2006;76:579–85.
43. Peeters KC, Tollenaar RA, Marijnen CA, et al. Risk factors for anastomotic failure after total mesorectal excision of rectal cancer. *Br J Surg.* 2005;92:211–6.
44. Park JS, Choi G-S, Kim SH, Kim HR, Kim NK, Lee KY, Kang SB, Kim JY, Lee KY, Kim BC, Bae BN, Son GM, Lee S, Kang H. Multicenter analysis of risk factors for anastomotic leakage after laparoscopic rectal cancer excision: the Korean laparoscopic colorectal surgery study group. *Ann Surg.* 2013;257(4):665–71.
45. Beard JD, Nicholson ML, Sayers RD, Lloyd D, Everson NW. Intraoperative air testing of colorectal anastomoses: a prospective, randomized trial. *Br J Surg.* 1990;77:1095–7.
46. Ricciardi R, Roberts PL, Read TE, Marcello PW, Hall JF, Schoetz DJ. How often do patients return to the operating room after colorectal resections? *Colorectal Dis.* 2012;14:515–21.
47. Jafari MD, Lee KH, Halabi WJ, Mills SD, Carmichael JC, Stamos MJ, Pigazzi A. The use of indocyanine green fluorescence to assess anastomotic perfusion during robotic assisted laparoscopic rectal surgery. *Surg Endosc.* 2013;27(8):3003–8.
48. Shogan BD, Carlisle EM, Alverdy JC, et al. Do we really know why colorectal anastomoses leak? *J Gastrointest Surg.* 2013;17(9):1698–707.
49. Shogan BD, An GC, Schardey HM, et al. Proceedings of the first international summit on intestinal anastomotic leak, Chicago, Illinois, October 4-5, 2012. *Surg Infect.* 2014;15(5):479–89.
50. Pickleman J, Watson W, Cunningham J, et al. The failed gastrointestinal anastomosis: an inevitable catastrophe? *J Am Surg.* 1999;188:473–82.
51. Platell C, Barwood N, Dorfmann G, et al. The incidence of anastomotic leaks in patient undergoing colorectal surgery. *Colorectal Dis.* 2006;9:71–9.
52. Larson E, Hyman N, Osler T. Abnormal vital signs are common after bowel resection and do not predict anastomotic leaks. *J Am Coll Surg.* 2014;218:1195–200.
53. Nesbakken A, Nygaard K, Lunde OC, et al. Anastomotic leak following mesorectal excision for rectal cancer: true incidence and diagnostic challenges. *Colorectal Dis.* 2005;7:576–81.
54. Power N, Atri M, Ryan S, et al. CT assessment of anastomotic bowel leak. *Clin Radiol.*



2007;62:37–42.

55. Hyman N, Manchester T, Osler T, et al. Anastomotic leaks after intestinal anastomosis: it's later than you think. *Ann Surg.* 2007;245:254–8.

56. Landman RG. Surgical management of anastomotic leak following colorectal surgery. *Semin Colon Rectal Surg.* 2014;25:58–66.

57. DiMaio CJ, Dorfman MP, Gardner GJ, et al. Covered esophageal self-expandable metal stents in the nonoperative management of postoperative colorectal anastomotic leaks. *Gastrointest Endosc.* 2012;76(2):431–5.

58. Lamazza A, Fiori E, Schillaci A, Sterpetti AV, Lezoche E. Treatment of anastomotic stenosis and leakage after colorectal resection for cancer with self-expandable metal stents. *Am J Surg.* 2014;208:465.

59. Weidenhagen R, Gruetzner KU, Wiecken T, Spelsberg F, Jauch KW. Endoscopic of the rectum: a new method. *Surg Endosc.* 2008;22(8):1818–25.

60. Luchtefeld MA, Milsom JW, Senagore A, Surrell JA, Mazier WP. Colorectal anastomotic stenosis. Results of a survey of the ASCRS membership. *Dis Colon Rectum.* 1989;32(9):733–6.

61. Orsay CP, Bass EM, Firfer B, Ramakrishnan V, Abcarian H. Blood flow in colon anastomotic stricture formation. *Dis Colon Rectum.* 1995;38(2):202–6.

62. Schlegel RD, Dehni N, Parc R, Caplin S, Tired E. Results of reoperations in colorectal anastomotic strictures. *Dis Colon Rectum.* 2001;44(10):1464–8.

63. Chung RS, Hitch DC, Armstrong DN. The role of tissue ischemia in the pathogenesis of anastomotic stricture. *Surgery.* 1988;104(5):824–9.

64. Aston NO, Owen WJ, Irving JD. Endoscopic balloon dilatation of colonic anastomotic strictures. *Br J Surg.* 1989;76(8):780–2.

65. Venkatesh KS, Ramanujam PS, McGee S. Hydrostatic balloon dilatation of benign colonic anastomotic strictures. *Dis Colon Rectum.* 1992;35(8):789–91.

66. Dinneen MD, Motson RW. Treatment of colonic anastomotic strictures with 'through the scope' balloon dilators. *J R Soc Med.* 1991;84(5):264–6. Pubmed Central PMCID: 1293221.

67. Werre A, Mulder C, van Heteren C, Bilgen ES. Dilation of benign strictures following low anterior resection using Savary-Gilliard bougies. *Endoscopy.* 2000;32(5):385–8.

68. Pietropaolo V, Masoni L, Ferrara M, Montori A. Endoscopic dilation of colonic postoperative strictures. *Surg Endosc.* 1990;4(1):26–30.

69. Hagiwara A, Sakakura C, Shirasu M, Torii T, Hirata Y, Yamagishi H. Sigmoidofiberscopic incision plus balloon dilatation for anastomotic cicatricial stricture after anterior resection of the rectum. *World J Surg.* 1999;23(7):717–20.

70. Luck A, Chapuis P, Sinclair G, Hood J. Endoscopic laser stricturotomy and balloon dilatation for benign colorectal strictures. *ANZ J Surg.* 2001;71(10):594–7.

71. Brandimarte G, Tursi A, Gasbarrini G. Endoscopic treatment of benign anastomotic colorectal stenosis with electrocautery. *Endoscopy.* 2000;32(6):461–3.

72. Truong S, Willis S, Schumpelick V. Endoscopic therapy of benign anastomotic strictures of the colorectum by electroincision and balloon dilatation. *Endoscopy.* 1997;29(9):845–9.

73. Kato K, Saito T, Matsuda M, Imai M, Kasai S, Mito M. Successful treatment of a rectal anastomotic stenosis by transanal endoscopic microsurgery (TEM) using the contact Nd:YAG laser. *Surg Endosc.* 1997;11(5):485–7.

74. Hunt TM, Kelly MJ. Endoscopic transanal resection (ETAR) of colorectal strictures in stapled

- anastomoses. *Ann R Coll Surg Engl*. 1994;76(2):121–2. Pubmed Central PMCID: 2502211.
75. Sabbagh C, Maggiori L, Panis Y. Management of failed low colorectal and coloanal anastomosis. *J Visc Surg*. 2013;150(3):181–7.
76. Conner WE, Jetmore AB, Heryer JW. Circular stapled rectal strictureplasty with the proximate intraluminal stapler. *Dis Colon Rectum*. 1995;38(6):660–3.
77. Small AJ, Young-Fadok TM, Baron TH. Expandable metal stent placement for benign colorectal obstruction: outcomes for 23 cases. *Surg Endosc*. 2008;22(2):454–62.
78. Repici A, Pagano N, Rando G, Carlino A, Vitetta E, Ferrara E, et al. A retrospective analysis of early and late outcome of biodegradable stent placement in the management of refractory anastomotic colorectal strictures. *Surg Endosc*. 2013;27(7):2487–91.
79. Caruso A, Conigliaro R, Manta R, Manno M, Bertani H, Barbera C, et al. Fully covered self-expanding metal stents for refractory anastomotic colorectal strictures. *Surg Endosc*. 2014;29:1175.
80. Lustosa SA, Matos D, Atallah AN, Castro AA. Stapled versus handsewn methods for colorectal anastomosis surgery. *Cochrane Database Syst Rev*. 2001; (3): CD003144
81. Malik AH, East JE, Buchanan GN, Kennedy RH. Endoscopic haemostasis of staple-line haemorrhage following colorectal resection. *Colorectal Dis*. 2008;10(6):616–8.
82. Linn TY, Moran BJ, Cecil TD. Staple line haemorrhage following laparoscopic left-sided colorectal resections may be more common when the inferior mesenteric artery is preserved. *Tech Coloproctol*. 2008;12(4):289–93.
83. Ishihara S, Watanabe T, Nagawa H. Intraoperative colonoscopy for stapled anastomosis in colorectal surgery. *Surg Today*. 2008;38(11):1063–5.
84. Perez RO, Sousa Jr A, Bresciani C, Proscurshim I, Coser R, Kiss D, et al. Endoscopic management of postoperative stapled colorectal anastomosis hemorrhage. *Tech Coloproctol*. 2007;11(1):64–6.
85. Cirocco WC, Golub RW. Endoscopic treatment of postoperative hemorrhage from a stapled colorectal anastomosis. *Am Surg*. 1995;61(5):460–3.
86. Atabek U, Pello MJ, Spence RK, Alexander JB, Camishion RC. Arterial vasopressin for control of bleeding from a stapled intestinal anastomosis. Report of two cases. *Dis Colon Rectum*. 1992;35(12):1180–2.
87. Jander HP, Russinovich NA. Transcatheter gelfoam embolization in abdominal, retroperitoneal, and pelvic hemorrhage. *Radiology*. 1980;136(2):337–44.

## 第 11 章

1. Lund JN, Nystrom PO, Coremans G, et al. An evidence-based treatment algorithm for anal fissure. *Tech Coloproctol*. 2006;10:177–80.
2. Perry WB, Dykes SL, Buie WD, et al. Practice parameters for the management of anal fissures (3rd revision). *Dis Colon Rectum*. 2010;53:1110–5.
3. Rossi DC, Bastaworus AL. Hemorrhoids. In: Bailey HR, Billingham RP, Stamos MJ, Snyder MJ, editors. *Colorectal surgery*. Philadelphia, PA: Elsevier; 2012.
4. Rivadeneira DE, Steele SR, Ternent C, et al. Practice parameters for the management of hemorrhoids. *Dis Colon Rectum*. 2011;54:1059–64.
5. MacRae HM, Temple LK, McLeod RS. A meta-analysis of hemorrhoidal treatments. *Semin*

- Colon Rectal Surg. 2002;13:77–83.
6. Loder PB, Kamm MA, Nicholls RJ, et al. Haemorrhoids: pathology, pathophysiology and aetiology. *Br J Surg*. 1994;81:946–54.
  7. Guillaumin E, Jeffrey Jr RB, Shea WJ, et al. Perirectal inflammatory disease: CT findings. *Radiology*. 1986;161:153–7.
  8. Ramanujam PS, Prasad ML, Abcarian H, et al. Perianal abscesses and fistulas. A study of 1023 patients. *Dis Colon Rectum*. 1984;27:593–7.
  9. Gilliland R, Wexner SD. Complicated anorectal sepsis. *Surg Clin North Am*. 1997;77:115–53.
  10. Steele SR, Kumar R, Feingold DL, et al. Practice parameters for the management of perianal abscess and fistula-in-ano. *Dis Colon Rectum*. 2011;54:1465–74.
  11. Bastawrous AL, Cintron JR. Anorectal abscess fistula. In: Cameron J, editor. *Current surgical therapy*. 8th ed. Philadelphia, PA: Mosby; 2004.
  12. Bastawrous AL, Chaudhry V. Specific pruritus ani. *Semin Colon Rectal Surg*. 2003;14(4):203–12.
  13. Chaudhry V, Bastawrous AL. Idiopathic pruritus ani. *Semin Colon Rectal Surg*. 2003;14(4):196–202.
  14. Ternent CA, Bastawrous AL, Morin NA, et al. Practice parameters for the evaluation and management of constipation. *Dis Colon Rectum*. 2007;50(12):2013.
  15. Hull TL, Milsom JW, Church J, Oakley J, Lavery I, Fazio V. Electrogalvanic stimulation for levator syndrome: how effective is it in the long-term? *Dis Colon Rectum*. 1993;36(8):731–3.
  16. Klas JV, Rothenberger DA, Wong WD, Madoff RD. Malignant tumors of the anal canal: the spectrum of disease, treatment, and outcomes. *Cancer*. 1999;85(8):1686–93.
  17. Monson JRT, Weiser MR, Buie WD, et al. Practice parameters for the management of rectal cancer. *Dis Colon Rectum*. 2013;56:535–50.
  18. Blumetti J, Bastawrous AL. Epidermoid cancers of the anal canal: current treatment. *Clin Colon Rectal Surg*. 2009;22:77–83.
  19. Steele SR, Varma MG, Melton GB, Ross HM, Rafferty JF, Buie WD. Standards Practice Task Force of the American Society of Colon and Rectal Surgeons. Practice parameters for anal squamous neoplasms. *Dis Colon Rectum*. 2012;55(7):735–49.
  20. Ben Amor I, Kassir R, Bachir E, et al. Perforated diverticulitis of the sigmoid colon revealed by a perianal fistula. *Int J Surg Case Rep*. 2015;8:73–5.
  21. Lengelé B, Scalliet P. Anatomical bases for the radiological delineation of lymph node areas. Part III: Pelvis and lower limbs. *Radiother Oncol*. 2009;92(1):22–33.
  22. Gretschel S, Warnick P, Bembenek A, et al. Lymphatic mapping and sentinel lymph node biopsy in epidermoid carcinoma of the anal canal. *Eur J Surg Oncol*. 2008;34(8):890–4.
  23. Gerard JP, Chapet O, Samiei F, et al. Management of inguinal lymph node metastases in patients with carcinoma of the anal canal: experience in a series of 270 patients treated in Lyon and review of the literature. *Cancer*. 2001;92(1):77–84.
  24. Grimaud JC, Bouvier M, Naudy B, Guien C, Salducci J. Manometric and radiologic investigations and biofeedback treatment of chronic idiopathic anal pain. *Dis Colon Rectum*. 1991;34(8):690–5.

## 第 12 章

1. Thomson WH. The nature of haemorrhoids. *Br J Surg*. 1975;62:542–52.
2. Parnaud E, Guntz M, Bernard A, Chome J. Normal macroscopic and microscopic anatomy of the hemorrhoidal vascular system. *Arch Fr Mal App Dig*. 1975;65:501–14.
3. Haas PA, Fox TA, Haas GP. The pathogenesis of hemorrhoids. *Dis Colon Rectum*. 1984;7:442–50.
4. Han W, Wang ZJ, Zhao B, Yang XQ, Wang D, Wand JP, Tang XY, Zhao F, Hung YT. Pathologic change of elastic fibers with difference of microvessel density and expression of angiogenesis-related proteins in internal hemorrhoid tissues. *Chin J Gastrointest Surg*. 2005;8:56–9.
5. Aigner F, Bodner G, Gruber H, Conrad F, Fritsch H, Margreiter R, Bonatti H. The vascular nature of hemorrhoids. *J Gastrointest Surg*. 2006;10:1044–50.
6. Aigner F, Gruber H, Conrad F, Eder J, Wedel T, Zelger B, Engelhardt V, Lametschwandtner A, Wienert V, Böhler U, Margreiter R, Fritsch H. Revised morphology and hemodynamics of the anorectal vascular plexus: impact on the curse of hemorrhoidal disease. *Int J Colorectal Dis*. 2009;1:105–13.
7. Chung YC, Hou YC, Pan AC. Endoglin (CD105) expression in the development of haemorrhoids. *Eur J Clin Invest*. 2004;34:107–12.
8. Hancock BD. Internal sphincter and the nature of haemorrhoids. *Gut*. 1977;18:651–5.
9. Loder PB, Kamm MA, Nicholls RJ, Phillips RK. Haemorrhoids: pathology, pathophysiology and aetiology. *Br J Surg*. 1994;81:946–54.
10. Sun WM, Read NW, Shorthouse AJ. Hemorrhoids are associated with hypertrophy of internal anal sphincter but with hypertension of the anal cushions. *Br J Surg*. 1992;79: 592–4.
11. Ho YH, Seow Choen F, Goh HS. Haemorrhoidectomy and disordered rectal and anal physiology in patients with prolapsed haemorrhoids. *Br J Surg*. 1995;82:596–8.
12. Ho YH, Tan M. Ambulatory anorectal manometric findings in patients before and after haemorrhoidectomy. *Int J Colorectal Dis*. 1997;12:296–7.
13. Burkitt DP, Graham-Stewart CW. Haemorrhoids--postulated pathogenesis and proposed prevention. *Postgrad Med J*. 1975;51:631–6.
14. Johanson JF, Sonnenberg A. The prevalence of hemorrhoids and chronic constipation. An epidemiologic study. *Gastroenterology*. 1990;98:380–6.
15. Everhart JE. The burden of digestive diseases in the United States. Bethesda, MD: US Department of Health and Human Services. Public Health Service, National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases. NIH Publication; 2008.
16. Banov L, Knoepp LF, Erdman LH, Alia RT. Management of hemorrhoidal disease. *J S C Med Assoc*. 1985;81:398.
17. Marderstein EL, Church JM. Classic “outlet” rectal bleeding does not require full colonoscopy to exclude significant pathology. *Dis Colon Rectum*. 2008;51:202–6.
18. Slavin JL. Dietary fiber and body weight. *Nutrition*. 2005;21:411–8.
19. McGill CR, Devareddy L. Ten-year trends in fiber and whole grain intakes and food sources for the United States population: National Health and Nutrition Examination Survey 2001-2010. *Nutrients*. 2015;7:1119–30.
20. Alonso-Coello P, Mills ED, Heels-Ansdell D, Lopez-Yarto M, Zhou Q, Johanson JF, Guyatt G. Fiber for the treatment of hemorrhoids complications: a systematic review and meta-analysis. *Am J Gastroenterol*. 2006;101:181–8.
21. Moesgaard F, Nielsen L, Hansen JB, Knudsen JT. High-fiber diet reduces bleeding and pain in

- patients with hemorrhoids. *Dis Colon Rectum*. 1982;25:454–6.
22. Ryoo S, Song YS, Seo MS, Oh H-K, Choe EK, Park KJ. Effect of electronic toilet system (Bidet) on anorectal pressure in normal healthy volunteers: influence of different types of water stream and temperature. *J Korean Med Sci*. 2011;26:71–7.
23. Johanson JF. Nonsurgical treatment of hemorrhoids. *J Gastrointest Surg*. 2002;6:290–4.
24. Tjandra JJ, Tan JJ, Lim JF, Murray-Green C, Kennedy ML, Lubowski DZ. Rectogesic (glyceryl trinitrate 0.2%) ointment relieves symptoms of haemorrhoids associated with high resting anal canal pressures. *Colorectal Dis*. 2007;9:457–63.
25. Perrotti P, Antropoli C, Molino D, DeStefano G, Antropoli M. Conservative treatment of acute thrombosed external hemorrhoids with topical nifedipine. *Dis Colon Rectum*. 2001;44:405–9.
26. Labrid C. Pharmacologic properties of Daflon 500 mg. *Angiology*. 1994;45:524–30.
27. Labrid C. A lymphatic function of Daflon 500 mg. *Int Angiol*. 1995;14:36–8.
28. Struckmann JR, Nicolaides AN. Flavonoids. A review of the pharmacology and therapeutic efficacy of Daflon 500 mg in patients with chronic venous insufficiency and related disorders. *Angiology*. 1994;45:419–28.
29. Perera N, Liolitsa D, Iype S, Croxford A, Yassin M, Lang P, Ukaegbu O, Van Issum C. Phlebotonics for haemorrhoids. *Cochrane Database Syst Rev*. 2012; (8): CD004322.
30. Alonso-Coello P, Zhou Q, Martinex Zapata MJ, Mills E, Heels-Ansdell D, Johanson JF, Guyatt G. Meta analysis of flavonoids for the treatment of haemorrhoids. *Br J Surg*. 2006;93:909–20.
31. Montes BB, Gorgul A, Tatlicioglu E, Ayoglu F, Unal S. Efficacy of calcium dobesilate in treating acute attacks of hemorrhoidal disease. *Dis Colon Rectum*. 2001;44:1489–95.
32. Barron J. Office ligation treatment of hemorrhoids. *Dis Colon Rectum*. 1963;6:109–13.
33. Ellesmore S, Windsor AC. Surgical history of haemorrhoids. In: Charles MV, editor. *Surgical treatment of haemorrhoids*. London: Springer; 2002. p. 1–4.
34. Lee HH, Spencer RJ, Beart RW. Multiple hemorrhoidal bandings in a single session. *Dis Colon Rectum*. 1994;37:37–41.
35. Maria G, Brisinda G, Palermo A, Civello IM. Multiple versus single rubber band ligation for internal hemorrhoids: a review of 450 consecutive cases. *Dig Surg*. 1992;14:52–5.
36. Chaleoykitti B. Comparative study between multiple and single rubber band ligation in one session for bleeding internal, hemorrhoids: a prospective study. *J Med Assoc Thai*. 2002;85:345–50.
37. Khubachandani IT. A randomized comparison of single and multiple rubber band ligations. *Dis Colon Rectum*. 1993;26:705–8.
38. Corman M. Hemorrhoids. In: *Colon & rectal surgery*. 3rd ed. Philadelphia, PA: JB Lippincott; 1993. p. 68.
39. Bat L, Melzer E, Koler M, Dreznick Z, Shemesh E. Complications of rubber band ligation of symptomatic internal hemorrhoids. *Dis Colon Rectum*. 1993;36:287–90.
40. O'Hara VS. Fatal clostridial infection following hemorrhoidal banding. *Dis Colon Rectum*. 1993;23:570–1.
41. Scarpa FJ, Hillis W, Sabetta JR. Pelvic cellulitis: a life-threatening complication of hemorrhoidal banding. *Surgery*. 1988;103:383–5.
42. Russell TR, Donohue JH. Hemorrhoidal banding. A warning. *Dis Colon Rectum*. 1985;28:291–3.
43. MacRae HM, McLeod RS. Comparison of hemorrhoidal treatment modalities. *Dis Colon*

Rectum. 1995;38:687–94.

44. MacRae HM, Temple LKF, McLeod RS. A meta-analysis of hemorrhoidal treatments. *Semin Colon Rectal Surg.* 2002;1:77–83.

45. Johanson JF, Rimm A. Optimal nonsurgical treatment of hemorrhoids: a comparative analysis of infrared coagulation, rubber band ligation, and injection sclerotherapy. *Am J Gastroenterol.* 1992;87:1600–6.

46. Bayer I, Myslovaty B, Picovsky BM. Rubber band ligation of hemorrhoids: convenient and economic treatment. *J Clin Gastroenterol.* 1996;23:50–2.

47. Savioz D, Roche B, Glauser T. Rubber band ligation of hemorrhoids: relapse as a function of time. *Int J Colorectal Dis.* 1998;13:154–6.

48. Dennison A, Whiston RJ, Rooney S, Chadderton RD, Wherry DC, Morris DL. A randomized comparison of infrared photocoagulation with bipolar diathermy for the outpatient treatment of hemorrhoids. *Dis Colon Rectum.* 1990;33:32–4.

49. Khaliq T, Shah SA, Mehboob A. Outcome of rubber band ligation of haemorrhoids using suction ligator. *J Ayub Med Coll Abbottabad.* 2004;16:34–7.

50. Poen AC, Felt-Bersma RJ, Cuesta MA, Devillé W, Meuwissen SG. A randomized controlled trial of rubber band ligation versus infra-red coagulation in the treatment of internal hemorrhoids. *Eur J Gastroenterol Hepatol.* 2000;12:535–9.

51. Quevedo-Bonilla G, Farkas AM, Abcarian H, Hambrick E, Orsay CP. Septic complications of hemorrhoidal banding. *Arch Surg.* 1988;123:650–1.

52. Hinton CP, Morris DL. A randomized trial comparing direct current therapy and bipolar diathermy in the outpatient treatment of third-degree hemorrhoids. *Dis Colon Rectum.* 1990;33:931–2.

53. Randall GM, Jensen DM, Machicado GA, Hirabayashi K, Jensen ME, You S, Pelayo E. Prospective randomized comparative study of bipolar versus direct current electrocoagulation for treatment of bleeding internal hemorrhoids. *Gastrointest Endosc.* 1994;40:403–10.

54. Morgan J. Varicose state of saphenous haemorrhoids treated successfully by the injection of tincture of persulphate of iron. *Medical Press and Circular* 1869;29–30.

55. Sim AJ, Murie JA, Mackenzie I. Three year follow up study on the treatment of first and second degree hemorrhoids by sclerosant injection or rubber band ligation. *Surg Gynecol Obstet.* 1983;157:534–6.

56. Bullock N. Impotence after sclerotherapy of haemorrhoids: case reports. *BMJ.* 1997;314:419.

57. Khoury GA, Lake SP, Lewis MC, Lewis AA. A randomized trial to compare single with multiple phenol injection treatment for haemorrhoids. *Br J Surg.* 1985;72:741–2.

58. Bleday R, Pena JP, Rothenberger DA, Goldberg SM, Buls JG. Symptomatic hemorrhoids: current incidence and complications of operative therapy. *Dis Colon Rectum.* 1992;35:477–81.

59. Ferguson JA, Mazier WP, Ganchrow MI, Friend WG. The closed technique of hemorrhoidectomy. *Surgery.* 1971;70:480–4.

60. Milone M, Maietta P, Leongito M, Pesce G, Salvatore G, Milone F. Ferguson hemorrhoidectomy: is still the gold standard treatment? *Updates Surg.* 2012;64:191–4.

61. Milsom JW, Mazier WP. Classification and management of postsurgical anal stenosis. *Surg Gynecol Obstet.* 1986;163:60–4.

62. Xu L, Chen H, Lin G, Ge Q. LigaSure versus Ferguson hemorrhoidectomy in the treatment of hemorrhoids: a meta-analysis of randomized control trials. *Surg Laparosc Endosc Percutan Tech.*

2015;25:106–10.

63. Milligan ET, Morgan CN, Jones LE, Officer R. Surgical anatomy of the anal canal and operative treatment of haemorrhoids. *Lancet*. 1937;11:1119–94.

64. Whitehead W. The surgical treatment of hemorrhoids. *Br Med J*. 1882;1:148–50.

65. Wolff BG, Culp CE. The Whitehead hemorrhoidectomy. An unjustly maligned procedure. *Dis Colon Rectum*. 1988;31:587–90.

66. Ho YH, Seow-Choen F, Tan M, Leong AF. Randomized controlled trial of open and closed haemorrhoidectomy. *Br J Surg*. 1997;84:1729–30.

67. Carapeti EA, Kamm MA, McDonald PJ, Chadwick SJ, Phillips RK. Randomized trial of open versus closed day-case haemorrhoidectomy. *Br J Surg*. 1999;86:612–3.

68. Arbmán G, Krook H, Haapaniemi S. Closed vs open hemorrhoidectomy – is there any difference? *Dis Colon Rectum*. 2000;43:31–4.

69. Gençosmanoğlu R, Sad O, Koç D, Inceoğlu R. Hemorrhoidectomy: open or closed technique? A prospective randomized clinical trial. *Dis Colon Rectum*. 2002;45:70–5.

70. Ho YH, Buettner PG. Open compared with closed haemorrhoidectomy: meta-analysis of randomized controlled trials. *Tech Coloproctol*. 2007;11:135–43.

71. Hetzer FH, Demartines N, Handschin AE, Clavien PA. Stapled vs excision hemorrhoidectomy: long term-results of a prospective randomized trial. *Arch Surg*. 2002;127:337–40.

72. Nienhuijs S, de Hingh I. Conventional versus LigaSure hemorrhoidectomy for patients with symptomatic hemorrhoids. *Cochrane Database Syst Rev* 2009; (1): CD006761.

73. Sohn VY, Martin MJ, Mullenix PS, Cuadrado DG, Place RJ, Steele SR. A comparison of open versus closed techniques using the Harmonic Scalpel in outpatient hemorrhoid surgery. *Mil Med*. 2008;73:689–92.

74. Wang JY, Chang-Chien CR, Chen JS, Lai CR, Tang RP. The role of lasers in hemorrhoidectomy. *Dis Colon Rectum*. 1991;34:78–82.

75. Iwagaki H, Higuchi Y, Fuchimoto S, Orita K. The laser treatment of hemorrhoids: results of a study on 1816 patients. *Jpn J Surg*. 1989;19:658–61.

76. Senagore A, Mazier WP, Luchtefeld MA, MacKeigan JM, Wengert T. Treatment of advanced hemorrhoidal disease: a prospective, randomized comparison of cold scalpel vs contact ND:YAG laser. *Dis Colon Rectum*. 1993;36:1042–9.

77. Mathai V, Ong BC, Ho YH. Randomized controlled trial of lateral internal sphincterotomy with haemorrhoidectomy. *Br J Surg*. 1996;83:380–2.

78. Wasvary HJ, Hain J, Mosed-Vogel M, Bendick P, Barkel DC, Klein SN. Randomized, prospective, double-blind, placebo controlled trial of effect of nitroglycerin ointment on pain after hemorrhoidectomy. *Dis Colon Rectum*. 2001;44:1069–73.

79. Ala S, Saeedi M, Eshghi F, Mirzabeygi P. Topical metronidazole can reduce pain after surgery and pain on defecation in postoperative hemorrhoidectomy. *Dis Colon Rectum*. 2008;51:235–8.

80. Zaheer S, Reilly WT, Pemberton JH, Ilstrup D. Urinary retention after operations for benign anorectal diseases. *Dis Colon Rectum*. 1998;41:696–704.

81. Toyonaga T, Matsushima M, Sogawa N, Jiang SF, Matsumura N, Shimojima Y, Tanaka Y, Suzuki K, Masuda J, Tanaka M. Postoperative urinary retention after surgery for benign anorectal disease: potential risk factors and strategy for prevention. *Int J Colorectal Dis*. 2006;21:676–82.

82. Hoff SD, Bailey HR, Butts DR, Max E, Smith KW, Zamora LF, Skakun GB. Ambulatory surgical hemorrhoidectomy--a solution to postoperative urinary retention? *Dis Colon Rectum*.

1994;37:1242–4.

83. Chik B, Law WL, Choi HK. Urinary retention after haemorrhoidectomy: impact of stapled haemorrhoidectomy. *Asian J Surg*. 2006;29:233–7.

84. Rosen L, Sipe P, Stasik JJ, Riether RD, Trimpi HD. Outcome of delayed hemorrhage following surgical hemorrhoidectomy. *Dis Colon Rectum*. 1993;36:743–6.

85. Basso L, Pescatori M. Outcome of delayed hemorrhage following surgical hemorrhoidectomy. *Dis Colon Rectum*. 1994;37:288–9.

86. Chen HH, Wang JY, Changchien CR, Chen JS, Hsu KC, Chiang JM, Yeh CY, Tang R. Risk factors associated with posthemorrhoidectomy secondary hemorrhage: a single-institution prospective study of 4,880 consecutive closed hemorrhoidectomies. *Dis Colon Rectum*. 2002;45:1096–9.

87. Chen HH, Wang JY, Changchien CR, Yeh CY, Tsai WS, Tang R. Effective management of posthemorrhoidectomy secondary hemorrhage using rectal irrigation. *Dis Colon Rectum*. 2002;45:234–8.

88. Eu KW, Teoh TA, Seow-Choen F, Goh HS. Anal stricture following haemorrhoidectomy: early diagnosis and treatment. *Aust N Z J Surg*. 1995;2:101–3.

89. Carditello A, Milone A, Stilo F, Mollo F, Basile M. Surgical treatment of anal stenosis following hemorrhoid surgery. Results of 150 combined mucosal advancement and internal sphincterotomy. *Chir Ital*. 2002;54:841–4.

90. McCloud JM, Jameson JS, Scott AN. Life-threatening sepsis following treatment for haemorrhoids: a systematic review. *Colorectal Dis*. 2006;8:748–55.

91. Nelson DW, Champagne BJ, Rivadeneira DE, Davis BR, Maykel JA, Ross HM, Johnson EK, Steele SR. Prophylactic antibiotics for hemorrhoidectomy: are they really needed? *Dis Colon Rectum*. 2014;57:365–9.

92. Pescatori M, Favetta U, Dedola S, Orsini S. Transanal stapled excision of rectal mucosal prolapsed. *Tech Coloproctol*. 1997;1:96–8.

93. Longo A. Treatment of hemorrhoidal disease by reduction of mucosa and haemorrhoidal prolapse with a circular stapling device: A new procedure. *Proceeding of the 6th World Congress of Endoscopic Surgery*, 777–784. 1998.

94. Senagore AJ, Singer M, Abcarian H, Fleshman J, Corman M, Wexner S, Nivatvongs S. A prospective, randomized, controlled multicenter trial comparing stapled hemorrhoidopexy and Ferguson hemorrhoidectomy: perioperative and one-year results. *Procedure for Prolapse and Hemorrhoids (PPH) Multicenter Study Group*. *Dis Colon Rectum*. 2004;47:1824–36.

95. Racalbuto A, Aliotta I, Corsaro G, Lanteri R, Di Cataldo A, Licata A. Hemorrhoidal stapler prolapsectomy vs. Milligan-Morgan hemorrhoidectomy: a long-term randomized trial. *Int J Colorectal Dis*. 2004;19:239–44.

96. Krska Z, Kvasnička J, Faltýn J, Schmidt D, Sváb J, Kormanová K, Hubík J. Surgical treatment of haemorrhoids according to Longo and Milligan Morgan: an evaluation of postoperative tissue response. *Colorectal Dis*. 2003;5:573–6.

97. Boccasanta P, Capretti PG, Venturi M, Cioffi U, De Simone M, Salamina G, Contessini-Avesani E, Peracchia A. Randomised controlled trial between stapled circumferential mucosectomy and conventional circular hemorrhoidectomy in advanced hemorrhoids with external mucosal prolapse. *Am J Surg*. 2001;182:64–8.

98. Jayaraman S, Colquhoun PH, Malthaner RA. Stapled versus conventional surgery for



hemorrhoids. *Cochrane Database Syst Rev*. 2006; 18: CD005393.

99. Shao WJ, Li GC, Zhang ZH, Yang BL, Sun GD, Chen YQ. Systematic review and meta-analysis of randomized controlled trials comparing stapled haemorrhoidopexy with conventional haemorrhoidectomy. *Br J Surg*. 2008;95: 147–60.

100. Morinaga K, Hasuda K, Ikeda T. A novel therapy for internal hemorrhoids: ligation of the hemorrhoidal artery with a newly devised instrument (Moricorn) in conjunction with a Doppler flowmeter. *Am J Gastroenterol*. 1995;90:610–3.

101. Charúa Guindic L, Fonseca Muñoz E, García Pérez NJ, Osorio Hernández RM, Navarrete Cruces T, Avendaño Espinosa O, Guerra Melgar LR. Hemorrhoidal desarterialization guided by Doppler. A surgical alternative in hemorrhoidal disease management. *Rev Gastroenterol Mex*. 2004;69:83–7.

102. Bursics A, Morvay K, Kupcsulik P, Flautner L. Comparison of early and 1-year follow-up results of conventional hemorrhoidectomy and hemorrhoid artery ligation: a randomized study. *Int J Colorectal Dis*. 2004;19:176–80.

103. Ramírez JM, Aguilera V, Elía M, Gracia JA, Martínez M. Doppler-guided hemorrhoidal artery ligation in the management of symptomatic hemorrhoids. *Rev Esp Enferm Dig*. 2005;97:97–103.

104. Felice G, Privitera A, Ellul E, Klaumann M. Doppler-guided hemorrhoidal artery ligation: an alternative to hemorrhoidectomy. *Dis Colon Rectum*. 2005;48:2090–3.

105. Giordano P, Overton J, Madeddu F, Zaman S, Gravante G. Transanal hemorrhoidal dearterialization: a systematic review. *Dis Colon Rectum*. 2009;52:1665–71.

106. Grosz CR. A surgical treatment of thrombosed external hemorrhoids. *Dis Colon Rectum*. 1990;33:249–50.

107. Grosz CR. A surgical treatment of thrombosed external hemorrhoids. *Dis Colon Rectum*. 1990;33:249–50.

108. Bernstein WC. What are hemorrhoids and what is their relationship to the portal venous system? *Dis Colon Rectum*. 1983;26:829–34.

109. Chawla Y, Dilawari JB. Anorectal varices--their frequency in cirrhotic and non-cirrhotic portal hypertension. *Gut*. 1991;32:309–11.

110. Montemurro S, Polignano FM, Caliendo C, Rucci A, Ruggieri E, Sciscio V. Inferior mesocaval shunt for bleeding anorectal varices and portal vein thrombosis. *Hepatogastroenterology*. 2001;48:980–3.

111. Rahmani O, Wolpert LM, Drezner AD. Distal inferior mesenteric veins to renal vein shunt for treatment of bleeding anorectal varices: case report and review of literature. *J Vasc Surg*. 2002;36:1264–6.

112. Saleeby Jr RG, Rosen L, Stasik JJ, Riether RD, Sheets J, Khubchandani IT. Hemorrhoidectomy during pregnancy: risk or relief? *Dis Colon Rectum*. 1991;34:260–1.

113. Jeffery PJ, Parks AG, Ritchie JK. Treatment of haemorrhoids in patients with inflammatory bowel disease. *Lancet*. 1977;21:1084–5.

114. Wolkomir AF, Luchtefeld MA. Surgery for symptomatic hemorrhoids and anal fissures in Crohn's disease. *Dis Colon Rectum*. 1993;36:545–7.

115. Morandi E, Merlini D, Salvaggio A, Foschi D, Trabucchi E. Prospective study of healing time after hemorrhoidectomy: influence of HIV infection, acquired immunodeficiency syndrome, and anal wound infection. *Dis Colon Rectum*. 1999;42:1140–4.

116. Grewal H, Guillem JG, Quan SH, Enker WE, Cohen AM. Anorectal disease in neutropenic

leukemic patients. Operative vs. nonoperative management. *Dis Colon Rectum*. 1994;37:1095–9.

## 第 13 章

1. Herzig DO, Lu KC. Anal fissure. *Surg Clin North Am*. 2010;90:33–44.
2. Ricciardi R, Dykes S, Madoff R. Anal fissure. In: Beck DE, Roberts P, Saclarides TK, Senagore AJ, Stamos MJ, Wexner SD, editors. *The ASCRS textbook of colon and rectal surgery*. 2nd ed. New York, NY: Springer; 2011. p. 203–18.
3. Hoexter B. Anal fissure. In: Fazio VW, Church J, Delaney CP, editors. *Current therapy in colon and rectal surgery*. 2nd ed. Philadelphia, PA: Elsevier Mosby; 2005. p. 19–22.
4. Perry GG. Fissure in ano--a complication of anusitis. *South Med J*. 1962;55:955–7.
5. Farouk R, Duthie GS, MacGregor AB, Bartolo DC. Sustained internal sphincter hypertonia in patients with chronic anal fissure. *Dis Colon Rectum*. 1994;37:424–9.
6. Nothmann BJ, Schuster MM. Internal anal sphincter derangement with anal fissures. *Gastroenterology*. 1974;67:216–20.
7. Gibbons CP, Read NW. Anal hypertonia in fissures: cause or effect? *Br J Surg*. 1986;73:443–5.
8. Klosterhalfen B, Vogel P, Rixen H, Mittermayer C. Topography of the inferior rectal artery: a possible cause of chronic, primary anal fissure. *Dis Colon Rectum*. 1989;32:43–52.
9. Schouten WR, Briel JW, Auwerda JJ, De Graaf EJ. Ischaemic nature of anal fissure. *Br J Surg*. 1996;83:63–5.
10. Perry WB, Dykes SL, Buie WD, Rafferty JF. Standards Practice Task Force of the American Society of C, Rectal S. Practice parameters for the management of anal fissures (3rd revision). *Dis Colon Rectum*. 2010;53:1110–5.
11. Jensen SL. Treatment of first episodes of acute anal fissure: prospective randomised study of lignocaine ointment versus hydrocortisone ointment or warm sitz baths plus bran. *Br Med J*. 1986;292:1167–9.
12. Nelson RL, Thomas K, Morgan J, Jones A. Non surgical therapy for anal fissure. *Cochrane Database Syst Rev*. 2012; (2): CD003431.
13. O’Kelly T, Brading A, Mortensen N. Nerve mediated relaxation of the human internal anal sphincter: the role of nitric oxide. *Gut*. 1993;34:689–93.
14. Loder PB, Kamm MA, Nicholls RJ, Phillips RK. ‘Reversible chemical sphincterotomy’ by local application of glyceryl trinitrate. *Br J Surg*. 1994;81:1386–9.
15. Lund JN, Scholefield JH. A randomised, prospective, double-blind, placebo-controlled trial of glyceryl trinitrate ointment in treatment of anal fissure. *Lancet*. 1997;349:11–4.
16. Jonas M, Barrett DA, Shaw PN, Scholefield JH. Systemic levels of glyceryl trinitrate following topical application to the anoderm do not correlate with the measured reduction in anal pressure. *Br J Surg*. 2001;88:1613–6.
17. Brisinda G, Maria G, Bentivoglio AR, Cassetta E, Gui D, Albanese A. A comparison of injections of botulinum toxin and topical nitroglycerin ointment for the treatment of chronic anal fissure. *N Engl J Med*. 1999;341:65–9.
18. Lund JN, Armitage NC, Scholefield JH. Use of glyceryl trinitrate ointment in the treatment of anal fissure. *Br J Surg*. 1996;83:776–7.
19. Watson SJ, Kamm MA, Nicholls RJ, Phillips RK. Topical glyceryl trinitrate in the treatment of

chronic anal fissure. *Br J Surg.* 1996;83:771–5.

20. Perez-Legaz J, Arroyo A, Moya P, Ruiz-Tovar J, Frangi A, Candela F, et al. Perianal versus endoanal application of glyceryl trinitrate 0.4% ointment in the treatment of chronic anal fissure: results of a randomized controlled trial. Is this the solution to the headaches? *Dis Colon Rectum.* 2012;55:893–9.

21. Chrysos E, Xynos E, Tzovaras G, Zoras OJ, Tsiaoussis J, Vassilakis SJ. Effect of nifedipine on rectoanal motility. *Dis Colon Rectum.* 1996;39:212–6.

22. Carapeti EA, Kamm MA, Phillips RK. Topical diltiazem and bethanechol decrease anal sphincter pressure and heal anal fissures without side effects. *Dis Colon Rectum.* 2000;43:1359–62.

23. Jonas M, Neal KR, Abercrombie JF, Scholefield JH. A randomized trial of oral vs. topical diltiazem for chronic anal fissures. *Dis Colon Rectum.* 2001;44:1074–8.

24. Bielecki K, Kolodziejczak M. A prospective randomized trial of diltiazem and glyceryltrinitrate ointment in the treatment of chronic anal fissure. *Colorectal Dis.* 2003;5:256–7.

25. Kocher HM, Steward M, Leather AJ, Cullen PT. Randomized clinical trial assessing the side-effects of glyceryl trinitrate and diltiazem hydrochloride in the treatment of chronic anal fissure. *Br J Surg.* 2002;89:413–7.

26. Cheng CM, Chen JS, Patel RP. Unlabeled uses of botulinum toxins: a review, part 1. *Am J Health Syst Pharm.* 2006;63:145–52.

27. Tjandra JJ. Ambulatory haemorrhoidectomy - has the time come? *ANZ J Surg.* 2005;75:183.

28. Gui D, Cassetta E, Anastasio G, Bentivoglio AR, Maria G, Albanese A. Botulinum toxin for chronic anal fissure. *Lancet.* 1994;344:1127–8.

29. Maria G, Brisinda G, Bentivoglio AR, Cassetta E, Gui D, Albanese A. Influence of botulinum toxin site of injections on healing rate in patients with chronic anal fissure. *Am J Surg.* 2000;179:46–50.

30. Maria G, Cassetta E, Gui D, Brisinda G, Bentivoglio AR, Albanese A. A comparison of botulinum toxin and saline for the treatment of chronic anal fissure. *N Engl J Med.* 1998;338:217–20.

31. Arroyo A, Perez F, Serrano P, Candela F, Lacueva J, Calpena R. Surgical versus chemical (botulinum toxin) sphincterotomy for chronic anal fissure: long-term results of a prospective randomized clinical and manometric study. *Am J Surg.* 2005;189:429–34.

32. Iswariah H, Stephens J, Rieger N, Rodda D, Hewett P. Randomized prospective controlled trial of lateral internal sphincterotomy versus injection of botulinum toxin for the treatment of idiopathic fissure in ano. *ANZ J Surg.* 2005;75:553–5.

33. Menten BB, Irkorucu O, Akin M, Leventoglu S, Tatlicioglu E. Comparison of botulinum toxin injection and lateral internal sphincterotomy for the treatment of chronic anal fissure. *Dis Colon Rectum.* 2003;46:232–7.

34. Chen HL, Woo XB, Wang HS, Lin YJ, Luo HX, Chen YH, et al. Botulinum toxin injection versus lateral internal sphincterotomy for chronic anal fissure: a meta-analysis of randomized control trials. *Tech Coloproctol.* 2014;18:693–8.

35. Gandomkar H, Zeinoddini A, Heidari R, Amoli HA. Partial lateral internal sphincterotomy versus combined botulinum toxin A injection and topical diltiazem in the treatment of chronic anal fissure: a randomized clinical trial. *Dis Colon Rectum.* 2015;58:228–34.

36. Saad AM, Omer A. Surgical treatment of chronic fissure-in-ano: a prospective randomised study. *East Afr Med J.* 1992;69:613–5.

37. Steele SR, Madoff RD. Systematic review: the treatment of anal fissure. *Aliment Pharmacol Ther.* 2006;24:247–57.
38. Nelson RL, Chattopadhyay A, Brooks W, Platt I, Paavana T, Earl S. Operative procedures for fissure in ano. *Cochrane Database Syst Rev.* 2011; (11): CD002199.
39. Renzi A, Izzo D, Di Sarno G, Talento P, Torelli F, Izzo G, et al. Clinical, manometric, and ultrasonographic results of pneumatic balloon dilatation vs. lateral internal sphincterotomy for chronic anal fissure: a prospective, randomized, controlled trial. *Dis Colon Rectum.* 2008;51:121–7.
40. Eisenhammer S. The evaluation of the internal anal sphincterotomy operation with special reference to anal fissure. *Surg Gynecol Obstet.* 1959;109:583–90.
41. Notaras MJ. Lateral subcutaneous sphincterotomy for anal fissure--a new technique. *Proc R Soc Med.* 1969;62:713.
42. Arroyo A, Perez F, Serrano P, Candela F, Calpena R. Open versus closed lateral sphincterotomy performed as an outpatient procedure under local anesthesia for chronic anal fissure: prospective randomized study of clinical and manometric longterm results. *J Am Coll Surg.* 2004;199:361–7.
43. Filingeri V, Gravante G. A prospective randomized trial between subcutaneous lateral internal sphincterotomy with radiofrequency bistoury and conventional parks' operation in the treatment of anal fissures. *Eur Rev Med Pharmacol Sci.* 2005;9:175–8.
44. Boulos PB, Araujo JG. Adequate internal sphincterotomy for chronic anal fissure: subcutaneous or open technique? *Br J Surg.* 1984;71:360–2.
45. Kortbeek JB, Langevin JM, Khoo RE, Heine JA. Chronic fissure-in-ano: a randomized study comparing open and subcutaneous lateral internal sphincterotomy. *Dis Colon Rectum.* 1992;35:835–7.
46. Wiley M, Day P, Rieger N, Stephens J, Moore J. Open vs. closed lateral internal sphincterotomy for idiopathic fissure-in-ano: a prospective, randomized, controlled trial. *Dis Colon Rectum.* 2004;47:847–52.
47. Garcia-Granero E, Sanahuja A, Garcia-Botello SA, Faiz O, Esclapez P, Espi A, et al. The ideal lateral internal sphincterotomy: clinical and endosonographic evaluation following open and closed internal anal sphincterotomy. *Colorectal Dis.* 2009;11:502–7.
48. Menten BB, Ege B, Leventoglu S, Oguz M, Karadag A. Extent of lateral internal sphincterotomy: up to the dentate line or up to the fissure apex? *Dis Colon Rectum.* 2005;48:365–70.
49. Elsebae MM. A study of fecal incontinence in patients with chronic anal fissure: prospective, randomized, controlled trial of the extent of internal anal sphincter division during lateral sphincterotomy. *World J Surg.* 2007;31:2052–7.
50. Magdy A, El Nakeeb A, el Fouda Y, Youssef M, Farid M. Comparative study of conventional lateral internal sphincterotomy, V-Y anoplasty, and tailored lateral internal sphincterotomy with V-Y anoplasty in the treatment of chronic anal fissure. *J Gastrointest Surg.* 2012;16:1955–62.
51. Menten BB, Guner MK, Leventoglu S, Akyurek N. Fine-tuning of the extent of lateral internal sphincterotomy: spasm-controlled vs. up to the fissure apex. *Dis Colon Rectum.* 2008;51:128–33.
52. Pelta AE, Davis KG, Armstrong DN. Subcutaneous fissurotomy: a novel procedure for chronic fissure-in-ano. a review of 109 cases. *Dis Colon Rectum.* 2007;50:1662–7.
53. Garcia-Aguilar J, Belmonte C, Wong WD, Lowry AC, Madoff RD. Open vs. closed sphincterotomy for chronic anal fissure: long-term results. *Dis Colon Rectum.* 1996;39:440–3.
54. Madoff RD, Fleshman JW. AGA technical review on the diagnosis and care of patients with anal

- fissure. *Gastroenterology*. 2003;124:235–45.
55. Floyd ND, Kondylis L, Kondylis PD, Reilly JC. Chronic anal fissure: 1994 and a decade later—are we doing better? *Am J Surg*. 2006;191:344–8.
  56. Lysy J, Israeli E, Levy S, Rozentzweig G, Strauss-Liviatan N, Goldin E. Long-term results of “chemical sphincterotomy” for chronic anal fissure: a prospective study. *Dis Colon Rectum*. 2006;49:858–64.
  57. Giordano P, Gravante G, Grondona P, Ruggiero B, Porrett T, Lunniss PJ. Simple cutaneous advancement flap anoplasty for resistant chronic anal fissure: a prospective study. *World J Surg*. 2009;33:1058–63.
  58. Nyam DC, Wilson RG, Stewart KJ, Farouk R, Bartolo DC. Island advancement flaps in the management of anal fissures. *Br J Surg*. 1995;82:326–8.
  59. Kenefick NJ, Gee AS, Durdey P. Treatment of resistant anal fissure with advancement anoplasty. *Colorectal Dis*. 2002;4:463–6.
  60. Sangwan YP, Schoetz Jr DJ, Murray JJ, Roberts PL, Collier JA. Perianal Crohn’s disease. Results of local surgical treatment. *Dis Colon Rectum*. 1996;39:529–35.
  61. Platell C, Mackay J, Collopy B, Fink R, Ryan P, Woods R. Anal pathology in patients with Crohn’s disease. *ANZ J Surg*. 1996;66:5–9.
  62. Wolkowicz AF, Luchtefeld MA. Surgery for symptomatic hemorrhoids and anal fissures in Crohn’s disease. *Dis Colon Rectum*. 1993;36:545–7.
  63. Fleshner PR, Schoetz Jr DJ, Roberts PL, Murray JJ, Collier JA, Veidenheimer MC. Anal fissure in Crohn’s disease: a plea for aggressive management. *Dis Colon Rectum*. 1995;38:1137–43.
  64. Ouraghi A, Nieuviarts S, Mouguel JL, Allez M, Barthet M, Carbonnel F, et al. Infliximab therapy for Crohn’s disease anoperineal lesions. *Gastroenterol Clin Biol*. 2001;25:949–56.
  65. Sweeney JL, Ritchie JK, Nicholls RJ. Anal fissure in Crohn’s disease. *Br J Surg*. 1988;75:56–7.
  66. Viamonte M, Dailey TH, Gottesman L. Ulcerative disease of the anorectum in the HIV+ patient. *Dis Colon Rectum*. 1993;36:801–5.
  67. Weiss EG, Wexner SD. Surgery for anal lesions in HIV-infected patients. *Ann Med*. 1995;27:467–75.

## 第 14 章

1. Abcarian H. Anorectal infection: abscess-fistula. *Clin Colon Rectal Surg*. 2011;24(1):14–21.
2. Shrum RC. Anorectal pathology in 1000 consecutive patients with suspected surgical disorders. *Dis Colon Rectum*. 1959;2:469–72.
3. Sl B. Practice proctology. Charles C Thomas: Springfield, IL; 1960.
4. Sainio P. Fistula-in-ano in a defined population. Incidence and epidemiological aspects. *Ann Chir Gynaecol*. 1984;73(4):219–24.
5. Ommer A, Herold A, Berg E, Furst A, Sailer M, Schiedeck T. German S3 guideline: anal abscess. *Int J Colorectal Dis*. 2012;27(6):831–7.
6. Khatri NJ, Sondel Lewis N, Frazier AA, Obias V, Zeman RK, Hill MC. CT of acute perianal abscesses and infected fistulae: a pictorial essay. *Emerg Radiol*. 2015;22(3):329–35. doi:10.1007/s10140-014-1284-3. Epub 2014 Nov 25. PubMed PMID: 25421387.
7. Eglitis J. The glands of the anal canal in man. *Ohio J Sci*. 1961;61(2):65–79.

8. Seow-Choen F, Ho JM. Histoanatomy of anal glands. *Dis Colon Rectum*. 1994;37(12):1215–8.
9. Eisenhammer S. The internal anal sphincter and the anorectal abscess. *Surg Gynecol Obstet*. 1956;103(4):501–6.
10. Parks AG. Pathogenesis and treatment of fistula-in-ano. *Br Med J*. 1961;1(5224):463–9.
11. McElwain JW, MacLean MD, Alexander RM, Hoexter B, Guthrie JF. Anorectal problems: experience with primary fistulectomy for anorectal abscess, a report of 1,000 cases. *Dis Colon Rectum*. 1975;18(8):646–9.
12. Snieder EB, Maykel JA. Anal abscess and fistula. *Gastroenterol Clin North Am*. 2013;42(4):773–84.
13. Steele SR, Kumar R, Feingold DL, Rafferty JL, Buie WD. Practice parameters for the management of perianal abscess and fistula-in-ano. *Dis Colon Rectum*. 2011;54(12):1465–74.
14. Garcia-Granero A, Granero-Castro P, Frasson M, Flor-Lorente B, Carreno O, Espi A, et al. Management of cryptoglandular supralelevator abscesses in the magnetic resonance imaging era: a case series. *Int J Colorectal Dis*. 2014;29(12):1557–64.
15. Visscher AP, Felt-Bersma RJ. Endoanal ultrasound in perianal fistulae and abscesses. *Ultrasound Q* 2015;31(2):130–7.
16. Plaikner M, Loizides A, Peer S, Aigner F, Pecival D, Zbar A, et al. Transperineal ultrasonography as a complementary diagnostic tool in identifying acute perianal sepsis. *Tech Coloproctol*. 2014;18(2):165–71.
17. Sozener U, Gedik E, Kessaf Aslar A, Ergun H, Halil Elhan A, Memikoglu O, et al. Does adjuvant antibiotic treatment after drainage of anorectal abscess prevent development of anal fistulas? A randomized, placebo-controlled, double-blind, multicenter study. *Dis Colon Rectum*. 2011;54(8):923–9.
18. Liu CK, Liu CP, Leung CH, Sun FJ. Clinical and microbiological analysis of adult perianal abscess. *J Microbiol Immunol Infect*. 2011;44(3):204–8.
19. Zinicola R, Cracco N. Draining an anal abscess: the skeletal muscle rule. *Colorectal Dis*. 2014;16(7):562.
20. Perera AP, Howell AM, Sodergren MH, Farne H, Darzi A, Purkayastha S, et al. A pilot randomised controlled trial evaluating postoperative packing of the perianal abscess. *Langenbecks Arch Surg*. 2015;400(2):267–71.
21. Hanley PH, Ray JE, Pennington EE, Grablowsky OM. Fistula-in-ano: a ten-year follow-up study of horseshoe-abscess fistula-in-ano. *Dis Colon Rectum*. 1976;19(6):507–15.
22. Tan KK, Koh DC, Tsang CB. Managing deep postanal space sepsis via an intersphincteric approach: our early experience. *Ann Coloproctol*. 2013;29(2):55–9.
23. Malik AI, Nelson RL, Tou S. Incision and drainage of perianal abscess with or without treatment of anal fistula. *Cochrane Database Syst Rev*. 2010;7:CD006827.
24. Ramanujam PS, Prasad ML, Abcarian H. The role of seton in fistulotomy of the anus. *Surg Gynecol Obstet*. 1983;157(5):419–22.
25. Cariati A. Fistulotomy or seton in anal fistula: a decisional algorithm. *Updates Surg*. 2013;65(3):201–5.
26. Schouten WR, van Vroonhoven TJ. Treatment of anorectal abscess with or without primary fistulectomy. Results of a prospective randomized trial. *Dis Colon Rectum*. 1991;34(1):60–3.
27. Hamalainen KP, Sainio AP. Incidence of fistulas after drainage of acute anorectal abscesses. *Dis Colon Rectum*. 1998;41(11):1357–61. discussion 61–2.

28. Rizzo JA, Naig AL, Johnson EK. Anorectal abscess and fistula-in-ano: evidence-based management. *Surg Clin North Am.* 2010;90(1):45–68. Table of Contents.
29. Paydar S, Izadpanah A, Ghahramani L, Hosseini SV, Bananzadeh A, Rahimikazerooni S, et al. How the anal gland orifice could be found in anal abscess operations. *J Res Med Sci.* 2015;20(1):22–5.
30. Ho YH, Tan M, Chui CH, Leong A, Eu KW, Seow-Choen F. Randomized controlled trial of primary fistulotomy with drainage alone for perianal abscesses. *Dis Colon Rectum.* 1997;40(12):1435–8.
31. Quah HM, Tang CL, Eu KW, Chan SY, Samuel M. Meta-analysis of randomized clinical trials comparing drainage alone vs primary sphincter-cutting procedures for anorectal abscess-fistula. *Int J Colorectal Dis.* 2006;21(6):602–9.
32. Read DR, Abcarian H. A prospective survey of 474 patients with anorectal abscess. *Dis Colon Rectum.* 1979;22(8):566–8.
33. Ramanujam PS, Prasad ML, Abcarian H, Tan AB. Perianal abscesses and fistulas. A study of 1023 patients. *Dis Colon Rectum.* 1984;27(9):593–7.
34. Oliver I, Lacueva FJ, Perez Vicente F, Arroyo A, Ferrer R, Cansado P, et al. Randomized clinical trial comparing simple drainage of anorectal abscess with and without fistula track treatment. *Int J Colorectal Dis.* 2003;18(2):107–10.
35. Toyonaga T, Matsushima M, Sogawa N, Jiang SF, Matsumura N, Shimojima Y, et al. Postoperative urinary retention after surgery for benign anorectal disease: potential risk factors and strategy for prevention. *Int J Colorectal Dis.* 2006;21(7):676–82.
36. Hamadani A, Haigh PI, Liu IL, Abbas MA. Who is at risk for developing chronic anal fistula or recurrent anal sepsis after initial perianal abscess? *Dis Colon Rectum.* 2009;52(2):217–21.
37. Yano T, Asano M, Matsuda Y, Kawakami K, Nakai K, Nonaka M. Prognostic factors for recurrence following the initial drainage of an anorectal abscess. *Int J Colorectal Dis.* 2010;25(12):1495–8.
38. Onaca N, Hirshberg A, Adar R. Early reoperation for perirectal abscess: a preventable complication. *Dis Colon Rectum.* 2001;44(10):1469–73.
39. Chrabot CM, Prasad ML, Abcarian H. Recurrent anorectal abscesses. *Dis Colon Rectum.* 1983;26(2):105–8.
40. Buchan R, Grace RH. Anorectal suppuration: the results of treatment and the factors influencing the recurrence rate. *Br J Surg.* 1973;60(7):537–40.
41. Vasilevsky CA, Gordon PH. The incidence of recurrent abscesses or fistula-in-ano following anorectal suppuration. *Dis Colon Rectum.* 1984;27(2):126–30.
42. Rosen SA, Colquhoun P, Efron J, Vernava 3rd AM, Nogueras JJ, Wexner SD, et al. Horseshoe abscesses and fistulas: how are we doing? *Surg Innov.* 2006;13(1):17–21.
43. Iqbal CW, Gasior AC, Snyder CL. Pilonidal disease mimicking fistula-in-ano in a 15-year-old female. *Case Rep Surg.* 2012;2012:310187.
44. Sorensen MD, Krieger JN, Rivara FP, Broghammer JA, Klein MB, Mack CD, et al. Fournier's gangrene: population based epidemiology and outcomes. *J Urol.* 2009;181(5):2120–6.
45. Wroblewska M, Kuzaka B, Borkowski T, Kuzaka P, Kawecki D, Radziszewski P. Fournier's gangrene – current concepts. *Pol J Microbiol.* 2014;63(3):267–73.
46. Anaya DA, Dellinger EP. Necrotizing soft-tissue infection: diagnosis and management. *Clin Infect Dis.* 2007;44(5):705–10.

47. Yang BL, Lin Q, Chen HJ, Gu YF, Zhu P, Sun XL, et al. Perianal necrotizing fasciitis treated with a loose-seton technique. *Colorectal Dis.* 2012;14(7):e422–4.
48. Laor E, Palmer LS, Tolia BM, Reid RE, Winter HI. Outcome prediction in patients with Fournier's gangrene. *J Urol.* 1995;154(1):89–92.
49. Buyukasik Y, Ozcebe OI, Sayinalp N, Haznedaroglu IC, Altundag OO, Ozdemir O, et al. Perianal infections in patients with leukemia: importance of the course of neutrophil count. *Dis Colon Rectum.* 1998;41(1):81–5.
50. Baker B, Al-Salman M, Daoud F. Management of acute perianal sepsis in neutropenic patients with hematological malignancy. *Tech Coloproctol.* 2014;18(4):327–33.
51. Schimpff SC, Wiernik PH, Block JB. Rectal abscesses in cancer patients. *Lancet.* 1972;2(7782):844–7.
52. Musa MB, Katakhar SB, Khaliq A. Anorectal and perianal complications of hematologic malignant neoplasms. *Can J Surg.* 1975;18(6):579–83.
53. Grewal H, Guillem JG, Quan SH, Enker WE, Cohen AM. Anorectal disease in neutropenic leukemic patients. Operative vs. nonoperative management. *Dis Colon Rectum.* 1994;37(11):1095–9.
54. Carlson GW, Ferguson CM, Amerson JR. Perianal infections in acute leukemia. Second place winner: Conrad Jobst Award. *Am Surg.* 1988;54(12):693–5.
55. Badgwell BD, Chang GJ, Rodriguez-Bigas MA, Smith K, Lupo PJ, Frankowski RF, et al. Management and outcomes of anorectal infection in the cancer patient. *Ann Surg Oncol.* 2009;16(10):2752–8.
56. Blumetti J, Abcarian A, Quinteros F, Chaudhry V, Prasad L, Abcarian H. Evolution of treatment of fistula in ano. *World J Surg.* 2012;36(5):1162–7.
57. Zanotti C, Martinez-Puente C, Pascual I, Pascual M, Herreros D, Garcia-Olmo D. An assessment of the incidence of fistula-in-ano in four countries of the European Union. *Int J Colorectal Dis.* 2007;22(12):1459–62.
58. Lockhart-Mummery JP. Discussion of fistula in ano. *Proc R Soc Med.* 1929;22(9):1331–58.
59. Kratzer GL, Dockerty MB. Histopathology of the anal ducts. *Surg Gynecol Obstet.* 1947;84(3):333–8.
60. Scoma JA, Salvati EP, Rubin RJ. Incidence of fistulas subsequent to anal abscesses. *Dis Colon Rectum.* 1974;17(3):357–9.
61. Wang D, Yang G, Qiu J, Song Y, Wang L, Gao J, et al. Risk factors for anal fistula: a case-control study. *Tech Coloproctol.* 2014;18(7):635–9.
62. Milligan ET, Morgan CN. Surgical anatomy of the anal canal. *Lancet.* 1934;2:1213.
63. Parks AG, Gordon PH, Hardcastle JD. A classification of fistula-in-ano. *Br J Surg.* 1976;63(1):1–12.
64. Sileri P, Cadeddu F, D'Ugo S, Franceschilli L, Del Vecchio Blanco G, De Luca E, et al. Surgery for fistula-in-ano in a specialist colorectal unit: a critical appraisal. *BMC Gastroenterol.* 2011;11:120.
65. Ozkavukcu E, Haliloglu N, Erden A. Frequencies of perianal fistula types using two classification systems. *Jpn J Radiol.* 2011;29(5):293–300.
66. Van Onkelen RS, Gosselink MP, van Rosmalen J, Thijsse S, Schouten WR. Different characteristics of high and low transsphincteric fistulae. *Colorectal Dis.* 2014;16(6):471–5.
67. Goodsall D. Diseases of the anus and rectum. London: Longman, Green; 1900. 271 p.
68. Cirocco WC, Reilly JC. Challenging the predictive accuracy of Goodsall's rule for anal fistulas.



Dis Colon Rectum. 1992;35(6):537–42.

69. Gunawardhana PA, Deen KI. Comparison of hydrogen peroxide instillation with Goodsall's rule for fistula-in-ano. ANZ J Surg. 2001;71(8):472–4.

70. Barwood N, Clarke G, Levitt S, Levitt M. Fistula-in-ano: a prospective study of 107 patients. Aust N Z J Surg. 1997;67(2–3):98–102.

71. Gonzalez-Ruiz C, Kaiser AM, Vukasin P, Beart Jr RW, Ortega AE. Intraoperative physical diagnosis in the management of anal fistula. Am Surg. 2006;72(1):11–5.

72. Liang C, Jiang W, Zhao B, Zhang Y, Du Y, Lu Y. CT imaging with fistulography for perianal fistula: does it really help the surgeon? Clin Imaging. 2013;37(6):1069–76.

73. Weisman RI, Orsay CP, Pearl RK, Abcarian H. The role of fistulography in fistula-in-ano. Report of five cases. Dis Colon Rectum. 1991;34(2):181–4.

74. Kuijpers HC, Schulpen T. Fistulography for fistula-in-ano. Is it useful? Dis Colon Rectum. 1985;28(2):103–4.

75. Pomerri F, Dodi G, Pintacuda G, Amadio L, Muzzio PC. Anal endosonography and fistulography for fistula-in-ano. Radiol Med. 2010;115(5):771–83.

76. Chew SS, Yang JL, Newstead GL, Douglas PR. Anal fistula: Levovist-enhanced endoanal ultrasound: a pilot study. Dis Colon Rectum. 2003;46(3):377–84.

77. Buchanan GN, Bartram CI, Williams AB, Halligan S, Cohen CR. Value of hydrogen peroxide enhancement of three-dimensional endoanal ultrasound in fistula-in-ano. Dis Colon Rectum. 2005;48(1):141–7.

78. Nagendranath C, Saravanan MN, Sridhar C, Varughese M. Peroxide-enhanced endoanal ultrasound in preoperative assessment of complex fistula-in-ano. Tech Coloproctol. 2014;18(5):433–8.

79. Siddiqui MR, Ashrafian H, Tozer P, Daulatzai N, Burling D, Hart A, et al. A diagnostic accuracy meta-analysis of endoanal ultrasound and MRI for perianal fistula assessment. Dis Colon Rectum. 2012;55(5):576–85.

80. Subasinghe D, Samarasekera DN. Comparison of preoperative endoanal ultrasonography with intraoperative findings for fistula in ano. World J Surg. 2010;34(5):1123–7.

81. Choen S, Burnett S, Bartram CI, Nicholls RJ. Comparison between anal endosonography and digital examination in the evaluation of anal fistulae. Br J Surg. 1991;78(4):445–7.

82. Buchanan GN, Halligan S, Bartram CI, Williams AB, Tarroni D, Cohen CR. Clinical examination, endosonography, and MR imaging in preoperative assessment of fistula in ano: comparison with outcome-based reference standard. Radiology. 2004;233(3):674–81.

83. Toyonaga T, Tanaka Y, Song JF, Katori R, Sogawa N, Kanyama H, et al. Comparison of accuracy of physical examination and endoanal ultrasonography for preoperative assessment in patients with acute and chronic anal fistula. Tech Coloproctol. 2008;12(3):217–23.

84. Weisman N, Abbas MA. Prognostic value of endoanal ultrasound for fistula-in-ano: a retrospective analysis. Dis Colon Rectum. 2008;51(7):1089–92.

85. Benjelloun EB, Souiki T, El Abkari M. Endoanal ultrasound in anal fistulas. Is there any influence on postoperative outcome? Tech Coloproctol. 2014;18(4):405–6.

86. Nevler A, Beer-Gabel M, Lebedyev A, Soffer A, Gutman M, Carter D, et al. Transperineal ultrasonography in perianal Crohn's disease and recurrent cryptogenic fistula-in-ano. Colorectal Dis. 2013;15(8):1011–8.

87. Halligan S, Bartram CI. MR imaging of fistula in ano: are endoanal coils the gold standard? Am

J Roentgenol. 1998;171(2):407–12.

88. Chang KJ, Kamel IR, Macura KJ, Bluemke DA. 3.0-T MR imaging of the abdomen: comparison with 1.5 T. *RadioGraphics*. 2008;28(7):1983–98.

89. Schaefer O, Oeksuez MO, Lohrmann C, Langer M. Differentiation of anal sphincters with high-resolution magnetic resonance imaging using contrast-enhanced fast low-angle shot 3-dimensional sequences. *J Comput Assist Tomogr*. 2004;28(2):174–9.

90. Lunniss PJ, Armstrong P, Barker PG, Reznick RH, Phillips RK. Magnetic resonance imaging of anal fistulae. *Lancet*. 1992;340(8816):394–6.

91. Lunniss PJ, Barker PG, Sultan AH, Armstrong P, Reznick RH, Bartram CI, et al. Magnetic resonance imaging of fistula-in-ano. *Dis Colon Rectum*. 1994;37(7):708–18.

92. Beekingham IJ, Spencer JA, Ward J, Dyke GW, Adams C, Ambrose NS. Prospective evaluation of dynamic contrast enhanced magnetic resonance imaging in the evaluation of fistula in ano. *Br J Surg*. 1996;83(10):1396–8.

93. Beets-Tan RG, Beets GL, van der Hoop AG, Kessels AG, Vliegen RF, Baeten CG, et al. Preoperative MR imaging of anal fistulas: does it really help the surgeon? *Radiology*. 2001;218(1):75–84.

94. Buchanan G, Halligan S, Williams A, Cohen CR, Tarroni D, Phillips RK, et al. Effect of MRI on clinical outcome of recurrent fistula-in-ano. *Lancet*. 2002;360(9346):1661–2.

95. Sahni VA, Ahmad R, Burling D. Which method is best for imaging of perianal fistula? *Abdom Imaging*. 2008;33(1):26–30.

96. Ellis CN. Sphincter-preserving fistula management: what patients want. *Dis Colon Rectum*. 2010;53(12):1652–5.

97. Gottgens KW, Smeets RR, Stassen LP, Beets G, Breukink SO. Systematic review and meta-analysis of surgical interventions for high cryptoglandular perianal fistula. *Int J Colorectal Dis*. 2015;30(5):583–93. doi:10.1007/s00384-014-2091-8. Epub 2014 Dec 10. Review. PubMed PMID: 25487858.

98. Jain BK, Vaibhaw K, Garg PK, Gupta S, Mohanty D. Comparison of a fistulectomy and a fistulotomy with marsupialization in the management of a simple anal fistula: a randomized, controlled pilot trial. *J Korean Soc Coloproctol*. 2012;28(2):78–82.

99. Ho YH, Tan M, Leong AF, Seow-Choen F. Marsupialization of fistulotomy wounds improves healing: a randomized controlled trial. *Br J Surg*. 1998;85(1):105–7.

100. Pescatori M, Ayabaca SM, Cafaro D, Iannello A, Magrini S. Marsupialization of fistulotomy and fistulectomy wounds improves healing and decreases bleeding: a randomized controlled trial. *Colorectal Dis*. 2006;8(1):11–4.

101. Garcia-Aguilar J, Belmonte C, Wong WD, Goldberg SM, Madoff RD. Anal fistula surgery. Factors associated with recurrence and incontinence. *Dis Colon Rectum*. 1996;39(7):723–9.

102. Visscher AP, Schuur D, Roos R, Van der Mijnsbrugge GJ, Meijerink WJ, Felt-Bersma RJ. Long-term follow-up after surgery for simple and complex cryptoglandular fistulas: fecal incontinence and impact on quality of life. *Dis Colon Rectum*. 2015;58(5):533–9.

103. Durgun V, Perek A, Kapan M, Kapan S, Perek S. Partial fistulotomy and modified cutting seton procedure in the treatment of high extrasphincteric perianal fistulae. *Dig Surg*. 2002;19(1):56–8.

104. Awad ML, Sell HW, Stahlfeld KR. Split-shot sinker facilitates seton treatment of anal fistulae. *Colorectal Dis*. 2009;11(5):524–6.

105. Isbister WH, Al Sanea N. The cutting seton: an experience at King Faisal Specialist Hospital.

Dis Colon Rectum. 2001;44(5):722–7.

106. Hamalainen KP, Sainio AP. Cutting seton for anal fistulas: high risk of minor control defects. Dis Colon Rectum. 1997;40(12):1443–6. discussion 7.

107. Vial M, Pares D, Pera M, Grande L. Faecal incontinence after seton treatment for anal fistulae with and without surgical division of internal anal sphincter: a systematic review. Colorectal Dis. 2010;12(3):172–8.

108. Ritchie RD, Sackier JM, Hodde JP. Incontinence rates after cutting seton treatment for anal fistula. Colorectal Dis. 2009;11(6):564–71.

109. Chuang-Wei C, Chang-Chieh W, Cheng-Wen H, Tsai-Yu L, Chun-Che F, Shu-Wen J. Cutting seton for complex anal fistulas. Surgeon. 2008;6(3):185–8.

110. Pearl RK, Andrews JR, Orsay CP, Weisman RI, Prasad ML, Nelson RL, et al. Role of the seton in the management of anorectal fistulas. Dis Colon Rectum. 1993;36(6):573–7. discussion 7–9.

111. Kodner IJ, Mazor A, Shemesh EI, Fry RD, Fleshman JW, Birnbaum EH. Endorectal advancement flap repair of rectovaginal and other complicated anorectal fistulas. Surgery. 1993;114(4):682–9. discussion 9-90.

112. Jones IT, Fazio VW, Jagelman DG. The use of transanal rectal advancement flaps in the management of fistulas involving the anorectum. Dis Colon Rectum. 1987;30(12):919–23.

113. Uribe N, Millan M, Minguez M, Ballester C, Asencio F, Sanchiz V, et al. Clinical and manometric results of endorectal advancement flaps for complex anal fistula. Int J Colorectal Dis. 2007;22(3):259–64.

114. Jarrar A, Church J. Advancement flap repair: a good option for complex anorectal fistulas. Dis Colon Rectum. 2011;54(12):1537–41.

115. Hall JF, Bordeianou L, Hyman N, Read T, Bartus C, Schoetz D, et al. Outcomes after operations for anal fistula: results of a prospective, multicenter, regional study. Dis Colon Rectum. 2014;57(11):1304–8.

116. Uribe N, Balciscueta Z, Minguez M, Martin MC, Lopez M, Mora F, et al. “Core out” or “curettage” in rectal advancement flap for cryptoglandular anal fistula. Int J Colorectal Dis. 2015;30(5):613–9.

117. Lee CL, Lu J, Lim TZ, Koh FH, Lieske B, Cheong WK, et al. Long-term outcome following advancement flaps for high anal fistulas in an Asian population: a single institution's experience. Int J Colorectal Dis. 2015;30(3):409–12.

118. Mitalas LE, Gosselink MP, Oom DM, Zimmerman DD, Schouten WR. Required length of follow-up after transanal advancement flap repair of high transsphincteric fistulas. Colorectal Dis. 2009;11(7):726–8.

119. Van Koperen PJ, Wind J, Bemelman WA, Bakx R, Reitsma JB, Slors JF. Long-term functional outcome and risk factors for recurrence after surgical treatment for low and high perianal fistulas of cryptoglandular origin. Dis Colon Rectum. 2008;51(10):1475–81.

120. Ortiz H, Marzo M, de Miguel M, Ciga MA, Oteiza F, Armendariz P. Length of follow-up after fistulotomy and fistulectomy associated with endorectal advancement flap repair for fistula in ano. Br J Surg. 2008;95(4):484–7.

121. Van Onkelen RS, Gosselink MP, Thijsse S, Schouten WR. Predictors of outcome after transanal advancement flap repair for high transsphincteric fistulas. Dis Colon Rectum. 2014;57(8):1007–11.

122. Mitalas LE, Dwarkasing RS, Verhaaren R, Zimmerman DD, Schouten WR. Is the outcome of transanal advancement flap repair affected by the complexity of high transsphincteric fistulas? Dis

Colon Rectum. 2011;54(7):857–62.

123. Mitalas LE, van Wijk JJ, Gosselink MP, Doornebosch P, Zimmerman DD, Schouten WR. Seton drainage prior to transanal advancement flap repair: useful or not? *Int J Colorectal Dis.* 2010;25(12):1499–502.

124. Stremitzer S, Riss S, Swoboda P, Dauser B, Dubsky P, Birsan T, et al. Repeat endorectal advancement flap after flap breakdown and recurrence of fistula-in-ano – is it an option? *Colorectal Dis.* 2012;14(11):1389–93.

125. Mitalas LE, Gosselink MP, Zimmerman DD, Schouten WR. Repeat transanal advancement flap repair: impact on the overall healing rate of high transsphincteric fistulas and on fecal continence. *Dis Colon Rectum.* 2007;50(10):1508–11.

126. Schouten WR, Zimmerman DD, Briel JW. Transanal advancement flap repair of transsphincteric fistulas. *Dis Colon Rectum.* 1999;42(11):1419–22. discussion 22–3.

127. Ozuner G, Hull TL, Cartmill J, Fazio VW. Long-term analysis of the use of transanal rectal advancement flaps for complicated anorectal/vaginal fistulas. *Dis Colon Rectum.* 1996;39(1):10–4.

128. Jacob TJ, Perakath B, Keighley MR. Surgical intervention for anorectal fistula. *Cochrane Database of Syst Rev.* 2010;5:CD006319.

129. Gottgens KW, Vening W, van der Hagen SJ, van Gemert WG, Smeets RR, Stassen LP, et al. Long-term results of mucosal advancement flap combined with platelet-rich plasma for high cryptoglandular perianal fistulas. *Dis Colon Rectum.* 2014;57(2):223–7.

130. Nessim A, Wexner SD, Agachan F, Alabaz O, Weiss EG, Nogueras JJ, et al. Is bowel confinement necessary after anorectal reconstructive surgery? A prospective, randomized, surgeon-blinded trial. *Dis Colon Rectum.* 1999;42(1):16–23.

131. Khafagy W, Omar W, El Nakeeb A, Fouda E, Yousef M, Farid M. Treatment of anal fistulas by partial rectal wall advancement flap or mucosal advancement flap: a prospective randomized study. *Int J Surg.* 2010;8(4):321–5.

132. Dubsky PC, Stift A, Friedl J, Teleky B, Herbst F. Endorectal advancement flaps in the treatment of high anal fistula of cryptoglandular origin: full-thickness vs. mucosal-rectum flaps. *Dis Colon Rectum.* 2008;51(6):852–7.

133. Zimmerman DD, Gosselink MP, Mitalas LE, Delemarre JB, Hop WJ, Briel JW, et al. Smoking impairs rectal mucosal blood flow – a pilot study: possible implications for transanal advancement flap repair. *Dis Colon Rectum.* 2005;48(6):1228–32.

134. Ellis CN, Clark S. Effect of tobacco smoking on advancement flap repair of complex anal fistulas. *Dis Colon Rectum.* 2007;50(4):459–63.

135. Schwandner O. Obesity is a negative predictor of success after surgery for complex anal fistula. *BMC Gastroenterol.* 2011;11:61.

136. Mizrahi N, Wexner SD, Zmora O, Da Silva G, Efron J, Weiss EG, et al. Endorectal advancement flap: are there predictors of failure? *Dis Colon Rectum.* 2002;45(12):1616–21.

137. Rojanasakul A, Pattanaarun J, Sahakitrungruang C, Tantiphlachiva K. Total anal sphincter saving technique for fistula-in-ano; the ligation of intersphincteric fistula tract. *J Med Assoc Thai.* 2007;90(3):581–6.

138. Ye F, Tang C, Wang D, Zheng S. Early experience with the modified approach of ligation of the intersphincteric fistula tract for high transsphincteric fistula. *World J Surg.* 2015;39(4):1059–65.

139. Madbouly KM, El Shazly W, Abbas KS, Hussein AM. Ligation of intersphincteric fistula tract

versus mucosal advancement flap in patients with high transsphincteric fistula-in-ano: a prospective randomized trial. *Dis Colon Rectum*. 2014;57(10):1202–8.

140. Bastawrous A, Hawkins M, Kratz R, Menon R, Pollock D, Charbel J, et al. Results from a novel modification to the ligation intersphincteric fistula tract. *Am J Surg*. 2015;209(5):793–8.

141. Tan KK, Lee PJ. Early experience of reinforcing the ligation of the intersphincteric fistula tract procedure with a bioprosthetic graft (BioLIFT) for anal fistula. *ANZ J Surg*. 2014;84(4):280–3.

142. Han JG, Yi BQ, Wang ZJ, Zheng Y, Cui JJ, Yu XQ, et al. Ligation of the intersphincteric fistula tract plus a bioprosthetic anal fistula plug (LIFT-Plug): a new technique for fistula-in-ano. *Colorectal Dis*. 2013;15(5):582–6.

143. Ellis CN. Outcomes with the use of bioprosthetic grafts to reinforce the ligation of the intersphincteric fistula tract (BioLIFT procedure) for the management of complex anal fistulas. *Dis Colon Rectum*. 2010;53(10):1361–4.

144. Abcarian AM, Estrada JJ, Park J, Corning C, Chaudhry V, Cintron J, et al. Ligation of intersphincteric fistula tract: early results of a pilot study. *Dis Colon Rectum*. 2012;55(7):778–82.

145. Campbell ML, Abboud EC, Dolberg ME, Sanchez JE, Marcet JE, Rasheid SH. Treatment of refractory perianal fistulas with ligation of the intersphincteric fistula tract: preliminary results. *Am Surg*. 2013;79(7):723–7.

146. Vergara-Fernandez O, Espino-Urbina LA. Ligation of intersphincteric fistula tract: what is the evidence in a review? *World J Gastroenterol*. 2013;19(40):6805–13.

147. Hong KD, Kang S, Kalaskar S, Wexner SD. Ligation of intersphincteric fistula tract (LIFT) to treat anal fistula: systematic review and meta-analysis. *Tech Coloproctol*. 2014;18(8):685–91.

148. Yassin NA, Hammond TM, Lunniss PJ, Phillips RK. Ligation of the intersphincteric fistula tract in the management of anal fistula. A systematic review. *Colorectal Dis*. 2013;15(5):527–35.

149. Tan KK, Tan IJ, Lim FS, Koh DC, Tsang CB. The anatomy of failures following the ligation of intersphincteric tract technique for anal fistula: a review of 93 patients over 4 years. *Dis Colon Rectum*. 2011;54(11):1368–72.

150. Van Onkelen RS, Gosselink MP, Schouten WR. Ligation of the intersphincteric fistula tract in low transsphincteric fistulae: a new technique to avoid fistulotomy. *Colorectal Dis*. 2013;15(5):587–91.

151. Van Onkelen RS, Gosselink MP, Schouten WR. Is it possible to improve the outcome of transanal advancement flap repair for high transsphincteric fistulas by additional ligation of the intersphincteric fistula tract? *Dis Colon Rectum*. 2012;55(2):163–6.

152. Hjortrup A, Moesgaard F, Kjaergard J. Fibrin adhesive in the treatment of perineal fistulas. *Dis Colon Rectum*. 1991;34(9):752–4.

153. Hammond TM, Grahn MF, Lunniss PJ. Fibrin glue in the management of anal fistulae. *Colorectal Dis*. 2004;6(5):308–19.

154. Singer M, Cintron J, Nelson R, Orsay C, Bastawrous A, Pearl R, et al. Treatment of fistulas-in-ano with fibrin sealant in combination with intra-adhesive antibiotics and/or surgical closure of the internal fistula opening. *Dis Colon Rectum*. 2005;48(4):799–808.

155. De Parades V, Far HS, Etienney I, Zeitoun JD, Atienza P, Bauer P. Seton drainage and fibrin glue injection for complex anal fistulas. *Colorectal Dis*. 2010;12(5):459–63.

156. Cintron JR, Park JJ, Orsay CP, Pearl RK, Nelson RL, Sone JH, et al. Repair of fistulas-in-ano using fibrin adhesive: long-term follow-up. *Dis Colon Rectum*. 2000;43(7):944–9. discussion 9–50.

157. Swinscoe MT, Ventakasubramaniam AK, Jayne DG. Fibrin glue for fistula-in-ano: the

evidence reviewed. *Tech Coloproctol.* 2005;9(2):89–94.

158. Haim N, Neufeld D, Ziv Y, Tulchinsky H, Koller M, Khaikin M, et al. Long-term results of fibrin glue treatment for cryptogenic perianal fistulas: a multicenter study. *Dis Colon Rectum.* 2011;54(10):1279–83.

159. Johnson EK, Gaw JU, Armstrong DN. Efficacy of anal fistula plug vs. fibrin glue in closure of anorectal fistulas. *Dis Colon Rectum.* 2006;49(3):371–6.

160. Cintron JR, Abcarian H, Chaudhry V, Singer M, Hunt S, Birnbaum E, et al. Treatment of fistula-in-ano using a porcine small intestinal submucosa anal fistula plug. *Tech Coloproctol.* 2013;17(2):187–91.

161. McGee MF, Champagne BJ, Stulberg JJ, Reynolds H, Marderstein E, Delaney CP. Tract length predicts successful closure with anal fistula plug in cryptoglandular fistulas. *Dis Colon Rectum.* 2010;53(8):1116–20.

162. O’Riordan JM, Datta I, Johnston C, Baxter NN. A systematic review of the anal fistula plug for patients with Crohn’s and non-Crohn’s related fistula-in-ano. *Dis Colon Rectum.* 2012;55(3):351–8.

163. Stamos MJ, Snyder M, Robb BW, Ky A, Singer M, Stewart DB, et al. Prospective multicenter study of a synthetic bioabsorbable anal fistula plug to treat cryptoglandular transsphincteric anal fistulas. *Dis Colon Rectum.* 2015;58(3):344–51.

164. Wilhelm A. A new technique for sphincter-preserving anal fistula repair using a novel radial emitting laser probe. *Tech Coloproctol.* 2011;15(4):445–9.

165. Giamundo P, Esercizio L, Geraci M, Tibaldi L, Valente M. Fistula-tract laser closure (FiLaC): long-term results and new operative strategies. *Tech Coloproctol.* 2015;19(8):449–53.

166. Garcia-Olmo D, Herreros D, Pascual I, Pascual JA, Del-Valle E, Zorrilla J, et al. Expanded adipose-derived stem cells for the treatment of complex perianal fistula: a phase II clinical trial. *Dis Colon Rectum.* 2009;52(1):79–86.

167. Sileri P, Boehm G, Franceschilli L, Giorgi F, Perrone F, Stolfi C, et al. Collagen matrix injection combined with flap repair for complex anal fistula. *Colorectal Dis.* 2012;14 Suppl 3:24–8.

168. Vasilevsky CA. Anorectal abscess and fistula-in ano. In: Beck DE, editor. *Handbook of colorectal surgery.* St Louis, Mo: Quality Medical Publishing; 1997.

169. Vasilevsky CA. *Fistula-in-Ano and Abscess.* In: Beck DE, Wexner SD, editors. *Fundamentals of anorectal surgery.* London: WB Saunders; 1998.

## 第 15 章

1. Steele SR, Kumar R, Feingold D, Rafferty JL, Buie WD. The standards practice task force, the American Society of Colon and Rectal Surgeons. Practice parameters for the treatment of perianal abscess and fistula-in-ano. *Dis Colon Rectum.* 2011;54:1465–74.

2. Abbas MA, Jackson C, Haigh PI. Predictors of outcome for anal fistula surgery. *Arch Surg.* 2011;146(9):1011–6.

3. Jorge JM, Wexner SD. Etiology and management of fecal incontinence. *Dis Colon Rectum.* 1993;36:77–97.

4. Deen KI, Williams JG, Hutchinson R, Keighley MR, Kumar D. Fistulas in ano: endoanal ultrasonographic assessment assists decision making for surgery. *Gut.* 1994;35:391–4.

5. Poen AC, Felt-Bersma RJF, Eijssbouts QA, Cuesta MA, Meuwissen SG. Hydrogen peroxide-enhanced transanal ultrasound in the assessment of fistula-in-ano. *Dis Colon Rectum*. 1998;41:1147–52.
6. Ratto C, Gentile E, Merico M, Spinazzola C, Mangini G, Sofo L, Doglietto G. How can the assessment of fistula-in-ano be improved? *Dis Colon Rectum*. 2000;43:1375–82.
7. Santoro GA, Fortling B. The advantages of volume rendering in three-dimensional endosonography of the anorectum. *Dis Colon Rectum*. 2007;50:359–68.
8. Vanbeckevoort D, Bielen D, Vanslebrouck R, Van Assche G. Magnetic resonance imaging of perianal fistulas. *Magn Reson Imaging Clin N Am*. 2014;22:113–23.
9. Weisman N, Abbas MA. Can pre-operative anal ultrasound predict surgical outcome for fistula-in-ano? *Dis Colon Rectum*. 2008;51:1089–92.
10. Buchanan G, Halligan S, Williams A, Cohen CR, Tarroni D, Phillips RK, Bartram CI. Effect of MRI on clinical outcome of recurrent fistula-in-ano. *Lancet*. 2002;360:1661–2.
11. Orsoni P, Barthet M, Portier F, Panuel M, Desjeux A, Grimaud JC. Prospective comparison of endosonography, magnetic resonance imaging and surgical findings in anorectal fistula and abscess complicating Crohn's disease. *Br J Surg*. 1999;86:360–4.
12. Schwartz DA, Wiersema MJ, Dudiak KM, Fletcher JG, Clain JE, Tremaine WJ, Zinsmeister AR, Norton ID, Boardman LA, Devine RM, Wolff BG, Young-Fadok TM, Diehl NN, Pemberton JH, Sandborn WJ. A comparison of endoscopic ultrasound, magnetic resonance imaging, and exam under anesthesia for evaluation of Crohn's perianal fistulas. *Gastroenterology*. 2001;121:1064–72.
13. Buchanan GN, Bartram CI, Williams AB, Halligan S, Cohen CR. Value of hydrogen peroxide enhancement of three-dimensional endoanal ultrasound in fistula-in-ano. *Dis Colon Rectum*. 2005;48:141–7.
14. West RL, Zimmerman DD, Dwarkasing S, Hussain SM, Hop WC, Schouten WR, Kuipers EJ, Felt-Bersma RJ. Prospective comparison of hydrogen peroxide-enhanced three-dimensional endoanal ultrasonography and endoanal magnetic resonance imaging of perianal fistulas. *Dis Colon Rectum*. 2003;46:1407–15.
15. Ratto C, Grillo E, Parello A, Costamagna G, Doglietto GB. Endoanal ultrasound-guided surgery for anal fistula. *Endoscopy*. 2005;37:722–8.
16. Buchanan GN, Halligan S, Bartram CI, Williams AB, Tarroni D, Cohen CR. Clinical examination, endosonography and MR imaging in preoperative assessment of fistula in ano: comparison with outcome-based reference standard. *Radiology*. 2004;233:674–81.
17. Sahni VA, Ahmad R, Burling D. Which method is best for imaging of perianal fistula? *Abdom Imaging*. 2008;33:26–30.
18. Soerensen MM, Pedersen BG, Santoro GA, Buntzen S, Bek K, Laurberg S. Long-term function and morphology of the anal sphincters and the pelvic floor after primary repair of obstetric anal sphincter injury. *Colorectal Dis*. 2014;16:347–55.
19. Vitton V, Ben Hadj Amor W, Baumstarck K, Behr M, Bouvier M, Grimaud JC. Comparison of three-dimensional high-resolution manometry and endoanal ultrasound in the diagnosis of anal sphincter defects. *Colorectal Dis*. 2013;15:607–11.
20. Limura E, Giordano P. Modern management of anal fistula. *World J Gastroenterol*. 2015;21:12–20.
21. Subhas G, Singh Bhullar J, Al-Omari A, Unawane A, Mittal VK, Pearlman R. Setons in the treatment of anal fistula: review of variations in materials and techniques. *Dig Surg*. 2012;29:292–

300.

22. Abbas MA, Sherman M. Endorectal advancement flap. In: Fleshman J, Wexner SD, editors. Master techniques in colon and rectal surgery. 1st ed. Baltimore, USA: Lippincott Williams & Wilkins; 2012.
23. Rojanasakul A, Pattanaarun J, Sahakitrungruang C, Tantiphlachiva K. Total anal sphincter saving technique for fistula-in-ano: the ligation of intersphincteric fistula tract. *J Med Assoc Thai.* 2007;90:581–6.
24. Ellis CN. Outcomes with the use of bioprosthetic grafts to reinforce the ligation of the intersphincteric fistula tract (BioLIFT procedure) for the management of complex anal fistulas. *Dis Colon Rectum.* 2010;53:1361–4.
25. Sirikurnpiboon S, Awapittaya B, Jivapaisarnpong P. Ligation of intersphincteric fistula tract and its modification: results from treatment of complex fistula. *World J Gastrointest Surg.* 2013;5:123–8.
26. Ratto C, Litta F, Parello A, Zaccone G, Donisi L, De Simone V. Fistulotomy with end-to-end primary sphincteroplasty for anal fistula: results from a prospective study. *Dis Colon Rectum.* 2013;56:226–33.
27. The Surgisis AFP anal fistula plug: report of a consensus conference. *Colorectal Dis.* 2008;10:17–20.
28. Ommer A, Herold A, Joos A, Schmidt C, Weyand G, Bussen D. Gore BioA Fistula Plug in the treatment of high anal fistulas – initial results from a German multicenter study. *Ger Med Sci.* 2012;10:1–17.
29. Swinscoe MT, Ventakasubramaniam AK, Jayne DG. Fibrin glue for fistula-in-ano: the evidence reviewed. *Tech Coloproctol.* 2005;9:89–94.
30. Meinero P, Mori L. Video-assisted anal fistula treatment (VAAFT): a novel sphincter-saving procedure for treating complex anal fistulas. *Tech Coloproctol.* 2011;15:417–22.
31. Giamundo P, Geraci M, Tibaldi L, Valente M. Closure of fistula-in-ano with laser-FiLaC™: an effective novel sphincter-saving procedure for complex disease. *Colorectal Dis.* 2014;16:110–5.
32. Georgiev-Hristov T, García-Arranz M, García-Olmo D. Adipose tissue-derived products for complex fistula treatment. *Tech Coloproctol.* 2013;17:675–6.
33. Beaulieu R, Bonekamp D, Sandone C, Gearhart S. Fistula-in-ano: when to cut, tie, plug, or sew. *J Gastrointest Surg.* 2013;17:1143–52.
34. Gupta PJ, Gupta SN, Heda PS. Which treatment for anal fistula? Cut or cover, plug or paste, loop or lift. *Acta Chir Iugosl.* 2012;59:15–20.
35. Zbar AP, Ramesh J, Beer-Gabel M, Salazar R, Pescatori M. Conventional cutting vs. internal anal sphincter-preserving seton for high trans-sphincteric fistula: a prospective randomized manometric and clinical trial. *Tech Coloproctol.* 2003;7:89–94.
36. García-Aguilar J, Belmonte C, Wong DW, Goldberg SM, Madoff RD. Cutting seton versus two-stage seton fistulotomy in the surgical management of high anal fistula. *Br J Surg.* 1998;85:243–5.
37. Vial M, Parés D, Pera M, Grande L. Faecal incontinence after seton treatment for anal fistulae with and without surgical division of internal anal sphincter: a systematic review. *Colorectal Dis.* 2010;12:172–8.
38. Hasegawa H, Radley S, Keighley MR. Long-term results of cutting seton fistulotomy. *Acta Chir Iugoslavica.* 2000;47:19–21.
39. Isbister WH, Sanea N. The cutting seton: an experience at King Faisal Specialist Hospital. *Dis*



Colon Rectum. 2001;44:722–7.

40. Menten BB, Oktemer S, Tezcaner T, Azili C, Leventoglu S, Oguz M. Elastic one-stage cutting seton for the treatment of high anal fistulas: preliminary results. *Tech Coloproctol*. 2004;8:159–62.
41. Williams JG, Farrands PA, Williams AB, Taylor BA, Lunniss PJ, Sagar PM, Varma JS, George BD, et al. The treatment of anal fistula: ACPGBI position statement. *Colorectal Dis*. 2007;9 Suppl 4:18–50.
42. Abbas MA, Lemus-Rangel R, Hamadani A. Long-term outcome of endorectal advancement flap for complex anorectal fistulae. *Am Surgeon*. 2008;74:921–4.
43. Perez F, Arroyo A, Serrano P, Sánchez A, Candela F, Perez MT, Calpena R. Randomized clinical and manometric study of advancement flap versus fistulotomy with sphincter reconstruction in the management of complex fistula-in-ano. *Am J Surg*. 2006;192:34–40.
44. Zimmerman DD, Briel JW, Gosselink MP, Schouten WR. Anocutaneous advancement flap repair of transsphincteric fistulas. *Dis Colon Rectum*. 2001;44:1474–80.
45. Ortiz H, Marzo J. Endorectal flap advancement repair and fistulectomy for high trans-sphincteric and suprasphincteric fistulas. *Br J Surg*. 2000;87:1680–3.
46. Schouten WR, Zimmerman DD, Briel JW. Transanal advancement flap repair of transsphincteric fistulas. *Dis Colon Rectum*. 1999;42:1419–23.
47. Jarrar A, Church J. Advancement flap repair: a good option for complex anorectal fistulas. *Dis Colon Rectum*. 2011;54:1537–41.
48. Dubsky PC, Stift A, Friedl J, Teleky B, Herbst F. Endorectal advancement flaps in the treatment of high anal fistula of cryptoglandular origin: full-thickness vs. mucosal-rectum flaps. *Dis Colon Rectum*. 2008;51:852–7.
49. Van der Hagen SJ, Baeten CG, Soeters PB, van Gemert WG. Autologous platelet derived growth factors (platelet rich plasma) as an adjunct to mucosal advancement flap in high cryptoglandular peri-anal fistulae: a pilot study. *Colorectal Dis*. 2011;13:784–90.
50. Zimmerman DD, Delemarre JB, Gosselink MP, Hop WC, Briel JW, Schouten WR. Smoking affects the outcome of transanal mucosal advancement flap repair of trans-sphincteric fistulas. *Br J Surg*. 2003;90:351–4.
51. Zimmerman DD, Gosselink MP, Mitalas LE, Mitalas LE, Delemarre JB, Hop WJ, Briel JW, Schouten WR. Smoking impairs rectal mucosal blood flow- a pilot study: possible implications for transanal advancement flap repair. *Dis Colon Rectum*. 2005;48:1228–32.
52. Shanwani A, Nor AM, Amri N. Ligation of the intersphincteric fistula tract (LIFT): a sphincter-saving technique for fistula-in-ano. *Dis Colon Rectum*. 2010;53:39–42.
53. Aboularian A, Kaji AH, Kumar RR. Early result of ligation of the intersphincteric fistula tract for fistula-in-ano. *Dis Colon Rectum*. 2011;54:289–92.
54. Tan KK, Tan IJ, Lim FS, Koh DC, Tsang CB. The anatomy of failures following the ligation of intersphincteric tract technique for anal fistula: a review of 93 patients over 4 years. *Dis Colon Rectum*. 2011;54:1368–72.
55. Abcarian AM, Estrada JJ, Park J, Corning C, Chaudhry V, Cintron J, Prasad L, Abcarian H. Ligation of intersphincteric fistula tract: early results of a pilot study. *Dis Colon Rectum*. 2012;55:778–82.
56. Mushaya C, Bartlett L, Schulze B, Ho YH. Ligation of intersphincteric fistula tract compared with advancement flap for complex anorectal fistulas requiring initial seton drainage. *Am J Surg*. 2012;204:283–9.

57. Ooi K, Skinner I, Croxford M, Faragher I, McLaughlin S. Managing fistula-in-ano with ligation of the intersphincteric fistula tract procedure: the Western Hospital experience. *Colorectal Dis.* 2012;14:599–603.
58. Wallin UG, Mellgren AF, Madoff RD, Goldberg SM. Does ligation of the intersphincteric fistula tract raise the bar in fistula surgery? *Dis Colon Rectum.* 2012;55:1173–8.
59. Han JG, Yi BQ, Wang ZJ, Zheng Y, Cui JJ, Yu XQ, Zhao BC, Yang XQ. Ligation of the intersphincteric fistula tract plus a bioprosthetic anal fistula plug (LIFT-Plug): a new technique for fistula-in-ano. *Colorectal Dis.* 2013;15:582–6.
60. Van Onkelen RS, Gosselink MP, Schouten WR. Ligation of the intersphincteric fistula tract in low transsphincteric fistulae: a new technique to avoid fistulotomy. *Colorectal Dis.* 2013;15:587–91.
61. Lehmann JP, Graf W. Efficacy of LIFT for recurrent anal fistulas. *Colorectal Dis.* 2013;15:592–5.
62. Sileri P, Giarratano G, Franceschilli L, Limura E, Perrone F, Stazi A, Toscana C, Gaspari AL. Ligation of the intersphincteric fistula tract (LIFT): a minimally invasive procedure for complex anal fistula: two-year results of a prospective multicentric study. *Surg Innov.* 2014;21:476–80.
63. Yassin NA, Hammond TM, Lunniss PJ, Phillips RK. Ligation of the intersphincteric fistula tract in the management of anal fistula. A systematic review. *Colorectal Dis.* 2013;15:527–35.
64. Vergara-Fernandez O, Espino-Urbina LA. Ligation of the intersphincteric fistula tract: what is the evidence in a review? *World J Gastroenterol.* 2013;19:6805–13.
65. Hong KD, Kang S, Kalaskar S, Wexner SD. Ligation of intersphincteric fistula tract (LIFT) to treat anal fistula: systematic review and meta-analysis. *Tech Coloproctol.* 2014;18:685–91.
66. Tan KK, Alsuwaigh R, Tan AM, Tan IJ, Liu X, Koh DC. To LIFT or to flap? Which surgery to perform following seton insertion for high anal fistulas? *Dis Colon Rectum.* 2012;55:1273–7.
67. Madbouly KM, El Shazly W, Abbas KS, Hussein AM. Ligation of intersphincteric fistula tract versus mucosal advancement flap in patients with high transsphincteric fistula-in-ano: a prospective randomized trial. *Dis Colon Rectum.* 2014;57:1202–8.
68. Chew MH, Lee PJ, Koh CE, Chew HE. Appraisal of the LIFT and BIOLIFT procedure: initial experience and short-term outcomes of 33 consecutive patients. *Int J Colorectal Dis.* 2013;28:1489–96.
69. Garg P, Song J, Bhatia A, Kalia H, Menon GR. The efficacy of anal fistula plug in fistula-in-ano: a systematic review. *Colorectal Dis.* 2010;12:965–70.
70. Johnson EK, Gaw JU, Armstrong DN. Efficacy of anal fistula plug vs. fibrin glue in closure of anorectal fistulas. *Dis Colon Rectum.* 2006;49:371–6.
71. Champagne BJ, O'Connor LM, Ferguson M, Orangio GR, Schertzer ME, Armstrong DN. Efficacy of anal fistula plug in closure of cryptoglandular fistulas: long-term follow-up. *Dis Colon Rectum.* 2006;49:1817–21.
72. Schwandner O, Stadler F, Dietl O, Wirsching RP, Fuerst A. Initial experience on efficacy in closure of cryptoglandular and Crohn's transsphincteric fistulas by the use of the anal fistula plug. *Int J Colorectal Dis.* 2008;23:319–24.
73. Christoforidis D, Etzioni DA, Goldberg SM, Madoff RD, Mellgren A. Treatment of complex anal fistulas with the collagen fistula plug. *Dis Colon Rectum.* 2008;51:1482–7.
74. Thekkinkattil DK, Botterill I, Ambrose NS, Lundby L, Sagar PM, Buntzen S, Finan PJ. Efficacy of the anal fistula plug in complex anorectal fistulae. *Colorectal Dis.* 2009;11:584–7.

75. Starck M, Bohe M, Zawadzki A. Success rate of closure of high transsphincteric fistula using anal fistula plug. *Dis Colon Rectum*. 2008;51:692.
76. Lawes DA, Efron JE, Abbas MA, Tejirian T, Hamadani A, Young-Fadok TM, Heppell J. Early experience with the bioabsorbable anal fistula plug. *World J Surg*. 2008;32:1157–9.
77. Safar B, Jobanputra S, Sands D, Weiss EG, Nogueras JJ, Wexner SD. Anal fistula plug: initial experience and outcomes. *Dis Colon Rectum*. 2009;52:248–52.
78. Ortiz H, Marzo J, Ciga MA, Oteiza F, Armendáriz P, de Miguel M. Randomized clinical trial of anal fistula plug versus endorectal advancement flap for the treatment of high cryptoglandular fistula in ano. *Br J Surg*. 2009;96:608–12.
79. Wang JY, Garcia-Aguilar J, Sternberg JA, Abel ME, Varma MG. Treatment of transsphincteric anal fistulas: are fistula plugs an acceptable alternative? *Dis Colon Rectum*. 2009;52:692–7.
80. McGee MF, Champagne BJ, Stulberg JJ, Reynolds H, Marderstein E, Delaney CP. Tract length predicts successful closure with anal fistula plug in cryptoglandular fistulas. *Dis Colon Rectum*. 2010;53:1116–20.
81. Anyadike C, Attuwaybi B, Visco J, Butler B, Barrios G. The anal fistula plug in simple and complex fistula-in-ano: a western New York experience. *Dis Colon Rectum*. 2010;53:575.
82. Van Koperen PJ, Bemelman WA, Gerhards MF, Janssen LW, van Tets WF, van Dalsen AD, Slors JF. The anal fistula plug treatment compared with the mucosal advancement flap for cryptoglandular high transsphincteric perianal fistula: a double-blinded multicenter randomized trial. *Dis Colon Rectum*. 2011;54:387–93.
83. O'Riordan JM, Datta I, Johnston C, Baxter NN. A systematic review of the anal fistula plug for patients with Crohn's and non-Crohn's related fistula-in-ano. *Dis Colon Rectum*. 2012;55:351–8.
84. Muhlmann MD, Hayes JL, Merrie AE, Parry BR, Bissett IP. Complex anal fistulas: plug or flap? *ANZ J Surg*. 2011;81:720–4.
85. Heydari A, Attinà GM, Merolla E, Piccoli M, Fazlalizadeh R, Melotti G. Bioabsorbable synthetic plug in the treatment of anal fistulas. *Dis Colon Rectum*. 2013;56:774–9.
86. Buchberg B, Masoomi H, Choi J, Bergman H, Mills S, Stamos MJ. A tale of two (anal fistula) plugs: is there a difference in short-term outcomes? *Am Surg*. 2010;76:1150–3.
87. Cintron JR, Park JJ, Orsay CP, Pearl RK, Nelson RL, Sone JH, Song R, Abcarian H. Repair of fistulas-in-ano using fibrin adhesive: long-term follow-up. *Dis Colon Rectum*. 2000;43:944–9.
88. Sentovich SM. Fibrin glue for anal fistulas: long-term results. *Dis Colon Rectum*. 2003;46:498–502.
89. Loungnarath R, Dietz DW, Mutch MG, Birnbaum EH, Kodner IJ, Fleshman JW. Fibrin glue treatment of complex anal fistulas has low success rate. *Dis Colon Rectum*. 2004;47:432–6.
90. Van Koperen PJ, Wind J, Bemelman WA, Slors JF. Fibrin glue and transanal rectal advancement flap for high transsphincteric perianal fistulas; is there any advantage? *Int J Colorectal Dis*. 2008;23:697–701.
91. Singer M, Cintron J, Nelson R, Orsay C, Bastawrous A, Pearl R, Sone J, Abcarian H. Treatment of fistulas-in-ano with fibrin sealant in combination with intra-adhesive antibiotics and/or surgical closure of the internal fistula opening. *Dis Colon Rectum*. 2005;48:799–808.
92. Jain SK, Kaza RC, Pahwa M, Bansal S. Role of cyanoacrylate in the management of low fistula in ano: a prospective study. *Int J Colorectal Dis*. 2008;23:355–8.
93. Barillari P, Basso L, Larcinese A, Gozzo P, Indinnimeo M. Cyanoacrylate glue in the treatment of ano-rectal fistulas. *Int J Colorectal Dis*. 2006;21:791–4.

94. Buchanan GN, Bartram CI, Phillips RK, Gould SW, Halligan S, Rockall TA, Sibbons P, Cohen RG. Efficacy of fibrin sealant in the management of complex anal fistula. *Dis Colon Rectum*. 2003;46:1167–74.
95. Jacob TJ, Perakath B, Keighley MR. Surgical intervention for anorectal fistula. *Cochrane Database Syst Rev*. 2010.
96. Parkash S, Lakshmiratan V, Gajendran V. Fistula-in-ano: treatment by fistulectomy, primary closure and reconstitution. *Aust N Z J Surg*. 1985;55:23–7.
97. Christiansen J, Rønholt C. Treatment of recurrent high anal fistula by total excision and primary sphincter reconstruction. *Int J Colorectal Dis*. 1995;10:207–9.
98. Roig JV, García-Armengol J, Jordán JC, Moro D, García-Granero E, Alós R. Fistulectomy and sphincteric reconstruction for complex cryptoglandular fistulas. *Colorectal Dis*. 2010;12:145–52.
99. Kraemer M, Picke D. Fistulotomy with primary sphincter repair for the treatment of anal fistula. *Coloproctology*. 2011;33:104–8.
100. Arroyo A, Perez-Legaz J, Moya P, Armananzas L, Lacueva J, Perez-Vicente F, Candela F, Calpena R. Fistulotomy and sphincter reconstruction in the treatment of complex fistula-in-ano. Long-term clinical and manometric results. *Ann Surg*. 2012;255:935–9.
101. Ommer A, Herold A, Berg E, Furst A, Sailer M, Schiedeck T. German Society for General and Visceral Surgery. Cryptoglandular anal fistulas. *Dtsch Arztebl Int*. 2011;108:707–13.
102. Kochhar G, Saha S, Andley M, Kumar A, Saurabh G, Pusuluri R, Bhise V, Kumar A. Video-assisted anal fistula treatment. *JSLS*. 2014;18:e2014.00127.
103. Wałęga P, Romaniszyn M, Nowak W. VAAFT: a new minimally invasive method in the diagnostics and treatment of anal fistulas-initial results. *Pol Przegl Chir*. 2014;86:7–10.
104. Oztürk E, Gülcü B. Laser ablation of fistula tract: a sphincter preserving method for treating fistula-in-ano. *Dis Colon Rectum*. 2014;57:360–4.
105. Herreros MD, Garcia-Arranz M, Guadalajara H, De-La-Quintana P, Garcia-Olmo D, Collaborative Group FATT. Autologous expanded adipose-derived stem cells for the treatment of complex cryptoglandular perianal fistulas: a phase III randomized clinical trial (FATT 1: fistula Advanced Therapy Trial 1) and long-term evaluation. *Dis Colon Rectum*. 2012;55:762–72.
106. Keller DS, Aboseif SR, Lesser T, Abbass MA, Tsay AT, Abbas MA. Algorithm based multidisciplinary team treatment approach to rectourethral fistula. *Int J Colorectal Disease*. 2015;30:631–8.
107. Lane BR, Stein DE, Remzi FH, Strong SA, Fazio VW, Angermeier KW. Management of radiotherapy induced rectourethral fistula. *J Urol*. 2006;175:1382–7.
108. Hechenbleikner EM, Buckley JC, Wick EC. Acquired rectourethral fistulas in adults: a systematic review of surgical repair techniques and outcomes. *Dis Colon Rectum*. 2013;56:374–83.
109. Hanna JM, Turley R, Castleberry A, Hopkins T, Peterson AC, Mantyh C, Migaly J. Surgical management of complex rectourethral fistulas in irradiated and nonirradiated patients. *Dis Colon Rectum*. 2014;57:1105–12.
110. Chun L, Abbas MA. Rectourethral fistula following laparoscopic radical prostatectomy. *Tech Coloproctol*. 2011;15:297–300.
111. Blumberg JM, Lesser T, Tran VQ, Aboseif SR, Bellman GC, Abbas MA. Management of rectal injuries sustained during laparoscopic radical prostatectomy. *Urology*. 2009;73(1):163–6.
112. Thomas C, Jones J, Jager W, Hampel C, Thuroff JW, Gillitzer R. Incidence, clinical symptoms and management of rectourethral fistulas after radical prostatectomy. *J Urol*. 2010;183:608–12.

113. Voelzke BB, McAninch JW, Breyer BN, Glass AS, Garcia-Aguilar J. Transperineal management for postoperative and radiation rectourethral fistulas. *J Urol*. 2013;189:966–71.
114. Bukowski TP, Chakrabarty A, Powell IJ, Frontera R, Perlmutter AD, Montie JE. Acquired rectourethral fistula: methods of repair. *J Urol*. 1995;153:730–3.
115. Lacarriere E, Suaud L, Caremel R, Rouache L, Tuech JJ, Pfister C. Rectourethral fistulae: diagnosis and management. Review of the literature. *Prog Urol*. 2011;21:585–94.
116. Choi JH, Jeon BG, Choi SG, Han EC, Ha HK, Oh HK, Choe EK, Moon SH, Ryoo SB, Park KJ. Rectourethral fistula: systemic review of and experiences with various surgical treatment methods. *Ann Coloproctol*. 2014;30:35–41.
117. Lesser T, Aboseif S, Abbas MA. Combined endorectal advancement flap with alloderm graft repair of radiation and cryoablation-induced rectourethral fistula. *American Surg*. 2008;74:341–5.
118. Patsouras D, Yassin NA, Phillips RK. Clinical outcomes of colo-anal pull-through procedure for complex rectal conditions. *Colorectal Dis*. 2014;16:253–8.
119. Linder BJ, Umbreit EC, Larson D, Dozois EJ, Thapa P, Elliott DS. Effect of prior radiotherapy and ablative therapy on surgical outcomes for the treatment of rectourethral fistulas. *J Urol*. 2013;190:1287–91.
120. Youssef AH, Fath-Alla M, El-Kassaby AW. Perineal subcutaneous dartos pedicled flap as a new technique for repairing urethrorectal fistula. *J Urol*. 1999;161:1498–500.
121. Garofalo TE, Delaney CP, Jones SM, Remzi FH, Fazio VW. Rectal advancement flap repair of rectourethral fistula: a 20-year experience. *Dis Colon Rectum*. 2003;46:762–9.
122. Wexner SD, Ruiz DE, Genua J, Nogueras JJ, Weiss EG, Zmora O. Gracilis muscle interposition for the treatment of rectourethral, rectovaginal, and pouch-vaginal fistulas: results in 53 patients. *Ann Surg*. 2008;248:39–43.
123. Kasraeian A, Rozet F, Cathelineau X, Barret E, Galiano M, Vallancien G. Modified York-Mason technique for repair of iatrogenic rectourinary fistula: the montsouris experience. *J Urol*. 2009;181:1178–83.
124. Vanni AJ, Buckley JC, Zinman LN. Management of surgical and radiation induced rectourethral fistulas with an interposition muscle flap and selective buccal mucosal onlay graft. *J Urol*. 2010;184:2400–4.
125. Ghoniem G, Elmissiry M, Weiss E, Langford C, Abdelwahab H, Wexner S. Transperineal repair of complex rectourethral fistula using gracilis muscle flap interposition--can urinary and bowel functions be preserved? *J Urol*. 2008;179:1882–6.
126. Gupta G, Kumar S, Kekre NS, Gopalakrishnan G. Surgical management of rectourethral fistula. *Urology*. 2008;71:267–71.
127. Ulrich D, Roos J, Jakse G, Pallua N. Gracilis muscle interposition for the treatment of rectourethral and rectovaginal fistulas: a retrospective analysis of 35 cases. *J Plast Reconstr Aesthet Surg*. 2009;62:352–6.
128. Samplaski MK, Wood HM, Lane BR, Remzi FH, Lucas A, Angermeier KW. Functional and quality-of-life outcomes in patients undergoing transperineal repair with gracilis muscle interposition for complex rectourethral fistula. *Urology*. 2011;77:736–41.
129. Lee TG, Park SS, Lee SJ. Treatment of a recurrent rectourethral fistula by using transanal rectal flap advancement and fibrin glue: a case report. *J Korean Soc Coloproctol*. 2012;28:165–9.
130. Al-Ali M, Kashmoula D, Saoud IJ. Experience with 30 posttraumatic rectourethral fistulas: presentation of posterior transsphincteric anterior rectal wall advancement. *J Urol*. 1997;158:421–

4.

131. Spotnitz WD. Fibrin sealant: past, present, and future: a brief review. *World J Surg.* 2010;34:632–4.

132. Takano S, Boutros M, Wexner SD. Gracilis muscle transposition for complex perineal fistulas and sinuses: a systematic literature review of surgical outcomes. *J Am Coll Surg.* 2014;219:313–23.

133. Varma MG, Wang JY, Garcia-Aguilar J, Shelton AA, McAninch JW, Goldberg SM. Dartos muscle interposition flap for the treatment of rectourethral fistula. *Dis Colon Rectum.* 2007;50:1849–55.

134. Shah NS, Remzi F, Massmann A, Baixauli J, Fazio VW. Management and treatment outcome of pouch-vaginal fistulas following restorative proctocolectomy. *Dis Colon Rectum.* 2003;46:911–7.

135. Maslekar S, Sagar PM, Harji D, Bruce C, Griffiths B. The challenge of pouch-vaginal fistulas: a systematic review. *Tech Coloproctol.* 2012;16:405–14.

136. Kim NK, Lim DJ, Yun SH, Sohn SK, Min JS. Ultralow anterior resection and coloanal anastomosis for distal rectal cancer: functional and oncological results. *Int J Colorectal Dis.* 2001;16:234–7.

137. Guerrieri M, Gesuita R, Ghiselli R, Lezoche G, Budassi A, Baldarelli M. Treatment of rectal cancer by transanal endoscopic microsurgery: experience with 425 patients. *World J Gastroenterol.* 2014;20:9556–63.

138. Musters GD, Lapid O, Bemelman WA, Tanis PJ. Surgery for complex perineal fistula following rectal cancer treatment using biological mesh combined with gluteal perforator flap. *Tech Coloproctol.* 2014;18:955–9.

139. Lolohea S, Lynch AC, Robertson GB, Frizelle FA. Ileal pouch-anal anastomosis-vaginal fistula: a review. *Dis Colon Rectum.* 2005;48:1802–10.

140. Gaertner WB, Witt J, Madoff RD, Mellgren A, Finne CO, Spencer MP. Ileal pouch fistulas after restorative proctocolectomy: management and outcomes. *Tech Coloproctol.* 2014;18:1061–6.

141. Mallick IH, Hull TL, Remzi FH, Kiran RP. Management and outcome of pouch-vaginal fistulas after IPAA surgery. *Dis Colon Rectum.* 2014;57:490–6.

142. Heriot AG, Tekkis PP, Smith JJ, Bona R, Cohen RG, Nicholls RJ. Management and outcome of pouch-vaginal fistulas following restorative proctocolectomy. *Dis Colon Rectum.* 2005;48:451–8.

## 第 16 章

1. Hoexter B, Laboow SB, Moseson MD. Transanal rectovaginal fistula repair. *Dis Colon Rectum.* 1985;28:572–5.

2. Venkatesh KS, Ramanujam PS, Larson DM, Haywood MA. Anorectal complications of vaginal delivery. *Dis Colon Rectum.* 1989;32:1039–41.

3. Halverson AL, Hull TL, Fazio VW, Church J, Hammel J, Floruta C. Repair of recurrent rectovaginal fistulas. *Surgery.* 2001;130(4):753–7.

4. Radcliffe AG, Ritchie JK, Hawley PR, et al. Anovaginal and rectovaginal fistulas in Crohn's disease. *Dis Colon Rectum.* 1988;31:94–9.

5. Schwartz DA, Loftus Jr EV, Tremaine WJ, et al. The natural history of fistulizing Crohn's disease

in Olmsted County, Minnesota. *Gastroenterology*. 2002;122:875–80.

6. Athanasiadis S, Yazigi R, Kohler A, Helmes C. Recovery rates and functional results after repair for rectovaginal fistula in Crohn's disease: a comparison of different techniques. *Int J Colorectal Dis*. 2007;22:1051–60.

7. Kraemer M, Kirschmeier A, Marth T. Perioperative adjuvant therapy with infliximab in complicated anal crohn's disease. *Int J Colorectal Dis*. 2008;23:965–9.

8. Sands BE, Blank MA, Patel K, van Deventer SJ. Long-term treatment of rectovaginal fistulas in Crohn's disease: response to infliximab in the ACCENT II Study. *Clin Gastroenterol Hepatol*. 2004;2:912–20.

9. Baig MK, Zhao RH, Yuen CH, Nogueras JJ, Singh JJ, Weiss EG, Wexner SD. Simple rectovaginal fistulas. *Int J Colorectal Dis*. 2000;15:323–7.

10. Luffler T, Welsch T, Muhl S, Hinz U, Schmidt J, Kienle P. Long-term success rate after surgical treatment of anorectal and rectovaginal fistulas in Crohns' disease. *Int J Colorectal Dis*. 2009;24:521–6.

11. Hull TL, Fazio VW. Surgical approaches to low anovaginal fistula in Crohn's disease. *Am J Surg*. 1997;173(2):95–8.

12. El-Gazzaz G, Hull T, Mignanelli E, Hammel J, Gurland B, Zutshi M. Analysis of function and predictors of failure in women undergoing repair of crohn's related rectovaginal fistula. *J Gastrointest Surg*. 2010;14:824–9.

13. Stoker J, Rociu E, Schouten WR, et al. Anovaginal and rectovaginal fistulas: endoluminal sonography versus endoluminal MR imaging. *Am J Roentgenol*. 2002;178:737–41.

14. Maconi G, Parente F, Bianchi PG. Hydrogen peroxide enhanced ultrasound fistulography in the assessment of enterocutaneous fistulas complicating Crohn's disease. *Gut*. 1999;45:874–8.

15. Pinto RA, Peterson TV, Shawki S, Davila GW, Wexner SD. Are there predictors of outcome following rectovaginal fistula repair? *Dis Colon Rectum*. 2010;53:1240–7.

16. Rothenberger DA, Christenson CE, Balcos EG, Schottler JL, Nemer FD, Nivatvongs S, Goldberg S. Endorectal advancement flap for treatment of simple rectovaginal fistula. *Dis Colon Rectum*. 1982;25:297–300.

17. Lowry AC, Thorson AG, Rothenberger DA, Goldberg SM. Repair of simple rectovaginal fistulas. Influence of previous repair. *Dis Colon Rectum*. 1988;31:676–8.

18. Ellis CN. Outcomes after repair of rectovaginal fistulas using bioprosthesis. *Dis Colon Rectum*. 2008;51:1084–8.

19. Sonoda T, Hull T, Piedmonte MR, Fazio VW. Outcomes of primary repair of anorectal and rectovaginal fistulas using the endorectal advancement flap. *Dis Colon Rectum*. 2002;45:1622–8.

20. Hull TL, El-Gazzaz G, Gurland B, Church J, Zutshi M. Surgeons should not hesitate to perform episiotomy for rectovaginal fistula secondary to cryptoglandular or obstetrical origin. *Dis Colon Rectum*. 2011;54:54–9.

21. Schwandner O, Fuerst A, Kunstreich K, Scherer R. Innovative technique for the closure of rectovaginal fistula using Surgisis mesh. *Tech Coloproctol*. 2009;13:135–40.

22. Schwandner O, Fuerst A. Preliminary results on efficacy in closure of transsphincteric and rectovaginal fistulas associated with crohn's disease using new biomaterials. *Surg Innov*. 2009;16(2):162–8.

23. Roberts PL. Rectovaginal fistula. *Semin Colon Rectal Surg*. 2007;18:69–78.

24. Mazier WP, Senegore AJ, Schiesel EC. Operative repair of anovaginal and rectovaginal fistulas.

Dis Colon Rectum. 1995;38:4–6.

25. Ozuner G, Hull TL, Cartmill J, Fazio VW. Long-term analysis of the use of transanal rectal advancement flaps for complicated anorectal/vaginal fistulas. *Dis Colon Rectum*. 1996;39:10–4.

26. Penninckx F, Moneghi D, D’Hoore A, Wyndaele J, Coremans G, Rutgeerts P. Success and failure after repair of rectovaginal fistula in Crohn’s disease; analysis of prognostic factors. *Colorectal Dis*. 2007;3:406–11.

27. White AJ, Buchsbaum HJ, Blythe JG, Lifshitz S. Use of the bulbocavernosus muscle (Martius procedure) for repair of radiation-induced rectovaginal fistulas. *Obstet Gynecol*. 1982;60:114–8.

28. Knierly K, Johnson EK, Steele SR. How I do It: Martius flap for rectovaginal fistulas. *J Gastrointest Surg*. 2015;19:570–4.

29. Pitel S, Lefevre JH, Parc Y, Chafai N, Shields C, Tiret E. Martius advancement flap for low rectovaginal fistula: short- and long- term results. *Colorectal Dis*. 2011;13:e112–5.

30. Aartsen EJ, Sindram IS. Repair of the radiation induced rectovaginal fistulas without or with interposition of the bulbocavernosus muscle (Martius procedure). *Eur J Surg Oncol*. 1988;14:171–7.

31. McNevin MS, Lee PY, Bax TW. Martius flap: an adjunct for repair of complex, low rectovaginal fistula. *Am J Surg*. 2007;193:597–9.

32. Songne K, Scotté M, Lubrano J, et al. Treatment of anovaginal or rectovaginal fistulas with modified Martius graft. *Colorectal Dis*. 2007;9:653–6.

33. Cui L, Chen D, Chen W, Jiang H. Interposition of vital bulbocavernosus graft in the treatment of both simple and recurrent rectovaginal fistulas. *Int J Colorectal Dis*. 2009;24:1255–9.

34. Kin C, Gurland B, Zutshi M, Hull T, Krummel T, Remzi F. Martius flap repair for complex rectovaginal fistula. *Pol Przegl Chir*. 2012;84:601–4.

35. Wexner SD, Ruiz DE, Genua J, Nogueras JJ, Weiss EG, Zmora O. Gracilis muscle interposition for the treatment of rectourethral, rectovaginal, and pouch-vaginal fistulas. Results in 53 patients. *Ann Surg*. 2008;248:39–43.

36. Furst A, Schmidbauer C, Swol-Ben J, Iesalnicks I, Schwandner O, Agha A. Gracilis transposition for repair of recurrent anovaginal and rectovaginal fistulas in Crohn’s disease. *Int J Colorectal Dis*. 2008;23:349–53.

37. Sher ME, Bauer JJ, Gelernt I. Surgical repair of rectovaginal fistulas in patients with Crohn’s disease: trans-vaginal approach. *Dis Colon Rectum*. 1991;34:641–8.

38. Van der Hagen SJ, Soeters PB, Baeten CG, van Gemert WG. Laparoscopic fistula excision and omentoplasty for high rectovaginal fistulas: a prospective study of 40 patients. *Int J Colorectal Dis*. 2011;26:1463–7.

39. Chu L, Wang J, Li L, Tong XW, Fan BZ, Guo Y, Li HF. Laparoscopic repair of iatrogenic vesicovaginal and rectovaginal fistula. *Int J Clin Exp Med*. 2015;8(2):2364–70.

40. Mukwege D, Mukanire N, Himpens J, Cadere GB. Minimally invasive treatment of traumatic high rectovaginal fistulas. *Surg Endosc*. 2015 Apr 7. [Epub ahead of print]

41. Gajsek U, McArthur DR, Sagar PM. Long-term efficacy of the button fistula plug in the treatment of ileal pouch-vaginal and crohn’s related rectovaginal fistulas. *Dis Colon Rectum*. 2011;54:999–1002.

42. Weerd D, Weum S, Norderval S. Novel treatment for recalcitrant rectovaginal fistulas: fat injection. *Int Urogynecol J*. 2015;26(1):139–44.

43. D’Ambrosio G, Paganini AM, Guerrieri M, et al. Minimally invasive treatment of rectovaginal



fistula. *Surg Endosc.* 2012;26:546–50.

44. Simmang CL, Lacey SW, Huber PJ. Rectal sleeve advancement. Repair of rectovaginal fistula associated with anorectal stricture in Crohn's disease. *Dis Colon Rectum.* 1998;41:787–9.
45. Present DH, Korelitz BI, Wisch N, Glass JL, Sachar DB, Pasternack BS. Treatment of Crohn's disease with 6-mercaptopurine. A long-term randomized, double-blind study. *N Engl J Med.* 1980;302:981–7.
46. Ricart E, Panaccione R, Loftus EV, Tremaine WJ, Sandborn WJ. Infliximab for Crohn's disease in clinical practice at the Mayo Clinic: the first 100 patients. *Am J Gastroenterol.* 2001;96:722–9.
47. Van Bodegraven AA, Sloots CE, Felt-Bersma RJ, Meuwissen SG. Endosonographic evidence of persistence of Crohn's disease associated fistulas after infliximab treatment, irrespective of clinical response. *Dis Colon Rectum.* 2002;45:39–45.
48. Parsi M, Lashner B, Achkar JP, Connor JT, Brzezinski A. Type of fistula determines response to infliximab in patients with fistulous Crohn's Disease. *Am J Gastroenterol.* 2004;99:445–9.
49. Jones IT, Fazio VW, Jagelman DG. The use of transanal rectal advancement flaps in the management of fistulas involving the anorectum. *Dis Colon Rectum.* 1987;30:919–23.
50. Watson SJ, Philips RKS. Non-inflammatory rectovaginal fistula. *Br J Surg.* 1995;82:1641–3.
51. Wiskind AK, Thompson JD. Transverse transperineal repair of rectovaginal fistulas in the lower vagina. *Am J Obstet Gynecol.* 1992;167:694–9.
52. Lefèvre JH, Bretagnol F, Maggiori L, Alves A, Ferron M, Panis Y. Operative results and quality of life after gracilis muscle transposition for recurrent rectovaginal fistula. *Dis Colon Rectum.* 2009;52:1290–5.
53. Kobayashi H, Sugihara K. Successful management of rectovaginal fistula treated by endorectal advancement flap: report of two cases and literature review. *Springerplus.* 2015;4:21.
54. Takano S, Boutros M, Wexner S. Gracilis transposition for complex perineal fistulas: rectovaginal fistula and rectourethral fistula. *Dis Colon Rectum.* 2014;57:538.
55. Rius J, Nessim A, Nogueras JJ, Wexner SD. Gracilis transposition in complicated perianal fistula and unhealed perineal wounds in Crohn's disease. *Eur J Surg.* 2000;166:218–22.
56. Cohen JL, Stricker JW, Schoetz DJ, Collier JA, Veidenheimer MC. Rectovaginal fistula in Crohn's disease. *Dis Colon Rectum.* 1989;32:825–8.
57. Andreani SM, Dang HH, Grondona P, Zhan AZ, Edwards DP. Rectovaginal fistula in Crohn's disease. *Dis Colon Rectum.* 2007;50:2215–22.
58. O'Leary DP, Milroy CE, Durdey P. Definitive repair of anovaginal fistula in Crohn's disease. *Ann R Coll Surg Engl.* 1998;80:250–2.
59. Hull TL, Bartus C, Bast RN, Floruta C, Lopez R. Success of episiotomy for cloaca and rectovaginal fistula. *Dis Colon Rectum.* 2006;50:97–101.
60. Chew SS, Reiger NA. Transperineal repair of obstetric-related anovaginal fistula. *Aust N Z J Obstet Gynaecol.* 2004;44:68–71.
61. MacRae HM, McLeod RS, Cohen Z, Stern H, Reznick R. Treatment of rectovaginal fistulas that has failed previous repair attempts. *Dis Colon Rectum.* 1995;38:921–5.
62. Gottgens KW, Smeets RR, Stassen LP, Beets G, Breukin SO. The disappointing quality of published studies on operative techniques for rectovaginal fistulas: a blueprint for a prospective multi-institutional study. *Dis Colon Rectum.* 2014;57:888–98.
63. Ulrich D, Roos J, Jakse G, Pallua N. Gracilis muscle interposition for the treatment of rectourethral and rectovaginal fistulas: a retrospective analysis of 35 cases. *J Plast Reconstr Aesthet Surg.*

2009;2:352–6.

64. Zmora O, Tulchinsky H, Gur E, Goldman G, Klausner JM, Rabau M. Gracilis muscle transposition for fistulas between the rectum and urethra or vagina. *Dis Colon Rectum*. 2006;49:1316–21.

65. Reichert M, Schwandner T, Hecker A, Behnk A, Baumgart-Vogt E, Wagenlehner F, Padberg W. Surgical approach for repair of rectovaginal fistula by modified martius flap. *Geburtshilfe Frauenheilkd*. 2014;74(10):923–7.

## 第 17 章

1. Hodges RM. Pilonidal sinus. *Boston Med Surg J*. 1880;103:485–6.

2. Anderson AW. Hair extracted from an ulcer. *Boston Med Surg J*. 1847;36:74.

3. Warren JM. Abscess, containing hair, on the nates. *Am J Med Sci*. 1854;28:113.

4. Buie LA. Jeep disease (pilonidal disease of mechanized warfare). *South Med J*. 1944;37:103–9.

5. Close AS. Pilonidal cysts: an analysis of surgical failures. *Ann Surg*. 1955;141:523–6.

6. Von Laffert M, Stadie V, Ulrich J, Marsch WC, Wohlrab J. Morphology of pilonidal sinus disease: some evidence of its being a unilocalized type of hidradenitis suppurativa. *Dermatology*. 2011;223:349–55.

7. Uysal AC, Alagoz MS, Unlu RE, Sensoz O. Hair dresser's syndrome: a case report of an interdigital pilonidal sinus and review of the literature. *Dermatol Surg*. 2003;29:288–90.

8. Coskun A, Bulus H, Akinci OF, Ozgonul A. Etiological factors in umbilical pilonidal sinus. *Indian J Surg*. 2011;73:54–7.

9. Armed Forces Health Surveillance Center (AFHSC). Pilonidal cysts, active component, U.S. Armed Forces, 2000–2012. *MSMR*. 2013;20:8–11.

10. Bolandparvaz S, Moghadam DP, Salahi R, Paydar S, Bananzadeh M, Abbasi HR, Eshraghian A. Evaluation of the risk factors of pilonidal sinus: a single center experience. *Turk J Gastroenterol*. 2012;23:535–7.

11. Doll D, Matevossian E, Wietelmann K, Evers T, Kriner M, Petersen S. Family history of pilonidal sinus predisposes to earlier onset of disease and a 50% long-term recurrence rate. *Dis Colon Rectum*. 2009;52:1610–5.

12. Harlak A, Menten O, Kilic S, Coskun K, Duman K, Yilmaz F. Sacrococcygeal pilonidal disease: analysis of previously proposed risk factors. *Clinics*. 2010;65:125–31.

13. Armstrong JH, Barcia PJ. Pilonidal sinus disease. The conservative approach. *Arch Surg*. 1994;129:914–7.

14. Odili J, Gault D. Laser depilation of the natal cleft—an aid to healing the pilonidal sinus. *Ann R Coll Surg Engl*. 2002;84:29–32.

15. Landa N, Aller O, Landa-Gundin N, Torrontegui J, Azpiazu JL. Successful treatment of recurrent pilonidal sinus with laser epilation. *Dermatol Surg*. 2005;31:726–8.

16. Lukish JR, Kindelan T, Marmon LM, Pennington M, Norwood C. Laser epilation is safe and effective therapy for teenagers with pilonidal disease. *J Pediatr Surg*. 2009;44:282–5.

17. Ghnnam WM, Hafez DM. Laser hair removal as adjunct to surgery for pilonidal sinus: our initial experience. *J Cutan Aesthet Surg*. 2011;4:192–5.

18. Petersen S, Wietelmann K, Evers T, Huser N, Matevossian E, Doll D. Long-term effects of

- postoperative razor epilation in pilonidal sinus disease. *Dis Colon Rectum*. 2009;52:131–4.
19. Schneider IH, Thaler K, Kockerling F. Treatment of pilonidal sinus by phenol injections. *Int J Colorectal Dis*. 1994;9:200–2.
  20. Dogru O, Camci C, Aygen E, Girgin M, Topuz O. Pilonidal sinus treated with crystallized phenol: an eight-year experience. *Dis Colon Rectum*. 2004;47:1934–8.
  21. Hegge HG, Vos GA, Patka P, Hoitsma HF. Treatment of complicated or infected pilonidal sinus disease by local application of phenol. *Surgery*. 1987;102:52–4.
  22. Stansby G, Greatorex R. Phenol treatment of pilonidal sinuses of the natal cleft. *Br J Surg*. 1989;729–30.
  23. Lund JN, Leveson SH. Fibrin glue treatment of pilonidal sinus: results of a pilot study. *Dis Colon Rectum*. 2005;48:1094–6.
  24. Seleem MI, Al-Hashemy AM. Management of pilonidal sinus using fibrin glue: a new concept and preliminary experience. *Colorectal Dis*. 2005;7:319–22.
  25. Greenberg R, Kashtan H, Skornik Y, Werbin N. Treatment of pilonidal sinus disease using fibrin glue as a sealant. *Tech Coloproctol*. 2004;8:95–8.
  26. Elsey E, Lund JN. Fibrin glue in the treatment for pilonidal sinus: high patient satisfaction and rapid return to normal activities. *Tech Coloproctol*. 2013;17:101–4.
  27. Milone M, Musella M, Di Sardo Spiezio A, Bifulco G, Salvatore G, Sosa Fernandez LM, Bianco P, Zizolfi B, Nappi C, Milone F. Video-assisted ablation of pilonidal sinus: a new minimally invasive treatment—a pilot study. *Surgery*. 2014;155:562–6.
  28. Alptekin H, Yilmaz H, Kayis SA, Sahin M. Volume of excised specimen and prediction of surgical site infection in pilonidal sinus procedures (surgical site infection after pilonidal sinus surgery). *Surg Today*. 2013;43:1365–70.
  29. Milone M, Musella M, Salvatore G, Leongito M, Milone F. Effectiveness of a drain in surgical treatment of sacrococcygeal pilonidal disease. Results of a randomized and controlled clinical trial on 803 consecutive patients. *Int J Colorectal Dis*. 2011;26:1601–7.
  30. Milone M, Di Minno MN, Musella M, Maietta P, Ambrosino P, Pisapia A, Salvatore G, Milone F. The role of drainage after excision and primary closure of pilonidal sinus: a meta-analysis. *Tech Coloproctol*. 2013;17:625–30.
  31. Lorant T, Ribbe I, Mahteme H, Gustafsson UM, Graf W. Sinus excision and primary closure versus laying open in pilonidal disease: a prospective randomized trial. *Dis Colon Rectum*. 2011;54:300–5.
  32. Rao MM, Zawislak W, Kennedy R, Gilliland R. A prospective randomized study comparing two treatment modalities for chronic pilonidal sinus with a 5-year follow-up. *Int J Colorectal Dis*. 2010;25:395–400.
  33. Aldagal SM, Kensarah AA, Alhabboubi M, Ashy AA. A new technique in management of pilonidal sinus, a university teaching hospital experience. *Int Surg*. 2013;98:304–6.
  34. Doll D, Novotny A, Rothe R, Kristiansen JE, Wietelmann K, Boulesteix AL, Dusel W, Petersen S. Methylene Blue halves the long-term recurrence rate in acute pilonidal sinus disease. *Int J Colorectal Dis*. 2008;23:181–7.
  35. Colv EP, Bertelsen CA. Short convalescence and minimal pain after out-patient Bascom's pit pick operation. *Dan Med Bull*. 2011;58:A4348.
  36. Olmez A, Kayaalp C, Aydin C. Treatment of pilonidal disease by combination of pit excision and phenol application. *Tech Coloproctol*. 2013;17:201–6.

37. Can MF, Sevinc MM, Yilmaz M. Comparison of Karydakis flap reconstruction versus primary midline closure in sacrococcygeal pilonidal disease: results of 200 military service members. *Surg Today*. 2009;39:580–6.
38. Can MF, Sevinc MM, Hancerliogullari O, Yilmaz M, Yagci G. Multicenter prospective randomized trial comparing modified Limberg flap transposition and Karydakis flap reconstruction in patients with sacrococcygeal pilonidal disease. *Am J Surg*. 2010;200:318–27.
39. Bessa SS. Comparison of short-term results between the modified Karydakis flap and the modified Limberg flap in the management of pilonidal sinus disease: a randomized controlled study. *Dis Colon Rectum*. 2013;56:491–8.
40. Gendy AS, Glick RD, Hong AR, Dolgin SE, Soffer SZ, Landers H, Herrforth M, Rosen NG. A comparison of the cleft lift procedure vs wide excision and packing for the treatment of pilonidal disease in adolescents. *J Pediatr Surg*. 2011;46:1256–9.
41. Dudink R, Veldkamp J, Nienhuijs S, Heemskerk J. Secondary healing versus midline closure and modified Bascom natal cleft lift for pilonidal sinus disease. *Scand J Surg*. 2011;100:110–3.
42. Guner A, Boz A, Ozkan OF, Ileri O, Kece C, Reis E. Limberg flap versus Bascom cleft lift techniques for sacrococcygeal pilonidal sinus: prospective, randomized trial. *World J Surg*. 2013;37:2074–80.
43. Altintoprak F, Gundogdu K, Ergonenc T, Dikicier E, Cakmak G, Celebi F. Retrospective review of pilonidal sinus patients with early discharge after limberg flap procedure. *Int Surg*. 2014;99:28–34.
44. Kaya B, Eris C, Atalay S, Bat O, Bulut NE, Mantoglu B, Karabulut K. Modified Limberg transposition flap in the treatment of pilonidal sinus disease. *Tech Coloproctol*. 2012;16:55–9.
45. Osmanoglu G, Yetisir F. Limberg flap is better for the surgical treatment of pilonidal sinus. Results of a 767 patients series with an at least five years follow-up period. *Chirurgia (Bucur)*. 2011;106:491–4.
46. Horwood J, Hanratty D, Chandran P, Billings P. Primary closure or rhomboid excision and Limberg flap for the management of primary sacrococcygeal pilonidal disease? A meta-analysis of randomized controlled trials. *Colorectal Dis*. 2012;14:143–51.
47. Khan PS, Hayat H, Hayat G. Limberg flap versus primary closure in the treatment of primary sacrococcygeal pilonidal disease; a randomized clinical trial. *Indian J Surg*. 2013;75:192–4.
48. Dass TA, Zaz M, Rather A, Bari S. Elliptical excision with midline primary closure versus rhomboid excision with limberg flap reconstruction in sacrococcygeal pilonidal disease: a prospective, randomized study. *Indian J Surg*. 2012;74:305–8.
49. Sit M, Aktas G, Yilmaz EE. Comparison of the three surgical flap techniques in pilonidal sinus surgery. *Am Surg*. 2013;79:1263–8.
50. Arslan K, Said Kokcam S, Koksall H, Turan E, Atay A, Dogru O. Which flap should be preferred for the treatment of pilonidal sinus? A prospective randomized study. *Tech Coloproctol*. 2014;18:29–37.
51. Saylam B, Balli DN, Duzgun AP, Ozer MV, Coskun F. Which surgical procedure offers the best treatment for pilonidal disease? *Langenbecks Arch Surg*. 2011;396:651–8.
52. Onder A, Girgin S, Kapan M, Toker M, Arikanoğlu Z, Palanci Y, Bac B. Pilonidal sinus disease: risk factors for postoperative complications and recurrence. *Int Surg*. 2012;97:224–9.
53. Sievert H, Evers T, Matevossian E, Hoenemann C, Hoffman S, Doll D. The influence of lifestyle (smoking and body mass index) on wound healing and long-term recurrence rate in 534 primary

- pilonidal sinus patients. *Int J Colorectal Dis.* 2013;28:1555–62.
54. Doll D, Matevossian E, Hoenemann C, Hoffman S. Incision and drainage preceding definitive surgery achieves lower 20-year long-term recurrence rate in 583 primary pilonidal sinus surgery patients. *J Dtsch Dermatol Ges.* 2013;11:60–4.
55. Doll D, Evers T, Krapohl B, Matevossian E. Is there a difference in outcome (long-term recurrence rate) between emergency and elective pilonidal sinus surgery? *Minerva Chir.* 2013;68:199–205.
56. Doll D, Krueger CM, Schrank S, Dettmann H, Petersen S, Duesel W. Timeline of recurrence after primary and secondary pilonidal sinus surgery. *Dis Colon Rectum.* 2007;50:1928–34.
57. Verneuil A. De l'hidrosadenite phlegmoneuse et des asbces sudoripares. *Arch Gen Med.* 1864;2:537–57.
58. Alavi A, Anooshirvani N, Kim WB, Coutts P, Sibbald RG. Quality-of-life impairment in patients with hidradenitis suppurativa. A Canadian study. *Am J Clin Dermatol.* 2015;16:61–5.
59. Shavit E, Dreier J, Freud T, Halevy S, Vinker S, Cohen AD. Psychiatric comorbidities in 3207 patients with hidradenitis suppurativa. *J Eur Acad Dermatol Venereol.* 2015;29:371–6.
60. Zouboulis CC, Desai N, Emtestam L, Hunger RE, Ioannides D, Juhasz I, Lapins J, Matusiak L, Prens EP, Revuz J, Schneider-Burrus S, Szepietowski JC, van der Zee HH, Jemec GB. European S1 guideline for the treatment of hidradenitis suppurativa/acne inversa. *J Eur Acad Dermatol Venereol.* 2015. doi: 10.1111/jdv.12966. [Epub ahead of print].
61. Shahi V, Alikhan A, Vazquez BG, Weaver AL, Davis MD. Prevalence of hidradenitis suppurativa: a population-based study in Olmstead County, Minnesota. *Dermatology.* 2014;229:154–8.
62. McMillan K. Hidradenitis suppurativa: number of diagnosed patients, demographic characteristics, and treatment patterns in the United States. *Am J Epidemiol.* 2014;179:1477–83.
63. Deckers IE, van der Zee HH, Boer J, Prens EP. Correlation of early-onset hidradenitis suppurativa with stronger genetic susceptibility and more widespread involvement. *J Am Acad Dermatol.* 2015;pii:S0190-9622(14)02202-6. doi: 10.1016/j.jaad.2014.11.017.
64. Kirby JS, Miller JJ, Adams DR, Leslie D. Health care utilization patterns and costs for patients with hidradenitis suppurativa. *JAMA Dermatol.* 2014;150:937–44.
65. Micheletti RG. Hidradenitis suppurativa: current views on epidemiology, pathogenesis, and pathophysiology. *Semin Cutan Med Surg.* 2014;33(3 suppl):S48–50.
66. Gill L, Williams M, Hamzavi I. Update on hidradenitis suppurativa: connecting the tracts. *F1000Prime Rep.* 2014;6:112.
67. Asgeirsson T, Nunoo R, Luchtefeld MA. Hidradenitis suppurativa and pruritus ani. *Clin Colon Rectal Surg.* 2011;24:71–80.
68. Danby FW, Jemec GB, Marsch WC, von Laffert M. Preliminary findings suggest hidradenitis suppurativa may be due to defective follicular support. *Br J Dermatol.* 2013;168:1034–9.
69. Micheletti RG. Natural history, presentation, and diagnosis of hidradenitis suppurativa. *Semin Cutan Med Surg.* 2014;33(3 suppl):S51–3.
70. Kromann CB, Deckers IE, Esmann S, Boer J, Prens EP, Jemec GB. Risk factors, clinical course and long-term prognosis in hidradenitis suppurativa: a cross-sectional study. *Br J Dermatol.* 2014;171:819–24.
71. Thomas CL, Gordon KD, Mortimer PS. Rapid resolution of hidradenitis suppurativa after bariatric surgical intervention. *Clin Exp Dermatol.* 2014;39:315–7.

72. Kromann CB, Ibler KS, Kristiansen VB, Jemec GB. The influence of body weight on the prevalence and severity of hidradenitis suppurativa. *Acta Derm Venereol*. 2014;94:553–7.
73. Von der Werth JM, Williams HC. The natural history of hidradenitis suppurativa. *J Eur Acad Dermatol Venereol*. 2000;14:389–92.
74. Melnik BC. Acneigenic stimuli converge in phosphoinositol-3 kinase/Akt/Foxo 1 signal transduction. *J Clin Exp Dermatol Res*. 2010;1:101.
75. Canoui-Poitaine F, Le Thaut A, Revuz JE, Vialette C, Gabison G, Poli F, Pouget F, Wolkenstein P, Bastuji-Garin S. Identification of three hidradenitis suppurativa phenotypes: latent class analysis of a cross-sectional study. *J Invest Dermatol*. 2013;133:1506–11.
76. Fimmel S, Zouboulis CC. Comorbidities of hidradenitis suppurativa (acne inversa). *Dermatoendocrinology*. 2010;2:9–16.
77. Rambhatla PV, Lim HW, Hamzavi I. A systematic review of treatments for hidradenitis suppurativa. *Arch Dermatol*. 2012;148:439–46.
78. Verdolini R, Clayton N, Smith A, Alwash N, Mannello B. Metformin for the treatment of hidradenitis suppurativa: a little help along the way. *J Eur Acad Dermatol Venereol*. 2013;27:1101–8.
79. Jahns AC, Killasli H, Nosek D, Lundskog B, Lenngren A, Muratova Z, Emtestam L, Alexeyev OA. Microbiology of hidradenitis suppurativa (acne inversa): a histological study of 27 patients. *APMIS*. 2014;122:804–9.
80. Blok JL, van Hattem S, Jonkmann MF, Horvath B. Systemic therapy with immunosuppressive agents and retinoids in hidradenitis suppurativa: a systematic review. *Br J Dermatol*. 2013;168:243–52.
81. Matusiak L, Bieniek A, Szebietowski JC. Acitretin treatment for hidradenitis suppurativa: a prospective series of 17 patients. *Br J Dermatol*. 2014;171:170–4.
82. Verdolini R, Simonacci F, Menon S, Pavlou P, Mannello B. Alitretinoin: a useful agent in the treatment of hidradenitis suppurativa, especially in women of child bearing age. *G Ital Dermatol Venereol*. 2014. [Epub ahead of print].
83. Alikhan A, Lynch PJ, Eisen DB. Hidradenitis suppurativa: a comprehensive review. *J Am Acad Dermatol*. 2009;60:539–61.
84. Marzano AV, Borghi A, Stadnicki A, Crosti C, Cugno M. Cutaneous manifestations in patients with inflammatory bowel diseases: pathophysiology, clinical features, and therapy. *Inflamm Bowel Dis*. 2014;20:213–27.
85. Kelly G, Sweeney CM, Tobin AM, Kirby B. Hidradenitis suppurativa: the role of immune dysregulation. *Int J Dermatol*. 2014;53:1186–96.
86. Dessinioti C, Katsambas A, Antoniou C. Hidradenitis suppurativa (acne inversa) as a systemic disease. *Clin Dermatol*. 2014;32:397–408.
87. Grant A, Gonzalez T, Montgomery MO, Cardenas V, Kerdel FA. Infliximab therapy for patients with moderate to severe hidradenitis suppurativa: a randomized, double-blind, placebo-controlled crossover trial. *J Am Acad Dermatol*. 2010;62:205–17.
88. Sullivan TP, Welsh E, Kerdel FA, Burdick AE, Kirsner RS. Infliximab for hidradenitis suppurativa. *Br J Dermatol*. 2003;149:1046–9.
89. Fernandez-Vozmediano JM, Armario-Hita JC. Infliximab for the treatment of hidradenitis suppurativa. *Dermatology*. 2007;215:41–4.
90. Usmani N, Clayton TH, Everett S, Goodfield MDJ. Variable response of hidradenitis

- suppurativa to infliximab in four patients. *Clin Exp Dermatol*. 2007;32:204–5.
91. Bahillo Monne C, Honorato Guerra S, Schoendorff Ortega C, Gargallo Quintero AB. Management of hidradenitis suppurativa with biological therapy: report of four cases and review of the literature. *Dermatology*. 2014;229:279–87.
92. Kerdel FA. Current and emerging nonsurgical treatment options for hidradenitis suppurativa. *Semi Cutan Med Surg*. 2014;33(3 suppl):S57–9.
93. Zhang J, Reeder VJ, Hamzavi IH. Use of biologics in the treatment of hidradenitis suppurativa: a review of the Henry Ford hospital experience. *Br J Dermatol*. 2014;171:1600–2.
94. Moriarty B, Jiyad Z, Creamer D. Four-weekly infliximab in the treatment of severe hidradenitis suppurativa. *Br J Dermatol*. 2014;170:986–7.
95. Diamantova D, Lomickova I, Cetkovska P. Adalimumab treatment for hidradenitis suppurativa associated with Crohn's disease. *Acta Dermatovenerol Croat*. 2014;22:291–3.
96. Fadel MA, Tawfik AA. New topical photodynamic therapy for treatment of hidradenitis suppurativa using methylene blue niosomal gel: a single-blind, randomized, comparative study. *Clin Exp Dermatol*. 2014. doi: 10.1111/ced.12459. [Epub ahead of print].
97. Scheinfeld N. The use of photodynamic therapy to treat hidradenitis suppurativa a review and critical analysis. *Dermatol Online J*. 2015;21(1):Pii:13030/qt62j7j3c1.
98. Piccolo D, DiMarcantonio D, Crisman G, Cannarozzo G, Sannino M, Chiricozzi A, Chimenti S. Unconventional use of intense pulsed light. *Biomed Res Int*. 2014;2014:618206. doi: 10.1155/2014/618206. Epub 2014 Sep 3.
99. Tierney E, Mahmoud BH, Hexsel C, Ozog D, Hamzavi I. Randomized controlled trial for the treatment of hidradenitis suppurativa with a neodymium-doped yttrium aluminum garnet laser. *Dermatol Surg*. 2009;35:1188–98.
100. Hazen PG, Hazen BP. Hidradenitis suppurativa: successful treatment using carbon dioxide laser excision and marsupialization. *Dermatol Surg*. 2010;36:208–13.
101. Blok JL, Spoo JR, Leeman FWJ, Jonkman MF, Horvath B. Skin-tissue-sparing excision with electrosurgical peeling (STEEP): a surgical treatment option for severe hidradenitis suppurativa Hurley stage II/III. *J Eur Acad Dermatol Venereol*. 2014.
102. Blok JL, Boersma M, Terra JB, Spoo JR, Leeman FW, van den Heuvel ER, Huizinga J, Jonkman MF, Horvath B. Surgery under general anesthesia in severe hidradenitis suppurativa: a study of 363 primary operations in 113 patients. *J Eur Acad Dermatol Venereol*. 2015. doi: 10.1111/jdv.12952. [Epub ahead of print].
103. Alharbi Z, Kauczok J, Pallua N. A review of wide surgical excision of hidradenitis suppurativa. *BMC Dermatol*. 2012;12:9.
104. Mizukami T, Fujiwara M, Ishikawa K, Aoyama S, Fukamizu H. Reconstruction for extensive groin hidradenitis suppurativa using combination of inferior abdominal flap and medial thigh-lift: a case report. *Aesthetic Plast Surg*. 2014;38:745–8.
105. Chen ML, Odom B, Santucci RA. Surgical management of genitoperineal hidradenitis suppurativa in men. *Urology*. 2014;83:1412–7.
106. Chen YE, Gerstle T, Verma K, Treiser MD, Kimball AB, Orgill DP. Management of hidradenitis suppurativa wounds with an internal vacuum-assisted closure device. *Plast Reconstr Surg*. 2014;133:370e–7.
107. Yamashita Y, Hashimoto I, Matsuo S, Abe Y, Ishida S, Nakanishi H. Two-stage surgery for hidradenitis suppurativa: staged artificial dermis and skin grafting. *Dermatol Surg*. 2014;40:110–5.

## 第 18 章

1. Hafenreffer S. Nosodochium, in quo cutis, eique adaerentium partium, affectus omnes, singulari methodo, et cognoscendi e curandi fidelissime traduntur. Ulmae (Westphalia) Kühnen; 1660. p. 98–102.
2. Billingham RP, Isler JT, Kimmins MH, et al. The diagnosis and management of common anorectal disorders. *Curr Probl Surg*. 2004;33(7):586–645.
3. Hanno R, Murphy P. Pruritus ani: classification and management. *Dermatol Clin*. 1987;5(4):811–6.
4. Zuccati G, Lotti T, Mastrolorenzo A, et al. Pruritus ani. *Dermatol Ther*. 2005;18(4):355–62.
5. Mazier WP. Hemorrhoids, fissures, and pruritus ani. *Surg Clin North Am*. 1994;74(6):1277–92.
6. Metcalf A. Anorectal disorders. Five common causes of pain, itching and bleeding. *Postgrad Med*. 1995;98(5):81. –4, 87–9, 92–4.
7. Ikoma A, Steinhoff M, Ständer S, Yosipovitch G, Schmelz M. The neurobiology of itch. *Nat Rev Neurosci*. 2006;7:535–47.
8. Steinhoff M, Bienenstock J, Schmelz M, Maurer M, Wei E, Biro T. Neurophysiological, neuroimmunological, and neuroendocrine basis of pruritus. *J Invest Dermatol*. 2006;126:1705–18.
9. Schmelz M, Schmidt R, Bickel A, Handwerker HO, Torebjork HE. Specific C-receptors for itch in human skin. *J Neurosci*. 1997;17:8003–8.
10. Patel KN, Dong X. Itch: cells, molecules, and circuits. *ACS Chem Neurosci*. 2011;2:17–25.
11. Andrew D, Craig AD. Spinothalamic lamina I neurons selectively sensitive to histamine: a central neural pathway for itch. *Nat Neurosci*. 2001;4:72.
12. Yosipovitch G, Greaves M, Schmelz M. Itch. *Lancet*. 2003;36:690–4.
13. Verbov J. Pruritus ani and its management – a study and reappraisal. *Clin Exp Dermatol*. 1984;9:46–52.
14. Caplan RM. The irritant role of feces in the genesis of perianal itch. *Gastroenterology*. 1966;50:19–23.
15. Eysers AA, Thomson JP. Pruritus ani: is anal sphincter dysfunction important in aetiology? *Br Med J*. 1979;2:1549–51.
16. Koblenzer CS. Psychologic and psychiatric aspects of itching. In: Bernhard JD, editor. *Itch: mechanisms and management of pruritus*. New York, NY: McGraw-Hill; 1994. p. 347–65.
17. Stamos MJ, Hicks TC. Pruritus ani: diagnosis and treatment. *Perspect Colon Rectal Surg*. 1998;11(1):1–20. Thieme Medical Publishers.
18. Gordon PH, Nivatvongs S. Perianal dermatologic disease. In: Gordon PH, editor. *Principles and practice of surgery for the colon, rectum and anus*. 3rd ed. New York, NY: Informa Healthcare; 2007. p. 247–73.
19. Bowyer A, McColl I. A study of 200 patients with pruritus ani. *Proc R Soc Med*. 1970;63(Suppl):96–8.
20. Andersen PH, Bucher AP, Saeed I, Lee PC, Davis JA, Maibach HI. Faecal enzymes: in vivo human skin irritation. *Contact Dermatitis*. 1994;30(3):152–8.
21. Friend WG. The cause and treatment of idiopathic pruritus ani. *Dis Colon Rectum*. 1977;20:40–2.



22. Andrews D, Grunau VJ. An uncommon adverse effect following bolus administration of intravenous dexamethasone. *J Can Dent Assoc.* 1986;52:309–11.
23. Kligman AM, Frosch PJ. Steroid addiction. *Int J Dermatol.* 1979;18:23–31.
24. Goldman L, Kitzmiller KW. Perianal atrophoderma from topical corticosteroids. *Arch Dermatol.* 1973;107:611–2.
25. Markell KW, Billingham RP. Pruritus ani: etiology and management. *Surg Clin North Am.* 2010;90(1):125–35.
26. Kranke B, Trummer M, Brabek E, Komericki P, Turek TD, Aberer W. Etiologic and causative factors in perianal dermatitis: results of a prospective study in 126 patients. *Wien Klin Wochenschr.* 2006;118(3-4):90–4.
27. Siddiqi S, Vijay V, Ward M, et al. Pruritus ani. *Ann R Coll Surg Engl.* 2008;90(6):457–63.
28. Sheth S, Schechtman AD. Itchy perianal erythema. *J Fam Pract.* 2007;56(12):1025–7.
29. Weismann K, Sand Petersen C, Roder B. Pruritus ani caused by beta-haemolytic streptococci. *Acta Derm Venereol.* 1996;76(5):415.
30. Dodi G, Pirone E, Bettin A, et al. The mycotic flora in proctological patients with and without pruritus ani. *Br J Surg.* 1985;72(12):967–9.
31. Bauer A, Geier J, Elsner P. Allergic contact dermatitis in patients with anogenital complaints. *J Reprod Med.* 2000;45(8):649–54.
32. Goldsmith PC, Rycroft RJ, White IR, Ridley CM, Neill SM, McFadden JP. Contact sensitivity in women with anogenital dermatoses. *Contact Dermatitis.* 1997;36(3):174–5.
33. Blecher P, Korting HC. Tolerance to different toilet paper preparations: toxicological and allergological aspects. *Dermatology.* 1995;191(4):299–304.
34. Wilkinson JD, Hambly EM, Wilkinson DS. Comparison of patch test results in two adjacent areas of England. II. Medicaments. *Acta Derm Venereol.* 1980;60(3):245–9.
35. Minet A, Eggers S, Willocx D, Bourlond A, Lachapelle JM. Allergic contact dermatitis from Kathon CG in moist toilet paper. *Contact Dermatitis.* 1989;21(2):107–8.
36. De Groot AC, Baar TJ, Terpstra H, Weyland JW. Contact allergy to moist toilet paper. *Contact Dermatitis.* 1991;24(2):135–6.
37. Smith FJ, Irvine AD, Terron-Kwiatkowski A, Sandilands A, Campbell LE, Zhao Y, et al. Loss-of-function mutations in the gene encoding filaggrin cause ichthyosis vulgaris. *Nat Genet.* 2006;38:337–42.
38. Segre JA. Epidermal differentiation complex yields a secret: mutations in the cornification protein filaggrin underlie ichthyosis vulgaris. *J Invest Dermatol.* 2006;126:1202–4.
39. Smith LE, Henrichs D, McCullah RD. Prospective studies on the etiology and treatment of pruritus ani. *Dis Colon Rectum.* 1982;25:358–63.
40. Dasan S, Neill SM, Donaldson DR, Scott HJ. Treatment of persistent pruritus ani in a combined colorectal and dermatological clinic. *Br J Surg.* 1999;86:1337–40.
41. Habif TP. *Clinical dermatology: a color guide to diagnosis and therapy.* 4th ed. Philadelphia, PA: Mosby; 2004.
42. Chuang TY, Stille L. Lichen planus. Emedicine website. <http://emedicine.medscape.com/article/1123213-overview>. Accessed 18 Apr 2008.
43. Meffert J. Lichen sclerosus et atrophicus. Emedicine website. <http://emedicine.medscape.com/article/1123316-overview>. Accessed 29 Jan 2009.
44. Hogan DJ, Mason SH, Bower SM. Lichen simplex chronicus. Emedicine website.

<http://emedicine.medscape.com/article/1123423-overview>. Accessed 10 Oct 2008.

45. Chang GJ, Berry JM, Jay N, Palefsky JM, Welton ML. Surgical treatment of high-grade anal squamous intraepithelial lesions: a prospective study. *Dis Colon Rectum*. 2002;45:453–8.
46. Goldstone SE, Winkler B, Ufford LJ, Alt E, Palefsky JM. High prevalence of anal squamous intraepithelial lesions and squamous-cell carcinoma in men who have sex with men as seen in a surgical practice. *Dis Colon Rectum*. 2001;44:690–8.
47. Berardi RS, Lee S, Chen HP. Perianal extramammary Paget's disease. *Surg Gynecol Obstet*. 1988;167:359–65.
48. Perez DR, Trakarnsanga A, Shia J, Nash GM, Temple LK, Paty PB, Guillem JG, Garcia-Aguilar J, Weiser MR. Management and outcome of perianal Paget's disease: a 6-decade institutional experience. *Dis Colon Rectum*. 2014;57(6):747–51.
49. Sarmiento JM, Wolff BG, Burgart LJ, Frizelle FA, Ilstrup DM. Paget's disease of the perianal region—an aggressive disease? *Dis Colon Rectum*. 1997;40:1187–94.
50. Marchesa P, Fazio VW, Oliart S, Goldblum JR, Lavery IC. Perianal Bowen's disease: a clinicopathologic study of 47 patients. *Dis Colon Rectum*. 1997;40:1286–93.
51. Daniel GL, Longo WE, Vernava III AM. Pruritus ani causes and concerns. *Dis Colon Rectum*. 1994;37:670–4.
52. Murie JA, Sim AJ, Mackenzie I. The importance of pain, pruritus and soiling as symptoms of haemorrhoids and their response to haemorrhoidectomy or rubber band ligation. *Br J Surg*. 1981;68:247–9.
53. Weichert GE. An approach to the treatment of anogenital pruritus. *Dermatol Ther*. 2004;17(1):129–33.
54. Sindhuphak W, MacDonald E, Smith EB. Erythrasma: overlooked or misdiagnosed? *Int J Dermatol*. 1985;24(2):95–6.
55. Bowyer A, McColl I. Erythrasma and pruritus ani. *Acta Derm Venereol*. 1971;51(6):444–7.
56. Alexander S. Dermatological aspects of anorectal disease. *Clin Gastroenterol*. 1975;4:651–7.
57. Pirone E, Infantino A, Masin A, Melega F, Pianon P, Dodi G, et al. Can proctological procedures resolve perianal pruritus and mycosis? A prospective study of 23 cases. *Int J Colorectal Dis*. 1992;7:18–20.
58. Meffert JJ, Davis BM, Grimwood RE. Lichen sclerosis. *J Am Acad Dermatol*. 1995;32:393–416. quiz 417–398.
59. Neill SM, Tatnall FM, Cox NH. Guidelines for the management of lichen sclerosis. *Br J Dermatol*. 2002;147:640–9.
60. Powell JJ, Wojnarowska F. Lichen sclerosis. *Lancet*. 1999;353:1777–83.
61. Wong YW, Powell J, Oxon MA. Lichen sclerosis: a review. *Minerva Med*. 2002;93:95–9.
62. Val I, Almeida G. An overview of lichen sclerosis. *Clin Obstet Gynecol*. 2005;48:808–17.
63. Carli P, Cattaneo A, De Magnis A, Biggeri A, Taddei G, Giannotti B. Squamous cell carcinoma arising in vulval lichen sclerosis: a longitudinal cohort study. *Eur J Cancer Prev*. 1995;4:491–5.
64. Lock MR, Katz DR, Parks A, Thomson JP. Perianal Paget's disease. *Postgrad Med J*. 1977;53:768–72.
65. McClatchey KD. Clinical laboratory medicine. 2nd ed. Philadelphia, PA: Lippincott Williams & Wilkins; 2002.
66. Health Inc IMS. Prescribing insights. Danbury, CT: IMS; 2011.
67. Al-Ghnam R, Short K, Pullen A, et al. 1% Hydrocortisone ointment is an effective treatment

- of pruritus ani: a pilot randomized controlled crossover trial. *Int J Colorectal Dis.* 2007;22(12):1463–7.
68. Lysy J, Sistiery-Ittah M, Israelit Y, et al. Topical capsaicin—a novel and effective treatment for idiopathic intractable pruritus ani: a randomized, placebo controlled, crossover study. *Gut.* 2003;52(9):1323–6.
69. Finne CO, Fenyk JR. Dermatology and pruritus ani. In: Fleshman JW, Wolff BG, editors. *The ASCRS textbook of colon and rectal surgery.* New York, NY: Springer; 2007. p. 277–94.
70. Shohrati M, Davoudi SM, Keshavarz S, Sadr B, Tajik A. Cetirizine, doxepine, and hydroxyzine in the treatment of pruritus due to sulfur mustard: a randomized clinical trial. *Cutan Ocul Toxicol.* 2007;26(3):249–55.
71. Siemens W, Xander C, Meerpohl JJ, Antes G, Becker G. Drug treatments for pruritus in adult palliative care. *Dtsch Arztebl Int.* 2014;111(50):863–70.
72. Eusebio EB, Graham J, Mody N. Treatment of intractable pruritus ani. *Dis Colon Rectum.* 1990;33(9):770–2.
73. Menten BB, Akin M, Leventoglu S, et al. Intradermal methylene blue injection for the treatment of intractable idiopathic pruritus ani: results of 30 cases. *Tech Coloproctol.* 2004;8(1):11–4.
74. Baral J. Pruritus ani and *Staphylococcus aureus* [letter]. *J Am Acad Dermatol.* 1983;9(6):962.
75. Schneider L, Tilles S, Lio P, et al. Atopic dermatitis: a practice parameter update 2012. *J Allergy Clin Immunol.* 2013;131:295–9.
76. Ucak H, Demir B, Cicek D, Dertlioglu SB, Akkurt ZM, Ucmak D, Halisdemir N. Efficacy of topical tacrolimus for the treatment of persistent pruritus ani in patients with atopic dermatitis. *J Dermatolog Treat.* 2013;24(6):454–7.
77. Suys E. Randomized study of topical tacrolimus ointment as possible treatment for resistant idiopathic pruritus ani. *J Am Acad Dermatol.* 2012;66(2):327–8.
78. Decock S, Roelandts R, Steenbergen WV, Laleman W, Cassiman D, Verslype C, Fevery J, Pelt JV, Nevens F. Cholestasis-induced pruritus treated with ultraviolet B phototherapy: an observational case series study. *J Hepatol.* 2012;57(3):637–41.
79. Panahi Y, Davoudi SM, Madanchi N, Abolhasani E. Recombinant human interferon gamma (Gamma Immunex) in treatment of atopic dermatitis. *Clin Exp Med.* 2012;12(4):241–5.
80. Alexander-Williams J. Causes and management of anal irritation. *Br Med J (Clin Res Ed).* 1983;287(6404):1528.
81. Fistarol SK, Itin PH. Diagnosis and treatment of lichen sclerosus: an update. *Am J Clin Dermatol.* 2013;14(1):27–47.
82. Beck DE, Fazio VW. Perianal Paget's disease. *Dis Colon Rectum.* 1987;30:263–6.

## 第 19 章

1. Mimiaga MJ, Helms DJ, Reisner SL, Grasso C, Bertrand T, Mosure DJ, et al. Gonococcal, chlamydia, and syphilis infection positivity among MSM attending a large primary care clinic, Boston, 2003 to 2004. *Sex Transm Dis.* 2009;36(8):507–11.
2. Van Liere GA, Hoebe CJ, Niekamp AM, Koedijk FD, Dukers-Muijters NH. Standard symptom- and sexual history-based testing misses anorectal Chlamydia trachomatis and neisseria gonorrhoeae infections in swingers and men who have sex with men. *Sex Transm Dis.* 2013;40(4):285–9.

3. Van Liere GA, Hoebe CJ, Dukers-Muijrers NH. Evaluation of the anatomical site distribution of chlamydia and gonorrhea in men who have sex with men and in high-risk women by routine testing: cross-sectional study revealing missed opportunities for treatment strategies. *Sex Transm Infect.* 2014;90(1):58–60.
4. Bissessor M, Fairley CK, Read T, Denham I, Bradshaw C, Chen M. The etiology of infectious proctitis in men who have sex with men differs according to HIV status. *Sex Transm Dis.* 2013;40(10):768–70.
5. Zakher B, Cantor AG, Pappas M, Daeges M, Nelson HD. Screening for gonorrhea and Chlamydia: a systematic review for the U.S. Preventive Services Task Force. *Ann Intern Med.* 2014;161(12):884–93.
6. Prevention CfDCA. Recommendations for the laboratory-based detection of Chlamydia trachomatis and Neisseria gonorrhoeae – 2014. *MMWR Recomm Rep.* 2014;63(RR-02):1–19.
7. Workowski KA, Berman SM, Douglas JM. Emerging antimicrobial resistance in Neisseria gonorrhoeae: urgent need to strengthen prevention strategies. *Ann Intern Med.* 2008;148(8):606–13.
8. (CDC) CfDCAp. Update to CDC’s sexually transmitted diseases treatment guidelines, 2010: oral cephalosporins no longer a recommended treatment for gonococcal infections. *MMWR Morb Mortal Wkly Rep.* 2012;61(31):590–4.
9. Bolan GA, Sparling PF, Wasserheit JN. The emerging threat of untreatable gonococcal infection. *N Engl J Med.* 2012;366(6):485–7.
10. (CDC) CfDCAp. Cephalosporin susceptibility among Neisseria gonorrhoeae isolates – United States, 2000–2010. *MMWR Morb Mortal Wkly Rep.* 2011;60(26):873–7.
11. Kirkcaldy RD, Zaidi A, Hook EW, Holmes KK, Holmes KH, Soge O, et al. Neisseria gonorrhoeae antimicrobial resistance among men who have sex with men and men who have sex exclusively with women: the Gonococcal Isolate Surveillance Project, 2005–2010. *Ann Intern Med.* 2013;158(5 Pt 1):321–8.
12. Kovari H, de Melo Oliveira MD, Hauser P, Lächli S, Meyer J, Weber R, et al. Decreased susceptibility of Neisseria gonorrhoeae isolates from Switzerland to Cefixime and Ceftriaxone: antimicrobial susceptibility data from 1990 and 2000 to 2012. *BMC Infect Dis.* 2013;13:603.
13. Van Liere GA, Hoebe CJ, Wolffs PF, Dukers-Muijrers NH. High co-occurrence of anorectal chlamydia with urogenital chlamydia in women visiting an STI clinic revealed by routine universal testing in an observational study; a recommendation towards a better anorectal chlamydia control in women. *BMC Infect Dis.* 2014;14:274.
14. LeFevre ML. Force USPST. Screening for Chlamydia and gonorrhea: U.S. Preventive Services Task Force recommendation statement. *Ann Intern Med.* 2014;161(12):902–10.
15. Geisler WM. Diagnosis and management of uncomplicated Chlamydia trachomatis infections in adolescents and adults: summary of evidence reviewed for the 2010 Centers for Disease Control and Prevention sexually transmitted diseases treatment guidelines. *Clin Infect Dis.* 2011;53 Suppl 3:S92–8.
16. Van der Bij AK, Spaargaren J, Morré SA, Fennema HS, Mindel A, Coutinho RA, et al. Diagnostic and clinical implications of anorectal lymphogranuloma venereum in men who have sex with men: a retrospective case-control study. *Clin Infect Dis.* 2006;42(2):186–94.
17. Stamm WE, Hicks CB, Martin DH, Leone P, Hook EW, Cooper RH, et al. Azithromycin for empirical treatment of the nongonococcal urethritis syndrome in men. A randomized double-blind

study. *JAMA*. 1995;274(7):545–9.

18. Workowski KA, Berman S, (CDC) CfDCAp. Sexually transmitted diseases treatment guidelines, 2010. *MMWR Recomm Rep*. 2010;59(RR-12):1–110.

19. Stamm WE, Batteiger BE, McCormack WM, Totten PA, Sternlicht A, Kivel NM, et al. A randomized, double-blind study comparing single-dose rifalazil with single-dose azithromycin for the empirical treatment of nongonococcal urethritis in men. *Sex Transm Dis*. 2007;34(8):545–52.

20. Martin-Iguacel R, Llibre JM, Nielsen H, Heras E, Matas L, Lugo R, et al. Lymphogranuloma venereum proctocolitis: a silent endemic disease in men who have sex with men in industrialised countries. *Eur J Clin Microbiol Infect Dis*. 2010;29(8):917–25.

21. Gallegos M, Bradly D, Jakate S, Keshavarzian A. Lymphogranuloma venereum proctosigmoiditis is a mimicker of inflammatory bowel disease. *World J Gastroenterol*. 2012;18(25):3317–21.

22. Arnold CA, Limketkai BN, Illei PB, Montgomery E, Voltaggio L. Syphilitic and lymphogranuloma venereum (LGV) proctocolitis: clues to a frequently missed diagnosis. *Am J Surg Pathol*. 2013;37(1):38–46.

23. Soni S, Srirajaskanthan R, Lucas SB, Alexander S, Wong T, White JA. Lymphogranuloma venereum proctitis masquerading as inflammatory bowel disease in 12 homosexual men. *Aliment Pharmacol Ther*. 2010;32(1):59–65.

24. Pathela P, Blank S, Schillinger JA. Lymphogranuloma venereum: old pathogen, new story. *Curr Infect Dis Rep*. 2007;9(2):143–50.

25. De Vries HJ, van der Bij AK, Fennema JS, Smit C, de Wolf F, Prins M, et al. Lymphogranuloma venereum proctitis in men who have sex with men is associated with anal enema use and high-risk behavior. *Sex Transm Dis*. 2008;35(2):203–8.

26. Mattei PL, Beachkofsky TM, Gilson RT, Wisco OJ. Syphilis: a reemerging infection. *Am Fam Physician*. 2012;86(5):433–40.

27. Patton ME, Su JR, Nelson R, Weinstock H, (CDC) CfDCAp. Primary and secondary syphilis – United States, 2005–2013. *MMWR Morb Mortal Wkly Rep*. 2014;63(18):402–6.

28. Lynn WA, Lightman S. Syphilis and HIV: a dangerous combination. *Lancet Infect Dis*. 2004;4(7):456–66.

29. Kemp M, Christensen JJ, Lautenschlager S, Vall-Mayans M, Moi H. European guideline for the management of chancroid, 2011. *Int J STD AIDS*. 2011;22(5):241–4.

30. Lewis DA. Epidemiology, clinical features, diagnosis and treatment of *Haemophilus ducreyi* – a disappearing pathogen? *Expert Rev Anti Infect Ther*. 2014;12(6):687–96.

31. Ernst AA, Marvez-Valls E, Martin DH. Incision and drainage versus aspiration of fluctuant buboes in the emergency department during an epidemic of chancroid. *Sex Transm Dis*. 1995;22(4):217–20.

32. Basta-Juzbašić A, Čeović R. Chancroid, lymphogranuloma venereum, granuloma inguinale, genital herpes simplex infection, and molluscum contagiosum. *Clin Dermatol*. 2014;32(2):290–8.

33. Barroso LF, Wispelwey B. Donovanosis presenting as a pelvic mass mimicking ovarian cancer. *South Med J*. 2009;102(1):104–5.

34. Sethi S, Sarkar R, Garg V, Agarwal S. Squamous cell carcinoma complicating donovanosis not a thing of the past! *Int J STD AIDS*. 2014;25(12):894–7.

35. Sardana K, Garg VK, Arora P, Khurana N. Malignant transformation of donovanosis (granuloma inguinale) in a HIV-positive patient. *Dermatol Online J*. 2008;14(9):8.

36. Bradley H, Markowitz LE, Gibson T, McQuillan GM. Seroprevalence of herpes simplex virus types 1 and 2 – United States, 1999–2010. *J Infect Dis.* 2014;209(3):325–33.
37. Xu F, Sternberg MR, Kottiri BJ, McQuillan GM, Lee FK, Nahmias AJ, et al. Trends in herpes simplex virus type 1 and type 2 seroprevalence in the United States. *JAMA.* 2006;296(8):964–73.
38. Ryder N, Jin F, McNulty AM, Grulich AE, Donovan B. Increasing role of herpes simplex virus type 1 in first-episode anogenital herpes in heterosexual women and younger men who have sex with men, 1992–2006. *Sex Transm Infect.* 2009;85(6):416–9.
39. Fanfair RN, Zaidi A, Taylor LD, Xu F, Gottlieb S, Markowitz L. Trends in seroprevalence of herpes simplex virus type 2 among non-Hispanic blacks and non-Hispanic whites aged 14 to 49 years – United States, 1988 to 2010. *Sex Transm Dis.* 2013;40(11):860–4.
40. Mertz GJ. Asymptomatic shedding of herpes simplex virus 1 and 2: implications for prevention of transmission. *J Infect Dis.* 2008;198(8):1098–100.
41. Mark KE, Wald A, Magaret AS, Selke S, Olin L, Huang ML, et al. Rapidly cleared episodes of herpes simplex virus reactivation in immunocompetent adults. *J Infect Dis.* 2008;198(8):1141–9.
42. Mark KE, Wald A, Magaret AS, Selke S, Kuntz S, Huang ML, et al. Rapidly cleared episodes of oral and anogenital herpes simplex virus shedding in HIV-infected adults. *J Acquir Immune Defic Syndr.* 2010;54(5):482–8.
43. Le Cleach L, Trinquart L, Do G, Maruani A, Lebrun-Vignes B, Ravaud P, et al. Oral antiviral therapy for prevention of genital herpes outbreaks in immunocompetent and nonpregnant patients. *Cochrane Database Syst Rev.* 2014;8, CD009036.
44. Corey L, Wald A, Patel R, Sacks SL, Tyring SK, Warren T, et al. Once-daily valacyclovir to reduce the risk of transmission of genital herpes. *N Engl J Med.* 2004;350(1):11–20.
45. Martin ET, Krantz E, Gottlieb SL, Magaret AS, Langenberg A, Stanberry L, et al. A pooled analysis of the effect of condoms in preventing HSV-2 acquisition. *Arch Intern Med.* 2009;169(13):1233–40.
46. Zuckerman RA, Lucchetti A, Whittington WL, Sanchez J, Coombs RW, Zuñiga R, et al. Herpes simplex virus (HSV) suppression with valacyclovir reduces rectal and blood plasma HIV-1 levels in HIV-1/HSV-2-seropositive men: a randomized, double-blind, placebo-controlled crossover trial. *J Infect Dis.* 2007;196(10):1500–8.
47. Zuckerman RA, Lucchetti A, Whittington WL, Sánchez J, Coombs RW, Magaret A, et al. HSV suppression reduces seminal HIV-1 levels in HIV-1/HSV-2 co-infected men who have sex with men. *AIDS.* 2009;23(4):479–83.
48. Mugwanya K, Baeten JM, Mugo NR, Irungu E, Ngure K, Celum C. High-dose valacyclovir HSV-2 suppression results in greater reduction in plasma HIV-1 levels compared with standard dose acyclovir among HIV-1/HSV-2 coinfecting persons: a randomized, crossover trial. *J Infect Dis.* 2011;204(12):1912–7.
49. Perti T, Saracino M, Baeten JM, Johnston C, Diem K, Ocbamichael N, et al. High-dose valacyclovir decreases plasma HIV-1 RNA more than standard-dose acyclovir in persons coinfecting with HIV-1 and HSV-2: a randomized crossover trial. *J Acquir Immune Defic Syndr.* 2013;63(2):201–8.
50. Nagot N, Ouédraogo A, Foulongne V, Konaté I, Weiss HA, Vergne L, et al. Reduction of HIV-1 RNA levels with therapy to suppress herpes simplex virus. *N Engl J Med.* 2007;356(8):790–9.
51. Baggaley RF, Griffin JT, Chapman R, Hollingsworth TD, Nagot N, Delany S, et al. Estimating the public health impact of the effect of herpes simplex virus suppressive therapy on plasma HIV-1

viral load. *AIDS*. 2009;23(8):1005–13.

52. Chin-Hong PV, Berry JM, Cheng SC, Catania JA, Da Costa M, Darragh TM, et al. Comparison of patient- and clinician-collected anal cytology samples to screen for human papillomavirus-associated anal intraepithelial neoplasia in men who have sex with men. *Ann Intern Med*. 2008;149(5):300–6.

53. Guimarães AG, da Costa AG, Martins-Filho OA, Pimentel JP, Zauli DA, Peruhype-Magalhães V, et al. CD11c + CD123Low dendritic cell subset and the triad TNF- $\alpha$ /IL-17A/IFN- $\gamma$  integrate mucosal and peripheral cellular responses in HIV patients with high-grade anal intraepithelial neoplasia: a systems biology approach. *J Acquir Immune Defic Syndr*. 2015;68(2):112–22.

54. Yaghoobi M, Le Gouvello S, Aloulou N, Duprez-Dutreuil C, Walker F, Sobhani I. FoxP3 overexpression and CD1a + and CD3+ depletion in anal tissue as possible mechanisms for increased risk of human papillomavirus-related anal carcinoma in HIV infection. *Colorectal Dis*. 2011;13(7):768–73.

55. Guimarães AG, Silva Junior RM, Costa OT, Silva IT, Gimenez FS, Araujo JR, et al. Morphometric analysis of dendritic cells from anal mucosa of HIV-positive patients and the relation to intraepithelial lesions and cancer seen at a tertiary health institution in Brazil. *Acta Cir Bras*. 2011;26(6):521–9.

56. Sobhani I, Walker F, Aparicio T, Abramowitz L, Henin D, Cremieux AC, et al. Effect of anal epidermoid cancer-related viruses on the dendritic (Langerhans') cells of the human anal mucosa. *Clin Cancer Res*. 2002;8(9):2862–9.

57. Bean SM, Chhieng DC. Anal-rectal cytology: a review. *Diagn Cytopathol*. 2010;38(7):538–46.

58. Goldstone SE, Johnstone AA, Moshier EL. Long-term outcome of ablation of anal high-grade squamous intraepithelial lesions: recurrence and incidence of cancer. *Dis Colon Rectum*. 2014;57(3):316–23.

59. Burgos J, Curran A, Tallada N, Guelar A, Navarro J, Landolfi S, et al. Risk of progression to high-grade anal intraepithelial neoplasia in HIV-infected MSM. *AIDS*. 2015;29(6):695–702.

60. Tong WW, Jin F, McHugh LC, Maher T, Sinclair B, Grulich AE, et al. Progression to and spontaneous regression of high-grade anal squamous intraepithelial lesions in HIV-infected and uninfected men. *AIDS*. 2013;27(14):2233–43.

61. Sendagorta E, Herranz P, Guadalajara H, Bernardino JJ, Viguer JM, Beato MJ, et al. Prevalence of abnormal anal cytology and high-grade squamous intraepithelial lesions among a cohort of HIV-infected men who have sex with men. *Dis Colon Rectum*. 2014;57(4):475–81.

62. Darwich L, Videla S, Cañadas MP, Piñol M, García-Cuyàs F, Vela S, et al. Distribution of human papillomavirus genotypes in anal cytological and histological specimens from HIV-infected men who have sex with men and men who have sex with women. *Dis Colon Rectum*. 2013;56(9):1043–52.

63. Palefsky JM, Giuliano AR, Goldstone S, Moreira ED, Aranda C, Jessen H, et al. HPV vaccine against anal HPV infection and anal intraepithelial neoplasia. *N Engl J Med*. 2011;365(17):1576–85.

64. Finlayson TJ, Le B, Smith A, Bowles K, Cribbin M, Miles I, et al. HIV risk, prevention, and testing behaviors among men who have sex with men – National HIV Behavioral Surveillance System, 21 U.S. cities, United States, 2008. *MMWR Surveill Summ*. 2011;60(14):1–34.

65. (CDC) CfDCaP. National HIV testing day and new testing recommendations. *MMWR Morb Mortal Wkly Rep*. 2014;63(25):537.

66. Villa L, Varela JA, Otero L, Sánchez C, Junquera ML, Río JS, et al. Molluscum contagiosum: a 20-year study in a sexually transmitted infections unit. *Sex Transm Dis*. 2010;37(7):423–4.
67. Nguyen HP, Franz E, Stiegel KR, Hsu S, Tyring SK. Treatment of molluscum contagiosum in adult, pediatric, and immunodeficient populations. *J Cutan Med Surg*. 2014;18(5):299–306.
68. Ianhez M, Cestari SC, Enokihara MY, Seize MB. Dermoscopic patterns of molluscum contagiosum: a study of 211 lesions confirmed by histopathology. *An Bras Dermatol*. 2011;86(1):74–9.
69. Hošnjak L, Kocjan BJ, Kušar B, Seme K, Poljak M. Rapid detection and typing of Molluscum contagiosum virus by FRET-based real-time PCR. *J Virol Methods*. 2013;187(2):431–4.
70. Simonart T, De Maertelaer V. Curettage treatment for molluscum contagiosum: a follow-up survey study. *Br J Dermatol*. 2008;159(5):1144–7.
71. Tyring SK. Molluscum contagiosum: the importance of early diagnosis and treatment. *Am J Obstet Gynecol*. 2003;189(3 Suppl):S12–6.
72. Liota E, Smith KJ, Buckley R, Menon P, Skelton H. Imiquimod therapy for molluscum contagiosum. *J Cutan Med Surg*. 2000;4(2):76–82.
73. Anderson AL, Chaney E. Pubic lice (*Phthirus pubis*): history, biology and treatment vs. knowledge and beliefs of US college students. *Int J Environ Res Public Health*. 2009;6(2):592–600.
74. Dholakia S, Buckler J, Jeans JP, Pillai A, Eagles N. Pubic lice: an endangered species? *Sex Transm Dis*. 2014;41(6):388–91.
75. Gunning K, Pippitt K, Kiraly B, Sayler M. Pediculosis and scabies: treatment update. *Am Fam Physician*. 2012;86(6):535–41.
76. Strong M, Johnstone P. Interventions for treating scabies. *Cochrane Database Syst Rev*. 2007;3, CD000320.
77. Wolf R, Davidovici B. Treatment of scabies and pediculosis: facts and controversies. *Clin Dermatol*. 2010;28(5):511–8.

## 第 20 章

1. Steele SR, Madhulika GV, Melton GB, Ross HM, Rafferty JF, Buie WD, on behalf of the Standards Practice Task Force of the American Society of Colon and Rectal Surgeons. Practice parameters for anal squamous neoplasms. *Dis Colon Rectum*. 2012;55:735–49.
2. Bean SM, Chhieng DC. Anal-rectal cytology: a review. *Diagn Cytopathol*. 2010;38:538–46.
3. Robb BW, Mutch MG. Epidermoid carcinoma of the anal canal. *Clin Colon Rect Surg*. 2006;19:54–60.
4. Ryan DP, Compton CC, Mayer RJ. Carcinoma of the anal canal. *N Engl J Med*. 2000;342:792–800.
5. Holly EA, Ralston ML, Darragh TM, Greenblatt RM, Jay N, Palefsky JM. Prevalence and risk factors for anal squamous intraepithelial lesions in women. *J Natl Cancer Inst*. 2001;93:843–9.
6. Chin-Hong PV, Berry JM, Cheng SC, et al. Comparison of patient and clinician collected anal cytology samples to screen for human papillomavirus-associated anal intraepithelial neoplasia in men who have sex with men. *Ann Intern Med*. 2008;149:300–6.
7. Ho GYF, Bierman R, Beardsley L, Chang CJ, Burk RD. Natural history of cervicovaginal papillomavirus infection in young women. *N Engl J Med*. 1998;338:423–8.



8. Garland SM, Steben M, Sings HL, James M, Lu S, Railkar R, et al. Natural history of genital warts: analysis of the placebo arm of 2 randomized phase III trials of a quadrivalent human papillomavirus (types 6, 11, 16, and 18) vaccine. *J Infect Dis.* 2009;199:805–14.
9. Forman D, de Martel C, Lacey CJ, Soerjomataram I, Lortet-Tieulent J, Bruni L, Vignat J, Ferlay J, Bray F, Plummer M, Franceschi S. Global burden of human papillomavirus and related diseases. *Vaccine.* 2012;30 Suppl 5:F12–23.
10. Markowitz LE, Hariri S, Lin C, Dunne EF, Steinau M, McQuillan G, et al. Reduction in human papillomavirus (HPV) prevalence among young women following HPV vaccine introduction in the United States, National Health and Nutrition Examination Surveys, 2003–2010. *J Infect Dis.* 2013;208:385–93.
11. 2013 STD Surveillance – Figure 49. IMS Health, Integrated Promotional Services™. IMS Health Report, 1966–2013. <http://www.cdc.gov/std/stats13/figures/49.htm>. Accessed 3 Aug 2015.
12. SEER Stat Fact Sheet-Anal Cancer. <http://seer.cancer.gov/statfacts/html/anus.html>. Accessed on 7 Aug 2015.
13. Berry JM, Jay N, Cranston RD, Darragh TM, Holly EA, Welton ML, Palefsky JM. Progression of anal high-grade squamous intraepithelial lesions to invasive anal cancer among HIV-infected men who have sex with men. *Int J Cancer.* 2014;134:1147–55.
14. Arends MJ, Buckley CH, Wells M. Aetiology, pathogenesis, and pathology of cervical neoplasia. *J Clin Pathol.* 1998;51:96.
15. World Health Organization, International Agency for Research on Cancer. IARC monographs on the evaluation of carcinogenic risks to humans. [Monographs.iarc.fr/ENG/Monographs/vol90/mono90.pdf](http://monographs.iarc.fr/ENG/Monographs/vol90/mono90.pdf). 3. Accessed 10 Sept 2013.
16. Gagne SE, Jensen R, Polvi A, et al. High-resolution analysis of genomic alterations and human papillomavirus integration in anal intraepithelial neoplasia. *J Acquir Immune Defic Syndr.* 2005;40:182–9.
17. Ricciardi R, Burks E, Schoetz DJ, Verma Y, Kershner E, Kilpatrick MW, Tsipouras P, Walat RJ. Is there a gain in chromosome 3q in the pathway to anal cancer? *Dis Colon Rectum.* 2014;57:1183–7.
18. Shayesteh L, Lu Y, Kuo WL, Baldocchi R, et al. PIK3CA is implicated as an oncogene in ovarian cancer. *Nat Genet.* 1999;21:99–102.
19. Ma YY, Wei SJ, Lin YC, et al. PIK3CA as an oncogene in cervical cancer. *Oncogene.* 2000;19:2739–44.
20. Welton ML, Varma MG. Anal cancer. In: Wolff BG, Fleshman JW, Beck DE, et al., editors. *The ASCRS textbook of colon and rectal surgery*. New York, NY: Springer; 2007. p. 482–500.
21. Arain S, Walts AE, Thomas P, Bose S. The anal Pap smear: cytomorphology of squamous intraepithelial lesions. *CytoJournal.* 2005;2:4.
22. Palefsky JM, Holly EA, Hogeboom CJ, Berry JM, Jay N, Darragh TM. Anal cytology as a screening tool for anal squamous intraepithelial lesions. *J Acquir Immune Defic Syndr Hum Retrovirol.* 1997;14:415–22.
23. Fox PA, Seet JE, Stebbing J, et al. The value of anal cytology and human papillomavirus typing in the detection of anal intraepithelial neoplasia: a review of cases from an anoscopy clinic. *Sex Transm Infect.* 2005;81:142–6.
24. Chin-Hong PV, Vittinghoff E, Cranston RD, et al. Age related prevalence of anal cancer precursors in homosexual men: the EXPLORE study. *J Natl Cancer Inst.* 2005;97:896–905.

25. Gaisa M, Sigel K, Hand J, Goldstone S. High rates of anal dysplasia in HIV-infected men who have sex with men, women, and heterosexual men. *AIDS*. 2014;28:215–22.
26. Gandra S, Azar A, Wessolossky M. Anal high-risk human papillomavirus infection and high-grade anal intraepithelial neoplasia detected in women and heterosexual men infected with human immunodeficiency virus. *HIV/AIDS (Auckl NZ)*. 2015;7:29–34.
27. Palefsky JM, Rubin M. The epidemiology of anal human papillomavirus and related neoplasia. *Obstet Gynecol Clin North Am*. 2009;36:187–200.
28. Sillman FH, Sentovich S, Shaffer D. Anogenital neoplasia in renal transplant patients. *Ann Transplant*. 1997;2:59–66.
29. Del Amo J, Gonzalez C, Geskus RB, et al. What drives the number of high-risk human papillomavirus types in the anal canal in HIV-positive men who have sex with men? *J Infect Dis*. 2013;207(8):1235–41.
30. National Cancer Institute. Anal cancer treatment. [cancer.gov/cancertopics/pdq/treatment/anal/HealthProfessional](http://cancer.gov/cancertopics/pdq/treatment/anal/HealthProfessional). Accessed on 7 Aug 2015.
31. Edgren G, Sparen P. Risk of anogenital cancer after diagnosis of cervical intraepithelial neoplasia: a prospective population based study. *Lancet Oncol*. 2007;8:311–6.
32. Hemminki K, Dong C, Vaitinen P. Second primary cancer after in situ and invasive cervical cancer. *Epidemiology*. 2000;11:457–61.
33. Saleem AM, Paulus JK, Shapter AP, Baxter NN, Roberts PL, Ricciardi R. Risk of anal cancer in a cohort with human papillomavirus-related gynecologic neoplasm. *Obstet Gynecol*. 2011;117:643–9.
34. Sobhani I, Walker F, Roudot-Thoraval F, Abramowitz L, Johanet H, Hénin D, Delchier JC, Soulé JC. Anal carcinoma: incidence and effect of cumulative infections. *AIDS*. 2004;18:1561–9.
35. Goldie SJ, Kuntz KM, Weinstein MC, et al. The clinical effectiveness and cost-effectiveness of screening for anal squamous intraepithelial lesions in homosexual and bisexual HIV-positive men. *JAMA*. 1999;281:1822–9.
36. Czoski-Murray C, Karnon J, Jones R, Smith K, Kinghorn G. Cost-effectiveness of screening high-risk HIV-positive men who have sex with men (MSM) and HIV-positive women for anal cancer. *Health Technol Assess*. 2010;14(53):3–4, 9–10.
37. Assoumou SA, Mayer KH, Panther L, Linas BP, Kim JJ. Cost-effectiveness of surveillance strategies after treatment for high-grade anal dysplasia in high risk patients. *Sex Transm Dis*. 2013;40:298–303.
38. Ong JJ, Chen M, Grulich AE, Fairley CK. Regional and national guideline recommendations for digital ano-rectal examination as a means for anal cancer screening in HIV positive men who have sex with men: a systematic review. *BMC Cancer*. 2014;14:557.
39. Jay N, Berry JM, Hogeboom CJ, Holly EA, Darragh TM, Palefsky JM. Colposcopic appearance of anal squamous intraepithelial lesions: relationship to histopathology. *Dis Colon Rectum*. 1997;40:919–28.
40. Crawshaw BP, Russ AJ, Stein SL, Reynolds HL, Marderstein EL, Delaney CP, Champagne BJ. High-resolution anoscopy or expectant management for anal intraepithelial neoplasia for the prevention of anal cancer: is there really a difference? *Dis Colon Rectum*. 2015;58:53–9.
41. Goldstone SE, Johnstone AA, Moshier EL. Long-term outcome of ablation of anal high-grade squamous intraepithelial lesions: recurrence and incidence of cancer. *Dis Colon Rectum*. 2014;57:316–23.

42. Palefsky JM, Giuliano AR, Goldstone S, Moreira Jr ED, Aranda C, Jessen H, Hillman R, Ferris D, Coutlee F, Stoler MH, Marshall JB, Radley D, Vuocolo S, Haupt RM, Guris D, Garner EI. HPV vaccine against anal HPV infection and anal intraepithelial neoplasia. *N Engl J Med*. 2011;365:1576–85.
43. Division of STD Prevention, National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention, Centers for Disease Control and Prevention. [www.cdc.gov/std/stats13/other.htm](http://www.cdc.gov/std/stats13/other.htm). Accessed 1 Mar 2015.
44. Devaraj B, Cosman BC. Expectant management of anal squamous dysplasia in patients with HIV. *Dis Colon Rectum*. 2006;49:36–40.
45. Ostor AG. Natural history of cervical intraepithelial neoplasia: a critical review. *Int J Gynecol Pathol*. 1993;12:186–92.
46. Melnikow J, Nuovo J, Willan AR, Chan BK, Howell LP. Natural history of cervical squamous intraepithelial lesions: a meta-analysis. *Obstet Gynecol*. 1998;92(4 Pt 2):727–35.
47. Wieland U, Brockmeyer NH, Weissenborn SJ, Hochdorfer B, Stücker M, Swoboda J, Altmeyer P, Pfister H, Kreuter A. Imiquimod treatment of anal intraepithelial neoplasia in HIV-positive men. *Arch Dermatol*. 2006;142:1438–44.
48. Kreuter A, Potthoff A, Brockmeyer NH, Gambichler T, Stücker M, Altmeyer P, Swoboda J, Pfister H, Wieland U. Imiquimod leads to a decrease of human papillomavirus DNA and to a sustained clearance of anal intraepithelial neoplasia in HIV-infected men. *J Invest Dermatol*. 2008;128:2078–83.
49. Fox PA, Nathan M, Francis N, Singh N, Weir J, Dixon G, Barton SE, Bower M. A double-blind, randomized controlled trial of the use of imiquimod cream for the treatment of anal canal high-grade anal intraepithelial neoplasia in HIV-positive. *AIDS*. 2010;24:2331–5.
50. Macaya A, Munoz-Santos C, Balaguer A, Barbera MJ. Interventions for anal canal intraepithelial neoplasia. *Cochrane Database Syst Rev*. 2012;12, CD009244.
51. Richel O, Wieland U, de Vries HJ, Brockmeyer NH, van Noesel C, Potthoff A, Prins JM, Kreuter A. Topical 5-fluorouracil treatment of anal intraepithelial neoplasia in human immunodeficiency virus-positive men. *Br J Dermatol*. 2010;163:1301–7.
52. Singh JC, Kuohung V, Palefsky JM. Efficacy of trichloroacetic acid in the treatment of anal intraepithelial neoplasia in HIV positive and HIV negative men who have sex with men. *J Acquir Immune Defic Syndr*. 2009;52:474–9.
53. Tristram A, Hurt CN, Madden T, Powell N, Man S, Hibbitts S, Dutton P, Jones S, Nordin AJ, Naik R, Fiander A, Griffiths G. Activity, safety, and feasibility of cidofovir and imiquimod for treatment of vulval intraepithelial neoplasia (RT3VIN): a multicentre, open-label, randomised, phase 2 trial. *Lancet Oncol*. 2014;15:1361–8.
54. Van der Snoek EM, Amelink A, van der Ende ME, et al. Photodynamic therapy with topical metatetrahydroxychlorin (Fosgel) is ineffective for the treatment of anal intraepithelial neoplasia, grade iii. *J Acquir Immune Defic Syndr*. 2009;52:141–3.
55. Goldstone RN, Goldstone AB, Russ J, Goldstone SE. Long-term follow-up of infrared coagulator ablation of anal high-grade dysplasia in men who have sex with men. *Dis Colon Rectum*. 2011;54:1284–92.
56. Goldstone SE, Kawalek AZ, Huyett JW. Infrared coagulator: a useful tool for treating anal squamous intraepithelial lesions. *Dis Colon Rectum*. 2005;48:1042–54.
57. Sirera G, Videla S, Piñol M, Coll J, García-Cuyás F, Vela S, Cañadas M, Darwich L, Pérez N,

- Gel S, Cobarsi P, Clotet B, HIV-HPV Study Group. Long-term effectiveness of infrared coagulation for the treatment of anal intraepithelial neoplasia grades 2 and 3 in HIV-infected men and women. *AIDS*. 2013;27(6):951–9.
58. Margenthaler JA, Dietz DW, Mutch MG, et al. Outcomes, risk of other malignancies, and need for formal mapping procedures in patients with perianal Bowen's disease. *Dis Colon Rectum*. 2004;47:1655–61.
  59. Brown SR, Skinner P, Tidy J, Smith JH, Sharp F, Hosie KB. Outcome after surgical resection for high-grade anal intraepithelial neoplasia (Bowen's disease). *Br J Surg*. 1999;8:1063–6.
  60. Marchesa P, Fazio VW, Oliart S, Goldblum JR, Lavery IC. Perianal Bowen's disease: a clinicopathologic study of 47 patients. *Dis Colon Rectum*. 1997;40:1286–93.
  61. Cleary RK, Schaldenbrand JD, Fowler JJ, Schuler JM, Lampman RM. Perianal Bowen's disease and anal intraepithelial neoplasia: review of the literature. *Dis Colon Rectum*. 1999;42:945–51.
  62. Richel O, de Vries HJ, van Noesel CJ, Dijkgraaf MG, Prins JM. Comparison of imiquimod, topical fluorouracil, and electrocautery for the treatment of anal intraepithelial neoplasia in HIV-positive men who have sex with men: an open-label, randomised controlled trial. *Lancet Oncol*. 2013;14:346–53.
  63. Schiffman MH, Castle P. Epidemiologic studies of a necessary causal risk factor: human papillomavirus infection and cervical neoplasia. *J Natl Cancer Inst*. 2003;95, E2.
  64. Palefsky JM, Holly EA, Ralston ML, et al. Anal squamous intraepithelial lesions in HIV-positive and HIV-negative homosexual and bisexual men. *J Acquir Immune Defic Syndr Hum Retrovirol*. 1998;17:320–6.
  65. Scholefield JH, Castle MT, Watson NF. Malignant transformation of high-grade anal intraepithelial neoplasia. *Br J Surg*. 2005;92(9):1133–6.
  66. Watson AJ, Smith BB, Whitehead MR, Sykes PH, Frizelle FA. Malignant progression of anal intra-epithelial neoplasia. *ANZ J Surg*. 2006;76(8):715–7.
  67. Centers for Disease Control and Prevention. Sexually transmitted diseases. 1600 Clifton Rd Atlanta, GA 30329-402. [cdc.gov/std/treatment/default.htm](http://cdc.gov/std/treatment/default.htm). Accessed 7 Aug 2015.
  68. Winer RL, Hughes JP, Feng Q, et al. Condom use and the risk of genital human papillomavirus infection in young women. *N Engl J Med*. 2006;354(25):2645–54.
  69. Shepherd J, Weston R, Peersman G, Napuli IZ. Interventions for encouraging sexual lifestyles and behaviours intended to prevent cervical cancer. *Cochrane Database Syst Rev*. 2000;2, CD001035.
  70. The FUTURE I/II Study Group. Four year efficacy of prophylactic human papillomavirus quadrivalent vaccine against low grade cervical, vulvar, and vaginal intraepithelial neoplasia and anogenital warts: randomised controlled trial. *BMJ*. 2013;341:3493.
  71. Muñoz N, Kjaer SK, Sigurdsson K, Iversen OE, Hernandez-Avila M, Wheeler CM, Perez G, Brown DR, Koutsky LA, Tay EH, Garcia PJ, Ault KA, Garland SM, Leodolter S, Olsson SE, Tang GW, Ferris DG, Paavonen J, Steben M, Bosch FX, Dillner J, Huh WK, Joura EA, Kurman RJ, Majewski S, Myers ER, Villa LL, Taddeo FJ, Roberts C, Tadesse A, Bryan JT, Lupinacci LC, Giacoletti KE, Sings HL, James MK, Hesley TM, Barr E, Haupt RM. Impact of human papillomavirus (HPV)-6/11/16/18 vaccine on all HPV-associated genital diseases in young women. *J Natl Cancer Inst*. 2010;102:325–39.
  72. Swedish KA, Factor SH, Goldstone SE. Prevention of recurrent high-grade anal neoplasia with quadrivalent human papillomavirus vaccination of men who have sex with men: a nonconcurrent

cohort study. *Clin Infect Dis*. 2012;54:891–8.

73. Brickman C, Palefsky JM. Human papillomavirus in the HIV-infected host: epidemiology and pathogenesis in the antiretroviral era. *Curr HIV/AIDS Rep*. 2015;12:6–15.

## 第 21 章

1. Simpson JAD, Scholefield JH. Diagnosis and management of anal intraepithelial neoplasia and anal cancer. *BMJ*. 2011;343:d6818.

2. American Cancer Society. Cancer facts and figures 2015. Atlanta, GA: American Cancer Society; 2015. Last accessed April 1, 2015.

3. Chin JY, Hong TS, Wo JY. Anal cancer: current and future treatment strategies. *Gastrointest Canc Targets Therapy*. 2013;3:19–27.

4. Drake RL, Wayne Vogl A, Mitchell AWM. Gray's anatomy for students. 3rd ed., vol 5; 2014. pp. 463–4.

5. Shia J. An update on tumors of the anal canal. *Arch Pathol Lab Med*. 2010;134(11):1601–11.

6. Pineda CE, Welton ML. Management of anal squamous intraepithelial lesions. *Clin Colon Rectal Surg*. 2009;22(2):94–101.

7. Ryan DP, Compton CC, Mayer RJ. Carcinoma of the anal canal. *N Engl J Med*. 2000;342:792–800.

8. Osborne MC, Maykel J, Johnson EK, Steele SR. Anal squamous cell carcinoma: an evolution in disease and management. *World J Gastroenterol*. 2014;20(36):13052–9.

9. Tanum G, Tveit K, Karlsen KO. Diagnosis of anal carcinoma – doctor's finger still the best? *Oncology*. 1991;48:383–6.

10. Glynne-Jones R, Northover JMA, Cervantes A. Anal cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. *Ann Oncol*. 2010;21 Suppl 5:v87–92.

11. Frisch M, Glimelius B, van den Brule AJ, et al. Sexually transmitted infection as a cause of anal cancer. *N Engl J Med*. 1997;337(19):1350–8.

12. Tonolini M, Bianco R. MRI and CT of anal carcinoma: a pictorial review. *Insights Imaging*. 2013;4(1):53–62.

13. Parikh J, Shaw A, Grant LA, et al. Anal carcinomas: the role of endoanal ultrasound and magnetic resonance imaging in staging, response evaluation and follow-up. *Eur Radiol*. 2011;21:776–85.

14. Roach SC, Hulse PA, Moulding FJ, et al. Magnetic resonance imaging of anal cancer. *Clin Radiol*. 2005;60:1111–9.

15. Otto SD, Lee L, Buhr HJ, et al. Staging anal cancer: prospective comparison of transanal endoscopic ultrasound and magnetic resonance imaging. *J Gastrointest Surg*. 2009;13(7):1292–8.

16. Cummings BJ, Ajani JA, Swallow CJ. Cancer of the anal region. In: DeVita Jr VT, Lawrence TS, Rosenberg SA et al. *Cancer: principles & practice of oncology*. 8th ed. Philadelphia, PA: Lippincott, Williams & Wilkins; 2008.

17. Nguyen BT, Joon DL, Khoo V, et al. Assessing the impact of FDG-PET in the management of anal cancer. *Radiother Oncol*. 2008;87(3):376–82.

18. Bhuva NJ, Glynne-Jones R, Sonoda L, Wong WL, Harrison MK, To PET or not to PET? That is the question. Staging in anal cancer. *Ann Oncol*. 2012;23(8):2078–82.

19. Caldarella C, Annunziata S, Treglia G, Sadeghi R, Ayati N, Giovannella L. Diagnostic performance of positron emission tomography/computed tomography using fluorine-18 fluorodeoxyglucose in detecting locoregional nodal involvement in patients with anal canal cancer: a systematic review and meta-analysis. *Sci World J.* 2014;2014:196068.
20. Mistrangelo M, Pelosi E, Bellò M, Ricardi U, et al. Role of positron emission tomography-computed tomography in the management of anal cancer. *Int J Radiat Oncol Biol Phys.* 2012;84(1):66–72.
21. Vercellino L, Montravers F, de Parades V, et al. Impact of FDG PET/CT in the staging and the follow-up of anal carcinoma. *Int J Colorectal Dis.* 2011;26(2):201–10.
22. Wayne F, Bhayani N, Ford D, Yang G, Thomas C. Anal carcinoma. *Curr Cancer Ther Rev.* 2009;5:142–50.
23. Nigro N, Seydel H, Considine B, Vaitkevicius V, Leichman L, Kinzie J. Combined preoperative radiation and chemotherapy for squamous cell carcinoma of the anal canal. *Cancer.* 1983;51:1826–9.
24. Goldman S, Glimelius B, Glas U, Lundell G, Pahlman L, Ståhle E. Management of anal epidermoid carcinoma – an evaluation of treatment results in two population-based series. *Int J Colorectal Dis.* 1989;4(4):234–43.
25. Flam M, John M, Pajak TF, et al. Role of mitomycin in combination with fluorouracil and radiotherapy, and of salvage chemoradiation in the definitive nonsurgical treatment of epidermoid carcinoma of the anal canal: results of a phase III randomized intergroup study. *J Clin Oncol.* 1996;14(9):2527–39.
26. Bartelink H, Roelofsen F, Eschwege F, et al. Concomitant radiotherapy and chemotherapy is superior to radiotherapy alone in the treatment of locally advanced anal cancer: results of a phase III randomized trial of the European Organization for Research and Treatment of Cancer Radiotherapy and Gastrointestinal Cooperative Groups. *J Clin Oncol.* 1997;15(5):2040–9.
27. Northover J, Glynne-Jones R, Sebag-Montefiore D, et al. Chemoradiation for the treatment of epidermoid anal cancer, 13-year follow-up of the first randomised UKCCCR Anal Cancer Trial (ACT I). *Br J Cancer.* 2010;102(7):1123–8.
28. Ajani JA, Winter KA, Gunderson LL, et al. Fluorouracil, mitomycin, and radiotherapy vs fluorouracil, cisplatin, and radiotherapy for carcinoma of the anal canal: a randomized controlled trial. *JAMA.* 2008;299(16):1914–21.
29. Ajani JA, Winter KA, Gunderson L, et al. Prognostic factors derived from a prospective database dictate clinical biology of anal cancer: the intergroup trial (RTOG 98-11). *Cancer.* 2010;116(17):10.
30. Peiffert D, Tournier-Rangear L, Gerard JP, et al. Induction chemotherapy and dose intensification of the radiation boost in locally advanced anal canal carcinoma: final analysis of the randomized UNICANCER ACCORD 03 trial. *J Clin Oncol.* 2012;30:1941–8.
31. John M, Pajak T, Flam M, Hoffman J, Markoe A, Wolkov H, et al. Dose escalation in chemoradiation for anal cancer: preliminary results of RTOG 92-08. *Cancer J Sci Am.* 1996;2(4):205–11.
32. Scher ED, Ahmed I, Yue NJ, Jabbour SK. Technical aspects of radiation therapy for anal cancer. *J Gastroint Oncol.* 2014;5(3):198–211.
33. Myerson RJ, Garofalo MC, El Naqa I, et al. Elective clinical target volumes for conformal therapy in anorectal cancer: a radiation therapy oncology group consensus panel contouring atlas. *Int J Radiat Oncol Biol Phys.* 2009;74:824–30.

34. Allal AS, Sprangers MAG, Laurencet F, Reymond MA, Kurtz JM. Assessment of long-term quality of life in patients with anal carcinomas treated by radiotherapy with or without chemotherapy. *Br J Cancer*. 1999;80(10):1588–94.
35. De Bree E, van Ruth S, Dewit LG, Zoetmulder FA. High risk of colostomy with primary radiotherapy for anal cancer. *Ann Surg Oncol*. 2007;14(1):100–8.
36. Shridhar R, Shibata D, Chan E, Thomas CR. Anal cancer: current standards in care and recent changes in practice. *CA Cancer J Clin*. 2015;65:139–62.
37. Ferrigno R, Nakamura RA, Dos Santos Novaes PE, et al. Radiochemotherapy in the conservative treatment of anal canal carcinoma: retrospective analysis of results and radiation dose effectiveness. *Int J Radiat Oncol Biol Phys*. 2005;61(4):1136–42.
38. Huang K, Haas-Kogan D, Weinberg V, Krieg R. Higher radiation dose with a shorter treatment duration improves outcome for locally advanced carcinoma of anal canal. *World J Gastroenterol*. 2007;13(6):895–900.
39. Faivre C, Rougier P, Ducreux M, et al. 5-Fluorouracil and cisplatin combination chemotherapy for metastatic squamous-cell anal cancer. *Bull Cancer*. 1999;86(10):861–5.
40. Cummings BJ, Keane TJ, O'sullivan B, Wong CS, Catton CN. Epidermoid anal cancer: treatment by radiation alone or by radiation and 5-fluorouracil with and without mitomycin C. *Int J Radiat Oncol Biol Phys*. 1991;21(5):1115–25.
41. Czado BG, Willett CG. Current management of anal canal cancer. *Curr Oncol Rep*. 2009;11(3):186–92.
42. Ben-Josef E, Moughan J, Ajani JA, Flam M, Gunderson L, Pollock J, et al. Impact of overall treatment time on survival and local control in patients with anal cancer: a pooled data analysis of Radiation Therapy Oncology Group trials 87-04 and 98-11. *J Clin Oncol*. 2010;28:5061–6.
43. Papaconstantinou HT, Bullard KM, Rothenberger DA, Madoff RD. Salvage abdominoperineal resection after failed Nigro protocol: modest success, major morbidity. *Colorectal Dis*. 2006;8:124–9.
44. Glynne-Jones R, James R, Meadows H, Begum R, Cunningham D, Northover J, Ledermann JA, Beare S, Kadalayil L, Sebag-Montefiore D. May 20 Supplement, 2012. ASCO Annual Meeting Abstracts. *J Clin Oncol*. 30(Suppl 15). Optimum time to assess complete clinical response (CR) following chemoradiation (CRT) using mitomycin (MMC) or cisplatin (CisP), with or without maintenance CisP/5FU in squamous cell carcinoma of the anus: Results of ACT II; 2012. p. 4004.
45. Van der Wal BC, Cleffken BI, Gulec B, Kaufman HS, Choti MA. Results of salvage abdominoperineal resection for recurrent anal carcinoma following combined chemoradiation therapy. *J Gastrointest Surg*. 2001;5:383–7.
46. Ghouti L, Houvenaeghel G, Moutardier V, Giovannini M, Magnin V, Lelong B, et al. Salvage abdominoperineal resection after failure of conservative treatment in anal epidermoid cancer. *Dis Colon Rectum*. 2005;48:16–22.
47. Chessin DB, Hartley J, Cohen AM, Mazumdar M, Cordeiro P, Disa J, et al. Rectus flap reconstruction decreases perineal wound complications after pelvic chemoradiation and surgery: a cohort study. *Ann Surg Oncol*. 2005;12:104–10.
48. Longo WE, Vernava 3rd AM, Wade TP, et al. Recurrent squamous cell carcinoma of the anal canal. Predictors of initial treatment failure and results of salvage therapy. *Ann Surg*. 1994;220(1):40–9.
49. Frisch M, Biggar R, Goedert J, et al. Human papillomavirus-associated cancers in patients with

human immunodeficiency virus infection and acquired immunodeficiency syndrome. *J Natl Cancer Inst.* 2000;92(18):1500–10.

50. Machalek DA, Poynten M, Jin F et al. Anal human papillomavirus infection and associated neoplastic lesions in men who have sex with men: a systematic review and meta-analysis. *Lancet Oncol.* 2012;3(5):487–500.

51. Goldie SJ, Kuntz KM, Weinstein MC, Freedberg KA, Welton ML, Palefsky JM. The clinical effectiveness and cost-effectiveness of screening for anal squamous intraepithelial lesions in homosexual and bisexual HIV-positive men. *JAMA.* 1999;281(19):1822–9.

52. Chang AE, Karnell LH, Menck HR. The National Cancer Data Base report on cutaneous and noncutaneous melanoma: a summary of 84,836 cases from the past decade: the American College of Surgeons Commission on Cancer and the American Cancer Society. *Cancer.* 1998;83(8):1664–78.

53. Parra RS, de Almeida ALNR, Badiale GB, da Silva Moraes MMF, Rocha JJR, Féres O. Melanoma of the anal canal. *Clinics.* 2010;65(10):1063–5.

54. Zhong J, Zhou JN, Xu FP, Shang JQ. Diagnosis and treatment of anorectal malignant melanoma: a report of 22 cases with literature review. *Ai Zheng.* 2006;25:619–24.

55. Pirenne Y, Bouckaert W, Vangertruyden G. Rectal melanoma: a rare tumor. *Acta Chir Belg.* 2008;108:756–8.

56. Brady MS, Kavolius JP, Quan SH. Anorectal melanoma. A 64 year experience at Memorial Sloan Kettering Cancer Center. *Dis Colon Rectum.* 1995;38:146–51.

57. Stroh C, Manger T. Primary amelanotic anorectal melanoma – a case report. *Zentralbl Chir.* 2007;132:560–3.

58. David AW, Perakath B. Management of anorectal melanomas: a 10-year review. *Trop Gastroenterol.* 2007;28:76–8.

59. Roviello F, Cioppa T, Marrelli D, Nastri G, De Stefano A, Hako L, et al. Primary ano - rectal melanoma: considerations on a clinical case and review of the literature. *Chir Ital.* 2003;55:575–80.

60. Roumen RM. Anorectal melanoma in the Netherlands: a report of 63 patients. *Eur J Surg Oncol.* 1996;22:598–601.

61. Droesch JT, Flum DR, Mann GN. Wide local excision or abdominoperineal resection as the initial treatment for anorectal melanoma? *Am J Surg.* 2005;189:446–9.

62. Homsí J, Garrett C. Melanoma of the anal canal: a case series. *Dis Colon Rectum.* 2007;50:1004–10.

63. Newlin HE, Zlotecki RA, Morris CG, Hochwald SN, Riggs CE, Mendenhall WM. Squamous cell carcinoma of the anal margin. *J Surg Oncol.* 2004;86(2):55–62.

64. Mendenhall WM, Zlotecki RA, Vauthey JN, Copeland EM. III Squamous cell carcinoma of the anal margin. *Oncology (Williston Park).* 1996;10(12):1843–8. Discussion 1848, 1853–1854.

65. Quan S. Anal cancers squamous and melanoma. *Cancer.* 1992;70 Suppl 5:1384–9.

66. Welton M, Varma M. In: Wolff B, Fleshman J, Beck D, Pemberton J, Wexner S, et al., editors. *The ASCRS textbook of colon and rectal surgery.* New York: Springer Science + Business Media; 2007. Anal Cancer. pp. 482–500.

67. Chawla AK, Willett CG. Squamous cell carcinoma of the anal canal and anal margin. *Hematol Oncol Clin North Am.* 2001;15(2):321–44.

68. Wietfeldt ED, Thiele J. Malignancies of the anal margin and perianal skin. *Clin Colon Rectal Surg.* 2009;22(2):127–35.



69. Chapet O, Gerard JP, Mornex F, et al. Prognostic factors of squamous cell carcinoma of the anal margin treated by radiotherapy: the lyon experience. *Int J Colorectal Dis.* 2007;22(2):191–9.
70. Belkacémi Y, Berger C, Poortmans P, et al. Management of primary anal canal adenocarcinoma: a large retrospective study from the rare cancer network. *Int J Radiat Oncol Biol Phys.* 2003;56(5):1274–83.
71. Chang GJ, Gonzalez RJ, Skibber JM, et al. A twenty-year experience with adenocarcinoma of the anal canal. *Dis Colon Rectum.* 2009;52(8):1375–80.
72. Kachnic LA, Winter K, Myerson RJ, et al. RTOG 0529: a phase II evaluation of dose-painted intensity modulated radiation therapy in combination with 5-fluorouracil and mitomycin-C for the reduction of acute morbidity in carcinoma of the anal canal. *Int J Radiat Oncol Biol Phys.* 2013;86(1):27–33.
73. DeFoe SG, Beriwal S, Jones H, et al. Concurrent chemotherapy and intensity-modulated radiation therapy for anal carcinoma – clinical outcomes in a large National Cancer Institute-designated integrated cancer centre network. *Clin Oncol (R Coll Radiol).* 2012;24(6):424–31.
74. Rothenstein DA, Dasgupta T, Chou JF, et al. Comparison of outcomes of intensity-modulated radiotherapy and 3-D conformal radiotherapy for anal squamous cell carcinoma using a propensity score analysis. (2011 ASCO Annual Meeting abstract number 3555). *J Clin Oncol.* 2011;29:2011.
75. Alvarez G, Perry A, Tan BR, Wang HL. Expression of epidermal growth factor receptor in squamous cell carcinomas of the anal canal is independent of gene amplification. *Mod Pathol.* 2006;19(7):942–9.
76. Le LH, Chetty R, Moore MJ. Epidermal growth factor receptor expression in anal canal carcinoma. *Am J Clin Pathol.* 2005;124:20–3.
77. Lukan N, Ströbel P, Willer A, et al. Cetuximab-based treatment of metastatic anal cancer: correlation of response with KRAS mutational status. *Oncology.* 2009;77(5):293–9.

## 第 22 章

1. Hobson KG, Ghaemmaghami V, Roe JP, Goodnight JE, Khatri VP. Tumors of the retrorectal space. *Dis Colon Rectum.* 2005;48(10):1964–74.
2. Cody 3rd HS, Marcove RC, Quan SH. Malignant retrorectal tumors: 28 years' experience at Memorial Sloan-Kettering Cancer Center. *Dis Colon Rectum.* 1981;24(7):501–6.
3. Uhlig BE, Johnson RL. Presacral tumors and cysts in adults. *Dis Colon Rectum.* 1975;18(7):581–9.
4. Jao SW, Beart Jr RW, Spencer RJ, Reiman HM, Ilstrup DM. Retrorectal tumors. Mayo Clinic experience, 1960-1979. *Dis Colon Rectum.* 1985;28(9):644–52.
5. Messick CA, Hull T, Rosselli G, Kiran RP. Lesions originating within the retrorectal space: a diverse group requiring individualized evaluation and surgery. *J Gastrointest Surg.* 2013;17(12):2143–52.
6. Gunterberg B, Kewenter J, Petersen I, Stener B. Anorectal function after major resections of the sacrum with bilateral or unilateral sacrifice of sacral nerves. *Br J Surg.* 1976;63(7):546–54.
7. Gunterberg B, Petersen I. Sexual function after major resections of the sacrum with bilateral or unilateral sacrifice of sacral nerves. *Fertil Steril.* 1976;27(10):1146–53.
8. Bullard Dunn K. Retrorectal tumors. *Surg Clin North Am.* 2010;90(1):163–71. Table of Contents.

9. Singer MA, Cintron JR, Martz JE, Schoetz DJ, Abcarian H. Retrorectal cyst: a rare tumor frequently misdiagnosed. *J Am Coll Surg*. 2003;196(6):880–6.
10. Abel ME, Nelson R, Prasad ML, Pearl RK, Orsay CP, Abcarian H. Parasacrococcygeal approach for the resection of retrorectal developmental cysts. *Dis Colon Rectum*. 1985;28(11):855–8.
11. Springall RG, Griffiths JD. Malignant change in rectal duplication. *J R Soc Med*. 1990;83(3):185–7.
12. Hickey RC, Martin RG. Sacrococcygeal teratomas. *Ann N Y Acad Sci*. 1964;114:951–7.
13. McMaster ML, Goldstein AM, Bromley CM, Ishibe N, Parry DM. Chordoma: incidence and survival patterns in the United States, 1973–1995. *Cancer Causes Control*. 2001;12(1):1–11.
14. Williams B. Cerebrospinal fluid pressure changes in response to coughing. *Brain*. 1976;99(2):331–46.
15. Stewart RJ, Humphreys WG, Parks TG. The presentation and management of presacral tumours. *Br J Surg*. 1986;73(2):153–5.
16. Freier DT, Stanley JC, Thompson NW. Retrorectal tumors in adults. *Surg Gynecol Obstet*. 1971;132(4):681–6.
17. Hosseini-Nik H, Hosseinzadeh K, Bhayana R, Jhaveri KS. MR imaging of the retrorectal-presacral tumors: an algorithmic approach. *Abdom Imaging*. 2015;40(7):2630–44.
18. Sung MS, Lee GK, Kang HS, Kwon ST, Park JG, Suh JS, et al. Sacrococcygeal chordoma: MR imaging in 30 patients. *Skeletal Radiol*. 2005;34(2):87–94.
19. Luken 3rd MG, Michelsen WJ, Whelan MA, Andrews DL. The diagnosis of sacral lesions. *Surg Neurol*. 1981;15(5):377–83.
20. Bohm B, Milsom JW, Fazio VW, Lavery IC, Church JM, Oakley JR. Our approach to the management of congenital presacral tumors in adults. *Int J Colorectal Dis*. 1993;8(3):134–8.
21. Lev-Chelouche D, Gutman M, Goldman G, Even-Sapir E, Meller I, Issakov J, et al. Presacral tumors: a practical classification and treatment of a unique and heterogeneous group of diseases. *Surgery*. 2003;133(5):473–8.
22. Macafee DA, Sagar PM, El-Khoury T, Hyland R. Retrorectal tumours: optimization of surgical approach and outcome. *Colorectal Dis*. 2012;14(11):1411–7.
23. Sagar AJ, Tan WS, Codd R, Fong SS, Sagar PM. Surgical strategies in the management of recurrent retrorectal tumours. *Tech Coloproctol*. 2014;18(11):1023–7.
24. Dozois EJ, Jacofsky DJ, Billings BJ, Privitera A, Cima RR, Rose PS, et al. Surgical approach and oncologic outcomes following multidisciplinary management of retrorectal sarcomas. *Ann Surg Oncol*. 2011;18(4):983–8.
25. Merchea A, Dozois EJ. Lesions originating within the retrorectal space. *J Gastrointest Surg*. 2014;18(12):2232–3.
26. Aktug T, Hakguder G, Sarioglu S, Akgur FM, Olguner M, Pabuccuoglu U. Sacrococcygeal extraspinal ependymomas: the role of coccygectomy. *J Pediatr Surg*. 2000;35(3):515–8.
27. Kaiser TE, Pritchard DJ, Unni KK. Clinicopathologic study of sacrococcygeal chordoma. *Cancer*. 1984;53(11):2574–8.
28. Wang JY, Hsu CH, Changchien CR, Chen JS, Hsu KC, You YT, et al. Presacral tumor: a review of forty-five cases. *Am Surg*. 1995;61(4):310–5.
29. Glasgow SC, Birnbaum EH, Lowney JK, Fleshman JW, Kodner IJ, Mutch DG, et al. Retrorectal tumors: a diagnostic and therapeutic challenge. *Dis Colon Rectum*. 2005;48(8):1581–7.
30. Ghosh J, Eglinton T, Frizelle FA, Watson AJ. Presacral tumours in adults. *Surgeon*.

2007;5(1):31–8.

31. Looock MT, Fornès P, Soyer P, Rousset P, Azizi L, Hoeffel C. MR imaging features of nongynaecologic cystic lesions of the pelvis. *Clin Imaging*. 2013;37(2):211–8.

32. Ludwig KA, Kalady MF. Transsacral approaches for presacral cyst: rectal tumor. *Oper Tech Gen Surg*. 2005;7:3-126-136.

## 第 23 章

1. Ogino S, Goel A. Molecular classification and correlates in colorectal cancer. *J Mol Diagn*. 2008;10(1):13–27.

2. Vogelstein B, Fearon ER, Hamilton SR, Kern SE, Preisinger AC, Leppert M, et al. Genetic alterations during colorectal-tumor development. *N Engl J Med*. 1988;319(9):525–32.

3. Dahabreh IJ, Terasawa T, Castaldi PJ, Trikalinos TA. Systematic review: anti-epidermal growth factor receptor treatment effect modification by KRAS mutations in advanced colorectal cancer. *Ann Intern Med*. 2011;154(1):37–49.

4. Cancer Genome Atlas N. Comprehensive molecular characterization of human colon and rectal cancer. *Nature*. 2012;487(7407):330–7.

5. Bahnassy AA, Zekri AR, Salem SE, Abou-Bakr AA, Sakr MA, Abdel-Samiaa AG, et al. Differential expression of p53 family proteins in colorectal adenomas and carcinomas: Prognostic and predictive values. *Histol Histopathol*. 2014;29(2):207–16.

6. Weisenberger DJ, Siegmund KD, Campan M, Young J, Long TI, Faasse MA, et al. CpG island methylator phenotype underlies sporadic microsatellite instability and is tightly associated with BRAF mutation in colorectal cancer. *Nat Genet*. 2006;38(7):787–93. see comment.

7. Kambara T, Simms LA, Whitehall VL, Spring KJ, Wynter CV, Walsh MD, et al. BRAF mutation is associated with DNA methylation in serrated polyps and cancers of the colorectum. *Gut*. 2004;53(8):1137–44.

8. Bettington M, Walker N, Clouston A, Brown I, Leggett B, Whitehall V. The serrated pathway to colorectal carcinoma: current concepts and challenges. *Histopathology*. 2013;62(3):367–86.

9. Sanchez JA, Krumroy L, Plummer S, Aung P, Merkulova A, Skacel M, et al. Genetic and epigenetic classifications define clinical phenotypes and determine patient outcomes in colorectal cancer. *Br J Surg*. 2009;96(10):1196–204.

10. Jass JR. Hereditary non-polyposis colorectal cancer: the rise and fall of a confusing term. *World J Gastroenterol*. 2006;12(31):4943–50.

11. Giardiello FM, Allen JI, Axilbund JE, Boland CR, Burke CA, Burt RW, et al. Guidelines on genetic evaluation and management of Lynch syndrome: a consensus statement by the US Multi-Society Task Force on colorectal cancer. *Gastroenterology*. 2014;147(2):502–26.

12. Sener SF, Miller HH, DeCosse JJ. The spectrum of polyposis. *Surg Gynecol Obstet*. 1984;159(6):525–32.

13. Itoh H, Hirata K, Ohsato K. Turcot's syndrome and familial adenomatous polyposis associated with brain tumor: review of related literature. *Int J Colorectal Dis*. 1993;8(2):87–94.

14. Knudsen AL, Bisgaard ML, Bulow S. Attenuated familial adenomatous polyposis (AFAP). A review of the literature. *Fam Cancer*. 2003;2(1):43–55.

15. De Vos tot Nederveen Cappel WH, Jarvinen HJ, Bjork J, Berk T, Griffioen G, Vasen HF.

Worldwide survey among polyposis registries of surgical management of severe duodenal adenomatosis in familial adenomatous polyposis. *Br J Surg*. 2003;90(6):705–10.

16. Wallace MH, Phillips RK. Upper gastrointestinal disease in patients with familial adenomatous polyposis. *Br J Surg*. 1998;85(6):742–50.

17. Clark SK, Neale KF, Landgrebe JC, Phillips RK. Desmoid tumours complicating familial adenomatous polyposis. *Br J Surg*. 1999;86(9):1185–9.

18. Soravia C, Berk T, McLeod RS, Cohen Z. Desmoid disease in patients with familial adenomatous polyposis. *Dis Colon Rectum*. 2000;43(3):363–9.

19. Elayi E, Manilich E, Church J. Polishing the crystal ball: knowing genotype improves ability to predict desmoid disease in patients with familial adenomatous polyposis. *Dis Colon Rectum*. 2009;52(10):1762–6.

20. Church J, Xhaja X, LaGuardia L, O'Malley M, Burke C, Kalady M. Desmoids and genotype in familial adenomatous polyposis. *Dis Colon Rectum*. 2015;58(4):444–8.

21. Feng X, Milas M, O'Malley M, LaGuardia L, Berber E, Jin J, et al. Characteristics of benign and malignant thyroid disease in familial adenomatous polyposis patients and recommendations for disease surveillance. *Thyroid*. 2015;25(3):325–32.

22. Donnellan KA, Bigler SA, Wein RO. Papillary thyroid carcinoma and familial adenomatous polyposis of the colon. *Am J Otolaryngol*. 2009;30(1):58–60.

23. Herraiz M, Barbesino G, Faquin W, Chan-Smutko G, Patel D, Shannon KM, et al. Prevalence of thyroid cancer in familial adenomatous polyposis syndrome and the role of screening ultrasound examinations. *Clin Gastroenterol Hepatol*. 2007;5(3):367–73.

24. Jarrar AM, Milas M, Mitchell J, Laguardia L, O'Malley M, Berber E, et al. Screening for thyroid cancer in patients with familial adenomatous polyposis. *Ann Surg*. 2011;253(3):515–21.

25. Giardiello FM, Offerhaus GJ, Lee DH, Krush AJ, Tersmette AC, Booker SV, et al. Increased risk of thyroid and pancreatic carcinoma in familial adenomatous polyposis. *Gut*. 1993;34(10):1394–6.

26. Giardiello FM, Offerhaus GJ, Krush AJ, Booker SV, Tersmette AC, Mulder JW, et al. Risk of hepatoblastoma in familial adenomatous polyposis. *J Pediatr*. 1991;119(5):766–8.

27. Hughes LJ, Michels VV. Risk of hepatoblastoma in familial adenomatous polyposis. *Am J Med Genet*. 1992;43(6):1023–5.

28. Hamilton SR, Liu B, Parsons RE, Papadopoulos N, Jen J, Powell SM, et al. The molecular basis of Turcot's syndrome. *N Engl J Med*. 1995;332(13):839–47.

29. Valanzano R, Cama A, Volpe R, Curia MC, Mencucci R, Palmirotta R, et al. Congenital hypertrophy of the retinal pigment epithelium in familial adenomatous polyposis. Novel criteria of assessment and correlations with constitutional adenomatous polyposis coli gene mutations. *Cancer*. 1996;78(11):2400–10.

30. Olsen KO, Juul S, Bulow S, Jarvinen HJ, Bakka A, Bjork J, et al. Female fecundity before and after operation for familial adenomatous polyposis. *Br J Surg*. 2003;90(2):227–31.

31. Bulow S, Bulow C, Vasen H, Jarvinen H, Bjork J, Christensen IJ. Colectomy and ileorectal anastomosis is still an option for selected patients with familial adenomatous polyposis. *Dis Colon Rectum*. 2008;51(9):1318–23.

32. Slors FJ, van Zuijlen PP, van Dijk GJ. Sexual and bladder dysfunction after total mesorectal excision for benign diseases. *Scand J Gastroenterol Suppl*. 2000;232:48–51.

33. Gunther K, Braunrieder G, Bittorf BR, Hohenberger W, Matzel KE. Patients with familial

adenomatous polyposis experience better bowel function and quality of life after ileorectal anastomosis than after ileoanal pouch. *Colorectal Dis.* 2003;5(1):38–44.

34. Church J, Burke C, McGannon E, Pastean O, Clark B. Risk of rectal cancer in patients after colectomy and ileorectal anastomosis for familial adenomatous polyposis: a function of available surgical options. *Dis Colon Rectum.* 2003;46(9):1175–81.

35. Wu JS, Paul P, McGannon EA, Church JM. APC genotype, polyp number, and surgical options in familial adenomatous polyposis. *Ann Surg.* 1998;227(1):57–62.

36. Church J. Ileoanal pouch neoplasia in familial adenomatous polyposis: an underestimated threat. *Dis Colon Rectum.* 2005;48(9):1708–13.

37. O'Connell PR, Pemberton JH, Weiland LH, Beart Jr RW, Dozois RR, Wolff BG, et al. Does rectal mucosa regenerate after ileoanal anastomosis? *Dis Colon Rectum.* 1987;30(1):1–5.

38. Remzi FH, Church JM, Bast J, Lavery IC, Strong SA, Hull TL, et al. Mucosectomy vs. stapled ileal pouch-anal anastomosis in patients with familial adenomatous polyposis: functional outcome and neoplasia control. *Dis Colon Rectum.* 2001;44(11):1590–6.

39. Lovegrove RE, Constantinides VA, Heriot AG, Athanasiou T, Darzi A, Remzi FH, et al. A comparison of hand-sewn versus stapled ileal pouch anal anastomosis (IPAA) following proctocolectomy: a meta-analysis of 4183 patients. *Ann Surg.* 2006;244(1):18–26.

40. Burke CA, Beck GJ, Church JM, van Stolk RU. The natural history of untreated duodenal and ampullary adenomas in patients with familial adenomatous polyposis followed in an endoscopic surveillance program. *Gastrointest Endosc.* 1999;49(3 Pt 1):358–64.

41. Church J, Simmang C. Practice parameters for the treatment of patients with dominantly inherited colorectal cancer (familial adenomatous polyposis and hereditary nonpolyposis colorectal cancer). *Dis Colon Rectum.* 2003;46(8):1001–12.

42. Spigelman AD, Williams CB, Talbot IC, Domizio P, Phillips RK. Upper gastrointestinal cancer in patients with familial adenomatous polyposis. *Lancet.* 1989;2(8666):783–5.

43. Groves CJ, Saunders BP, Spigelman AD, Phillips RKS. Duodenal cancer in patients with familial adenomatous polyposis (FAP): results of a 10 year prospective study. *Gut.* 2002;50(5):636–41.

44. Church J, Berk T, Boman BM, Guillem J, Lynch C, Lynch P, et al. Staging intra-abdominal desmoid tumors in familial adenomatous polyposis: a search for a uniform approach to a troubling disease. *Dis Colon Rectum.* 2005;48(8):1528–34.

45. Tsukada K, Church JM, Jagelman DG, Fazio VW, McGannon E, George CR, et al. Noncytotoxic drug therapy for intra-abdominal desmoid tumor in patients with familial adenomatous polyposis. *Dis Colon Rectum.* 1992;35(1):29–33.

46. Tonelli F, Ficari F, Valanzano R, Brandi ML. Treatment of desmoids and mesenteric fibromatosis in familial adenomatous polyposis with raloxifene. *Tumori.* 2003;89(4):391–6.

47. Azzarelli A, Gronchi A, Bertulli R, Tesoro JD, Baratti D, Pennacchioli E, et al. Low-dose chemotherapy with methotrexate and vinblastine for patients with advanced aggressive fibromatosis. *Cancer.* 2001;92(5):1259–64.

48. Bertagnoli MM, Morgan JA, Fletcher CDM, Raut CP, Dileo P, Gill RR, et al. Multimodality treatment of mesenteric desmoid tumours. *Eur J Cancer.* 2008;44(16):2404–10.

49. Poritz LS, Blackstein M, Berk T, Gallinger S, McLeod RS, Cohen Z. Extended follow-up of patients treated with cytotoxic chemotherapy for intra-abdominal desmoid tumors. *Dis Colon Rectum.* 2001;44(9):1268–73.

50. Chatzipetrou MA, Tzakis AG, Pinna AD, Kato T, Misiakos EP, Tsaroucha AK, et al. Intestinal transplantation for the treatment of desmoid tumors associated with familial adenomatous polyposis. *Surgery*. 2001;129(3):277–81.
51. Nikeghbalian S, Aliakbarian M, Shamsaeefar A, Kazemi K, Bahreini A, Malekhosseini SA. Multivisceral transplantation for the treatment of intra-abdominal tumors. *Transplant Proc*. 2013;45(10):3528–30.
52. Bell B, Mazzaferri EL. Familial adenomatous polyposis (Gardner's syndrome) and thyroid carcinoma. A case report and review of the literature. *Dig Dis Sci*. 1993;38(1):185–90.
53. Bulow C, Bulow S. Is screening for thyroid carcinoma indicated in familial adenomatous polyposis? The Leeds Castle Polyposis Group. *Int J Colorectal Dis*. 1997;12(4):240–2.
54. Sampson JR, Dolwani S, Jones S, Eccles D, Ellis A, Evans DG, et al. Autosomal recessive colorectal adenomatous polyposis due to inherited mutations of MYH. *Lancet*. 2003;362(9377):39–41.
55. Nielsen M, Franken PF, Reinards TH, Weiss MM, Wagner A, van der Klift H, et al. Multiplicity in polyp count and extracolonic manifestations in 40 Dutch patients with MYH associated polyposis coli (MAP). *J Med Genet*. 2005;42(9):e54.
56. Croitoru ME, Cleary SP, Berk T, Di Nicola N, Kopolovic I, Bapat B, et al. Germline MYH mutations in a clinic-based series of Canadian multiple colorectal adenoma patients. *J Surg Oncol*. 2007;95(6):499–506.
57. Grover S, Kastrinos F, Steyerberg EW, Cook EF, Dewanwala A, Burbidge LA, et al. Prevalence and phenotypes of APC and MUTYH mutations in patients with multiple colorectal adenomas. *JAMA*. 2012;308(5):485–92.
58. Cleary SP, Cotterchio M, Jenkins MA, Kim H, Bristow R, Green R, et al. Germline MutY human homologue mutations and colorectal cancer: a multisite case-control study. *Gastroenterology*. 2009;136(4):1251–60.
59. Church J, Heald B, Burke C, Kalady M. Understanding MYH-associated neoplasia. *Dis Colon Rectum*. 2012;55(3):359–62.
60. Tenesa A, Campbell H, Barnetson R, Porteous M, Dunlop M, Farrington SM. Association of MUTYH and colorectal cancer. *Br J Cancer*. 2006;95(2):239–42.
61. Jones S, Emmerson P, Maynard J, Best JM, Jordan S, Williams GT, et al. Biallelic germline mutations in MYH predispose to multiple colorectal adenoma and somatic G:C → T:A mutations. *Hum Mol Genet*. 2002;11(23):2961–7.
62. Parker AR, Eshleman JR. Human MutY: gene structure, protein functions and interactions, and role in carcinogenesis. *Cell Mol Life Sci*. 2003;60(10):2064–83.
63. Guillen-Ponce C, Castillejo A, Barbera VM, Pascual-Ramirez JC, Andrada E, Castillejo MI, et al. Biallelic MYH germline mutations as cause of Muir-Torre syndrome. *Fam Cancer*. 2010;9(2):151–4.
64. Boparai KS, Dekker E, Van Eeden S, Polak MM, Bartelsman JF, Mathus-Vliegen EM, et al. Hyperplastic polyps and sessile serrated adenomas as a phenotypic expression of MYH-associated polyposis. *Gastroenterology*. 2008;135(6):2014–8.
65. Castells A. MYH-associated polyposis: adenomas and hyperplastic polyps, partners in crime? *Gastroenterology*. 2008;135(6):1857–9.
66. Gismondi V, Meta M, Bonelli L, Radice P, Sala P, Bertario L, et al. Prevalence of the Y165C, G382D and 1395delGGA germline mutations of the MYH gene in Italian patients with adenomatous

- polyposis coli and colorectal adenomas. *Int J Cancer*. 2004;109(5):680–4.
67. Sieber OM, Lipton L, Crabtree M, Heinemann K, Fidalgo P, Phillips RK, et al. Multiple colorectal adenomas, classic adenomatous polyposis, and germ-line mutations in MYH. *N Engl J Med*. 2003;348(9):791–9.
68. Win AK, Dowty JG, Cleary SP, Kim H, Buchanan DD, Young JP, et al. Risk of colorectal cancer for carriers of mutations in MUTYH, with and without a family history of cancer. *Gastroenterology*. 2014;146(5):1208–11.e1–5.
69. Goodenberger M, Lindor NM. Lynch syndrome and MYH-associated polyposis: review and testing strategy. *J Clin Gastroenterol*. 2011;45(6):488–500.
70. Wang L, Baudhuin LM, Boardman LA, Steenblock KJ, Petersen GM, Halling KC, et al. MYH mutations in patients with attenuated and classic polyposis and with young-onset colorectal cancer without polyps. *Gastroenterology*. 2004;127(1):9–16.
71. Vogt S, Jones N, Christian D, Engel C, Nielsen M, Kaufmann A, et al. Expanded extracolonic tumor spectrum in MUTYH-associated polyposis. *Gastroenterology*. 2009;137(6):1976–85.e1–10.
72. Ponti G, Ponz de Leon M, Maffei S, Pedroni M, Losi L, Di Gregorio C, et al. Attenuated familial adenomatous polyposis and Muir-Torre syndrome linked to compound biallelic constitutional MYH gene mutations. *Clin Genet*. 2005;68(5):442–7.
73. National Comprehensive Cancer Network Practice Guidelines in Oncology 2015. version 2.
74. Syngal S, Brand RE, Church JM, Giardiello FM, Hampel HL, Burt RW, et al. ACG clinical guideline: genetic testing and management of hereditary gastrointestinal cancer syndromes. *Am J Gastroenterol*. 2015;110(2):223–62. quiz 63.
75. Nascimbeni R, Pucciarelli S, Di Lorenzo D, Urso E, Casella C, Agostini M, et al. Rectum-sparing surgery may be appropriate for biallelic MutYH-associated polyposis. *Dis Colon Rectum*. 2010;53(12):1670–5.
76. Palles C, Cazier JB, Howarth KM, Domingo E, Jones AM, Broderick P, et al. Germline mutations affecting the proofreading domains of POLE and POLD1 predispose to colorectal adenomas and carcinomas. *Nat Genet*. 2013;45(2):136–44.
77. Briggs S, Tomlinson I. Germline and somatic polymerase epsilon and delta mutations define a new class of hypermutated colorectal and endometrial cancers. *J Pathol*. 2013;230(2):148–53.
78. Desai DC, Neale KF, Talbot IC, Hodgson SV, Phillips RK. Juvenile polyposis. *Br J Surg*. 1995;82(1):14–7.
79. Merg A, Howe JR. Genetic conditions associated with intestinal juvenile polyps. *Am J Med Genet C Semin Med Genet*. 2004;129(1):44–55.
80. Jass JR, Williams CB, Bussey HJ, Morson BC. Juvenile polyposis – a precancerous condition. *Histopathology*. 1988;13(6):619–30.
81. O'Malley M, LaGuardia L, Kalady MF, Parambil J, Heald B, Eng C, et al. The prevalence of hereditary hemorrhagic telangiectasia in juvenile polyposis syndrome. *Dis Colon Rectum*. 2012;55(8):886–92.
82. Gallione CJ, Repetto GM, Legius E, Rustgi AK, Schelley SL, Tejpar S, et al. A combined syndrome of juvenile polyposis and hereditary haemorrhagic telangiectasia associated with mutations in MADH4 (SMAD4). *Lancet*. 2004;363(9412):852–9.
83. Iyer NK, Burke CA, Leach BH, Parambil JG. SMAD4 mutation and the combined syndrome of juvenile polyposis syndrome and hereditary haemorrhagic telangiectasia. *Thorax*. 2010;65(8):745–6.

84. Howe JR, Sayed MG, Ahmed AF, Ringold J, Larsen-Haidle J, Merg A, et al. The prevalence of MADH4 and BMPR1A mutations in juvenile polyposis and absence of BMPR2, BMPR1B, and ACVR1 mutations. *J Med Genet.* 2004;41(7):484–91.
85. Aretz S, Stienen D, Uhlhaas S, Stolte M, Entius MM, Loff S, et al. High proportion of large genomic deletions and a genotype phenotype update in 80 unrelated families with juvenile polyposis syndrome. *J Med Genet.* 2007;44(11):702–9.
86. Van Hattem WA, Brosens LA, de Leng WW, Morsink FH, Lens S, Carvalho R, et al. Large genomic deletions of SMAD4, BMPR1A and PTEN in juvenile polyposis. *Gut.* 2008;57(5):623–7.
87. Sweet K, Willis J, Zhou XP, Gallione C, Sawada T, Alhopuro P, et al. Molecular classification of patients with unexplained hamartomatous and hyperplastic polyposis. *JAMA.* 2005;294(19):2465–73.
88. Sayed MG, Ahmed AF, Ringold JR, Anderson ME, Bair JL, Mitros FA, et al. Germline SMAD4 or BMPR1A mutations and phenotype of juvenile polyposis. *Ann Surg Oncol.* 2002;9(9):901–6.
89. Agnifili A, Verzaro R, Gola P, Marino M, Mancini E, Carducci G, et al. Juvenile polyposis: case report and assessment of the neoplastic risk in 271 patients reported in the literature. *Dig Surg.* 1999;16(2):161–6.
90. Howe JR, Mitros FA, Summers RW. The risk of gastrointestinal carcinoma in familial juvenile polyposis. *Ann Surg Oncol.* 1998;5(8):751–6.
91. Jass J. Juvenile polyposis. 1st ed. In: Spiegelman RPaA, editor. London: Edward Arnold; 1994. 203–14 p.
92. Brosens LA, van Hattem A, Hyland LM, Iacobuzio-Donahue C, Romans KE, Axilbund J, et al. Risk of colorectal cancer in juvenile polyposis. *Gut.* 2007;56(7):965–7.
93. Scott-Conner CE, Hausmann M, Hall TJ, Skelton DS, Anglin BL, Subramony C. Familial juvenile polyposis: patterns of recurrence and implications for surgical management. *J Am Coll Surg.* 1995;181(5):407–13.
94. Aytac E, Sulu B, Heald B, O'Malley M, LaGuardia L, Remzi FH, et al. Genotype-defined cancer risk in juvenile polyposis syndrome. *Br J Surg.* 2015;102(1):114–8.
95. Calva D, Howe JR. Hamartomatous polyposis syndromes. *Surg Clin North Am.* 2008;88(4):779–817. vii.
96. Oncel M, Church JM, Remzi FH, Fazio VW. Colonic surgery in patients with juvenile polyposis syndrome: a case series. *Dis Colon Rectum.* 2005;48(1):49–55. discussion 6.
97. Utsunomiya J, Gocho H, Miyanaga T, Hamaguchi E, Kashimura A. Peutz-Jeghers syndrome: its natural course and management. *Johns Hopkins Med J.* 1975;136(2):71–82.
98. Giardiello FM, Trimbath JD. Peutz-Jeghers syndrome and management recommendations. *Clin Gastroenterol Hepatol.* 2006;4(4):408–15.
99. Zbuk KM, Eng C. Hamartomatous polyposis syndromes. *Nat Clin Pract Gastroenterol Hepatol.* 2007;4(9):492–502.
100. Hemminki A, Markie D, Tomlinson I, Avizienyte E, Roth S, Loukola A, et al. A serine/threonine kinase gene defective in Peutz-Jeghers syndrome. *Nature.* 1998;391(6663):184–7.
101. Giardiello FM, Brensinger JD, Tersmette AC, Goodman SN, Petersen GM, Booker SV, et al. Very high risk of cancer in familial Peutz-Jeghers syndrome. *Gastroenterology.* 2000;119(6):1447–53.
102. Oncel M, Remzi FH, Church JM, Connor JT, Fazio VW. Benefits of “clean sweep” in Peutz-Jeghers patients. *Colorectal Dis.* 2004;6(5):332–5.



103. Heald B, Mester J, Rybicki L, Orloff MS, Burke CA, Eng C. Frequent gastrointestinal polyps and colorectal adenocarcinomas in a prospective series of PTEN mutation carriers. *Gastroenterology*. 2010;139(6):1927–33.
104. Stanich PP, Owens VL, Sweetser S, Khambatta S, Smyrk TC, Richardson RL, et al. Colonic polyposis and neoplasia in Cowden syndrome. *Mayo Clin Proc*. 2011;86(6):489–92.
105. Marsh DJ, Dahia PL, Caron S, Kum JB, Frayling IM, Tomlinson IP, et al. Germline PTEN mutations in Cowden syndrome-like families. *J Med Genet*. 1998;35(11):881–5.
106. Marsh DJ, Dahia PL, Coulon V, Zheng Z, Dorion-Bonnet F, Call KM, et al. Allelic imbalance, including deletion of PTEN/MMAC1, at the Cowden disease locus on 10q22-23, in hamartomas from patients with Cowden syndrome and germline PTEN mutation. *Genes Chromosomes Cancer*. 1998;21(1):61–9.
107. Gustafson S, Zbuk KM, Scacheri C, Eng C. Cowden syndrome. *Semin Oncol*. 2007;34(5):428–34.
108. Gorlin RJ, Cohen Jr MM, Condon LM, Burke BA. Bannayan-Riley-Ruvalcaba syndrome. *Am J Med Genet*. 1992;44(3):307–14.
109. Tan MH, Mester JL, Ngeow J, Rybicki LA, Orloff MS, Eng C. Lifetime cancer risks in individuals with germline PTEN mutations. *Clin Cancer Res*. 2012;18(2):400–7.
110. Riegert-Johnson DL, Gleeson FC, Roberts M, Tholen K, Youngborg L, Bullock M, et al. Cancer and Lhermitte-Duclos disease are common in Cowden syndrome patients. *Hered Cancer Clin Pract*. 2010;8(1):6.
111. Boparai KS, Mathus-Vliegen EM, Koornstra JJ, Nagengast FM, van Leerdam M, van Noesel CJ, et al. Increased colorectal cancer risk during follow-up in patients with hyperplastic polyposis syndrome: a multicentre cohort study. *Gut*. 2010;59(8):1094–100.
112. Carvajal-Carmona LG, Howarth KM, Lockett M, Polanco-Echeverry GM, Volikos E, Gorman M, et al. Molecular classification and genetic pathways in hyperplastic polyposis syndrome. *J Pathol*. 2007;212(4):378–85.
113. Chow E, Lipton L, Lynch E, D’Souza R, Aragona C, Hodgkin L, et al. Hyperplastic polyposis syndrome: phenotypic presentations and the role of MBD4 and MYH. *Gastroenterology*. 2006;131(1):30–9.
114. Kalady MF, Jarrar A, Leach B, LaGuardia L, O’Malley M, Eng C, et al. Defining phenotypes and cancer risk in hyperplastic polyposis syndrome. *Dis Colon Rectum*. 2011;54(2):164–70.
115. Rosty C, Buchanan DD, Walsh MD, Pearson SA, Pavluk E, Walters RJ, et al. Phenotype and polyp landscape in serrated polyposis syndrome: a series of 100 patients from genetics clinics. *Am J Surg Pathol*. 2012;36(6):876–82.
116. Hazewinkel Y, Reitsma JB, Nagengast FM, Vasen HF, van Os TA, van Leerdam ME, et al. Extracolonic cancer risk in patients with serrated polyposis syndrome and their first-degree relatives. *Fam Cancer*. 2013;12(4):669–73.
117. Snover D, Ahnen D, Burt R, Odze RD. Serrated polyps of the colon and rectum and serrated polyposis. In: Bosman FT, Carneiro F, Hruban RH, editors. *WHO classification of tumours of the digestive system*. 4th ed. Lyon, France: IARC; 2010.
118. Ferrandez A, Samowitz W, DiSario JA, Burt RW. Phenotypic characteristics and risk of cancer development in hyperplastic polyposis: case series and literature review. *Am J Gastroenterol*. 2004;99(10):2012–8.
119. Hyman NH, Anderson P, Blasyk H. Hyperplastic polyposis and the risk of colorectal cancer.

Dis Colon Rectum. 2004;47(12):2101–4.

120. Leggett BA, Devereaux B, Biden K, Searle J, Young J, Jass J. Hyperplastic polyposis: association with colorectal cancer. *Am J Surg Pathol*. 2001;25(2):177–84.

121. Rubio CA, Stemme S, Jaramillo E, Lindblom A. Hyperplastic polyposis coli syndrome and colorectal carcinoma. *Endoscopy*. 2006;38(3):266–70.

122. Yeoman A, Young J, Arnold J, Jass J, Parry S. Hyperplastic polyposis in the New Zealand population: a condition associated with increased colorectal cancer risk and European ancestry. *N Z Med J*. 2007;120(1266):U2827.

123. Lage P, Cravo M, Sousa R, Chaves P, Salazar M, Fonseca R, et al. Management of Portuguese patients with hyperplastic polyposis and screening of at-risk first-degree relatives: a contribution for future guidelines based on a clinical study. *Am J Gastroenterol*. 2004;99(9):1779–84.

124. Rashid A, Houlihan PS, Booker S, Petersen GM, Giardiello FM, Hamilton SR. Phenotypic and molecular characteristics of hyperplastic polyposis. *Gastroenterology*. 2000;119(2):323–32.

125. Jaspersion KW, Kanth P, Kirchhoff AC, Huismann D, Gammon A, Kohlmann W, et al. Serrated polyposis: colonic phenotype, extracolonic features, and familial risk in a large cohort. *Dis Colon Rectum*. 2013;56(11):1211–6.

126. Rex DK, Ahnen DJ, Baron JA, Batts KP, Burke CA, Burt RW, et al. Serrated lesions of the colorectum: review and recommendations from an expert panel. *Am J Gastroenterol*. 2012;107(9):1315–29. quiz 4, 30.

127. Kalady MF. Sessile serrated polyps: an important route to colorectal cancer. *J Natl Compr Canc Netw*. 2013;11(12):1585–94.

128. Hazewinkel Y, Tytgat KM, van Eeden S, Bastiaansen B, Tanis PJ, Boparai KS, et al. Incidence of colonic neoplasia in patients with serrated polyposis syndrome who undergo annual endoscopic surveillance. *Gastroenterology*. 2014;147(1):88–95.

129. Win AK, Walters RJ, Buchanan DD, Jenkins MA, Sweet K, Frankel WL, et al. Cancer risks for relatives of patients with serrated polyposis. *Am J Gastroenterol*. 2012;107(5):770–8.

130. Hazewinkel Y, Koornstra JJ, Boparai KS, van Os TA, Tytgat KM, Van Eeden S, et al. Yield of screening colonoscopy in first-degree relatives of patients with serrated polyposis syndrome. *J Clin Gastroenterol*. 2015;49(5):407–12.

131. Aaltonen LA, Sankila R, Mecklin JP, Jarvinen H, Pukkala E, Peltomaki P, et al. A novel approach to estimate the proportion of hereditary nonpolyposis colorectal cancer of total colorectal cancer burden. *Cancer Detect Prev*. 1994;18(1):57–63.

132. De la Chapelle A. The incidence of Lynch syndrome. *Fam Cancer*. 2005;4(3):233–7.

133. Hampel H, Frankel WL, Martin E, Arnold M, Khanduja K, Kuebler P, et al. Screening for the Lynch syndrome (hereditary nonpolyposis colorectal cancer). *N Engl J Med*. 2005;352(18):1851–60.

134. Salovaara R, Loukola A, Kristo P, Kaariainen H, Ahtola H, Eskelinen M, et al. Population-based molecular detection of hereditary nonpolyposis colorectal cancer. *J Clin Oncol*. 2000;18(11):2193–200.

135. Lynch HT, Smyrk T, Lynch J. An update of HNPCC (Lynch syndrome). *Cancer Genet Cytogenet*. 1997;93(1):84–99.

136. Lynch HT, Shaw MW, Magnuson CW, Larsen AL, Krush AJ. Hereditary factors in cancer. Study of two large midwestern kindreds. *Arch Intern Med*. 1966;117(2):206–12.

137. Ionov Y, Peinado MA, Malkhosyan S, Shibata D, Perucho M. Ubiquitous somatic mutations in

simple repeated sequences reveal a new mechanism for colonic carcinogenesis. *Nature*. 1993;363(6429):558–61.

138. Umar A, Boland CR, Terdiman JP, Syngal S, de la Chapelle A, Ruschoff J, et al. Revised Bethesda Guidelines for hereditary nonpolyposis colorectal cancer (Lynch syndrome) and microsatellite instability. *J Natl Cancer Inst*. 2004;96(4):261–8.

139. Rodriguez-Bigas MA, Boland CR, Hamilton SR, Henson DE, Jass JR, Khan PM, et al. A National Cancer Institute Workshop on Hereditary Nonpolyposis Colorectal Cancer Syndrome: meeting highlights and Bethesda guidelines. *J Natl Cancer Inst*. 1997;89(23):1758–62.

140. Lindor NM. Familial colorectal cancer type X: the other half of hereditary nonpolyposis colon cancer syndrome. *Surg Oncol Clin N Am*. 2009;18(4):637–45.

141. Shiovitz S, Copeland WK, Passarelli MN, Burnett-Hartman AN, Grady WM, Potter JD, et al. Characterisation of familial colorectal cancer Type X, Lynch syndrome, and non-familial colorectal cancer. *Br J Cancer*. 2014;111(3):598–602.

142. Lindor NM, Rabe K, Petersen GM, Haile R, Casey G, Baron J, et al. Lower cancer incidence in Amsterdam-I criteria families without mismatch repair deficiency: familial colorectal cancer type X. *JAMA*. 2005;293(16):1979–85.

143. Durno CA, Holter S, Sherman PM, Gallinger S. The gastrointestinal phenotype of germline biallelic mismatch repair gene mutations. *Am J Gastroenterol*. 2010;105(11):2449–56.

144. Boland CR. The mystery of mismatch repair deficiency: lynch or lynch-like? *Gastroenterology*. 2013;144(5):868–70.

145. Buchanan DD, Rosty C, Clendenning M, Spurdle AB, Win AK. Clinical problems of colorectal cancer and endometrial cancer cases with unknown cause of tumor mismatch repair deficiency (suspected Lynch syndrome). *Appl Clin Genet*. 2014;7:183–93.

146. Rodriguez-Soler M, Perez-Carbonell L, Guarinos C, Zapater P, Castillejo A, Barbera VM, et al. Risk of cancer in cases of suspected lynch syndrome without germline mutation. *Gastroenterology*. 2013;144(5):926–32.e1. quiz e13–4.

147. You YN, Vilar E. Classifying MMR variants: time for revised nomenclature in Lynch syndrome. *Clin Cancer Res*. 2013;19(9):2280–2.

148. Lynch HT, Riegert-Johnson DL, Snyder C, Lynch JF, Hagenkord J, Boland CR, et al. Lynch syndrome-associated extracolonic tumors are rare in two extended families with the same EPCAM deletion. *Am J Gastroenterol*. 2011;106(10):1829–36.

149. Kovacs ME, Papp J, Szentirmay Z, Otto S, Olah E. Deletions removing the last exon of TACSTD1 constitute a distinct class of mutations predisposing to Lynch syndrome. *Hum Mutat*. 2009;30(2):197–203.

150. Palomaki GE, McClain MR, Melillo S, Hampel HL, Thibodeau SN. EGAPP supplementary evidence review: DNA testing strategies aimed at reducing morbidity and mortality from Lynch syndrome. *Genet Med*. 2009;11(1):42–65.

151. Weissman SM, Burt R, Church J, Erdman S, Hampel H, Holter S, et al. Identification of individuals at risk for Lynch syndrome using targeted evaluations and genetic testing: National Society of Genetic Counselors and the Collaborative Group of the Americas on Inherited Colorectal Cancer joint practice guideline. *J Genet Couns*. 2012;21(4):484–93.

152. Boland CR, Thibodeau SN, Hamilton SR, Sidransky D, Eshleman JR, Burt RW, et al. A National Cancer Institute Workshop on Microsatellite Instability for cancer detection and familial predisposition: development of international criteria for the determination of microsatellite

- instability in colorectal cancer. *Cancer Res.* 1998;58(22):5248–57.
153. Hegde M, Ferber M, Mao R, Samowitz W, Ganguly A, Working Group of the American College of Medical Genetics, et al. ACMG technical standards and guidelines for genetic testing for inherited colorectal cancer (Lynch syndrome, familial adenomatous polyposis, and MYH-associated polyposis). *Genet Med.* 2014;16(1):101–16.
154. Bellizzi AM, Frankel WL. Colorectal cancer due to deficiency in DNA mismatch repair function: a review. *Adv Anat Pathol.* 2009;16(6):405–17.
155. Shia J. Immunohistochemistry versus microsatellite instability testing for screening colorectal cancer patients at risk for hereditary nonpolyposis colorectal cancer syndrome. Part I. The utility of immunohistochemistry. *J Mol Diagn.* 2008;10(4):293–300.
156. Domingo E, Niessen RC, Oliveira C, Alhopuro P, Moutinho C, Espin E, et al. BRAF-V600E is not involved in the colorectal tumorigenesis of HNPCC in patients with functional MLH1 and MSH2 genes. *Oncogene.* 2005;24(24):3995–8.
157. Nakagawa H, Nagasaka T, Cullings HM, Notohara K, Hoshijima N, Young J, et al. Efficient molecular screening of Lynch syndrome by specific 3' promoter methylation of the MLH1 or BRAF mutation in colorectal cancer with high-frequency microsatellite instability. *Oncol Rep.* 2009;21(6):1577–83.
158. Sourrouille I, Coulet F, Lefevre JH, Colas C, Eyries M, Svreck M, et al. Somatic mosaicism and double somatic hits can lead to MSI colorectal tumors. *Fam Cancer.* 2013;12(1):27–33.
159. Poynter JN, Siegmund KD, Weisenberger DJ, Long TI, Thibodeau SN, Lindor N, et al. Molecular characterization of MSI-H colorectal cancer by MLH1 promoter methylation, immunohistochemistry, and mismatch repair germline mutation screening. *Cancer Epidemiol Biomarkers Prev.* 2008;17(11):3208–15.
160. Niessen RC, Hofstra RM, Westers H, Ligtenberg MJ, Kooi K, Jager PO, et al. Germline hypermethylation of MLH1 and EPCAM deletions are a frequent cause of Lynch syndrome. *Genes Chromosomes Cancer.* 2009;48(8):737–44.
161. Vasen HF, Blanco I, Aktan-Collan K, Gopie JP, Alonso A, Aretz S, et al. Revised guidelines for the clinical management of Lynch syndrome (HNPCC): recommendations by a group of European experts. *Gut.* 2013;62(6):812–23.
162. Giardiello FM, Allen JI, Axilbund JE, Boland CR, Burke CA, Burt RW, et al. Guidelines on genetic evaluation and management of Lynch syndrome: a consensus statement by the US Multi-society Task Force on colorectal cancer. *Am J Gastroenterol.* 2014;109(8):1159–79.
163. Wijnen JT, Brohet RM, van Eijk R, Jagmohan-Changur S, Middeldorp A, Tops CM, et al. Chromosome 8q23.3 and 11q23.1 variants modify colorectal cancer risk in Lynch syndrome. *Gastroenterology.* 2009;136(1):131–7.
164. Talseth-Palmer BA, Scott RJ, Vasen HF, Wijnen JT. 8q23.3 and 11q23.1 as modifying loci influencing the risk for CRC in Lynch syndrome. *Eur J Hum Genet.* 2012;20(5):487–8. author reply 8.
165. Lazar AJ, Lyle S, Calonje E. Sebaceous neoplasia and Torre-Muir syndrome. *Curr Diagn Pathol.* 2007;13(4):301–19.
166. Roberts ME, Riegert-Johnson DL, Thomas BC, Thomas CS, Heckman MG, Krishna M, et al. Screening for Muir-Torre syndrome using mismatch repair protein immunohistochemistry of sebaceous neoplasms. *J Genet Couns.* 2013;22(3):393–405.
167. Cesinaro AM, Ubiali A, Sighinolfi P, Trentini GP, Gentili F, Facchetti F. Mismatch repair

proteins expression and microsatellite instability in skin lesions with sebaceous differentiation: a study in different clinical subgroups with and without extracutaneous cancer. *Am J Dermatopathol*. 2007;29(4):351–8.

168. Lee BA, Yu L, Ma L, Lind AC, Lu D. Sebaceous neoplasms with mismatch repair protein expressions and the frequency of co-existing visceral tumors. *J Am Acad Dermatol*. 2012;67(6):1228–34.

169. Merlo A, Rochlitz C, Scott R. Survival of patients with Turcot's syndrome and glioblastoma. *N Engl J Med*. 1996;334(11):736–7.

170. Barrow E, Hill J, Evans DG. Cancer risk in Lynch syndrome. *Fam Cancer*. 2013;12(2):229–40.

171. Parry S, Win AK, Parry B, Macrae FA, Gurrin LC, Church JM, et al. Metachronous colorectal cancer risk for mismatch repair gene mutation carriers: the advantage of more extensive colon surgery. *Gut*. 2011;60(7):950–7.

172. Vasen HF, Tomlinson I, Castells A. Clinical management of hereditary colorectal cancer syndromes. *Nat Rev Gastroenterol Hepatol*. 2015;12(2):88–97.

173. Lanspa SJ, Lynch HT, Smyrk TC, Strayhorn P, Watson P, Lynch JF, et al. Colorectal adenomas in the Lynch syndromes. Results of a colonoscopy screening program. *Gastroenterology*. 1990;98(5 Pt 1):1117–22.

174. Winawer SJ, Zauber AG, Ho MN, O'Brien MJ, Gottlieb LS, Sternberg SS, et al. Prevention of colorectal cancer by colonoscopic polypectomy. The National Polyp Study Workgroup. *N Engl J Med*. 1993;329(27):1977–81.

175. Stoffel E, Mukherjee B, Raymond VM, Tayob N, Kastrinos F, Sparr J, et al. Calculation of risk of colorectal and endometrial cancer among patients with Lynch syndrome. *Gastroenterology*. 2009;137(5):1621–7.

176. Baglietto L, Lindor NM, Dowty JG, White DM, Wagner A, Gomez Garcia EB, et al. Risks of Lynch syndrome cancers for MSH6 mutation carriers. *J Natl Cancer Inst*. 2010;102(3):193–201.

177. Lu KH, Broaddus RR. Gynecologic cancers in Lynch syndrome/HNPCC. *Fam Cancer*. 2005;4(3):249–54.

178. Westin SN, Lacour RA, Urbauer DL, Luthra R, Bodurka DC, Lu KH, et al. Carcinoma of the lower uterine segment: a newly described association with Lynch syndrome. *J Clin Oncol*. 2008;26(36):5965–71.

179. Pal T, Permeth-Wey J, Sellers TA. A review of the clinical relevance of mismatch-repair deficiency in ovarian cancer. *Cancer*. 2008;113(4):733–42.

180. Win AK, Young JP, Lindor NM, Tucker KM, Ahnen DJ, Young GP, et al. Colorectal and other cancer risks for carriers and noncarriers from families with a DNA mismatch repair gene mutation: a prospective cohort study. *J Clin Oncol*. 2012;30(9):958–64.

181. Raymond VM, Mukherjee B, Wang F, Huang SC, Stoffel EM, Kastrinos F, et al. Elevated risk of prostate cancer among men with Lynch syndrome. *J Clin Oncol*. 2013;31(14):1713–8.

182. Kastrinos F, Mukherjee B, Tayob N, Wang F, Sparr J, Raymond VM, et al. Risk of pancreatic cancer in families with Lynch syndrome. *JAMA*. 2009;302(16):1790–5.

183. Buerki N, Gautier L, Kovac M, Marra G, Buser M, Mueller H, et al. Evidence for breast cancer as an integral part of Lynch syndrome. *Genes Chromosomes Cancer*. 2012;51(1):83–91.

184. Prince AE, Roche MI. Genetic information, non-discrimination, and privacy protections in genetic counseling practice. *J Genet Couns*. 2014;23(6):891–902.

185. Balmana J, Balaguer F, Castellvi-Bel S, Steyerberg EW, Andreu M, Llor X, et al. Comparison

of predictive models, clinical criteria and molecular tumour screening for the identification of patients with Lynch syndrome in a population-based cohort of colorectal cancer patients. *J Med Genet.* 2008;45(9):557–63.

186. Pinol V, Castells A, Andreu M, Castellvi-Bel S, Alenda C, Llor X, et al. Accuracy of revised Bethesda guidelines, microsatellite instability, and immunohistochemistry for the identification of patients with hereditary nonpolyposis colorectal cancer. *JAMA.* 2005;293(16):1986–94.

187. Green RC, Parfrey PS, Woods MO, Younghusband HB. Prediction of Lynch syndrome in consecutive patients with colorectal cancer. *J Natl Cancer Inst.* 2009;101(5):331–40.

188. Teresposky D. The MMRpro model accurately predicted the probability of carrying a cancer-susceptibility gene mutation for the Lynch syndrome. *ACP J Club.* 2007;146(2):53.

189. Kastrinos F, Steyerberg EW, Mercado R, Balmana J, Holter S, Gallinger S, et al. The PREMM(1,2,6) model predicts risk of MLH1, MSH2, and MSH6 germline mutations based on cancer history. *Gastroenterology.* 2011;140(1):73–81.

190. Barzi A, Sadeghi S, Kattan MW, Meropol NJ. Comparative effectiveness of screening strategies for Lynch syndrome. *J Natl Cancer Inst.* 2015;107(4), djv005.

191. The National Comprehensive Cancer Network Guideline on Genetic/Familial High-risk Assessment: Colorectal. Version 1.2015. [www.ncc.org](http://www.ncc.org).

192. Moreira L, Balaguer F, Lindor N, de la Chapelle A, Hampel H, Aaltonen LA, et al. Identification of Lynch syndrome among patients with colorectal cancer. *JAMA.* 2012;308(15):1555–65.

193. Ladabaum U, Wang G, Terdiman J, Blanco A, Kuppermann M, Boland CR, et al. Strategies to identify the Lynch syndrome among patients with colorectal cancer: a cost-effectiveness analysis. *Ann Intern Med.* 2011;155(2):69–79.

194. Evaluation of Genomic Applications in Practice and Prevention (EGAPP) Working Group. Recommendations from the EGAPP Working Group: can UGT1A1 genotyping reduce morbidity and mortality in patients with metastatic colorectal cancer treated with irinotecan? *Genet Med.* 2009;11(1):15–20.

195. Mensenkamp AR, Vogelaar IP, van Zelst-Stams WA, Goossens M, Ouchene H, Hendriks-Cornelissen SJ, et al. Somatic mutations in MLH1 and MSH2 are a frequent cause of mismatch-repair deficiency in Lynch syndrome-like tumors. *Gastroenterology.* 2014;146(3):643–6. e8.

196. Yurgelun MB, Allen B, Kaldete RR, Bowles KR, Judkins T, Kaushik P, et al. Identification of a variety of mutations in cancer-predisposition genes in patients with suspected Lynch syndrome. *Gastroenterology.* 2015;149(3):604–613.e20.

197. Jarvinen HJ, Aarnio M, Mustonen H, Aktan-Collan K, Aaltonen LA, Peltomaki P, et al. Controlled 15-year trial on screening for colorectal cancer in families with hereditary nonpolyposis colorectal cancer. *Gastroenterology.* 2000;118(5):829–34.

198. Mork M, Hubosky SG, Roupret M, Margulis V, Raman J, Lotan Y, et al. Lynch syndrome: a primer for urologists and panel recommendations. *J Urol.* 2015;194(1):21–9.

199. Botma A, Vasen HF, van Duijnhoven FJ, Kleibeuker JH, Nagengast FM, Kampman E. Dietary patterns and colorectal adenomas in Lynch syndrome: the GEOLynch cohort study. *Cancer.* 2013;119(3):512–21.

200. Winkels RM, Botma A, Van Duijnhoven FJ, Nagengast FM, Kleibeuker JH, Vasen HF, et al. Smoking increases the risk for colorectal adenomas in patients with Lynch syndrome. *Gastroenterology.* 2012;142(2):241–7.

201. Botma A, Nagengast FM, Braem MG, Hendriks JC, Kleibeuker JH, Vasen HF, et al. Body mass index increases risk of colorectal adenomas in men with Lynch syndrome: the GEOLynch cohort study. *J Clin Oncol*. 2010;28(28):4346–53.
202. Mathers JC, Movahedi M, Macrae F, Mecklin JP, Moeslein G, Olschwang S, et al. Long-term effect of resistant starch on cancer risk in carriers of hereditary colorectal cancer: an analysis from the CAPP2 randomised controlled trial. *Lancet Oncol*. 2012;13(12):1242–9.
203. Burn J, Gerdes AM, Macrae F, Mecklin JP, Moeslein G, Olschwang S, et al. Long-term effect of aspirin on cancer risk in carriers of hereditary colorectal cancer: an analysis from the CAPP2 randomised controlled trial. *Lancet*. 2011;378(9809):2081–7.
204. Burn J, Mathers JC, Bishop DT. Chemoprevention in Lynch syndrome. *Fam Cancer*. 2013;12(4):707–18.
205. Smith AJ, Driman DK, Spithoff K, Hunter A, McLeod RS, Simunovic M, et al. Guideline for optimization of colorectal cancer surgery and pathology. *J Surg Oncol*. 2010;101(1):5–12.
206. Fitzgibbons Jr RJ, Lynch HT, Stanislav GV, Watson PA, Lanspa SJ, Marcus JN, et al. Recognition and treatment of patients with hereditary nonpolyposis colon cancer (Lynch syndromes I and II). *Ann Surg*. 1987;206(3):289–95.
207. Natarajan N, Watson P, Silva-Lopez E, Lynch HT. Comparison of extended colectomy and limited resection in patients with Lynch syndrome. *Dis Colon Rectum*. 2010;53(1):77–82.
208. Vasen HF, Mecklin JP, Watson P, Utsunomiya J, Bertario L, Lynch P, et al. Surveillance in hereditary nonpolyposis colorectal cancer: an international cooperative study of 165 families. The International Collaborative Group on HNPCC. *Dis Colon Rectum*. 1993;36(1):1–4.
209. Kalady MF, McGannon E, Vogel JD, Manilich E, Fazio VW, Church JM. Risk of colorectal adenoma and carcinoma after colectomy for colorectal cancer in patients meeting Amsterdam criteria. *Ann Surg*. 2010;252(3):507–11. discussion 11–3.
210. De Vos Tot Nederveen Cappel WH, Buskens E, van Duijvendijk P, Cats A, Menko FH, Griffioen G, et al. Decision analysis in the surgical treatment of colorectal cancer due to a mismatch repair gene defect. *Gut*. 2003;52(12):1752–5.
211. You YN, Chua HK, Nelson H, Hassan I, Barnes SA, Harrington J. Segmental vs. extended colectomy: measurable differences in morbidity, function, and quality of life. *Dis Colon Rectum*. 2008;51(7):1036–43.
212. Haanstra JF, de Vos Tot Nederveen Cappel WH, Gopie JP, Vecht J, Vanhoutvin SA, Cats A, et al. Quality of life after surgery for colon cancer in patients with Lynch syndrome: partial versus subtotal colectomy. *Dis Colon Rectum*. 2012;55(6):653–9.
213. Fazio VW, Kiran RP, Remzi FH, Coffey JC, Heneghan HM, Kirat HT, et al. Ileal pouch anal anastomosis: analysis of outcome and quality of life in 3707 patients. *Ann Surg*. 2013;257(4):679–85.
214. Win AK, Parry S, Parry B, Kalady MF, Macrae FA, Ahnen DJ, et al. Risk of metachronous colon cancer following surgery for rectal cancer in mismatch repair gene mutation carriers. *Ann Surg Oncol*. 2013;20(6):1829–36.
215. Kalady MF, Lipman J, McGannon E, Church JM. Risk of colonic neoplasia after proctectomy for rectal cancer in hereditary nonpolyposis colorectal cancer. *Ann Surg*. 2012;255(6):1121–5.
216. Lee JS, Petrelli NJ, Rodriguez-Bigas MA. Rectal cancer in hereditary nonpolyposis colorectal cancer. *Am J Surg*. 2001;181(3):207–10.
217. Cirillo L, Urso ED, Parrinello G, Pucciarelli S, Moneghini D, Agostini M, et al. High risk of

- rectal cancer and of metachronous colorectal cancer in probands of families fulfilling the Amsterdam criteria. *Ann Surg*. 2013;257(5):900–4.
218. Wertzberger BE, Sherman SK, Byrn JC. Differences in short-term outcomes among patients undergoing IPAA with or without preoperative radiation: a National Surgical Quality Improvement Program analysis. *Dis Colon Rectum*. 2014;57(10):1188–94.
219. Schmeler KM, Lynch HT, Chen LM, Munsell MF, Soliman PT, Clark MB, et al. Prophylactic surgery to reduce the risk of gynecologic cancers in the Lynch syndrome. *N Engl J Med*. 2006;354(3):261–9.
220. Kwon JS, Sun CC, Peterson SK, White KG, Daniels MS, Boyd-Rogers SG, et al. Cost-effectiveness analysis of prevention strategies for gynecologic cancers in Lynch syndrome. *Cancer*. 2008;113(2):326–35.
221. Bannon SA, Mork M, Vilar E, Peterson SK, Lu K, Lynch PM, et al. Patient-reported disease knowledge and educational needs in Lynch syndrome: findings of an interactive multidisciplinary patient conference. *Hered Cancer Clin Pract*. 2014;12(1):1.
222. Barrow P, Khan M, Lalloo F, Evans DG, Hill J. Systematic review of the impact of registration and screening on colorectal cancer incidence and mortality in familial adenomatous polyposis and Lynch syndrome. *Br J Surg*. 2013;100(13):1719–31.
223. Kalady MF, Heald B. Diagnostic approach to hereditary colorectal cancer syndromes. *Clin Colon Rectal Surg*. 2015;28:205–214.

## 第 24 章

1. Colorectal (Colon) Cancer Centers for Disease Control and Prevention [cited 2015]. 2015. <http://www.cdc.gov/cancer/colorectal/>.
2. Winawer SJ, Zauber AG, Ho MN, O'Brien MJ, Gottlieb LS, Sternberg SS, et al. Prevention of colorectal cancer by colonoscopic polypectomy. The National Polyp Study Workgroup. *N Engl J Med*. 1993;329(27):1977–81.
3. Kahi CJ, Imperiale TF, Juliar BE, Rex DK. Effect of screening colonoscopy on colorectal cancer incidence and mortality. *Clin Gastroenterol Hepatol*. 2009;7(7):770–5. quiz 11.
4. American Cancer Society Recommendations for colorectal cancer early detection. 2014. <http://www.cancer.org/cancer/colonandrectumcancer/moreinformation/colonandrectumcancerearlydetection/colorectal-cancer-early-detection-ac-s-recommendations>. Accessed 5 Feb 2015.
5. Champagne B. Rectal cancer. <https://www.fascrs.org/patients/disease-condition/rectal-cancer>. Accessed 27 Mar 2015.
6. Colorectal cancer prevention and treatment. 2014. <http://www.gastro.org/patient-center/digestive-conditions/colorectal-cancer>. Accessed 27 Mar 2015.
7. Levin B, Lieberman DA, McFarland B, Andrews KS, Brooks D, Bond J, et al. Screening and surveillance for the early detection of colorectal cancer and adenomatous polyps, 2008: a joint guideline from the American Cancer Society, the US Multi-Society Task Force on Colorectal Cancer, and the American College of Radiology. *Gastroenterology*. 2008;134(5):1570–95.
8. Winawer S, Fletcher R, Rex D, Bond J, Burt R, Ferrucci J, et al. Colorectal cancer screening and surveillance: clinical guidelines and rationale-update based on new evidence. *Gastroenterology*. 2003;124(2):544–60.



9. U.S. Preventive Services Task Force. Screening for colorectal cancer: U.S. Preventive Services Task Force recommendation statement. *Ann Intern Med.* 2008;149:627–37.
10. Wolff WI. Colonoscopy: history and development. *Am J Gastroenterol.* 1989;84(9):1017–25.
11. Peery AF, Dellon ES, Lund J, Crockett SD, McGowan CE, Bulsiewicz WJ, et al. Burden of gastrointestinal disease in the United States: 2012 update. *Gastroenterology.* 2012;143(5):1179–87.
12. Mandel JS, Church TR, Bond JH, Ederer F, Geisser MS, Mongin SJ, et al. The effect of fecal occult-blood screening on the incidence of colorectal cancer. *N Engl J Med.* 2000;343(22):1603–7.
13. Citarda F, Tomaselli G, Capocaccia R, Barcherini S, Crespi M, Group IMS. Efficacy in standard clinical practice of colonoscopic polypectomy in reducing colorectal cancer incidence. *Gut.* 2001;48(6):812–5.
14. Zauber AG, Winawer SJ, O'Brien MJ, Lansdorp-Vogelaar I, van Ballegooijen M, Hankey BF, et al. Colonoscopic polypectomy and long-term prevention of colorectal-cancer deaths. *N Engl J Med.* 2012;366(8):687–96.
15. Rex DK, Schoenfeld PS, Cohen J, Pike IM, Adler DG, Fennerty MB, et al. Quality indicators for colonoscopy. *Am J Gastroenterol.* 2015;110(1):72–90.
16. Sherer EA, Imler TD, Imperiale TF. The effect of colonoscopy preparation quality on adenoma detection rates. *Gastrointest Endosc.* 2012;75(3):545–53.
17. Van Rijn JC, Reitsma JB, Stoker J, Bossuyt PM, van Deventer SJ, Dekker E. Polyp miss rate determined by tandem colonoscopy: a systematic review. *Am J Gastroenterol.* 2006;101(2):343–50.
18. Pickhardt PJ, Nugent PA, Mysliwiec PA, Choi JR, Schindler WR. Location of adenomas missed by optical colonoscopy. *Ann Intern Med.* 2004;141(5):352–9.
19. Bressler B, Paszat LF, Chen Z, Rothwell DM, Vinden C, Rabeneck L. Rates of new or missed colorectal cancers after colonoscopy and their risk factors: a population-based analysis. *Gastroenterology.* 2007;132(1):96–102.
20. Baxter NN, Goldwasser MA, Paszat LF, Saskin R, Urbach DR, Rabeneck L. Association of colonoscopy and death from colorectal cancer. *Ann Intern Med.* 2009;150(1):1–8.
21. Neerincx M, Terhaar sive Droste JS, Mulder CJ, Rakers M, Bartelsman JF, Loffeld RJ, et al. Colonic work-up after incomplete colonoscopy: significant new findings during follow-up. *Endoscopy.* 2010;42(9):730–5.
22. Gawron AJ, Veerappan A, McCarthy ST, Kankanala V, Keswani RN. Impact of an incomplete colonoscopy referral program on recommendations after incomplete colonoscopy. *Dig Dis Sci.* 2013;58(7):1849–55.
23. Subramanian V, Mannath J, Hawkey CJ, Ragunath K. High definition colonoscopy vs. standard video endoscopy for the detection of colonic polyps: a meta-analysis. *Endoscopy.* 2011;43(6):499–505.
24. Kahi CJ, Anderson JC, Waxman I, Kessler WR, Imperiale TF, Li X, et al. High-definition chromocolonoscopy vs. high-definition white light colonoscopy for average-risk colorectal cancer screening. *Am J Gastroenterol.* 2010;105(6):1301–7.
25. Pohl J, Schneider A, Vogell H, Mayer G, Kaiser G, Ell C. Pancolonial chromoendoscopy with indigo carmine versus standard colonoscopy for detection of neoplastic lesions: a randomised two-centre trial. *Gut.* 2011;60(4):485–90.
26. De Wijkerslooth TR, Stoop EM, Bossuyt PM, Mathus-Vliegen EM, Dees J, Tytgat KM, et al. Adenoma detection with cap-assisted colonoscopy versus regular colonoscopy: a randomised controlled trial. *Gut.* 2012;61(10):1426–34.

27. Rastogi A, Bansal A, Rao DS, Gupta N, Wani SB, Shipe T, et al. Higher adenoma detection rates with cap-assisted colonoscopy: a randomised controlled trial. *Gut*. 2012;61(3):402–8.
28. Dinesen L, Chua TJ, Kaffes AJ. Meta-analysis of narrow-band imaging versus conventional colonoscopy for adenoma detection. *Gastrointest Endosc*. 2012;75(3):604–11.
29. Pasha SF, Leighton JA, Das A, Harrison ME, Gurudu SR, Ramirez FC, et al. Comparison of the yield and miss rate of narrow band imaging and white light endoscopy in patients undergoing screening or surveillance colonoscopy: a meta-analysis. *Am J Gastroenterol*. 2012;107(3):363–70. quiz 71.
30. Gross SA, Buchner AM, Crook JE, Cangemi JR, Picco MF, Wolfsen HC, et al. A comparison of high definition-image enhanced colonoscopy and standard white-light colonoscopy for colorectal polyp detection. *Endoscopy*. 2011;43(12):1045–51.
31. Haringsma J, Tytgat GN, Yano H, Iishi H, Tatsuta M, Ogihara T, et al. Autofluorescence endoscopy: feasibility of detection of GI neoplasms unapparent to white light endoscopy with an evolving technology. *Gastrointest Endosc*. 2001;53(6):642–50.
32. Pohl J, May A, Rabenstein T, Pech O, Ell C. Computed virtual chromoendoscopy: a new tool for enhancing tissue surface structures. *Endoscopy*. 2007;39(1):80–3.
33. Chung SJ, Kim D, Song JH, Kang HY, Chung GE, Choi J, et al. Comparison of detection and miss rates of narrow band imaging, flexible spectral imaging chromoendoscopy and white light at screening colonoscopy: a randomised controlled back-to-back study. *Gut*. 2014;63(5):785–91.
34. Omata F, Ohde S, Deshpande GA, Kobayashi D, Masuda K, Fukui T. Image-enhanced, chromo, and cap-assisted colonoscopy for improving adenoma/neoplasia detection rate: a systematic review and meta-analysis. *Scand J Gastroenterol*. 2014;49(2):222–37.
35. Sharma VK, Nguyen CC, Crowell MD, Lieberman DA, de Garmo P, Fleischer DE. A national study of cardiopulmonary unplanned events after GI endoscopy. *Gastrointest Endosc*. 2007;66(1):27–34.
36. Rutter CM, Johnson E, Miglioretti DL, Mandelson MT, Inadomi J, Buist DS. Adverse events after screening and follow-up colonoscopy. *Cancer Causes Control*. 2012;23(2):289–96.
37. Ko CW, Dominitz JA. Complications of colonoscopy: magnitude and management. *Gastrointest Endosc Clin N Am*. 2010;20(4):659–71.
38. Kim DH, Pickhardt PJ, Hoff G, Kay CL. Computed tomographic colonography for colorectal screening. *Endoscopy*. 2007;39(6):545–9.
39. ACR-SAR-SCBT-MR practice parameter for the performance of Computed Tomography (CT) colonography in adults.  
[http://www.acr.org/%7E/media/ACR/Documents/PGTS/guidelines/CT\\_Colonography.pdf](http://www.acr.org/%7E/media/ACR/Documents/PGTS/guidelines/CT_Colonography.pdf).
40. Pickhardt PJ. CT colonography for population screening: ready for prime time? *Dig Dis Sci*. 2015;60(3):647–59.
41. Zalis ME, Barish MA, Choi JR, Dachman AH, Fenlon HM, Ferrucci JT, et al. CT colonography reporting and data system: a consensus proposal. *Radiology*. 2005;236(1):3–9.
42. Pickhardt PJ, Taylor AJ. Extracolonic findings identified in asymptomatic adults at screening CT colonography. *AJR Am J Roentgenol*. 2006;186(3):718–28.
43. Chin M, Mendelson R, Edwards J, Foster N, Forbes G. Computed tomographic colonography: prevalence, nature, and clinical significance of extracolonic findings in a community screening program. *Am J Gastroenterol*. 2005;100(12):2771–6.
44. Pickhardt PJ. Incidence of colonic perforation at CT colonography: review of existing data and

- implications for screening of asymptomatic adults. *Radiology*. 2006;239(2):313–6.
45. Liedenbaum MH, Venema HW, Stoker J. Radiation dose in CT colonography—trends in time and differences between daily practice and screening protocols. *Eur Radiol*. 2008;18(10):2222–30.
46. On the risk to low doses (<100 mSv) of ionizing radiation during medical imaging procedures—IOMP policy statement. *J Med Phys*. 2013;38(2):57–8.
47. Pickhardt PJ, Choi JR, Hwang I, Butler JA, Puckett ML, Hildebrandt HA, et al. Computed tomographic virtual colonoscopy to screen for colorectal neoplasia in asymptomatic adults. *N Engl J Med*. 2003;349(23):2191–200.
48. Johnson CD, Chen MH, Toledano AY, Heiken JP, Dachman A, Kuo MD, et al. Accuracy of CT colonography for detection of large adenomas and cancers. *N Engl J Med*. 2008;359(12):1207–17.
49. Pickhardt PJ, Hassan C, Halligan S, Marmo R. Colorectal cancer: CT colonography and colonoscopy for detection—systematic review and meta-analysis. *Radiology*. 2011;259(2):393–405.
50. Kim DH, Pickhardt PJ, Taylor AJ, Leung WK, Winter TC, Hinshaw JL, et al. CT colonography versus colonoscopy for the detection of advanced neoplasia. *N Engl J Med*. 2007;357(14):1403–12.
51. Kim DH, Pooler BD, Weiss JM, Pickhardt PJ. Five year colorectal cancer outcomes in a large negative CT colonography screening cohort. *Eur Radiol*. 2012;22(7):1488–94.
52. Doria-Rose VP, Newcomb PA, Levin TR. Incomplete screening flexible sigmoidoscopy associated with female sex, age, and increased risk of colorectal cancer. *Gut*. 2005;54(9):1273–8.
53. Imperiale TF, Wagner DR, Lin CY, Larkin GN, Rogge JD, Ransohoff DF. Risk of advanced proximal neoplasms in asymptomatic adults according to the distal colorectal findings. *N Engl J Med*. 2000;343(3):169–74.
54. Littlejohn C, Hilton S, Macfarlane GJ, Phull P. Systematic review and meta-analysis of the evidence for flexible sigmoidoscopy as a screening method for the prevention of colorectal cancer. *Br J Surg*. 2012;99(11):1488–500.
55. Brenner H, Stock C, Hoffmeister M. Effect of screening sigmoidoscopy and screening colonoscopy on colorectal cancer incidence and mortality: systematic review and meta-analysis of randomised controlled trials and observational studies. *BMJ*. 2014;348:g2467.
56. Schoen RE, Pinsky PF, Weissfeld JL, Yokochi LA, Church T, Laiyemo AO, et al. Colorectal-cancer incidence and mortality with screening flexible sigmoidoscopy. *N Engl J Med*. 2012;366(25):2345–57.
57. Holme Ø, Løberg M, Kalager M, Bretthauer M, Hernán MA, Aas E, et al. Effect of flexible sigmoidoscopy screening on colorectal cancer incidence and mortality: a randomized clinical trial. *JAMA*. 2014;312(6):606–15.
58. Levin TR, Conell C, Shapiro JA, Chazan SG, Nadel MR, Selby JV. Complications of screening flexible sigmoidoscopy. *Gastroenterology*. 2002;123(6):1786–92.
59. Gatto NM, Frucht H, Sundararajan V, Jacobson JS, Grann VR, Neugut AI. Risk of perforation after colonoscopy and sigmoidoscopy: a population-based study. *J Natl Cancer Inst*. 2003;95(3):230–6.
60. Miglioretti DL, Rutter CM, Bradford SC, Zauber AG, Kessler LG, Feuer EJ, et al. Improvement in the diagnostic evaluation of a positive fecal occult blood test in an integrated health care organization. *Med Care*. 2008;46(9 Suppl 1):S91–6.
61. Kronborg O, Fenger C, Olsen J, Jørgensen OD, Søndergaard O. Randomised study of screening for colorectal cancer with faecal-occult-blood test. *Lancet*. 1996;348(9040):1467–71.
62. Hardcastle JD, Chamberlain JO, Robinson MH, Moss SM, Amar SS, Balfour TW, et al.

Randomised controlled trial of faecal-occult-blood screening for colorectal cancer. *Lancet*. 1996;348(9040):1472–7.

63. Lee JK, Liles EG, Bent S, Levin TR, Corley DA. Accuracy of fecal immunochemical tests for colorectal cancer: systematic review and meta-analysis. *Ann Intern Med*. 2014;160(3):171.

64. Rennert G. Fecal occult blood screening—trial evidence, practice and beyond. *Recent Results Cancer Res*. 2003;163:248–53. discussion 64–6.

65. Imperiale TF, Ransohoff DF, Itzkowitz SH. Multitarget stool DNA testing for colorectal-cancer screening. *N Engl J Med*. 2014;371(2):187–8.

66. Heigh RI, Yab TC, Taylor WR, Hussain FT, Smyrk TC, Mahoney DW, et al. Detection of colorectal serrated polyps by stool DNA testing: comparison with fecal immunochemical testing for occult blood (FIT). *PLoS One*. 2014;9(1):e85659.

67. Lidgard GP, Domanico MJ, Bruinsma JJ, Light J, Gagrut ZD, Oldham-Haltom RL, et al. Clinical performance of an automated stool DNA assay for detection of colorectal neoplasia. *Clin Gastroenterol Hepatol*. 2013;11(10):1313–8.

68. Winawer SJ, Stewart ET, Zauber AG, Bond JH, Ansel H, Waye JD, et al. A comparison of colonoscopy and double-contrast barium enema for surveillance after polypectomy. National Polyp Study Work Group. *N Engl J Med*. 2000;342(24):1766–72.

69. Rockey DC, Paulson E, Niedzwiecki D, Davis W, Bosworth HB, Sanders L, et al. Analysis of air contrast barium enema, computed tomographic colonography, and colonoscopy: prospective comparison. *Lancet*. 2005;365(9456):305–11.

70. Sosna J, Sella T, Sy O, Lavin PT, Eliahou R, Fraifeld S, et al. Critical analysis of the performance of double-contrast barium enema for detecting colorectal polyps  $\geq 6$  mm in the era of CT colonography. *AJR Am J Roentgenol*. 2008;190(2):374–85.

71. Rex DK, Rahmani EY, Haseman JH, Lemmel GT, Kaster S, Buckley JS. Relative sensitivity of colonoscopy and barium enema for detection of colorectal cancer in clinical practice. *Gastroenterology*. 1997;112(1):17–23.

72. Toma J, Paszat LF, Gunraj N, Rabeneck L. Rates of new or missed colorectal cancer after barium enema and their risk factors: a population-based study. *Am J Gastroenterol*. 2008;103(12):3142–8.

73. Simon S. Achieving 80% by 2018 screening goal could prevent 200,000 colon cancer deaths in less than 2 decades. 2015. <http://www.cancer.org/cancer/news/news/impact-of-achieving-80-by-2018-screening-goal>. Accessed 27 Mar 2015.

74. Crockett SD, Snover DC, Ahnen DJ, Baron JA. Sessile serrated adenomas: an evidence-based guide to management. *Clin Gastroenterol Hepatol*. 2015;13(1):11–26.

75. Boparai KS, Mathus-Vliegen EM, Koornstra JJ, Nagengast FM, van Leerdam M, van Noesel CJ, et al. Increased colorectal cancer risk during follow-up in patients with hyperplastic polyposis syndrome: a multicentre cohort study. *Gut*. 2010;59(8):1094–100.

76. Hamilton SR, Aaltonen LA, editors. World Health Organization classification of tumours. Pathology and genetics of tumours of the digestive system. Lyon: IARC Press; 2000. p. 103–44.

77. Rex DK, Ahnen DJ, Baron JA, Batts KP, Burke CA, Burt RW, et al. Serrated lesions of the colorectum: review and recommendations from an expert panel. *Am J Gastroenterol*. 2012;107(9):1315–29.

78. Hamilton SR, Bofetta P, et al. Carcinoma of the Colon and Rectum. WHO Classification of tumours of the digestive system. 2010. p. 134–46.

79. Amersi F, Agustin M, Ko CY. Colorectal cancer: epidemiology, risk factors, and health services.

Clin Colon Rectal Surg. 2005;18(3):133–40.

80. Hassan C, Quintero E, Dumonceau JM, Regula J, Brandão C, Chaussade S, et al. Post-polypectomy colonoscopy surveillance: European Society of Gastrointestinal Endoscopy (ESGE) Guideline. *Endoscopy*. 2013;45(10):842–51.

81. Ransohoff DF, Yankaskas B, Gizlice Z, Gangarosa L. Recommendations for post-polypectomy surveillance in community practice. *Dig Dis Sci*. 2011;56(9):2623–30.

82. Hassan C, Repici A, Sharma P, Correale L, Zullo A, Bretthauer M, et al. Efficacy and safety of endoscopic resection of large colorectal polyps: a systematic review and meta-analysis. *Gut*. 2015. doi: 10.1136/gutjnl-2014-308481.

83. Larsen Haidle J, Howe JR. Juvenile polyposis syndrome. In: Pagon RA, Adam MP, Ardinger HH, Wallace SE, Amemiya A, Bean LJH, editors. *Gene reviews (R)*. Seattle, WA: University of Washington, Seattle; 1993.

84. Beggs AD, Latchford AR, Vasen HF, Moslein G, Alonso A, Aretz S, et al. Peutz-Jeghers syndrome: a systematic review and recommendations for management. *Gut*. 2010;59(7):975–86.

85. DeRoche TC, Xiao SY, Liu X. Histological evaluation in ulcerative colitis. *Gastroenterol Rep (Oxf)*. 2014;2(3):178–92.

86. Nascimbeni R, Burgart LJ, Nivatvongs S, Larson DR. Risk of lymph node metastasis in T1 carcinoma of the colon and rectum. *Dis Colon Rectum*. 2002;45(2):200–6.

87. Nivatvongs S, Rojanasakul A, Reiman HM, Dozois RR, Wolff BG, Pemberton JH, et al. The risk of lymph node metastasis in colorectal polyps with invasive adenocarcinoma. *Dis Colon Rectum*. 1991;34(4):323–8.

88. Resch A, Langner C. Risk assessment in early colorectal cancer: histological and molecular markers. *Dig Dis*. 2015;33(1):77–85.

89. Freeman HJ. Long-term follow-up of patients with malignant pedunculated colon polyps after colonoscopic polypectomy. *Can J Gastroenterol*. 2013;27(1):20–4.

90. Cottet V, Jooste V, Fournel I, Bouvier AM, Faivre J, Bonithon-Kopp C. Long-term risk of colorectal cancer after adenoma removal: a population-based cohort study. *Gut*. 2012;61(8):1180–6.

91. Brenner H, Chang-Claude J, Jansen L, Seiler CM, Hoffmeister M. Role of colonoscopy and polyp characteristics in colorectal cancer after colonoscopic polyp detection: a population-based case-control study. *Ann Intern Med*. 2012;157:225–32.

92. Hassan C, Gimeno-Garcia A, Kalager M, Spada C, Zullo A, Costamagna G, et al. Systematic review with meta-analysis: the incidence of advanced neoplasia after polypectomy in patients with and without low-risk adenomas. *Aliment Pharmacol Ther*. 2014;39(9):905–12.

93. Mysliwiec PA, Brown ML, Klabunde CN, Ransohoff DF. Are physicians doing too much colonoscopy? A national survey of colorectal surveillance after polypectomy. *Ann Intern Med*. 2004;141:264–71.

94. Levin TR. Dealing with uncertainty: surveillance colonoscopy after polypectomy. *Am J Gastroenterol*. 2007;102:1745–7.

95. Cooper K, Squires H, Carroll C, Papaioannou D, Booth A, Logan RF, et al. Chemoprevention of colorectal cancer: systematic review and economic evaluation. *Health Technol Assess*. 2010;14(32):1–206.

## 25 章

1. Cunningham D, Atkin W, Lenz HJ, Lynch HT, Minsky B, Nordlinger B, et al. Colorectal cancer. *Lancet*. 2010;375:1030–47.
2. Haggard FA, Boushey RP. Colorectal cancer epidemiology: incidence, mortality, survival, and risk factors. *Clin Colon Rectal Surg*. 2009;22:191–7.
3. Cappell MS. Pathophysiology, clinical presentation, and management of colon cancer. *Gastroenterol Clin North Am*. 2008;37:1–24. v.
4. Chang GJ, Kaiser AM, Mills S, Rafferty JF, Buie WD. Practice parameters for the management of colon cancer. *Dis Colon Rectum*. 2012;55:831–43.
5. Aarons CB, Mahmoud NN. Current surgical considerations for colorectal cancer. *Chin Clin Oncol*. 2013;2:14.
6. Engstrom PF, Arnoletti JP, Benson 3rd AB, Chen YJ, Choti MA, Cooper HS, et al. NCCN Clinical Practice Guidelines in Oncology: colon cancer. *J Natl Compr Canc Netw*. 2009;7:778–831.
7. Engstrom PF, Arnoletti JP, Benson 3rd AB, Chen YJ, Choti MA, Cooper HS, et al. NCCN Clinical Practice Guidelines in Oncology: rectal cancer. *J Natl Compr Canc Netw*. 2009;7:838–81.
8. Govindarajan R, Shah RV, Erkman LG, Hutchins LF. Racial differences in the outcome of patients with colorectal carcinoma. *Cancer*. 2003;97:493–8.
9. Tammana VS, Laiyemo AO. Colorectal cancer disparities: issues, controversies and solutions. *World J Gastroenterol*. 2014;20:869–76.
10. Winawer SJ, Stewart ET, Zauber AG, Bond JH, Ansel H, Waye JD, et al. A comparison of colonoscopy and double-contrast barium enema for surveillance after polypectomy. National Polyp Study Work Group. *N Engl J Med*. 2000;342:1766–72.
11. Lynch ML, Brand MI. Preoperative evaluation and oncologic principles of colon cancer surgery. *Clin Colon Rectal Surg*. 2005;18:163–73.
12. Moiel D, Thompson J. Early detection of colon cancer-the kaiser permanente northwest 30-year history: how do we measure success? Is it the test, the number of tests, the stage, or the percentage of screen-detected patients? *Perm J*. 2011;15:30–8.
13. Joseph DA, King JB, Miller JW, Richardson LC. Prevalence of colorectal cancer screening among adults—Behavioral Risk Factor Surveillance System, United States, 2010. *MMWR Morb Mortal Wkly Rep*. 2012;61(Suppl):51–6.
14. Fleshman JW, Wolff BG. *The ASCRS textbook of colon and rectal surgery*. New York: Springer; 2007.
15. Majumdar SR, Fletcher RH, Evans AT. How does colorectal cancer present? Symptoms, duration, and clues to location. *Am J Gastroenterol*. 1999;94:3039–45.
16. Amri R, Bordeianou LG, Sylla P, Berger DL. Impact of screening colonoscopy on outcomes in colon cancer surgery. *JAMA Surg*. 2013;148:747–54.
17. Mulder SA, Kranse R, Damhuis RA, de Wilt JH, Ouwendijk RJ, Kuipers EJ, et al. Prevalence and prognosis of synchronous colorectal cancer: a Dutch population-based study. *Cancer Epidemiol*. 2011;35:442–7.
18. Luigiano C, Ferrara F, Morace C, Mangiavillano B, Fabbri C, Cennamo V, et al. Endoscopic tattooing of gastrointestinal and pancreatic lesions. *Adv Ther*. 2012;29:864–73.
19. Dawson K, Wiebusch A, Thirlby RC. Preoperative tattooing and improved lymph node retrieval rates from colectomy specimens in patients with colorectal cancers. *Arch Surg*. 2010;145:826–30.
20. Bartels SA, van der Zaag ES, Dekker E, Buskens CJ, Bemelman WA. The effect of colonoscopic

tattooing on lymph node retrieval and sentinel lymph node mapping. *Gastrointest Endosc.* 2012;76:793–800.

21. Compton CC, Fielding LP, Burgart LJ, Conley B, Cooper HS, Hamilton SR, et al. Prognostic factors in colorectal cancer. College of American Pathologists Consensus Statement 1999. *Arch Pathol Lab Med.* 2000;124:979–94.

22. Au FC, Stein BS, Gennaro AR, Tyson RR. Tissue CEA in colorectal carcinoma. *Dis Colon Rectum.* 1984;27:16–8.

23. Fletcher RH. Carcinoembryonic antigen. *Ann Intern Med.* 1986;104:66–73.

24. McCall JL, Black RB, Rich CA, Harvey JR, Baker RA, Watts JM, et al. The value of serum carcinoembryonic antigen in predicting recurrent disease following curative resection of colorectal cancer. *Dis Colon Rectum.* 1994;37:875–81.

25. Wiratkapun S, Kraemer M, Seow-Choen F, Ho YH, Eu KW. High preoperative serum carcinoembryonic antigen predicts metastatic recurrence in potentially curative colonic cancer: results of a five-year study. *Dis Colon Rectum.* 2001;44:231–5.

26. Huh JW, Oh BR, Kim HR, Kim YJ. Preoperative carcinoembryonic antigen level as an independent prognostic factor in potentially curative colon cancer. *J Surg Oncol.* 2010;101:396–400.

27. Kirat HT, Ozturk E, Lavery IC, Kiran RP. The predictive value of preoperative carcinoembryonic antigen level in the prognosis of colon cancer. *Am J Surg.* 2012;204:447–52.

28. Locker GY, Hamilton S, Harris J, Jessup JM, Kemeny N, Macdonald JS, et al. ASCO 2006 update of recommendations for the use of tumor markers in gastrointestinal cancer. *J Clin Oncol.* 2006;24:5313–27.

29. Park IJ, Choi GS, Lim KH, Kang BM, Jun SH. Serum carcinoembryonic antigen monitoring after curative resection for colorectal cancer: clinical significance of the preoperative level. *Ann Surg Oncol.* 2009;16:3087–93.

30. Mauchley DC, Lynge DC, Langdale LA, Stelzner MG, Mock CN, Billingsley KG. Clinical utility and cost-effectiveness of routine preoperative computed tomography scanning in patients with colon cancer. *Am J Surg.* 2005;189:512–7. discussion 517.

31. Gollub MJ, Schwartz LH, Akhurst T. Update on colorectal cancer imaging. *Radiol Clin North Am.* 2007;45:85–118.

32. Sahani DV, Bajwa MA, Andrabi Y, Bajpai S, Cusack JC. Current status of imaging and emerging techniques to evaluate liver metastases from colorectal carcinoma. *Ann Surg.* 2014;259:861–72.

33. Furukawa H, Ikuma H, Seki A, Yokoe K, Yuen S, Aramaki T, et al. Positron emission tomography scanning is not superior to whole body multidetector helical computed tomography in the preoperative staging of colorectal cancer. *Gut.* 2006;55:1007–11.

34. Pelosi E, Deandreis D. The role of 18F-fluoro-deoxy-glucose positron emission tomography (FDG-PET) in the management of patients with colorectal cancer. *Eur J Surg Oncol.* 2007;33:1–6.

35. Whiteford MH, Whiteford HM, Yee LF, Ogunbiyi OA, Dehdashti F, Siegel BA, et al. Usefulness of FDG-PET scan in the assessment of suspected metastatic or recurrent adenocarcinoma of the colon and rectum. *Dis Colon Rectum.* 2000;43:759–67. discussion 767–70.

36. Edge SB, Byrd DR, Compton CC, Fritz AG, Greene FL, Trotti AIII. *AJCC cancer staging manual.* New York: Springer; 2010.

37. Flamen P, Hoekstra OS, Homans F, Van Cutsem E, Maes A, Stroobants S, et al. Unexplained rising carcinoembryonic antigen (CEA) in the postoperative surveillance of colorectal cancer: the utility of positron emission tomography (PET). *Eur J Cancer.* 2001;37:862–9.

38. Ruers TJ, Wiering B, van der Sijp JR, Roumen RM, de Jong KP, Comans EF, et al. Improved selection of patients for hepatic surgery of colorectal liver metastases with (18)F-FDG PET: a randomized study. *J Nucl Med*. 2009;50:1036–41.
39. Parsons DP. Preoperative evaluation and risk management. *Clin Colon Rectal Surg*. 2009;22:5–13.
40. Menke H, Klein A, John KD, Junginger T. Predictive value of ASA classification for the assessment of the perioperative risk. *Int Surg*. 1993;78:266–70.
41. Fleisher LA, Fleischmann KE, Auerbach AD, Barnason SA, Beckman JA, Bozkurt B, et al. 2014 ACC/AHA guideline on perioperative cardiovascular evaluation and management of patients undergoing noncardiac surgery: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. *Circulation*. 2014;130:e278–333.
42. Smetana GW, Lawrence VA, Cornell JE. Preoperative pulmonary risk stratification for noncardiothoracic surgery: systematic review for the American College of Physicians. *Ann Intern Med*. 2006;144:581–95.
43. Taylor A, DeBoard Z, Gauvin JM. Prevention of postoperative pulmonary complications. *Surg Clin North Am*. 2015;95(2):237–54.
44. Mills E, Eyawo O, Lockhart I, Kelly S, Wu P, Ebbert JO. Smoking cessation reduces postoperative complications: a systematic review and meta-analysis. *Am J Med*. 2011;124:144–54.
45. Gunderson LL, Jessup JM, Sargent DJ, Greene FL, Stewart AK. Revised TN categorization for colon cancer based on national survival outcomes data. *J Clin Oncol*. 2010;28:264–71.
46. Compton CC. Colorectal carcinoma: diagnostic, prognostic, and molecular features. *Mod Pathol*. 2003;16:376–88.
47. Fleming M, Ravula S, Tatishchev SF, Wang HL. Colorectal carcinoma: pathologic aspects. *J Gastrointest Oncol*. 2012;3:153–73.
48. Chang GJ, Rodriguez-Bigas MA, Skibber JM, Moyer VA. Lymph node evaluation and survival after curative resection of colon cancer: systematic review. *J Natl Cancer Inst*. 2007;99:433–41.
49. Ueno H, Hashiguchi Y, Shimazaki H, Shinto E, Kajiwarra Y, Nakanishi K, et al. Peritumoral deposits as an adverse prognostic indicator of colorectal cancer. *Am J Surg*. 2014;207:70–7.
50. Read TE, Fleshman JW, Caushaj PF. Sentinel lymph node mapping for adenocarcinoma of the colon does not improve staging accuracy. *Dis Colon Rectum*. 2005;48:80–5.
51. Broderick-Villa G, Ko A, O’Connell TX, Guenther JM, Danial T, DiFronzo LA. Does tumor burden limit the accuracy of lymphatic mapping and sentinel lymph node biopsy in colorectal cancer? *Cancer J*. 2002;8:445–50.
52. Joosten JJ, Strobbe LJ, Wauters CA, Pruszczyński M, Wobbes T, Ruers TJ. Intraoperative lymphatic mapping and the sentinel node concept in colorectal carcinoma. *Br J Surg*. 1999;86:482–6.
53. Nelson H, Petrelli N, Carlin A, Couture J, Fleshman J, Guillem J, et al. Guidelines 2000 for colon and rectal cancer surgery. *J Natl Cancer Inst*. 2001;93:583–96.
54. Aarons CB, Shanmugan S, Bleier JI. Management of malignant colon polyps: current status and controversies. *World J Gastroenterol*. 2014;20:16178–83.
55. Bujanda L. Malignant colorectal polyps. *World J Gastroenterol*. 2010;16:3103–11.
56. Hassan C, Zullo A, Risio M, Rossini FP, Morini S. Histologic risk factors and clinical outcome in colorectal malignant polyp: a pooled-data analysis. *Dis Colon Rectum*. 2005;48:1588–96.
57. Tominaga K, Nakanishi Y, Nimura S, Yoshimura K, Sakai Y, Shimoda T. Predictive



histopathologic factors for lymph node metastasis in patients with nonpedunculated submucosal invasive colorectal carcinoma. *Dis Colon Rectum*. 2005;48:92–100.

58. Coppede F, Lopomo A, Spisni R, Migliore L. Genetic and epigenetic biomarkers for diagnosis, prognosis and treatment of colorectal cancer. *World J Gastroenterol*. 2014;20:943–56.

59. Gausachs M, Mur P, Corral J, Pineda M, Gonzalez S, Benito L, et al. MLH1 promoter hypermethylation in the analytical algorithm of Lynch syndrome: a cost-effectiveness study. *Eur J Hum Genet*. 2012;20:762–8.

60. Kurzawski G, Suchy J, Debniak T, Kladny J, Lubinski J. Importance of microsatellite instability (MSI) in colorectal cancer: MSI as a diagnostic tool. *Ann Oncol*. 2004;15 Suppl 4:iv283–4.

61. Benatti P, Gafa R, Barana D, Marino M, Scarselli A, Pedroni M, et al. Microsatellite instability and colorectal cancer prognosis. *Clin Cancer Res*. 2005;11:8332–40.

62. Ribic CM, Sargent DJ, Moore MJ, Thibodeau SN, French AJ, Goldberg RM, et al. Tumor microsatellite-instability status as a predictor of benefit from fluorouracil-based adjuvant chemotherapy for colon cancer. *N Engl J Med*. 2003;349:247–57.

63. Lee TH, Marcantonio ER, Mangione CM, Thomas EJ, Polanczyk CA, Cook EF, et al. Derivation and prospective validation of a simple index for prediction of cardiac risk of major noncardiac surgery. *Circulation*. 1999;100:1043–9.

## 第 26 章

1. Teeuwen PH, Bremers AJ, Groenewoud JM, van Laarhoven CJ, Bleichrodt RP. Predictive value of POSSUM and ACPGBI scoring in mortality and morbidity of colorectal resection: a case-control study. *J Gastrointest Surg*. 2011;15(2):294–303.

2. Tekkis PP, Prytherch DR, Kocher HM, Senapati A, Poloniecki JD, Stamatakis JD, Windsor AC. Development of a dedicated risk-adjustment scoring system for colorectal surgery (colorectal POSSUM). *Br J Surg*. 2004;91(9):1174–82.

3. Oomen JL, Cuesta MA, Engel AF. Comparison of outcome of POSSUM, p-POSSUM, and cr-POSSUM scoring after elective resection of the sigmoid colon for carcinoma or complicated diverticular disease. *Scand J Gastroenterol*. 2007;42(7):841–7.

4. Leung E, Ferjani AM, Stellard N, Wong LS. Predicting post-operative mortality in patients undergoing colorectal surgery using P-POSSUM and CR-POSSUM scores: a prospective study. *Int J Colorectal Dis*. 2009;24(12):1459–64.

5. Ren L, Upadhyay AM, Wang L, Li L, Lu J, Fu W. Mortality rate prediction by Physiological and Operative Severity Score for the Enumeration of Mortality and Morbidity (POSSUM), Portsmouth POSSUM and Colorectal POSSUM and the development of new scoring systems in Chinese colorectal cancer patients. *Am J Surg*. 2009;198(1):31–8.

6. Hariharan S, Chen D, Ramkissoon A, Taklalsingh N, Bodkyn C, Cupidore R, Ramdin A, Ramsaroop A, Sinanan V, Teelucksingh S, Verma S. Perioperative outcome of colorectal cancer and validation of CR-POSSUM in a Caribbean country. *Int J Surg*. 2009;7(6):534–8.

7. Gomes A, Rocha R, Marinho R, Sousa M, Pignatelli N, Carneiro C, Nunes V. Colorectal surgical mortality and morbidity in elderly patients: comparison of POSSUM, P-POSSUM, CR-POSSUM, and CR-BHOM. *Int J Colorectal Dis*. 2015;30(2):173–9.

8. Cologne KG, Keller DS, Liwanag L, Devaraj B, Senagore AJ. Use of the American College of

Surgeons NSQIP surgical risk calculator for laparoscopic colectomy: how good is it and how can we improve it? *J Am Coll Surg*. 2015;220(3):281–6.

9. Kohut AY, Liu JJ, Stein DE, Sensenig R, Poggio JL. Patient-specific risk factors are predictive for postoperative adverse events in colorectal surgery: an American College of Surgeons National Surgical Quality Improvement Program-based analysis. *Am J Surg*. 2015;209(2):219–29.

10. Cohen ME, Bilimoria KY, Ko CY, Hall BL. Development of an American College of Surgeons National Surgery Quality Improvement Program: morbidity and mortality risk calculator for colorectal surgery. *J Am Coll Surg*. 2009;208(6):1009–16.

11. Vignati P, Welch JP, Cohen JL. Endoscopic localization of colon cancers. *Surg Endosc*. 1994;8(9):1085–7.

12. Cho YB, Lee WY, Yun HR, Lee WS, Yun SH, Chun HK. Tumor localization for laparoscopic colorectal surgery. *World J Surg*. 2007;31(7):1491–5.

13. Park SH, Lee JH, Lee SS, Kim JC, Yu CS, Kim HC, Ye BD, Kim MJ, Kim AY, Ha HK. CT colonography for detection and characterization of synchronous proximal colonic lesions in patients with stenosing colorectal cancer. *Gut*. 2012;61(12):1716–22.

14. Morrin MM, Farrell RJ, Raptopoulos V, McGee JB, Bleday R, Kruskal JB. Role of virtual computed tomographic colonography in patients with colorectal cancers and obstructing colorectal lesions. *Dis Colon Rectum*. 2000;43(3):303–11.

15. Kim JH, Kim WH, Kim TI, Kim NK, Lee KY, Kim MJ, Kim KW. Incomplete colonoscopy in patients with occlusive colorectal cancer: usefulness of CT colonography according to tumor location. *Yonsei Med J*. 2007;48(6):934–41.

16. McArthur DR, Mehrzad H, Patel R, Dadds J, Pallan A, Karandikar SS, Roy-Choudhury S. CT colonography for synchronous colorectal lesions in patients with colorectal cancer: initial experience. *Eur Radiol*. 2010;20(3):621–9.

17. Maras-Simunic M, Druzijanic N, Simunic M, Roglic J, Tomic S, Perko Z. Use of modified multidetector CT colonography for the evaluation of acute and subacute colon obstruction caused by colorectal cancer: a feasibility study. *Dis Colon Rectum*. 2009;52(3):489–95.

18. [Http://www.nccn.org/professionals/physician\\_gls/f\\_guidelines.asp#site](http://www.nccn.org/professionals/physician_gls/f_guidelines.asp#site)

19. Rørvig S, Schlesinger N, Mårtensson NL, Engel S, Engel U, Holck S. Is the longitudinal margin of carcinoma-bearing colon resections a neglected parameter? *Clin Colorectal Cancer*. 2014;13(1):68–72.

20. Read TE, Mutch MG, Chang BW, McNevin MS, Fleshman JW, Birnbaum EH, Fry RD, Caushaj PF, Kodner IJ. Locoregional recurrence and survival after curative resection of adenocarcinoma of the colon. *J Am Coll Surg*. 2002;195(1):33–40.

21. Matsuda K, Hotta T, Takifuji K, Yokoyama S, Oku Y, Watanabe T, Mitani Y, Ieda J, Mizumoto Y, Yamaue H. Randomized clinical trial of defaecatory function after anterior resection for rectal cancer with high versus low ligation of the inferior mesenteric artery. *Br J Surg*. 2015;102(5):501–8.

22. Kanemitsu Y, Hirai T, Komori K, Kato T. Survival benefit of high ligation of the inferior mesenteric artery in sigmoid colon or rectal cancer surgery. *Br J Surg*. 2006;93(5):609–15.

23. Chin CC, Yeh CY, Tang R, Changchien CR, Huang WS, Wang JY. The oncologic benefit of high ligation of the inferior mesenteric artery in the surgical treatment of rectal or sigmoid colon cancer. *Int J Colorectal Dis*. 2008;23(8):783–8.

24. Hohenberger W, Weber K, Matzel K, Papadopoulos T, Merkel S. Standardized surgery for

colonic cancer: complete mesocolic excision and central ligation—technical notes and outcome. *Colorectal Dis.* 2009;11(4):354–64.

25. Galizia G, Lieto E, De Vita F, Ferraraccio F, Zamboli A, Mabilia A, Auricchio A, Castellano P, Napolitano V, Orditura M. Is complete mesocolic excision with central vascular ligation safe and effective in the surgical treatment of right-sided colon cancers? A prospective study. *Int J Colorectal Dis.* 2014;29(1):89–97.

26. West NP, Kobayashi H, Takahashi K, Perrakis A, Weber K, Hohenberger W, Sugihara K, Quirke P. Understanding optimal colonic cancer surgery: comparison of Japanese D3 resection and European complete mesocolic excision with central vascular ligation. *J Clin Oncol.* 2012;30(15):1763–9.

27. Kwon S, Morris A, Billingham R, Frankhouse J, Horvath K, Johnson M, McNevin S, Simons A, Symons R, Steele S, Thirlby R, Whiteford M, Flum DR, Surgical Care and Outcomes Assessment Program (SCOAP) collaborative. Routine leak testing in colorectal surgery in the Surgical Care and Outcomes Assessment Program. *Arch Surg.* 2012;147(4):345–51.

28. Ricciardi R, Roberts PL, Marcello PW, Hall JF, Read TE, Schoetz DJ. Anastomotic leak testing after colorectal resection: what are the data? *Arch Surg.* 2009;144(5):407–11.

29. Li VK, Wexner SD, Pulido N, Wang H, Jin HY, Weiss EG, Nogebras JJ, Sands DR. Use of routine intraoperative endoscopy in elective laparoscopic colorectal surgery: can it further avoid anastomotic failure? *Surg Endosc.* 2009;23(11):2459–65.

30. Kamal T, Pai A, Velchuru V, Zawadzki M, Park J, Marecik S, Abcarian H, Prasad L. Should anastomotic assessment with flexible sigmoidoscopy be routine following laparoscopic restorative left colorectal resection? *Colorectal Dis.* 2015;17(2):160–4.

31. Weeks JC, Nelson H, Gelber S, Sargent D, Schroeder G, Clinical Outcomes of Surgical Therapy (COST) Study Group. Short-term quality-of-life outcomes following laparoscopic-assisted colectomy vs. open colectomy for colon cancer: a randomized trial. *JAMA.* 2002;287(3):321–8.

32. Clinical Outcomes of Surgical Therapy Study Group. A comparison of laparoscopically assisted and open colectomy for colon cancer. *N Engl J Med.* 2004;350(20):2050–9.

33. Fleshman J, Sargent DJ, Green E, Anvari M, Stryker SJ, Beart Jr RW, Hellinger M, Flanagan Jr R, Peters W, Nelson H, Clinical Outcomes of Surgical Therapy Study Group. Laparoscopic colectomy for cancer is not inferior to open surgery based on 5-year data from the COST Study Group trial. *Ann Surg.* 2007;246(4):655–62.

34. Stucky CC, Pockaj BA, Novotny PJ, Sloan JA, Sargent DJ, O'Connell MJ, Beart RW, Skibber JM, Nelson H, Weeks JC. Long-term follow-up and individual item analysis of quality of life assessments related to laparoscopic-assisted colectomy in the COST trial 93-46-53 (INT 0146). *Ann Surg Oncol.* 2011;18(9):2422–31.

35. Guillou PJ, Quirke P, Thorpe H, Walker J, Jayne DG, Smith AM, Heath RM, Brown JM, MRC CLASICC trial group. Short-term endpoints of conventional versus laparoscopic-assisted surgery in patients with colorectal cancer (MRC CLASICC trial): multicentre, randomised controlled trial. *Lancet.* 2005;365(9472):1718–26.

36. Franks PJ, Bosanquet N, Thorpe H, Brown JM, Copeland J, Smith AM, Quirke P, Guillou PJ, CLASICC trial participants. Short-term costs of conventional vs. laparoscopic assisted surgery in patients with colorectal cancer (MRC CLASICC trial). *Br J Cancer.* 2006;95(1):6–12.

37. Jayne DG, Guillou PJ, Thorpe H, Quirke P, Copeland J, Smith AM, Heath RM, Brown JM, UK MRC CLASICC Trial Group. Randomized trial of laparoscopic-assisted resection of colorectal

carcinoma: 3-year results of the UK MRC CLASICC Trial Group. *J Clin Oncol*. 2007;25(21):3061–8.

38. Green BL, Marshall HC, Collinson F, Quirke P, Guillou P, Jayne DG, Brown JM. Long-term follow-up of the Medical Research Council CLASICC trial of conventional versus laparoscopically assisted resection in colorectal cancer. *Br J Surg*. 2013;100(1):75–82.

39. Jayne DG, Thorpe HC, Copeland J, Quirke P, Brown JM, Guillou PJ. Five-year follow-up of the Medical Research Council CLASICC trial of laparoscopically assisted versus open surgery for colorectal cancer. *Br J Surg*. 2010;97(11):1638–45.

40. Hazebroek EJ, Color Study Group. COLOR: a randomized clinical trial comparing laparoscopic and open resection for colon cancer. *Surg Endosc*. 2002;16(6):949–53.

41. Veldkamp R, Kuhry E, Hop WC, Jeekel J, Kazemier G, Bonjer HJ, Haglind E, Pahlman L, Cuesta MA, Msika S, Morino M, Lacy AM, Colon cancer Laparoscopic or Open Resection Study Group (COLOR). Laparoscopic surgery versus open surgery for colon cancer: short-term outcomes of a randomised trial. *Lancet Oncol*. 2005;6(7):477–84.

42. Kuhry E, Bonjer HJ, Haglind E, Hop WC, Veldkamp R, Cuesta MA, Jeekel J, Pahlman L, Morino M, Lacy A, Delgado S, COLOR Study Group. Impact of hospital case volume on short-term outcome after laparoscopic operation for colonic cancer. *Surg Endosc*. 2005;19(5):687–92.

43. Colon Cancer Laparoscopic or Open Resection Study Group, Buunen M, Veldkamp R, Hop WC, Kuhry E, Jeekel J, Haglind E, Pahlman L, Cuesta MA, Msika S, Morino M, Lacy A, Bonjer HJ. Survival after laparoscopic surgery versus open surgery for colon cancer: long-term outcome of a randomised clinical trial. *Lancet Oncol*. 2009;10(1):44–52.

44. Yamamoto S, Inomata M, Katayama H, Mizusawa J, Etoh T, Konishi F, Sugihara K, Watanabe M, Moriya Y, Kitano S, Japan Clinical Oncology Group Colorectal Cancer Study Group. Short-term surgical outcomes from a randomized controlled trial to evaluate laparoscopic and open D3 dissection for stage II/III colon cancer: Japan Clinical Oncology Group Study JCOG 0404. *Ann Surg*. 2014;260(1):23–30.

45. Bagshaw PF, Allardyce RA, Frampton CM, Frizelle FA, Hewett PJ, McMurrick PJ, Rieger NA, Smith JS, Solomon MJ, Stevenson AR, Australasian Laparoscopic Colon Cancer Study Group. Long-term outcomes of the australasian randomized clinical trial comparing laparoscopic and conventional open surgical treatments for colon cancer: the Australasian Laparoscopic Colon Cancer Study trial. *Ann Surg*. 2012;256(6):915–9.

46. Cortet M, Grimault A, Cheynel N, Lepage C, Bouvier AM, Faivre J. Patterns of recurrence of obstructing colon cancers after surgery for cure: a population-based study. *Colorectal Dis*. 2013;15(9):1100–6.

47. Gianotti L, Tamini N, Nespoli L, Rota M, Bolzonaro E, Frego R, Redaelli A, Antolini L, Ardito A, Nespoli A, Dinelli M. A prospective evaluation of short-term and long-term results from colonic stenting for palliation or as a bridge to elective operation versus immediate surgery for large-bowel obstruction. *Surg Endosc*. 2013;27(3):832–42.

48. Huang X, Lv B, Zhang S, Meng L. Preoperative colonic stents versus emergency surgery for acute left-sided malignant colonic obstruction: a meta-analysis. *J Gastrointest Surg*. 2014;18(3):584–91.

49. Van Hooft JE, Bemelman WA, Oldenburg B, Marinelli AW, Lutke Holzik MF, Grubben MJ, Sprangers MA, Dijkgraaf MG, Fockens P, Collaborative Dutch Stent-In study group. Colonic stenting versus emergency surgery for acute left-sided malignant colonic obstruction: a multicentre

randomised trial. *Lancet Oncol.* 2011;12(4):344–52.

50. Dastur JK, Forshaw MJ, Modarai B, Solkar MM, Raymond T, Parker MC. Comparison of short- and long-term outcomes following either insertion of self-expanding metallic stents or emergency surgery in malignant large bowel obstruction. *Tech Coloproctol.* 2008;12(1):51–5.

51. Kim JS, Hur H, Min BS, Sohn SK, Cho CH, Kim NK. Oncologic outcomes of self-expanding metallic stent insertion as a bridge to surgery in the management of left-sided colon cancer obstruction: comparison with nonobstructing elective surgery. *World J Surg.* 2009;33(6):1281–6.

52. Cirocchi R, Farinella E, Trastulli S, Desiderio J, Listorti C, Boselli C, Parisi A, Noya G, Sagar J. Safety and efficacy of endoscopic colonic stenting as a bridge to surgery in the management of intestinal obstruction due to left colon and rectal cancer: a systematic review and meta-analysis. *Surg Oncol.* 2013;22(1):14–21.

53. Sagar J. Colorectal stents for the management of malignant colonic obstructions. *Cochrane Database Syst Rev.* 2011;11, CD007378.

54. Knight AL, Trompetas V, Saunders MP, Anderson HJ. Does stenting of left-sided colorectal cancer as a “bridge to surgery” adversely affect oncological outcomes? A comparison with non-obstructing elective left-sided colonic resections. *Int J Colorectal Dis.* 2012;27(11):1509–14.

55. Trompetas V. Emergency management of malignant acute left-sided colonic obstruction. *Ann R Coll Surg Engl.* 2008;90(3):181–6.

56. Ansaloni L, Andersson RE, Bazzoli F, Catena F, Cennamo V, Di Saverio S, Fuccio L, Jeekel H, Leppäniemi A, Moore E, Pinna AD, Pisano M, Repici A, Sugarbaker PH, Tuech JJ. Guidelines in the management of obstructing cancer of the left colon: consensus conference of the world society of emergency surgery (WSES) and peritoneum and surgery (PnS) society. *World J Emerg Surg.* 2010;5:29.

57. Cheynel N, Cortet M, Lepage C, Ortega-Debalon P, Faivre J, Bouvier AM. Incidence, patterns of failure, and prognosis of perforated colorectal cancers in a well-defined population. *Dis Colon Rectum.* 2009;52(3):406–11.

58. Zielinski MD, Merchea A, Heller SF, You YN. Emergency management of perforated colon cancers: how aggressive should we be? *J Gastrointest Surg.* 2011;15(12):2232–8.

59. Muratore A, Zorzi D, Bouzari H, Amisano M, Massucco P, Sperti E, Capussotti L. Asymptomatic colorectal cancer with un-resectable liver metastases: immediate colorectal resection or up-front systemic chemotherapy? *Ann Surg Oncol.* 2007;14(2):766–70.

60. Scheer MG, Sloots CE, van der Wilt GJ, Ruers TJ. Management of patients with asymptomatic colorectal cancer and synchronous irresectable metastases. *Ann Oncol.* 2008;19(11):1829–35.

61. Lam VW, Spiro C, Laurence JM, Johnston E, Hollands MJ, Pleass HC, Richardson AJ. A systematic review of clinical response and survival outcomes of downsizing systemic chemotherapy and rescue liver surgery in patients with initially unresectable colorectal liver metastases. *Ann Surg Oncol.* 2012;19(4):1292–301.

62. <http://seer.cancer.gov/statfacts/html/colorect.html>

63. Kuebler JP, Wieand HS, O’Connell MJ, Smith RE, Colangelo LH, Yothers G, Petrelli NJ, Findlay MP, Seay TE, Atkins JN, Zapas JL, Goodwin JW, Fehrenbacher L, Ramanathan RK, Conley BA, Flynn PJ, Soori G, Colman LK, Levine EA, Lanier KS, Wolmark N. Oxaliplatin combined with weekly bolus fluorouracil and leucovorin as surgical adjuvant chemotherapy for stage II and III colon cancer: results from NSABP C-07. *J Clin Oncol.* 2007;25(16):2198–204.

64. André T, Boni C, Mounedji-Boudiaf L, Navarro M, Tabernero J, Hickish T, Topham C, Zaninelli

M, Clingan P, Bridgewater J, Tabah-Fisch I, de Gramont A, Multicenter International Study of Oxaliplatin/5-Fluorouracil/Leucovorin in the Adjuvant Treatment of Colon Cancer (MOSAIC) Investigators. Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer. *N Engl J Med*. 2004;350(23):2343–51.

## 第 27 章

1. Mason A. President's address. Rectal cancer: the spectrum of selective surgery. *Proc R Soc Med*. 1976;69(4):237–44.
2. Nicholls RJ, York-Mason A, Morson BC, Dixon AK, Fry IK. The clinical staging of rectal cancer. *Br J Surg*. 1982;69:404–9.
3. Sinha R, Verma R, Rajesh A, Richards CJ. Diagnostic value of multidetector row CT in rectal cancer staging: comparison of multiplanar and axial images with histopathology. *Clin Radiol*. 2006;61(11):924–31.
4. Kumar A, Scholefield JH. Endosonography of the anal canal and rectum. *World J Surg*. 2000;24:208–15.
5. Hildebrandt U, Feifel G. Preoperative staging of rectal cancer by intrarectal ultrasound. *Dis Colon Rectum*. 1985;28:42–6.
6. Marone P, Bellis M, D'Angelo V, et al. Role of endoscopic ultrasonography in the loco-regional staging of patients with rectal cancer. *World J Gastrointest Endosc*. 2015;7:688–701.
7. Puli S, Bechtold M, Reddy J, Choudhary A, Antillon M, Brugge W. How good is endoscopic ultrasound in differentiating various T stages of rectal cancer? Meta-analysis and systematic review. *Ann Surg Oncol*. 2009;16:254–65.
8. Marusch F, Ptak H, Sahm M, Schmidt U, Ridwelski K, Gastinger I, Lippert H. Endorectal ultrasound in rectal carcinoma—do the literature results really correspond to the realities of routine clinical care? *Endoscopy*. 2011;43:425–31.
9. Puli SR, Bechtold ML, Reddy JB, Choudhary A, Antillon MR. Can endoscopic ultrasound predict early rectal cancers that can be resected endoscopically? A meta-analysis and systematic review. *Dig Dis Sci*. 2010;55:1221–9.
10. Solomon MJ, McLeod RS, Cohen EK, Simons ME, Wilson S. Reliability and validity studies of endoluminal ultrasonography for anorectal disorders. *Dis Colon Rectum*. 1994;37:546–51.
11. Anderson BO, Hann LE, Enker WE, Dershaw DD, Guillem JG, Cohen AM. Transrectal ultrasonography and operative selection for early carcinoma of the rectum. *J Am Coll Surg*. 1994;179:513–7.
12. Mackay SG, Pager CK, Joseph D, Stewart PJ, Solomon MJ. Assessment of the accuracy of transrectal ultrasonography in anorectal neoplasia. *Br J Surg*. 2003;90:346–50.
13. Kneist W, Terzic A, Burghardt J, Heintz A, Junginger T. Selection of patients with rectal tumors for local excision based on preoperative diagnosis. Results of a consecutive evaluation study of 552 patients. *Chirurg*. 2004;75:168–75.
14. Hildebrandt U, Klein T, Feifel G, Schwarz H, Koch B, Schimtt R. Endosonography of pararectal lymph nodes: in vitro and in vivo evaluation. *Dis Colon Rectum*. 1990;33:863–8.
15. Katsura Y, Yamada K, Ishizawa T, Yoshinaka H, Shimazu H. Endorectal ultrasonography for the assessment of wall invasion and lymph node metastasis in rectal cancer. *Dis Colon Rectum*.

1992;35:362–8.

16. Akasu T, Sugihara K, Moriya Y, Fujita S. Limitations and pitfalls of transrectal ultrasonography for staging of rectal cancer. *Dis Colon Rectum*. 1997;40:S10–5.
17. Puli SR, Reddy JB, Bechtold ML, Choudhary A, Antillon MR, Brugge WR. Accuracy of endoscopic ultrasound to diagnose nodal invasion by rectal cancers: a meta-analysis and systematic review. *Ann Surg Oncol*. 2009;16:1255–65.
18. Landmann RG, Wong WD, Hoepfl J, Shia J, Guillem JG, Temple LK, Paty PB, Weiser MR. Limitations of early rectal cancer nodal staging may explain failure after local excision. *Dis Colon Rectum*. 2007;50:1520–5.
19. Kim NK, Kim MJ, Yun SH, Sohn SK, Min JS. Comparative study of transrectal ultrasonography, pelvic computerized tomography, and magnetic resonance imaging in preoperative staging of rectal cancer. *Dis Colon Rectum*. 1999;42:770–5.
20. Scialpi M, Rotondo A, Angelelli G. Water enema transvaginal ultrasound for local staging of stenotic rectal carcinoma. *Abdom Imaging*. 1999;24:132–6.
21. Garcia-Aguilar J, Pollack J, Lee SH, et al. Accuracy of endorectal ultrasonography in preoperative staging of rectal tumors. *Dis Colon Rectum*. 2002;45:10–5.
22. Marusch F, Koch A, Schmidt U, et al. Routine use of transrectal ultrasound in rectal carcinoma: results of a prospective multicenter study. *Endoscopy*. 2002;34:385–90.
23. Nougaret S, Reinhold C, Mikhael HW, Rouanet P, Bibeau F, Brown G. The use of MR imaging in treatment planning for patients with rectal carcinoma: have you checked the “DISTANCE”? *Radiology*. 2013;268:330–44.
24. Beets-Tan RG, Lambregts DM, Maas M, Bipat S, Barbaro B, Caseiro-Alves F, et al. Magnetic resonance imaging for the clinical management of rectal cancer patients: recommendations from the 2012 European Society of Gastrointestinal and Abdominal Radiology (ESGAR) consensus meeting. *Eur Radiol*. 2013;23:2522–31.
25. Arya S, Das D, Engineer R, Saklani A. Imaging in rectal cancer with emphasis on local staging with MRI. *Indian J Radiol Imaging*. 2015;25:148–61.
26. Al-Sukhni E, Milot L, Fruitman M, Beyene J, Victor J, Schmocker S, Brown G, McLeod R, Kennedy E. Diagnostic accuracy of MRI for assessment of T category, lymph node metastases, and circumferential resection margin involvement in patients with rectal cancer: a systematic review and meta-analysis. *Ann Surg Oncol*. 2012;19:2212–23.
27. Park J, Jang Y, Choi G, Park S, Kim H, Kang H, Cho S. Accuracy of preoperative MRI in predicting pathology stage in rectal cancers: node-for-node matched histopathology validation of MRI features. *Dis Colon Rectum*. 2014;57:32–8.
28. Skandarajah A, Tjandra J. Preoperative loco-regional imaging in rectal cancer. *ANZ J Surg*. 2006;76:497–504.
29. Dewhurst C, Rosen M, Blake M, Baker M, Cash B, Fidler J, Greene F, Hindman N, Jones B, Katz D, Lalani T, Miller F, Small W, Sudakoff G, Tulchinsky M, Yaghmai V, Yee J. ACR appropriateness criteria retreatment staging of colorectal cancer. *J Am Coll Radiol*. 2012;9:775–81.
30. Raman S, Chen Y, Fishman E. Evolution of imaging in rectal cancer: multimodality imaging with MDCT, MRI, and PET. *J Gastrointest Oncol*. 2015;6:172–84.
31. Whiteford MH, Whiteford HM, Yee LF, Ogunbiyi OA, Dehdashti F, Siegel BA, Birnbaum EH, Fleshman JW, Kodner IJ, Read TE. Usefulness of FDG-PET scan in the assessment of suspected metastatic or recurrent adenocarcinoma of the colon and rectum. *Dis Colon Rectum*. 2000;53:759–

70.

32. Llamas-Elvira JM, Rodríguez-Fernández A, Gutiérrez-Sáinz J, et al. Fluorine-18 fluorodeoxyglucose PET in the preoperative staging of colorectal cancer. *Eur J Nucl Med Mol Imaging*. 2007;34:859–67.
33. Berger-Kulemann V, Schima W, Baroud S, Koelblinger C, Kaczirek K, Gruenberger T, Schindl M, Maresch J, Weber M, Ba-Ssalamah A. Gadoteric acid-enhanced 3.0 T MR imaging versus multidetector-row CT in the detection of colorectal metastases in fatty liver using intraoperative ultrasound and histopathology as a standard of reference. *Eur J Surg Oncol*. 2012;38:670–6.
34. Jones E, Chezmar J, Nelson R, Bernardino M. The frequency and significance of small (less than or equal to 15 mm) hepatic lesions detected by CT. *AJR Am J Roentgenol*. 1992;158:535–9.
35. Kirke R, Rajesh A, Verma R, Bankart M. Rectal cancer: incidence of pulmonary metastases on thoracic CT and correlation with T staging. *J Comput Assist Tomogr*. 2007;31:569–71.
36. Gearhart SL, Frassica D, Rosen R, Choti M, Schulick R, Wahl R. Improved staging with pretreatment positron emission tomography/computed tomography in low rectal cancer. *Ann Surg Oncol*. 2006;13:397–404.
37. Guillem JG, Ruby JA, Leibold T, Akhurst TJ, Yeung HW, Gollub MJ, Ginsberg MS, Shia J, Suriawinata AA, Riedel ER, Mazumdar M, Saltz LB, Minsky BD, Nash GM, Paty PB, Temple LK, Weiser MR, Larson SM. Neither FDG-PET Nor CT can distinguish between a pathological complete response and an incomplete response after neoadjuvant chemoradiation in locally advanced rectal cancer: a prospective study. *Ann Surg*. 2013;258(2):289–95.
38. Benson 3rd AB, Venook AP, Bekaii-Saab T, Chan E, Chen YJ, Cooper HS, Engstrom PF, Enzinger PC, Fenton MJ, Fuchs CS, Grem JL, Grothey A, Hochster HS, Hunt S, Kamel A, Kirilcuk N, Leong LA, Lin E, Messersmith WA, Mulcahy MF, Murphy JD, Nurkin S, Rohren E, Ryan DP, Saltz L, Sharma S, Shibata D, Skibber JM, Sofocleous CT, Stoffel EM, Stotsky-Himelfarb E, Willett CG, Gregory KM, Freedman-Cass D. NCCN guidelines for rectal cancer, version 2.2015. *J Natl Compr Canc Netw*. 2015;13(6):719–28.

## 第 28 章

1. De Campos-Lobato LF, Stocchi L, da Luz Moreira A, et al. Pathologic complete response after neoadjuvant treatment for rectal cancer decreases distant recurrence and could eradicate local recurrence. *Ann Surg Oncol*. 2011;18:1590–8.
2. Maas M, Nelemans PJ, Valentini V, et al. Long-term outcome in patients with a pathological complete response after chemoradiation for rectal cancer: a pooled analysis of individual patient data. *Lancet Oncol*. 2010;11:835–44.
3. Martin ST, Heneghan HM, Winter DC. Systematic review and meta-analysis of outcomes following pathological complete response to neoadjuvant chemoradiotherapy for rectal cancer. *Br J Surg*. 2012;99:918–28.
4. Janeway HH. Treatment of cancer, particularly of the tongue, tonsil and rectum, by buried emanation. Read at the Third Annual Meeting of the American Radium Society. 1919 June 5; Atlantic City, NJ.
5. Binkley GE. Radiation in the treatment of cancer of the rectum. *Ann Surg*. 1929;90(6):1000–14.
6. Prolongation of the disease-free interval in surgically treated rectal carcinoma. *Gastrointestinal*



Tumor Study Group. *N Engl J Med*. 1985;312:1465–72.

7. Improved survival with preoperative radiotherapy in resectable rectal cancer. Swedish Rectal Cancer Trial. *N Engl J Med*. 1997;336(14):980–7. Erratum in: *N Engl J Med*. 1997;336(21):1539.

8. Gerard A, Buyse M, Nodingler B, et al. Preoperative radiotherapy as adjuvant treatment in rectal cancer. Final results of a randomized study of the European Organization for Research and Treatment of Cancer (EORTC). *Ann Surg*. 1988;208(5):606–14.

9. Adjuvant therapy for patients with colon and rectum cancer. Consensus Statement. 1990;8(4):1–25.

10. Bujko K, Nowacki MP, Nasierowska-Guttmejer A, et al. Long-term results of a randomized trial comparing preoperative short-course radiotherapy with preoperative conventionally fractionated chemoradiation for rectal cancer. *Br J Surg*. 2006;93:1215–23.

11. Ngan SY, Burmeister B, Fisher RJ, et al. Randomized trial of short-course radiotherapy versus long-course chemoradiation comparing rates of local recurrence in patients with T3 rectal cancer: Trans-Tasman Radiation Oncology Group trial 01.04. *J Clin Oncol*. 2012;30:3827–33.

12. Heald RJ, Ryall RD. Recurrence and survival after total mesorectal excision for rectal cancer. *Lancet*. 1986;1:1479–82.

13. Kapiteijn E, Marijnen CA, Nagtegaal ID, et al. Preoperative radiotherapy combined with total mesorectal excision for resectable rectal cancer. *N Engl J Med*. 2001;345:638–46.

14. Colorectal Cancer Collaborative Group. Adjuvant radiotherapy for rectal cancer: a systematic overview of 8,507 patients from 22 randomised trials. *Lancet*. 2001;358:1291–304.

15. Balslev I, Pedersen M, Teglbjaerg PS, Hanberg-Soerensen F, Bone J, Jacobsen NO, Overgaard J, Sell A, Bertelsen K, Hage E, et al. Postoperative radiotherapy in Dukes' B and C carcinoma of the rectum and rectosigmoid. A randomized multicenter study. *Cancer*. 1986;58(1):22–8.

16. Randomised trial of surgery alone versus surgery followed by radiotherapy for mobile cancer of the rectum. Medical Research Council Rectal Cancer Working Party. *Lancet*. 1996;348(9042):1610–4.

17. Wolmark N, Wieand HS, Hyams DM, Colangelo L, Dimitrov NV, Romond EH, Wexler M, Prager D, Cruz Jr AB, Gordon PH, Petrelli NJ, Deutsch M, Mamounas E, Wickerham DL, Fisher ER, Rockette H, Fisher B. Randomized trial of postoperative adjuvant chemotherapy with or without radiotherapy for carcinoma of the rectum: National Surgical Adjuvant Breast and Bowel Project Protocol R-02. *J Natl Cancer Inst*. 2000;92(5):388–96.

18. Cammà C, Giunta M, Fiorica F, et al. Preoperative radiotherapy for resectable rectal cancer: a meta-analysis. *JAMA*. 2000;284:1008–15.

19. Van Gijn W, Marijnen CA, Nagtegaal ID, Kranenbarg EM, Putter H, Wiggers T, Rutten HJ, Pålman L, Glimelius B, van de Velde CJ, Dutch Colorectal Cancer Group. Preoperative radiotherapy combined with total mesorectal excision for resectable rectal cancer: 12-year follow-up of the multicentre, randomised controlled TME trial. *Lancet Oncol*. 2011;12(6):575–82.

20. Byfield JE. 5-Fluorouracil radiation sensitization—a brief review. *Invest New Drugs*. 1989;7:111–6.

21. O'Connell MJ, Martenson JA, Wieand HS, et al. Improving adjuvant therapy for rectal cancer by combining protracted-infusion fluorouracil with radiation therapy after curative surgery. *N Engl J Med*. 1994;331:502–7.

22. Smalley SR, Benedetti JK, Williamson SK, et al. Phase III trial of fluorouracil-based chemotherapy regimens plus radiotherapy in postoperative adjuvant rectal cancer: GI INT 0144. *J Clin Oncol*. 2006;24:3542–7.

23. Bosset J-F, Calais G, Mineur L, et al. Enhanced tumoricidal effect of chemotherapy with preoperative radiotherapy for rectal cancer: preliminary results—EORTC 22921. *J Clin Oncol.* 2005;23:5620–7.
24. Gerard JP, Conroy T, Bonnetain F, et al. Preoperative radiotherapy with or without concurrent fluorouracil and leucovorin in T3-4 rectal cancers: results of FFCD 9203. *J Clin Oncol.* 2006;24:4620–5.
25. Hofheinz R-D, Wenz F, Post S, et al. Chemoradiotherapy with capecitabine versus fluorouracil for locally advanced rectal cancer: a randomised, multicentre, non-inferiority, phase 3 trial. *Lancet Oncol.* 2012;13:579–88.
26. O’Connell MJ, Colangelo LH, Beart RW, Petrelli NJ, Allegra CJ, Sharif S, Pitot HC, Shields AF, Landry JC, Ryan DP, Parda DS, Mohiuddin M, Arora A, Evans LS, Bahary N, Soori GS, Eakle J, Robertson JM, Moore Jr DF, Mullane MR, Marchello BT, Ward PJ, Wozniak TF, Roh MS, Yothers G, Wolmark N. Capecitabine and oxaliplatin in the preoperative multimodality treatment of rectal cancer: surgical end points from National Surgical Adjuvant Breast and Bowel Project trial R-04. *J Clin Oncol.* 2014;32(18):1927–34.
27. Aschele C, Cionini L, Lonardi S, et al. Primary tumor response to preoperative chemoradiation with or without oxaliplatin in locally advanced rectal cancer: pathologic results of the STAR-01 randomized phase III trial. *J Clin Oncol.* 2011;29:2773–80.
28. Gérard J-P, Azria D, Gourgou-Bourgade S, et al. Comparison of two neoadjuvant chemoradiotherapy regimens for locally advanced rectal cancer: results of the phase III trial ACCORD 12/0405-Prodige 2. *J Clin Oncol.* 2010;28:1638–44.
29. Rödel C, Liersch T, Becker H, et al. Preoperative chemoradiotherapy and postoperative chemotherapy with fluorouracil and oxaliplatin versus fluorouracil alone in locally advanced rectal cancer: initial results of the German CAO/ARO/AIO-04 randomised phase 3 trial. *Lancet Oncol.* 2012;13:679–87.
30. Navarro M, Dotor E, Rivera F, et al. A phase II study of preoperative radiotherapy and concomitant weekly irinotecan in combination with protracted venous infusion 5-fluorouracil, for resectable locally advanced rectal cancer. *Int J Radiat Oncol Biol Phys.* 2006;66(1):201–5.
31. Willeke F, Horisberger K, Kraus-Tiefenbacher U, et al. A phase II study of capecitabine and irinotecan in combination with concurrent pelvic radiotherapy (CapIri-RT) as neoadjuvant treatment of locally advanced rectal cancer. *Br J Cancer.* 2007;96(6):912–7.
32. Velenik V, Ocvirk J, Oblak I, et al. A phase II study of cetuximab, capecitabine and radiotherapy in neoadjuvant treatment of patients with locally advanced resectable rectal cancer. *Eur J Surg Oncol.* 2010;36(3):244–50. doi: 10.1016/j.ejso.2009.12.002.
33. Horisberger K, Treschl A, Mai S, et al. Cetuximab in combination with capecitabine, irinotecan, and radiotherapy for patients with locally advanced rectal cancer: results of a Phase II MARGIT trial. *Int J Radiat Oncol Biol Phys.* 2009;74(5):1487–93. doi: 10.1016/j.ijrobp.2008.10.014.
34. Dewdney A, Cunningham D, Tabernero J, et al. Multicenter randomized phase II clinical trial comparing neoadjuvant oxaliplatin, capecitabine, and preoperative radiotherapy with or without cetuximab followed by total mesorectal excision in patients with high-risk rectal cancer (EXPERT-C). *J Clin Oncol.* 2012;30(14):1620–7. doi: 10.1200/JCO.2011.39.6036.
35. Pahlman L, Glimelius B. Pre- or postoperative radiation in rectal and rectosigmoid carcinoma. *Ann Surg.* 1990;21:187–94.
36. Roh MS, Colangelo LH, O’Connell MJ, Yothers G, Deutsch M, Allegra CJ, Kahlenberg MS,

- Baez-Diaz L, Ursiny CS, Petrelli NJ, Wolmark N. Preoperative multimodality therapy improves disease-free survival in patients with carcinoma of the rectum: NSABP R-03. *J Clin Oncol*. 2009;27(31):5124–30.
37. Sauer R, Becker H, Hohenberger W, et al. Preoperative versus postoperative chemoradiotherapy for rectal cancer. *N Engl J Med*. 2004;351:1731–40.
38. Tan D, Glynne-Jones R. But some neoadjuvant schedules are more equal than others. *J Clin Oncol*. 2013;31:1799–800.
39. Bujko K. Short-course preoperative radiotherapy for low rectal cancer. *J Clin Oncol*. 2013;31:1799.
40. Peeters KC, van de Velde CJ, Leer JW, et al. Late side effects of short-course preoperative radiotherapy combined with total mesorectal excision for rectal cancer: increased bowel dysfunction in irradiated patients—a Dutch colorectal cancer group study. *J Clin Oncol*. 2005;23:6199–206.
41. Benson AB, Bekaii-Saab T, Chan E, et al. Rectal cancer [Internet]. *J Natl Compr Canc Netw*. 2012;10:1528–64. <http://www.ncbi.nlm.nih.gov/pubmed/23221790>. Accessed 25 Oct 2014.
42. Petersen SH, Harling H, Kirkeby LT, et al. Postoperative adjuvant chemotherapy in rectal cancer operated for cure. *Cochrane database Syst Rev*. 2012;3, CD004078. <http://www.ncbi.nlm.nih.gov/pubmed/22419291>. Accessed 6 Nov 2014.
43. Bosset JF, Calais G, Mineur L, Maingon P, Stojanovic-Rundic S, Bensadoun RJ, Bardet E, Beny A, Ollier JC, Bolla M, Marchal D, Van Laethem JL, Klein V, Giralt J, Clavère P, Glanzmann C, Cellier P, Collette L, EORTC Radiation Oncology Group. Fluorouracil-based adjuvant chemotherapy after preoperative chemoradiotherapy in rectal cancer: long-term results of the EORTC 22921 randomised study. *Lancet Oncol*. 2014;15(2):184–90.
44. Hayden DM, Pinzon MC, Francescatti AB, et al. Hospital readmission for fluid and electrolyte abnormalities following ileostomy construction: preventable or unpredictable? *J Gastrointest Surg*. 2013;17:298–303. <http://www.ncbi.nlm.nih.gov/pubmed/23192425>. Accessed 10 Sep 2014.
45. Khrizman P, Niland JC, ter Veer A, et al. Postoperative adjuvant chemotherapy use in patients with stage II/III rectal cancer treated with Neoadjuvant therapy, LARC: a national comprehensive cancer network analysis. *J Clin Oncol*. 2013;31:30–8. <http://www.ncbi.nlm.nih.gov/pubmed/23169502>. Accessed 21 Oct 2014.
46. Biagi JJ, Raphael MJ, Mackillop W, et al. Association between time to initiation of adjuvant chemotherapy and survival in colorectal cancer: a systematic review and meta-analysis. *JAMA*. 2011;305:2335–42. <http://www.ncbi.nlm.nih.gov/pubmed/21642686>. Accessed 25 Oct 2014.
47. Breugom AJ, Swets M, Bosset JF, et al. Adjuvant chemotherapy after preoperative (chemo)radiotherapy and surgery for patients with rectal cancer: a systematic review and meta-analysis of individual patient data. *Lancet Oncol*. 2015;16:200–7.
48. Glynne-Jones R, Counsell N, Quirke P, et al. Chronicle: results of a randomised phase III trial in locally advanced rectal cancer after neoadjuvant chemoradiation randomising postoperative adjuvant capecitabine plus oxaliplatin (XELOX) versus control. *Ann Oncol*. 2014;25:1356–62.
49. Calvo FA, Serrano FJ, Diaz-González JA, et al. Improved incidence of pT0 downstaged surgical specimens in locally advanced rectal cancer (LARC) treated with induction oxaliplatin plus 5-fluorouracil and preoperative chemoradiation. *Ann Oncol*. 2006;17:1103–10. <http://www.ncbi.nlm.nih.gov/pubmed/16670204>. Accessed 22 Sep 2014.
50. Chau I, Brown G, Cunningham D, et al. Neoadjuvant capecitabine and oxaliplatin followed by synchronous chemoradiation and total mesorectal excision in magnetic resonance imaging-defined

- poor-risk rectal cancer. *J Clin Oncol.* 2006;24:668–74. <http://www.ncbi.nlm.nih.gov/pubmed/16446339>. Accessed 22 Sep 2014.
51. Fernández-Martos C, Pericay C, Aparicio J, et al. Phase II, randomized study of concomitant chemoradiotherapy followed by surgery and adjuvant capecitabine plus oxaliplatin (CAPOX) compared with induction CAPOX followed by concomitant chemoradiotherapy and surgery in magnetic resonance imaging-defined, I. *J Clin Oncol.* 2010;28:859–65. <http://www.ncbi.nlm.nih.gov/pubmed/20065174>. Accessed 22 Sep 2014.
52. Maréchal R, Vos B, Polus M, et al. Short course chemotherapy followed by concomitant chemoradiotherapy and surgery in locally advanced rectal cancer: a randomized multicentric phase II study. *Ann Oncol.* 2012;23:1525–30. <http://www.ncbi.nlm.nih.gov/pubmed/22039087>. Accessed 6 Oct 2014.
53. Schou JV, Larsen FO, Rasch L, et al. Induction chemotherapy with capecitabine and oxaliplatin followed by chemoradiotherapy before total mesorectal excision in patients with locally advanced rectal cancer. *Ann Oncol.* 2012;23:2627–33. <http://www.ncbi.nlm.nih.gov/pubmed/22473488>. Accessed 4 Sep 2014.
54. Glynne-Jones R, Grainger J, Harrison M, et al. Neoadjuvant chemotherapy prior to preoperative chemoradiation or radiation in rectal cancer: should we be more cautious? *Br J Cancer.* 2006;94:363–71. <http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=2361136&tool=pmcentrez&rendertype=abstract>. Accessed 21 Oct 2014.
55. Cercek A, Goodman KA, Hajj C, et al. Neoadjuvant chemotherapy first, followed by chemoradiation and then surgery, in the management of locally advanced rectal cancer. *J Natl Compr Canc Netw.* 2014;12(4):513–9.
56. Garcia-Aguilar J, Chow OS, Smith DD, et al. Effect of adding mFOLFOX6 after neoadjuvant chemoradiation in locally advanced rectal cancer: a multicentre, phase 2 trial. *Lancet Oncol.* 2015;16(8):957–66. doi: 10.1016/S1470-2045(15)00004-2.
57. Glynne-Jones R, Harrison M, Hughes R. Challenges in the neoadjuvant treatment of rectal cancer: balancing the risk of recurrence and quality of life. *Cancer Radiother.* 2013;17:675–85. <http://www.ncbi.nlm.nih.gov/pubmed/24183502>. Accessed 5 Sep 2014.
58. Glimelius B, Tiret E, Cervantes A, et al. Rectal cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. *Ann Oncol.* 2013;24:vi81–8.
59. Smith N, Brown G. Preoperative staging of rectal cancer. *Acta Oncol.* 2008;47:20–31.
60. Chang GJ, Park IJ, Eng C, et al. Exploratory analysis of adjuvant chemotherapy benefits after preoperative chemoradiotherapy and radical resection for rectal cancer. *ASCO Meet Abstr.* 2012;30:3556. [http://hwmaint.meeting.ascopubs.org.proxy.library.vanderbilt.edu/cgi/content/abstract/30/15\\_suppl/3556](http://hwmaint.meeting.ascopubs.org.proxy.library.vanderbilt.edu/cgi/content/abstract/30/15_suppl/3556). Accessed 7 Nov 2014.
61. Fietkau R, Barten M, Klautke G, et al. Postoperative chemotherapy may not be necessary for patients with ypN0-category after neoadjuvant chemoradiotherapy of rectal cancer. *Dis Colon Rectum.* 2006;49:1284–92. <http://www.ncbi.nlm.nih.gov/pubmed/16758130>. Accessed 7 Nov 2014.
62. Nelson VM, Benson AB. Pathological complete response after neoadjuvant therapy for rectal cancer and the role of adjuvant therapy. *Curr Oncol Rep.* 2013;15:152–61. <http://www.ncbi.nlm.nih.gov/pubmed/23381584>. Accessed 19 Nov 2014.
63. Maas M, Nelemans PJ, Valentini V, et al. Adjuvant chemotherapy in rectal cancer: defining

subgroups who may benefit after neoadjuvant chemoradiation and resection: a pooled analysis of 3,313 patients. *Int J Cancer*. 2015;137(1):212–20. doi: 10.1002/ijc.29355.

64. Hong YS, Nam B-H, Kim K-P, et al. Oxaliplatin, fluorouracil, and leucovorin versus fluorouracil and leucovorin as adjuvant chemotherapy for locally advanced rectal cancer after preoperative chemoradiotherapy (ADORE): an open-label, multicentre, phase 2, randomised controlled trial. *Lancet Oncol*. 2014;15:1245–53. <http://www.ncbi.nlm.nih.gov/pubmed/25201358>. Accessed 12 Sep 2014.

65. Taylor FG, Quirke P, Heald RJ, et al. Preoperative high-resolution magnetic resonance imaging can identify good prognosis stage I, II, and III rectal cancer best managed by surgery alone: a prospective, multicenter, European study. *Ann Surg*. 2011;253:711–9. <http://www.ncbi.nlm.nih.gov/pubmed/21475011>. Accessed 27 Oct 2014.

66. Birgisson H, Pahlman L, Gunnarsson U, et al. Adverse effects of preoperative radiation therapy for rectal cancer: long-term follow-up of the Swedish Rectal Cancer Trial. *J Clin Oncol*. 2005;23:8697–705. <http://www.ncbi.nlm.nih.gov/pubmed/16314629>. Accessed 27 Oct 2014.

67. Joye I, Haustermans K. Early and late toxicity of radiotherapy for rectal cancer. *Recent Results Cancer Res*. 2014;203:189–201. <http://www.ncbi.nlm.nih.gov/pubmed/25103006>. Accessed 7 Nov 2014.

68. Gunderson LL, Sargent DJ, Tepper JE, et al. Impact of T and N stage and treatment on survival and relapse in adjuvant rectal cancer: a pooled analysis. *J Clin Oncol*. 2004;22:1785–96. <http://www.ncbi.nlm.nih.gov/pubmed/15067027>. Accessed 13 Oct 2014.

69. Schrag D. Evolving role of neoadjuvant therapy in rectal cancer. *Curr Treat Options Oncol*. 2013;14:350–64. <http://www.ncbi.nlm.nih.gov/pubmed/23828092>. Accessed 13 Oct 2014.

70. Schrag D, Weiser MR, Goodman KA, et al. Neoadjuvant chemotherapy without routine use of radiation therapy for patients with locally advanced rectal cancer: a pilot trial. *J Clin Oncol*. 2014;32:513–8. <http://www.ncbi.nlm.nih.gov/pubmed/24419115>. Accessed 4 Sep 2014.

71. Alliance for clinical trials in oncology: PROSPECT Trial. <http://clinicaltrials.gov/sho/NCT01515787>

72. Fernandez-Martos C, Safont M, Feliu J, et al. Induction chemotherapy with or without chemoradiation in intermediate-risk rectal cancer patients defined by magnetic resonance imaging (MRI): a GEMCAD study. *J Clin Oncol (Meeting Abstracts)*. 2010;28:15. Suppl TPS 196.

73. Bevacizumab And Combination Chemotherapy in Rectal Cancer Until Surgery (BACCHUS). [www.clinicaltrials.gov](http://www.clinicaltrials.gov). Accessed 9 Sep 2015.

74. Francois Y, Nemoz CJ, Baulieux J, et al. Influence of the interval between preoperative radiation therapy and surgery on downstaging and on the rate of sphincter-sparing surgery for rectal cancer: the Lyon R90-01 randomized trial. *J Clin Oncol*. 1999;17:2396. <http://www.ncbi.nlm.nih.gov/pubmed/10561302>. Accessed 9 Nov 2014.

75. Park IJ, You YN, Agarwal A, et al. Neoadjuvant treatment response as an early response indicator for patients with rectal cancer. *J Clin Oncol*. 2012;30:1770–6. <http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=3383178&tool=pmcentrez&rendertype=abstract>. Accessed 6 Nov 2014.

76. Zorcolo L, Rosman AS, Restivo A, et al. Complete pathologic response after combined modality treatment for rectal cancer and long-term survival: a meta-analysis. *Ann Surg Oncol*. 2012;19(9):2822–32. doi: 10.1245/s10434-011-2209-y.

77. Guillem JG, Chessin DB, Shia J, et al. Clinical examination following preoperative

- chemoradiation for rectal cancer is not a reliable surrogate end point. *J Clin Oncol.* 2005;23:3475–9. <http://www.ncbi.nlm.nih.gov/pubmed/15908656>. Accessed 23 Sep 2014.
78. Pastor C, Subtil JC, Sola J, et al. Accuracy of endoscopic ultrasound to assess tumor response after neoadjuvant treatment in rectal cancer: can we trust the findings? *Dis Colon Rectum.* 2011;54:1141–6. <http://www.ncbi.nlm.nih.gov/pubmed/21825895>. Accessed 3 Nov 2014.
79. Guillem JG, Ruby JA, Leibold T, et al. Neither FDG-PET nor CT can distinguish between a pathological complete response and an incomplete response after neoadjuvant chemoradiation in locally advanced rectal cancer: a prospective study. *Ann Surg.* 2013;258:289–95. <http://www.ncbi.nlm.nih.gov/pubmed/23187748>. Accessed 4 Nov 2014.
80. Habr-Gama A, Perez RO, Nadalin W, et al. Operative versus nonoperative treatment for stage 0 distal rectal cancer following chemoradiation therapy: long-term results. *Ann Surg.* 2004;240:711–7. <http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=1356472&tool=pmcentrez&rendertype=abstract>. Accessed 22 Sep 2014.
81. Habr-Gama A, Perez RO, Proscurshim I, et al. Patterns of failure and survival for nonoperative treatment of stage c0 distal rectal cancer following neoadjuvant chemoradiation therapy. *J Gastrointest Surg.* 2006;10:1319–28. <http://www.ncbi.nlm.nih.gov/pubmed/17175450>. Accessed 4 Nov 2014.
82. Habr-Gama A, Gama-Rodrigues J, São Julião GP, et al. Local recurrence after complete clinical response and watch and wait in rectal cancer after neoadjuvant chemoradiation: impact of salvage therapy on local disease control. *Int J Radiat Oncol Biol Phys.* 2014;88:822–8. <http://www.ncbi.nlm.nih.gov/pubmed/24495589>. Accessed 2 Nov 2014.
83. Maas M, Beets-Tan RG, Lambregts DM, et al. Wait-and-see policy for clinical complete responders after chemoradiation for rectal cancer. *J Clin Oncol.* 2011;29:4633–40. <http://www.ncbi.nlm.nih.gov/pubmed/22067400>. Accessed 19 Sep 2014.
84. Smith JD, Ruby JA, Goodman KA, et al. Nonoperative management of rectal cancer with complete clinical response after neoadjuvant therapy. *Ann Surg.* 2012;256:965–72. <http://www.ncbi.nlm.nih.gov/pubmed/23154394>. Accessed 18 Sep 2014.
85. Vejle Hospital. Watchful waiting. An observational study of patients with rectal cancer after concomitant radiation and chemotherapy. <http://clinicaltrials.gov/show/NCT00952926>.
86. Maria Skłodowska-Curie Memorial Cancer Center I of O: organ preservation in elderly patients with rectal cancer. <http://clinicaltrials.gov/show/NCT01863862>.
87. Paulo I do C do E de S. Observation versus surgical resection in patients with rectal cancer who achieved complete clinical response after neoadjuvant chemoradiotherapy. <http://clinicaltrials.gov/show/NCT02052921>
88. Hospital RM. Timing and deferral of rectal surgery following a continued response to pre-operative chemoradiotherapy. <http://public.ukcrn.org.uk/search/StudyDetail.aspx>
89. Garcia Aguilar J and collaborators. Trial evaluating 3-year DFS in patients with locally advanced rectal cancer treated with chemoradiation plus induction or consolidation chemotherapy and TME or NOM. 2014. <http://clinicaltrials.gov/show/NCT02008656>.
90. Dalton RS, Velineni R, Osborne ME, Thomas R, Harries S, Gee AS, Daniels IR. A single-centre experience of chemoradiotherapy for rectal cancer: is there potential for nonoperative management? *Colorectal Dis.* 2012;14(5):567–71.

## 第 29 章

1. Corman ML. Jacques Lisfranc 1790–1847. *Dis Colon Rectum*. 1983;26(10):694–5.
2. Parks AG. A technique for excising extensive villous papillomatous change in the lower rectum. *Proc R Soc Med*. 1968;61(5):441–2.
3. Buess G, Hutterer F, Theiss J, Böbel M, Isselhard W, Pichlmaier H. A system for a transanal endoscopic rectum operation. *Chirurg*. 1984;55(10):677–80.
4. Atallah S, Albert M, Larach S. Transanal minimally invasive surgery: a giant leap forward. *Surg Endosc*. 2010;24(9):2200–5.
5. Albert MR, Atallah SB, deBeche-Adams TC, Izfar S, Larach SW. Transanal minimally invasive surgery (TAMIS) for local excision of benign neoplasms and early-stage rectal cancer: efficacy and outcomes in the first 50 patients. *Dis Colon Rectum*. 2013;56(3):301–7.
6. Salehomoum NM, Nogueras JJ. Conventional transanal excision: current status and role in the era of transanal endoscopic surgery. *Sem Colon Rectal Surg*. 2015;26(1):9–14.
7. Buess G, Whiteford MH, Swantsrom LL. Transanal endoscopic microsurgery procedure for low rectal tumors. In: Asbun HJ, Young-Fadok TM, editors. *American College of Surgeons Multimedia Atlas of Surgery*. Woodbury: Ciné-Med Inc.; 2008.
8. Lezoche E, Guerrieri M, Paganini AM, D'Ambrosio G, Baldarelli M, Lezoche G, Feliciotti F, De Sanctis A. Transanal endoscopic versus total mesorectal laparoscopic resections of T2-N0 low rectal cancers after neoadjuvant treatment: a prospective randomized trial with a 3-years minimum follow-up period. *Surg Endosc*. 2005;19(6):751–6.
9. Gavagan JA, Whiteford MH, Swanstrom LL. Full-thickness intraperitoneal excision by transanal endoscopic microsurgery does not increase short-term complications. *Am J Surg*. 2004;187(5):630–4.
10. Morino M, Allaix ME, Famiglietti F, Caldart M, Arezzo A. Does peritoneal perforation affect short- and long-term outcomes after transanal endoscopic microsurgery? *Surg Endosc*. 2013;27(1):181–8.
11. Hahnloser D, Cantero R, Salgado G, Dindo D, Rega D, Delrio P. Transanal minimal invasive surgery for rectal lesions: should the defect be closed? *Colorectal Dis*. 2015;17(5):397–402.
12. Cataldo PA. Local excision of rectal cancer. In: Beck DE et al., editors. *The ASCRS textbook of colon and rectal surgery*. 2nd ed. New York: Springer; 2011.
13. Middleton PF, Sutherland LM, Maddern GJ. Transanal endoscopic microsurgery: a systematic review. *Dis Colon Rectum*. 2005;48(2):270–84.
14. Moore JS, Cataldo PA, Osler T, Hyman NH. Transanal endoscopic microsurgery is more effective than traditional transanal excision for resection of rectal masses. *Dis Colon Rectum*. 2008;51(7):1026–30. discussion 1030–1.
15. De Graaf EJ, Burger JW, van Ijsseldijk AL, Tetteroo GW, Dawson I, Hop WC. Transanal endoscopic microsurgery is superior to transanal excision of rectal adenomas. *Colorectal Dis*. 2011;13(7):762–7.
16. Clancy C, Burke JP, Albert MR, O'Connell PR, Winter DC. Transanal endoscopic microsurgery versus standard transanal excision for the removal of rectal neoplasms: a systematic review and meta-analysis. *Dis Colon Rectum*. 2015;58(2):254–61.
17. Barendse RM, van den Broek FJ, Dekker E, Bemelman WA, de Graaf EJ, Fockens P, Reitsma

JB. Systematic review of endoscopic mucosal resection versus transanal endoscopic microsurgery for large rectal adenomas. *Endoscopy*. 2011;43(11):941–9.

18. Arezzo A, Passera R, Saito Y, Sakamoto T, Kobayashi N, Sakamoto N, Yoshida N, Naito Y, Fujishiro M, Niimi K, Ohya T, Ohata K, Okamura S, Iizuka S, Takeuchi Y, Uedo N, Fusaroli P, Bonino MA, Verra M, Morino M. Systematic review and meta-analysis of endoscopic submucosal dissection versus transanal endoscopic microsurgery for large noninvasive rectal lesions. *Surg Endosc*. 2014;28(2):427–38.

19. Swellengrebel HA, Marijnen CA, Verwaal VJ, Vincent A, Heuff G, Gerhards MF, van Geloven AA, van Tets WF, Verheij M, Cats A. Toxicity and complications of preoperative chemoradiotherapy for locally advanced rectal cancer. *Br J Surg*. 2011;98(3):418–26.

20. Van der Pas MH, Haglind E, Cuesta MA, Fürst A, Lacy AM, Hop WC, Bonjer HJ, COLOrectal cancer Laparoscopic or Open Resection II (COLOR II) Study Group. Laparoscopic versus open surgery for rectal cancer (COLOR II): short-term outcomes of a randomised, phase 3 trial. *Lancet Oncol*. 2013;14(3):210–8.

21. Paun BC, Cassie S, MacLean AR, Dixon E, Buie WD. Postoperative complications following surgery for rectal cancer. *Ann Surg*. 2010;251(5):807–18.

22. Chang HC, Huang SC, Chen JS, Tang R, Changchien CR, Chiang JM, Yeh CY, Hsieh PS, Tsai WS, Hung HY, You JF. Risk factors for lymph node metastasis in pT1 and pT2 rectal cancer: a single-institute experience in 943 patients and literature review. *Ann Surg Oncol*. 2012;19(8):2477–84.

23. Rasheed S, Bowley DM, Aziz O, Tekkis PP, Sadat AE, Guenther T, Boello ML, McDonald PJ, Talbot IC, Northover JM. Can depth of tumour invasion predict lymph node positivity in patients undergoing resection for early rectal cancer? A comparative study between T1 and T2 cancers. *Colorectal Dis*. 2008;10(3):231–8.

24. Kobayashi H, Mochizuki H, Kato T, Mori T, Kameoka S, Shirouzu K, Saito Y, Watanabe M, Morita T, Hida J, Ueno M, Ono M, Yasuno M, Sugihara K. Is total mesorectal excision always necessary for T1-T2 lower rectal cancer? *Ann Surg Oncol*. 2010;17(4):973–80.

25. Salinas HM, Dursun A, Klos CL, Shellito P, Sylla P, Berger D, Bordeianou L. Determining the need for radical surgery in patients with T1 rectal cancer. *Arch Surg*. 2011;146(5):540–4.

26. Kikuchi R, Takano M, Takagi K, Fujimoto N, Nozaki R, Fujiyoshi T, Uchida Y. Management of early invasive colorectal cancer. Risk of recurrence and clinical guidelines. *Dis Colon Rectum*. 1995;38(12):1286–95.

27. Okuyama T, Oya M, Ishikawa H. Budding as a risk factor for lymph node metastasis in pT1 or pT2 well-differentiated colorectal adenocarcinoma. *Dis Colon Rectum*. 2002;45(5):628–34.

28. Bach SP, Hill J, Monson JR, Simson JN, Lane L, Merrie A, Warren B, Mortensen NJ, Association of Coloproctology of Great Britain and Ireland Transanal Endoscopic Microsurgery (TEM) Collaboration. A predictive model for local recurrence after transanal endoscopic microsurgery for rectal cancer. *Br J Surg*. 2009;96(3):280–90.

29. Nascimbeni R, Burgart LJ, Nivatvongs S, Larson DR. Risk of lymph node metastasis in T1 carcinoma of the colon and rectum. *Dis Colon Rectum*. 2002;45(2):200–6.

30. Masaki T, Sugiyama M, Atomi Y, Matsuoka H, Abe N, Watanabe T, Nagawa H, Muto T. The indication of local excision for T2 rectal carcinomas. *Am J Surg*. 2001;181(2):133–7.

31. Bosch SL, Teerenstra S, de Wilt JH, Cunningham C, Nagtegaal ID. Predicting lymph node metastasis in pT1 colorectal cancer: a systematic review of risk factors providing rationale for



therapy decisions. *Endoscopy*. 2013;45(10):827–34.

32. Glasgow SC, Bleier JI, Burgart LJ, Finne CO, Lowry AC. Meta-analysis of histopathological features of primary colorectal cancers that predict lymph node metastases. *J Gastrointest Surg*. 2012;16(5):1019–28.

33. Wang HS, Liang WY, Lin TC, Chen WS, Jiang JK, Yang SH, Chang SC, Lin JK. Curative resection of T1 colorectal carcinoma: risk of lymph node metastasis and long-term prognosis. *Dis Colon Rectum*. 2005;48(6):1182–92.

34. Benson III AB, Venook AP, Bekaii-Saab T, Chan E, Chen YJ, Cooper HS, Engstrom PF, Enzinger PC, Fenton MJ, Fuchs CS, Grem JL, Grothey A, Hochster HS, Hunt S, Kamel A, Kirilcuk N, Leong LA, Lin E, Messersmith WA, Mulcahy MF, Murphy JD, Nurkin S, Rohren E, Ryan DP, Saltz L, Sharma S, Shibata D, Skibber JM, Sofocleous CT, Stoffel EM, Stotsky-Himelfarb E, Willett CG, Gregory KM, Freedman-Cass D. Rectal cancer, version 2.2015. *J Natl Compr Canc Netw*. 2015;13(6):719–28.

35. Beets-Tan RG, Lambregts DM, Maas M, Bipat S, Barbaro B, Caseiro-Alves F, Curvo-Semedo L, Fenlon HM, Gollub MJ, Gourtsoyianni S, Halligan S, Hoeffel C, Kim SH, Laghi A, Maier A, Rafaelsen SR, Stoker J, Taylor SA, Torkzad MR, Blomqvist L. Magnetic resonance imaging for the clinical management of rectal cancer patients: recommendations from the 2012 European Society of Gastrointestinal and Abdominal Radiology (ESGAR) consensus meeting. *Eur Radiol*. 2013;23(9):2522–31.

36. Van de Velde CJ, Boelens PG, Tanis PJ, Espin E, Mroczkowski P, Naredi P, Pahlman L, Ortiz H, Rutten HJ, Breugom AJ, Smith JJ, Wibe A, Wiggers T, Valentini V. Experts reviews of the multidisciplinary consensus conference colon and rectal cancer 2012: science, opinions and experiences from the experts of surgery. *Eur J Surg Oncol*. 2014;40(4):454–68.

37. Lambregts DM, Beets GL, Maas M, Kessels AG, Bakers FC, Cappendijk VC, Engelen SM, Lahaye MJ, de Bruïne AP, Lammering G, Leiner T, Verwoerd JL, Wildberger JE, Beets-Tan RG. Accuracy of gadofosveset-enhanced MRI for nodal staging and restaging in rectal cancer. *Ann Surg*. 2011;253(3):539–45.

38. Steele Jr GD, Herndon JE, Bleday R, Russell A, Benson III A, Hussain M, Burgess A, Tepper JE, Mayer RJ. Sphincter-sparing treatment for distal rectal adenocarcinoma. *Ann Surg Oncol*. 1999;6(5):433–41.

39. Mellgren A, Sirivongs P, Rothenberger DA, Madoff RD, García-Aguilar J. Is local excision adequate therapy for early rectal cancer? *Dis Colon Rectum*. 2000;43:1064–71. discussion 1071–4.

40. Paty PB, Nash GM, Baron P, Zakowski M, Minsky BD, Blumberg D, Nathanson DR, Guillem JG, Enker WE, Cohen AM, Wong WD. Long-term results of local excision for rectal cancer. *Ann Surg*. 2002;236(4):522–9. discussion 529–30.

41. Nascimbeni R, Nivatvongs S, Larson DR, Burgart LJ. Long-term survival after local excision for T1 carcinoma of the rectum. *Dis Colon Rectum*. 2004;47:1773–9.

42. Madbouly KM, Remzi FH, Erkek BA, Senagore AJ, Baeslach CM, Khandwala F, Fazio VW, Lavery IC. Recurrence after transanal excision of T1 rectal cancer: should we be concerned? *Dis Colon Rectum*. 2005;48(4):711–9. discussion 719–21.

43. You YN, Baxter NN, Stewart A, Nelson H. Is the increasing rate of local excision for stage I rectal cancer in the United States justified? A nationwide cohort study from the National Cancer Database. *Ann Surg*. 2007;245(5):726–33.

44. Kidane B, Chadi SA, Kanters S, Colquhoun PH, Ott MC. Local resection compared with radical

resection in the treatment of T1N0M0 rectal adenocarcinoma: a systematic review and meta-analysis. *Dis Colon Rectum*. 2015;58(1):122–40.

45. Hahnloser D, Wolff BG, Larson DW, Ping J, Nivatvongs S. Immediate radical resection after local excision of rectal cancer: an oncologic compromise? *Dis Colon Rectum*. 2005;48(3):429–37.

46. Read TE, Andujar JE, Caushaj PF, Johnston DR, Dietz DW, Myerson RJ, Fleshman JW, Birnbaum EH, Mutch MG, Kodner IJ. Neoadjuvant therapy for rectal cancer: histologic response of the primary tumor predicts nodal status. *Dis Colon Rectum*. 2004;47(6):825–31.

47. Rullier E, Denost Q. Transanal surgery for cT2T3 rectal cancer: patient selection, adjuvant therapy, and outcomes. *Sem Colon Rectal Surg*. 2015;26(1):26–31.

48. Rullier E, Vendrely V. Can mesorectal lymph node excision be avoided in rectal cancer surgery? *Colorectal Dis*. 2011;13 Suppl 7:37–42.

49. Garcia-Aguilar J, Shi Q, Thomas Jr CR, Chan E, Cataldo P, Marcet J, Medich D, Pigazzi A, Oommen S, Posner MC. A phase II trial of neoadjuvant chemoradiation and local excision for T2N0 rectal cancer: preliminary results of the ACOSOG Z6041 trial. *Ann Surg Oncol*. 2012;19(2):384–91.

50. Garcia-Aguilar J, Renfro LA, Chow OS, Shi Q, Carrero XW, Lynn PB, Thomas CR Jr, Chan E, Cataldo PA, Marcet JE, Medich DS, Johnson CS, Oommen SC, Wolff BG, Pigazzi A, McNevin SM, Pons RK, Bleday R. Organ preservation for clinical T2N0 distal rectal cancer using neoadjuvant chemoradiotherapy and local excision (ACOSOG Z6041): results of an open-label, single-arm, multi-institutional, phase 2 trial. *Lancet Oncol*. 2015;16(15):1537–46.

51. Lezoche G, Baldarelli M, Guerrieri M, Paganini AM, De Sanctis A, Bartolacci S, Lezoche E. A prospective randomized study with a 5-year minimum follow-up evaluation of transanal endoscopic microsurgery versus laparoscopic total mesorectal excision after neoadjuvant therapy. *Surg Endosc*. 2008;22(2):352–8.

52. Chakravarti A, Compton CC, Shellito PC, Wood WC, Landry J, Machuta SR, Kaufman D, Ancukiewicz M, Willett CG. Long-term follow-up of patients with rectal cancer managed by local excision with and without adjuvant irradiation. *Ann Surg*. 1999;230(1):49–54.

53. Friel CM, Cromwell JW, Marra C, Madoff RD, Rothenberger DA, Garcia-Aguilar J. Salvage radical surgery after failed local excision for early rectal cancer. *Dis Colon Rectum*. 2002;45:875–9.

54. Weiser MR, Landmann RG, Wong WD, Shia J, Guillem JG, Temple LK, Minsky BD, Cohen AM, Paty PB. Surgical salvage of recurrent rectal cancer after transanal excision. *Dis Colon Rectum*. 2005;48(6):1169–75.

55. Greenberg JA, Shibata D, Herndon II JE, Steele Jr GD, Mayer R, Bleday R. Local excision of distal rectal cancer: an update of cancer and leukemia group B 8984. *Dis Colon Rectum*. 2008;51(8):1185–91.

56. Doornebosch PG, Ferenschild FT, de Wilt JH, Dawson I, Tetteroo GW, de Graaf EJ. Treatment of recurrence after transanal endoscopic microsurgery (TEM) for T1 rectal cancer. *Dis Colon Rectum*. 2010;53(9):1234–9.

57. De Graaf EJ, Doornebosch PG, Tetteroo GW, Geldof H, Hop WC. Transanal endoscopic microsurgery is feasible for adenomas throughout the entire rectum: a prospective study. *Dis Colon Rectum*. 2009;52(6):1107–13.

58. Kumar AS, Coralic J, Kelleher DC, Sidani S, Kolli K, Smith LE. Complications of transanal endoscopic microsurgery are rare and minor: a single institution's analysis and comparison to

existing data. *Dis Colon Rectum*. 2013;56(3):295–300.

59. Ramwell A, Evans J, Bignell M, Mathias J, Simson J. The creation of a peritoneal defect in transanal endoscopic microsurgery does not increase complications. *Colorectal Dis*. 2009;11(9):964–6.

60. Cataldo PA, O'Brien S, Osler T. Transanal endoscopic microsurgery: a prospective evaluation of functional results. *Dis Colon Rectum*. 2005;48(7):1366–71.

61. Fenech DS, Takahashi T, Liu M, Spencer L, Swallow CJ, Cohen Z, Macrae HM, McLeod RS. Function and quality of life after transanal excision of rectal polyps and cancers. *Dis Colon Rectum*. 2007;50(5):598–603.

## 第 30 章

1. Monson JR, Weiser MR, Buie WD, Chang GJ, Rafferty JF, Buie WD, et al. Practice parameters for the management of rectal cancer (revised). *Dis Colon Rectum*. 2013;56(5):535–50.

2. Sauer R, Becker H, Hohenberger W, Rodel C, Wittekind C, Fietkau R, et al. Preoperative versus postoperative chemoradiotherapy for rectal cancer. *N Engl J Med*. 2004;351(17):1731–40.

3. Nedrebo BS, Soreide K, Eriksen MT, Dorum LM, Kvaloy JT, Soreide JA, et al. Survival effect of implementing national treatment strategies for curatively resected colonic and rectal cancer. *Br J Surg*. 2011;98(5):716–23.

4. Habr-Gama A, Perez RO, Nadalin W, Sabbaga J, Ribeiro Jr U, Silva e Sousa Jr AH, et al. Operative versus nonoperative treatment for stage 0 distal rectal cancer following chemoradiation therapy: long-term results. *Ann Surg*. 2004;240(4):711–7. discussion 7-8.

5. Heald RJ, Ryall RD. Recurrence and survival after total mesorectal excision for rectal cancer. *Lancet*. 1986;1(8496):1479–82.

6. Kapiteijn E, Marijnen CA, Nagtegaal ID, Putter H, Steup WH, Wiggers T, et al. Preoperative radiotherapy combined with total mesorectal excision for resectable rectal cancer. *N Engl J Med*. 2001;345(9):638–46.

7. Van Gijn W, Marijnen CA, Nagtegaal ID, Kranenbarg EM, Putter H, Wiggers T, et al. Preoperative radiotherapy combined with total mesorectal excision for resectable rectal cancer: 12-year follow-up of the multicentre, randomised controlled TME trial. *Lancet Oncol*. 2011;12(6):575–82.

8. Bosset JF, Collette L, Calais G, Mineur L, Maingon P, Radosevic-Jelic L, et al. Chemotherapy with preoperative radiotherapy in rectal cancer. *N Engl J Med*. 2006;355(11):1114–23.

9. Gerard JP, Conroy T, Bonnetain F, Bouche O, Chapet O, Closon-Dejardin MT, et al. Preoperative radiotherapy with or without concurrent fluorouracil and leucovorin in T3-4 rectal cancers: results of FFCD 9203. *J Clin Oncol*. 2006;24(28):4620–5.

10. Rodel C, Martus P, Papadopoulos T, Fuzesi L, Klimpfinger M, Fietkau R, et al. Prognostic significance of tumor regression after preoperative chemoradiotherapy for rectal cancer. *J Clin Oncol*. 2005;23(34):8688–96.

11. Crane CH, Skibber JM, Feig BW, Vauthey JN, Thames HD, Curley SA, et al. Response to preoperative chemoradiation increases the use of sphincter-preserving surgery in patients with locally advanced low rectal carcinoma. *Cancer*. 2003;97(2):517–24.

12. Bujko K, Rutkowski A, Chang GJ, Michalski W, Chmielik E, Kusnierz J. Is the 1-cm rule of distal bowel resection margin in rectal cancer based on clinical evidence? A systematic review. *Ann*

Surg Oncol. 2012;19(3):801–8.

13. Silberfein EJ, Kattepogu KM, Hu CY, Skibber JM, Rodriguez-Bigas MA, Feig B, et al. Long-term survival and recurrence outcomes following surgery for distal rectal cancer. *Ann Surg Oncol.* 2010;17(11):2863–9.

14. Ngan SY, Burmeister B, Fisher RJ, Solomon M, Goldstein D, Joseph D, et al. Randomized trial of short-course radiotherapy versus long-course chemoradiation comparing rates of local recurrence in patients with T3 rectal cancer: Trans-Tasman Radiation Oncology Group trial 01.04. *J Clin Oncol.* 2012;30(31):3827–33.

15. Pettersson D, Lorinc E, Holm T, Iversen H, Cedermark B, Glimelius B, et al. Tumour regression in the randomized Stockholm III Trial of radiotherapy regimens for rectal cancer. *Br J Surg.* 2015;102(8):972–8. discussion 8.

16. Bujko K, Nowacki MP, Nasierowska-Guttmejer A, Michalski W, Bebenek M, Kryj M. Long-term results of a randomized trial comparing preoperative short-course radiotherapy with preoperative conventionally fractionated chemoradiation for rectal cancer. *Br J Surg.* 2006;93(10):1215–23.

17. Habr-Gama A, Gama-Rodrigues J, Sao Juliao GP, Proscurshim I, Sabbagh C, Lynn PB, et al. Local recurrence after complete clinical response and watch and wait in rectal cancer after neoadjuvant chemoradiation: impact of salvage therapy on local disease control. *Int J Radiat Oncol Biol Phys.* 2014;88(4):822–8.

18. Maas M, Nelemans PJ, Valentini V, Das P, Rodel C, Kuo LJ, et al. Long-term outcome in patients with a pathological complete response after chemoradiation for rectal cancer: a pooled analysis of individual patient data. *Lancet Oncol.* 2010;11(9):835–44.

19. Agarwal A, Chang GJ, Hu CY, Taggart M, Rashid A, Park IJ, et al. Quantified pathologic response assessed as residual tumor burden is a predictor of recurrence-free survival in patients with rectal cancer who undergo resection after neoadjuvant chemoradiotherapy. *Cancer.* 2013;119:4231–41.

20. Martin ST, Heneghan HM, Winter DC. Systematic review and meta-analysis of outcomes following pathological complete response to neoadjuvant chemoradiotherapy for rectal cancer. *Br J Surg.* 2012;99(7):918–28.

21. Park IJ, You YN, Agarwal A, Skibber JM, Rodriguez-Bigas MA, Eng C, et al. Neoadjuvant treatment response as an early response indicator for patients with rectal cancer. *J Clin Oncol.* 2012;30(15):1770–6.

22. Mandard AM, Dalibard F, Mandard JC, Marnay J, Henry-Amar M, Petiot JF, et al. Pathologic assessment of tumor regression after preoperative chemoradiotherapy of esophageal carcinoma. Clinicopathologic correlations. *Cancer.* 1994;73(11):2680–6.

23. Dworak O, Keilholz L, Hoffmann A. Pathological features of rectal cancer after preoperative radiochemotherapy. *Int J Colorectal Dis.* 1997;12(1):19–23.

24. Ryan R, Gibbons D, Hyland JM, Treanor D, White A, Mulcahy HE, et al. Pathological response following long-course neoadjuvant chemoradiotherapy for locally advanced rectal cancer. *Histopathology.* 2005;47(2):141–6.

25. Washington MK, Berlin J, Branton P, Burgart LJ, Carter DK, Fitzgibbons PL, et al. Protocol for the examination of specimens from patients with primary carcinoma of the colon and rectum. *Arch Pathol Lab Med.* 2009;133(10):1539–51.

26. Miles WE. A method of performing abdomino-perineal excision for carcinoma of the rectum

- and of the terminal portion of the pelvic colon (1908). *Lancet*. 1908;2:1812–3.
27. Juul T, Ahlberg M, Biondo S, Emmertsen KJ, Espin E, Jimenez LM, et al. International validation of the low anterior resection syndrome score. *Ann Surg*. 2014;259(4):728–34.
28. Chen TY, Wiltink LM, Nout RA, Meershoek-Klein Kranenbarg E, Laurberg S, Marijnen CA, et al. Bowel function 14 years after preoperative short-course radiotherapy and total mesorectal excision for rectal cancer: report of a multicenter randomized trial. *Clin Colorectal Cancer*. 2015;14(2):106–14.
29. Lange MM, van de Velde CJ. Urinary and sexual dysfunction after rectal cancer treatment. *Nat Rev Urol*. 2011;8(1):51–7.
30. Hendren SK, O'Connor BI, Liu M, Asano T, Cohen Z, Swallow CJ, et al. Prevalence of male and female sexual dysfunction is high following surgery for rectal cancer. *Ann Surg*. 2005;242(2):212–23.
31. Dalton RS, Velineni R, Osborne ME, Thomas R, Harries S, Gee AS, et al. A single-centre experience of chemoradiotherapy for rectal cancer: is there potential for nonoperative management? *Colorectal Dis*. 2012;14(5):567–71.
32. Nakagawa WT, Rossi BM, de O Ferreira F, Ferrigno R, David Filho WJ, Nishimoto IN, et al. Chemoradiation instead of surgery to treat mid and low rectal tumors: is it safe? *Ann Surg Oncol*. 2002;9(6):568–73.
33. Smith JD, Ruby JA, Goodman KA, Saltz LB, Guillem JG, Weiser MR, et al. Nonoperative management of rectal cancer with complete clinical response after neoadjuvant therapy. *Ann Surg*. 2012;256(6):965–72.
34. Smith JJ, Chow OS, Eaton A, Widmar M, Nash GM, Temple L, et al. Organ preservation in rectal cancer patients with clinical complete response after neoadjuvant therapy. *Society of Surgical Oncology, 68th Cancer Symposium; March 25, 2015; Houston, 2015; p. 8.*
35. Glynne-Jones R, Hughes R. Critical appraisal of the ‘wait and see’ approach in rectal cancer for clinical complete responders after chemoradiation. *Br J Surg*. 2012;99(7):897–909.
36. Maas M, Beets-Tan RG, Lambregts DM, Lammering G, Nelemans PJ, Engelen SM, et al. Wait-and-see policy for clinical complete responders after chemoradiation for rectal cancer. *J Clin Oncol*. 2011;29(35):4633–40.
37. Smith RK, Fry RD, Mahmoud NN, Paulson EC. Surveillance after neoadjuvant therapy in advanced rectal cancer with complete clinical response can have comparable outcomes to total mesorectal excision. *Int J Colorectal Dis*. 2015;30(6):769–74.
38. Glynne-Jones R, Wallace M, Livingstone JJ, Meyrick-Thomas J. Complete clinical response after preoperative chemoradiation in rectal cancer: is a “wait and see” policy justified? *Dis Colon Rectum*. 2008;51(1):10–9. discussion 9-20.
39. Guillem JG, Chessin DB, Shia J, Moore HG, Mazumdar M, Bernard B, et al. Clinical examination following preoperative chemoradiation for rectal cancer is not a reliable surrogate end point. *J Clin Oncol*. 2005;23(15):3475–9.
40. Habr-Gama A, Perez RO, Wynn G, Marks J, Kessler H, Gama-Rodrigues J. Complete clinical response after neoadjuvant chemoradiation therapy for distal rectal cancer: characterization of clinical and endoscopic findings for standardization. *Dis Colon Rectum*. 2010;53(12):1692–8.
41. Smith FM, Wiland H, Mace A, Pai RK, Kalady MF. Clinical criteria underestimate complete pathological response in rectal cancer treated with neoadjuvant chemoradiotherapy. *Dis Colon Rectum*. 2014;57(3):311–5.

42. Garcia-Aguilar J, Shi Q, Thomas Jr CR, Chan E, Cataldo P, Marcet J, et al. A phase II trial of neoadjuvant chemoradiation and local excision for T2N0 rectal cancer: preliminary results of the ACOSOG Z6041 trial. *Ann Surg Oncol*. 2012;19(2):384–91.
43. Perez RO, Habr-Gama A, Pereira GV, Lynn PB, Alves PA, Proscurshim I, et al. Role of biopsies in patients with residual rectal cancer following neoadjuvant chemoradiation after downsizing: can they rule out persisting cancer? *Colorectal Dis*. 2012;14(6):714–20.
44. Park IJ, You YN, Skibber JM, Rodriguez-Bigas MA, Feig B, Nguyen S, et al. Comparative analysis of lymph node metastases in patients with ypT0-2 rectal cancers after neoadjuvant chemoradiotherapy. *Dis Colon Rectum*. 2013;56(2):135–41.
45. Pucciarelli S, Capirci C, Emanuele U, Toppan P, Friso ML, Pennelli GM, et al. Relationship between pathologic T-stage and nodal metastasis after preoperative chemoradiotherapy for locally advanced rectal cancer. *Ann Surg Oncol*. 2005;12(2):111–6.
46. Chang GJ, You YN, Park IJ, Kaur H, Hu CY, Rodriguez-Bigas MA, et al. Pretreatment high-resolution rectal MRI and treatment response to neoadjuvant chemoradiation. *Dis Colon Rectum*. 2012;55(4):371–7.
47. Marks JH, Valsdottir EB, DeNittis A, Yarandi SS, Newman DA, Nweze I, et al. Transanal endoscopic microsurgery for the treatment of rectal cancer: comparison of wound complication rates with and without neoadjuvant radiation therapy. *Surg Endosc*. 2009;23(5):1081–7.
48. Perez RO, Habr-Gama A, Sao Juliao GP, Proscurshim I, Scanavini Neto A, Gama-Rodrigues J. Transanal endoscopic microsurgery for residual rectal cancer after neoadjuvant chemoradiation therapy is associated with significant immediate pain and hospital readmission rates. *Dis Colon Rectum*. 2011;54(5):545–51.
49. Gornicki A, Richter P, Polkowski W, Szczepkowski M, Pietrzak L, Kepka L, et al. Anorectal and sexual functions after preoperative radiotherapy and full-thickness local excision of rectal cancer. *Eur J Surg Oncol*. 2014;40(6):723–30.
50. Guillem JG, Ruby JA, Leibold T, Akhurst TJ, Yeung HW, Gollub MJ, et al. Neither FDG-PET Nor CT can distinguish between a pathological complete response and an incomplete response after neoadjuvant chemoradiation in locally advanced rectal cancer: a prospective study. *Ann Surg*. 2013;258(2):289–95.
51. Perez RO, Habr-Gama A, Sao Juliao GP, Lynn PB, Sabbagh C, Proscurshim I, et al. Predicting complete response to neoadjuvant CRT for distal rectal cancer using sequential PET/CT imaging. *Tech Coloproctol*. 2014;18(8):699–708.
52. Patel UB, Blomqvist LK, Taylor F, George C, Guthrie A, Bees N, et al. MRI after treatment of locally advanced rectal cancer: how to report tumor response—the MERCURY experience. *Am J Roentgenol*. 2012;199(4):W486–95.
53. Beets-Tan RG, Beets GL. MRI for assessing and predicting response to neoadjuvant treatment in rectal cancer. *Nat Rev Gastroenterol Hepatol*. 2014;11(8):480–8.
54. Patel UB, Taylor F, Blomqvist L, George C, Evans H, Tekkis P, et al. Magnetic resonance imaging-detected tumor response for locally advanced rectal cancer predicts survival outcomes: MERCURY experience. *J Clin Oncol*. 2011;29(28):3753–60.
55. Engels B, Platteaux N, Van den Begin R, Gevaert T, Sermeus A, Storme G, et al. Preoperative intensity-modulated and image-guided radiotherapy with a simultaneous integrated boost in locally advanced rectal cancer: report on late toxicity and outcome. *Radiother Oncol*. 2014;110(1):155–9.
56. Gerard JP, Chapet O, Nemoz C, Hartweg J, Romestaing P, Coquard R, et al. Improved sphincter

preservation in low rectal cancer with high-dose preoperative radiotherapy: the lyon R96-02 randomized trial. *J Clin Oncol*. 2004;22(12):2404–9.

57. Schrag D, Weiser MR, Goodman KA, Gonen M, Hollywood E, Cercek A, et al. Neoadjuvant chemotherapy without routine use of radiation therapy for patients with locally advanced rectal cancer: a pilot trial. *J Clin Oncol*. 2014;32(6):513–8.

58. Aschele C, Cionini L, Lonardi S, Pinto C, Cordio S, Rosati G, et al. Primary tumor response to preoperative chemoradiation with or without oxaliplatin in locally advanced rectal cancer: pathologic results of the STAR-01 randomized phase III trial. *J Clin Oncol*. 2011;29(20):2773–80.

59. O’Connell MJ, Colangelo LH, Beart RW, Petrelli NJ, Allegra CJ, Sharif S, et al. Capecitabine and oxaliplatin in the preoperative multimodality treatment of rectal cancer: surgical end points from National Surgical Adjuvant Breast and Bowel Project trial R-04. *J Clin Oncol*. 2014;32(18):1927–34.

60. Rodel C, Liersch T, Becker H, Fietkau R, Hohenberger W, Hothorn T, et al. Preoperative chemoradiotherapy and postoperative chemotherapy with fluorouracil and oxaliplatin versus fluorouracil alone in locally advanced rectal cancer: initial results of the German CAO/ARO/AIO-04 randomised phase 3 trial. *Lancet Oncol*. 2012;13(7):679–87.

61. Gerard JP, Azria D, Gourgou-Bourgade S, Martel-Laffay I, Hennequin C, Etienne PL, et al. Comparison of two neoadjuvant chemoradiotherapy regimens for locally advanced rectal cancer: results of the phase III trial ACCORD 12/0405-Prodige 2. *J Clin Oncol*. 2010;28(10):1638–44.

62. Francois Y, Nemoz CJ, Baulieux J, Vignal J, Grandjean JP, Partensky C, et al. Influence of the interval between preoperative radiation therapy and surgery on downstaging and on the rate of sphincter-sparing surgery for rectal cancer: the Lyon R90-01 randomized trial. *J Clin Oncol*. 1999;17(8):2396.

63. Glehen O, Chapet O, Adham M, Nemoz JC, Gerard JP, Lyons Oncology Group. Long-term results of the Lyons R90-01 randomized trial of preoperative radiotherapy with delayed surgery and its effect on sphincter-saving surgery in rectal cancer. *Br J Surg*. 2003;90(8):996–8.

64. Chau I, Brown G, Cunningham D, Tait D, Wotherspoon A, Norman AR, et al. Neoadjuvant capecitabine and oxaliplatin followed by synchronous chemoradiation and total mesorectal excision in magnetic resonance imaging-defined poor-risk rectal cancer. *J Clin Oncol*. 2006;24(4):668–74.

65. Dewdney A, Cunningham D, Tabernero J, Capdevila J, Glimelius B, Cervantes A, et al. Multicenter randomized phase II clinical trial comparing neoadjuvant oxaliplatin, capecitabine, and preoperative radiotherapy with or without cetuximab followed by total mesorectal excision in patients with high-risk rectal cancer (EXPERT-C). *J Clin Oncol*. 2012;30(14):1620–7.

66. Garcia-Aguilar J, Chow OS, Smith DD, Marcet JE, Cataldo PA, Varma MG, et al. Effect of adding mFOLFOX6 after neoadjuvant chemoradiation in locally advanced rectal cancer: a multicentre, phase 2 trial. *Lancet Oncol*. 2015;16(8):957–66.

67. Habr-Gama A, Perez RO, Sabbaga J, Nadalin W, Sao Juliao GP, Gama-Rodrigues J. Increasing the rates of complete response to neoadjuvant chemoradiotherapy for distal rectal cancer: results of a prospective study using additional chemotherapy during the resting period. *Dis Colon Rectum*. 2009;52(12):1927–34.

68. Nilsson PJ, van Etten B, Hospers GA, Pahlman L, van de Velde CJ, Beets-Tan RG, et al. Short-course radiotherapy followed by neo-adjuvant chemotherapy in locally advanced rectal cancer—the RAPIDO trial. *BMC Cancer*. 2013;13:279.

69. Taylor FG, Quirke P, Heald RJ, Moran B, Blomqvist L, Swift I, et al. Preoperative high-

resolution magnetic resonance imaging can identify good prognosis stage I, II, and III rectal cancer best managed by surgery alone: a prospective, multicenter, European study. *Ann Surg.* 2011;253(4):711–9.

70. Sao Juliao GP, Smith FM, Macklin CP, George ML, Wynn GR. Opinions have changed on the management of rectal cancer with a complete clinical response to neoadjuvant chemoradiotherapy. *Colorectal Dis.* 2014;16(5):392–4.

## 第 31 章

1. Miles WE. A method of performing abdomino-perineal excision for carcinoma of the rectum and of the terminal portion of the pelvic colon. *Lancet.* 1908;2:1812–3.

2. Miles WE. The radical abdomino-perineal operation for cancer of the pelvic colon. *BMJ.* 1910;11:941–3.

3. Abel AL. The modern treatment of cancer of the rectum. *Milwaukee Proc.* March 3–5 1931; pp. 296–300.

4. Heald RJ. The ‘Holy Plane’ of rectal surgery. *J R Soc Med.* 1988;81(9):503–8.

5. Heald RJ, Ryall RD. Recurrence and survival after total mesorectal excision for rectal cancer. *Lancet.* 1986;1:1479–82.

6. Zaheer S, Pemberton JH, Farouk R, Dozois RR, Wolff BG, Ilstrup D. Surgical treatment of adenocarcinoma of the rectum. *Ann Surg Oncol.* 1998;227:800–11.

7. Quirke P, et al. Local recurrence of rectal adenocarcinoma due to inadequate surgical resection. Histopathological study of lateral tumour spread and surgical excision. *Lancet.* 1986;2(8514):996–9.

8. Wilson SM, Beahrs OH. The curative treatment of carcinoma of the sigmoid, rectosigmoid, and rectum. *Ann Surg.* 1976;183:556–65.

9. Dukes C. The surgical pathology of rectal cancer. *Proc R Soc Med.* 1943;37:131.

10. McCall J, Cox MR, Wattchow DA. Analysis of local recurrence rates after surgery alone for rectal cancer. *Int J Colorectal Dis.* 1955;10:126–32.

11. Nagtegaal ID, Quirke P. What is the role for the circumferential margin in the modern treatment of rectal cancer? *J Clin Oncol.* 2008;26(2):303–12.

12. Quer EA, Dahlin DC, Mayo CW. Retrograde intramural spread of carcinoma of the rectum and rectosigmoid. *Surg Gynecol Obstet.* 1953;96:24–30.

13. Grinnel RS. Distal intramural spread of rectal carcinoma. *Surg Gynecol Obstet.* 1954;99:421–30.

14. Black WA, Waugh JM. The intramural extension of carcinoma of the descending colon, sigmoid and rectosigmoid. A pathological study. *Surg Gynecol Obstet.* 1948;1948:457–64.

15. Scott N, Jackson P, Al-Jaberi T, Dixon MF, Quirke P, Finan PJ. Total mesorectal excision and local recurrence: a study of tumour spread in the mesorectum distal to rectal cancer. *Br J Surg.* 1995;82:1031–3.

16. Williams NS, Dixon MF, Johnston D. Reappraisal of the 5 centimetre rule of distal excision for carcinoma of the rectum: a study of distal intramural spread and of patients’ survival. *Br J Surg.* 1983;70:150–4.

17. Karanjia ND, Corder AP, Bearn P, Heald RJ. Leakage from stapled low anastomosis after total



- mesorectal excision for carcinoma of the rectum. *Br J Surg.* 1994;81:1224–6.
18. Bokey EL, Öjerskog B, Chapuis PH, Dent OF, Newland RC, Sinclair G. Local recurrence after curative excision of the rectum for cancer without adjuvant therapy: role of total anatomical dissection. *Br J Surg.* 1999;86:1164–70.
  19. Heald RJ, et al. Rectal cancer: the Basingstoke experience of total mesorectal excision, 1978–1997. *Arch Surg.* 1998;133(8):894–9.
  20. Arenas RB, Fichera A, Mhoon D, Michelassi F. Total mesorectal excision in the surgical treatment of rectal cancer: a prospective study. *Arch Surg.* 1998;133:608–11.
  21. Hainsworth PJ, Egan MJ, Cunliffe WJ. Evaluation of a policy of total mesorectal excision for rectal and rectosigmoid cancers. *Br J Surg.* 1997;84(5):652–6.
  22. Arbmán G, et al. Local recurrence following total mesorectal excision for rectal cancer. *Br J Surg.* 1996;83(3):375–9.
  23. Moran B, Heald RJ. *Manual of total mesorectal excision.* London: CRC; 2013.
  24. Quirke P, Dixon MF. The prediction of local recurrence in rectal adenocarcinoma by histopathological examination. *Int J Colorectal Dis.* 1988;3(2):127–31.
  25. Maslekar S, et al. Mesorectal grades predict recurrences after curative resection for rectal cancer. *Dis Colon Rectum.* 2007;50(2):168–75.
  26. Quirke P, et al. Effect of the plane of surgery achieved on local recurrence in patients with operable rectal cancer: a prospective study using data from the MRC CR07 and NCIC-CTG CO16 randomised clinical trial. *Lancet.* 2009;373(9666):821–8.
  27. Nagtegaal ID, et al. Macroscopic evaluation of rectal cancer resection specimen: clinical significance of the pathologist in quality control. *J Clin Oncol.* 2002;20(7):1729–34.
  28. College of American Pathologists. Protocol for the examination of specimens from patients with primary carcinoma of the colon and rectum. 2013 [cited 2015 July 17]. <http://www.cap.org/ShowProperty?nodePath=/UCMCon/Contribution%20Folders/WebContent/pdf/colon-13protocol-3300.pdf>.
  29. Contant CM, et al. Mechanical bowel preparation for elective colorectal surgery: a multicentre randomised trial. *Lancet.* 2007;370(9605):2112–7.
  30. Jung B, et al. Multicentre randomized clinical trial of mechanical bowel preparation in elective colonic resection. *Br J Surg.* 2007;94(6):689–95.
  31. Guenaga KF, Matos D, Wille-Jørgensen P. Mechanical bowel preparation for elective colorectal surgery. *Cochrane Database Syst Rev.* 2011(9):p. CD001544.
  32. Dahabreh IJ, Steele DW, Shah N, Trikalinos TA (2014) Agency for healthcare research and quality. Comparative effectiveness review. Number 128. Oral Mechanical Bowel Preparation for Colorectal Surgery. 2014 [cited 2015 July 17]. <http://effectivehealthcare.ahrq.gov/ehc/products/458/1900/colorectal-surgery-preparation-report-140428.pdf>.
  33. Nelson RL, Gladman E, Barbateskovic M. Antimicrobial prophylaxis for colorectal surgery. *Cochrane Database Syst Rev.* 2014;5: p. CD001181.
  34. Bratzler DW, et al. Clinical practice guidelines for antimicrobial prophylaxis in surgery. *Am J Health Syst Pharm.* 2013;70(3):195–283.
  35. Poggio JL. Perioperative strategies to prevent surgical-site infection. *Clin Colon Rectal Surg.* 2013;26(3):168–73.
  36. Kakkos SK, et al. Combined intermittent pneumatic leg compression and pharmacological

prophylaxis for prevention of venous thromboembolism in high-risk patients. *Cochrane Database Syst Rev*. 2008(4): p. CD005258.

37. Danielsen AK, Burcharth J, Rosenberg J. Patient education has a positive effect in patients with a stoma: a systematic review. *Colorectal Dis*. 2013;15(6):e276–83.

38. Bardram L, et al. Recovery after laparoscopic colonic surgery with epidural analgesia, and early oral nutrition and mobilisation. *Lancet*. 1995;345(8952):763–4.

39. Serclova Z, et al. Fast-track in open intestinal surgery: prospective randomized study (Clinical Trials Gov Identifier no. NCT00123456). *Clin Nutr*. 2009;28(6):618–24.

40. Spanjersberg WR, et al. Fast track surgery versus conventional recovery strategies for colorectal surgery. *Cochrane Database Syst Rev*. 2011(2): p. CD007635.

41. Lin S, et al. Meta-analysis of robotic and laparoscopic surgery for treatment of rectal cancer. *World J Gastroenterol*. 2011;17(47):5214–20.

42. Marr R, et al. The modern abdominoperineal excision: the next challenge after total mesorectal excision. *Ann Surg*. 2005;242(1):74–82.

43. Den Dulk M, et al. The abdominoperineal resection itself is associated with an adverse outcome: the European experience based on a pooled analysis of five European randomised clinical trials on rectal cancer. *Eur J Cancer*. 2009;45(7):1175–83.

44. Nagtegaal ID, et al. Low rectal cancer: a call for a change of approach in abdominoperineal resection. *J Clin Oncol*. 2005;23(36):9257–64.

45. Enker WE, Levi GS. Macroscopic assessment of mesorectal excision. *Cancer*. 2009;115(21):4890–4.

46. Enker WE, et al. Abdominoperineal resection via total mesorectal excision and autonomic nerve preservation for low rectal cancer. *World J Surg*. 1997;21(7):715–20.

47. Holm T, et al. Extended abdominoperineal resection with gluteus maximus flap reconstruction of the pelvic floor for rectal cancer. *Br J Surg*. 2007;94(2):232–8.

48. West NP, et al. Multicentre experience with extralevator abdominoperineal excision for low rectal cancer. *Br J Surg*. 2010;97(4):588–99.

49. Han JG, et al. A prospective multicenter clinical study of extralevator abdominoperineal resection for locally advanced low rectal cancer. *Dis Colon Rectum*. 2014;57(12):1333–40.

50. Prytz M, et al. Extralevator abdominoperineal excision (ELAPE) for rectal cancer—short-term results from the Swedish Colorectal Cancer Registry. Selective use of ELAPE warranted. *Int J Colorectal Dis*. 2014;29(8):981–7.

51. Kang CY, et al. Robotic-assisted extralevator abdominoperineal resection in the lithotomy position: technique and early outcomes. *Am Surg*. 2012;78(10):1033–7.

52. Marecik SJ, et al. Robotic cylindrical abdominoperineal resection with transabdominal levator transection. *Dis Colon Rectum*. 2011;54(10):1320–5.

53. Weiser MR, et al. Sphincter preservation in low rectal cancer is facilitated by preoperative chemoradiation and intersphincteric dissection. *Ann Surg*. 2009;249(2):236–42.

54. Kodeda K, et al. Rectal washout and local recurrence of cancer after anterior resection. *Br J Surg*. 2010;97(10):1589–97.

55. Karanjia ND, et al. ‘Close shave’ in anterior resection. *Br J Surg*. 1990;77(5):510–2.

56. Pollett WG, Nicholls RJ. The relationship between the extent of distal clearance and survival and local recurrence rates after curative anterior resection for carcinoma of the rectum. *Ann Surg*. 1983;198(2):159–63.

57. Vernava III AM, et al. A prospective evaluation of distal margins in carcinoma of the rectum. *Surg Gynecol Obstet.* 1992;175(4):333–6.
58. Paty PB, et al. Treatment of rectal cancer by low anterior resection with coloanal anastomosis. *Ann Surg.* 1994;219(4):365–73.
59. Paty PB, et al. Long-term functional results of coloanal anastomosis for rectal cancer. *Am J Surg.* 1994;167(1):90–4. discussion 94-5.
60. Brown CJ, Fenech DS, McLeod RS. Reconstructive techniques after rectal resection for rectal cancer. *Cochrane Database Syst Rev.* 2008(2): p. CD006040.
61. Hallbook O, et al. Randomized comparison of straight and colonic J pouch anastomosis after low anterior resection. *Ann Surg.* 1996;224(1):58–65.
62. Heriot AG, et al. Meta-analysis of colonic reservoirs versus straight coloanal anastomosis after anterior resection. *Br J Surg.* 2006;93(1):19–32.
63. Si C, Zhang Y, Sun P. Colonic J-pouch versus Baker type for rectal reconstruction after anterior resection of rectal cancer. *Scand J Gastroenterol.* 2013;48(12):1428–35.
64. Matthiessen P, et al. Defunctioning stoma reduces symptomatic anastomotic leakage after low anterior resection of the rectum for cancer: a randomized multicenter trial. *Ann Surg.* 2007;246(2):207–14.
65. Tan WS, et al. Meta-analysis of defunctioning stomas in low anterior resection for rectal cancer. *Br J Surg.* 2009;96(5):462–72.
66. Gu WL, Wu SW. Meta-analysis of defunctioning stoma in low anterior resection with total mesorectal excision for rectal cancer: evidence based on thirteen studies. *World J Surg Oncol.* 2015;13(1):9.
67. Gunderson LL, et al. Revised TN categorization for colon cancer based on national survival outcomes data. *J Clin Oncol.* 2010;28(2):264–71.
68. Derici H, et al. Multivisceral resections for locally advanced rectal cancer. *Colorectal Dis.* 2008;10(5):453–9.
69. Smith JD, et al. Multivisceral resections for rectal cancer. *Br J Surg.* 2012;99(8):1137–43.
70. Sugihara K, et al. Indication and benefit of pelvic sidewall dissection for rectal cancer. *Dis Colon Rectum.* 2006;49(11):1663–72.
71. Yano H, Moran BJ. The incidence of lateral pelvic side-wall nodal involvement in low rectal cancer may be similar in Japan and the West. *Br J Surg.* 2008;95(1):33–49.
72. Georgiou P, et al. Extended lymphadenectomy versus conventional surgery for rectal cancer: a meta-analysis. *Lancet Oncol.* 2009;10(11):1053–62.
73. Dubois JB, et al. Intra-operative radiotherapy of rectal cancer: results of the French multi-institutional randomized study. *Radiother Oncol.* 2011;98(3):298–303.
74. Wiig JN, Giercksky KE, Tveit KM. Intraoperative radiotherapy for locally advanced or locally recurrent rectal cancer: does it work at all? *Acta Oncol.* 2014;53(7):865–76.
75. Killeen S, Devaney A, Mannion M, Martin ST, Winter DC. Omental pedicle flaps following proctectomy: a systematic review. *Colorectal Dis.* 2013;15(11):e634–45.
76. Chessin DB, Hartley J, Cohen AM, Mazumdar M, Cordeiro P, Disa J, Mehrara B, Minsky BD, Paty P, Weiser M, Wong WD, Guillem JG. Rectus flap reconstruction decreases perineal wound complications after pelvic chemoradiation and surgery: a cohort study. *Ann Surg Oncol.* 2005;12(2):104–10.
77. Camilleri-Brennan J, Steele RJ. Quality of life after treatment for rectal cancer. *Br J Surg.*

1998;85(8):1036–43.

78. Bruheim K, et al. Late side effects and quality of life after radiotherapy for rectal cancer. *Int J Radiat Oncol Biol Phys*. 2010;76(4):1005–11.

79. Enker WE. Potency, cure, and local control in the operative treatment of rectal cancer. *Arch Surg*. 1992;127(12):1396–401. discussion 1402.

80. Havenga K, et al. Male and female sexual and urinary function after total mesorectal excision with autonomic nerve preservation for carcinoma of the rectum. *J Am Coll Surg*. 1996;182(6):495–502.

81. Shirouzu K, Ogata Y, Araki Y. Oncologic and functional results of total mesorectal excision and autonomic nerve-preserving operation for advanced lower rectal cancer. *Dis Colon Rectum*. 2004;47(9):1442–7.

82. Cornish JA, et al. A meta-analysis of quality of life for abdominoperineal excision of rectum versus anterior resection for rectal cancer. *Ann Surg Oncol*. 2007;14(7):2056–68.

83. Engel J, et al. Quality of life in rectal cancer patients: a four-year prospective study. *Ann Surg*. 2003;238(2):203–13.

84. Kasperek MS, et al. Quality of life after coloanal anastomosis and abdominoperineal resection for distal rectal cancers: sphincter preservation vs quality of life. *Colorectal Dis*. 2011;13(8):872–7.

85. Guren MG, et al. Quality of life and functional outcome following anterior or abdominoperineal resection for rectal cancer. *Eur J Surg Oncol*. 2005;31(7):735–42.

86. Birgisson H, et al. Late adverse effects of radiation therapy for rectal cancer—a systematic overview. *Acta Oncol*. 2007;46(4):504–16.

87. Lange MM, et al. Risk factors for faecal incontinence after rectal cancer treatment. *Br J Surg*. 2007;94(10):1278–84.

88. MacFarlane JK, Ryall RD, Heald RJ. Mesorectal excision for rectal cancer. *Lancet*. 1993;341(8843):457–60.

89. Enker WE, et al. Total mesorectal excision in the operative treatment of carcinoma of the rectum. *J Am Coll Surg*. 1995;181(4):335–46.

90. Bjerkeset T, Edna TH. Rectal cancer: the influence of type of operation on local recurrence and survival. *Eur J Surg*. 1996;162(8):643–8.

91. Kockerling F, et al. Influence of surgery on metachronous distant metastases and survival in rectal cancer. *J Clin Oncol*. 1998;16(1):324–9.

92. Syk E, et al. Local recurrence in rectal cancer: anatomic localization and effect on radiation target. *Int J Radiat Oncol Biol Phys*. 2008;72(3):658–64.

93. Kapiteijn E, Putter H, van de Velde CJ. Impact of the introduction and training of total mesorectal excision on recurrence and survival in rectal cancer in The Netherlands. *Br J Surg*. 2002;89(9):1142–9.

94. Martling A, et al. The surgeon as a prognostic factor after the introduction of total mesorectal excision in the treatment of rectal cancer. *Br J Surg*. 2002;89(8):1008–13.

95. Wibe A, et al. Total mesorectal excision for rectal cancer—what can be achieved by a national audit? *Colorectal Dis*. 2003;5(5):471–7.

96. Wibe A, et al. A national strategic change in treatment policy for rectal cancer—implementation of total mesorectal excision as routine treatment in Norway. A national audit. *Dis Colon Rectum*. 2002;45(7):857–66.

97. Martling AL, et al. Effect of a surgical training programme on outcome of rectal cancer in the

County of Stockholm. Stockholm Colorectal Cancer Study Group, Basingstoke Bowel Cancer Research Project. *Lancet*. 2000;356(9224):93–6.

98. Helsper JT. Impact of the surgeon on cancer management outcomes. *J Surg Oncol*. 2003;82(1):1–2.

99. Luna-Perez P, et al. The surgeon as prognostic factor for local recurrence and survival in the anal sphincter preservation for mid-rectal cancer. *Rev Invest Clin*. 1999;51(4):205–13.

100. Renzulli P, Laffer UT. Learning curve: the surgeon as a prognostic factor in colorectal cancer surgery. *Recent Results Cancer Res*. 2005;165:86–104.

101. Dietz DW. Multidisciplinary management of rectal cancer: the OSTRICH. *J Gastrointest Surg*. 2013;17(10):1863–8.

102. The Consortium for Optimizing the Treatment of Rectal Cancer (OSTRiCh). 2014 [cited 2015 July 17]. <http://www.ostrichconsortium.org/index.html>.

103. Monson JR, et al. Failure of evidence-based cancer care in the United States: the association between rectal cancer treatment, cancer center volume, and geography. *Ann Surg*. 2014;260(4):625–31. discussion 631–2.

104. Guillem JG, Lee-Kong SA. Autonomic nerve preservation during rectal cancer resection. *J Gastrointest Surg*. 2010;14:416–22.

105. Janjua AZ, Moran B, Heald RJ. Open surgical management of rectal cancer. In: Patel HRH, Mould T, Joseph JV, Delaney CP, editors. *Pelvic cancer surgery: modern breakthroughs and future advances*. New York: Springer; 2015. p. 531.

106. Heald RJ, et al. Embryology and anatomy of the rectum. *Semin Surg Oncol*. 1998;15(2):66–71.

107. Hockel M. Laterally extended endopelvic resection for the treatment of locally advanced and recurrent cervical cancer. In: Patel HRH, Mould T, Joseph JV, Delaney CP, editors. *Pelvic cancer surgery: modern breakthroughs and future advances*. New York: Springer; 2005.

## 第 32 章

1. Valentini V, Beets-Tan R, Borras JM, Krivokapic Z, Leer JW, Pahlman L, Rodel C, Schmoll HJ, Scott N, Velde CV, Verfaillie C. Evidence and research in rectal cancer. *Radiother Oncol*. 2008;87:449–74.

2. Muthusamy VR, Chang KJ. Optimal methods for staging rectal cancer. *Clin Cancer Res*. 2007;13:6877s–84s.

3. Lee TH, Marcantonio ER, Mangione CM, Thomas EJ, Polanczyk CA, Cook EF, Sugarbaker DJ, Donaldson MC, Poss R, Ho KK, Ludwig LE, Pedan A, Goldman L. Derivation and prospective validation of a simple index for prediction of cardiac risk of major noncardiac surgery. *Circulation*. 1999;100:1043–9.

4. Cohen ME, Bilimoria KY, Ko CY, Hall BL. Development of an American College of Surgeons National Surgery Quality Improvement Program: morbidity and mortality risk calculator for colorectal surgery. *J Am Coll Surg*. 2009;208:1009–16.

5. Buie WD, MacLean AR. Perioperative risk assessment. In: Steele S, Maykel J, Champagne BJ, Orangio GR, editors. *Complexities in colorectal surgery*. New York: Springer; 2014. p. 17–28.

6. Snelgrove RC, Subendran J, Jhaveri K, Thippavong S, Cummings B, Brierly J, Kirsch R,

Kennedy ED. Effect of multidisciplinary cancer conference on treatment plan for patients with primary rectal cancer. *Dis Colon Rectum*. 2015;58(7):653–8.

7. Bipat S, Glas AS, Slors FJ, Zwinderman AH, Bossuyt PM, Stoker J. Rectal cancer: local staging and assessment of lymph node involvement with endoluminal US, CT, and MR imaging—a meta-analysis. *Radiology*. 2004;232:773–83.

8. Lahaye MJ, Engelen SM, Nelemans PJ, Beets GL, van de Velde CJ, van Engelshoven JM, Beets-Tan RG. Imaging for predicting the risk factors—the circumferential resection margin and nodal disease—of local recurrence in rectal cancer: a meta-analysis. *Semin Ultrasound CT MR*. 2005;26:259–68.

9. Mercury Study Group. Diagnostic accuracy of preoperative magnetic resonance imaging in predicting curative resection of rectal cancer: prospective observational study. *Br Med J*. 2006;333:779.

10. Brown G, Daniels IR, Richardson C, et al. Techniques and trouble shooting in high spatial resolution thin slice MRI for Rectal cancer. *Br J Radiol*. 2005;78:245–51.

11. Langer C, Liersch T, Suss M, Siemer A, Markus P, Ghadimi BM, Fuzesi L, Becker H. Surgical cure for early rectal carcinoma and large adenoma: transanal endoscopic microsurgery (using ultrasound or electrosurgery) compared to conventional local and radical resection. *Int J Colorectal Dis*. 2003;18:222–9.

12. Doornebosch PG, Tollenaar RA, De Graaf EJ. Is the increasing role of Transanal Endoscopic Microsurgery in curation for T1 rectal cancer justified? A systematic review. *Acta Oncol*. 2009;48:343–53.

13. Neary P, Makin GB, White TJ, White E, Hartley J, MacDonald A, Lee PW, Monson JR. Transanal endoscopic microsurgery: a viable operative alternative in selected patients with rectal lesions. *Ann Surg Oncol*. 2003;10:1106–11.

14. Christoforidis D, Cho HM, Dixon MR, Mellgren AF, Madoff RD, Finne CO. Transanal endoscopic microsurgery versus conventional transanal excision for patients with early rectal cancer. *Ann Surg*. 2009;249:776–82.

15. Ueno H, Mochizuki H, Hasiguchi Y, et al. Risk factors for an adverse outcome in early invasive colorectal carcinoma. *Gastroenterology*. 2004;127:385–94.

16. Ueno H, Hase K, Hashiguchi Y, Shimasake H, Shinji Y, et al. Novel risk factors for lymph node metastasis in early invasive colorectal cancer: a multi-institution pathology review. *J Gastroenterol*. 2014;49:1314–23.

17. Choi JY, Jung SA, Cho WY, Keum B, et al. Meta-analysis of predictive clinicopathologic factors for lymph node metastases in patients with early rectal colorectal carcinoma. *J Korean Med Sci*. 2015;30:398–406.

18. Kawachi H, Eishi Y, Ueno H, Nemoto T, et al. A three-tier classification system based on the depth of submucosal invasion and budding/sprouting can improve the treatment strategy for T1 colorectal cancer: a retrospective multicenter study. *Mod Pathol*. 2015;28:872–9.

19. Kikuchi R, Takano M, Takaguchi K, et al. Management of early invasive colorectal cancer. Risk of recurrence and clinical guidelines. *Dis Colon Rectum*. 1995;38(12):1286–95.

20. Butte JM, Tang P, Gonen M, et al. Rate of residual disease after complete endoscopic resection of malignant colonic polyp. *Dis Colon Rectum*. 2012;55:122–7.

21. Garcia-Aguilar J, Shi Q, Thomas Jr CR, et al. A phase II trial of neoadjuvant chemoradiation and local excision for T2N0 rectal cancer: preliminary results of the ACOSOG Z6041 trial. *Ann*

Surg Oncol. 2012;19(2):384–91.

22. Russell AH, Harris J, Rosenberg PJ, et al. Anal sphincter conservation for patients with adenocarcinoma of the distal rectum: long-term results of radiation therapy oncology group protocol 89-02. *Int J Radiat Oncol Biol Phys.* 2000;46(2):313–22.

23. NCCN Clinical practice guidelines in oncology (NCCN Guidelines) Rectal cancer Version 2.2015. <http://www.tri-kobe.org/nccn/guideline/colorectal/english/rectal.pdf>. Accessed 28 Aug 2015.

24. Peeters KC, vande Velde CJ, Leer JW, et al. Late side effects of short-course preoperative radiotherapy combined with total mesorectal excision for rectal cancer: increased bowel dysfunction in irradiated patients—a Dutch colorectal cancer group study. *J Clin Oncol.* 2005;23:6199–206.

25. Birgisson H, Pahlman L, Gunnarsson U, et al. Adverse effects of preoperative radiation therapy for rectal cancer: long-term follow-up of the Swedish rectal cancer trial. *J Clin Oncol.* 2005;23:8697–705.

26. Joye I, Hautermans K. Early and late toxicity of radiotherapy for rectal cancer. *Recent Results Cancer Res.* 2014;203:189–201.

27. Smith JJ, Garcia-Aguilar JG. Advances and challenges in treatment for locally advanced rectal cancer. *J Clin Oncol.* 2015;33:1797–808.

28. Costa-Silva L, Brown G. Magnetic resonance imaging of rectal cancer. *Magn Reson Imaging Clin N Am.* 2013;21:385–408.

29. Kwok H, Bissett IP, Hill GL. Preoperative staging of rectal cancer. *Int J Colorectal Dis.* 2000;15:9–20.

30. Brown G, Davies S, Williams GT, et al. Effectiveness of preoperative staging in rectal cancer: digital rectal examination, endoluminal ultrasound or magnetic resonance imaging? *Br J Cancer.* 2004;91:23–9.

31. Beets-Tan RG, Beets GL. Local staging of rectal cancer: a review of imaging. *J Magn Reson Imaging.* 2011;33:1012–9.

32. Burton S, Brown G, Daniels IR, Norman AR, Mason B, Cunningham D. MRI directed multidisciplinary team preoperative treatment strategy: the way to eliminate positive circumferential margins? *Br J Cancer.* 2006;94(3):351–7.

33. Taylor FG, Quirke P, Heald RJ, on behalf of the mercury study group, et al. Preoperative high-resolution magnetic resonance imaging can identify good prognosis stage i, ii, and iii rectal cancer best managed by surgery alone: a prospective, multi-center, European study. *Ann Surg.* 2011;253:711–19.

34. Merkel S, Mansmann U, siassi M, Papadopoulos T, et al. The prognostic inhomogeneity in pT3 rectal carcinomas. *Int J Colorectal Dis.* 2001;16:298–304.

35. Sauer R, Becker H, Hohenberger W, Rodel C, Wittekind C, Fietkau R, Martus P, Tschmelitsch J, Hager E, Hess CF, Karstens JH, Liersch T, Schmidberger H, Raab R. Preoperative versus postoperative chemoradiotherapy for rectal cancer. *N Engl J Med.* 2004;351:1731–40.

36. Habr-Gama A, Perez RO, Nadalin W, et al. Operative versus nonoperative treatment for stage 0 distal rectal cancer following chemoradiation therapy: long-term results. *Ann Surg.* 2004;240:711–7.

37. Habr-Gama A, Perez RO, Proscurshim I, et al. Patterns of failure and survival for nonoperative treatment of stage c0 distal rectal cancer following neoadjuvant chemoradiation therapy. *J Gastrointest Surg.* 2006;10:1319–28.

38. Habr-Gama A, Gama-Rodrigues J, São Julião GP, et al. Local recurrence after complete clinical response and watch and wait in rectal cancer after neoadjuvant chemoradiation: impact of salvage therapy on local disease control. *Int J Radiat Oncol Biol Phys*. 2014;88:822–8.
39. Glynne-Jones R, Hughes R. Critical appraisal of the ‘wait and see’ approach in rectal cancer for clinical complete responders after chemoradiation. *Br J Surg*. 2012;99:897–909.
40. Quirke P, Durdey P, Dixon MF, Williams NS. Local recurrence of rectal adenocarcinoma due to inadequate surgical resection. Histopathological study of lateral tumour spread and surgical excision. *Lancet*. 1986;2:996–9.
41. Adam IJ, Mohamdee MO, Martin IG, Scott N, Finan PJ, Johnston D, Dixon MF, Quirke P. Role of circumferential margin involvement in the local recurrence of rectal cancer. *Lancet*. 1994;344:707–11.
42. Scott N, Jackson P, al-Jaberi T, Dixon MF, Quirke P, Finan PJ. Total mesorectal excision and local recurrence: a study of tumour spread in the mesorectum distal to rectal cancer. *Br J Surg*. 1995;82:1031–3.
43. Hida J, Yasutomi M, Maruyama T, Fujimoto K, Uchida T, Okuno K. Lymph node metastases detected in the mesorectum distal to carcinoma of the rectum by the clearing method: justification of total mesorectal excision. *J Am Coll Surg*. 1997;184:584–8.
44. Weiser MR, Quah HM, Shia J, Guillem JG, et al. Sphincter preservation in low rectal cancer is facilitated by preoperative chemoradiation and intersphincteric dissection. *Ann Surg*. 2009;249:236–42.
45. Mercury Study Group. Extramural depth of tumor invasion at thin-section MR in patients with rectal cancer: results of the Mercury study. *Radiology*. 2007;243:132–9.
46. Schiessel R, Novi G, Holzer B, et al. Technique and long-term results of intersphincteric resection for low rectal cancer. *Dis Colon Rectum*. 2005;48:1858–65. discussion 1865–1867.
47. Hohenberger W, Merkel S, Matzel K, et al. The influence of abdominoperianal (intersphincteric) resection of lower third rectal carcinoma on the rates of sphincter preservation and locoregional recurrence. *Colorectal Dis*. 2006;8:23–33.
48. Portier G, Ghouti L, Kirzin S, et al. Oncological outcome of ultra-low coloanal anastomosis with and without intersphincteric resection for low rectal adenocarcinoma. *Br J Surg*. 2007;94:341–5.
49. Rullier E, Zerbib F, Laurent C, et al. Intersphincteric resection with excision of internal anal sphincter for conservative treatment of very low rectal cancer. *Dis Colon Rectum*. 1999;42:1168–75.
50. Gamagami R, Istvan G, Cabarrot P, et al. Fecal continence following partial resection of the anal canal in distal rectal cancer: long-term results after coloanal anastomoses. *Surgery*. 2000;127:291–5.
51. Bittorf B, Stadelmaier U, Gohl J, et al. Functional outcome after intersphincteric resection of the rectum with coloanal anastomosis in low rectal cancer. *Eur J Surg Oncol*. 2004;30:260–5.
52. Bretagnol F, Rullier E, Laurent C, et al. Comparison of functional results and quality of life between intersphincteric resection and conventional coloanal anastomosis for low rectal cancer. *Dis Colon Rectum*. 2004;47(6):832–8.
53. Rullier E, Laurent C, Bretagnol F, et al. Sphincter-saving resection for all rectal carcinomas: the end of the 2-cm distal rule. *Ann Surg*. 2005;241:465–9.
54. Moore HG, Riedel E, Minsky BD, et al. Adequacy of 1-cm distal margin after restorative rectal



cancer resection with sharp mesorectal excision and preoperative combined-modality therapy. *Ann Surg Oncol*. 2003;10:80–5.

55. Attalah S, Martin-Perez B, Albert M, et al. Transanal minimally invasive surgery for total mesorectal excision (TAMIS-TME): results and experience with the first 20 patients undergoing curative-intent rectal cancer surgery at a single institution. *Tech Coloproctol*. 2014;18:473–80.

56. Fernandez-Hevia M, Delgado S, Castells A, et al. Transanal total mesorectal excision in rectal cancer: short-term outcomes in comparison with laparoscopic surgery. *Ann Surg*. 2015;261:221–7.

57. Denost Q, Adam JP, Rullier A, Buscail E, et al. Perineal transanal approach: a new standard for laparoscopic sphincter-saving resection in low rectal cancer, a randomized trial. *Ann Surg*. 2014;260:993–9.

58. Holm T, Hjung A, Haggnek T. Extended abdominoperineal resection with gluteus maximus flap reconstruction of the pelvic floor for rectal cancer. *Br J Surg*. 2007;94:232–8.

59. West NP, Finana PJ, Anderin C, et al. Evidence of the oncologic superiority of cylindrical abdominoperineal excision for low rectal cancer. *J Clin Oncol*. 2008;26:3517–22.

60. Molina Rodríguez JL, Flor-Lorente B, Frasson M, et al. Low rectal cancer: abdominoperineal resection or low Hartmann resection? A postoperative outcome analysis. *Dis Colon Rectum*. 2011;54:958–62.

61. Hunerbein M, Krause M, Moesta KT, Rau B, Schlag PM. Palliation of malignant rectal obstruction with self-expanding metal stents. *Surgery*. 2005;137:42–7.

62. Watson AJ, Shanmugam V, Mackay I, Chaturvedi S, Loudon MA, Duddalwar V, Hussey JK. Outcomes after placement of colorectal stents. *Colorectal Dis*. 2005;7:70–3.

63. Kelly ME, Spolverato G, Le GN, Mavros MN, Doyle F, Pawlik TM, et al. Synchronous colorectal liver metastasis: a network meta-analysis review comparing classical, combined, and liver-first surgical strategies. *J Surg Oncol*. 2015;111(3):341–51.

64. Lykoudis PM, O'Reilly D, Nastos K, Fusai G. Systematic review of surgical management of synchronous colorectal liver metastases. *Br J Surg*. 2014;101:605–12.

65. D'Angelica MI, Kemeny NE. Metastatic colorectal cancer to the liver: involve the surgeon early and often. *Ann Surg Oncol*. 2015;22:2104–6.

66. Slessor AAP, Simillis C, Goldin R, Brown G, Mudan S, Tekkis PP. A meta-analysis comparing simultaneous versus delayed resections in patients with synchronous colorectal liver metastases. *Surgical Oncol*. 2013;22:36–47.

67. Weber JC, Bachellier P, Oussoultzoglou E, Jaeck D. Simultaneous resection of colorectal primary tumour and synchronous liver metastases. *Br J Surg*. 2003;90:956–62.

68. Ejaz A, Semenov E, Spolverato G, Kim Y, Tanner D, Hundt J, et al. Synchronous primary colorectal and liver metastasis: impact of operative approach on clinical outcomes and hospital charges. *HPB (Oxford)*. 2014;16:1117–26.

69. Thelen A, Jonas S, Benckert C, Spinelli A, et al. Simultaneous versus staged liver resection of synchronous liver metastases from colorectal cancer. *Int J Colorectal Dis*. 2007;22(10):1269–76.

70. Silberhumer GR, Paty PB, Temple LK, Araujo RLC, Dentond B, et al. Simultaneous resection for rectal cancer with synchronous liver metastasis is a safe procedure. *Am J Surg*. 2015;209:935–42.

71. McKenzie SP, Vargas HD, Evers BM, Davenport DL. Selection criteria for combined resection of synchronous colorectal cancer hepatic metastases: a cautionary note. *Int J Colorectal Dis*. 2014;29:729–35.

72. Tanaka K, Shimada H, Matsuo K, et al. Outcome after simultaneous colorectal and hepatic resection for colorectal cancer with synchronous metastases. *Surgery*. 2004;136:650–9.
73. Lam VW, Laurence JM, Pang T, et al. A systematic review of a liver-first approach in patients with colorectal cancer and synchronous colorectal liver metastases. *HPB*. 2014;16:101–8.
74. Brouquet A, Mortenson MM, Vauthey JN, Rodriguez-Bigas MA, Overman MJ, Chang GJ, et al. Surgical strategies for synchronous colorectal liver metastases in 156 consecutive patients: classic, combined or reverse strategy? *J Am Coll Surg*. 2010;210:934–41.
75. Andres A, Toso C, Adam R, Barroso E, Hubert C, Capussotti L, et al. A survival analysis of the liver-first reversed management of advanced simultaneous colorectal liver metastases: a LiverMetSurvey-based study. *Ann Surg*. 2012;256:772–8. discussion 778-9.
76. Mayo SC, Pulitano C, Marques H, Lamelas J, Wolfgang CL, de Saussure W, et al. Surgical management of patients with synchronous colorectal liver metastasis: a multicenter international analysis. *J Am Coll Surg*. 2013;216:707–16. discussion 16-18.
77. Mentha G, Majno P, Terraz S, Rubbia-Brandt L, et al. Treatment strategies for the management of advanced colorectal liver metastases detected synchronously with the primary tumour. *Eur J Surg Oncol*. 2007;33 Suppl 2:S76–83.
78. Nilsson PJ, van Etten B, Hospers GA, Pålman L, van de Velde CJ, et al. Short-course radiotherapy followed by neo-adjuvant chemotherapy in locally advanced rectal cancer—the RAPIDO trial. *BMC Cancer*. 2013;13:279.

## 第 33 章

1. Conference NC. Adjuvant therapy for patients with colon and rectal cancer. *JAMA*. 1990;264:1444–50.
2. National Quality Forum. Endorsement summary: Cancer measures. 2012. <http://www.qualityforum.org>.
3. Laurie JA, Moertel CG, Fleming TR, Wieand HS, Leigh JE, Rubin J, et al. Surgical adjuvant therapy of large-bowel carcinoma: an evaluation of levamisole and the combination of levamisole and fluorouracil. The North Central Cancer Treatment Group and the Mayo Clinic. *J Clin Oncol*. 1989;7(10):1447–56.
4. Moertel CG, Fleming TR, Macdonald JS, Haller DG, Laurie JA, Goodman PJ, et al. Levamisole and fluorouracil for adjuvant therapy of resected colon carcinoma. *N Engl J Med*. 1990;322(6):352–8.
5. Jemal A, Siegel R, Ward E, Murray T, Xu J, Smigal C, et al. Cancer statistics, 2006. *CA Cancer J Clin*. 2006;56(2):106–30.
6. André T, Boni C, Navarro M, Tabernero J, Hickish T, Topham C, et al. Improved overall survival with oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment in stage II or III colon cancer in the MOSAIC trial. *J Clin Oncol*. 2009;27(19):3109–16.
7. Efficacy of adjuvant fluorouracil and folinic acid in colon cancer. International Multicentre Pooled Analysis of Colon Cancer Trials (IMPACT) investigators. *Lancet*. 1995;345(8955):939–44.
8. Comparison of fluorouracil with additional levamisole, higher-dose folinic acid, or both, as adjuvant chemotherapy for colorectal cancer: a randomised trial. QUASAR Collaborative Group. *Lancet*. 2000;355(9215):1588–96.

9. Efficacy of adjuvant fluorouracil and folinic acid in B2 colon cancer. International Multicentre Pooled Analysis of B2 Colon Cancer Trials (IMPACT B2) investigators. *J Clin Oncol.* 1999;17(5):1356–63.
10. Mamounas E, Wieand S, Wolmark N, Bear HD, Atkins JN, Song K, et al. Comparative efficacy of adjuvant chemotherapy in patients with Dukes' B versus Dukes' C Colon cancer: results from four National Surgical Adjuvant Breast and Bowel Project adjuvant studies (C-01, C-02, C-03, and C-04). *J Clin Oncol.* 1999;17(5):1349–55.
11. Haller DG, Tabernero J, Maroun J, de Braud F, Price T, Van Cutsem E, et al. Capecitabine plus oxaliplatin compared with fluorouracil and folinic acid as adjuvant therapy for stage III colon cancer. *J Clin Oncol.* 2011;29(11):1465–71.
12. National Comprehensive Cancer Network. Colon Cancer version 2.2015. 2015. <http://www.nccn.org>.
13. André T, Boni C, Mounedji-Boudiaf L, Navarro M, Tabernero J, Hickish T, et al. Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer. *N Engl J Med.* 2004;350(23):2343–51.
14. Kuebler JP, Wieand HS, O'Connell MJ, Smith RE, Colangelo LH, Yothers G, et al. Oxaliplatin combined with weekly bolus fluorouracil and leucovorin as surgical adjuvant chemotherapy for stage II and III Colon cancer: results from NSABP C-07. *J Clin Oncol.* 2007;25(16):2198–204.
15. Twelves C, Wong A, Nowacki MP, Abt M, Burris 3rd H, Carrato A, et al. Capecitabine as adjuvant treatment for stage III colon cancer. *N Engl J Med.* 2005;352(26):2696–704.
16. Alberts SR, Sargent DJ, Nair S, Mahoney MR, Mooney M, Thibodeau SN, et al. Effect of oxaliplatin, fluorouracil, and leucovorin with or without cetuximab on survival among patients with resected stage III Colon cancer: a randomized trial. *JAMA.* 2012;307(13):1383–93.
17. Taieb J, Tabernero J, Mini E, Subtil F, Folprecht G, Van Laethem JL, et al. Oxaliplatin, fluorouracil, and leucovorin with or without cetuximab in patients with resected stage III colon cancer (PETACC-8): an open-label, randomised phase 3 trial. *Lancet Oncol.* 2014;15(8):862–73.
18. Allegra CJ, Yothers G, O'Connell MJ, Sharif S, Petrelli NJ, Lopa SH, et al. Bevacizumab in stage II-III Colon cancer: 5-year update of the National Surgical Adjuvant Breast and Bowel Project C-08 trial. *J Clin Oncol.* 2013;31(3):359–64.
19. De Gramont A, Van Cutsem E, Schmoll HJ, Tabernero J, Clarke S, Moore MJ, et al. Bevacizumab plus oxaliplatin-based chemotherapy as adjuvant treatment for colon cancer (AVANT): a phase 3 randomised controlled trial. *Lancet Oncol.* 2012;13(12):1225–33.
20. Zedan AH, Hansen TF, Fex S, Sørensen A, Vilholm OJ. Oxaliplatin-induced neuropathy in colorectal cancer: many questions with few answers. *Clin Colorectal Cancer.* 2014;13(2):73–80.
21. Nagore E, Insa A, Sanmartín O. Antineoplastic therapy-induced palmar plantar erythrodysesthesia ('hand-foot') syndrome. Incidence, recognition and management. *Am J Clin Dermatol.* 2000;1(4):225–34.
22. Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. *CA Cancer J Clin.* 2005;55(2):74–108.
23. Schrag D, Gelfand S, Bach P, et al. Adjuvant chemotherapy for stage II Colon cancer: insight from a SEER-Medicare cohort. *Proc Am Soc Clin Oncol.* 2001;20:488.
24. Sargent DJ, Marsoni S, Monges G, Thibodeau SN, Labianca R, Hamilton SR, et al. Defective mismatch repair as a predictive marker for lack of efficacy of fluorouracil-based adjuvant therapy in colon cancer. *J Clin Oncol.* 2010;28(20):3219–26.

25. O'Connell MJ, Lavery I, Yothers G, Paik S, Clark-Langone KM, Lopatin M, et al. Relationship between tumor gene expression and recurrence in four independent studies of patients with stage II/III colon cancer treated with surgery alone or surgery plus adjuvant fluorouracil plus leucovorin. *J Clin Oncol*. 2010;28(25):3937–44.
26. Gray RG, Quirke P, Handley K, Lopatin M, Magill L, Baehner FL, et al. Validation study of a quantitative multigene reverse transcriptase-polymerase chain reaction assay for assessment of recurrence risk in patients with stage II colon cancer. *J Clin Oncol*. 2011;29(35):4611–9.
27. Venook AP, Niedzwiecki D, Lopatin M, Ye X, Lee M, Friedman PN, et al. Biologic determinants of tumor recurrence in stage II Colon cancer: validation study of the 12-gene recurrence score in cancer and leukemia group B (CALGB) 9581. *J Clin Oncol*. 2013;31(14):1775–81.
28. Yothers G, O'Connell MJ, Lee M, Lopatin M, Clark-Langone KM, Millward C, et al. Validation of the 12-gene colon cancer recurrence score in NSABP C-07 as a predictor of recurrence in patients with stage II and III colon cancer treated with fluorouracil and leucovorin (FU/LV) and FU/LV plus oxaliplatin. *J Clin Oncol*. 2013;31(36):4512–9.
29. Salazar R, Roepman P, Capella G, Moreno V, Simon I, Dreezen C, et al. Gene expression signature to improve prognosis prediction of stage II and III colorectal cancer. *J Clin Oncol*. 2011;29(1):17–24.
30. Kopetz S, Tabernero J, Rosenberg R, Jiang ZQ, Moreno V, Bachleitner-Hofmann T, et al. Genomic classifier ColoPrint predicts recurrence in stage II colorectal cancer patients more accurately than clinical factors. *Oncologist*. 2015;20(2):127–33.
31. Kennedy RD, Bylesjo M, Kerr P, Davison T, Black JM, Kay EW, et al. Development and independent validation of a prognostic assay for stage II colon cancer using formalin-fixed paraffin-embedded tissue. *J Clin Oncol*. 2011;29(35):4620–6.
32. Willett CG, Fung CY, Kaufman DS, Efird J, Shellito PC. Postoperative radiation therapy for high-risk colon carcinoma. *J Clin Oncol*. 1993;11(6):1112–7.
33. Schild SE, Gunderson LL, Haddock MG, Wong WW, Nelson H, et al. The treatment of locally advanced colon cancer. *Int J Radiat Oncol Biol Phys*. 1997;37(1):51–8.
34. Amos EH, Mendenhall WM, McCarty PJ, Gage JO, Emlet JL, Lowrey GC, et al. Postoperative radiotherapy for locally advanced colon cancer. *Ann Surg Oncol*. 1996;3(5):431–6.
35. Martenson Jr JA, Willett CG, Sargent DJ, Mailliard JA, Donohue JH, Gunderson LL, et al. Phase III study of adjuvant chemotherapy and radiation therapy compared with chemotherapy alone in the surgical adjuvant treatment of Colon cancer: results of intergroup protocol 0130. *J Clin Oncol*. 2004;22(16):3277–83.
36. National Comprehensive Cancer Network. Rectal Cancer version 2.2015. 2015. <http://www.nccn.org>.
37. Gunderson LL, et al. Impact of T and N substage on survival and disease relapse in adjuvant rectal cancer: a pooled analysis. *Int J Radiat Oncol Biol Phys*. 2002;54(2):386–96.
38. Monson JR, Weiser MR, Buie WD, Chang GJ, Rafferty JF, et al. Practice parameters for the management of rectal cancer (revised). *Dis Colon Rectum*. 2013;56(5):535–50.
39. Biagi JJ, Raphael MJ, Mackillop WJ, Kong W, King WD, Booth CM. Association between time to initiation of adjuvant chemotherapy and survival in colorectal cancer: a systematic review and meta-analysis. *JAMA*. 2011;305(22):2335–42.
40. Petersen SH, Harling H, Kirkeby LT, Wille-Jørgensen P, Mocellin S. Postoperative adjuvant chemotherapy in rectal cancer operated for cure. *Cochrane Database Syst Rev*. 2012;3, CD004078.

41. Breugom AJ, Swets M, Bosset JF, Collette L, Sainato A, Cionini L, et al. Adjuvant chemotherapy after preoperative (chemo)radiotherapy and surgery for patients with rectal cancer: a systematic review and meta-analysis of individual patient data. *Lancet Oncol.* 2015;16(2):200–7.
42. Hong YS, Nam BH, Kim KP, Kim JE, Park SJ, Park YS, et al. Oxaliplatin, fluorouracil, and leucovorin versus fluorouracil and leucovorin as adjuvant chemotherapy for locally advanced rectal cancer after preoperative chemoradiotherapy (ADORE): an open-label, multicentre, phase 2, randomised controlled trial. *Lancet Oncol.* 2014;15(11):1245–53.
43. Rödel C, Liersch T, Becker H, Fietkau R, Hohenberger W, Hothorn T, et al. Preoperative chemoradiotherapy and postoperative chemotherapy with fluorouracil and oxaliplatin versus fluorouracil alone in locally advanced rectal cancer: initial results of the German CAO/ARO/AIO-04 randomised phase 3 trial. *Lancet Oncol.* 2012;13(7):679–87.
44. Rodel C, et al. Preoperative chemoradiotherapy and postoperative chemotherapy with 5-fluorouracil and oxaliplatin versus 5-fluorouracil alone in locally advanced rectal cancer: results of the German CAO/ARO/AIO-04 randomized phase III trial. *J Clin Oncol.* 2014;32:5s. (suppl; abstr 3500).
45. Fernández-Martos C, Pericay C, Aparicio J, Salud A, Safont M, Massuti B, et al. Phase II, randomized study of concomitant chemoradiotherapy followed by surgery and adjuvant capecitabine plus oxaliplatin (CAPOX) compared with induction CAPOX followed by concomitant chemoradiotherapy and surgery in magnetic resonance imaging-defined, locally advanced rectal cancer: Grupo cancer de recto 3 study. *J Clin Oncol.* 2010;28(5):859–65.
46. Cercek A, Goodman KA, Hajj C, Weisberger E, Segal NH, Reidy-Lagunes DL, et al. Neoadjuvant chemotherapy first, followed by chemoradiation and then surgery, in the management of locally advanced rectal cancer. *J Natl Compr Canc Netw.* 2014;12(4):513–9.
47. Kapiteijn E, Marijnen CA, Nagtegaal ID, Putter H, Steup WH, Wiggers T, et al. Preoperative radiotherapy combined with total mesorectal excision for resectable rectal cancer. *N Engl J Med.* 2001;345(9):638–46.
48. Initial report from a Swedish multicentre study examining the role of preoperative irradiation in the treatment of patients with resectable rectal carcinoma. Swedish Rectal Cancer Trial. *Br J Surg.* 1993;80(10):1333–6.
49. Sauer R, Fietkau R, Wittekind C, Rödel C, Martus P, Hohenberger W, et al. Adjuvant vs. neoadjuvant radiochemotherapy for locally advanced rectal cancer: the German trial CAO/ARO/AIO-94. *Colorectal Dis.* 2003;5(5):406–15.
50. Sauer R, Liersch T, Merkel S, Fietkau R, Hohenberger W, Hess C, et al. Preoperative versus postoperative chemoradiotherapy for locally advanced rectal cancer: results of the German CAO/ARO/AIO-94 randomized phase III trial after a median follow-up of 11 years. *J Clin Oncol.* 2012;30(16):1926–33.
51. Bosset JF, Collette L, Calais G, Mineur L, Maingon P, Radosevic-Jelic L, et al. Chemotherapy with preoperative radiotherapy in rectal cancer. *N Engl J Med.* 2006;355(11):1114–23.
52. Collette L, Bosset JF, den Dulk M, Nguyen F, Mineur L, Maingon P, et al. Patients with curative resection of cT3-4 rectal cancer after preoperative radiotherapy or radiochemotherapy: does anybody benefit from adjuvant fluorouracil-based chemotherapy? A trial of the European Organisation for Research and Treatment of Cancer Radiation Oncology Group. *J Clin Oncol.* 2007;25(28):4379–86.
53. Read TE, Andujar JE, Caushaj PF, Johnston DR, Dietz DW, Myerson RJ, et al. Neoadjuvant

therapy for rectal cancer: histologic response of the primary tumor predicts nodal status. *Dis Colon Rectum*. 2004;47(6):825–31.

54. Garcia-Aguilar J, Shi Q, Thomas Jr CR, Chan E, Cataldo P, Marcet J, et al. A phase II trial of neoadjuvant chemoradiation and local excision for T2N0 rectal cancer: preliminary results of the ACOSOG Z6041 trial. *Ann Surg Oncol*. 2012;19(2):384–91.

55. Noh JM, Park W, Kim JS, Koom WS, Kim JH, Choi DH, et al. Outcome of local excision following preoperative chemoradiotherapy for clinically t2 distal rectal cancer: a multicenter retrospective study (KROG 12-06). *Cancer Res Treat*. 2014;46(3):243–9.

56. Haller DG, Catalano PJ, Macdonald JS, O'Rourke MA, Frontiera MS, Jackson DV, et al. Phase III study of fluorouracil, leucovorin, and levamisole in high-risk stage II and III Colon cancer: final report of Intergroup 0089. *J Clin Oncol*. 2005;23(34):8671–8.

57. Chan AT, Ogino S, Fuchs CS. Aspirin and the risk of colorectal cancer in relation to the expression of COX-2. *N Engl J Med*. 2007;356(21):2131–42.

58. Chan AT, Ogino S, Fuchs CS. Aspirin use and survival after diagnosis of colorectal cancer. *JAMA*. 2009;302(6):649–58.

59. Schrag D, Weiser MR, Goodman KA, Gonen M, Hollywood E, Cercek A, et al. Neoadjuvant chemotherapy without routine use of radiation therapy for patients with locally advanced rectal cancer: a pilot trial. *J Clin Oncol*. 2014;32(6):513–8.

## 第 34 章

1. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2013. *CA Cancer J Clin*. 2013;63(1):11–30. <http://www.ncbi.nlm.nih.gov/pubmed/23335087>.

2. DeSantis CE, Lin CC, Mariotto AB, Siegel RL, Stein KD, Kramer JL, et al. Cancer treatment and survivorship statistics, 2014. *CA Cancer J Clin*. 2014;64(4):252–71. <http://www.ncbi.nlm.nih.gov/pubmed/24890451>.

3. Vernava III A, Longo W, Virgo K, Coplin M, Wade T, Johnson F. Current follow-up strategies after resection of colon cancer. *Dis Colon Rectum*. 1994;37(6):573–83. doi: 10.1007/BF02050993.

4. Grossmann EM, Johnson FE, Virgo KS, Longo WE, Fossati R. Follow-up of colorectal cancer patients after resection with curative intent—the GILDA trial. *Surg Oncol*. 2004;13(2–3):119–24.

5. NCCN Clinical Practice Guidelines in Oncology—Genetic/familial high-risk assessment: colorectal, Version 2.2014. 2014. [http://www.nccn.org/professionals/physician\\_gls/pdf/genetics\\_colon.pdf](http://www.nccn.org/professionals/physician_gls/pdf/genetics_colon.pdf). Accessed 24 Apr 2015.

6. Fahy BN. Follow-up after curative resection of colorectal cancer. *Ann Surg Oncol*. 2014;21(3):738–46. <http://www.ncbi.nlm.nih.gov/pubmed/24271157>.

7. Cancer of the colon and rectum—SEER stat fact sheets. <http://seer.cancer.gov/statfacts/html/colorect.html>. Accessed 2 Apr 2015.

8. Tsikitis VL, Malireddy K, Green EA, Christensen B, Whelan R, Hyder J, et al. Postoperative surveillance recommendations for early stage colon cancer based on results from the clinical outcomes of surgical therapy trial. *J Clin Oncol*. 2009;27(22):3671–6. <http://jco.ascopubs.org/content/27/22/3671.abstract>.

9. Arriola E, Navarro M, Parés D, Muñoz M, Pareja L, Figueras J, et al. Imaging techniques contribute to increased surgical rescue of relapse in the follow-up of colorectal cancer. *Dis Colon*

- Rectum. 2006;49(4):478–84. doi: 10.1007/s10350-005-0280-9.
10. Kobayashi H, Mochizuki H, Sugihara K, Morita T, Kotake K, Teramoto T, et al. Characteristics of recurrence and surveillance tools after curative resection for colorectal cancer: a multicenter study. *Surgery*. 2007;141(1):67–75.
  11. Fong Y, Fortner J, Sun RL, Brennan MF, Blumgart LH. Clinical score for predicting recurrence after hepatic resection for metastatic colorectal cancer: analysis of 1001 consecutive cases. *Ann Surg*. 1999;230(3):309–18. discussion 318–21.
  12. Sargent D, Sobrero A, Grothey A, O’Connell MJ, Buyse M, Andre T, et al. Evidence for cure by adjuvant therapy in colon cancer: observations based on individual patient data from 20,898 patients on 18 randomized trials. *J Clin Oncol*. 2009;27(6):872–7. <http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2738431/>.
  13. Seo SI, Lim S-B, Yoon YS, Kim CW, Yu CS, Kim TW, et al. Comparison of recurrence patterns between  $\leq 5$  years and  $> 5$  years after curative operations in colorectal cancer patients. *J Surg Oncol*. 2013;108(1):9–13. <http://www.ncbi.nlm.nih.gov/pubmed/23754582>.
  14. Fora A, Patta A, Attwood K, Wilding G, Fakih M. Intensive radiographic and biomarker surveillance in stage II and III colorectal cancer. *Oncology*. 2012;82(1):41–7.
  15. Sargent DJ, Patiyil S, Yothers G, Haller DG, Gray R, Benedetti J, et al. End points for colon cancer adjuvant trials: observations and recommendations based on individual patient data from 20,898 patients enrolled onto 18 randomized trials from the ACCENT group. *J Clin Oncol*. 2007;25(29):4569–74.
  16. Ohlsson B, Breland U, Ekberg H, Graffner H, Tranberg KG. Follow-up after curative surgery for colorectal carcinoma. Randomized comparison with no follow-up. *Dis Colon Rectum*. 1995;38(6):619–26.
  17. Makela JT, Laitinen SO, Kairaluoma MI. Five-year follow-up after radical surgery for colorectal cancer. Results of a prospective randomized trial. *Arch Surg*. 1995;130(10):1062–7.
  18. Kjeldsen BJ, Kronborg O, Fenger C, Jorgensen OD. A prospective randomized study of follow-up after radical surgery for colorectal cancer. *Br J Surg*. 1997;84(5):666–9. <http://www.ncbi.nlm.nih.gov/pubmed/9171758>.
  19. Schoemaker D, Black R, Giles L, Toouli J. Yearly colonoscopy, liver CT, and chest radiography do not influence 5-year survival of colorectal cancer patients. *Gastroenterology*. 1998;114(1):7–14. <http://www.sciencedirect.com/science/article/pii/S0016508598706262>.
  20. Rodríguez-Moranta F, Saló J, Arcusa A, Boadas J, Piñol V, Bessa X, et al. Postoperative surveillance in patients with colorectal cancer who have undergone curative resection: a prospective, multicenter, randomized, controlled trial. *J Clin Oncol*. 2006;24(3):386–93.
  21. Pietra N, Sarli L, Costi R, Ouchemi C, Grattarola M, Peracchia A. Role of follow-up in management of local recurrences of colorectal cancer. *Dis Colon Rectum*. 1998;41(9):1127–33. doi: 10.1007/BF02239434.
  22. Secco GB, Fardelli R, Gianquinto D, Bonfante P, Baldi E, Ravera G, et al. Efficacy and cost of risk-adapted follow-up in patients after colorectal cancer surgery: a prospective, randomized and controlled trial. *Eur J Surg Oncol*. 2002;28(4):418–23. <http://www.sciencedirect.com/science/article/pii/S0748798301912508>.
  23. Primrose JN, Perera R, Gray A, Rose P, Fuller A, Corkhill A, et al. Effect of 3 to 5 years of scheduled CEA and CT follow-up to detect recurrence of colorectal cancer: the FACS randomized clinical trial. *JAMA*. 2014;311(3):263–70. <http://www.ncbi.nlm.nih.gov/pubmed/24430319>.

24. Baca B, Beart RW, Etzioni DA. Surveillance after colorectal cancer resection: a systematic review. *Dis Colon Rectum*. 2011;54(8):1036–48.
25. Jeffery M, Hickey B, Hider P. Follow up strategies for patients treated for non-metastatic colorectal cancer. *Cochrane Database Syst Rev*. 2007;1, CD002200. <http://espace.library.uq.edu.au/view/UQ:137177>.
26. Tjandra J, Chan MY. Follow-up after curative resection of colorectal cancer: a meta-analysis. *Dis Colon Rectum*. 2007;50(11):1783–99. doi: 10.1007/s10350-007-9030-5.
27. Jain N, Pietrobon R, Hocker S, Guller U, Shankar A, Higgins LD. The relationship between surgeon and hospital volume and outcomes for shoulder arthroplasty. *J Bone Joint Surg Am*. 2004;86-A(3):496–505.
28. Pita-Fernandez S, Alhayek-Ai M, Gonzalez-Martin C, Lopez-Calvino B, Seoane-Pillado T, Pertega-Diaz S. Intensive follow-up strategies improve outcomes in nonmetastatic colorectal cancer patients after curative surgery: a systematic review and meta-analysis. *Ann Oncol*. 2015;26(4):644–56. doi: 10.1093/annonc/mdu543.
29. Renehan AG, Egger M, Saunders MP, O'Dwyer ST. Impact on survival of intensive follow up after curative resection for colorectal cancer: systematic review and meta-analysis of randomised trials. *BMJ*. 2002;324(7341):1–8.
30. Colofol—evaluation of the frequency of a surveillance program. <http://www.colofol.com>. Accessed 17 Apr 2015.
31. Juul T, Ahlberg M, Biondo S, Emmertsen KJ, Espin E, Jimenez LM, et al. International validation of the low anterior resection syndrome score. *Ann Surg*. 2014;259(4):728–34. <http://www.ncbi.nlm.nih.gov/pubmed/23598379>.
32. Peeters KCMJ, van de Velde CJH, Leer JWH, Martijn H, Junggeburst JMC, Kranenbarg EK, et al. Late side effects of short-course preoperative radiotherapy combined with total mesorectal excision for rectal cancer: increased bowel dysfunction in irradiated patients—a Dutch colorectal cancer group study. *J Clin Oncol*. 2005;23(25):6199–206.
33. Ramsey SD, Berry K, Moinpour C, Giedzinska A, Andersen MR. Quality of life in long term survivors of colorectal cancer. *Am J Gastroenterol*. 2002;97(5):1228–34.
34. Meyerhardt JA, Niedzwiecki D, Hollis D, Saltz LB, Hu FB, Mayer RJ, et al. Association of dietary patterns with cancer recurrence and survival in patients with stage III colon cancer. *JAMA*. 2007;298(7):754–64.
35. McCullough ML, Gapstur SM, Shah R, Jacobs EJ, Campbell PT. Association between red and processed meat intake and mortality among colorectal cancer survivors. *J Clin Oncol*. 2013;31(22):2773–82.
36. Meyerhardt JA, Heseltine D, Niedzwiecki D, Hollis D, Saltz LB, Mayer RJ, et al. Impact of physical activity on cancer recurrence and survival in patients with stage III colon cancer: findings from CALGB 89803. *J Clin Oncol*. 2006;24(22):3535–41. [http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list\\_uids=16822843](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=16822843).
37. Steele SR, Chang G, Hendren S, Weiser MR, Irani J, Buie WD, et al. Practice guidelines for the surveillance of patients after curative treatment of colon and rectal cancer. *Dis Colon Rectum*. 2015;58(8):713–25.
38. Chau I, Allen MJ, Cunningham D, Norman AR, Brown G, Ford HER, et al. The value of routine serum carcino-embryonic antigen measurement and computed tomography in the surveillance of



- patients after adjuvant chemotherapy for colorectal cancer. *J Clin Oncol.* 2004;22(8):1420–9.
39. Graham RA, Wang S, Catalano PJ, Haller DG. Postsurgical surveillance of colon cancer: preliminary cost analysis of physician examination, carcinoembryonic antigen testing, chest X-ray, and colonoscopy. *Ann Surg.* 1998;228(1):59–63.
  40. Moertel CG, Fleming TR, Macdonald JS, Haller DG, Laurie JA, Tangen C. An evaluation of the carcinoembryonic antigen (CEA) test for monitoring patients with resected colon cancer. *JAMA.* 1993;270(8):943–7.
  41. Glover C, Douse P, Kane P, Karani J, Meire H, Mohammadtaghi S, et al. Accuracy of investigations for asymptomatic colorectal liver metastases. *Dis Colon Rectum.* 2002;45(4):476–84.
  42. Carriquiry LA, Piñeyro A. Should carcinoembryonic antigen be used in the management of patients with colorectal cancer? *Dis Colon Rectum.* 1999;42(7):921–9.
  43. Tan E, Gouvas N, Nicholls RJ, Ziprin P, Xynos E, Tekkis PP. Diagnostic precision of carcinoembryonic antigen in the detection of recurrence of colorectal cancer. *Surg Oncol.* 2009;18(1):15–24.
  44. Metser U, You J, McSweeney S, Freeman M, Hendler A. Assessment of tumor recurrence in patients with colorectal cancer and elevated carcinoembryonic antigen level: FDG PET/CT versus contrast-enhanced 64-MDCT of the chest and abdomen. *Am J Roentgenol.* 2010;194(3):766–71.
  45. Irvine T, Scott M, Clark CI. A small rise in CEA is sensitive for recurrence after surgery for colorectal cancer. *Colorectal Dis.* 2007;9(6):527–31.
  46. Verberne C, Wiggers T, Vermeulen KM, de Jong KP. Detection of recurrences during follow-up after liver surgery for colorectal metastases: both Carcino-Embryonic Antigen (CEA) and imaging are important. *Ann Surg Oncol.* 2013;20:457–63.
  47. Goslin R, O'Brien MJ, Steele G, Mayer R, Wilson R, Corson JM, et al. Correlation of plasma CEA and CEA tissue staining in poorly differentiated colorectal cancer. *Am J Med.* 1981;71(2):246–53.
  48. NCCN Clinical Practice Guidelines in Oncology: colon cancer. [http://www.nccn.org/professionals/physician\\_gls/pdf/colon.pdf](http://www.nccn.org/professionals/physician_gls/pdf/colon.pdf). Accessed 14 Apr 2015.
  49. NCCN Clinical Practice Guidelines in Oncology: rectal cancer. [http://www.nccn.org/professionals/physician\\_gls/pdf/rectal.pdf](http://www.nccn.org/professionals/physician_gls/pdf/rectal.pdf). Accessed 14 Apr 2015.
  50. Kjeldsen BJ, Kronborg O, Fenger C, Jørgensen OD. The pattern of recurrent colorectal cancer in a prospective randomised study and the characteristics of diagnostic tests. *Int J Color Dis.* 1997;12(6):329–34.
  51. Earle C, Annis R, Sussman J, Haynes AE, Vafaei A. Follow-up care, surveillance protocol, and secondary prevention measures for survivors of colorectal cancer. Toronto, ON; 2012. <https://www.cancercare.on.ca/common/pages/UserFile.aspx?fileId=124839>.
  52. Labianca R, Nordlinger B, Beretta GD, Mosconi S, Mandalà M, Cervantes A, et al. Early colon cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. *Ann Oncol.* 2013;24 suppl 6:vi64–72. [http://annonc.oxfordjournals.org/content/24/suppl\\_6/vi64.short](http://annonc.oxfordjournals.org/content/24/suppl_6/vi64.short).
  53. Anthony T, Simmang C, Hyman N, Buie D, Kim D, Cataldo P, et al. Practice parameters for the surveillance and follow-up of patients with colon and rectal cancer. *Dis Colon Rectum.* 2004;47(6):807–17. [http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list\\_uids=15108028](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=15108028).
  54. Cummings LC, Payes JD, Cooper GS. Survival after hepatic resection in metastatic colorectal

- cancer: a population-based study. *Cancer*. 2007;109(4):718–26.
55. Meyerhardt JA, Mangu PB, Flynn PJ, Korde L, Loprinzi CL, Minsky BD, et al. Follow-up care, surveillance protocol, and secondary prevention measures for survivors of colorectal cancer: American Society of Clinical Oncology clinical practice guideline endorsement. *J Clin Oncol*. 2013;31(35):4465–70. <http://www.ncbi.nlm.nih.gov/pubmed/24220554>.
56. Sobhani I, Tired E, Lebtahi R, Aparicio T, Itti E, Montravers F, et al. Early detection of recurrence by 18FDG-PET in the follow-up of patients with colorectal cancer. *Br J Cancer*. 2008;98(5):875–80.
57. Patel K, Hadar N, Lee J, Siegel BA, Hillner BE, Lau J. The lack of evidence for PET or PET/CT surveillance of patients with treated lymphoma, colorectal cancer, and head and neck cancer: a systematic review. *J Nucl Med*. 2013;54(9):1518–27. <http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=3980728&tool=pmcentrez&rendertype=abstract>.
58. Flanagan FL, Dehdashti F, Ogunbiyi OA, Kodner IJ, Siegel BA. Utility of FDG-PET for investigating unexplained plasma CEA elevation in patients with colorectal cancer. *Ann Surg*. 1998;227(3):319–23.
59. Flamen P, Hoekstra OS, Homans F, Van Cutsem E, Maes A, Stroobants S, et al. Unexplained rising carcinoembryonic antigen (CEA) in the postoperative surveillance of colorectal cancer: the utility of positron emission tomography (PET). *Eur J Cancer*. 2001;37(7):862–9.
60. Shen Y-Y, Liang J-A, Chen Y-K, Tsai C-Y, Kao C-H. Clinical impact of 18F-FDG-PET in the suspicion of recurrent colorectal cancer based on asymptotically elevated serum level of carcinoembryonic antigen (CEA) in Taiwan. *Hepatogastroenterology*. 2006;53(69):348–50.
61. Kyoto Y, Momose M, Kondo C, Itabashi M, Kameoka S, Kusakabe K. Ability of 18F-FDG PET/CT to diagnose recurrent colorectal cancer in patients with elevated CEA concentrations. *Ann Nucl Med*. 2010;24(5):395–401.
62. Lu YY, Chen JH, Chien CR, Chen WTL, Tsai SC, Lin WY, et al. Use of FDG-PET or PET/CT to detect recurrent colorectal cancer in patients with elevated CEA: a systematic review and meta-analysis. *Int J Colorectal Dis*. 2013;28(8):1039–47.
63. Huebner RH, Park KC, Shepherd JE, Schwimmer J, Czernin J, Phelps ME, et al. A meta-analysis of the literature for whole-body FDG PET detection of recurrent colorectal cancer. *J Nucl Med*. 2000;41:1177–89. <http://www.ncbi.nlm.nih.gov/pubmed/10914907>.
64. Grossmann I, Doornbos PM, Klaase JM, de Bock GH, Wiggers T. Changing patterns of recurrent disease in colorectal cancer. *Eur J Surg Oncol*. 2014;40:234–9.
65. Ohlsson B, Pålsson B. Follow-up after colorectal cancer surgery. *Acta Oncol*. 2003;42(8):816–26. doi: 10.1080/02841860310019016.
66. Ding P, Liska D, Tang P, Shia J, Saltz L, Goodman K, et al. Pulmonary recurrence predominates after combined modality therapy for rectal cancer. *Ann Surg*. 2012;256(1):111–6.
67. Nordholm-Carstensen A, Krarup P-M, Jorgensen LN, Wille-Jorgensen PA, Harling H. Occurrence and survival of synchronous pulmonary metastases in colorectal cancer: a nationwide cohort study. *Eur J Cancer*. 2014;50(2):447–56.
68. Piñol V, Andreu M, Castells A, Payá A, Bessa X, Jover R. Synchronous colorectal neoplasms in patients with colorectal cancer: predisposing individual and familial factors. *Dis Colon Rectum*. 2004;47(7):1192–200. doi: 10.1007/s10350-004-0562-7.
69. Van Leersum NJ, Aalbers AG, Snijders HS, Henneman D, Wouters MW, Tollenaar RA, et al.

Synchronous colorectal carcinoma: a risk factor in colorectal cancer surgery. *Dis Colon Rectum*. 2014;57(4):460–6.

[http://journals.lww.com/dcrjournal/Fulltext/2014/04000/Synchronous\\_Colorectal\\_Carcinoma\\_\\_\\_A\\_Risk\\_Factor.8.aspx](http://journals.lww.com/dcrjournal/Fulltext/2014/04000/Synchronous_Colorectal_Carcinoma___A_Risk_Factor.8.aspx).

70. Rex DK, Kahi CJ, Levin B, Smith RA, Bond JH, Brooks D, et al. Guidelines for colonoscopy surveillance after cancer resection: a consensus update by the American Cancer Society and the US multi-society task force on colorectal cancer. *Gastroenterology*. 2006;130(6):1865–71.

71. Cone MM, Beck DE, Hicks TE, Rea JD, Whitlow CB, Vargas HD, et al. Timing of colonoscopy after resection for colorectal cancer: are we looking too soon? *Dis Colon Rectum*. 2013;56(11):1233–6.

[http://journals.lww.com/dcrjournal/Fulltext/2013/11000/Timing\\_of\\_Colonoscopy\\_After\\_Resection\\_for.7.aspx](http://journals.lww.com/dcrjournal/Fulltext/2013/11000/Timing_of_Colonoscopy_After_Resection_for.7.aspx).

72. Scholefield JH, Steele RJ. Guidelines for follow up after resection of colorectal cancer. *Gut*. 2002;51 suppl 5:v3–5. [http://gut.bmj.com/content/51/suppl\\_5/v3.short](http://gut.bmj.com/content/51/suppl_5/v3.short).

73. Cairns SR, Scholefield JH, Steele RJ, Dunlop MG, Thomas HJW, Evans GD, et al. Guidelines for colorectal cancer screening and surveillance in moderate and high risk groups (update from 2002). *Gut*. 2010;59(5):666–89.

74. Cali RL, Pitsch RM, Thorson AG, Watson P, Tapia P, Blatchford GJ, et al. Cumulative incidence of metachronous colorectal cancer. *Dis Colon Rectum*. 1993;36(4):388–93.

75. Wang T, Cui Y, Huang W-S, Deng Y-H, Gong W, Li C, et al. The role of postoperative colonoscopic surveillance after radical surgery for colorectal cancer: a prospective, randomized clinical study. *Gastrointest Endosc*. 2009;69(3, Part 2):609–15. <http://www.sciencedirect.com/science/article/pii/S0016510708018397>.

76. Lan Y-T, Lin J-K, Li A-Y, Lin T-C, Chen W-S, Jiang J-K, et al. Metachronous colorectal cancer: necessity of post-operative colonoscopic surveillance. *Int J Colorectal Dis*. 2005;20(2):121–5. doi: 10.1007/s00384-004-0635-z.

77. Barillari P, Ramacciato G, Manetti G, Bovino A, Sammartino P, Stipa V. Surveillance of colorectal cancer: effectiveness of early detection of intraluminal recurrences on prognosis and survival of patients treated for cure. *Dis Colon Rectum*. 1996;39(4):388–93. [http://journals.lww.com/dcrjournal/Fulltext/1996/39040/Surveillance\\_of\\_colorectal\\_cancer\\_\\_\\_Effectiveness.5.aspx](http://journals.lww.com/dcrjournal/Fulltext/1996/39040/Surveillance_of_colorectal_cancer___Effectiveness.5.aspx).

78. Green RJ, Metlay JP, Propert K, Catalano PJ, Macdonald JS, Mayer RJ, et al. Surveillance for second primary colorectal cancer after adjuvant chemotherapy: an analysis of intergroup 0089. *Ann Intern Med*. 2002;136(4):261–9. doi: 10.7326/0003-4819-136-4-200202190-00005.

79. Glimelius B, Tiret E, Cervantes A, Arnold D, Group on behalf of the EGW. Rectal cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. *Ann Oncol*. 2013;24 suppl 6:vi81–8. [http://annonc.oxfordjournals.org/content/24/suppl\\_6/vi81.short](http://annonc.oxfordjournals.org/content/24/suppl_6/vi81.short).

80. Davila RE, Rajan E, Baron TH. ASGE guideline: colorectal cancer screening and surveillance. *Gastrointest Endosc*. 2006;63(4):546–57. <http://www.ncbi.nlm.nih.gov/pubmed/16564851>.

81. Mulder SA, Kranse R, Damhuis RA, Ouwendijk RJ, Kuipers EJ, van Leerdam ME. The incidence and risk factors of metachronous colorectal cancer: an indication for follow-up. *Dis Colon Rectum*. 2012;55(5):522–31.

[http://journals.lww.com/dcrjournal/Fulltext/2012/05000/The\\_Incidence\\_and\\_Risk\\_Factors\\_of\\_Metachronous.5.aspx](http://journals.lww.com/dcrjournal/Fulltext/2012/05000/The_Incidence_and_Risk_Factors_of_Metachronous.5.aspx).

82. Bouvier A-M, Latournerie M, Jooste V, Lepage C, Cottet V, Faivre J. The lifelong risk of metachronous colorectal cancer justifies long-term colonoscopic follow-up. *Eur J Cancer*. 2008;44(4):522–7. <http://www.sciencedirect.com/science/article/pii/S0959804908000129>.
83. Chen F, Stuart M. Colonoscopic follow-up of colorectal carcinoma. *Dis Colon Rectum*. 1994;37(6):568–72. doi: 10.1007/BF02050992.
84. Battersby NJ, Coupland A, Bouliotis G, Mirza N, Williams JG. Metachronous colorectal cancer: a competing risks analysis with consideration for a stratified approach to surveillance colonoscopy. *J Surg Oncol*. 2014;109(5):445–50.
85. Day LW, Walter LC, Velayos F. Colorectal cancer screening and surveillance in the elderly patient. *Am J Gastroenterol*. 2011;106(7):1197–206. doi: 10.1038/ajg.2011.128.
86. Tran AH, Man Ngor EW, Wu BU. Surveillance colonoscopy in elderly patients: a retrospective cohort study. *JAMA*. 2014;90027(10):1675–82. <http://www.ncbi.nlm.nih.gov/pubmed/25111954>.
87. Winawer SJ, Stewart ET, Zauber AG, Bond JH, Ansel H, Waye JD, et al. A comparison of colonoscopy and double-contrast barium enema for surveillance after polypectomy. *N Engl J Med*. 2000;342(24):1766–72. doi: 10.1056/NEJM200006153422401.
88. Choi YJ, Park SH, Lee SS, Choi EK, Yu CS, Kim HC, et al. CT colonography for follow-up after surgery for colorectal cancer. *AJR Am J Roentgenol*. 2007;189(2):283–9.
89. Kim HJ, Park SH, Pickhardt PJ, Yoon SN, Lee SS, Yee J, et al. CT colonography for combined colonic and extracolonic surveillance after curative resection of colorectal cancer. *Radiology*. 2010;257(3):697–704.
90. Cotton PB, Durkalski VL, Pineau BC, Palesch YY, Mauldin PD, Hoffman B, et al. Computed tomographic colonography (virtual colonoscopy): a multicenter comparison with standard colonoscopy for detection of colorectal neoplasia. *JAMA*. 2004;291(14):1713–9.
91. Zakaria S, Donohue JH, Que FG, Farnell MB, Schleck CD, Ilstrup DM, et al. Hepatic resection for colorectal metastases: value for risk scoring systems? *Ann Surg*. 2007;246(2):183–91.
92. Chao M, Gibbs P. Caution is required before recommending routine carcinoembryonic antigen and imaging follow-up for patients with early-stage colon cancer. *J Clin Oncol*. 2009;27(36):e279–80. <http://jco.ascopubs.org/content/27/36/e279.long>.
93. A comparison of laparoscopically assisted and open colectomy for colon cancer. *N Engl J Med*. 2004;350(20):2050–9. <http://www.ncbi.nlm.nih.gov/pubmed/15141043>
94. Cancer Genome Atlas Network. Comprehensive molecular characterization of human colon and rectal cancer. *Nature*. 2012;487(7407):330–7. <http://www.ncbi.nlm.nih.gov/pubmed/22810696>.
95. Zhuang C-L, Ye X-Z, Zhang X-D, Chen B-C, Yu Z. Enhanced recovery after surgery programs versus traditional care for colorectal surgery: a meta-analysis of randomized controlled trials. *Dis Colon Rectum*. 2013;56(5):667–78. doi: 10.1097/DCR.0b013e3182812842.
96. Yamauchi M, Morikawa T, Kuchiba A, Imamura Y, Qian ZR, Nishihara R, et al. Assessment of colorectal cancer molecular features along bowel subsites challenges the conception of distinct dichotomy of proximal versus distal colorectum. *Gut*. 2012;61(6):847–54. <http://www.ncbi.nlm.nih.gov/pubmed/22427238>.
97. Sauer R, Liersch T, Merkel S, Fietkau R, Hohenberger W, Hess C, et al. Preoperative versus postoperative chemoradiotherapy for locally advanced rectal cancer: results of the German CAO/ARO/AIO-94 randomized phase III trial after a median follow-up of 11 years. *J Clin Oncol*. 2012;30(16):1926–33. <http://www.ncbi.nlm.nih.gov/pubmed/22529255>.
98. Quirke P, Steele R, Monson J, Grieve R, Khanna S, Couture J, et al. Effect of the plane of surgery

- achieved on local recurrence in patients with operable rectal cancer: a prospective study using data from the MRC CR07 and NCIC-CTG CO16 randomised clinical trial. *Lancet*. 2009;373(9666):821–8. <http://www.ncbi.nlm.nih.gov/pubmed/19269520>.
99. Van Gijn W, Marijnen CA, Nagtegaal ID, Kranenbarg EM, Putter H, Wiggers T, et al. Preoperative radiotherapy combined with total mesorectal excision for resectable rectal cancer: 12-year follow-up of the multicentre, randomised controlled TME trial. *Lancet Oncol*. 2011;12(6):575–82. <http://www.ncbi.nlm.nih.gov/pubmed/21596621>.
  100. Kusters M, Marijnen CA, van de Velde CJ, Rutten HJ, Lahaye MJ, Kim JH, et al. Patterns of local recurrence in rectal cancer; a study of the Dutch TME trial. *Eur J Surg Oncol*. 2010;36(5):470–6. <http://www.ncbi.nlm.nih.gov/pubmed/20096534>.
  101. Rasanen M, Carpelan-Holmstrom M, Mustonen H, Renkonen-Sinisalo L, Lepisto A. Pattern of rectal cancer recurrence after curative surgery. *Int J Colorectal Dis*. 2015;30(6):775–85. <http://www.ncbi.nlm.nih.gov/pubmed/25796493>.
  102. MacFarlane JK, Ryall RD, Heald RJ. Mesorectal excision for rectal cancer. *Lancet*. 1993;341(8843):457–60. <http://www.ncbi.nlm.nih.gov/pubmed/8094488>.
  103. Wibe A, Rendedal PR, Svensson E, Norstein J, Eide TJ, Myrvold HE, et al. Prognostic significance of the circumferential resection margin following total mesorectal excision for rectal cancer. *Br J Surg*. 2002;89(3):327–34. [http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list\\_uids=11872058](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=11872058).
  104. Nagtegaal ID, van de Velde CJ, van der Worp E, Kapiteijn E, Quirke P, van Krieken JH. Macroscopic evaluation of rectal cancer resection specimen: clinical significance of the pathologist in quality control. *J Clin Oncol*. 2002;20(7):1729–34. [http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list\\_uids=11919228](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=11919228).
  105. Patel SA, Chen Y-H, Hornick JL, Catalano P, Nowak JA, Zukerberg LR, et al. Early-stage rectal cancer: clinical and pathologic prognostic markers of time to local recurrence and overall survival after resection. *Dis Colon Rectum*. 2014;57(4):449–59. <http://www.ncbi.nlm.nih.gov/pubmed/24608301>.
  106. Park IJ, You YN, Agarwal A, Skibber JM, Rodriguez-Bigas MA, Eng C, et al. Neoadjuvant treatment response as an early response indicator for patients with rectal cancer. *J Clin Oncol*. 2012;30(15):1770–6. <http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=3383178&tool=pmcentrez&rendertype=abstract>.
  107. Trakarnsanga A, Gonen M, Shia J, Goodman KA, Nash GM, Temple LK, et al. What is the significance of the circumferential margin in locally advanced rectal cancer after neoadjuvant chemoradiotherapy? *Ann Surg Oncol*. 2013;20(4):1179–84. <http://www.ncbi.nlm.nih.gov/pubmed/23328971>.
  108. Nagtegaal ID, Quirke P. What is the role for the circumferential margin in the modern treatment of rectal cancer? *J Clin Oncol*. 2008;26(2):303–12. <http://www.ncbi.nlm.nih.gov/pubmed/18182672>.
  109. Lohnert MS, Doniec JM, Henne-Bruns D. Effectiveness of endoluminal sonography in the identification of occult local rectal cancer recurrences. *Dis Colon Rectum*. 2000;43(4):483–91. <http://www.ncbi.nlm.nih.gov/pubmed/10789743>.
  110. De Anda EH, Lee SH, Finne CO, Rothenberger DA, Madoff RD, Garcia-Aguilar J. Endorectal

ultrasound in the follow-up of rectal cancer patients treated by local excision or radical surgery. *Dis Colon Rectum*. 2004;47(6):818–24. <http://www.ncbi.nlm.nih.gov/pubmed/15085436>.

111. Ramirez JM, Mortensen NJ, Takeuchi N, Humphreys MM. Endoluminal ultrasonography in the follow-up of patients with rectal cancer. *Br J Surg*. 1994;81(5):692–4.

112. Morken JJ, Baxter NN, Madoff RD, Finne 3rd CO. Endorectal ultrasound-directed biopsy: a useful technique to detect local recurrence of rectal cancer. *Int J Color Dis*. 2006;21(3):258–64. <http://www.ncbi.nlm.nih.gov/pubmed/15942740>.

113. Gleeson FC, Larson DW, Dozois EJ, Boardman LA, Clain JE, Rajan E, et al. Local recurrence detection following transanal excision facilitated by EUS-FNA. *Hepatogastroenterology*. 2012;59(116):1102–7. <http://www.ncbi.nlm.nih.gov/pubmed/22281976>.

114. Maleki Z, Erozan Y, Geddes S, Li QK. Endorectal ultrasound-guided fine-needle aspiration: a useful diagnostic tool for perirectal and intraluminal lesions. *Acta Cytol*. 2013;57(1):9–18. doi: 10.1159/000342919.

115. Lambregts DM, Cappendijk VC, Maas M, Beets GL, Beets-Tan RG. Value of MRI and diffusion-weighted MRI for the diagnosis of locally recurrent rectal cancer. *Eur Radiol*. 2011;21(6):1250–8. <http://www.ncbi.nlm.nih.gov/pubmed/21240647>.

116. Titu LV, Nicholson AA, Hartley JE, Breen DJ, Monson JR. Routine follow-up by magnetic resonance imaging does not improve detection of resectable local recurrences from colorectal cancer. *Ann Surg*. 2006;243(3):348–52. <http://www.ncbi.nlm.nih.gov/pubmed/16495699>.

117. Nash GM, Weiser MR, Guillem JG, Temple LK, Shia J, Gonen M, et al. Long-term survival after transanal excision of T1 rectal cancer. *Dis Colon Rectum*. 2009;52(4):577–82.

118. You YN, Baxter NN, Stewart A, Nelson H. Is the increasing rate of local excision for stage I rectal cancer in the United States justified? A nationwide cohort study from the National Cancer Database. *Ann Surg*. 2007;245(5):726–33.

119. Paty PB, Nash GM, Baron P, Zakowski M, Minsky BD, Blumberg D, et al. Long-term results of local excision for rectal cancer. *Ann Surg*. 2002;236(4):522–30.

120. Mellgren A, Sirivongs P, Rothenberger DA, Madoff RD, Garcia-Aguilar J. Is local excision adequate therapy for early rectal cancer? *Dis Colon Rectum*. 2000;43(8):1064. <http://www.ncbi.nlm.nih.gov/pubmed/10950004>.

121. Habr-Gama A, Perez RO, Sabbaga J, Nadalin W, São Julião GP, Gama-Rodrigues J. Increasing the rates of complete response to neoadjuvant chemoradiotherapy for distal rectal cancer: results of a prospective study using additional chemotherapy during the resting period. *Dis Colon Rectum*. 2009;52(12):1927–34.

122. Smith JD, Ruby JA, Goodman KA, Saltz LB, Guillem JG, Weiser MR, et al. Nonoperative management of rectal cancer with complete clinical response after neoadjuvant therapy. *Ann Surg*. 2012;256(6):965–72. <http://www.ncbi.nlm.nih.gov/pubmed/23154394>.

123. Smith JJ, Chow OS, Eaton A, Widmar M, Nash GM, Temple LKF, et al. Organ preservation in patients with rectal cancer with clinical complete response after neoadjuvant therapy. *J Clin Oncol*. 2015;33(suppl 3):a509. <http://meetinglibrary.asco.org/content/140433-158>.

124. Weiser MR, Beets-Tan R, Beets G. Management of complete response after chemoradiation in rectal cancer. *Surg Oncol Clin N Am*. 2014;23(1):113–25. <http://www.ncbi.nlm.nih.gov/pubmed/24267169>.

125. Habr-Gama A, Perez RO, Proscurshim I, Campos FG, Nadalin W, Kiss D, et al. Patterns of failure and survival for nonoperative treatment of stage c0 distal rectal cancer following neoadjuvant

chemoradiation therapy. *J Gastrointest Surg.* 2006;10(10):1319.  
<http://www.ncbi.nlm.nih.gov/pubmed/17175450>.

126. Castells A, Bessa X, Daniels M, Ascaso C, Lacy AM, Garcia-Valdecasas JC, et al. Value of postoperative surveillance after radical surgery for colorectal cancer: results of a cohort study. *Dis Colon Rectum.* 1998;41(6):714–23. discussion 723–4.

127. Laubert T, Bader FG, Oevermann E, Jungbluth T, Unger L, Roblick UJ, et al. Intensified surveillance after surgery for colorectal cancer significantly improves survival. *Eur J Med Res.* 2010;15(1):25–30.

128. Vargas GM, Sheffield KM, Parmar AD, Han Y, Brown KM, Riall TS. Physician follow-up and observation of guidelines in the post treatment surveillance of colorectal cancer. *Surgery.* 2013;154(2):244–55. doi: 10.1016/j.surg.2013.04.013.

129. Sisler JJ, Seo B, Katz A, Shu E, Chateau D, Czaykowski P, et al. Concordance with ASCO guidelines for surveillance after colorectal cancer treatment: a population-based analysis. *J Oncol Pract.* 2012;8(4):e69–79. <http://jop.ascopubs.org/content/8/4/e69.abstract>.

130. Cheung WY, Pond GR, Rother M, Krzyzanowska MK, Swallow C, Brierley J, et al. Adherence to surveillance guidelines after curative resection for stage II/III colorectal cancer. *Clin Colorectal Cancer.* 2008;7(3):191–6. <http://www.sciencedirect.com/science/article/pii/S1533002811704194>.

131. Grossmann I, de Bock GH, van de Velde CJH, Kievit J, Wiggers T. Results of a national survey among Dutch surgeons treating patients with colorectal carcinoma. Current opinion about follow-up, treatment of metastasis, and reasons to revise follow-up practice. *Colorectal Dis.* 2007;9(9):787–92.

132. Van Steenberghe LN, de Hingh IHJT, Rutten HJT, Rijk MCM, Orsini RG, Coebergh JWW, et al. Large variation between hospitals in follow-up for colorectal cancer in southern Netherlands. *Int J Colorectal Dis.* 2013;28(9):1257–65. doi: 10.1007/s00384-013-1693-x.

133. Søreide K, Træland JH, Stokkeland PJ, Glomsaker T, Søreide JA, Kørner H. Adherence to national guidelines for surveillance after curative resection of nonmetastatic colon and rectum cancer: a survey among Norwegian gastrointestinal surgeons. *Colorectal Dis.* 2012;14(3):320–4. doi: 10.1111/j.1463-1318.2011.02631.x.

134. Cooper GS, Kou TD, Reynolds HL. Receipt of guideline-recommended follow-up in older colorectal cancer survivors. *Cancer.* 2008;113(8):2029–37. doi: 10.1002/cncr.23823.

135. Giordano P, Efron J, Vernava AM, Weiss EG, Nogueras JJ, Wexner SD. Strategies of follow-up for colorectal cancer: a survey of the American society of colon and rectal surgeons. *Tech Coloproctol.* 2006;10(3):199–207.

136. Cardella J, Coburn NG, Gagliardi A, Maier B-A, Greco E, Last L, et al. Compliance, attitudes and barriers to post-operative colorectal cancer follow-up. *J Eval Clin Pract.* 2008;14(3):407–15. doi: 10.1111/j.1365-2753.2007.00880.x.

137. Wattchow DA, Weller DP, Esterman AJ, Pilotto L. General practice vs. surgical-based follow-up for patients with colon cancer: randomised controlled trial. *Br J Cancer.* 2006;94(8):1116–21.

138. Augestad KM, Norum J, Dehof S, Aspevik R, Ringberg U, Nestvold T, et al. Cost-effectiveness and quality of life in surgeon versus general practitioner-organised colon cancer surveillance: a randomised controlled trial. *BMJ Open.* 2013;3(4):e002391. <http://bmjopen.bmj.com/content/3/4/e002391.abstract>.

139. Haggstrom D, Arora N, Helft P, Clayman M, Oakley-Girvan I. Follow-up care delivery among colorectal cancer survivors most often seen by primary and subspecialty care physicians. *J Gen*

Intern Med. 2009;24(2):472–9. doi: 10.1007/s11606-009-1017-6.

140. Standeven L, Price Hiller J, Mulder K, Zhu G, Ghosh S, Spratlin JL. Impact of a dedicated cancer center surveillance program on guideline adherence for patients with stage II and III colorectal cancer. *Clin Colorectal Cancer*. 2013;12(2):103–12. doi: 10.1016/j.clcc.2012.09.006.

141. Strand E, Nygren I, Bergkvist L, Smedh K. Nurse or surgeon follow-up after rectal cancer: a randomized trial. *Colorectal Dis*. 2011;13(9):999–1003. doi: 10.1111/j.1463-1318.2010.02317.x.

142. Papagrigoriadis S, Heyman B. Patients' views on follow up of colorectal cancer: implications for risk communication and decision making. *Postgrad Med J*. 2003;79(933):403–7. <http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1742752/>.

143. Kjeldsen BJ, Thorsen H, Whalley D, Kronborg O. Influence of follow-up on health-related quality of life after radical surgery for colorectal cancer. *Scand J Gastroenterol*. 1999;34(5):509–15.

144. Stiggelbout AM, de Haes JC, Vree R, van de Velde CJ, Bruijninckx CM, van Groningen K, et al. Follow-up of colorectal cancer patients: quality of life and attitudes towards follow-up. *Br J Cancer*. 1997;75(6):914–20. <http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2063387/>.

145. Virgo KS, Vernava AM, Longo WE, McKirgan LW, Johnson FE. Cost of patient follow-up after potentially curative colorectal cancer treatment. *JAMA*. 1995;273(23):1837–41.

146. Dinan MA, Curtis LH, Hammill BG, Patz EF, Abernethy AP, Shea AM, et al. Changes in the use and costs of diagnostic imaging among Medicare beneficiaries with cancer, 1999–2006. *JAMA*. 2010;303(16):1625–31.

147. Audisio R, Setti-Carraro P, Segala M, Capko D, Andreoni B, Tiberio G. Follow-up in colorectal cancer patients: a cost-benefit analysis. *Ann Surg Oncol*. 1996;3(4):349–57. doi: 10.1007/BF02305664.

148. Renehan AG, O'Dwyer ST, Whynes DK, Renehan AG, O'Dwyer ST, Whynes DK. Cost effectiveness analysis of intensive versus conventional follow up after curative resection for colorectal cancer. *BMJ Br Med J*. 2004;328(7431):81. <http://www.ncbi.nlm.nih.gov/pmc/articles/PMC314047/>.

149. Borie F, Combescure C, Daurès J-P, Trétarre B, Millat B. Cost-effectiveness of two follow-up strategies for curative resection of colorectal cancer: comparative study using a markov model. *World J Surg*. 2004;28(6):563–9. doi: 10.1007/s00268-004-7256-0.

150. Longley DB, McDermott U, Johnston PG. Predictive markers for colorectal cancer: current status and future prospects. *Clin Colorectal Cancer*. 2003;2(4):223–30.

151. Rose J, Augestad K, Kong C, Meropol N, Kattan M, Hong Q, et al. A simulation model of colorectal cancer surveillance and recurrence. *BMC Med Inform Decis Mak*. 2014;14(1):1–13. doi: 10.1186/1472-6947-14-29.

152. Radespiel-Tröger M, Hohenberger W, Reingruber B. Improved prediction of recurrence after curative resection of colon carcinoma using tree-based risk stratification. *Cancer*. 2004;100(5):958–67. doi: 10.1002/cncr.20065.

153. Soreide K. Endoscopic surveillance after curative surgery for sporadic colorectal cancer: patient-tailored, tumor-targeted or biology-driven? *Scand J Gastroenterol*. 2010;45(10):1255–61.

154. Johnson FE, Virgo KS, Grossmann EM, Longo WE, Fossati R. Colorectal cancer patient follow-up following surgery with curative intent: the GILDA trial. *J Clin Oncol*. 2004;22(14 suppl):3645. [http://hwmain.meeeting.ascopubs.org/cgi/content/abstract/22/14\\_suppl/3645](http://hwmain.meeeting.ascopubs.org/cgi/content/abstract/22/14_suppl/3645).



## 第 35 章

1. Cripps H. Rectal cancer: rectal excision for cancer: the selection of suitable cases and prognosis. *BMJ*. 1892;10(2):1277–9.
2. Mayo CH. Cancer of the large bowel. *Med Sentinel*. 1904;12:466–73.
3. Miles WE. A method of performing abdominoperineal excision for carcinoma of the rectum and the terminal portion of the pelvic colon. *Lancet*. 1908;2:1812–3.
4. Mayo WJ. Grafting and traumatic dissemination of carcinoma in the course of operations for malignant disease. *JAMA*. 1913;60(7):512–3.
5. Sugarbaker ED. Coincident removal of additional structures in resections for carcinoma of the colon and rectum. *Ann Surg*. 1946;123(6):1036–46.
6. Dixon CF. Anterior resection for malignant lesions of the upper part of the rectum and lower part of the sigmoid. *Ann Surg*. 1948;128:425–42.
7. Heald RJ, Ryall RD. Recurrence and survival after total mesorectal excision for rectal cancer. *Lancet*. 1986;1(8496):1479–82.
8. Mathis KL, Larson DW, Dozois EJ, Cima RR, Huebner M, Haddock MG, et al. Outcomes following surgery without radiotherapy for rectal cancer. *Br J Surg*. 2012;99(1):137–43.
9. Bosset JF, Calais G, Mineur L, Maingon P, Stojanovic-Rundic S, Bensadoun RJ, et al. Fluorouracil-based adjuvant chemotherapy after preoperative chemoradiotherapy in rectal cancer: long-term results of the EORTC 22921 randomised study. *Lancet Oncol*. 2014;15(2):184–90.
10. Gray J. Evaluation of conservative resection with end to end anastomosis for carcinoma of the rectum and lower sigmoid colon. *Arch Surg*. 1948;57(3):361–72.
11. Lofgren EP, Waugh JM, Dockerty MB. Local recurrence of carcinoma after anterior resection of the rectum and the sigmoid; relationship with the length of normal mucosa excised distal to the lesion. *AMA Arch Surg*. 1957;74(6):825–38.
12. Pollard SG, Macfarlane R, Everett WG. Surgery for recurrent colorectal carcinoma—is it worthwhile? *Ann R Coll Surg Engl*. 1989;71(5):293–8.
13. Gunderson LL, Nelson H, Martenson JA, Cha S, Haddock M, Devine R, et al. Intraoperative electron and external beam irradiation with or without 5-fluorouracil and maximum surgical resection for previously unirradiated, locally recurrent colorectal cancer. *Dis Colon Rectum*. 1996;39(12):1379–95.
14. Wanebo HJ, Koness RJ, Vezeridis MP, Cohen SI, Wroblewski DE. Pelvic resection of recurrent rectal cancer. *Ann Surg*. 1994;220(4):586–95. discussion 95–7.
15. Hahnloser D, Nelson H, Gunderson LL, Hassan I, Haddock MG, O’Connell MJ, et al. Curative potential of multimodality therapy for locally recurrent rectal cancer. *Ann Surg*. 2003;237(4):502–8.
16. Suzuki K, Dozois RR, Devine RM, Nelson H, Weaver AL, Gunderson LL, et al. Curative reoperations for locally recurrent rectal cancer. *Dis Colon Rectum*. 1996;39(7):730–6.
17. Colibaseanu DT, Dozois EJ, Mathis KL, Rose PS, Ugarte ML, Abdelsattar ZM, et al. Extended sacropelvic resection for locally recurrent rectal cancer: can it be done safely and with good oncologic outcomes? *Dis Colon Rectum*. 2014;57(1):47–55.
18. Milne T, Solomon MJ, Lee P, Young JM, Stalley P, Harrison JD, et al. Sacral resection with pelvic exenteration for advanced primary and recurrent pelvic cancer: a single-institution experience of 100 sacrectomies. *Dis Colon Rectum*. 2014;57(10):1153–61.

19. Konski AA, Suh WW, Herman JM, Blackstock Jr AW, Hong TS, Poggi MM, et al. ACR appropriateness criteria(R)-recurrent rectal cancer. *Gastrointest Cancer Res.* 2012;5(1):3–12.
20. Miller AR, Cantor SB, Peoples GE, Pearlstone DB, Skibber JM. Quality of life and cost effectiveness analysis of therapy for locally recurrent rectal cancer. *Dis Colon Rectum.* 2000;43(12):1695–701. discussion 701-3.
21. Haddock MG, Gunderson LL, Nelson H, Cha SS, Devine RM, Dozois RR, et al. Intraoperative irradiation for locally recurrent colorectal cancer in previously irradiated patients. *Int J Radiat Oncol Biol Phys.* 2001;49(5):1267–74.
22. Sjovall A, Granath F, Cedermark B, Glimelius B, Holm T. Loco-regional recurrence from colon cancer: a population-based study. *Ann Surg Oncol.* 2007;14(2):432–40.
23. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2015. *CA Cancer J Clin.* 2015;65(1):5–29.
24. Bouchard P, Efron J. Management of recurrent rectal cancer. *Ann Surg Oncol.* 2010;17(5):1343–56.
25. Gunderson LL, Sosin H. Areas of failure found at reoperation (second or symptomatic look) following “curative surgery” for adenocarcinoma of the rectum. Clinicopathologic correlation and implications for adjuvant therapy. *Cancer.* 1974;34(4):1278–92.
26. McCall JL, Cox MR, Wattchow DA. Analysis of local recurrence rates after surgery alone for rectal cancer. *Int J Colorectal Dis.* 1995;10(3):126–32.
27. Wanebo HJ, Antoniuk P, Koness RJ, Levy A, Vezeridis M, Cohen SI, et al. Pelvic resection of recurrent rectal cancer: technical considerations and outcomes. *Dis Colon Rectum.* 1999;42(11):1438–48.
28. McDermott FT, Hughes ES, Pihl E, Johnson WR, Price AB. Local recurrence after potentially curative resection for rectal cancer in a series of 1008 patients. *Br J Surg.* 1985;72(1):34–7.
29. Eroglu A, Camlibel S. Risk factors for locoregional recurrence of scar carcinoma. *Br J Surg.* 1997;84(12):1744–6.
30. Porter GA, Soskolne CL, Yakimets WW, Newman SC. Surgeon-related factors and outcome in rectal cancer. *Ann Surg.* 1998;227(2):157–67.
31. Bulow S, Christensen IJ, Iversen LH, Harling H, Danish Colorectal Cancer G. Intra-operative perforation is an important predictor of local recurrence and impaired survival after abdominoperineal resection for rectal cancer. *Colorectal Dis.* 2011;13(11):1256–64.
32. Dresen RC, Peters EE, Rutten HJ, Nieuwenhuijzen GA, Demeyere TB, van den Brule AJ, et al. Local recurrence in rectal cancer can be predicted by histopathological factors. *Eur J Surg Oncol.* 2009;35(10):1071–7.
33. Kuru B, Camlibel M, Dinc S, Gulcelik MA, Gonullu D, Alagol H. Prognostic factors for survival in breast cancer patients who developed distant metastasis subsequent to definitive surgery. *Singapore Med J.* 2008;49(11):904–11.
34. Dogan L, Karaman N, Yilmaz KB, Ozaslan C, Atalay C, Altinok M. Characteristics and risk factors for colorectal cancer recurrence. *J BUON.* 2010;15(1):61–7.
35. Birbeck KF, Macklin CP, Tiffin NJ, Parsons W, Dixon MF, Mapstone NP, et al. Rates of circumferential resection margin involvement vary between surgeons and predict outcomes in rectal cancer surgery. *Ann Surg.* 2002;235(4):449–57.
36. Nagtegaal ID, Quirke P. What is the role for the circumferential margin in the modern treatment of rectal cancer? *J Clin Oncol.* 2008;26(2):303–12.
37. Monson JR, Weiser MR, Buie WD, Chang GJ, Rafferty JF, Buie WD, et al. Practice parameters

- for the management of rectal cancer (revised). *Dis Colon Rectum*. 2013;56(5):535–50.
38. Chang GJ, Kaiser AM, Mills S, Rafferty JF, Buie WD, Standards Practice Task Force of the American Society of C, et al. Practice parameters for the management of colon cancer. *Dis Colon Rectum*. 2012;55(8):831–43.
39. Boyle KM, Sagar PM, Chalmers AG, Sebag-Montefiore D, Cairns A, Eardley I. Surgery for locally recurrent rectal cancer. *Dis Colon Rectum*. 2005;48(5):929–37.
40. Colibaseanu DT, Mathis KL, Abdelsattar ZM, Larson DW, Haddock MG, Dozois EJ. Is curative resection and long-term survival possible for locally re-recurrent colorectal cancer in the pelvis? *Dis Colon Rectum*. 2013;56(1):14–9.
41. Dozois EJ, Privitera A, Holubar SD, Aldrete JF, Sim FH, Rose PS, et al. High sacrectomy for locally recurrent rectal cancer: can long-term survival be achieved? *J Surg Oncol*. 2011;103(2):105–9.
42. Milne T, Solomon MJ, Lee P, Young JM, Stalley P, Harrison JD. Assessing the impact of a sacral resection on morbidity and survival after extended radical surgery for locally recurrent rectal cancer. *Ann Surg*. 2013;258(6):1007–13.
43. Sagar PM, Pemberton JH. Surgical management of locally recurrent rectal cancer. *Br J Surg*. 1996;83(3):293–304.
44. Arulampalam T, Costa D, Visvikis D, Boulos P, Taylor I, Ell P. The impact of FDG-PET on the management algorithm for recurrent colorectal cancer. *Eur J Nucl Med*. 2001;28(12):1758–65.
45. Moore HG, Akhurst T, Larson SM, Minsky BD, Mazumdar M, Guillem JG. A case-controlled study of 18-fluorodeoxyglucose positron emission tomography in the detection of pelvic recurrence in previously irradiated rectal cancer patients. *J Am Coll Surg*. 2003;197(1):22–8.
46. Whiteford MH, Whiteford HM, Yee LF, Ogunbiyi OA, Dehdashti F, Siegel BA, et al. Usefulness of FDG-PET scan in the assessment of suspected metastatic or recurrent adenocarcinoma of the colon and rectum. *Dis Colon Rectum*. 2000;43(6):759–67. discussion 67-70.
47. Ogunbiyi OA, Flanagan FL, Dehdashti F, Siegel BA, Trask DD, Birnbaum EH, et al. Detection of recurrent and metastatic colorectal cancer: comparison of positron emission tomography and computed tomography. *Ann Surg Oncol*. 1997;4(8):613–20.
48. Chessin DB, Kiran RP, Akhurst T, Guillem JG. The emerging role of 18F-fluorodeoxyglucose positron emission tomography in the management of primary and recurrent rectal cancer. *J Am Coll Surg*. 2005;201(6):948–56.
49. Simo M, Lomena F, Setoain J, Perez G, Castellucci P, Costansa JM, et al. FDG-PET improves the management of patients with suspected recurrence of colorectal cancer. *Nucl Med Commun*. 2002;23(10):975–82.
50. Wang JY, Tang R, Chiang JM. Value of carcinoembryonic antigen in the management of colorectal cancer. *Dis Colon Rectum*. 1994;37(3):272–7.
51. Older P, Smith R. Experience with the preoperative invasive measurement of haemodynamic, respiratory and renal function in 100 elderly patients scheduled for major abdominal surgery. *Anaesth Intensive Care*. 1988;16(4):389–95.
52. Shoemaker WC, Appel PL, Kram HB, Waxman K, Lee TS. Prospective trial of supranormal values of survivors as therapeutic goals in high-risk surgical patients. *Chest*. 1988;94(6):1176–86.
53. Bass EM, Del Pino A, Tan A, Pearl RK, Orsay CP, Abcarian H. Does preoperative stoma marking and education by the enterostomal therapist affect outcome? *Dis Colon Rectum*. 1997;40(4):440–2.

54. Haugen V, Bliss DZ, Savik K. Perioperative factors that affect long-term adjustment to an incontinent ostomy. *J Wound Ostomy Continence Nurs.* 2006;33(5):525–35.
55. Nugent KP, Daniels P, Stewart B, Patankar R, Johnson CD. Quality of life in stoma patients. *Dis Colon Rectum.* 1999;42(12):1569–74.
56. Sagar PM, Gonsalves S, Heath RM, Phillips N, Chalmers AG. Composite abdominosacral resection for recurrent rectal cancer. *Br J Surg.* 2009;96(2):191–6.
57. Sagar PM. Ultraradical resection for locally recurrent rectal cancer. *Dis Colon Rectum.* 2014;57(1):1–2.
58. Stocchi L, Nelson H, Sargent DJ, Engen DE, Haddock MG. Is en-bloc resection of locally recurrent rectal carcinoma involving the urinary tract indicated? *Ann Surg Oncol.* 2006;13(5):740–4.
59. Cima RR. Rectal cancer: locally advanced and recurrent. In: Beck ED, Roberts PL, Saclarides TJ, Senagore AJ, Stamos MJ, Wexner SD, editors. *The ASCRS textbook of colon and rectal surgery.* 2nd ed. New York: Springer; 2011. p. 761–72.
60. Moriya Y, Akasu T, Fujita S, Yamamoto S. Total pelvic exenteration with distal sacrectomy for fixed recurrent rectal cancer. *Surg Oncol Clin N Am.* 2005;14(2):225–38.
61. Beyond TMEC. Consensus statement on the multidisciplinary management of patients with recurrent and primary rectal cancer beyond total mesorectal excision planes. *Br J Surg.* 2013;100(8):1009–14.
62. Bowne WB, Lee B, Wong WD, Ben-Porat L, Shia J, Cohen AM, et al. Operative salvage for locoregional recurrent colon cancer after curative resection: an analysis of 100 cases. *Dis Colon Rectum.* 2005;48(5):897–909.
63. Taylor WE, Donohue JH, Gunderson LL, Nelson H, Nagorney DM, Devine RM, et al. The Mayo Clinic experience with multimodality treatment of locally advanced or recurrent colon cancer. *Ann Surg Oncol.* 2002;9(2):177–85.
64. Torricelli P, Pecchi A, Luppi G, Romagnoli R. Gadolinium-enhanced MRI with dynamic evaluation in diagnosing the local recurrence of rectal cancer. *Abdom Imaging.* 2003;28(1):19–27.
65. Colosio A, Soyer P, Rousset P, Barbe C, Nguyen F, Bouche O, et al. Value of diffusion-weighted and gadolinium-enhanced MRI for the diagnosis of pelvic recurrence from colorectal cancer. *J Magn Reson Imaging.* 2014;40(2):306–13.
66. Haddock MG, Miller RC, Nelson H, Pemberton JH, Dozois EJ, Alberts SR, et al. Combined modality therapy including intraoperative electron irradiation for locally recurrent colorectal cancer. *Int J Radiat Oncol Biol Phys.* 2011;79(1):143–50.
67. Heriot AG, Byrne CM, Lee P, Dobbs B, Tilney H, Solomon MJ, et al. Extended radical resection: the choice for locally recurrent rectal cancer. *Dis Colon Rectum.* 2008;51(3):284–91.
68. Dresen RC, Gosens MJ, Martijn H, Nieuwenhuijzen GA, Creemers G-J, Daniels-Gooszen AW, et al. Radical resection after IORT-containing multimodality treatment is the most important determinant for outcome in patients treated for locally recurrent rectal cancer. *Ann Surg Oncol.* 2008;15(7):1937–47.
69. Abdelsattar ZM, Mathis KL, Colibaseanu DT, Merchea A, Bower TC, Larson DW, et al. Surgery for locally advanced recurrent colorectal cancer involving the aortoiliac axis: can we achieve R0 resection and long-term survival? *Dis Colon Rectum.* 2013;56(6):711–6.
70. Hugate Jr RR, Dickey ID, Phimolsarnti R, Yaszemski MJ, Sim FH. Mechanical effects of partial sacrectomy: when is reconstruction necessary? *Clin Orthop Relat Res.* 2006;450:82–8.

71. Dickey ID, Hugate Jr RR, Fuchs B, Yaszemski MJ, Sim FH. Reconstruction after total sacrectomy: early experience with a new surgical technique. *Clin Orthop Relat Res.* 2005;438:42–50.
72. Chessin DB, Hartley J, Cohen AM, Mazumdar M, Cordeiro P, Disa J, et al. Rectus flap reconstruction decreases perineal wound complications after pelvic chemoradiation and surgery: a cohort study. *Ann Surg Oncol.* 2005;12(2):104–10.
73. Radice E, Nelson H, Mercill S, Farouk R, Petty P, Gunderson L. Primary myocutaneous flap closure following resection of locally advanced pelvic malignancies. *Br J Surg.* 1999;86(3):349–54.
74. Sullivan PS, Dozois EJ. Exenterative surgery and reconstruction. In: Zbar AP, Madoff RD, Wexner SD, editors. *Reconstructive surgery of the rectum, anus and perineum.* London: Springer; 2013. p. 137–53.
75. Liebermann-Meffert D. The greater omentum. Anatomy, embryology, and surgical applications. *Surg Clin North Am.* 2000;80(1):275–93.
76. Harji DP, Sagar PM, Boyle K, Griffiths B, McArthur DR, Evans M. Surgical resection of recurrent colonic cancer. *Br J Surg.* 2013;100(7):950–8.
77. Nielsen M, Rasmussen P, Pedersen B, Hagemann-Madsen R, Lindegaard J, Laurberg S. Early and late outcomes of surgery for locally recurrent rectal cancer: a prospective 10-year study in the total mesorectal excision era. *Ann Surg Oncol.* 2015;22(8):2677–84.
78. You YN, Baxter NN, Stewart A, Nelson H. Is the increasing rate of local excision for stage I rectal cancer in the United States justified? A nationwide cohort study from the National Cancer Database. *Ann Surg.* 2007;245(5):726–33.
79. Bikhchandani J, Ong GK, Dozois EJ, Mathis KL. Outcomes of salvage surgery for cure in patients with locally recurrent disease after local excision of rectal cancer. *Dis Colon Rectum.* 2015;58(3):283–7.
80. You YN, Roses RE, Chang GJ, Rodriguez-Bigas MA, Feig BW, Slack R, et al. Multimodality salvage of recurrent disease after local excision for rectal cancer. *Dis Colon Rectum.* 2012;55(12):1213–9.
81. Bhangu A, Ali SM, Darzi A, Brown G, Tekkis P. Meta-analysis of survival based on resection margin status following surgery for recurrent rectal cancer. *Colorectal Dis.* 2012;14(12):1457–66.
82. Harji DP, Sagar PM, Boyle K, Maslekar S, Griffiths B, McArthur DR. Outcome of surgical resection of second-time locally recurrent rectal cancer. *Br J Surg.* 2013;100(3):403–9.
83. Carpenter SG, Stone WM, Bower TC, Fowl RJ, Money SR. Surgical management of tumors invading the aorta and major arterial structures. *Ann Vasc Surg.* 2011;25(8):1026–35.
84. Austin KK, Solomon MJ. Pelvic exenteration with en bloc iliac vessel resection for lateral pelvic wall involvement. *Dis Colon Rectum.* 2009;52(7):1223–33.
85. Melton GB, Paty PB, Boland PJ, Healey JH, Savatta SG, Casas-Ganem JE, et al. Sacral resection for recurrent rectal cancer: analysis of morbidity and treatment results. *Dis Colon Rectum.* 2006;49(8):1099–107.
86. Rahbari NN, Ulrich AB, Bruckner T, Munter M, Nickles A, Contin P, et al. Surgery for locally recurrent rectal cancer in the era of total mesorectal excision: is there still a chance for cure? *Ann Surg.* 2011;253(3):522–33.
87. Austin KK, Young JM, Solomon MJ. Quality of life of survivors after pelvic exenteration for rectal cancer. *Dis Colon Rectum.* 2010;53(8):1121–6.
88. Harji DP, Griffiths B, Velikova G, Sagar PM, Brown J. Systematic review of health-related

- quality of life issues in locally recurrent rectal cancer. *J Surg Oncol*. 2015;111(4):431–8.
89. Cirocchi R, Trastulli S, Abraha I, Vettoretto N, Boselli C, Montedori A, et al. Non-resection versus resection for an asymptomatic primary tumour in patients with unresectable stage IV colorectal cancer. *Cochrane Database Syst Rev*. 2012;8, CD008997.
  90. Allum WH, Mack P, Priestman TJ, Fielding JW. Radiotherapy for pain relief in locally recurrent colorectal cancer. *Ann R Coll Surg Engl*. 1987;69(5):220–1.
  91. Khot UP, Lang AW, Murali K, Parker MC. Systematic review of the efficacy and safety of colorectal stents. *Br J Surg*. 2002;89(9):1096–102.
  92. Spinelli P, Mancini A. Use of self-expanding metal stents for palliation of rectosigmoid cancer. *Gastrointest Endosc*. 2001;53(2):203–6.
  93. Colucci G, Gebbia V, Paoletti G, Giuliani F, Caruso M, Gebbia N, et al. Phase III randomized trial of FOLFIRI versus FOLFOX4 in the treatment of advanced colorectal cancer: a multicenter study of the Gruppo Oncologico Dell'Italia Meridionale. *J Clin Oncol*. 2005;23(22):4866–75.
  94. Goldberg RM, Sargent DJ, Morton RF, Fuchs CS, Ramanathan RK, Williamson SK, et al. A randomized controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer. *J Clin Oncol*. 2004;22(1):23–30.
  95. Tournigand C, Andre T, Achille E, Lledo G, Flesh M, Mery-Mignard D, et al. FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study. *J Clin Oncol*. 2004;22(2):229–37.
  96. Amado RG, Wolf M, Peeters M, Van Cutsem E, Siena S, Freeman DJ, et al. Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer. *J Clin Oncol*. 2008;26(10):1626–34.
  97. Cunningham D, Humblet Y, Siena S, Khayat D, Bleiberg H, Santoro A, et al. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. *N Engl J Med*. 2004;351(4):337–45.
  98. Giantonio BJ, Catalano PJ, Meropol NJ, O'Dwyer PJ, Mitchell EP, Alberts SR, et al. Bevacizumab in combination with oxaliplatin, fluorouracil, and leucovorin (FOLFOX4) for previously treated metastatic colorectal cancer: results from the Eastern Cooperative Oncology Group Study E3200. *J Clin Oncol*. 2007;25(12):1539–44.

## 第 36 章

1. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2015. *CA Cancer J Clin*. 2015;65(1):5–29.
2. O'Connell JB, Maggard MA, Ko CY. Colon cancer survival rates with the new American Joint Committee on Cancer sixth edition staging. *J Natl Cancer Inst*. 2004;96(19):1420–5.
3. Nordic Gastrointestinal Tumor Adjuvant Therapy Group. Expectancy or primary chemotherapy in patients with advanced asymptomatic colorectal cancer: a randomized trial. *J Clin Oncol*. 1992;10(6):904–11.
4. Scheithauer W, Rosen H, Kornek GV, Sebesta C, Depisch D. Randomised comparison of combination chemotherapy plus supportive care with supportive care alone in patients with metastatic colorectal cancer. *BMJ*. 1993;306(6880):752–5.
5. Tournigand C, André T, Achille E, Lledo G, Flesh M, Mery-Mignard D, et al. FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study.

J Clin Oncol. 2004;22(2):229–37.

6. Hurwitz H, Fehrenbacher L, Novotny W, Cartwright T, Hainsworth J, Heim W, et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med. 2004;350(23):2335–42.

7. Bokemeyer C, Bondarenko I, Makhson A, et al. Fluorouracil, leucovorin, and oxaliplatin with and without cetuximab in the first-line treatment of metastatic colorectal cancer. J Clin Oncol. 2009;27(5):663–71.

8. Grothey A, Sugrue MM, Purdie DM, Dong W, Sargent D, Hedrick E, et al. Bevacizumab beyond first progression is associated with prolonged overall survival in metastatic colorectal cancer: results from a large observational cohort study (BRiTE). J Clin Oncol. 2008;26(33):5326–34.

9. Hanahan D, Weinberg RA. The hallmarks of cancer. Cell. 2000;100(1):57–70.

10. Woodhouse EC, Chuaqui RF, Liotta LA. General mechanisms of metastasis. Cancer. 1997;80(8 Suppl):1529–37.

11. Fidler IJ. Critical factors in the biology of human cancer metastasis: twenty-eighth G.H.A. Clowes memorial award lecture. Cancer Res. 1990;50(19):6130–8.

12. Folkman J. How is blood vessel growth regulated in normal and neoplastic tissue? G.H.A. Clowes memorial Award lecture. Cancer Res. 1986;46(2):467–73.

13. Hynes RO. Metastatic potential: generic predisposition of the primary tumor or rare, metastatic variants-or both? Cell. 2003;113(7):821–3.

14. Bogenrieder T, Herlyn M. Axis of evil: molecular mechanisms of cancer metastasis. Oncogene. 2003;22(42):6524–36.

15. Chambers AF, Groom AC, MacDonald IC. Dissemination and growth of cancer cells in metastatic sites. Nat Rev Cancer. 2002;2(8):563–72.

16. Messick CA, Church JM, Liu X, Ting AH, Kalady MF. Stage III colorectal cancer: molecular disparity between primary cancers and lymph node metastases. Ann Surg Oncol. 2010;17(2):425–31.

17. Chang GJ, Kaiser AM, Mills S, Rafferty JF, Buie WD, Standards Practice Task Force of the American Society of Colon and Rectal Surgeons. Practice parameters for the management of colon cancer. Dis Colon Rectum. 2012;55(8):831–43.

18. Xu LH, Cai SJ, Cai GX, Peng WJ. Imaging diagnosis of colorectal liver metastases. World J Gastroenterol. 2011;17(42):4654–9.

19. Chen CC, Yang SH, Lin JK, Lin TC, Chen WS, Jiang JK, et al. Is it reasonable to add preoperative serum level of CEA and CA19-9 to staging for colorectal cancer? J Surg Res. 2005;124(2):169–74.

20. Johnson CD, Chen M-H, Toledano AY, Heiken JP, Dachman A, Kuo MD, et al. Accuracy of CT colonography for detection of large adenomas and cancers. N Engl J Med. 2008;359(12):1207–17.

21. Levin B, Lieberman DA, McFarland B, Smith RA, Brooks D, Andrews KS, American Cancer Society Colorectal Cancer Advisory Group, US Multi-Society Task Force, American College of Radiology Colon Cancer Committee, et al. Screening and surveillance for the early detection of colorectal cancer and adenomatous polyps, 2008: a joint guideline from the American Cancer Society, the US Multi-Society Task Force on Colorectal Cancer, and the American College of Radiology. CA Cancer J Clin. 2008;58(3):130–60.

22. Macari M, Berman P, Dicker M, Milano A, Megibow AJ. Usefulness of CT colonography in patients with incomplete colonoscopy. AJR Am J Roentgenol. 1999;173(3):561–4.

23. Ch'en IY, Katz DS, Jeffrey RB, Daniel BL, Li KC, Beaulieu CF, et al. Do arterial phase helical CT images improve detection or characterization of colorectal liver metastases? *J Comput Assist Tomogr.* 1997;21(3):391–7.
24. Meijerink MR, van Waesberghe JH, Golding RP, van der Weide L, van den Tol P, Meijer S, et al. Subtraction-multiphase-CT unbeneficial for early detection of colorectal liver metastases. *Eur J Radiol.* 2010;74(3):e132–7.
25. Wicherts DA, de Haas RJ, van Kessel CS, Bisschops RHC, Takahara T, van Hillegersberg R, et al. Incremental value of arterial and equilibrium phase compared to hepatic venous phase CT in the preoperative staging of colorectal liver metastases: an evaluation with different reference standards. *Eur J Radiol.* 2011;77(2):305–11.
26. Scott DJ, Guthrie JA, Arnold P, Ward J, Atchley J, Wilson D, et al. Dual phase helical CT versus portal venous phase CT for the detection of colorectal liver metastases: correlation with intra-operative sonography, surgical and pathological findings. *Clin Radiol.* 2001;56(3):235–42.
27. Valls C, Andía E, Sánchez A, Gumà A, Figueras J, Torras J, et al. Hepatic metastases from colorectal cancer: preoperative detection and assessment of resectability with helical CT. *Radiology.* 2001;218(1):55–60.
28. Ruhlmann J, Schomburg A, Bender H, Oehr P, Robertz-Vaupel GM, Vaupel H, et al. Fluorodeoxyglucose whole-body positron emission tomography in colorectal cancer patients studied in routine daily practice. *Dis Colon Rectum.* 1997;40(10):1195–204.
29. Johnson K, Bakhsh A, Young D, Martin TE, Arnold M. Correlating computed tomography and positron emission tomography scan with operative findings in metastatic colorectal cancer. *Dis Colon Rectum.* 2001;44(3):354–7.
30. Chin BB, Wahl RL. 18F-Fluoro-2-deoxyglucose positron emission tomography in the evaluation of gastrointestinal malignancies. *Gut.* 2003;52 Suppl 4:iv23–9.
31. Brush J, Boyd K, Chappell F, Crawford F, Dozier M, Fenwick E, et al. The value of FDG positron emission tomography/computerised tomography (PET/CT) in pre-operative staging of colorectal cancer: a systematic review and economic evaluation. *Health Technol Assess.* 2011;15(35):1–192. iii–iv.
32. Jung EJ, Kim SR, Ryu CG, Paik JH, Yi JG, Hwang DY. Indeterminate pulmonary nodules in colorectal cancer. *World J Gastroenterol.* 2015;21(10):2967–72.
33. Tan YN, Li XF, Li JJ, Song YM, Jiang B, Yang J, et al. The accuracy of computed tomography in the pretreatment staging of colorectal cancer. *Hepatogastroenterology.* 2014;61(133):1207–12.
34. Potter KC, Husband JE, Houghton SL, Thomas K, Brown G. Diagnostic accuracy of serial CT/magnetic resonance imaging review vs. positron emission tomography/CT in colorectal cancer patients with suspected and known recurrence. *Dis Colon Rectum.* 2009;52(2):253–9.
35. Cho JY, Lee YJ, Han H-S, Yoon Y-S, Kim J, Choi Y, et al. Role of gadoteric acid-enhanced magnetic resonance imaging in the preoperative evaluation of small hepatic lesions in patients with colorectal cancer. *World J Surg.* 2015;39(5):1161–6.
36. Scharitzer M, Ba-Ssalamah A, Ringl H, Kölblinger C, Grünberger T, Weber M, et al. Preoperative evaluation of colorectal liver metastases: comparison between gadoteric acid-enhanced 3.0-T MRI and contrast-enhanced MDCT with histopathological correlation. *Eur Radiol.* 2013;23(8):2187–96.
37. Barabasch A, Kraemer NA, Ciritsis A, Hansen NL, Lierfeld M, Heinzel A, et al. Diagnostic accuracy of diffusion-weighted magnetic resonance imaging versus positron emission



tomography/computed tomography for early response assessment of liver metastases to y90-radioembolization. *Invest Radiol*. 2015;50(6):409–15.

38. Bernatik T, Strobel D, Hahn EG, Becker D. Detection of liver metastases: comparison of contrast-enhanced wide-band harmonic imaging with conventional ultrasonography. *J Ultrasound Med*. 2001;20(5):509–15.

39. Schüle S, Altendorf-Hofmann A, Dittmar Y, Rauchfuß F, Settmacher U. Incidence of non-metastatic liver lesions in tumor patients: consequences for chemotherapy and local ablative procedures. *Chirurg*. 2014;85(9):806–11.

40. Sotiropoulos GC, Saner FH, Molmenti EP, Radtke A, Timm S, Baba HA, et al. Unexpected liver failure after right hemihepatectomy for colorectal liver metastasis due to chemotherapy-associated steato-hepatitis: time for routine preoperative liver biopsy? *Int J Colorectal Dis*. 2009;24(2):241.

41. Fahy BN, D'Angelica M, DeMatteo RP, Blumgart LH, Weiser MR, Ostrovnaya I, et al. Synchronous hepatic metastases from colon cancer: changing treatment strategies and results of surgical intervention. *Ann Surg Oncol*. 2009;16(2):361–70.

42. Hillingsø JG, Wille-Jørgensen P. Staged or simultaneous resection of synchronous liver metastases from colorectal cancer—a systematic review. *Colorectal Dis*. 2009;11(1):3–10.

43. Scheele J, Stangl R, Altendorf-Hofmann A. Hepatic metastases from colorectal carcinoma: impact of surgical resection on the natural history. *Br J Surg*. 1990;77(11):1241–6.

44. Nordlinger B, Sorbye H, Glimelius B, Poston GJ, Schlag PM, Rougier P, EORTC Gastro-Intestinal Tract Cancer Group, Cancer Research UK, Arbeitsgruppe Lebermetastasen und-tumoren in der Chirurgischen Arbeitsgemeinschaft Onkologie (ALM-CAO), Australasian Gastro-Intestinal Trials Group (AGITG), Fédération Francophone de Cancérologie Digestive (FFCD), et al. Perioperative chemotherapy with FOLFOX4 and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC Intergroup trial 40983): a randomised controlled trial. *Lancet*. 2008;371(9617):1007–16.

45. De Salvo GL, Gava C, Pucciarelli S, Lise M. Curative surgery for obstruction from primary left colorectal carcinoma: primary or staged resection? *Cochrane Database Syst Rev*. 2004;2, CD002101.

46. Smithers BM, Theile DE, Cohen JR, Evans EB, Davis NC. Emergency right hemicolectomy in colon carcinoma: a prospective study. *Aust N Z J Surg*. 1986;56(10):749–52.

47. Deans GT, Krukowski ZH, Irwin ST. Malignant obstruction of the left colon. *Br J Surg*. 1994;81(9):1270–6.

48. Phillips RK, Hittinger R, Fry JS, Fielding LP. Malignant large bowel obstruction. *Br J Surg*. 1985;72(4):296–302.

49. Van Hooft JE, Bemelman WA, Fockens P. A study of the value of colonic stenting as a bridge to elective surgery for the management of acute left-sided malignant colonic obstruction: the STENT-IN 2 study. *Ned Tijdschr Geneesk*. 2007;151(22):1249–51.

50. Vemulapalli R, Lara LF, Sreenarasimhaiah J, Harford WV, Siddiqui AA. A comparison of palliative stenting or emergent surgery for obstructing incurable colon cancer. *Dig Dis Sci*. 2010;55(6):1732–7.

51. Gandrup P, Lund L, Balslev I. Surgical treatment of acute malignant large bowel obstruction. *Eur J Surg*. 1992;158(8):427–30.

52. Loizou LA, Grigg D, Boulos PB, Bown SG. Endoscopic Nd:YAG laser treatment of rectosigmoid cancer. *Gut*. 1990;31(7):812–6.

53. Daneker GW, Carlson GW, Hohn DC, Lynch P, Rouben L, Levin B. Endoscopic laser

recanalization is effective for prevention and treatment of obstruction in sigmoid and rectal cancer. *Arch Surg.* 1991;126(11):1348–52.

54. Mandava N, Petrelli N, Herrera L, Nava H. Laser palliation for colorectal carcinoma. *Am J Surg.* 1991;162(3):212–4. discussion 215.

55. Brunetaud JM, Maunoury V, Cochelard D. Lasers in rectosigmoid tumors. *Semin Surg Oncol.* 1995;11(4):319–27.

56. Gevers AM, Macken E, Hiele M, Rutgeerts P. Endoscopic laser therapy for palliation of patients with distal colorectal carcinoma: analysis of factors influencing long-term outcome. *Gastrointest Endosc.* 2000;51(5):580–5.

57. Rao VS, Al-Mukhtar A, Rayan F, Stojkovic S, Moore PJ, Ahmad SM. Endoscopic laser ablation of advanced rectal carcinoma—a DGH experience. *Colorectal Dis.* 2005;7(1):58–60.

58. Salvati EP, Rubin RJ, Eisenstat TE, Siemons GO, Mangione JS. Electrocoagulation of selected carcinoma of the rectum. *Surg Gynecol Obstet.* 1988;166(5):393–6.

59. Eisenstat TE, Oliver GC. Electrocoagulation for adenocarcinoma of the low rectum. *World J Surg.* 1992;16(3):458–62.

60. Van Hoof JE, van Halsema EE, Vanbiervliet G, Beets-Tan RGH, DeWitt JM, Donnellan F, et al. Self-expandable metal stents for obstructing colonic and extracolonic cancer: European Society of Gastrointestinal Endoscopy (ESGE) Clinical Guideline. *Endoscopy.* 2014;46(11):990–1053.

61. Small AJ, Coelho-Prabhu N, Baron TH. Endoscopic placement of self-expandable metal stents for malignant colonic obstruction: long-term outcomes and complication factors. *Gastrointest Endosc.* 2010;71(3):560–72.

62. Lo SK. Metallic stenting for colorectal obstruction. *Gastrointest Endosc Clin N Am.* 1999;9(3):459–77.

63. Khot UP, Lang AW, Murali K, Parker MC. Systematic review of the efficacy and safety of colorectal stents. *Br J Surg.* 2002;89(9):1096–102.

64. Law WL, Choi HK, Lee YM, Chu KW. Palliation for advanced malignant colorectal obstruction by self-expanding metallic stents: prospective evaluation of outcomes. *Dis Colon Rectum.* 2004;47(1):39–43.

65. Dronamraju SS, Ramamurthy S, Kelly SB, Hayat M. Role of self-expanding metallic stents in the management of malignant obstruction of the proximal colon. *Dis Colon Rectum.* 2009;52(9):1657–61.

66. Choi JH, Lee YJ, Kim ES, Choi JH, Cho KB, Park KS, et al. Covered self-expandable metal stents are more associated with complications in the management of malignant colorectal obstruction. *Surg Endosc.* 2013;27(9):3220–7.

67. Watt AM, Faragher IG, Griffin TT, Rieger NA, Maddern GJ. Self-expanding metallic stents for relieving malignant colorectal obstruction: a systematic review. *Ann Surg.* 2007;246(1):24–30.

68. Mauro MA, Koehler RE, Baron TH. Advances in gastrointestinal intervention: the treatment of gastroduodenal and colorectal obstructions with metallic stents. *Radiology.* 2000;215(3):659–69.

69. Cook AD, Single R, McCahill LE. Surgical resection of primary tumors in patients who present with stage IV colorectal cancer: an analysis of surveillance, epidemiology, and end results data, 1988 to 2000. *Ann Surg Oncol.* 2005;12(8):637–45.

70. Rosen SA, Buell JF, Yoshida A, Kazsuba S, Hurst R, Michelassi F, et al. Initial presentation with stage IV colorectal cancer: how aggressive should we be? *Arch Surg.* 2000;135(5):530–4. discussion 534–5.

71. Tevis SE, Kohlnhofer BM, Stringfield S, Foley EF, Harms BA, Heise CP, et al. Postoperative complications in patients with rectal cancer are associated with delays in chemotherapy that lead to worse disease-free and overall survival. *Dis Colon Rectum*. 2013;56(12):1339–48.
72. Poultsides GA, Servais EL, Saltz LB, Patil S, Kemeny NE, Guillem JG, et al. Outcome of primary tumor in patients with synchronous stage IV colorectal cancer receiving combination chemotherapy without surgery as initial treatment. *J Clin Oncol*. 2009;27(20):3379–84.
73. Matsumoto T, Hasegawa S, Matsumoto S, Horimatsu T, Okoshi K, Yamada M, et al. Overcoming the challenges of primary tumor management in patients with metastatic colorectal cancer unresectable for cure and an asymptomatic primary tumor. *Dis Colon Rectum*. 2014;57(6):679–86.
74. Ruo L, Gougoutas C, Paty PB, Guillem JG, Cohen AM, Wong WD. Elective bowel resection for incurable stage IV colorectal cancer: prognostic variables for asymptomatic patients. *J Am Coll Surg*. 2003;196(5):722–8.
75. Scoggins CR, Meszoely IM, Blanke CD, Beauchamp RD, Leach SD. Nonoperative management of primary colorectal cancer in patients with stage IV disease. *Ann Surg Oncol*. 1999;6(7):651–7.
76. Liu SK, Church JM, Lavery IC, Fazio VW. Operation in patients with incurable colon cancer—is it worthwhile? *Dis Colon Rectum*. 1997;40(1):11–4.
77. Costi R, Mazzeo A, Di Mauro D, Veronesi L, Sansebastiano G, Violi V, et al. Palliative resection of colorectal cancer: does it prolong survival? *Ann Surg Oncol*. 2007;14(9):2567–76.
78. Hapani S, Chu D, Wu S. Risk of gastrointestinal perforation in patients with cancer treated with bevacizumab: a meta-analysis. *Lancet Oncol*. 2009;10(6):559–68.
79. Chang GJ. Challenge of primary tumor management in patients with stage IV colorectal cancer. *J Clin Oncol*. 2012;30(26):3165–6.
80. Karoui M, Koubaa W, Delbaldo C, Charachon A, Laurent A, Piedbois P, et al. Chemotherapy has also an effect on primary tumor in colon carcinoma. *Ann Surg Oncol*. 2008;15(12):3440–6.
81. Schrag D, Weiser MR, Goodman KA, Gonen M, Hollywood E, Cercek A, et al. Neoadjuvant chemotherapy without routine use of radiation therapy for patients with locally advanced rectal cancer: a pilot trial. *J Clin Oncol*. 2014;32(6):513–8.
82. Kawamura YJ, Umetani N, Sunami E, Watanabe T, Masaki T, Muto T. Effect of high ligation on the long-term result of patients with operable colon cancer, particularly those with limited nodal involvement. *Eur J Surg*. 2000;166(10):803–7.
83. Stillwell AP, Buettner PG, Ho YH. Meta-analysis of survival of patients with stage IV colorectal cancer managed with surgical resection versus chemotherapy alone. *World J Surg*. 2010;34(4):797–807.
84. Eisenberger A, Whelan RL, Neugut AI. Survival and symptomatic benefit from palliative primary tumor resection in patients with metastatic colorectal cancer: a review. *Int J Colorectal Dis*. 2008;23(6):559–68.
85. Damjanov N, Weiss J, Haller DG. Resection of the primary colorectal cancer is not necessary in nonobstructed patients with metastatic disease. *Oncologist*. 2009;14(10):963–9.
86. Cirocchi R, Trastulli S, Abraha I, Vettoretto N, Boselli C, Montedori A, et al. Non-resection versus resection for an asymptomatic primary tumour in patients with unresectable stage IV colorectal cancer. *Cochrane Database Syst Rev*. 2012;8, CD008997.
87. McCahill LE, Yothers G, Sharif S, Petrelli NJ, Lai LL, Bechar N, et al. Primary mFOLFOX6 plus bevacizumab without resection of the primary tumor for patients presenting with surgically

unresectable metastatic colon cancer and an intact asymptomatic colon cancer: definitive analysis of NSABP trial C-10. *J Clin Oncol*. 2012;30(26):3223–8.

88. Tebbutt NC, Norman AR, Cunningham D, Hill ME, Tait D, Oates J, et al. Intestinal complications after chemotherapy for patients with unresected primary colorectal cancer and synchronous metastases. *Gut*. 2003;52(4):568–73.

89. Scheer MG, Sloots CE, van der Wilt GJ, Ruers TJM. Management of patients with asymptomatic colorectal cancer and synchronous irresectable metastases. *Ann Oncol*. 2008;19(11):1829–35.

90. Karoui M, Roudot-Thoraval F, Mesli F, Mitry E, Aparicio T, Des Guetz G, et al. Primary colectomy in patients with stage IV colon cancer and unresectable distant metastases improves overall survival: results of a multicentric study. *Dis Colon Rectum*. 2011;54(8):930–8.

91. Bipat S, van Leeuwen MS, Comans EFI, Pijl MEJ, Bossuyt PMM, Zwinderman AH, et al. Colorectal liver metastases: CT, MR imaging, and PET for diagnosis—meta-analysis. *Radiology*. 2005;237(1):123–31.

92. Simmonds PC, Primrose JN, Colquitt JL, Garden OJ, Poston GJ, Rees M. Surgical resection of hepatic metastases from colorectal cancer: a systematic review of published studies. *Br J Cancer*. 2006;94(7):982–99.

93. Neeff H, Hörth W, Makowiec F, Fischer E, Imdahl A, Hopt UT, et al. Outcome after resection of hepatic and pulmonary metastases of colorectal cancer. *J Gastrointest Surg*. 2009;13(10):1813–20.

94. Shah SA, Haddad R, Al-Sukhni W, Kim RD, Greig PD, Grant DR, et al. Surgical resection of hepatic and pulmonary metastases from colorectal carcinoma. *J Am Coll Surg*. 2006;202(3):468–75.

95. Lam VWT, Laurence JM, Pang T, Johnston E, Hollands MJ, Pleass HCC, et al. A systematic review of a liver-first approach in patients with colorectal cancer and synchronous colorectal liver metastases. *HPB (Oxford)*. 2014;16(2):101–8.

96. Pawlik TM, Choti MA. Surgical therapy for colorectal metastases to the liver. *J Gastrointest Surg*. 2007;11(8):1057–77.

97. Simmonds PC. Palliative chemotherapy for advanced colorectal cancer: systematic review and meta-analysis. Colorectal Cancer Collaborative Group. *BMJ*. 2000;321(7260):531–5.

98. Kassahun WT. Unresolved issues and controversies surrounding the management of colorectal cancer liver metastasis. *World J Surg Oncol*. 2015;13:61.

99. Kopetz S, Chang GJ, Overman MJ, Eng C, Sargent DJ, Larson DW, et al. Improved survival in metastatic colorectal cancer is associated with adoption of hepatic resection and improved chemotherapy. *J Clin Oncol*. 2009;27(22):3677–83.

100. Martin R, Paty P, Fong Y, Grace A, Cohen A, DeMatteo R, et al. Simultaneous liver and colorectal resections are safe for synchronous colorectal liver metastasis. *J Am Coll Surg*. 2003;197(2):233–41. discussion 241–2.

101. Capussotti L, Viganò L, Ferrero A, Lo Tesoriere R, Ribero D, Polastri R. Timing of resection of liver metastases synchronous to colorectal tumor: proposal of prognosis-based decisional model. *Ann Surg Oncol*. 2007;14(3):1143–50.

102. Capussotti L, Ferrero A, Viganò L, Ribero D, Lo Tesoriere R, Polastri R. Major liver resections synchronous with colorectal surgery. *Ann Surg Oncol*. 2007;14(1):195–201.

103. Reddy SK, Pawlik TM, Zorzi D, Gleisner AL, Ribero D, Assumpcao L, et al. Simultaneous resections of colorectal cancer and synchronous liver metastases: a multi-institutional analysis. *Ann*

Surg Oncol. 2007;14(12):3481–91.

104. Adam R. Colorectal cancer with synchronous liver metastases. *Br J Surg*. 2007;94(2):129–31.

105. Yin Z, Liu C, Chen Y, Bai Y, Shang C, Yin R, et al. Timing of hepatectomy in resectable synchronous colorectal liver metastases (SCRLM): simultaneous or delayed? *Hepatology*. 2013;57(6):2346–57.

106. Thelen A, Jonas S, Benckert C, Spinelli A, Lopez-Hänninen E, Rudolph B, et al. Simultaneous versus staged liver resection of synchronous liver metastases from colorectal cancer. *Int J Colorectal Dis*. 2007;22(10):1269–76.

107. Kelly ME, Spolverato G, Lê GN, Mavros MN, Doyle F, Pawlik TM, et al. Synchronous colorectal liver metastasis: a network meta-analysis review comparing classical, combined, and liver-first surgical strategies. *J Surg Oncol*. 2015;111(3):341–51.

108. Brouquet A, Mortenson MM, Vauthey J-N, Rodriguez-Bigas MA, Overman MJ, Chang GJ, et al. Surgical strategies for synchronous colorectal liver metastases in 156 consecutive patients: classic, combined or reverse strategy? *J Am Coll Surg*. 2010;210(6):934–41.

109. Ayez N, Burger JWA, van der Pool AE, Eggermont AMM, Grunhagen DJ, de Wilt JH, et al. Long-term results of the “liver first” approach in patients with locally advanced rectal cancer and synchronous liver metastases. *Dis Colon Rectum*. 2013;56(3):281–7.

110. Van der Wal GE, Gouw AS, Kamps JA, Moorlag HE, Bulthuis ML, Molema G, et al. Angiogenesis in synchronous and metachronous colorectal liver metastases: the liver as a permissive soil. *Ann Surg*. 2012;255(1):86–94.

111. Jegatheeswaran S, Mason JM, Hancock HC, Siriwardena AK. The liver-first approach to the management of colorectal cancer with synchronous hepatic metastases: a systematic review. *JAMA Surg*. 2013;148(4):385–91.

112. Millikan KW, Staren ED, Doolas A. Invasive therapy of metastatic colorectal cancer to the liver. *Surg Clin North Am*. 1997;77(1):27–48.

113. Reddy SK, Barbas AS, Clary BM. Synchronous colorectal liver metastases: is it time to reconsider traditional paradigms of management? *Ann Surg Oncol*. 2009;16(9):2395–410.

114. Ruers TJ, Hagendoorn J. Treatment dilemmas in patients with synchronous colorectal liver metastases. *Recent Results Cancer Res*. 2012;196:37–49.

115. Nordlinger B, Sorbye H, Glimelius B, Poston GJ, Schlag PM, Rougier P, EORTC Gastro-Intestinal Tract Cancer Group, Cancer Research UK, Arbeitsgruppe Lebermetastasen und–tumoren in der Chirurgischen Arbeitsgemeinschaft Onkologie (ALM-CAO), Australasian Gastro-Intestinal Trials Group (AGITG), Fédération Francophone de Cancérologie Digestive (FFCD), et al. Perioperative FOLFOX4 chemotherapy and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC 40983): long-term results of a randomised, controlled, phase 3 trial. *Lancet Oncol*. 2013;14(12):1208–15.

116. Nanji S, Cleary S, Ryan P, Guindi M, Selvarajah S, Al-Ali H, et al. Up-front hepatic resection for metastatic colorectal cancer results in favorable long-term survival. *Ann Surg Oncol*. 2013;20(1):295–304.

117. Jones RP, Malik HZ, Fenwick SW, Poston GJ. Perioperative chemotherapy for resectable colorectal liver metastases: where now? *Eur J Surg Oncol*. 2013;39(8):807–11.

118. Reddy SK, Zorzi D, Lum YW, Barbas AS, Pawlik TM, Ribero D, et al. Timing of multimodality therapy for resectable synchronous colorectal liver metastases: a retrospective multi-institutional analysis. *Ann Surg Oncol*. 2009;16(7):1809–19.

119. Vauthey JN, Nordlinger B, Kopetz S, Poston G. Sequenced chemotherapy and surgery for potentially resectable colorectal liver metastases: a debate over goals of research and an approach while the jury remains out. *Ann Surg Oncol*. 2010;17(8):1983–6.
120. Adam R, Pascal G, Castaing D, Azoulay D, Delvart V, Paule B, et al. Tumor progression while on chemotherapy: a contraindication to liver resection for multiple colorectal metastases? *Ann Surg*. 2004;240(6):1052–61. discussion 1061–4.
121. Mentha G, Roth AD, Terraz S, Giostra E, Gervaz P, Andres A, et al. “Liver first” approach in the treatment of colorectal cancer with synchronous liver metastases. *Dig Surg*. 2008;25(6):430–5.
122. Verhoef C, van der Pool AE, Nuyttens JJ, Planting AS, Eggermont AM, de Wilt JH. The “liver-first approach” for patients with locally advanced rectal cancer and synchronous liver metastases. *Dis Colon Rectum*. 2009;52(1):23–30.
123. De Jong MC, van Dam RM, Maas M, Bemelmans MH, Olde Damink SW, Beets GL, et al. The liver-first approach for synchronous colorectal liver metastasis: a 5-year single-centre experience. *HPB (Oxford)*. 2011;13(10):745–52.
124. Lehmann K, Rickenbacher A, Weber A, Pestalozzi BC, Clavien P-A. Chemotherapy before liver resection of colorectal metastases: friend or foe? *Ann Surg*. 2012;255(2):237–47.
125. De Rosa A, Gomez D, Brooks A, Cameron IC. “Liver-first” approach for synchronous colorectal liver metastases: is this a justifiable approach? *J Hepatobiliary Pancreat Sci*. 2013;20(3):263–70.
126. Adam R, De Gramont A, Figueras J, Guthrie A, Kokudo N, Kunstlinger F, Jean-Nicolas Vauthey of the EGOSLIM (Expert Group on OncoSurgery management of Liver Metastases) group, et al. The oncosurgery approach to managing liver metastases from colorectal cancer: a multidisciplinary international consensus. *Oncologist*. 2012;17(10):1225–39.
127. Kimura F, Miyazaki M, Suwa T, Kakizaki S, Itoh H, Kaiho T, et al. Reduced hepatic acute-phase response after simultaneous resection for gastrointestinal cancer with synchronous liver metastases. *Br J Surg*. 1996;83(7):1002–6.
128. Belghiti J. Synchronous and resectable hepatic metastases of colorectal cancer: should there be a minimum delay before hepatic resection? *Ann Chir*. 1990;44(6):427–9. discussion 429–32.
129. Shimizu Y, Yasui K, Sano T, Hirai T, Kanemitsu Y, Komori K, et al. Validity of observation interval for synchronous hepatic metastases of colorectal cancer: changes in hepatic and extrahepatic metastatic foci. *Langenbecks Arch Surg*. 2008;393(2):181–4.
130. Yoshidome H, Kimura F, Shimizu H, Ohtsuka M, Kato A, Yoshitomi H, et al. Interval period tumor progression: does delayed hepatectomy detect occult metastases in synchronous colorectal liver metastases? *J Gastrointest Surg*. 2008;12(8):1391–8.
131. Fujita S, Akasu T, Moriya Y. Resection of synchronous liver metastases from colorectal cancer. *Jpn J Clin Oncol*. 2000;30(1):7–11.
132. Chua HK, Sondenaa K, Tsiotos GG, Larson DR, Wolff BG, Nagorney DM. Concurrent vs. staged colectomy and hepatectomy for primary colorectal cancer with synchronous hepatic metastases. *Dis Colon Rectum*. 2004;47(8):1310–6.
133. Weber JC, Bachellier P, Oussoultzoglou E, Jaeck D. Simultaneous resection of colorectal primary tumour and synchronous liver metastases. *Br J Surg*. 2003;90(8):956–62.
134. Fong Y, Fortner J, Sun RL, Brennan MF, Blumgart LH. Clinical score for predicting recurrence after hepatic resection for metastatic colorectal cancer: analysis of 1001 consecutive cases. *Ann Surg*. 1999;230(3):309–18. discussion 318–21.

135. Choti MA, Sitzmann JV, Tiburi MF, Sumetchotimetha W, Rangsin R, Schulick RD, et al. Trends in long-term survival following liver resection for hepatic colorectal metastases. *Ann Surg.* 2002;235(6):759–66.
136. De Haas RJ, Wicherts DA, Flores E, Azoulay D, Castaing D, Adam R. R1 resection by necessity for colorectal liver metastases: is it still a contraindication to surgery? *Ann Surg.* 2008;248(4):626–37.
137. Nuzzo G, Giuliente F, Ardito F, Vellone M, Giovannini I, Federico B, et al. Influence of surgical margin on type of recurrence after liver resection for colorectal metastases: a single-center experience. *Surgery.* 2008;143(3):384–93.
138. Park J, Chen Y-J, Lu W-P, Fong Y. The evolution of liver-directed treatments for hepatic colorectal metastases. *Oncology.* 2014;28(11):991–1003.
139. Evrard S, Poston G, Kissmeyer-Nielsen P, Diallo A, Desolneux G, Brouste V, et al. Combined ablation and resection (CARE) as an effective parenchymal sparing treatment for extensive colorectal liver metastases. *PLoS One.* 2014;9(12):e114404.
140. Stang A, Fischbach R, Teichmann W, Bokemeyer C, Braumann D. A systematic review on the clinical benefit and role of radiofrequency ablation as treatment of colorectal liver metastases. *Eur J Cancer.* 2009;45(10):1748–56.
141. Amersi FF, McElrath-Garza A, Ahmad A, Zogakis T, Allegra DP, Krasne R, et al. Long-term survival after radiofrequency ablation of complex unresectable liver tumors. *Arch Surg.* 2006;141(6):581–7. discussion 587–8.
142. Kuvshinov BW, Ota DM. Radiofrequency ablation of liver tumors: influence of technique and tumor size. *Surgery.* 2002;132(4):605–11. discussion 611–2.
143. Hildebrand P, Kleemann M, Roblick UJ, Mirow L, Birth M, Leibecke T, et al. Radiofrequency-ablation of unresectable primary and secondary liver tumors: results in 88 patients. *Langenbecks Arch Surg.* 2006;391(2):118–23.
144. Hildebrand P, Leibecke T, Kleemann M, Mirow L, Birth M, Bruch HP, et al. Influence of operator experience in radiofrequency ablation of malignant liver tumours on treatment outcome. *Eur J Surg Oncol.* 2006;32(4):430–4.
145. Ahmad A, Chen SL, Kavanagh MA, Allegra DP, Bilchik AJ. Radiofrequency ablation of hepatic metastases from colorectal cancer: are newer generation probes better? *Am Surg.* 2006;72(10):875–9.
146. Wong SL, Mangu PB, Choti MA, Crocenzi TS, Dodd GD, Dorfman GS, et al. American Society of Clinical Oncology 2009 clinical evidence review on radiofrequency ablation of hepatic metastases from colorectal cancer. *J Clin Oncol.* 2010;28(3):493–508.
147. Decadt B, Siriwardena AK. Radiofrequency ablation of liver tumours: systematic review. *Lancet Oncol.* 2004;5(9):550–60.
148. Curley SA, Izzo F, Delrio P, Ellis LM, Granchi J, Vallone P, et al. Radiofrequency ablation of unresectable primary and metastatic hepatic malignancies: results in 123 patients. *Ann Surg.* 1999;230(1):1–8.
149. Machi J, Oishi AJ, Sumida K, Sakamoto K, Furumoto NL, Oishi RH, et al. Long-term outcome of radiofrequency ablation for unresectable liver metastases from colorectal cancer: evaluation of prognostic factors and effectiveness in first- and second-line management. *Cancer J.* 2006;12(4):318–26.
150. Siperstein AE, Berber E, Ballem N, Parikh RT. Survival after radiofrequency ablation of

- colorectal liver metastases: 10-year experience. *Ann Surg.* 2007;246(4):559–65. discussion 565–7.
151. Ruers T, Punt C, Van Coevorden F, Pierie JPEN, Borel-Rinkes I, Ledermann JA, EORTC Gastro-Intestinal Tract Cancer Group, Arbeitsgruppe Lebermetastasen und—tumoren in der Chirurgischen Arbeitsgemeinschaft Onkologie (ALM-CAO), The National Cancer Research Institute Colorectal Clinical Study Group (NCRI CCSG), et al. Radiofrequency ablation combined with systemic treatment versus systemic treatment alone in patients with non-resectable colorectal liver metastases: a randomized EORTC Intergroup phase II study (EORTC 40004). *Ann Oncol.* 2012;23(10):2619–26.
152. Solbiati L, Ahmed M, Cova L, Ierace T, Brioschi M, Goldberg SN. Small liver colorectal metastases treated with percutaneous radiofrequency ablation: local response rate and long-term survival with up to 10-year follow-up. *Radiology.* 2012;265(3):958–68.
153. Aloia TA, Vauthey J-N, Loyer EM, Ribero D, Pawlik TM, Wei SH, et al. Solitary colorectal liver metastasis: resection determines outcome. *Arch Surg.* 2006;141(5):460–6. discussion 466–7.
154. Abdalla EK, Vauthey J-N, Ellis LM, Ellis V, Pollock R, Broglio KR, et al. Recurrence and outcomes following hepatic resection, radiofrequency ablation, and combined resection/ablation for colorectal liver metastases. *Ann Surg.* 2004;239(6):818–25. discussion 825–7.
155. Ruers TJ, Joosten JJ, Wiering B, Langenhoff BS, Dekker HM, Wobbes T, et al. Comparison between local ablative therapy and chemotherapy for non-resectable colorectal liver metastases: a prospective study. *Ann Surg Oncol.* 2007;14(3):1161–9.
156. Otto G, Düber C, Hoppe-Lotichius M, König J, Heise M, Pitton MB. Radiofrequency ablation as first-line treatment in patients with early colorectal liver metastases amenable to surgery. *Ann Surg.* 2010;251(5):796–803.
157. White RR, Avital I, Sofocleous CT, Brown KT, Brody LA, Covey A, et al. Rates and patterns of recurrence for percutaneous radiofrequency ablation and open wedge resection for solitary colorectal liver metastasis. *J Gastrointest Surg.* 2007;11(3):256–63.
158. Lee WS, Yun SH, Chun HK, Lee WY, Kim S-J, Choi SH, et al. Clinical outcomes of hepatic resection and radiofrequency ablation in patients with solitary colorectal liver metastasis. *J Clin Gastroenterol.* 2008;42(8):945–9.
159. Gleisner AL, Choti MA, Assumpcao L, Nathan H, Schulick RD, Pawlik TM. Colorectal liver metastases: recurrence and survival following hepatic resection, radiofrequency ablation, and combined resection-radiofrequency ablation. *Arch Surg.* 2008;143(12):1204–12.
160. Cirocchi R, Trastulli S, Boselli C, Montedori A, Cavaliere D, Parisi A, et al. Radiofrequency ablation in the treatment of liver metastases from colorectal cancer. *Cochrane Database Syst Rev.* 2012;6, CD006317.
161. De Baère T, Risse O, Kuocho V, Dromain C, Sengel C, Smayra T, et al. Adverse events during radiofrequency treatment of 582 hepatic tumors. *AJR Am J Roentgenol.* 2003;181(3):695–700.
162. Breedis C, Young G. The blood supply of neoplasms in the liver. *Am J Pathol.* 1954;30(5):969–77.
163. Collins JM. Pharmacologic rationale for regional drug delivery. *J Clin Oncol.* 1984;2(5):498–504.
164. Ducreux M, Ychou M, Laplanche A, Gamelin E, Lasser P, Husseini F, gastrointestinal group of the Federation Nationale des Centres de Lutte Contre le Cancer, et al. Hepatic arterial oxaliplatin infusion plus intravenous chemotherapy in colorectal cancer with inoperable hepatic metastases: a trial of the gastrointestinal group of the Federation Nationale des Centres de Lutte Contre le Cancer.



J Clin Oncol. 2005;23(22):4881–7.

165. Boige V, Malka D, Elias D, Castaing M, De Baere T, Goere D, et al. Hepatic arterial infusion of oxaliplatin and intravenous LV5FU2 in unresectable liver metastases from colorectal cancer after systemic chemotherapy failure. *Ann Surg Oncol*. 2008;15(1):219–26.

166. Chen Y, Wang X, Yan Z, Wang J, Luo J, Liu Q. Hepatic arterial infusion with irinotecan, oxaliplatin, and floxuridine plus systemic chemotherapy as first-line treatment of unresectable liver metastases from colorectal cancer. *Onkologie*. 2012;35(9):480–4.

167. Kemeny N, Jarnagin W, Paty P, Gönen M, Schwartz L, Morse M, et al. Phase I trial of systemic oxaliplatin combination chemotherapy with hepatic arterial infusion in patients with unresectable liver metastases from colorectal cancer. *J Clin Oncol*. 2005;23(22):4888–96.

168. Aliberti C, Tilli M, Benea G, Fiorentini G. Trans-arterial chemoembolization (TACE) of liver metastases from colorectal cancer using irinotecan-eluting beads: preliminary results. *Anticancer Res*. 2006;26(5B):3793–5.

169. Sanz-Altamira PM, Spence LD, Huberman MS, Posner MR, Steele G, Perry LJ, et al. Selective chemoembolization in the management of hepatic metastases in refractory colorectal carcinoma: a phase II trial. *Dis Colon Rectum*. 1997;40(7):770–5.

170. Martin RC, Joshi J, Robbins K, Tomalty D, Bosnjakovic P, Derner M, et al. Hepatic intra-arterial injection of drug-eluting bead, irinotecan (DEBIRI) in unresectable colorectal liver metastases refractory to systemic chemotherapy: results of multi-institutional study. *Ann Surg Oncol*. 2011;18(1):192–8.

171. Fiorentini G, Aliberti C, Tilli M, Mulazzani L, Graziano F, Giordani P, et al. Intra-arterial infusion of irinotecan-loaded drug-eluting beads (DEBIRI) versus intravenous therapy (FOLFIRI) for hepatic metastases from colorectal cancer: final results of a phase III study. *Anticancer Res*. 2012;32(4):1387–95.

172. Kemeny N, Niedzwiecki D, Hollis DR. Hepatic arterial infusion (HAI) versus systemic therapy for hepatic metastases from colorectal cancer: a CALGB randomized trial of efficacy, quality of life (QOL), cost effectiveness, and molecular markers. *Proc Am Soc Clin Oncol*. 2003;22:252. abstract 1010.

173. Mocellin S, Pasquali S, Nitti D. Fluoropyrimidine-HAI (hepatic arterial infusion) versus systemic chemotherapy (SCT) for unresectable liver metastases from colorectal cancer. *Cochrane Database Syst Rev*. 2009;3, CD007823.

174. Liu W, Song Q-K, Xing B-C. A systematic review and meta-analysis to reappraise the role of adjuvant hepatic arterial infusion for colorectal cancer liver metastases. *Int J Colorectal Dis*. 2015;30(8):1091–102.

175. Mitry E, Guiu B, Coscinea S, Jooste V, Faivre J, Bouvier A-M. Epidemiology, management and prognosis of colorectal cancer with lung metastases: a 30-year population-based study. *Gut*. 2010;59(10):1383–8.

176. Tan KK, Lopes Gde L, Sim R. How uncommon are isolated lung metastases in colorectal cancer? A review from database of 754 patients over 4 years. *J Gastrointest Surg*. 2009;13(4):642–8.

177. August DA, Ottow RT, Sugarbaker PH. Clinical perspective of human colorectal cancer metastasis. *Cancer Metastasis Rev*. 1984;3(4):303–24.

178. McCormack PM, Attiyeh FF. Resected pulmonary metastases from colorectal cancer. *Dis Colon Rectum*. 1979;22(8):553–6.

179. Dahabre J, Vasilaki M, Stathopoulos GP, Kondaxis A, Iliadis K, Papadopoulos G, et al. Surgical management in lung metastases from colorectal cancer. *Anticancer Res.* 2007;27(6C):4387–90.
180. Watanabe K, Saito N, Sugito M, Ito M, Kobayashi A, Nishizawa Y. Predictive factors for pulmonary metastases after curative resection of rectal cancer without preoperative chemoradiotherapy. *Dis Colon Rectum.* 2011;54(8):989–98.
181. Kim CH, Huh JW, Kim HJ, Lim SW, Song SY, Kim HR, et al. Factors influencing oncological outcomes in patients who develop pulmonary metastases after curative resection of colorectal cancer. *Dis Colon Rectum.* 2012;55(4):459–64.
182. Suzuki H, Kiyoshima M, Kitahara M, Asato Y, Amemiya R. Long-term outcomes after surgical resection of pulmonary metastases from colorectal cancer. *Ann Thorac Surg.* 2015;99(2):435–40.
183. Nagakura S, Shirai Y, Yamato Y, Yokoyama N, Suda T, Hatakeyama K. Simultaneous detection of colorectal carcinoma liver and lung metastases does not warrant resection. *J Am Coll Surg.* 2001;193(2):153–60.
184. Dematteo R, Minnard E, Kemeny N. Outcomes after resection of both liver and lung metastases in patients with colorectal cancer. *Proc Am Soc Clin Oncol.* 1999;(abstract 958).
185. McAfee MK, Allen MS, Trastek VF, Ilstrup DM, Deschamps C, Pairolero PC. Colorectal lung metastases: results of surgical excision. *Ann Thorac Surg.* 1992;53(5):780–5. discussion 785–6.
186. Rizk NP, Downey RJ. Resection of pulmonary metastases from colorectal cancer. *Semin Thorac Cardiovasc Surg.* 2002;14(1):29–34.
187. Roth JA, Pass HI, Wesley MN, White D, Putnam JB, Seipp C. Comparison of median sternotomy and thoracotomy for resection of pulmonary metastases in patients with adult soft-tissue sarcomas. *Ann Thorac Surg.* 1986;42(2):134–8.
188. McCormack PM, Bains MS, Begg CB, Burt ME, Downey RJ, Panicek DM, et al. Role of video-assisted thoracic surgery in the treatment of pulmonary metastases: results of a prospective trial. *Ann Thorac Surg.* 1996;62(1):213–6. discussion 216–7.
189. Muacevic A, Drexler C, Wowra B, Schweikard A, Schlaefer A, Hoffmann RT, et al. Technical description, phantom accuracy, and clinical feasibility for single-session lung radiosurgery using robotic image-guided real-time respiratory tumor tracking. *Technol Cancer Res Treat.* 2007;6(4):321–8.
190. Treasure T, Fallowfield L, Lees B, Farewell V. Pulmonary metastasectomy in colorectal cancer: the PulMiCC trial. *Thorax.* 2012;67(2):185–7.
191. Sugarbaker PH, Cunliffe WJ, Belliveau J, de Bruijn EA, Graves T, Mullins RE, et al. Rationale for integrating early postoperative intraperitoneal chemotherapy into the surgical treatment of gastrointestinal cancer. *Semin Oncol.* 1989;16(4 Suppl 6):83–97.
192. Dawson LE, Russell AH, Tong D, Wisbeck WM. Adenocarcinoma of the sigmoid colon: sites of initial dissemination and clinical patterns of recurrence following surgery alone. *J Surg Oncol.* 1983;22(2):95–9.
193. Russell AH, Tong D, Dawson LE, Wisbeck WM, Griffin TW, Laramore GE, et al. Adenocarcinoma of the retroperitoneal ascending and descending colon: sites of initial dissemination and clinical patterns of recurrence following surgery alone. *Int J Radiat Oncol Biol Phys.* 1983;9(3):361–5.
194. Jayne DG, Fook S, Loi C, Seow-Choen F. Peritoneal carcinomatosis from colorectal cancer. *Br J Surg.* 2002;89(12):1545–50.
195. Sugarbaker PH. Management of peritoneal-surface malignancy: the surgeon's role.

- Langenbecks Arch Surg. 1999;384(6):576–87.
196. Glehen O, Osinsky D, Beaujard AC, Gilly FN. Natural history of peritoneal carcinomatosis from nongynecologic malignancies. *Surg Oncol Clin N Am*. 2003;12(3):729–39.
  197. Franko J, Shi Q, Goldman CD, Pockaj BA, Nelson GD, Goldberg RM, et al. Treatment of colorectal peritoneal carcinomatosis with systemic chemotherapy: a pooled analysis of north central cancer treatment group phase III trials N9741 and N9841. *J Clin Oncol*. 2012;30(3):263–7.
  198. Chu DZ, Lang NP, Thompson C, Osteen PK, Westbrook KC. Peritoneal carcinomatosis in nongynecologic malignancy. A prospective study of prognostic factors. *Cancer*. 1989;63(2):364–7.
  199. Willett CG, Tepper JE, Cohen AM, Orlow E, Welch CE. Failure patterns following curative resection of colonic carcinoma. *Ann Surg*. 1984;200(6):685–90.
  200. Hansen E, Wolff N, Knuechel R, Ruschoff J, Hofstaedter F, Taeger K. Tumor cells in blood shed from the surgical field. *Arch Surg*. 1995;130(4):387–93.
  201. Sadeghi B, Arvieux C, Glehen O, Beaujard AC, Rivoire M, Baulieux J, et al. Peritoneal carcinomatosis from non-gynecologic malignancies: results of the EVOCAPE 1 multicentric prospective study. *Cancer*. 2000;88(2):358–63.
  202. Jacquet P, Jelinek JS, Steves MA, Sugarbaker PH. Evaluation of computed tomography in patients with peritoneal carcinomatosis. *Cancer*. 1993;72(5):1631–6.
  203. González-Moreno S, González-Bayón L, Ortega-Pérez G, González-Hernando C. Imaging of peritoneal carcinomatosis. *Cancer J*. 2009;15(3):184–9.
  204. Gilly FN, Beaujard A, Glehen O, Grandclement E, Caillot JL, Francois Y, et al. Peritonectomy combined with intraperitoneal chemohyperthermia in abdominal cancer with peritoneal carcinomatosis: phase I-II study. *Anticancer Res*. 1999;19(3B):2317–21.
  205. Jacquet P, Sugarbaker PH. Clinical research methodologies in diagnosis and staging of patients with peritoneal carcinomatosis. *Cancer Treat Res*. 1996;82:359–74.
  206. Pestieau SR, Sugarbaker PH. Treatment of primary colon cancer with peritoneal carcinomatosis: comparison of concomitant vs. delayed management. *Dis Colon Rectum*. 2000;43(10):1341–6. discussion 1347–8.
  207. Machover D. A comprehensive review of 5-fluorouracil and leucovorin in patients with metastatic colorectal carcinoma. *Cancer*. 1997;80(7):1179–87.
  208. Sugarbaker PH. Colorectal carcinomatosis: a new oncologic frontier. *Curr Opin Oncol*. 2005;17(4):397–9.
  209. Speyer JL. The rationale behind intraperitoneal chemotherapy in gastrointestinal malignancies. *Semin Oncol*. 1985;12(3 Suppl 4):23–8.
  210. Sugarbaker PH, Graves T, DeBruijn EA, Cunliffe WJ, Mullins RE, Hull WE, et al. Early postoperative intraperitoneal chemotherapy as an adjuvant therapy to surgery for peritoneal carcinomatosis from gastrointestinal cancer: pharmacological studies. *Cancer Res*. 1990;50(18):5790–4.
  211. Elias D, Gilly F, Boutitie F, Quenet F, Bereder J-M, Mansvelt B, et al. Peritoneal colorectal carcinomatosis treated with surgery and perioperative intraperitoneal chemotherapy: retrospective analysis of 523 patients from a multicentric French study. *J Clin Oncol*. 2010;28(1):63–8.
  212. Verwaal VJ, van Ruth S, de Bree E, van Sloothen GW, van Tinteren H, Boot H, et al. Randomized trial of cytoreduction and hyperthermic intraperitoneal chemotherapy versus systemic chemotherapy and palliative surgery in patients with peritoneal carcinomatosis of colorectal cancer. *J Clin Oncol*. 2003;21(20):3737–43.

213. Elias D, Delperro JR, Sideris L, Benhamou E, Pocard M, Baton O, et al. Treatment of peritoneal carcinomatosis from colorectal cancer: impact of complete cytoreductive surgery and difficulties in conducting randomized trials. *Ann Surg Oncol*. 2004;11(5):518–21.
214. Verwaal VJ, Bruin S, Boot H, van Slooten G, van Tinteren H. 8-Year follow-up of randomized trial: cytoreduction and hyperthermic intraperitoneal chemotherapy versus systemic chemotherapy in patients with peritoneal carcinomatosis of colorectal cancer. *Ann Surg Oncol*. 2008;15(9):2426–32.
215. Mahteme H, Hansson J, Berglund A, Pahlman L, Glimelius B, Nygren P, et al. Improved survival in patients with peritoneal metastases from colorectal cancer: a preliminary study. *Br J Cancer*. 2004;90(2):403–7.
216. Glehen O, Kwiattkowski F, Sugarbaker PH, Elias D, Levine EA, De Simone M, et al. Cytoreductive surgery combined with perioperative intraperitoneal chemotherapy for the management of peritoneal carcinomatosis from colorectal cancer: a multi-institutional study. *J Clin Oncol*. 2004;22(16):3284–92.
217. Yan TD, Black D, Savady R, Sugarbaker PH. Systematic review on the efficacy of cytoreductive surgery combined with perioperative intraperitoneal chemotherapy for peritoneal carcinomatosis from colorectal carcinoma. *J Clin Oncol*. 2006;24(24):4011–9.
218. Esquivel J, Lowy AM, Markman M, Chua T, Pelz J, Baratti D, et al. The American Society of Peritoneal Surface Malignancies (ASPSM) Multiinstitution Evaluation of the Peritoneal Surface Disease Severity Score (PSDSS) in 1,013 Patients with Colorectal Cancer with Peritoneal Carcinomatosis. *Ann Surg Oncol*. 2014;21(13):4195–201.
219. Elias D, Lefevre JH, Chevalier J, Brouquet A, Marchal F, Classe J-M, et al. Complete cytoreductive surgery plus intraperitoneal chemohyperthermia with oxaliplatin for peritoneal carcinomatosis of colorectal origin. *J Clin Oncol*. 2009;27(5):681–5.
220. Yan TD, Zappa L, Edwards G, Alderman R, Marquardt CE, Sugarbaker PH. Perioperative outcomes of cytoreductive surgery and perioperative intraperitoneal chemotherapy for non-appendiceal peritoneal carcinomatosis from a prospective database. *J Surg Oncol*. 2007;96(2):102–12.
221. National Comprehensive Cancer Network (NCCN). NCCN clinical practice guidelines in oncology. [http://www.nccn.org/professionals/physician\\_gls/f\\_guidelines.asp](http://www.nccn.org/professionals/physician_gls/f_guidelines.asp). Accessed 19 May 2015.
222. Esquivel J, Sticca R, Sugarbaker P, Levine E, Yan TD, Alexander R, Society of Surgical Oncology Annual Meeting, et al. Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in the management of peritoneal surface malignancies of colonic origin: a consensus statement. Society of Surgical Oncology. *Ann Surg Oncol*. 2007;14(1):128–33.
223. Ulbright TM, Roth LM, Stehman FB. Secondary ovarian neoplasia. A clinicopathologic study of 35 cases. *Cancer*. 1984;53(5):1164–74.
224. Omranipour R, Abasahl A. Ovarian metastases in colorectal cancer. *Int J Gynecol Cancer*. 2009;19(9):1524–8.
225. Webb MJ, Decker DG, Mussey E. Cancer metastatic to the ovary: factors influencing survival. *Obstet Gynecol*. 1975;45(4):391–6.
226. Blamey S, McDermott F, Pihl E, Price AB, Milne BJ, Hughes E. Ovarian involvement in adenocarcinoma of the colon and rectum. *Surg Gynecol Obstet*. 1981;153(1):42–4.
227. Morrow M, Enker WE. Late ovarian metastases in carcinoma of the colon and rectum. *Arch*

- Surg. 1984;119(12):1385–8.
228. Cutait R, Lesser ML, Enker WE. Prophylactic oophorectomy in surgery for large-bowel cancer. *Dis Colon Rectum*. 1983;26(1):6–11.
229. Barr SS, Valiente MA, Bacon HE. Rationale of bilateral oophorectomy concomitant with resection for carcinoma of the rectum and colon. *Dis Colon Rectum*. 1962;5:450–2.
230. Young-Fadok TM, Wolff BG, Nivatvongs S, Metzger PP, Ilstrup DM. Prophylactic oophorectomy in colorectal carcinoma: preliminary results of a randomized, prospective trial. *Dis Colon Rectum*. 1998;41(3):277–83. discussion 83–5.
231. Burt CA. Carcinoma of the ovaries secondary to cancer of the colon and rectum. *Dis Colon Rectum*. 1960;3:352–7.
232. Stearns MW, Deddish MR. Five-year results of abdominopelvic lymph node dissection for carcinoma of the rectum. *Dis Colon Rectum*. 1959;2(2):169–72.
233. Graffner HO, Alm PO, Oscarson JE. Prophylactic oophorectomy in colorectal carcinoma. *Am J Surg*. 1983;146(2):233–5.
234. Koves I, Vamosi-Nagy I, Besznyak I. Ovarian metastases of colorectal tumours. *Eur J Surg Oncol*. 1993;19(6):633–5.
235. Harcourt KF, Dennis DL. Laparotomy for “ovarian tumors” in unsuspected carcinoma of the colon. *Cancer*. 1968;21(6):1244–6.
236. Lindner V, Gasser B, Debbiche A, Tomb L, Vetter JM, Walter P. Ovarian metastasis of colorectal adenocarcinomas. A clinico-pathological study of 41 cases. *Ann Pathol*. 1999;19(6):492–8.
237. Rayson D, Bouttell E, Whiston F, Stitt L. Outcome after ovarian/adnexal metastasectomy in metastatic colorectal carcinoma. *J Surg Oncol*. 2000;75(3):186–92.
238. Loy TS, Calaluce RD, Keeney GL. Cytokeratin immunostaining in differentiating primary ovarian carcinoma from metastatic colonic adenocarcinoma. *Mod Pathol*. 1996;9(11):1040–4.
239. DeCostanzo DC, Elias JM, Chumas JC. Necrosis in 84 ovarian carcinomas: a morphologic study of primary versus metastatic colonic carcinoma with a selective immunohistochemical analysis of cytokeratin subtypes and carcinoembryonic antigen. *Int J Gynecol Pathol*. 1997;16(3):245–9.
240. Wauters CC, Smedts F, Gerrits LG, Bosman FT, Ramaekers FC. Keratins 7 and 20 as diagnostic markers of carcinomas metastatic to the ovary. *Hum Pathol*. 1995;26(8):852–5.
241. Dionigi A, Facco C, Tibiletti MG, Bernasconi B, Riva C, Capella C. Ovarian metastases from colorectal carcinoma. Clinicopathologic profile, immunophenotype, and karyotype analysis. *Am J Clin Pathol*. 2000;114(1):111–22.
242. Blamey SL, McDermott FT, Pihl E, Hughes ES. Resected ovarian recurrence from colorectal adenocarcinoma: a study of 13 cases. *Dis Colon Rectum*. 1981;24(4):272–5.
243. Herrera-Ornelas L, Mittelman A. Results of synchronous surgical removal of primary colorectal adenocarcinoma and ovarian metastases. *Oncology*. 1984;41(2):96–100.
244. Huang PP, Weber TK, Mendoza C, Rodriguez-Bigas MA, Petrelli NJ. Long-term survival in patients with ovarian metastases from colorectal carcinoma. *Ann Surg Oncol*. 1998;5(8):695–8.
245. Wright JD, Powell MA, Mutch DG, Rader JS, Gibb RK, Huettner PC, et al. Synchronous ovarian metastases at the time of laparotomy for colon cancer. *Gynecol Oncol*. 2004;92(3):851–5.
246. Miller BE, Pittman B, Wan JY, Fleming M. Colon cancer with metastasis to the ovary at time of initial diagnosis. *Gynecol Oncol*. 1997;66(3):368–71.

247. MacKeigan JM, Ferguson JA. Prophylactic oophorectomy and colorectal cancer in premenopausal patients. *Dis Colon Rectum*. 1979;22(6):401–5.
248. Ballantyne GH, Reigel MM, Wolff BG, Ilstrup DM. Oophorectomy and colon cancer. Impact on survival. *Ann Surg*. 1985;202(2):209–14.
249. Sielezneff I, Salle E, Antoine K, Thirion X, Brunet C, Sastre B. Simultaneous bilateral oophorectomy does not improve prognosis of postmenopausal women undergoing colorectal resection for cancer. *Dis Colon Rectum*. 1997;40(11):1299–302.
250. Kontoravdis A, Kalogirou D, Antoniou G, Kontoravdis N, Karakitsos P, Zourlas PA. Prophylactic oophorectomy in ovarian cancer prevention. *Int J Gynaecol Obstet*. 1996;54(3):257–62.
251. Barringer PL, Dockerty MB, Waugh JM, Barga JA. Carcinoma of the large intestine; a new approach to the study of venous spread. *Surg Gynecol Obstet*. 1954;98(1):62–72.
252. Katoh M, Unakami M, Hara M, Fukuchi S. Bone metastasis from colorectal cancer in autopsy cases. *J Gastroenterol*. 1995;30(5):615–8.
253. Santini D, Tampellini M, Vincenzi B, Ibrahim T, Ortega C, Virzi V, et al. Natural history of bone metastasis in colorectal cancer: final results of a large Italian bone metastases study. *Ann Oncol*. 2012;23(8):2072–7.
254. Besbeas S, Stearns MW. Osseous metastases from carcinomas of the colon and rectum. *Dis Colon Rectum*. 1978;21(4):266–8.
255. Buckley N, Peebles Brown DA. Metastatic tumors in the hand from adenocarcinoma of the colon. *Dis Colon Rectum*. 1987;30(2):141–3.
256. Cascino TL, Leavengood JM, Kemeny N, Posner JB. Brain metastases from colon cancer. *J Neurooncol*. 1983;1(3):203–9.
257. Rovirosa A, Bodi R, Vicente P, Alastuey I, Giralt J, Salvador L. Cerebral metastases in adenocarcinoma of the colon. *Rev Esp Enferm Dig*. 1991;79(4):281–3.
258. Alden TD, Gianino JW, Saclarides TJ. Brain metastases from colorectal cancer. *Dis Colon Rectum*. 1996;39(5):541–5.
259. Zimm S, Wampler GL, Stablein D, Hazra T, Young HF. Intracerebral metastases in solid-tumor patients: natural history and results of treatment. *Cancer*. 1981;48(2):384–94.
260. Wroński M, Arbit E. Resection of brain metastases from colorectal carcinoma in 73 patients. *Cancer*. 1999;85(8):1677–85.
261. Ko FC, Liu JM, Chen WS, Chiang JK, Lin TC, Lin JK. Risk and patterns of brain metastases in colorectal cancer: 27-year experience. *Dis Colon Rectum*. 1999;42(11):1467–71.
262. Sio TT, Jang S, Lee S-W, Curran B, Pyakuryal AP, Sternick ES. Comparing gamma knife and cyberknife in patients with brain metastases. *J Appl Clin Med Phys*. 2014;15(1):4095.
263. Nakamura E, Shimizu M, Itoh T, Manabe T. Secondary tumors of the pancreas: clinicopathological study of 103 autopsy cases of Japanese patients. *Pathol Int*. 2001;51(9):686–90.
264. Rumancik WM, Megibow AJ, Bosniak MA, Hilton S. Metastatic disease to the pancreas: evaluation by computed tomography. *J Comput Assist Tomogr*. 1984;8(5):829–34.
265. Sperti C, Pasquali C, Berselli M, Frison L, Vicario G, Pedrazzoli S. Metastasis to the pancreas from colorectal cancer: is there a place for pancreatic resection? *Dis Colon Rectum*. 2009;52(6):1154–9.
266. Inagaki H, Nakao A, Ando N, Kotake K, Imaizumi T, Okuda N, et al. A case of solitary metastatic pancreatic cancer from rectal carcinoma: a case report. *Hepatogastroenterology*.

1998;45(24):2413–7.

267. Cedermark BJ, Blumenson LE, Pickren JW, Holyoke DE, Elias EG. The significance of metastases to the adrenal glands in adenocarcinoma of the colon and rectum. *Surg Gynecol Obstet.* 1977;144(4):537–46.

268. Mourra N, Hoeffel C, Duvillard P, Guettier C, Flejou J-F, Tiret E. Adrenalectomy for clinically isolated metastasis from colorectal carcinoma: report of eight cases. *Dis Colon Rectum.* 2008;51(12):1846–9.

269. Fujita K, Kameyama S, Kawamura M. Surgically removed adrenal metastasis from cancer of the rectum. Report of a case. *Dis Colon Rectum.* 1988;31(2):141–3.

270. Katayama A, Mafune K, Makuuchi M. Adrenalectomy for solitary adrenal metastasis from colorectal carcinoma. *Jpn J Clin Oncol.* 2000;30(9):414–6.

271. Watatani M, Ooshima M, Wada T, Terashita H, Matsuda T, Shindo K, et al. Adrenal metastasis from carcinoma of the colon and rectum: a report of three cases. *Surg Today.* 1993;23(5):444–8.

272. Kanjo T, Albertini M, Weber S. Long-term disease-free survival after adrenalectomy for isolated colorectal metastases. *Asian J Surg.* 2006;29(4):291–3.

273. Marangos IP, Kazaryan AM, Rosseland AR, Røsok BI, Carlsen HS, Kromann-Andersen B, et al. Should we use laparoscopic adrenalectomy for metastases? Scandinavian multicenter study. *J Surg Oncol.* 2009;100(1):43–7.

274. De Haas RJ, Rahy Martin AC, Wicherts DA, Azoulay D, Castaing D, Adam R. Long-term outcome in patients with adrenal metastases following resection of colorectal liver metastases. *Br J Surg.* 2009;96(8):935–40.

275. Choi PW, Kim HC, Kim AY, Jung SH, Yu CS, Kim JC. Extensive lymphadenectomy in colorectal cancer with isolated para-aortic lymph node metastasis below the level of renal vessels. *J Surg Oncol.* 2010;101(1):66–71.

276. Min BS, Kim NK, Sohn SK, Cho CH, Lee KY, Baik SH. Isolated paraaortic lymph-node recurrence after the curative resection of colorectal carcinoma. *J Surg Oncol.* 2008;97(2):136–40.

277. Shibata D, Paty PB, Guillem JG, Wong WD, Cohen AM. Surgical management of isolated retroperitoneal recurrences of colorectal carcinoma. *Dis Colon Rectum.* 2002;45(6):795–801.

278. Biasco G, Derenzini E, Grazi G, Ercolani G, Ravaioli M, Pantaleo MA, et al. Treatment of hepatic metastases from colorectal cancer: many doubts, some certainties. *Cancer Treat Rev.* 2006;32(3):214–28.

279. Saltz LB. Metastatic colorectal cancer: is there one standard approach? *Oncology (Williston Park).* 2005;19(9):1147–54.

280. Ho TW, Mack LA, Temple WJ. Operative salvage for retroperitoneal nodal recurrence in colorectal cancer: a systematic review. *Ann Surg Oncol.* 2011;18(3):697–703.

281. Ferlay J, Shin H-R, Bray F, Forman D, Mathers C, Parkin DM. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. *Int J Cancer.* 2010;127(12):2893–917.

282. CancerStats Incidence 2008-UK. 2011. <http://www.cancerresearchuk.org/cancer-info/cancerstats/types/bowel/incidence/#trends>. Accessed 15 May 2015.

283. Yancik R, Ries LA. Aging and cancer in America. Demographic and epidemiologic perspectives. *Hematol Oncol Clin North Am.* 2000;14(1):17–23.

284. Extermann M, Balducci L, Lyman GH. What threshold for adjuvant therapy in older breast cancer patients? *J Clin Oncol.* 2000;18(8):1709–17.

285. Lichtman SM. Therapy insight: therapeutic challenges in the treatment of elderly cancer

- patients. *Nat Clin Pract Oncol*. 2006;3(2):86–93.
286. Van Gestel YR, Lemmens VE, de Hingh IH, Steevens J, Rutten HJ, Nieuwenhuijzen GA, et al. Influence of comorbidity and age on 1-, 2-, and 3-month postoperative mortality rates in gastrointestinal cancer patients. *Ann Surg Oncol*. 2013;20(2):371–80.
287. Power D, Lichtman S. Adjuvant and palliative chemotherapy for colon cancer in the elderly patient. *Semin Colon Rectal Surg*. 2008;19:239–46.
288. Papamichael D, Audisio R, Horiot J-C, Glimelius B, Sastre J, Mitry E, et al. SIOG. Treatment of the elderly colorectal cancer patient: SIOG expert recommendations. *Ann Oncol*. 2009;20(1):5–16.
289. Hamaker ME, Jonker JM, de Rooij SE, Vos AG, Smorenburg CH, van Munster BC. Frailty screening methods for predicting outcome of a comprehensive geriatric assessment in elderly patients with cancer: a systematic review. *Lancet Oncol*. 2012;13(10):e437–44.
290. Smets IH, Kempen GI, Janssen-Heijnen ML, Deckx L, Buntinx FJ, van den Akker M. Four screening instruments for frailty in older patients with and without cancer: a diagnostic study. *BMC Geriatr*. 2014;14:26.
291. Kenig J, Zychiewicz B, Olszewska U, Richter P. Screening for frailty among older patients with cancer that qualify for abdominal surgery. *J Geriatr Oncol*. 2015;6(1):52–9.
292. Papamichael D, Audisio RA, Glimelius B, de Gramont A, Glynne-Jones R, Haller D, et al. Treatment of colorectal cancer in older patients: International Society of Geriatric Oncology (SIOG) consensus recommendations 2013. *Ann Oncol*. 2015;26(3):463–76.
293. Mori M, Tomoda H, Ishida T, Kido A, Shimono R, Matsushima T, et al. Surgical resection of pulmonary metastases from colorectal adenocarcinoma. Special reference to repeated pulmonary resections. *Arch Surg*. 1991;126(10):1297–301. discussion 1302.
294. McCormack PM, Burt ME, Bains MS, Martini N, Rusch VW, Ginsberg RJ. Lung resection for colorectal metastases. 10-year results. *Arch Surg*. 1992;127(12):1403–6.
295. Yano T, Hara N, Ichinose Y, Yokoyama H, Miura T, Ohta M. Results of pulmonary resection of metastatic colorectal cancer and its application. *J Thorac Cardiovasc Surg*. 1993;106(5):875–9.
296. Saclarides TJ, Krueger BL, Szeluga DJ, Warren WH, Faber LP, Economou SG. Thoracotomy for colon and rectal cancer metastases. *Dis Colon Rectum*. 1993;36(5):425–9.
297. Van Halteren HK, van Geel AN, Hart AA, Zoetmulder FA. Pulmonary resection for metastases of colorectal origin. *Chest*. 1995;107(6):1526–31.
298. Shirouzu K, Isomoto H, Hayashi A, Nagamatsu Y, Kakegawa T. Surgical treatment for patients with pulmonary metastases after resection of primary colorectal carcinoma. *Cancer*. 1995;76(3):393–8.
299. Girard P, Ducreux M, Baldeyrou P, Rougier P, Le Chevalier T, Bougaran J, et al. Surgery for lung metastases from colorectal cancer: analysis of prognostic factors. *J Clin Oncol*. 1996;14(7):2047–53.
300. Okumura S, Kondo H, Tsuboi M, Nakayama H, Asamura H, Tsuchiya R, et al. Pulmonary resection for metastatic colorectal cancer: experiences with 159 patients. *J Thorac Cardiovasc Surg*. 1996;112(4):867–74.
301. Zanella A, Marchet A, Mainente P, Nitti D, Lise M. Resection of pulmonary metastases from colorectal carcinoma. *Eur J Surg Oncol*. 1997;23(5):424–7.
302. Zink S, Kayser G, Gabius HJ, Kayser K. Survival, disease-free interval, and associated tumor features in patients with colon/rectal carcinomas and their resected intra-pulmonary metastases. *Eur*



J Cardiothorac Surg. 2001;19(6):908–13.

303. DeVita VT, Hellman S, Rosenberg SA. Cancer: principles and practice of oncology. 6th ed. Philadelphia: Lippincott Williams and Wilkins; 2001.

## 第 37 章

1. Barrett ML, Hines AL, Andrews RM (2006) Trends in rates of perforated appendix, 2001–2010: statistical brief #159. <http://www.ncbi.nlm.nih.gov/pubmed/24199256>. Accessed 6 Apr 2015.
2. McCusker ME, Cote TR, Clegg LX, et al. Primary malignant neoplasms of the appendix: a population-based study from the surveillance, epidemiology and end-results program, 1973–1998. *Cancer*. 2002;94:3307–12.
3. Whitfield CG, Amin SN, Garner JP. Surgical management of primary appendiceal malignancy. *Colorectal Dis*. 2012;14:1507–11.
4. Overman MJ, Fournier K, Hu CY, et al. Improving the AJCC/TNM staging for adenocarcinomas of the appendix: the prognostic impact of histological grade. *Ann Surg*. 2013;257:1072–8.
5. Marmor S, Portschiy PR, Tuttle TM, et al. The rise in appendiceal cancer incidence: 2000–2009. *J Gastrointest Surg*. 2015;19(4):743–50.
6. McGory ML, Maggard MA, Kang H, et al. Malignancies of the appendix: beyond case series reports. *Dis Colon Rectum*. 2005;48:2264–71.
7. Collins DC. A study of 50,000 specimens of the human vermiform appendix. *Surg Gynecol Obstet*. 1955;101:437–45.
8. Carr NJ, Sobin LH. Adenocarcinoma of the appendix. In: Bosman FT, Carneiro F, Hruban RH, Theise ND, editors. WHO classification of tumors of the digestive system (IARC WHO classification of tumours). 4th ed. Lyon: World Health Organization; 2010. p. 122–5.
9. Maggard MA, O’Connell JB, Ko CY. Updated population-based review of carcinoid tumors. *Ann Surg*. 2004;240:117–22.
10. Goede AC, Caplin ME, Winslet MC. Carcinoid tumour of the appendix. *Br J Surg*. 2003;90:1317–22.
11. Misraji J. Tumors of the appendix. In: Shepherd NA, Warren BF, Williams GT, Greenson JK, Lauwers GY, Novelli MR, editors. *Morson’s and Dawson’s gastrointestinal pathology*. 5th ed. London: Wiley; 2013. p. 490–8.
12. Ronnett BM, Zahn CM, Kurman RJ, et al. Disseminated peritoneal adenomucinosis and peritoneal mucinous carcinomatosis. A clinicopathologic analysis of 109 cases with emphasis on distinguishing pathologic features, site of origin, prognosis, and relationship to “pseudomyxoma peritonei”. *Am J Surg Pathol*. 1995;19:1390–408.
13. Appendix. In: Edge SB, Byrd DR, Compton CC, Fritz AG, Greene FL, Trotti A, editors. *AJCC cancer staging manual*. 7th ed. New York: Springer; 2010.
14. Komminoth P, Arnold R, Capella C, et al. Neuroendocrine neoplasms of the appendix. In: Bosman FT, Carneiro F, Hruban RH, Theise ND, editors. WHO classification of tumors of the digestive system (IARC WHO classification of tumours). 4th ed. Lyon: World Health Organization; 2010.
15. Pape UF, Perren A, Niederle B, et al. ENETS consensus guidelines for the management of patients with neuroendocrine neoplasms from the jejunum-ileum and the appendix including goblet

cell carcinomas. *Neuroendocrinology*. 2012;95:135–56.

16. Kulke MH, Mayer RJ. Carcinoid tumors. *N Engl J Med*. 1999;340:858–68.

17. Rindi G, Kloppel G, Couvelard A, et al. TNM staging of midgut and hindgut (neuro) endocrine tumors: a consensus proposal including a grading system. *Virchows Arch*. 2007;451:757–62.

18. Mullen JT, Savarese DMF. Carcinoid tumors of the appendix: a population-based study. *J Surg Oncol*. 2011;104:41–4.

19. Roy P, Chetty R. Goblet cell carcinoid tumors of the appendix: an overview. *World J Gastrointest Oncol*. 2010;2:251–8.

20. Pham TH, Wolff B, Abraham SC, et al. Surgical and chemotherapy treatment outcomes of goblet cell carcinoid: a tertiary cancer center experience. *Ann Surg Oncol*. 2006;13:370–6.

21. Tang LH, Shia J, Soslow RA, et al. Pathologic classification and clinical behavior of the spectrum of goblet cell carcinoid tumors of the appendix. *Am J Surg Pathol*. 2008;32:1429–43.

22. Ng D, Falck V, McConnell YJ, et al. Appendiceal goblet cell carcinoid and mucinous neoplasms are closely associated tumors: lessons from their coexistence in primary tumors and concurrence in peritoneal dissemination. *J Surg Oncol*. 2014;109:548–55.

23. Trivedi AN, Levine EA, Mishra G. Adenocarcinoma of the appendix is rarely detected by colonoscopy. *J Gastrointest Surg*. 2009;13:668–75.

24. Esquivel J, Chua TC, Stojadinovic A, et al. Accuracy and clinical relevance of computed tomography scan interpretation of peritoneal cancer index in colorectal cancer peritoneal carcinomatosis: a multi-institutional study. *J Surg Oncol*. 2010;102:565–70.

25. Low RN, Barone RM, Lee MJ. Surveillance MR imaging is superior to serum tumor markers for detecting early tumor recurrence in patients with appendiceal cancer treated with surgical cytoreduction and HIPEC. *Ann Surg Oncol*. 2013;20:1074–81.

26. Madwed D, Mindelzun R, Jeffrey Jr RB. Mucocele of the appendix: imaging findings. *AJR Am J Roentgenol*. 1992;159:69–72.

27. Puvaneswary M, Proietto A. Mucocele of the appendix with magnetic resonance imaging findings. *Australas Radiol*. 2006;50:71–4.

28. Gerstle JT, Kauffman Jr GL, Koltun WA. The incidence, management, and outcome of patients with gastrointestinal carcinoids and second primary malignancies. *J Am Coll Surg*. 1995;180:427–32.

29. Franko J, Shi Q, Goldman CD, et al. Treatment of colorectal peritoneal carcinomatosis with systemic chemotherapy: a pooled analysis of north central cancer treatment group phase III trials N9741 and N9841. *J Clin Oncol*. 2012;30:263–7.

30. Bijelic L, Kumar AS, Stuart OA, et al. Systemic chemotherapy prior to cytoreductive surgery and HIPEC for carcinomatosis from appendix cancer: impact on perioperative outcomes and short-term survival. *Gastroenterol Res Pract*. 2012;2012:163284.

31. Eveno C, Passot G, Goere D, et al. Bevacizumab doubles the early postoperative complication rate after cytoreductive surgery with hyperthermic intraperitoneal chemotherapy (HIPEC) for peritoneal carcinomatosis of colorectal origin. *Ann Surg Oncol*. 2014;21:1792–800.

32. Dhage-Ivatury S, Sugarbaker PH. Update on the surgical approach to mucocele of the appendix. *J Am Coll Surg*. 2006;202:680–4.

33. Nitecki SS, Wolff BG, Schlinkert R, et al. The natural history of surgically treated primary adenocarcinoma of the appendix. *Ann Surg*. 1994;219:51–7.

34. Gonzalez-Moreno S, Sugarbaker PH. Right hemicolectomy does not confer a survival advantage

in patients with mucinous carcinoma of the appendix and peritoneal seeding. *Br J Surg*. 2004;91:304–11.

35. Kusamura S, Moran BJ, Sugarbaker PH, et al. Multicentre study of the learning curve and surgical performance of cytoreductive surgery with intraperitoneal chemotherapy for pseudomyxoma peritonei. *Br J Surg*. 2014;101:1758–65.

36. Chua TC, Moran BJ, Sugarbaker PH, et al. Early- and long-term outcome data of patients with pseudomyxoma peritonei from appendiceal origin treated by a strategy of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy. *J Clin Oncol*. 2012;30:2449–56.

37. Yan TD, Black D, Savady R, et al. A systematic review on the efficacy of cytoreductive surgery and perioperative intraperitoneal chemotherapy for pseudomyxoma peritonei. *Ann Surg Oncol*. 2007;14:484–92.

38. Valle M, Federici O, Carboni F, et al. Postoperative infections after cytoreductive surgery and HIPEC for peritoneal carcinomatosis: proposal and results from a prospective protocol study of prevention, surveillance and treatment. *Eur J Surg Oncol*. 2014;40:950–6.

39. Votanopoulos KI, Newman NA, Russell G, et al. Outcomes of Cytoreductive Surgery (CRS) with hyperthermic intraperitoneal chemotherapy (HIPEC) in patients older than 70 years; survival benefit at considerable morbidity and mortality. *Ann Surg Oncol*. 2013;20:3497–503.

40. Glockzin G, von Breitenbuch P, Schlitt HJ, et al. Treatment-related morbidity and toxicity of CRS and oxaliplatin-based HIPEC compared to a mitomycin and doxorubicin-based HIPEC protocol in patients with peritoneal carcinomatosis: a matched-pair analysis. *J Surg Oncol*. 2013;107:574–8.

41. Deraco M, Baratti D, Kusamura S. Morbidity and quality of life following cytoreduction and HIPEC. *Cancer Treat Res*. 2007;134:403–18.

42. Glehen O, Mohamed F, Sugarbaker PH. Incomplete cytoreduction in 174 patients with peritoneal carcinomatosis from appendiceal malignancy. *Ann Surg*. 2004;240:278–85.

43. Verwaal VJ, van Ruth S, de Bree E, et al. Randomized trial of cytoreduction and hyperthermic intraperitoneal chemotherapy versus systemic chemotherapy and palliative surgery in patients with peritoneal carcinomatosis of colorectal cancer. *J Clin Oncol*. 2003;21:3737–43.

44. Sugarbaker PH, Ryan DP. Cytoreductive surgery plus hyperthermic perioperative chemotherapy to treat peritoneal metastases from colorectal cancer: standard of care or an experimental approach? *Lancet Oncol*. 2012;13:e362–9.

45. Evrard S, Maziere C, Desolneux G. HIPEC: standard of care or an experimental approach? *Lancet Oncol*. 2012;13:e462–3.

46. Markman M. Continued uncertainty regarding hyperthermic intraperitoneal chemotherapy in malignant peritoneal mesothelioma. *J Clin Oncol*. 2010;28:e418. Author reply e419.

47. Caneparo A, Massucco P, Vaira M, et al. Contamination risk for operators performing semi-closed HIPEC procedure using cisplatin. *Eur J Surg Oncol*. 2014;40:925–9.

48. Konate A, Poupon J, Villa A, et al. Evaluation of environmental contamination by platinum and exposure risks for healthcare workers during a heated intraperitoneal perioperative chemotherapy (HIPEC) procedure. *J Surg Oncol*. 2011;103:6–9.

49. Stinner B, Kisker O, Zielke A, et al. Surgical management for carcinoid tumors of small bowel, appendix, colon, and rectum. *World J Surg*. 1996;20:183–8.

50. Stephens AD, Alderman R, Chang D, et al. Morbidity and mortality analysis of 200 treatments with cytoreductive surgery and hyperthermic intraoperative intraperitoneal chemotherapy using the

coliseum technique. *Ann Surg Oncol*. 1999;6:790–6.

51. Ahmad SA, Kim J, Sussman JJ, et al. Reduced morbidity following cytoreductive surgery and intraperitoneal hyperthermic chemoperfusion. *Ann Surg Oncol*. 2004;11:387–92.

52. Stewart JH, Shen P, Russell GB, et al. Appendiceal neoplasms with peritoneal dissemination: outcomes after cytoreductive surgery and intraperitoneal hyperthermic chemotherapy. *Ann Surg Oncol*. 2006;13:624–34.

53. Baratti D, Kusamura S, Nonaka D, et al. Pseudomyxoma peritonei: clinical pathological and biological prognostic factors in patients treated with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (HIPEC). *Ann Surg Oncol*. 2008;15:526–34.

54. Bijelic L, Yan TD, Sugarbaker PH. Treatment failure following complete cytoreductive surgery and perioperative intraperitoneal chemotherapy for peritoneal dissemination from colorectal or appendiceal mucinous neoplasms. *J Surg Oncol*. 2008;98:295–9.

55. El Halabi H, Gushchin V, Francis J, et al. The role of cytoreductive surgery and heated intraperitoneal chemotherapy (CRS/HIPEC) in patients with high-grade appendiceal carcinoma and extensive peritoneal carcinomatosis. *Ann Surg Oncol*. 2012;19:110–4.

56. Teo MCC, Tan GHC, Tham CK, et al. Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in Asian patients: 100 consecutive patients in a single institution. *Ann Surg Oncol*. 2013;20:2968–74.

57. Tabrizian P, Shrager B, Jibara G, et al. Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for peritoneal carcinomatosis: outcomes from a single tertiary institution. *J Gastrointest Surg*. 2014;18:1024–31.

58. Lord AC, Shihab O, Chandrakumaran K, et al. Recurrence and outcome after complete tumour removal and hyperthermic intraperitoneal chemotherapy in 512 patients with pseudomyxoma peritonei from perforated appendiceal mucinous tumours. *Eur J Surg Oncol*. 2015;41:396–9.

59. Votanopoulos KI, Russell G, Randle RW, et al. Peritoneal Surface Disease (PSD) from appendiceal cancer treated with Cytoreductive Surgery (CRS) and Hyperthermic Intraperitoneal Chemotherapy (HIPEC): overview of 481 cases. *Ann Surg Oncol*. 2015;22:1274–9.

## 第 38 章

1. Oberndorfer S. Karzinoide tumoren des dunndarms. *Frankf Z Pathol*. 1907;1:7.

2. Kulke MH, Mayer RJ. Carcinoid tumors. *N Engl J Med*. 1999;340(11):858–68.

3. Ganim RB, Norton JA. Recent advances in carcinoid pathogenesis, diagnosis and management. *Surg Oncol*. 2000;9(4):173–9.

4. Eriksson B, Oberg K, Stridsberg M. Tumor markers in neuroendocrine tumors. *Digestion*. 2000;62 Suppl 1:33–8.

5. Lips CJ, Lentjes EG, Hoppener JW. The spectrum of carcinoid tumours and carcinoid syndromes. *Ann Clin Biochem*. 2003;40(Pt 6):612–27.

6. Godwin 2nd JD. Carcinoid tumors. An analysis of 2,837 cases. *Cancer*. 1975;36(2):560–9.

7. Modlin IM, Sandor A. An analysis of 8305 cases of carcinoid tumors. *Cancer*. 1997;79(4):813–29.

8. Taghavi S, Jayarajan SN, Powers BD, Davey A, Willis AI. Examining rectal carcinoids in the era of screening colonoscopy: a surveillance, epidemiology, and end results analysis. *Dis Colon Rectum*.

2013;56(8):952–9.

9. Habal N, Sims C, Bilchik AJ. Gastrointestinal carcinoid tumors and second primary malignancies. *J Surg Oncol*. 2000;75(4):310–6.
10. Tichansky DS, Cagir B, Borrazzo E, Topham A, Palazzo J, Weaver EJ, et al. Risk of second cancers in patients with colorectal carcinoids. *Dis Colon Rectum*. 2002;45(1):91–7.
11. Rosenberg JM, Welch JP. Carcinoid tumors of the colon. A study of 72 patients. *Am J Surg*. 1985;149(6):775–9.
12. Orloff MJ. Carcinoid tumors of the rectum. *Cancer*. 1971;28(1):175–80.
13. Ballantyne GH, Savoca PE, Flannery JT, Ahlman MH, Modlin IM. Incidence and mortality of carcinoids of the colon. Data from the Connecticut Tumor Registry. *Cancer*. 1992;69(10):2400–5.
14. Murray SE, Lloyd RV, Sippel RS, Chen H. Clinicopathologic characteristics of colonic carcinoid tumors. *J Surg Res*. 2013;184(1):183–8.
15. Matsui K, Iwase T, Kitagawa M. Small, polypoid-appearing carcinoid tumors of the rectum: clinicopathologic study of 16 cases and effectiveness of endoscopic treatment. *Am J Gastroenterol*. 1993;88(11):1949–53.
16. Pronay G, Nagy G, Ujszaszy L, Minik K. Carcinoid tumours of the rectum. *Dtsch Z Verdau Stoffwechselkr*. 1983;43(2):78–81.
17. Lucas KJ, Feldman JM. Flushing in the carcinoid syndrome and plasma kallikrein. *Cancer*. 1986;58(10):2290–3.
18. Schreurs AJ, Westermann CJ, van den Bosch JM, Vanderschueren RG, Brutel de la Riviere A, Knaepen PJ. A twenty-five-year follow-up of ninety-three resected typical carcinoid tumors of the lung. *J Thorac Cardiovasc Surg*. 1992;104(5):1470–5.
19. Barclay TH, Schapira DV. Malignant tumors of the small intestine. *Cancer*. 1983;51(5):878–81.
20. Yoshikane H, Tsukamoto Y, Niwa Y, Goto H, Hase S, Mizutani K, et al. Carcinoid tumors of the gastrointestinal tract: evaluation with endoscopic ultrasonography. *Gastrointest Endosc*. 1993;39(3):375–83.
21. Kobayashi K, Katsumata T, Yoshizawa S, Sada M, Igarashi M, Saigenji K, et al. Indications of endoscopic polypectomy for rectal carcinoid tumors and clinical usefulness of endoscopic ultrasonography. *Dis Colon Rectum*. 2005;48(2):285–91.
22. Feldman JM. Carcinoid tumors and syndrome. *Semin Oncol*. 1987;14(3):237–46.
23. Reubi JC, Laissue J, Waser B, Horisberger U, Schaer JC. Expression of somatostatin receptors in normal, inflamed, and neoplastic human gastrointestinal tissues. *Ann N Y Acad Sci*. 1994;733:122–37.
24. Hoegerle S, Althoefer C, Ghanem N, Koehler G, Waller CF, Scheruebl H, et al. Whole-body 18F dopa PET for detection of gastrointestinal carcinoid tumors. *Radiology*. 2001;220(2):373–80.
25. Krausz Y, Freedman N, Rubinstein R, Lavie E, Orevi M, Tshori S, et al. 68Ga-DOTA-NOC PET/CT imaging of neuroendocrine tumors: comparison with (1)(1)(1)In-DTPA-octreotide (OctreoScan(R)). *Mol Imaging Biol*. 2011;13(3):583–93.
26. Stinner B, Kisker O, Zielke A, Rothmund M. Surgical management for carcinoid tumors of small bowel, appendix, colon, and rectum. *World J Surg*. 1996;20(2):183–8.
27. Memon MA, Nelson H. Gastrointestinal carcinoid tumors: current management strategies. *Dis Colon Rectum*. 1997;40(9):1101–18.
28. Welch JP, Donaldson GA. Recent experience in the management of cancer of the colon and rectum. *Am J Surg*. 1974;127(3):258–66.

29. Berardi RS. Carcinoid tumors of the colon (exclusive of the rectum): review of the literature. *Dis Colon Rectum*. 1972;15(5):383–91.
30. Sanders RJ, Axtell HK. Carcinoids of the gastrointestinal tract. *Surg Gynecol Obstet*. 1964;119:369–80.
31. Spread C, Berkel H, Jewell L, Jenkins H, Yakimets W. Colon carcinoid tumors. A population-based study. *Dis Colon Rectum*. 1994;37(5):482–91.
32. Al Natour RH, Saund MS, Sanchez VM, Whang EE, Sharma AM, Huang Q, et al. Tumor size and depth predict rate of lymph node metastasis in colon carcinoids and can be used to select patients for endoscopic resection. *J Gastrointest Surg*. 2012;16(3):595–602.
33. Naunheim KS, Zeitels J, Kaplan EL, Sugimoto J, Shen KL, Lee CH, et al. Rectal carcinoid tumors—treatment and prognosis. *Surgery*. 1983;94(4):670–6.
34. Wang M, Peng J, Yang W, Chen W, Mo S, Cai S. Prognostic analysis for carcinoid tumours of the rectum: a single institutional analysis of 106 patients. *Colorectal Dis*. 2011;13(2):150–3.
35. Wang YZ, Diebold A, Boudreaux P, Raines D, Campeau R, Anthony L, et al. Surgical treatment options for rectal carcinoid cancer: local versus low radical excision. *Am Surg*. 2014;80(1):31–5.
36. Shields CJ, Tired E, Winter DC, International Rectal Carcinoid Study Group. Carcinoid tumors of the rectum: a multi-institutional international collaboration. *Ann Surg*. 2010;252(5):750–5.
37. Yoon SN, Yu CS, Shin US, Kim CW, Lim SB, Kim JC. Clinicopathological characteristics of rectal carcinoids. *Int J Colorectal Dis*. 2010;25(9):1087–92.
38. Sarmiento JM, Heywood G, Rubin J, Ilstrup DM, Nagorney DM, Que FG. Surgical treatment of neuroendocrine metastases to the liver: a plea for resection to increase survival. *J Am Coll Surg*. 2003;197(1):29–37.
39. Christante D, Pommier S, Givi B, Pommier R. Hepatic artery chemoinfusion with chemoembolization for neuroendocrine cancer with progressive hepatic metastases despite octreotide therapy. *Surgery*. 2008;144(6):885–93. discussion 93-4.
40. Gedaly R, Daily MF, Davenport D, McHugh PP, Koch A, Angulo P, et al. Liver transplantation for the treatment of liver metastases from neuroendocrine tumors: an analysis of the UNOS database. *Arch Surg*. 2011;146(8):953–8.
41. Sun W, Lipsitz S, Catalano P, Mailliard JA, Haller DG, Eastern Cooperative Oncology Group. Phase II/III study of doxorubicin with fluorouracil compared with streptozocin with fluorouracil or dacarbazine in the treatment of advanced carcinoid tumors: Eastern Cooperative Oncology Group Study E1281. *J Clin Oncol*. 2005;23(22):4897–904.
42. Moertel CG, Kvols LK, O’Connell MJ, Rubin J. Treatment of neuroendocrine carcinomas with combined etoposide and cisplatin. Evidence of major therapeutic activity in the anaplastic variants of these neoplasms. *Cancer*. 1991;68(2):227–32.
43. Brizzi MP, Berruti A, Ferrero A, Milanesi E, Volante M, Castiglione F, et al. Continuous 5-fluorouracil infusion plus long acting octreotide in advanced well-differentiated neuroendocrine carcinomas. A phase II trial of the Piemonte oncology network. *BMC Cancer*. 2009;9:388.
44. Modlin IM, Pavel M, Kidd M, Gustafsson BI. Review article: somatostatin analogues in the treatment of gastroenteropancreatic neuroendocrine (carcinoid) tumours. *Aliment Pharmacol Ther*. 2010;31(2):169–88.
45. Rinke A, Muller HH, Schade-Brittinger C, Klose KJ, Barth P, Wied M, et al. Placebo-controlled, double-blind, prospective, randomized study on the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors: a report from the PROMID Study

Group. *J Clin Oncol*. 2009;27(28):4656–63.

46. Di Bartolomeo M, Bajetta E, Zilembo N, de Braud F, Di Leo A, Verusio C, et al. Treatment of carcinoid syndrome with recombinant interferon alpha-2a. *Acta Oncol*. 1993;32(2):235–8.

47. Kolby L, Persson G, Franzen S, Ahren B. Randomized clinical trial of the effect of interferon alpha on survival in patients with disseminated midgut carcinoid tumours. *Br J Surg*. 2003;90(6):687–93.

48. Mazur MT, Clark HB. Gastric stromal tumors. Reappraisal of histogenesis. *Am J Surg Pathol*. 1983;7(6):507–19.

49. Davila RE, Faigel DO. GI stromal tumors. *Gastrointest Endosc*. 2003;58(1):80–8.

50. Steigen SE, Eide TJ. Gastrointestinal stromal tumors (GISTs): a review. *APMIS*. 2009;117(2):73–86.

51. Kingham TP, DeMatteo RP. Multidisciplinary treatment of gastrointestinal stromal tumors. *Surg Clin North Am*. 2009;89(1):217–33. x.

52. Miettinen M, Fetsch JF, Sobin LH, Lasota J. Gastrointestinal stromal tumors in patients with neurofibromatosis 1: a clinicopathologic and molecular genetic study of 45 cases. *Am J Surg Pathol*. 2006;30(1):90–6.

53. Stelow EB, Stanley MW, Mallery S, Lai R, Linzie BM, Bardales RH. Endoscopic ultrasound-guided fine-needle aspiration findings of gastrointestinal leiomyomas and gastrointestinal stromal tumors. *Am J Clin Pathol*. 2003;119(5):703–8.

54. Goerres GW, Stupp R, Barghouth G, Hany TF, Pestalozzi B, Dizendorf E, et al. The value of PET, CT and in-line PET/CT in patients with gastrointestinal stromal tumours: long-term outcome of treatment with imatinib mesylate. *Eur J Nucl Med Mol Imaging*. 2005;32(2):153–62.

55. DeMatteo RP, Lewis JJ, Leung D, Mudan SS, Woodruff JM, Brennan MF. Two hundred gastrointestinal stromal tumors: recurrence patterns and prognostic factors for survival. *Ann Surg*. 2000;231(1):51–8.

56. Eisenberg BL, Judson I. Surgery and imatinib in the management of GIST: emerging approaches to adjuvant and neoadjuvant therapy. *Ann Surg Oncol*. 2004;11(5):465–75.

57. Liu H, Yan Z, Liao G, Yin H. Treatment strategy of rectal gastrointestinal stromal tumor (GIST). *J Surg Oncol*. 2014;109(7):708–13.

58. Changchien CR, Wu MC, Tasi WS, Tang R, Chiang JM, Chen JS, et al. Evaluation of prognosis for malignant rectal gastrointestinal stromal tumor by clinical parameters and immunohistochemical staining. *Dis Colon Rectum*. 2004;47(11):1922–9.

59. DeMatteo RP, Ballman KV, Antonescu CR, Corless C, Kolesnikova V, von Mehren M, et al. Long-term results of adjuvant imatinib mesylate in localized, high-risk, primary gastrointestinal stromal tumor: ACOSOG Z9000 (Alliance) intergroup phase 2 trial. *Ann Surg*. 2013;258(3):422–9.

60. Fernandes Gdos S, Blanke CD, Freitas D, Guedes R, Hoff PM. Perioperative treatment of gastrointestinal stromal tumors. *Oncology*. 2009;23(1):54–61.

61. Gold JS, DeMatteo RP. Combined surgical and molecular therapy: the gastrointestinal stromal tumor model. *Ann Surg*. 2006;244(2):176–84.

62. Wang JP, Wang T, Huang MJ, Wang L, Kang L, Wu XJ. The role of neoadjuvant imatinib mesylate therapy in sphincter-preserving procedures for anorectal gastrointestinal stromal tumor. *Am J Clin Oncol*. 2011;34(3):314–6.

63. Tielen R, Verhoef C, van Coevorden F, Reyners AK, van der Graaf WT, Bonenkamp JJ, et al. Surgical management of rectal gastrointestinal stromal tumors. *J Surg Oncol*. 2013;107(4):320–3.

64. Yeh CY, Chen HH, Tang R, Tasi WS, Lin PY, Wang JY. Surgical outcome after curative resection of rectal leiomyosarcoma. *Dis Colon Rectum*. 2000;43(11):1517–21.
65. Verweij J, Casali PG, Zalcberg J, LeCesne A, Reichardt P, Blay JY, et al. Progression-free survival in gastrointestinal stromal tumours with high-dose imatinib: randomised trial. *Lancet*. 2004;364(9440):1127–34.
66. Blanke CD, Rankin C, Demetri GD, Ryan CW, von Mehren M, Benjamin RS, et al. Phase III randomized, intergroup trial assessing imatinib mesylate at two dose levels in patients with unresectable or metastatic gastrointestinal stromal tumors expressing the kit receptor tyrosine kinase: S0033. *J Clin Oncol*. 2008;26(4):626–32.
67. Koch P, del Valle F, Berdel WE, Willich NA, Reers B, Hiddemann W, et al. Primary gastrointestinal non-Hodgkin's lymphoma: II. Combined surgical and conservative or conservative management only in localized gastric lymphoma—results of the prospective German Multicenter Study GIT NHL 01/92. *J Clin Oncol*. 2001;19(18):3874–83.
68. Gustafsson BI, Siddique L, Chan A, Dong M, Drozdov I, Kidd M, et al. Uncommon cancers of the small intestine, appendix and colon: an analysis of SEER 1973–2004, and current diagnosis and therapy. *Int J Oncol*. 2008;33(6):1121–31.
69. Myung SJ, Joo KR, Yang SK, Jung HY, Chang HS, Lee HJ, et al. Clinicopathologic features of ileocolonic malignant lymphoma: analysis according to colonoscopic classification. *Gastrointest Endosc*. 2003;57(3):343–7.
70. Howell JM, Auer-Grzesiak I, Zhang J, Andrews CN, Stewart D, Urbanski SJ. Increasing incidence rates, distribution and histological characteristics of primary gastrointestinal non-Hodgkin lymphoma in a North American population. *Can J Gastroenterol*. 2012;26(7):452–6.
71. Shaheen S, Guddati AK. Secondary mucosa-associated lymphoid tissue (MALT) lymphoma of the colon. *Med Oncol*. 2013;30(2):502.
72. Dawson IM, Cornes JS, Morson BC. Primary malignant lymphoid tumours of the intestinal tract. Report of 37 cases with a study of factors influencing prognosis. *Br J Surg*. 1961;49:80–9.
73. Fan CW, Changchien CR, Wang JY, Chen JS, Hsu KC, Tang R, et al. Primary colorectal lymphoma. *Dis Colon Rectum*. 2000;43(9):1277–82.
74. Dionigi G, Annoni M, Rovera F, Boni L, Villa F, Castano P, et al. Primary colorectal lymphomas: review of the literature. *Surg Oncol*. 2007;16 Suppl 1:S169–71.
75. Henry CA, Berry RE. Primary lymphoma of the large intestine. *Am Surg*. 1988;54(5):262–6.
76. Devine RM, Beart Jr RW, Wolff BG. Malignant lymphoma of the rectum. *Dis Colon Rectum*. 1986;29(12):821–4.
77. Aviles A, Neri N, Huerta-Guzman J. Large bowel lymphoma: an analysis of prognostic factors and therapy in 53 patients. *J Surg Oncol*. 2002;80(2):111–5.
78. Jinnai D, Iwasa Z, Watanuki T. Malignant lymphoma of the large intestine—operative results in Japan. *Jpn J Surg*. 1983;13(4):331–6.
79. Lai YL, Lin JK, Liang WY, Huang YC, Chang SC. Surgical resection combined with chemotherapy can help achieve better outcomes in patients with primary colonic lymphoma. *J Surg Oncol*. 2011;104(3):265–8.
80. Kim YH, Lee JH, Yang SK, Kim TI, Kim JS, Kim HJ, et al. Primary colon lymphoma in Korea: a KASID (Korean Association for the Study of Intestinal Diseases) study. *Dig Dis Sci*. 2005;50(12):2243–7.



## 第 39 章

1. Almy TP, Howell DA. Medical progress. Diverticular disease of the colon. *N Engl J Med*. 1980;302(6):324–31.
2. Jacobs DO. Clinical practice. Diverticulitis. *N Engl J Med*. 2007;357(20):2057–66.
3. Hughes LE. Postmortem survey of diverticular disease of the colon. II. The muscular abnormality of the sigmoid colon. *Gut*. 1969;10:344–51.
4. Boles Jr RS, Jordan SM. The clinical significance of diverticulosis. *Gastroenterology*. 1958;35:579–82.
5. Nakada I, Ubukata H, Goto Y, Wantanabe Y, Sato S, Tabuchi T, et al. Diverticular disease of the colon at a regional general hospital in Japan. *Dis Colon Rectum*. 1995;38:755–9.
6. Chia JG, Wilde CC, Ngoi SS, Goh PM, Ong CL. Trends of diverticular disease of the large bowel in a newly developed country. *Dis Colon Rectum*. 1991;34:498–501.
7. Sugihara K, Muto T, Morioka Y, Asano A, Yamamoto T. Diverticular disease of the colon in Japan. A review of 615 cases. *Dis Colon Rectum*. 1984;27:531–7.
8. Rafferty J, Shellito P, Hyman NH, Buie WD, Standards Committee of the American Society of Colon and Rectal Surgeons. Practice parameters for sigmoid diverticulitis. *Dis Colon Rectum*. 2006;49:939–44.
9. Schoetz DJ. Diverticular disease of the colon: a century old problem. *Dis Colon Rectum*. 1999;42:703–9.
10. Stollman N, Raskin JB. Diverticular disease of the colon. *Lancet*. 2004;363:63.
11. Janes S, Meagher A, Frizelle FA. Elective surgery after acute diverticulitis. *Br J Surg*. 2005;92:133–42.
12. Parks TG. Natural history of diverticular disease of the colon. A review of 521 cases. *BMJ*. 1969;4:639–45.
13. Agency for Healthcare Research and Quality. Rockville, MD. HCUPnet: a tool for identifying, tracking and analyzing national hospital statistics. 2009. <http://www.hcupnet.ahrq.gov/>. Accessed 28 Mar 2009.
14. Etzioni DA, Mack TM, Beart Jr RW, Kaiser AM. Diverticulitis in the United States: 1998–2005: changing patterns of disease and treatment. *Ann Surg*. 2009;249(2):210–7.
15. Ricciardi R, Baxter NN, Read TE, Marcello PW, Hall J, Roberts PL. Is the decline in the surgical treatment for diverticulitis associated with an increase in complicated diverticulitis? *Dis Colon Rectum*. 2009;52(9):1558–63.
16. Jamal Talabani A, Lydersen S, Endreseth BH, Edna TH. Major increase in admission and incidence rates of acute colonic diverticulitis. *Int J Colorectal Dis*. 2014;29(8):937–45.
17. Wheat CL, Strate LL. Trends in hospitalization for diverticulitis and diverticular bleeding in the United States from 2000 to 2010. *Clin Gastroenterol Hepatol*. 2015 Apr 8. pii: S1542-3565(15)00375-4.
18. Slack WW. The anatomy, pathology, and some clinical features of diverticulitis of the colon. *Br J Surg*. 1962;50:185–90.
19. Brook I, Frazier EH. Aerobic and anaerobic microbiology in intra-abdominal infections associated with diverticulitis. *J Med Microbiol*. 2000;49:827–30.
20. West AB. The pathology of diverticulitis. *J Clin Gastroenterol*. 2008;42:1137–8.

21. Goldstein NS, Leon-Armin C, Mani A. Crohn's colitis-like changes in sigmoid diverticulitis specimens is usually an idiosyncratic inflammatory response to the diverticulosis rather than Crohn's colitis. *Am J Surg Pathol*. 2000;24:668–75.
22. Hinchey EJ, Schaal PG, Richards GK. Treatment of perforated diverticular disease of the colon. *Adv Surg*. 1978;12:85–109.
23. Warsavary H, Turfah KO, Kadro O, Beauregard W. Same hospitalization resection for acute diverticulitis. *Am Surg*. 1999;65:622–5.
24. Chang YJ, Marcello PW, Rusin LC, Roberts PL, Schoetz DJ. Hand-assisted laparoscopic sigmoid colectomy: helping hand or hindrance? *Surg Endosc*. 2005;19(5):656–61.
25. Painter NS, Burkitt DP. Diverticular disease of the colon: a deficiency disease of western civilization. *BMJ*. 1971;2:450–4.
26. Commane DM, Arasardnam RP, Mills S, Mathers JC, Bradburn M. Diet, ageing and genetic factors in the pathogenesis of diverticular disease. *World J Gastroenterol*. 2009;15:2479–88.
27. Kiguli-Malwadde E, Kasozi H. Diverticular disease of the colon in Kampala, Uganda. *Afr Health Sci*. 2002;2:29–32.
28. Aldoori WH, Giovannucci EL, Rimm EB, Wing AL, Trochopoulos DV, Willet WC. A prospective study of diet and the risk of symptomatic diverticular disease in men. *Am J Clin Nutr*. 1994;60:757–64.
29. Manousos O, Day NE, Tzonou A, Papadimitriou C, Kapetanakis A, Polychronopoulou-Trichopoulou A, et al. Diet and other factors in the aetiology of diverticulosis: an epidemiological study in Greece. *Gut*. 1985;26:544–9.
30. Strate LL, Liu YL, Syngal S, Aldoori WH, Giovannucci EL. Nut, corn, and popcorn consumption and the incidence of diverticular disease. *JAMA*. 2008;300(8):907–14.
31. Morson BC. The muscle abnormality in diverticular disease of the colon. *Proc Royal Soc Med*. 1963;56:798–800.
32. Stumpf M, Cao W, Klinge U, Klosterhalfen B, Kasperk R, Schumpelick V. Increased distribution of collagen type III and reduced expression of matrix metalloproteinase 1 in patients with diverticular disease. *Int J Colorectal Dis*. 2001;16:271–5.
33. Wess TJ, Eastwood MA, Busuttill A, Miller A. Cross-linking of collagen is increased in colonic diverticulosis. *Gut*. 1995;37:91–4.
34. Cook JM. Spontaneous perforation of the colon: report of two cases in a family exhibiting Marfan's stigmata. *Ohio State Med J*. 1968;64:73.
35. Beighton PH, Murdoch JL, Votteler T. Gastrointestinal complications of the Ehlers-Danlos syndrome. *Gut*. 1969;10:1004–8.
36. Sheth A, Longo W, Floch MH. Diverticular disease and diverticulitis. *Am J Gastroenterol*. 2008;103:1550–6.
37. Thorson A, Goldberg S. Benign colon: diverticular disease. In: Wolff BG, Fleshman JW, Beck DE, Pemberton JH, Wexner SD, editors. *The ASCRS textbook of colon and rectal surgery*. 1st ed. New York: Springer; 2007. p. 269–85.
38. Ouriel K, Schwartz SI. Diverticular disease in the young patient. *Surg Gynecol Obstet*. 1983;156:1–5.
39. Schauer PR, Ramos R, Ghiatas AA, Sirinek KR. Virulent diverticular disease in young obese men. *Am J Surg*. 1992;164:443–6.
40. Acosta JA, Grebene ML, Doberneck RC, et al. Colonic diverticular disease in patients 40 years

old or younger. *Am Surg*. 1992;58:605–7.

41. Fraser GA. A case of multiple jejunal diverticula causing chronic volvulus with associated megacolon. *Br J Surg*. 1964;51:333–7.

42. Hall JF, Roberts PL, Ricciardi R, Marcello PW, Scheirey C, Wald C, et al. Colonic diverticulitis: does age predict severity of disease on CT imaging? *Dis Colon Rectum*. 2010;53(2):121–5.

43. McConnell EJ, Tessier DJ, Wolff BG. Population based incidence of complicated diverticular disease of the sigmoid colon based on gender and age. *Dis Colon Rectum*. 2003;46:1110–4.

44. Bohrer DP, Lewis EA. Diverticula of the colon in Ibadan, Nigeria. *Trop Geogr Med*. 1974;26:9–14.

45. Archampong EQ, Christian F, Badoe EA. Diverticular disease in an indigenous African community. *Ann R Coll Surg Engl*. 1978;60:464–70.

46. Calder JF. Diverticular disease of the colon in Africans. *BMJ*. 1979;1:1465–6.

47. Ogunbuiyi OA. Diverticular disease of the colon in Idaban, Nigeria. *African J Med Sci*. 1989;18:241–4.

48. Munakata A, Nakaji S, Takami H, Nakajima H, Iwane S, Tuchida S. Epidemiological evaluation of colonic diverticulosis and dietary fiber in Japan. *Tohoku J Exp Med*. 1993;171:145–51.

49. Lee YS. Diverticular disease of the large bowel in Singapore. An autopsy survey. *Dis Colon Rectum*. 1986;29:330–5.

50. Heaton KW, Thompson WG. Exercise and diverticular disease. *BMJ*. 1995;310:1332.

51. Aldoori WH, Giovannucci EL, Rimm EB, Wing AL, Trichopoulos DV, Willett WC. A prospective study of alcohol, smoking, caffeine and the risk of symptomatic diverticular disease in men. *Ann Epidemiol*. 1995;5:221–8.

52. Papagrigoriadis S, Macey L, Bourantas N, Rennie JA. Smoking may be associated with complications in diverticular disease. *Br J Surg*. 1999;86(7):923–6.

53. Campbell K, Steele RJ. Non-steroidal anti-inflammatory drugs and complicated diverticular disease: a case-control study. *Br J Surg*. 1991;78:190–1.

54. Goh H, Bourne R. Non-steroidal anti-inflammatory drugs and perforated diverticular disease: as case-control study. *Ann R Coll Surg Engl*. 2002;84:93–6.

55. Aldoori WH, Giovannucci EL, Rockett HRH, Sampson L, Rimm EB, Willett WC. A prospective study of dietary fiber types and symptomatic diverticular disease in men. *J Nutr*. 1998;128:714–9.

56. Corder A. Steroids, non-steroidal anti-inflammatory drugs and serious septic complications of diverticular disease. *Br Med J*. 1987;295:1238.

57. Wilson RG, Smith AN, Macintyre IM. Complications of diverticular disease and non-steroidal anti-inflammatory drugs: a prospective study. *Br J Surg*. 1990;77:1103–4.

58. Wald A, Back C, Bayless TM. Effect of caffeine on the human small intestine. *Gastroenterology*. 1976;71:738–42.

59. Dobbins C, Defontgalland D, Duthie G, Wattchow DA. The relationship of obesity to the complications of diverticular disease. *Colorectal Dis*. 2006;8:37–40.

60. Zaidi E, Daly B. CT and clinical features of acute diverticulitis in the urban US population: rising frequency in young, obese adults. *Am J Roentgenol*. 2006;187:689–94.

61. Strate LL, Liu YL, Aldoori WH, Syngal S, Giovannucci EL. Obesity increases the risks of diverticulitis and diverticular bleeding. *Gastroenterology*. 2009;136(1):115–22.

62. Rosemar A, Angeras U, Rosengren A. Body mass index and diverticular disease: a 28 year follow-up study in men. *Dis Colon Rectum*. 2008;51:450–5.

63. Jeong JH, Lee HL, Kim JO, Tae HJ, Jung SH, Lee KN, Jun DW, Lee OY, Yoon BC, Choi HS, Hahm JS, Song SY. Correlation between complicated diverticulitis and visceral fat. *J Korean Med Sci.* 2011;26(10):1339–43.
64. Shoelson SE, Herrero L, Naaz A. Obesity, inflammation, and insulin resistance. *Gastroenterology.* 2007;132:2169–80.
65. Korzenik JR. Case closed? Diverticulitis: epidemiology and fiber. *J Clin Gastroenterol.* 2006;40:S112–6.
66. Ley RE, Turnbaugh PJ, Klein S, Gordon JI. Microbial ecology: human gut microbes associated with obesity. *Nature.* 2006;444:1022–3.
67. Gill SR, Pop M, DeBoy RT, et al. Metagenomic analysis of the human distal gut microbiome. *Science.* 2006;312:1355–9.
68. Daniels L, Philipszoon LE, Boermeester MA. Hypothesis: important role for gut microbiota in the etiopathogenesis of diverticular disease. *Dis Colon Rectum.* 2014;57(4):539–43.
69. Horgan AF, McConnell EJ, Wolff BG, The S, Paterson C. Atypical diverticular disease: surgical results. *Dis Colon Rectum.* 2001;44(9):1315–8.
70. Rosen MP, Sands DZ, Longmaid III HE, Reynolds KF, Wagner M, Raptopoulos V. Impact of abdominal CT on the management of patients presenting to the emergency department with acute abdominal pain. *Am J Roentgenol.* 2000;174:1391–6.
71. Hulnick DH, Megibow AJ, Balthazar EJ, Naidich DP, Bosniak MA. Computed tomography in the evaluation of diverticulitis. *Radiology.* 1984;152:491–5.
72. Ambrosetti P, Robert JH, Witzig JA, Mirescu D, Mathey P, Borst F, Rohner A. Acute left colonic diverticulitis: a prospective analysis of 226 consecutive cases. *Surgery.* 1994;115(5):546–50.
73. Ambrosetti P, Becker C, Terrier F. Colonic diverticulitis: impact of imaging on surgical management—a prospective study of 542 patients. *Eur Radiol.* 2002;12(5):1145–9.
74. Poletti PA, Platon A, Rutschmann O, Kinkel K, Nyikus V, Ghiorghiu S, Morel P, Terrier F, Becker CD. Acute left colonic diverticulitis: can CT findings be used to predict recurrence? *Am J Roentgenol.* 2004;182(5):1159–65.
75. Baker M. Imaging and interventional techniques in acute left-sided diverticulitis. *J Gastrointest Surg.* 2008;12:1314–7.
76. Kaiser AM, Jiang JK, Lake JP, Ault G, Artinyan A, Gonzalez-Ruiz C, Essani R, Beart Jr RW. The management of complicated diverticulitis and the role of computed tomography. *Am J Gastroenterol.* 2005;100(4):910–7.
77. Van de Wall BJ, Reuling EM, Consten EC, van Grinsven JH, Schwartz MP, Broeders IA, Draaisma WA. Endoscopic evaluation of the colon after an episode of diverticulitis: a call for a more selective approach. *Int J Colorectal Dis.* 2012;27(9):1145–50. doi: 10.1007/s00384-012-1448-0. Epub 2012 Mar 13.
78. Lau KC, Spilsbury K, Farooque Y, Kariyawasam SB, Owen RG, Wallace MH, Makin GB. Is colonoscopy still mandatory after a CT diagnosis of left-sided diverticulitis: can colorectal cancer be confidently excluded? *Dis Colon Rectum.* 2011;54(10):1265–70. doi: 10.1097/DCR.0b013e31822899a2.
79. Lahat A, Yanai H, Sakhnini E, Menachem Y, Bar-Meir S. Role of colonoscopy in patients with persistent acute diverticulitis. *World J Gastroenterol.* 2008;14(17):2763–6.
80. Sakhnini E, Lahat A, Melzer E, Apter S, Simon C, Natour M, Bardan E, Bar-Meir S. Early colonoscopy in patients with acute diverticulitis: results of a prospective pilot study. *Endoscopy.*

2004;36:504–7.

81. Touzios JG, Dozois E. Diverticulosis and acute diverticulitis. *Gastroenterol Clin N Am*. 2009;38:513–25.

82. Byrnes MC, Mazuski JE. Antimicrobial therapy for acute diverticulitis. *Surg Infect*. 2009;10:143–54.

83. Chang GJ, Shelton AA, Welton ML. Large intestine. In: Doherty GM, Way LW, editors. *Current surgical diagnosis & treatment*. 12th ed. New York: McGraw Hill; 2006. p. 685–737.

84. Kellum JM, Sugerman HJ, Coppa GF, Way LR, Fine R, Herz B, et al. Randomized, prospective comparison of cefoxitin and gentamicin–clindamycin in the treatment of acute colonic diverticulitis. *Clin Ther*. 1992;14:376–84.

85. Feingold D, Steele SR, Lee S, Kaiser A, Boushey R, Buie WD, Rafferty JF. Practice parameters for the treatment of sigmoid diverticulitis. *Dis Colon Rectum*. 2014;57(3):284–9.

86. De Korte N, Klarenbeek BR, Kuyvenhoven JP, Roumen RM, Cuesta MA, Stockmann HB. Management of diverticulitis: results of a survey among gastroenterologists and surgeons. *Colorectal Dis*. 2011;13(12):411–7. doi: 10.1111/j.1463-1318.2011.02744.x.

87. Chabok A, Pålman L, Hjern F, Haapaniemi S, Smedh K, AVOD Study Group. Randomized clinical trial of antibiotics in acute uncomplicated diverticulitis. *Br J Surg*. 2012;99:532–9.

88. Shabanzadeh DM, Wille-Jørgensen P. Antibiotics for uncomplicated diverticulitis. *Cochrane Database Syst Rev*. 2012 Nov 14;11:CD009092. doi: 10.1002/14651858.CD009092.pub2. Review.

89. Heise CP. Epidemiology and pathogenesis of diverticular disease. *J Gastrointest Surg*. 2008;12:1309–11.

90. Tarleton S, DiBaise JK. Low-residue diet in diverticular disease: putting an end to a myth. *Nutr Clin Pract*. 2011;26(2):137–42. doi: 10.1177/0884533611399774.

91. Marcason W. What is the latest research regarding the avoidance of nuts, seeds, corn, and popcorn in diverticular disease? *J Am Diet Assoc*. 2008;108(11):1956. doi: 10.1016/j.jada.2008.09.029.

92. MacDermott RP, Schloemann SR, Bertovich MJ, Nash GS, Peters M, Stenson WF. Inhibition of antibody secretion by 5-aminosalicylic acid. *Gastroenterology*. 1989;96:442–8.

93. Trespi E, Colla C, Panizza P, Polino MG, Venturini A, Bottani G, et al. Ruolo terapeutico e profilattico della mesalazina nella malattia diverticolare sintomatica del crasso. *Minerva Gastroenterol Dietol*. 1999;45:245–52.

94. Tursi A, Brandimarte G, Daffina R. Long-term treatment with mesalamine and rifaximin versus rifaximin alone for patients with recurrent attacks of acute diverticulitis of colon. *Dig Liver Dis*. 2002;34:510–5.

95. Di Mario F, Aragona G, Leandro G, Comparato G, Fanigliulo L, Cavallaro LG, et al. Efficacy of mesalazine in the treatment of symptomatic diverticular disease. *Dig Dis Sci*. 2005;50:581–6.

96. Gatta L, Vakil N, Vaira D, Pilotto A, Curlo M, Comparato G, et al. Efficacy of 5-ASA in the treatment of colonic diverticular disease. *J Clin Gastroenterol*. 2010;44(2):113–9.

97. Trivedi C, Das K. Emerging therapies for diverticular disease of the colon. *J Clin Gastroenterol*. 2008;42:1145–51.

98. Giaccari S, Tronci S, Falconieri M, Ferrieri A. Long term treatment with rifaximin and lactobacilli in post-diverticulitic stenoses of the colon. *Eur Rev Med Pharmacol Sci*. 1993;15:29–34.

99. Fric P, Zavoral M. The effect of non-pathogenic *Escherichia coli* in symptomatic uncomplicated

- diverticular disease of the colon. *Eur J Gastroenterol Hepatol*. 2003;15:313–5.
100. Kohler L, Sauerland S, Neugebauer E. Diagnosis and treatment of diverticular disease: results of a consensus development conference. The Scientific Committee of the European Association for Endoscopic Surgery. *Surg Endosc*. 1999;13:430–6.
101. Patient Care Committee of the Society for Surgery of the Alimentary Tract (SSAT). Surgical treatment of diverticulitis. *J Gastrointestinal Surg*. 1999;3:212–3.
102. Wong WD, Wexner SD, Lowry A, Vernava III A, Burnstein M, Denstman F, et al. Practice parameters for the treatment of sigmoid diverticulitis—supporting documentation. The Standards Task Force. The American Society of Colon and Rectal Surgeons. *Dis Colon Rectum*. 2000;43:290–7.
103. Salem L, Flum DR. Primary anastomosis or Hartmann's procedure for patients with diverticular peritonitis? A systematic review. *Dis Colon Rectum*. 2004;47:1953–64.
104. Chapman J, Davies M, Wolff B, Dozois E, Tessier D, Harrington J, et al. Complicated diverticulitis: is it time to rethink the rules? *Ann Surg*. 2005;242:576–81.
105. Anaya DA, Flum DR. Risk of emergency colectomy and colostomy in patients with diverticular disease. *Arch Surg*. 2005;140(7):681–5.
106. Guzzo J, Hyman N. Diverticulitis in young patients: is resection after a single attack always warranted? *Dis Colon Rectum*. 2004;47:1187–90.
107. Panghaal VS, Chernyak V, Patlas M, Rozenblit AM. CT features of adnexal involvement in patients with diverticulitis. *Am J Roentgenol*. 2009;192:963–6.
108. Franklin ME, Dorman JP, Jacobs M, Plasencia G. Is laparoscopic surgery applicable to complicated colonic diverticular disease? *Surg Endosc*. 1997;11:1021–8.
109. Siewert B, Tye G, Kruskal J, Sosna J, Opelka F, Raptopoulos V, Goldberg SN. Impact of CT-guided drainage in the treatment of diverticular abscesses: size matters. *Am J Roentgenol*. 2006;186:680–6.
110. Kumar RR, Kim JT, Haukoos JS, Macias LH, Dixon MR, Stamos MJ, Konyalian VR. Factors affecting the successful management of intra-abdominal abscesses with antibiotics and the need for percutaneous drainage. *Dis Colon Rectum*. 2006;49:183–9.
111. Soumian S, Thomas S, Mohan PP, Khan N, Khan Z, Raju T. Management of Hinchey II diverticulitis. *World J Gastroenterol*. 2008;14(47):716–9.
112. Golfieri R, Cappeli A. Computer tomography-guided percutaneous abscess drainage in coloproctology: review of the literature. *Tech Coloproctol*. 2007;11:197–208.
113. Ambrosetti P, Chautems R, Soravia C, Peiris-Waser N, Terrier F. Long-term outcome of mesocolic and pelvic diverticular abscesses of the left colon: a prospective study of 73 cases. *Dis Colon Rectum*. 2005;48:787–91.
114. Macias AM, Haukoos JS, Dixon MR, Sorial E, Arnell TD, Stamos MJ, et al. Diverticulitis: truly minimally invasive management. *Am Surg*. 2004;70(10):932–5.
115. Maggard MA, Zingmoud D, O'Connell JB, Ko CY. What proportion of patients with an ostomy for diverticulitis get reversed? *Am Surg*. 2004;70:928–32.
116. Salem L, Anaya DA, Roberts KE, Flum DR. Hartmann's colectomy and reversal in diverticulitis: a population-level assessment. *Dis Colon Rectum*. 2005;48(5):988–95.
117. Abbas S. Resection and primary anastomosis in acute complicated diverticulitis: a systematic review of the literature. *Int J Colorectal Dis*. 2007;22:351–7.
118. Rothenberger DA, Garcia-Aguilar J. Diverticular disease of the colon. In: Cameron JL, editor.

Current surgical therapy. St. Louis: Mosby; 1998. p. 173–9.

119. Myers E, Hurley M, O’Sullivan GC, Kavanagh D, Wilson I, Winter DC. Laparoscopic peritoneal lavage for generalized peritonitis due to perforated diverticulitis. *Br J Surg.* 2008;95(1):97–101.

120. Alamili M, Gogenur I, Rosenberg J. Acute complicated diverticulitis managed by laparoscopic lavage. *Dis Colon Rectum.* 2009;52(7):1345–9.

121. Young-Fadok RM, Roberts PL, Spencer MP, Wolff BG. Current Problems in Surgery. Colonic Diverticular Dis. 2000;37(7):457–516.

122. Woods RJ, Lavery IC, Fazio VW, Jagelman DG, Weakley FL. Internal fistulas in diverticular disease. *Dis Colon Rectum.* 1988;31(8):591–6.

123. Bahadursingh AM, Longo WE. Colovaginal fistulas. Etiology and management. *J Reprod Med.* 2003;48(7):489–95.

124. Pontari MA, McMillen MA, Garvey RH, Ballantyne GH. Diagnosis and treatment of enterovesical fistulae. *Am Surg.* 1992;58(4):258–63.

125. Melchior S, Cudovic D, Jones J, Thomas C, Gillitzer R, Thuroff J. Diagnosis and surgical management of colovesical fistulas due to sigmoid diverticulitis. *J Urol.* 2009;182(3):978–82.

126. Greenlee HB, Peinkos FJ, Vanderbilt PC, Byrne MP, Mason JH, Banich FE, et al. Proceedings: acute large bowel obstruction. Comparison of county, Veterans Administration, and community hospital publications. *Arch Surg.* 1974;108:470–6.

127. Murray JJ, Schoetz Jr DJ, Collier JA, Roberts PL, Veidenheimer MC. Intraoperative colonic lavage and primary anastomosis in nonelective colon resection. *Dis Colon Rectum.* 1991;34(7):527–31.

128. Guenaga KF, Matos D, Castro AA, Atallah AN, Willie-Jorgensen P. Mechanical bowel preparation for elective colorectal surgery. *Cochrane Database Syst Rev.* 2005; 25(1): CD001544.

129. Lee EC, Murray JJ, Collier JA, Roberts PL, Schoetz Jr DJ. Intraoperative colonic lavage in nonelective surgery for diverticular disease. *Dis Colon Rectum.* 1997;40(6):669–74.

130. Davidson R, Sweeney WB. Endoluminal stenting for benign colonic obstruction. *Surg Endosc.* 1998;12:353–4.

131. Tamim WL, Ghellai A, Counihan TC, Swanson RS, Colby JM, Sweeney WB. Experience with endoluminal colonic wall stents for the management of large bowel obstruction for benign and malignant disease. *Arch Surg.* 2000;135:434–8.

132. Meisner S, Hensler M, Knop FK, West F, Wille-Jørgensen P. Self-expanding metal stents for colon obstruction: experiences from 104 procedures in a single center. *Dis Colon Rectum.* 2004;47(4):444–50.

133. Rayhanabad J, Abbas MA. Long-term outcome of endoscopic colorectal stenting for malignant and benign disease. *Am Surg.* 2009;75(10):897–900.

134. Small AJ, Young-Fadok TM, Baron TH. Expandable metal stent placement for benign colorectal obstruction: outcomes for 23 cases. *Surg Endosc.* 2008;22(2):454–62.

135. Forshaw MJ, Sankararajah D, Stewart M, Parker MC. Self-expanding metallic stents in the treatment of benign colorectal disease: indications and outcomes. *Colorectal Dis.* 2006;8(2):102–11.

136. Benn PL, Wolff BG, Ilstrup DM. Level of anastomosis and recurrent colonic diverticulitis. *Am J Surg.* 1986;151:269–71.

137. Thaler K, Baig MK, Berho M, Weiss EG, et al. Determinants of recurrence after sigmoid

- resection for uncomplicated diverticulitis. *Dis Colon Rectum*. 2003;46(3):385–8.
138. Tocchi A, Mazzoni G, Fornasari V, Miccini M, Daddi G, Tagliacozzo S. Preservation of the inferior mesenteric artery in colorectal resection for complicated diverticular disease. *Am J Surg*. 2001;182(2):162–7.
  139. Leff EJ, Groff W, Rubin RJ, Eisenstat TE, Salvati EP. Use of ureteral catheters in colonic and rectal surgery. *Dis Colon Rectum*. 1982;25:457–60.
  140. Abcarian H. The difficult resection in diverticulitis. *Semin Colon Rectal Surg*. 1990;1:97–8.
  141. Malek MM, Greenstein AJ, Chin EH, Nguyen SQ, Sandler AL, Wong RK, Byrn JC, Katz LB, Divino CM. Comparison of iatrogenic splenectomy during open and laparoscopic colon resection. *Sur Laparosc Endosc Percutan Tech*. 2007;17:385–7.
  142. Vargas HD, Ramirez RT, Hoffman GC, Hubbard GW, Gould RJ, Wohlgemuth SD, Ruffin WK, Hatter JE, Kolm P. Defining the role of laparoscopic-assisted sigmoid colectomy for diverticulitis. *Dis Colon Rectum*. 2000;43:1726–31.
  143. Tuech JJ, Pessaux P, Rouge C, Regenet N, Bergamaschi R, Arnaud JP. Laparoscopic vs. open colectomy for sigmoid diverticulitis: a prospective comparative study in the elderly. *Surg Endosc*. 2000;14(11):1031–3.
  144. Noel JK, Fahrbach K, Estok R, Cella C, Frame D, Linz H, Cima RR, Dozois EJ, Senagore AJ. Minimally invasive colorectal resection outcomes: short-term comparison with open procedures. *J Am Coll Surg*. 2007;204(2):291–307.
  145. Schwandner O, Farke S, Bruch HP. Laparoscopic colectomy for diverticulitis is not associated with increased morbidity when compared with non-diverticular disease. *Int J Colorectal Dis*. 2005;20(2):165–72.
  146. Klarenbeek BR, Veenhof AA, Bergamaschi R, van der Peet DL, van den Broek WT, de Lange ES, Bemelman WA, Heres P, Lacy AM, Engel AF, Cuesta MA. Laparoscopic sigmoid resection for diverticulitis decreases major morbidity rates: a randomized control trial: short-term results of the Sigma Trial. *Ann Surg*. 2009;249(1):39–44.
  147. Jones OM, Stevenson AR, Clark D, Stitz RW, Lumley JW. Laparoscopic resection for diverticular disease: followup of 500 consecutive patients. *Ann Surg*. 2008;248(6):1092–7.
  148. Cole K, Fassler S, Suryadevara S, Zebley DM. Increasing the number of attacks increases the conversion rate in laparoscopic diverticulitis surgery. *Surg Endosc*. 2009;23(5):1088–92.
  149. Hassan I, Cima RR, Larson DW, Dozois EJ, O’Byrne MM, Larson DR, Pemberton JH. The impact of uncomplicated and complicated diverticulitis on laparoscopic surgery conversion rates and patient outcomes. *Surg Endosc*. 2007;21(10):1690–4.
  150. Belizon A, Sardinha CT, Sher ME. Converted laparoscopic colectomy: what are the consequences? *Surg Endosc*. 2006;20(6):947–51.
  151. Chang YJ, Marcello PW, Rusin LC, Roberts PL, Schoetz DJ. Hand-assisted laparoscopic sigmoid colectomy: helping hand or hindrance? *Surg Endosc*. 2005;19(5):656–61.
  152. Schwandner O, Farke S, Bruch HP. Laparoscopic colectomy for diverticulitis is not associated with increased morbidity when compared with non-diverticular disease. *Int J Colorectal Dis*. 2005;20(2):165–72.
  153. Bouillot JL, Berthou JC, Champault G, Meyer C, Arnaud JP, Samama G, Collet D, Bressler P, Gainant A, Delaitre B. Elective laparoscopic colonic resection for diverticular disease: results of a multicenter study in 179 patients. *Surg Endosc*. 2002;16(9):1320–3.
  154. XXX.



155. Vargas HD, Ramirez RT, Hoffman GC, Hubbard GW, Gould RJ, Wohlgemuth SD, Ruffin WK, Hatter JE, Kolm P. Defining the role of laparoscopic-assisted sigmoid colectomy for diverticulitis. *Dis Colon Rectum* 2000;43:1726–31.
156. Burgel JS, Navarro F, Lemoine MC, Michel J, Caraballona JP, Fabre JM, Domergue J. Elective laparoscopic colectomy for sigmoid diverticulitis. Prospective study of 56 cases. *Ann Chir.* 2000;125(3):231–7.
157. Siriser F. Laparoscopic-assisted colectomy for diverticular sigmoiditis. A single-surgeon prospective study of 65 patients. *Surg Endosc.* 1999;13(8):811–3.
158. Berthou JC, Charbonneau P. Elective laparoscopic management of sigmoid diverticulitis. Results in a series of 110 patients. *Surg Endosc.* 1999;13(5):457–60.
159. Köckerling F, Schneider C, Reymond MA, Scheidbach H, Scheuerlein H, Konradt J, Bruch HP, Zornig C, Köhler L, Bärlehner E, Kuthe A, Szinicz G, Richter HA, Hohenberger W. Laparoscopic resection of sigmoid diverticulitis. Results of a multicenter study. *Laparoscopic Colorectal Surgery Study Group. Surg Endosc.* 1999;13(6):567–71.
160. Smadja C, Sbati Idrissi M, Tahrat M, Vons C, Bobocescu E, Baillet P, Franco D. Elective laparoscopic sigmoid colectomy for diverticulitis. Results of a prospective study. *Surg Endosc.* 1999;13(7):645–8.
161. Stevenson AR, Stitz RW, Lumley JW, Fielding GA. Laparoscopically assisted anterior resection for diverticular disease: follow-up of 100 consecutive patients. *Ann Surg.* 1998;227(3):335–42.
162. Goyal A, Schein M. Current practices in left-sided colonic emergencies: a survey of US gastrointestinal surgeons. *Dig Surg.* 2001;18:399–402.
163. Sher ME, Agachan F, Bortul M, Nogueras JJ, Weiss EG, Wexner SD. Laparoscopic surgery for diverticulitis. *Surg Endosc.* 1997;11:264–7.
164. Aydin HN, Tekkis PP, Remzi FH, Constantinides V, Fazio VW. Evaluation of the risk of a nonrestorative resection for the treatment of diverticular disease: the Cleveland Clinic diverticular disease propensity score. *Dis Colon Rectum.* 2006;49:629–39.
165. Jones OM, Stevenson AR, Clark D, Stitz RW, Lumley JW. Laparoscopic resection for diverticular disease: follow-up of 500 consecutive patients. *Ann Surg.* 2008;248(6):1092–7.
166. Martel G, Bouchard A, Soto CM, Poulin EC, Mamazza J, Boushey RP. Laparoscopic colectomy for complex diverticular disease: a justifiable choice? *Surg Endosc.* 2010;24:2273–80.
167. Poulin EC, Schlachta CM, Mamazza J, Seshadri PA. Should enteric fistulas from Crohn's disease or diverticulitis be treated laparoscopically or by open surgery? A matched cohort study. *Dis Colon Rectum.* 2000;43:621–6.
168. Menenakos E, Hahnloser D, Nassiopoulou K, Chanson C, Sinclair V, Petropoulos P. Laparoscopic surgery for fistulas that complicate diverticular disease. *Langenbecks Arch Surg.* 2003;388:189–93.
169. Li JC, Ng SS, Lee JF, Yiu RY, Hon SS, Leung WW, Leung KL. Emergency laparoscopic-assisted versus open right hemicolectomy for complicated cecal diverticulitis: a comparative study. *J Laparoendosc Adv Surg Tech A.* 2009;19(4):479–83.
170. Parks TG, Connell AM. The outcome of 455 patients admitted for treatment of diverticular disease of the colon. *Br J Surg.* 1970;57:775–8.
171. Bonvin MMP, Bonte G. Diverticulues giants due sigmoïde. *Arch Mal Appar Dig Mal Nutr.* 1946;35:353–5.

172. Toiber-Levy M, Golffier-Rosete C, Martinez-Munive A, Baquera J, Stoppen ME, D'Hyver C, et al. Giant sigmoid diverticulum: case report and review of the literature. *Gastroenterol Clin Biol*. 2008;32(6-7):581-4.
173. Majeski J, Durst Jr G. Obstructing giant colonic diverticulum. *South Med J*. 2000;93(8):797-9.
174. Nakaji S, Danjo K, Munakaata A, Sugawara K, MacAuley D, Kernohan G. Comparison of etiology of right-sided diverticula in Japan with that of left-sided diverticula in the West. *Int J Colorectal Dis*. 2002;17:365-73.
175. Lane JS, Sarkar R, Schmit PJ, Chandler CF, Thompson Jr JE. Surgical approach to cecal diverticulitis. *J Am Coll Surg*. 1999;188(6):629-34.
176. Fang JF, Chen RJ, Lin BC, Hsu YB, Kao JL, Chen MF. Aggressive resection is indicated for cecal diverticulitis. *Am J Surg*. 2003;185(2):135-40.
177. Thorson AG, Ternent CA. Cecal diverticulitis. In: Welch JP, Cohen JL, Sardella WV, Vignati PV, editors. *Diverticular disease, management of the difficult surgical case*. Baltimore: Williams and Wilkins; 1998. p. 428-41.
178. Jasper DR, Weinstock LB, Balfe DM, Heiken J, Lyss CA, Silvermintz SD. Transverse colon diverticulitis: successful management in four patients. Report of four cases. *Dis Colon Rectum*. 1999;42(7):955-8.
179. Nagourney DM, Adson MA, Pemberton JH. Sigmoid diverticulitis with perforation and generalized peritonitis. *Dis Colon Rectum*. 1985;28:71-5.
180. Tyau ES, Prystowsky JB, Joehl RJ, Nahrwold DL. Acute diverticulitis. A complicated problem in the immunocompromised patient. *Arch Surg*. 1991;126:855-8. discussion 858-9.
181. Lederman ED, Conti DJ, Lempert N, Singh TP, Lee EC. Complicated diverticulitis following renal transplantation. *Dis Colon Rectum*. 1998;41:613-8.
182. Perkins JD, Shiled III CF, Chang FC, Farha GJ. Acute diverticulitis: comparison of treatment in immunocompromised and nonimmunocompromised patients. *Am J Surg*. 1984;148:745-8.

## 第 40 章

1. Yeo HL, Lee SW. Colorectal emergencies: review and controversies in the management of large bowel obstruction. *J Gastrointest Surg*. 2013;17(11):2007-12.
2. Ballantyne GH. Review of sigmoid volvulus. Clinical patterns and pathogenesis. *Dis Colon Rectum*. 1982;25(8):823-30.
3. Friedman JD, Odland MD, Bubrick MP. Experience with colonic volvulus. *Dis Colon Rectum*. 1989;32(5):409-16.
4. Ballantyne GH. Sigmoid volvulus: high mortality in county hospital patients. *Dis Colon Rectum*. 1981;24(7):515-20.
5. Schagen van Leeuwen JH. Sigmoid volvulus in a West African population. *Dis Colon Rectum*. 1985;28(10):712-6.
6. Rabinovici R, Simansky DA, Kaplan O, Mavor E, Manny J. Cecal volvulus. *Dis Colon Rectum*. 1990;33(9):765-9.
7. Saegesser F, Sandblom P. Ischemic lesions of the distended colon: a complication of obstructive colorectal cancer. *Am J Surg*. 1975;129(3):309-15.

8. Boley SJ, Agrawal GP, Warren AR, Veith FJ, Levowitz BS, Treiber W, et al. Pathophysiologic effects of bowel distention on intestinal blood flow. *Am J Surg*. 1969;117(2):228–34.
9. Stillwell GK. The law of Laplace. Some clinical applications. *Mayo Clinic Proc*. 1973;48(12):863–9.
10. Saegesser F, Chapuis G, Rausis C, Tabrizian M, Sandblom P. Intestinal distension and colonic ischemia: occlusive complications and perforations of colo-rectal cancers. A clinical application of Laplace's law. *Chirurgie*. 1974;100(7):502–16.
11. Saunders MD. Acute colonic pseudo-obstruction. *Gastrointest Endosc Clin N Am*. 2007;17(2):341–60. vi–vii.
12. De Giorgio R, Knowles CH. Acute colonic pseudo-obstruction. *Br J Surg*. 2009;96(3):229–39.
13. Vanek VW, Al-Salti M. Acute pseudo-obstruction of the colon (Ogilvie's syndrome). An analysis of 400 cases. *Dis Colon Rectum*. 1986;29(3):203–10.
14. Sawai RS. Management of colonic obstruction: a review. *Clin Colon Rectal Surg*. 2012;25(4):200–3.
15. Jain A, Vargas HD. Advances and challenges in the management of acute colonic pseudo-obstruction (ogilvie syndrome). *Clin Colon Rectal Surg*. 2012;25(1):37–45.
16. Burrell HC, Baker DM, Wardrop P, Evans AJ. Significant plain film findings in sigmoid volvulus. *Clin Radiol*. 1994;49(5):317–9.
17. Osman N, Subar D, Loh MY, Goscimski A. Gallstone ileus of the sigmoid colon: an unusual cause of large-bowel obstruction. *HPB Surg*. 2010;2010:153740.
18. Raveenthiran V, Madiba TE, Atamanalp SS, De U. Volvulus of the sigmoid colon. *Colorectal Dis*. 2010;12(7 Online):e1–17.
19. Gingold D, Murrell Z. Management of colonic volvulus. *Clin Colon Rectal Surg*. 2012;25(4):236–44.
20. Hiltunen KM, Syrja H, Matikainen M. Colonic volvulus. Diagnosis and results of treatment in 82 patients. *Eur J Surg*. 1992;158(11–12):607–11.
21. Swenson BR, Kwaan MR, Burkart NE, Wang Y, Madoff RD, Rothenberger DA, et al. Colonic volvulus: presentation and management in metropolitan Minnesota, United States. *Dis Colon Rectum*. 2012;55(4):444–9.
22. Selcuk Atamanalp S. Treatment for ileosigmoid knotting: a single-center experience of 74 patients. *Tech Coloproctol*. 2014;18(3):233–7.
23. Mallick IH, Winslet MC. Ileosigmoid knotting. *Colorectal Dis*. 2004;6(4):220–5.
24. Racnic J. Colonic volvulus. In: Beck DE, Roberts PL, Saclarides TJ, Senagore AJ, Stamos MJ, Nasser Y, editors. *The ASCRS textbook of colon and rectal surgery*. 2nd ed. New York: Springer; 2011. p. 395–406.
25. Stewart J, Finan PJ, Courtney DF, Brennan TG. Does a water soluble contrast enema assist in the management of acute large bowel obstruction: a prospective study of 117 cases. *Br J Surg*. 1984;71(10):799–801.
26. Koruth NM, Koruth A, Matheson NA. The place of contrast enema in the management of large bowel obstruction. *J R Coll Surg Edinb*. 1985;30(4):258–60.
27. Chapman AH, McNamara M, Porter G. The acute contrast enema in suspected large bowel obstruction: value and technique. *Clin Radiol*. 1992;46(4):273–8.
28. Sgouros SN, Vlachogiannakos J, Vassiliadis K, Bergele C, Stefanidis G, Nastos H, et al. Effect of polyethylene glycol electrolyte balanced solution on patients with acute colonic pseudo

obstruction after resolution of colonic dilation: a prospective, randomised, placebo controlled trial. *Gut*. 2006;55(5):638–42.

29. Vehmas T. Factors influencing the detection of abnormalities in barium enemas performed by junior radiologists. *Clin Radiol*. 2006;61(3):270–5.

30. Godfrey EM, Addley HC, Shaw AS. The use of computed tomography in the detection and characterisation of large bowel obstruction. *N Z Med J*. 2009;122(1305):57–73.

31. Beattie GC, Peters RT, Guy S, Mendelson RM. Computed tomography in the assessment of suspected large bowel obstruction. *ANZ J Surg*. 2007;77(3):160–5.

32. Jacob SE, Lee SH, Hill J. The demise of the instant/unprepared contrast enema in large bowel obstruction. *Colorectal Dis*. 2008;10(7):729–31.

33. Frager D, Rovno HD, Baer JW, Bashist B, Friedman M. Prospective evaluation of colonic obstruction with computed tomography. *Abdom Imaging*. 1998;23(2):141–6.

34. Lopez-Kostner F, Hool GR, Lavery IC. Management and causes of acute large-bowel obstruction. *Surg Clin N Am*. 1997;77(6):1265–90.

35. Gutman M, Kaplan O, Skornick Y, Greif F, Kahn P, Rozin RR. Proximal colostomy: still an effective emergency measure in obstructing carcinoma of the large bowel. *J Surg Oncol*. 1989;41(3):210–2.

36. Kronborg O. Acute obstruction from tumour in the left colon without spread. A randomized trial of emergency colostomy versus resection. *Int J Colorectal Dis*. 1995;10(1):1–5.

37. Hsu TC. Comparison of one-stage resection and anastomosis of acute complete obstruction of left and right colon. *Am J Surg*. 2005;189(4):384–7.

38. Lee YM, Law WL, Chu KW, Poon RT. Emergency surgery for obstructing colorectal cancers: a comparison between right-sided and left-sided lesions. *J Am Coll Surg*. 2001;192(6):719–25.

39. Sajid MS, Caswell J, Bhatti MI, Sains P, Baig MK, Miles WF. Carbon dioxide insufflation versus conventional air insufflation for colonoscopy: a systematic review and meta-analysis of published randomized controlled trials. *Colorectal Dis*. 2015;17:111–23.

40. Bretthauer M, Lynge AB, Thiis-Evensen E, Hoff G, Fausa O, Aabakken L. Carbon dioxide insufflation in colonoscopy: safe and effective in sedated patients. *Endoscopy*. 2005;37(8):706–9.

41. Yasumasa K, Nakajima K, Endo S, Ito T, Matsuda H, Nishida T. Carbon dioxide insufflation attenuates parietal blood flow obstruction in distended colon: potential advantages of carbon dioxide insufflated colonoscopy. *Surg Endosc*. 2006;20(4):587–94.

42. Dohmoto M. New method: endoscopic implantation of rectal stent in palliative treatment of malignant stenosis. *Endosc Dig*. 1991;3:1507–12.

43. Tejero E, Mainar A, Fernandez L, Tobio R, De Gregorio MA. New procedure for the treatment of colorectal neoplastic obstructions. *Dis Colon Rectum*. 1994;37(11):1158–9.

44. Tejero E, Fernandez-Lobato R, Mainar A, Montes C, Pinto I, Fernandez L, et al. Initial results of a new procedure for treatment of malignant obstruction of the left colon. *Dis Colon Rectum*. 1997;40(4):432–6.

45. Gandrup P, Lund L, Balslev I. Surgical treatment of acute malignant large bowel obstruction. *Eur J Surg*. 1992;158(8):427–30.

46. Lee HJ, Hong SP, Cheon JH, Kim TI, Min BS, Kim NK, et al. Long-term outcome of palliative therapy for malignant colorectal obstruction in patients with unresectable metastatic colorectal cancers: endoscopic stenting versus surgery. *Gastrointest Endosc*. 2011;73(3):535–42.

47. Bonin EA, Baron TH. Update on the indications and use of colonic stents. *Curr Gastroenterol*

Rep. 2010;12(5):374–82.

48. Cheung HY, Chung CC, Tsang WW, Wong JC, Yau KK, Li MK. Endolaparoscopic approach vs conventional open surgery in the treatment of obstructing left-sided colon cancer: a randomized controlled trial. *Arch Surg.* 2009;144(12):1127–32.

49. Watt AM, Faragher IG, Griffin TT, Rieger NA, Maddern GJ. Self-expanding metallic stents for relieving malignant colorectal obstruction: a systematic review. *Ann Surg.* 2007;246(1):24–30.

50. Van Hooft JE, Fockens P, Marinelli AW, Timmer R, van Berkel AM, Bossuyt PM, et al. Early closure of a multicenter randomized clinical trial of endoscopic stenting versus surgery for stage IV left-sided colorectal cancer. *Endoscopy.* 2008;40(3):184–91.

51. Khot UP, Lang AW, Murali K, Parker MC. Systematic review of the efficacy and safety of colorectal stents. *Br J Surg.* 2002;89(9):1096–102.

52. Van Hooft JE, van Halsema EE, Vanbiervliet G, Beets-Tan RG, DeWitt JM, Donnellan F, et al. Self-expandable metal stents for obstructing colonic and extracolonic cancer: European Society of Gastrointestinal Endoscopy (ESGE) Clinical Guideline. *Gastrointest Endosc.* 2014;80(5):747–61. e1-75.

53. Small AJ, Coelho-Prabhu N, Baron TH. Endoscopic placement of self-expandable metal stents for malignant colonic obstruction: long-term outcomes and complication factors. *Gastrointest Endosc.* 2010;71(3):560–72.

54. Cennamo V, Fuccio L, Mutri V, Minardi ME, Eusebi LH, Ceroni L, et al. Does stent placement for advanced colon cancer increase the risk of perforation during bevacizumab-based therapy? *Clin Gastroenterol Hepatol.* 2009;7(11):1174–6.

55. Pirlet IA, Slim K, Kwiatkowski F, Michot F, Millat BL. Emergency preoperative stenting versus surgery for acute left-sided malignant colonic obstruction: a multicenter randomized controlled trial. *Surg Endosc.* 2011;25(6):1814–21.

56. Van Hooft JE, Bemelman WA, Oldenburg B, Marinelli AW, Lutke Holzik MF, Grubben MJ, et al. Colonic stenting versus emergency surgery for acute left-sided malignant colonic obstruction: a multicentre randomised trial. *Lancet Oncol.* 2011;12(4):344–52.

57. Farrell JJ. Preoperative colonic stenting: how, when and why? *Curr Opin Gastroenterol.* 2007;23(5):544–9.

58. Sebastian S, Johnston S, Geoghegan T, Torreggiani W, Buckley M. Pooled analysis of the efficacy and safety of self-expanding metal stenting in malignant colorectal obstruction. *Am J Gastroenterol.* 2004;99(10):2051–7.

59. Sagar J. Colorectal stents for the management of malignant colonic obstructions. *Cochrane Database Syst Rev.* 2011(11):CD007378.

60. Choi JH, Lee YJ, Kim ES, Choi JH, Cho KB, Park KS, et al. Covered self-expandable metal stents are more associated with complications in the management of malignant colorectal obstruction. *Surg Endosc.* 2013;27(9):3220–7.

61. Kim BK, Hong SP, Heo HM, Kim JY, Hur H, Lee KY, et al. Endoscopic stenting is not as effective for palliation of colorectal obstruction in patients with advanced gastric cancer as emergency surgery. *Gastrointest Endosc.* 2012;75(2):294–301.

62. Meisner S, Hensler M, Knop FK, West F, Wille-Jorgensen P. Self-expanding metal stents for colonic obstruction: experiences from 104 procedures in a single center. *Dis Colon Rectum.* 2004;47(4):444–50.

63. Paul L, Pinto I, Gomez H, Fernandez-Lobato R, Moyano E. Metallic stents in the treatment of

- benign diseases of the colon: preliminary experience in 10 cases. *Radiology*. 2002;223(3):715–22.
64. Repici A, Adler DG, Gibbs CM, Malesci A, Preatoni P, Baron TH. Stenting of the proximal colon in patients with malignant large bowel obstruction: techniques and outcomes. *Gastrointest Endosc*. 2007;66(5):940–4.
  65. Wangenstein OH. Cancer of the colon and rectum; with special reference to earlier recognition of alimentary tract malignancy; secondary delayed re-entry of the abdomen in patients exhibiting lymph node involvement; subtotal primary excision of the colon; operation in obstruction. *Wisconsin Med J*. 1949;48(7):591–7.
  66. Chereau N, Lefevre JH, Lefrancois M, Chafai N, Parc Y, Tiret E. Management of malignant left colonic obstruction: is an initial temporary colostomy followed by surgical resection a better option? *Colorectal Dis*. 2013;15(11):e646–53.
  67. Maggard MA, Zingmond D, O’Connell JB, Ko CY. What proportion of patients with an ostomy (for diverticulitis) get reversed? *Am Surg*. 2004;70(10):928–31.
  68. Vermeulen J, Coene PP, Van Hout NM, van der Harst E, Gosselink MP, Mannaerts GH, et al. Restoration of bowel continuity after surgery for acute perforated diverticulitis: should Hartmann’s procedure be considered a one-stage procedure? *Colorectal Dis*. 2009;11(6):619–24.
  69. Toro A, Mannino M, Reale G, Cappello G, Di Carlo I. Primary anastomosis vs. Hartmann procedure in acute complicated diverticulitis. Evolution over the last twenty years. *Chirurgia (Bucharest, Romania: 1990)*. 2012;107(5):598–604.
  70. Banerjee S, Leather AJ, Rennie JA, Samano N, Gonzalez JG, Papagrigoriadis S. Feasibility and morbidity of reversal of Hartmann’s. *Colorectal Dis*. 2005;7(5):454–9.
  71. Foster ME, Leaper DJ, Williamson RC. Changing patterns in colostomy closure: the Bristol experience 1975–1982. *Br J Surg*. 1985;72(2):142–5.
  72. Sweeney JL, Hoffmann DC. Restoration of continuity after Hartmann’s procedure for the complications of diverticular disease. *Aust NZ J Surg*. 1987;57(11):823–5.
  73. Wigmore SJ, Duthie GS, Young IE, Spalding EM, Rainey JB. Restoration of intestinal continuity following Hartmann’s procedure: the Lothian experience 1987–1992. *Br J Surg*. 1995;82(1):27–30.
  74. Geoghegan JG, Rosenberg IL. Experience with early anastomosis after the Hartmann procedure. *Ann R Coll Surg Engl*. 1991;73(2):80–2.
  75. Garber A, Hyman N, Osler T. Complications of Hartmann takedown in a decade of preferred primary anastomosis. *Am J Surg*. 2014;207(1):60–4.
  76. Van de Wall BJ, Draaisma WA, Schouten ES, Broeders IA, Consten EC. Conventional and laparoscopic reversal of the Hartmann procedure: a review of literature. *J Gastrointest Surg*. 2010;14(4):743–52.
  77. Schilling MK, Maurer CA, Kollmar O, Buchler MW. Primary vs. secondary anastomosis after sigmoid colon resection for perforated diverticulitis (Hinchey Stage III and IV): a prospective outcome and cost analysis. *Dis Colon Rectum*. 2001;44(5):699–703; discussion 5.
  78. Sule AZ, Misauno M, Opaluwa AS, Ojo E. One-stage treatment of left-sided large bowel emergencies. *East African Med J*. 2008;85(2):80–4.
  79. Poon RT, Law WL, Chu KW, Wong J. Emergency resection and primary anastomosis for left-sided obstructing colorectal carcinoma in the elderly. *Br J Surg*. 1998;85(11):1539–42.
  80. Goyal A, Schein M. Current practices in left-sided colonic emergencies: a survey of US gastrointestinal surgeons. *Dig Surg*. 2001;18(5):399–402.
  81. Singhal R, Hull P, Budhoo M. Management of left sided colorectal emergencies. Results of a

- postal questionnaire. *Minerva Chirurgica*. 2007;62(6):437–41.
82. Engledow AH, Bond-Smith G, Motson RW, Jenkinson A. Treatment of left-sided colonic emergencies: a comparison of US and UK surgical practices. *Colorectal Dis*. 2009;11(6):642–7.
83. Single-stage treatment for malignant left-sided colonic obstruction: a prospective randomized clinical trial comparing subtotal colectomy with segmental resection following intraoperative irrigation. The SCOTIA Study Group. Subtotal Colectomy versus On-table Irrigation and Anastomosis. *Br J Surg*. 1995;82(12):1622–7.
84. You YN, Chua HK, Nelson H, Hassan I, Barnes SA, Harrington J. Segmental vs. extended colectomy: measurable differences in morbidity, function, and quality of life. *Dis Colon Rectum*. 2008;51(7):1036–43.
85. Eskicioglu C, Forbes SS, Fenech DS, McLeod RS. Best practice in General Surgery C. Preoperative bowel preparation for patients undergoing elective colorectal surgery: a clinical practice guideline endorsed by the Canadian Society of Colon and Rectal Surgeons. *Can J Surg*. 2010;53(6):385–95.
86. Smith SR, Connolly JC, Gilmore OJ. The effect of faecal loading on colonic anastomotic healing. *Br J Surg*. 1983;70(1):49–50.
87. Sasaki K, Kazama S, Sunami E, Tsuno NH, Nozawa H, Nagawa H, et al. One-stage segmental colectomy and primary anastomosis after intraoperative colonic irrigation and total colonoscopy for patients with obstruction due to left-sided colorectal cancer. *Dis Colon Rectum*. 2012;55(1):72–8.
88. Jung SH, Kim JH. Comparative study of postoperative complications in patients with and without an obstruction who had left-sided colorectal cancer and underwent a single-stage operation after mechanical bowel preparation. *Ann Coloproctol*. 2014;30(6):251–8.
89. Murray JJ, Schoetz Jr DJ, Collier JA, Roberts PL, Veidenheimer MC. Intraoperative colonic lavage and primary anastomosis in nonelective colon resection. *Dis Colon Rectum*. 1991;34(7):527–31.
90. Forloni B, Reduzzi R, Paludetti A, Colpani L, Cavallari G, Frosali D. Intraoperative colonic lavage in emergency surgical treatment of left-sided colonic obstruction. *Dis Colon Rectum*. 1998;41(1):23–7.
91. Torralba JA, Robles R, Parrilla P, Lujan JA, Liron R, Pinero A, et al. Subtotal colectomy vs. intraoperative colonic irrigation in the management of obstructed left colon carcinoma. *Dis Colon Rectum*. 1998;41(1):18–22.
92. Hsu TC. One-stage resection and anastomosis for acute obstruction of the left colon. *Dis Colon Rectum*. 1998;41(1):28–32.
93. Cross KL, Rees JR, Soulsby RH, Dixon AR. Primary anastomosis without colonic lavage for the obstructed left colon. *Ann R Coll Surg Engl*. 2008;90(4):302–4.
94. Naraynsingh V, Rampaul R, Maharaj D, Kuruvilla T, Ramcharan K, Pouchet B. Prospective study of primary anastomosis without colonic lavage for patients with an obstructed left colon. *Br J Surg*. 1999;86(10):1341–3.
95. Alcantara M, Serra-Aracil X, Falco J, Mora L, Bombardo J, Navarro S. Prospective, controlled, randomized study of intraoperative colonic lavage versus stent placement in obstructive left-sided colonic cancer. *World J Surg*. 2011;35(8):1904–10.
96. Ballantyne GH, Brandner MD, Beart Jr RW, Ilstrup DM. Volvulus of the colon. Incidence and mortality. *Ann Surg*. 1985;202(1):83–92.
97. Atamanalp SS, Ozturk G. Sigmoid volvulus in the elderly: outcomes of a 43-year, 453-patient

- experience. *Surg Today*. 2011;41(4):514–9.
98. Feldman D. The coffee bean sign. *Radiology*. 2000;216(1):178–9.
99. Levsky JM, Den EI, DuBrow RA, Wolf EL, Rozenblit AM. CT findings of sigmoid volvulus. *Am J Roentgenol*. 2010;194(1):136–43.
100. Macari M, Spieler B, Babb J, Pachter HL. Can the location of the CT whirl sign assist in differentiating sigmoid from caecal volvulus? *Clin Radiol*. 2011;66(2):112–7.
101. Turan M, Sen M, Karadayi K, Koyuncu A, Topcu O, Yildirim C, et al. Our sigmoid colon volvulus experience and benefits of colonoscope in detortion process. *Rev Esp Enferm Dig*. 2004;96(1):32–5.
102. Bruzzi M, Lefevre JH, Desaint B, Nion-Larmurier I, Bennis M, Chafai N, et al. Management of acute sigmoid volvulus: short- and long-term results. *Colorectal Dis*. 2015;17:922–8.
103. Hougaard HT, Qvist N. Elective surgery after successful endoscopic decompression of sigmoid volvulus may be considered. *Danish Med J*. 2013;60(7):A4660.
104. Basato S, Lin Sun Fui S, Pautrat K, Tresallet C, Pocard M. Comparison of two surgical techniques for resection of uncomplicated sigmoid volvulus: laparoscopy or open surgical approach? *J Visc Surg*. 2014;151(6):431–4.
105. Choi BJ, Jeong WJ, Kim SJ, Lee SC. Single-port laparoscopic surgery for sigmoid volvulus. *World J Gastroenterol*. 2015;21(8):2381–6.
106. Chandrasekaran TV, Al-Dahiri A, Beynon J, Carr ND. Minimally invasive stapled surgical approach to the management of sigmoid volvulus. *Ann R Coll Surg Engl*. 2005;87(5):381–2.
107. Hsu TC. Feasibility of colectomy with mini-incision. *Am J Surg*. 2005;190(1):48–50.
108. Suleyman O, Kessaf AA, Ayhan KM. Sigmoid volvulus: long-term surgical outcomes and review of the literature. *S Afr J Surg*. 2012;50(1):9–15.
109. Atamanalp SS. Treatment of sigmoid volvulus: a single-center experience of 952 patients over 46.5 years. *Tech Coloproctol*. 2013;17(5):561–9.
110. Chung YF, Eu KW, Nyam DC, Leong AF, Ho YH, Seow-Choen F. Minimizing recurrence after sigmoid volvulus. *Br J Surg*. 1999;86(2):231–3.
111. Morrissey TB, Deitch EA. Recurrence of sigmoid volvulus after surgical intervention. *Am Surg*. 1994;60(5):329–31.
112. Bhatnagar BN, Sharma CL. Nonresective alternative for the cure of nongangrenous sigmoid volvulus. *Dis Colon Rectum*. 1998;41(3):381–8.
113. Gordon-Weeks AN, Lorenzi B, Lim J, Cristaldi M. Laparoscopic-assisted endoscopic sigmoidopexy: a new surgical option for sigmoid volvulus. *Dis Colon Rectum*. 2011;54(5):645–7.
114. Bach O, Rudloff U, Post S. Modification of mesosigmoidoplasty for nongangrenous sigmoid volvulus. *World J Surg*. 2003;27(12):1329–32.
115. Ponticelli A, Mastrobuono I, Matarazzo E, Zaccara A, Appetito C, Insera A, et al. Mesosigmoidoplasty in the treatment of sigmoid volvulus in children. *S Afr J Surg*. 1989;27(3):105–7.
116. Mortensen NJ, Hoffman G. Volvulus of the transverse colon. *Postgraduate Med J*. 1979;55(639):54–7.
117. Gupta SS, Singh O, Paramhans D, Mathur RK. Tube sigmoidostomy: a valuable alternative to sigmoidopexy for sigmoid volvulus. *J Visc Surg*. 2011;148(2):e129–33.
118. Ifversen AK, Kjaer DW. More patients should undergo surgery after sigmoid volvulus. *World J Gastroenterol*. 2014;20(48):18384–9.



119. Khan MA, Ullah S, Beckly D, Oppong FC. Percutaneous endoscopic colostomy (PEC): an effective alternative in high risk patients with recurrent sigmoid volvulus. *J Coll Physicians Surg Pak.* 2013;23(10):806–8.
120. Baraza W, Brown S, McAlindon M, Hurlstone P. Prospective analysis of percutaneous endoscopic colostomy at a tertiary referral centre. *Br J Surg.* 2007;94(11):1415–20.
121. Kuzu MA, Aslar AK, Soran A, Polat A, Topcu O, Hengirmen S. Emergent resection for acute sigmoid volvulus: results of 106 consecutive cases. *Dis Colon Rectum.* 2002;45(8):1085–90.
122. Oren D, Atamanalp SS, Aydinli B, Yildirgan MI, Basoglu M, Polat KY, et al. An algorithm for the management of sigmoid colon volvulus and the safety of primary resection: experience with 827 cases. *Dis Colon Rectum.* 2007;50(4):489–97.
123. Aftab Z, Toro A, Abdelaal A, Dasovsky M, Gehani S, Abdel Mola A, et al. Endoscopic reduction of a volvulus of the sigmoid colon in pregnancy: case report and a comprehensive review of the literature. *World J Emerg Surg.* 2014;9:41.
124. Atamanalp SS, Kisaoglu A, Ozogul B. Factors affecting bowel gangrene development in patients with sigmoid volvulus. *Ann Saudi Med.* 2013;33(2):144–8.
125. Vandendries C, Jules MC, Boulay-Coletta I, Loriau J, Zins M. Diagnosis of colonic volvulus: findings on multidetector CT with three-dimensional reconstructions. *Br J Radiol.* 2010;83(995):983–90.
126. Consorti ET, Liu TH. Diagnosis and treatment of caecal volvulus. *Postgraduate Med J.* 2005;81(962):772–6.
127. Tuech JJ, Becouarn G, Cattani F, Arnaud JP. Volvulus of the right colon. Plea for right hemicolectomy. Apropos of a series of 23 cases. *Chirurgie.* 1996;133(6):267–9.
128. Madiba TE, Thomson SR. The management of cecal volvulus. *Dis Colon Rectum.* 2002;45(2):264–7.
129. Puthu D, Rajan N, Shenoy GM, Pai SU. The ileosigmoid knot. *Dis Colon Rectum.* 1991;34(2):161–6.
130. Alver O, Oren D, Tireli M, Kayabasi B, Akdemir D. Ileosigmoid knotting in Turkey. Review of 68 cases. *Dis Colon Rectum.* 1993;36(12):1139–47.
131. Halabi WJ, Jafari MD, Kang CY, Nguyen VQ, Carmichael JC, Mills S, et al. Colonic volvulus in the United States: trends, outcomes, and predictors of mortality. *Ann Surg.* 2014;259(2):293–301.
132. Plorde JJ, Raker EJ. Transverse colon volvulus and associated Chilaiditi's syndrome: case report and literature review. *Am J Gastroenterol.* 1996;91(12):2613–6.
133. Moaven O, Hodin RA. Chilaiditi syndrome: a rare entity with important differential diagnoses. *Gastroenterol Hepatol.* 2012;8(4):276–8.
134. Mindelzun RE, Stone JM. Volvulus of the splenic flexure: radiographic features. *Radiology.* 1991;181(1):221–3.
135. Chen MH, Chou CM, Lin CC. Transverse colon volvulus presenting as 'inverted' coffee-bean sign. *Arch Dis Child.* 2012;97(2):123.
136. Choi JS, Lim JS, Kim H, Choi JY, Kim MJ, Kim NK, et al. Colonic pseudoobstruction: CT findings. *Am J Roentgenol.* 2008;190(6):1521–6.
137. Wegener M, Borsch G. Acute colonic pseudo-obstruction (Ogilvie's syndrome). Presentation of 14 of our own cases and analysis of 1027 cases reported in the literature. *Surg Endosc.* 1987;1(3):169–74.
138. Poncet RJ, Saunders MD, Kimmey MB. Neostigmine for the treatment of acute colonic pseudo-

- obstruction. *N Engl J Med*. 1999;341(3):137–41.
139. Van der Spoel JI, Oudemans-van Straaten HM, Stoutenbeek CP, Bosman RJ, Zandstra DF. Neostigmine resolves critical illness-related colonic ileus in intensive care patients with multiple organ failure—a prospective, double-blind, placebo-controlled trial. *Intensive Care Med*. 2001;27(5):822–7.
140. Amaro R, Rogers AI. Neostigmine infusion: new standard of care for acute colonic pseudo-obstruction? *Am J Gastroenterol*. 2000;95(1):304–5.
141. Stephenson BM, Morgan AR, Salaman JR, Wheeler MH. Ogilvie's syndrome: a new approach to an old problem. *Dis Colon Rectum*. 1995;38(4):424–7.
142. Valle RG, Godoy FL. Neostigmine for acute colonic pseudo-obstruction: a meta-analysis. *Ann Med Surg*. 2014;3(3):60–4.
143. White L, Sandhu G. Continuous neostigmine infusion versus bolus neostigmine in refractory Ogilvie syndrome. *Am J Emerg Med*. 2011;29(5):576. e1–3.
144. O'Dea CJ, Brookes JH, Wattchow DA. The efficacy of treatment of patients with severe constipation or recurrent pseudo-obstruction with pyridostigmine. *Colorectal Dis*. 2010;12(6):540–8.
145. Weinstock LB, Chang AC. Methylnaltrexone for treatment of acute colonic pseudo-obstruction. *J Clin Gastroenterol*. 2011;45(10):883–4.
146. Smart CJ, Ramesh AN. The successful treatment of acute refractory pseudo-obstruction with prucalopride. *Colorectal Dis*. 2012;14(8), e508.
147. Harrison ME, Anderson MA, Appalaneni V, Banerjee S, Ben-Menachem T, Cash BD, et al. The role of endoscopy in the management of patients with known and suspected colonic obstruction and pseudo-obstruction. *Gastrointest Endosc*. 2010;71(4):669–79.
148. Wang WL, Wu ZH, Sun Q, Wei JF, Chen XF, Zhou DK, et al. Meta-analysis: the use of carbon dioxide insufflation vs. room air insufflation for gastrointestinal endoscopy. *Aliment Pharmacol Ther*. 2012;35(10):1145–54.
149. Wiersema US, Bruno MJ, Tjwa ET. On colonoscopy in acute colonic pseudo obstruction. *Eur J Intern Med*. 2013;24(8):e86–7.
150. Rex DK. Colonoscopy and acute colonic pseudo-obstruction. *Gastrointest Endosc Clin N Am*. 1997;7(3):499–508.
151. Lynch CR, Jones RG, Hilden K, Wills JC, Fang JC. Percutaneous endoscopic cecostomy in adults: a case series. *Gastrointest Endosc*. 2006;64(2):279–82.
152. Pereira P, Djeudji F, Leduc P, Fanget F, Barth X. Ogilvie's syndrome-acute colonic pseudo-obstruction. *J Visc Surg*. 2015;152:99–105.
153. Bailey HR, Ott MT, Hartendorp P. Aggressive surgical management for advanced colorectal endometriosis. *Dis Colon Rectum*. 1994;37(8):747–53.
154. Ruffo G, Crippa S, Sartori A, Partelli S, Minelli L, Falconi M. Management of rectosigmoid obstruction due to severe bowel endometriosis. *Updates Surg*. 2014;66(1):59–64.
155. Giudice LC, Kao LC. Endometriosis. *Lancet*. 2004;364(9447):1789–99.
156. De Jong MJ, Mijatovic V, van Waesberghe JH, Cuesta MA, Hompes PG. Surgical outcome and long-term follow-up after segmental colorectal resection in women with a complete obstruction of the rectosigmoid due to endometriosis. *Digest Surg*. 2009;26(1):50–5.
157. Wald A. Management and prevention of fecal impaction. *Curr Gastroenterol Rep*. 2008;10(5):499–501.

158. Reisner RM, Cohen JR. Gallstone ileus: a review of 1001 reported cases. *Am Surg.* 1994;60(6):441–6.
159. Howard N, Pranesh N, Carter P. Colo-colonic intussusception secondary to a lipoma. *Int J Surg Case Rep.* 2012;3(2):52–4.
160. Wilson A, Elias G, Dupiton R. Adult colocolic intussusception and literature review. *Case Rep Gastroenterol.* 2013;7(3):381–7.

## 第 41 章

1. Longstreth GF. Epidemiology and outcome of patients hospitalized with acute lower gastrointestinal hemorrhage: a population-based study. *Am J Gastroenterol.* 1997;92(3):419–24.
2. Herinsson JP, Guomundsson S, Kalaitzakis E, et al. Lower gastrointestinal bleeding: incidence, etiology, and outcomes in a population-based setting. *Eur J Gastroenterol Hepatol.* 2013;25(1):37–43.
3. Strate LL, Orav J, Syngal S. Early predictors of severity in acute lower intestinal tract bleeding. *Arch Intern Med.* 2003;163(7):838–43.
4. Gayer C, Chino A, Lucas C, et al. Acute lower gastrointestinal bleeding in 1,112 patients admitted to an urban emergency medical center. *Surgery.* 2009;146(4):600–7.
5. Whelan CT, Chen C, Kaboli P, et al. Upper versus lower gastrointestinal bleeding: a direct comparison of clinical presentation, outcome, and resource utilization. *J Hosp Med.* 2010;5(3):141–7.
6. Prakash C, Zucker GR. Acute small bowel bleeding: a distinct entity with significantly different economic implications compared with GI bleeding from other locations. *Gastrointest Endosc.* 2003;58(3):330–5.
7. Peery AF, Dellon ES, Lund J, et al. Burden of gastrointestinal disease in the United States: 2012 update. *Gastroenterology.* 2012;143(5):1179–87.
8. Laine L, Yang H, Chang SC, et al. Trends for incidence of hospitalization and death due to GI complications in the United States from 2001 to 2009. *Am J Gastroenterol.* 2012;107(8):1190–5.
9. Zhao Y, Encinosa W. Hospitalizations for gastrointestinal bleeding in 1998 and 2006. Healthcare Cost and Utilization Project (H-CUP) STATISTICAL BRIEF #65, Rockville; Agency for Healthcare Research and Quality; Dec 2008. <https://www.hcupus.ahrq.gov/reports/statbriefs/sb65.jsp>
10. Lanas A, García-Rodríguez LA, Polo-Tomás M, et al. Time trends and impact of upper and lower gastrointestinal bleeding and perforation in clinical practice. *Am J Gastroenterol.* 2009;104(7):1633–41.
11. Wheat CL, Strate LL. Trends in hospitalization for diverticulitis and diverticular bleeding in the United States from 2000 to 2010. *Clin Gastroenterol Hepatol.* 2016;14(1):96–103.e1.
12. Strate LL, Ayanian JZ, Kotler G, et al. Risk factors for mortality in lower intestinal bleeding. *Clin Gastroenterol Hepatol.* 2008;6(9):1004–10.
13. Kluiber RM, Wolff BG. Evaluation of anemia caused by bleeding hemorrhoids. *Dis Colon Rectum.* 1994;37(10):1006–7.
14. Cheskin LJ, Bohlman M, Schuster MM. Diverticular disease in the elderly. *Gastroenterol Clin N Am.* 1990;19(2):391–403.

15. McGuire Jr HH, Haynes Jr BW. Massive hemorrhage for diverticulosis of the colon: guidelines for therapy based on bleeding patterns observed in fifty cases. *Ann Surg.* 1972;175(6):847–55.
16. Painter NS, Burkitt DP. Diverticular disease of the colon, a 20th century problem. *Clin Gastroenterol.* 1975;4(1):3–21.
17. Parks TG. Natural history of diverticular disease of the colon. *Clin Gastroenterol.* 1975;4(1):53–69.
18. McGuire Jr HH. Bleeding colonic diverticula. A reappraisal of natural history and management. *Ann Surg.* 1994;220(5):653–6.
19. Aldoori WH, Giovannucci EL, Rimm EB, et al. Use of acetaminophen and nonsteroidal anti-inflammatory drugs: a prospective study and the risk of symptomatic diverticular disease in men. *Arch Fam Med.* 1998;7(3):255–60.
20. Lee KK, Shah SM, Moser MA. Risk factors predictive of severe diverticular hemorrhage. *Int J Surg.* 2011;9(1):83–5.
21. Yamada A, Sugimoto T, Kondo S, et al. Assessment of the risk factors for colonic diverticular hemorrhage. *Dis Colon Rectum.* 2008;51(1):116–20.
22. Anthony T, Penta P, Todd RD, et al. Rebleeding and survival after acute lower gastrointestinal bleeding. *Am J Surg.* 2004;188(5):485–90.
23. Boley SJ, Sammartano R, Adams A, et al. On the nature and etiology of vascular ectasias of the colon: degenerative lesions of aging. *Gastroenterology.* 1977;72(4 pt 1):650–60.
24. Strate LL, Naumann CR. The role of colonoscopy and radiological procedures in the management of acute lower intestinal bleeding. *Clin Gastroenterol Hepatol.* 2010;8(4):333–43.
25. Bollinger E, Raines D, Saitta P. Distribution of bleeding gastrointestinal angioectasias in a Western population. *World J Gastroenterol.* 2012;18(43):6235–9.
26. Diggs NG, Holub JL, Lieberman DA, et al. Factors that contribute to blood loss in patients with colonic angiodysplasia from a population-based study. *Clin Gastroenterol Hepatol.* 2011;9(5):415–20.
27. Strate LL. Lower GI bleeding: epidemiology and diagnosis. *Gastroenterol Clin N Am.* 2005;34(4):643–64.
28. Foutch PG. Angiodysplasia of the gastrointestinal tract. *Am J Gastroenterol.* 1993;88(6):807–18.
29. Gupta N, Longo WE, Vernava III AM. Angiodysplasia of the lower gastrointestinal tract: an entity readily diagnosed by colonoscopy and primarily managed non-operatively. *Dis Colon Rectum.* 1995;38(9):979–82.
30. Lewis BS, Salomon P, Rivera-MacMurray S, et al. Does hormonal therapy have any benefit for bleeding angiodysplasia? *J Clin Gastroenterol.* 1992;15(2):99–103.
31. Sekino Y, Endo H, Yamada E, et al. Clinical associations and risk factors for bleeding from colonic angioectasia: a case-controlled study. *Colorectal Dis.* 2012;14(10):e740–6.
32. Naveau S, Auber A, Poynard T, et al. Long-term results of treatment of vascular malformation of the gastrointestinal tract by neodymium YAG laser photocoagulation. *Dig Dis Sci.* 1990;35(7):821–6.
33. Saperas E, Videla S, Dot J, et al. Risk factors for recurrence of acute gastrointestinal bleeding from angiodysplasia. *Eur J Gastroenterol Hepatol.* 2009;21(12):1333–9.
34. Strate LL, Saltzman JR, Ookubbo R, et al. Validation of a clinical prediction rule for severe acute lower intestinal bleeding. *Am J Gastroenterol.* 2005;100(8):1821–7.

35. Brandt LJ, Feuerstadt P, Longstreth GF, et al. ACG clinical guideline: epidemiology, risk Factors, patterns of presentation, diagnosis, and management of colon ischemia (CI). *Am J Gastroenterol*. 2015;110(1):18–44.
36. Longstreth GF, Yao JF. Epidemiology, clinical features, high-risk factors, and outcome of acute large bowel ischemia. *Clin Gastroenterol Hepatol*. 2009;7(10):1075–80.
37. Scharff JR, Longo WE, Vartarian SM, et al. Ischemic colitis: spectrum of disease and outcome. *Surgery*. 2003;134(4):624–9; discussion 629–30.
38. Castleberry AW, Turley RS, Hanna JM, et al. A 10-year longitudinal analysis of surgical management for acute ischemic colitis. *J Gastrointest Surg*. 2013;17(4):784–92.
39. Reissfelder C, Sweiti H, Antolovic D, et al. Ischemic colitis: who will survive? *Surgery*. 2011;149(4):585–92.
40. Siegel R, DeSantis C, Jemal A. Colorectal cancer statistics, 2014. *CA Cancer J Clin*. 2014;64(2):104–17.
41. Warren JL, Klabunde CN, Mariotto AB, et al. Adverse events after outpatient colonoscopy in the Medicare population. *Ann Intern Med*. 2009;150(12):849–57. W152.
42. Bounds BC, Kelsey PB. Lower gastrointestinal bleeding. *Gastrointest Endosc Clin N Am*. 2007;17(2):273–88. vi.
43. Robert JR, Sachar DB, Greenstein AJ. Severe gastrointestinal hemorrhage in Crohn's disease. *Ann Surg*. 1991;213(3):207–11.
44. Pardi DS, Loftus Jr EV, Tremaine WJ, et al. Acute major gastrointestinal hemorrhage in inflammatory bowel disease. *Gastrointest Endosc*. 1999;49(2):153–7.
45. Robert JR, Sachar DB, Greenstein AJ. Management of severe hemorrhage in ulcerative colitis. *Am J Surg*. 1990;159(6):550–5.
46. Lanis A, Sekar MC, Hirschowitz BI. Objective evidence of aspirin use in both ulcer and nonulcer upper and lower gastrointestinal bleeding. *Gastroenterology*. 1992;103(3):862–9.
47. Bjarnason I, Hayllar J, MacPherson AJ, et al. Side effects of nonsteroidal anti-inflammatory drugs on the small and large intestine in humans. *Gastroenterology*. 1993;104(6):1832–47.
48. DuPont HL. Approach to the patient with infectious colitis. *Curr Opin Gastroenterol*. 2012;28(1):39–46.
49. Papaconstatinou HT, Thomas JS. Bacterial colitis. *Clin Colon Rectal Surg*. 2007;20(1):18–27.
50. Huang D, Okhuysen P, Jiang Z, et al. Enterohemorrhagic *Escherichia coli*: an emerging enteric pathogen. *Am J Gastroenterol*. 2004;99(2):383–9.
51. Griffin P, Mead P, Sivapalasingam S. *Escherichia coli* O157:H7 and other enterohemorrhagic *E. coli*. In: Blaser M, Smith P, Greenberg H, et al., editors. *Infections of the gastrointestinal tract*. Philadelphia: Lippincott Williams & Wilkins; 2002. p. 627–42.
52. Crump JA, Sulka AC, Langer AJ, et al. An outbreak of *Escherichia coli* O157:H7 infections among visitors to a dairy farm. *N Engl J Med*. 2002;347(8):555–60.
53. Buchi K. Radiation proctitis: therapy and prognosis. *JAMA*. 1991;265(9):1180.
54. Hasleton PS, Carr N, Schofield PF. Vascular changes in radiation bowel disease. *Histopathology*. 1985;9(5):517–34.
55. Fajardo LF. The pathology of ionizing radiation as defined by morphologic patterns. *Acta Oncol*. 2005;44(1):13–22.
56. Kennedy GD, Heise CP. Radiation colitis and proctitis. *Clin Colon Rectal Surg*. 2007;20(1):64–72.

57. Andreyev HJ, Vlavianos P, Blake P, et al. Gastrointestinal symptoms after pelvic radiotherapy: role for the gastroenterologist. *Int J Radiat Oncol Biol Phys*. 2005;62(5):1464–71.
58. Theodorescu D, Gillenwater JY, Koutrouvelis PG. Prostatourethral-rectal fistula after prostate brachytherapy. *Cancer*. 2000;89(10):2085–91.
59. Baxter M, Aly EH. Dieulafoy's lesion: current trends in diagnosis and management. *Ann R Coll Surg Engl*. 2010;92(7):548–54.
60. Jain R, Chetty R. Dieulafoy disease of the colon. *Arch Pathol Lab Med*. 2009;133(11):1865–7.
61. Maslekar S, Toh EW, Adair R, et al. Systematic review of anorectal varices. *Colorectal Dis*. 2013;15(12):e702–10.
62. Triger DR, Hosking SW, Smart HL, Johnson AG. Prevalence of anorectal varices in cirrhosis. *J Gastroenterol Hepatol*. 1989;4 Suppl 1:291–2.
63. Groszmann RJ. Reassessing portal venous pressure measurements. *Gastroenterology*. 1984;86(6):1611–4.
64. McCormack TT, Bailey HR, Simms JM, et al. Rectal varices are not piles. *Br J Surg*. 1984;71(2):163.
65. Johansen K, Bardin J, Orloff MJ. Massive bleeding from hemorrhoidal varices in portal hypertension. *JAMA*. 1980;224(18):2084–5.
66. Wilson SE, Stone RT, Christie JP, et al. Massive lower gastrointestinal bleeding from intestinal varices. *Arch Surg*. 1979;114(10):1158–61.
67. Herman BE, Baum S, Donobile J, et al. Massive bleeding from rectal varices. *Am J Gastroenterol*. 1993;88(6):939–42.
68. Norton ID, Andrews JC, Kamath PS. Management of Ectopic Varices. *Hepatology*. 1998;28(4):1154–58.
69. Yoshino K, Imai Y, Nakazawa M, et al. Therapeutic strategy for patients with bleeding rectal varices complicating liver cirrhosis. *Hepatol Res*. 2014;44(11):1088–94.
70. Yahchouchy EK, Marano AF, Etienne JC, et al. Meckel's diverticulum. *J Am Coll Surg*. 2001;192(5):658–62.
71. Simon TG, Travis AC, Saltzman JR. Initial assessment and resuscitation in nonvariceal upper gastrointestinal bleeding. *Gastrointest Endoscopy Clin N Am*. 2015;25(3):429–42.
72. Velayos FS, Williamson A, Sousa KH, et al. Early predictors of severe lower gastrointestinal bleeding and adverse outcomes: a prospective study. *Clin Gastroenterol Hepatol*. 2004;2(6):485–90.
73. Patel R, Clancy R, Crowther E, et al. A rectal bleeding algorithm can successfully reduce emergency admissions. *Colorectal Dis*. 2014;16(5):377–81.
74. Villanueva C, Colomo A, Bosch A, et al. Transfusion strategies for acute upper gastrointestinal bleeding. *N Engl J Med*. 2013;368(1):11–21.
75. Al-Jaghbeer M, Yende S. Blood transfusion for upper gastrointestinal bleeding: is less more again? *Crit Care*. 2013;17(5):325.
76. Wang J, Bao YX, Bai M, et al. Restrictive vs. liberal transfusion for upper gastrointestinal bleeding: a meta-analysis of randomized controlled trials. *World J Gastroenterol*. 2013;19(40):6919–27.
77. Vernava III AM, Moore BA, Longo WE, et al. Lower gastrointestinal bleeding. *Dis Colon Rectum*. 1997;40(7):846–58.
78. Angtuaco TL, Reddy SK, Drapkin S, et al. The utility of urgent colonoscopy in the evaluation of acute lower gastrointestinal tract bleeding: a 2-year experience from a single center. *Am J*

Gastroenterol. 2001;96(6):1782–5.

79. Jensen DM, Machicado GA, Juthaba R, et al. Urgent colonoscopy for the diagnosis and treatment of severe diverticular hemorrhage. *N Engl J Med*. 2000;342(2):78–82.

80. Green BT, Rockey DC, Portwood G, et al. Urgent colonoscopy for evaluation and management of acute lower gastrointestinal hemorrhage: a randomized controlled trial. *Am J Gastroenterol*. 2005;100(11):2395–402.

81. Bloomfeld RS, Rockey DC, Shetzline MA. Endoscopic therapy of acute diverticular hemorrhage. *Am J Gastroenterol*. 2001;96(8):2367–72.

82. Richter JM, Christensen MR, Kaplan LM, et al. Effectiveness of current technology in the diagnosis and management of lower gastrointestinal hemorrhage. *Gastrointest Endosc*. 1995;41(2):93–8.

83. Al Qahtani AR, Satin R, Stern J, et al. Investigative modalities for massive lower gastrointestinal bleeding. *World J Surg*. 2002;26(5):733–6.

84. Strate LL, Syngal S. Timing of colonoscopy: impact on length of hospital stay in patients with acute lower intestinal bleeding. *Am J Gastroenterol*. 2003;98(2):317–22.

85. Jensen DM, Machicado GA. Diagnosis and treatment of severe hematochezia. The role of urgent colonoscopy after purge. *Gastroenterology*. 1988;95(6):1569–74.

86. Navaneethan U, Njei B, Venkatesh PG, et al. Timing of colonoscopy and outcomes in patients with lower GI bleeding: a nationwide population-based study. *Gastrointest Endosc*. 2014;79(2):297–306.

87. Laine L, Shah A. Randomized trial of urgent vs. elective colonoscopy in patients hospitalized with lower GI bleeding. *Am J Gastroenterol*. 2010;105(12):2636–41.

88. Smoot RL, Gostout CJ, Rajan E, et al. Is early colonoscopy after admission for acute diverticular bleeding needed? *Am J Gastroenterol*. 2003;98(9):1996–9.

89. Lim DS, Kim HG, Jeon SR, et al. Comparison of clinical effectiveness of the emergent colonoscopy in patients with hematochezia according to the type of bowel preparation. *J Gastroenterol Hepatol*. 2013;28(11):1733–7.

90. Hoedema RE, Luchtefeld MA. The management of lower gastrointestinal hemorrhage. *Dis Colon Rectum*. 2005;48(11):2010–24.

91. Repaka A, Atkinson MR, Faulx AL, et al. Immediate unprepped hydroflush colonoscopy for severe lower GI bleeding: a feasibility study. *Gastrointest Endosc*. 2012;76(2):367–73.

92. Bloomfeld RS, Shetzline M, Rockey D. Urgent colonoscopy for the diagnosis and treatment of severe diverticular hemorrhage. *N Engl J Med*. 2000;342(21):1608–9. author reply 1610–1.

93. Kaltenbach T, Watson R, Shah J, et al. Colonoscopy with clipping is useful in the diagnosis and treatment of diverticular bleeding. *Clin Gastroenterol Hepatol*. 2012;10(2):131–7.

94. Hokama A, Uehara T, Nakayoshi T, et al. Utility of endoscopic hemoclipping for colonic diverticular bleeding. *Am J Gastroenterol*. 1997;92(3):543–6.

95. Ohyama T, Sakurai Y, Ito M, et al. Analysis of urgent colonoscopy for lower gastrointestinal tract bleeding. *Digestion*. 2000;61(3):189–92.

96. Simpson PW, Nguyen MH, Lim JK, et al. Use of endoclips in the treatment of massive colonic diverticular bleeding. *Gastrointest Endosc*. 2004;59(3):433–7.

97. Ishii N, Hirata N, Omata F, et al. Location in the ascending colon is a predictor of refractory colonic diverticular hemorrhage after endoscopic clipping. *Gastrointest Endosc*. 2012;76(6):1175–81.

98. Ishii N, Itoh T, Uemura M, et al. Endoscopic band ligation with a water-jet scope for the treatment of colonic diverticular hemorrhage. *Dig Endosc.* 2010;22(3):323–5.
99. Ishii N, Setoyama T, Deshpande GA, et al. Endoscopic band ligation for colonic diverticular hemorrhage. *Gastrointest Endosc.* 2012;75(2):382–7.
100. Setoyama T, Ishii N, Fujita Y. Endoscopic band ligation (EBL) is superior to endoscopic clipping for the treatment of colonic diverticular hemorrhage. *Surg Endosc.* 2011;25(11):3574–8.
101. Olmos JA, Marcolongo M, Pogorelsky V, et al. Long-term outcome of argon plasma ablation therapy for bleeding in 100 consecutive patients with colonic angiodysplasia. *Dis Colon Rectum.* 2006;49(10):1507–16.
102. Jovanovic I, Knezevic A. Combined endoclippping and argon plasma coagulation (APC)—daisy technique for cecal angiodysplasia. *Endoscopy.* 2013;45(Suppl 2 UCTN), E384.
103. Kratt T, Lange J, Königsrainer A, et al. Successful Hemospray treatment for recurrent diclofenac-induced severe diffuse lower gastrointestinal bleeding avoiding the need for colectomy. *Endoscopy.* 2014;46(Suppl 1 UCTN):E173–4.
104. Bunker SR, Lull RJ, Tanasescu DE, et al. Scintigraphy of gastrointestinal hemorrhage: superiority of 99mTc red blood cells over 99mTc sulfur colloid. *Am J Roentgenol.* 1984;143(3):543–8.
105. Siddiqui AR, Schauwecker DS, Wellman HN, et al. Comparison of technetium-99m sulfur colloid and in vitro labeled technetium-99mRBC's in the detection of gastrointestinal bleeding. *Clin Nucl Med.* 1985;10(8):546–9.
106. Hammond KL, Beck DE, Hicks TC, et al. Implications of negative technetium 99m-labeled red blood cell scintigraphy in patients presenting with lower gastrointestinal bleeding. *Am J Surg.* 2007;193(3):404–7.
107. Currie GM, Towers PA, Wheat JM. Improved detection and localization of lower gastrointestinal tract hemorrhage by subtraction scintigraphy: phantom analysis. *J Nucl Med Technol.* 2006;34(3):160–8.
108. Thorne DA, Datz FL, Remley K, et al. Bleeding rates necessary for detecting acute gastrointestinal bleeding with technetium-99m-labeled red blood cells in an experimental model. *J Nucl Med.* 1987;28(4):514–20.
109. Feingold DL, Caliendo FJ, Chinn BT, et al. Does hemodynamic instability predict positive technetium-labeled red blood cell scintigraphy in patients with acute lower gastrointestinal bleeding? A review of 50 patients. *Dis Colon Rectum.* 2005;48(5):1001–4.
110. Hunter JM, Pezim ME. Limited value of technetium 99m-labeled red cell scintigraphy in localization of lower gastrointestinal bleeding. *Am J Surg.* 1990;159(5):504–6.
111. Nicholson ML, Neoptolemos JP, Sharp JF, et al. Localization of lower gastrointestinal bleeding using in vivo technetium-99m-labeled red blood cell scintigraphy. *Br J Surg.* 1989;76(4):358–61.
112. Gunderman R, Leef J, Ong K, et al. Scintigraphic screening prior to visceral arteriography in acute lower gastrointestinal bleeding. *J Nucl Med.* 1998;39(6):1081–3.
113. Suzman MS, Talmor M, Jennis R, et al. Accurate localization and surgical management of active lower gastrointestinal hemorrhage with technetium-labeled erythrocyte scintigraphy. *Ann Surg.* 1996;224(1):29–36.
114. Gutierrez C, Mariano M, Vander Laan T, et al. The use of technetium-labeled erythrocyte scintigraphy in the evaluation and treatment of lower gastrointestinal hemorrhage. *Am Surg.* 1998;64(10):989–92.



115. Ren JZ, Zhang MF, Rong AM, et al. Lower gastrointestinal bleeding: role of 64-row computed tomographic angiography in diagnosis and therapeutic planning. *World J Gastroenterol*. 2015;21(13):4030–7.
116. Kuhle WG, Sheiman RG. Detection of active colonic hemorrhage with use of helical CT: findings in a swine model. *Radiology*. 2003;228(3):743–52.
117. Rafaeli T, Menon R. Current treatment of lower gastrointestinal hemorrhage. *Clin Colon Rectal Surg*. 2012;25(4):219–27.
118. Marti M, Artigas JM, Garzón G, et al. Acute lower intestinal bleeding: feasibility and diagnostic performance of CT angiography. *Radiology*. 2012;262(1):109–16.
119. Obana T, Fujita N, Sugita R, et al. Prospective evaluation of contrast-enhanced computed tomography for the detection of colonic diverticular bleeding. *Dig Dis Sci*. 2013;58(7):1985–90.
120. Nagata N, Niikura R, Aoki T, et al. Role of urgent contrast-enhanced multidetector computed tomography for acute lower gastrointestinal bleeding in patients undergoing early colonoscopy. *J Gastroenterol*. 2015;50(12):1162–72.
121. Nusbaum M, Baum S. Radiographic demonstration of unknown sites of gastrointestinal bleeding. *Surg Forum*. 1963;14:374–5.
122. Ng DA, Opelka FG, Beck DE, et al. Predictive value of technetium Tc 99m-labeled red blood cell scintigraphy for positive angiogram in massive lower gastrointestinal hemorrhage. *Dis Colon Rectum*. 1997;40(4):471–7.
123. Leitman IM, Paull DE, Shires III GT. Evaluation and management of massive lower gastrointestinal hemorrhage. *Ann Surg*. 1989;209(2):175–80.
124. Nath RL, Sequeira JC, Weitzman AF, et al. Lower gastrointestinal bleeding. Diagnostic approaches and management conclusions. *Am J Surg*. 1981;141(4):478–81.
125. Abbas SM, Bissett IP, Holden A, et al. Clinical variables associated with positive angiographic localization of lower gastrointestinal bleeding. *ANZ J Surg*. 2005;75(11):953–7.
126. Tan KK, Shore T, Strong DH, et al. Factors predictive for a positive invasive mesenteric angiogram following a positive CT angiogram in patients with acute lower gastrointestinal hemorrhage. *Int J Colorectal Dis*. 2013;28(12):1715–9.
127. Koh FH, Soong J, Lieske B, et al. Does the timing of an invasive mesenteric angiography following a positive CT mesenteric angiography make a difference? *Int J Colorectal Dis*. 2015;30(1):57–61.
128. Rasuli P, Doumit J, Boulos M, et al. Factors influencing the yield of mesenteric angiography in lower gastrointestinal hemorrhage. *World J Radiol*. 2014;6(5):218–2.
129. Kim CY, Suhocki PV, Miller Jr MJ, et al. Provocative mesenteric angiography for lower gastrointestinal hemorrhage: results from a single-institution study. *J Vasc Interv Radiol*. 2010;21(4):477–83.
130. Ryan JM, Key SM, Dumbleton DA, et al. Nonlocalized lower gastrointestinal bleeding: provocative bleeding studies with intraarterial tPA, heparin, and tolazoline. *J Vasc Interv Radiol*. 2001;12(11):1273–7.
131. Bloomfield RS, Smith TP, Schneider AM, et al. Provocative angiography in patients with gastrointestinal hemorrhage of obscure origin. *Am J Gastroenterol*. 2000;95(10):2807–12.
132. Darcy M. Treatment of lower gastrointestinal bleeding: vasopressin infusion versus embolization. *J Vasc Interv Radiol*. 2003;14(5):535–43.
133. DeBarros J, Rosas L, Cohen J, et al. The changing paradigm for the treatment of colonic

- hemorrhage: superselective angiographic embolization. *Dis Colon Rectum*. 2002;45(6):802–8.
134. Tan KK, Wong D, Sim R. Superselective embolization for lower gastrointestinal hemorrhage: an institutional review over 7 years. *World J Surg*. 2008;32(12):2707–15.
135. Gillespie CJ, Sutherland AD, Mossop PJ, et al. Mesenteric embolization for lower gastrointestinal bleeding. *Dis Colon Rectum*. 2010;53(9):1258–64.
136. Yi WS, Garg G, Sava JA. Localization and definitive control of lower gastrointestinal bleeding with angiography and embolization. *Am Surg*. 2013;79(4):375–80.
137. Jacovides CL, Nadolski G, Aller SR, et al. Arteriography for lower gastrointestinal hemorrhage: role of preceding abdominal computed tomogram angiography in diagnosis and localization. *JAMA Surg*. 2015;150(7):650–6.
138. Kamalporn P, Cho S, Basset N, et al. Double-balloon enteroscopy following capsule endoscopy in the management of obscure gastrointestinal bleeding: outcome of a combined approach. *Can J Gastroenterol*. 2008;22(5):491–5.
139. Leung WK, Ho SS, Suen BY, et al. Capsule endoscopy or angiography in patients with acute overt obscure gastrointestinal bleeding: a prospective randomized study with long-term follow-up. *Am J Gastroenterol*. 2012;107(9):1370–6.
140. Mönkemüller K, Neumann H, Meyer F. A retrospective analysis of emergency double-balloon enteroscopy for small-bowel bleeding. *Endoscopy*. 2009;41(8):715–7.
141. Mariani G, Pauwels EK, AlSharif A, et al. Radionucleotide evaluation of the lower gastrointestinal tract. *J Nucl Med*. 2008;49(5):776–87.
142. Sfakianakis GN, Haase GM. Abdominal scintigraphy for ectopic gastric mucosa: a retrospective analysis of 143 studies. *Am J Roentgenol*. 1982;138(1):7–12.
143. Lin S, Suhocki PV, Ludwig KA, et al. Gastrointestinal bleeding in adult patients with Meckel's diverticulum: the role of technetium 99m pertechnetate scan. *South Med J*. 2002;95(11):1338–41.
144. Bender JS, Wiencek RG, Bouwman DL. Morbidity and mortality following total abdominal colectomy for massive lower gastrointestinal bleeding. *Am Surg*. 1991;57(8):536–40; discussion 540–1.
145. Plummer JM, Gibson TN, Mitchell DI, et al. Emergency subtotal colectomy for lower gastrointestinal hemorrhage: over-utilised or under-estimated? *Int J Clin Pract*. 2009;63(6):865–8.
146. Farner R, Lichliter W, Kuhn J, et al. Total colectomy versus limited colonic resection for acute lower gastrointestinal bleeding. *Am J Surg*. 1999;178(6):587–91.
147. Britt LG, Warren L, Moore III OF. Selective management of lower gastrointestinal bleeding. *Am Surg*. 1983;49(3):121–5.
148. Parkes BM, Obeid FN, Sorensen VJ, et al. The management of massive lower gastrointestinal bleeding. *Am Surg*. 1993;59(10):676–8.
149. Colacchio TA, Forde KA, Patsos TJ, et al. Impact of modern diagnostic methods on the management of active rectal bleeding. Ten year experience. *Am J Surg*. 1982;143(5):607–10.
150. Gianfrancisco JA, Abcarian H. Pitfalls in the treatment of massive lower gastrointestinal bleeding with “blind” subtotal colectomy. *Dis Colon Rectum*. 1982;25(5):441–5.
151. Baker R, Senagore A. Abdominal colectomy offers safe management for massive lower GI bleed. *Am Surg*. 1994;60(8):578–81; discussion 582.
152. You YN, Chua HK, Nelson H, et al. Segmental vs. extended colectomy: measurable differences in morbidity, function, and quality of life. *Dis Colon Rectum*. 2008;51(7):1036–43.
153. Eaton AC. Emergency surgery for acute colonic haemorrhage—a retrospective study. *Br J Surg*.

1981;68(2):109–12.

154. Drapanas T, Pennington DG, Kappelman M, et al. Emergency subtotal colectomy: preferred approach to management of massively bleeding diverticular disease. *Ann Surg.* 1973;177(5):519–26.

## 第 42 章

1. Hasson HM. Incidence of endometriosis in diagnostic laparoscopy. *J Reprod Med.* 1976;16:135–8.

2. Drake TS, Grunert GM. The unsuspected pelvic factor in the infertility evaluation. *Fertil Steril.* 1980;34:27–31.

3. Houston DE, Noller KL, Melton III J, Selwyn BJ. The epidemiology of pelvic endometriosis. *Clin Obst Gynecol.* 1988;31(4):787–800.

4. Kjerulff KH, Erickson BA, Langenberg PW. Chronic gynecological conditions reported by US women: findings from the National Health Information Survey, 1984 to 1992. *Am J Public Health.* 1996;86:195.

5. Halme J, Stovall D. Endometriosis and its medical management. In: Walch EE, Zacur HA, editors. *Reproductive medicine and surgery.* St. Louis: Mosby; 1995. p. 695–710.

6. Moen MH. Is a long period without childbirth a risk factor for endometriosis? *Hum Reprod.* 1991;6:1404–7.

7. Miyazawa K. Incidence of endometriosis among Japanese women. *Obstet Gynecol.* 1976;48:407–9.

8. Ridley JH. The histogenesis of endometriosis. A review of facts and fancies. *Obstet Gynecol Surv.* 1968;20:1–35.

9. Sampson JA. Perforating hemorrhagic (chocolate) cysts of the ovary, their importance and especially their relation to pelvic adenomas of endometrial type. *Arch Surg.* 1921;3:245–323.

10. Telinde RW, Scott RB. Experimental endometriosis. *Am J Obstet Gynecol.* 1950;60:1147–73.

11. Ridley JH, Edwards KI. Experimental endometriosis in the human. *Am J Obstet Gynecol.* 1958;76:783–90.

12. Simpson JL, Elias S, Malinak LR, Buttram VC. Heritable aspects of endometriosis. 1. Genetic studies. *Am J Obstet Gynecol.* 1980;137:327–31.

13. Dmowski WP, Steele RW, Baker GF. Deficient cellular immunity in endometriosis. *Am J Obstet Gynecol.* 1981;141:377–83.

14. Vigano P, Vercellini P, DiBlasio AM, et al. Deficient anti-endometrium lymphocyte mediated cytotoxicity in patients with endometriosis. *Fertil Steril.* 1991;56:894–99.

15. Oosterlynck DJ, Cornillie FJ, Waer M, et al. Women with endometriosis show a defect in natural killer activity resulting in a decreased cytotoxicity to autologous endometrium. *Fertil Steril.* 1991;56:45–51.

16. Thomas EJ, Cooke ID. Impact of gestrinone on the course of asymptomatic endometriosis. *Br Med J.* 1987;294:272–4.

17. Bergqvist A, Thorbjorn B, Hogstrom L, et al. Effects of triptorelin versus placebo on the symptoms of endometriosis. *Fertil Steril.* 1998;69:702–8.

18. Evers JLH. The second-look laparoscopy for evaluation of the result of medical treatment of

- endometriosis should not be performed during ovarian suppression. *Fertil Steril*. 1987;47:502–4.
19. Vercillini P, Fedele L, Molteni P, et al. Laparoscopy in the diagnosis of gynecologic chronic pelvic pain. *Int J Gynaecol Obstet*. 1990;32:261–65.
  20. Koninckx PR, Meuleman C, Demeyere S, et al. Suggestive evidence that pelvic endometriosis is a progressive disease, whereas deeply infiltrating endometriosis is associated with pelvic pain. *Fertil Steril*. 1991;55:759–65.
  21. Schulman H, Duvivier R, Blattner P. The uterine contractility index: a research and diagnostic tool in dysmenorrhea. *Am J Obstet Gynecol*. 1983;145:1049–58.
  22. Liu DTY, Hitchcock A. Endometriosis: its association with retrograde menstruation, dysmenorrhea and tubal pathology. *Br J Obstet Gynecol*. 1986;93:859–62.
  23. Cornillie FJ, Oosterlynck DJ, Lauweryns J, et al. Deeply infiltrating pelvic endometriosis: histology and clinical significance. *Fertil Steril*. 1990;53:978–93.
  24. Badaway S, Marshall L, Gabal A, et al. The concentration of 13,14-dihydro-15-keto-prostaglandin F2alpha and prostaglandin E2 in peritoneal fluid of infertile patients with and without endometriosis. *Fertil Steril*. 1982;38:166–70.
  25. Dawood M, Khan-Dawood F, Wilson L. Peritoneal fluid prostaglandins and prostanoids in women with endometriosis, chronic pelvic inflammatory disease, and pelvic pain. *Am J Obstet Gynecol*. 1984;148:391–5.
  26. Hull MGR, Glazener CMA, Kelly NJ, et al. Population study of causes, treatment, and outcome of infertility. *Brit Med J*. 1985;291:1693–7.
  27. Fortier KJ, Haney AF. The pathologic spectrum of uterotubal junction obstruction. *Obstet Gynecol*. 1985;65:93–8.
  28. Buttram Jr VC, Reiter RC. Endometriosis. In: Buttram Jr VC, Reiter RC, editors. *Surgical treatment of the infertile female*. Baltimore: Williams & Wilkins; 1985. p. 89–148.
  29. Garcia CR, David SS. Pelvic endometriosis: infertility and pelvic pain. *Am J Obstet Gynecol*. 1977;129:740–7.
  30. Inoue M, Kobayshi Y, Honda I, et al. The impact of endometriosis on the reproductive outcome of infertile patients. *Am J Obstet Gynecol*. 1992;167:278–82.
  31. Jansen RPS. Minimal endometriosis and reduced fecundability: prospective evidence from an artificial insemination by donor program. *Fertil Steril*. 1986;46:141–3.
  32. Malbrouk M, Ferrini G, Montanari G, et al. Does colo-rectal endometriosis alter intestinal functions? A prospective manometric and questionnaire-based study. *Fertil Steril*. 2012;97:652–6.
  33. Floberg J, Backdahl M, Silfersward C, et al. Postpartum perforation of the colon due to endometriosis. *Acta Obstet Gynecol Scand*. 1984;63:183–4.
  34. Prystowsky JB, Stryker SJ, Ujiki GT, Poticha SM. Gastrointestinal endometriosis. *Arch Surg*. 1988;123:855–8.
  35. Somigliana E, Vigano P, Parradini F, et al. Association between endometriosis and cancer: a comprehensive review and a critical analysis of clinical and epidemiological evidence. *Gynecol Oncol*. 2006;101:331–41.
  36. Ness RB. Endometriosis and ovarian cancer: thoughts on shared pathophysiology. *Am J Obstet Gynecol*. 2003;189:280–94.
  37. Aure JC, Hoeg K, Kolstad P. Carcinoma of the ovary and endometriosis. *Acta Obstet Gynecol Scand*. 1971;50:63–7.
  38. Modugno F, Ness RB, Allen GP, et al. Oral contraceptive use, reproductive history. And risk of

epithelial ovarian cancer in women with and without endometriosis. *Am J Obstet Gynecol.* 2004;191:733–40.

39. Yantiss RK, Clement PB, Young RH. Neoplastic and pre-neoplastic changes in gastrointestinal endometriosis. *Am J Surg Pathol.* 2000;24:513–24.

40. Kennedy SH, Starkey PM, Sargent I, et al. Anti-endometrial antibodies in endometriosis measured by an enzyme-linked immunosorbent assay before and after treatment with danazol and nafarelin. *Obstet Gynecol.* 1990;75:914–7.

41. Chapron C, Dumontier I, Dousset B, et al. Results and role of rectal endoscopic ultrasonography for patients with deep pelvic endometriosis. *Hum Reprod.* 1998;13:2266–70.

42. Doniec JM, Kahlke V, Peetz F, et al. Rectal endometriosis: high sensitivity and specificity of endorectal ultrasound with an impact for the operative management. *Dis Colon Rectum.* 2003;46:1667–73.

43. Bazot M, Darai E, Hourani R, et al. Deep pelvic endometriosis: MR imaging for diagnosis and prediction of extension of disease. *Radiology.* 2004;232:379–89.

44. Kinkel K, Chapron C, Balleyguier C, et al. Magnetic resonance imaging characteristics of deep endometriosis. *Hum Reprod.* 1999;14:1080–6.

45. Kennedy SH, Soper ND, Mojiminiyi OA. Immunoscintigraphy of endometriosis. A preliminary study. *Br J Obstet Gynecol.* 1988;95:693–7.

46. Buchweitz O, Poel T, Diedrich K, et al. The diagnostic dilemma of minimal and mild endometriosis under routine conditions. *J Am Assoc Gynecol Laparosc.* 2003;10(1):85–9.

47. Kennedy S, Bergqvist A, Chapron C, et al. ESHRE guideline for the diagnosis and treatment of endometriosis. *Hum Reprod.* 2004;20(10):2698–704.

48. Vasquez G, Cornillie FJ, Brosens IO. Peritoneal endometriosis: scanning electron microscopy in visually normal peritoneum. *Fertil Steril.* 1986;42:696–703.

49. American Society for Reproductive Medicine. Revised American Society for Reproductive Medicine classification of endometriosis: 1996. *Fertil Steril.* 1997;67:817–21.

50. Donnez J, Nisolle M, Casanas-Roux F, et al. Stereometric evaluation of peritoneal endometriosis and endometriotic nodules of the rectovaginal septum. *Hum Reprod.* 1995;11:224–8.

51. Koninckx PR. Deeply infiltrating endometriosis. In: Brosens I, Donnez J, editors. *Endometriosis: research and management.* Carnforth: Parthenon; 1993. p. 437–46.

52. Martin DC, Hubert GD, Van der Zwaag R, et al. Laparoscopic appearances of peritoneal endometriosis. *Fertil Steril.* 1989;51:63–7.

53. Koninckx PR, Martin DC. Deep endometriosis: a consequence of infiltration or retraction or possibly adenomyosis externa? *Fertil Steril.* 1992;58:924–8.

54. Hall LH, Malone JM, Ginsburg KA. Flare-up of endometriosis induced by gonadotropin-releasing hormone agonist leading to bowel obstruction. *Fertil Steril.* 1995;64:1204–6.

55. Schindler AE. Gonadotropin-releasing hormone agonists for prevention of postoperative adhesions: an overview. *Gynecol Endocrinol.* 2004;19:51–5.

56. Dmowski WP, Gebel H, Braun DP. The role of cell mediated immunity in pathogenesis of endometriosis. *Acta Obstet Gynecol Scand.* 1994;159(S):7–14.

57. Noble AD, Letchworth AT. Medical treatment of endometriosis: a comparative trial. *Postgrad Med J.* 1979;55:37–9.

58. Knitte JD, Wheeler JM, Miller JD. Depot Leuprolide versus danazol in treatment of women with symptomatic endometriosis. *Am J Obstet Gynecol.* 1992;167:1367–71.

59. Raffi F, Amer S. Endometriosis. *Obstet Gynecol Rep Med*. 2010;21(4):112–7.
60. Yap V, Furness S, Farquahar C. Pre and post operative medical therapy for endometriosis surgery *Cochrane Database Syst Rev*. 2004;3. CD003678.
61. Soysal S, Soysal ME, Ozer S, et al. The effects of post-surgical administration of goserelin plus anastrozole compared to goserelin alone in patients with severe endometriosis: a prospective randomized trial. *Hum Reprod*. 2004;19:160–7.
62. Vercellini P, Somigliana E, Vigano P, et al. Endometriosis: current and future medical therapies. *Best Pract Res Clin Obstet Gynecol*. 2008;22(2):275–306.
63. Donnez J, Squifflet J. Complications, pregnancy and recurrence in a prospective series of 500 patients operated on by the shaving technique for deep rectovaginal endometriotic nodules. *Hum Reprod*. 2010;25(8):1949–58.
64. Vercellini P, Aimi G, Panazza S, et al. A gonadotropin-releasing hormone agonist versus a low-dose oral contraceptive for pelvic pain associated with endometriosis. *Fertil Steril*. 1992;60:75–9.
65. Dmowski WP, Radwanska E, Rana N. Recurrent endometriosis following hysterectomy and oophorectomy: the role of residual ovarian fragments. *Int J Obstet*. 1988;26:93–103.
66. Stepniewska A, Pomini P, Bruni F, et al. Laparoscopic treatment of bowel endometriosis in infertile women. *Hum Reprod*. 2009;24(7):1619–25.
67. Vercellini P, Somigliana E, Vigano P, et al. The effect of second-line surgery on reproductive performance of women with recurrent endometriosis: a systematic review. *Acta Obstet Gynecol Scand*. 2009;88(10):1074–82.
68. Wattiez A, Puga M, Albornoz J, et al. Surgical strategy in endometriosis. *Best Pract Res Clin Obstet Gynecol*. 2013;27(3):381–92.
69. Fanfani F, Fagotti A, Gagliardi ML, et al. Segmental rectosigmoid resection for deep infiltrating endometriosis: a case-control study. *Fertil Steril*. 2010;94(2):444–9.
70. Landi S, Pontrelli G, Surico D, et al. Laparoscopic disk resection for bowel endometriosis using a circular stapler and a new endoscopic method to control postoperative bleeding from the stapler line. *J Am Coll Surg*. 2008;207(2):205–9.
71. Redwine DB. Endometriosis persisting after castration: clinical characteristics and results of surgical management. *Obstet Gynecol*. 1994;83:405–13.
72. Nezhat C, Pennington E, Nezhat F, Silfen SL. Laparoscopically assisted anterior rectal wall resection and reanastomosis for deeply infiltrating endometriosis. *Surg Laparosc Endosc*. 1991;1:106–8.
73. Redwine DB, Koning M, Sharpe DR. Laparoscopically assisted transvaginal segmental resection of the rectosigmoid colon for endometriosis. *Fertil Steril*. 1996;65:193–7.
74. Dupree HJ, Senagore AJ, Delaney CP, et al. Laparoscopic resection of deep pelvic endometriosis with rectosigmoid involvement. *J Am Coll Surg*. 2002;195:754–58.
75. Olive DL, Lee KL. Analysis of sequential treatment protocols for endometriosis-associated infertility. *Am J Obstet Gynecol*. 1986;154:613.
76. Wheeler JM, Malinak LR. Recurrent endometriosis. *Contr Gynecol Obstet*. 1987;16:13–21.
77. Bailey HR, Ott MT, Hartendorp P. Aggressive surgical management for advanced colorectal endometriosis. *Dis Colon Rectum*. 1994;37:747–53.
78. Buttram VC, Reiter RC, Ward SM. Treatment of endometriosis with Danazol: Report of a six year prospective study. *Fertil Steril*. 1985;43:353.

## 第 43 章

1. Demetriades D, Velmahos G, Cornwell III E, et al. Selective nonoperative management of gunshot wounds to the anterior abdomen. *Arch Surg*. 1997;132(2):178–83.
2. Ross SE, Cobean RA, Hoyt DB, et al. Blunt colonic injury—a multicenter review. *J Trauma*. 1992;33(3):379–84.
3. Moore EE, Cogbill TH, Malangoni MA, et al. Organ injury scaling II, pancreas, duodenum, small bowel, colon, and rectum. *J Trauma*. 1990;30(11):1427–9.
4. Velmahos GC, Constantinou C, Tillou A, et al. Abdominal computed tomographic scan for patients with gunshot wounds to the abdomen selected for nonoperative management. *J Trauma*. 2005;50(5):1155–60.
5. Root HD, Hauser CW, McKinley CR. Diagnostic peritoneal lavage. *Surgery*. 1965;57(6):633–8.
6. Perry WB, Brooks JP, Muskat PC. The history of military colorectal trauma management. *Semin Colon Rectal Surg*. 2004;15(2):70–9.
7. Wallace G. War surgery of the abdomen, lecture I. *Lancet*. 1917;ii:571–8.
8. Bamberger PK. The adoption of laparotomy for the treatment of penetrating abdominal wounds in war. *Military Med*. 1996;161(1):189–96.
9. Ogilvie WH. Abdominal wounds in the Western Desert. *Surg Gyn Obst*. 1994;78(2):225–38.
10. Office of the Surgeon General. Circular Letter No. 178. October 23, 1943.
11. Ventrees A, Wakefield M, Pickett C, et al. Outcomes of primary repair and primary anastomosis in war-related colon injuries. *J Trauma*. 2009;66(6):1286–93.
12. Glasgow SC, Steele SR, Duncan JE, et al. Epidemiology of modern battlefield colorectal trauma: a review of 977 coalition casualties. *J Trauma Acute Care Surg*. 2012;73(6):S503–8.
13. Woodhall JP, Ochsner A. The management of perforating injuries of the colon and rectum. *Surgery*. 1951;29(2):305–20.
14. Stone HH, Fabian TC. Management of perforating colon trauma: randomization between primary closure and exteriorization. *Ann Surg*. 1979;190(4):430–6.
15. Chappuis CW, Frey DJ, Deitzen CD, et al. Management of penetrating colon injuries. A prospective randomized trial. *Ann Surg*. 1991;213(5):492–7.
16. Sasaki LS, Allaben RD, Golwala R, et al. Primary repair of colon injuries: a prospective randomized study. *J Trauma*. 1995;39(5):895–901.
17. Gonzalez PR, Falimirski ME, Holeyvar MR. Further evaluation of colostomy in penetrating colon injury. *Am Surg*. 2000;66(4):342–6.
18. Cornwell III E, Velmahos G, Berne TV, et al. The fate of colonic suture lines in high-risk trauma patients: a prospective analysis. *J Am Coll Surg*. 1998;187(1):58–63.
19. Stewart RM, Fabian TC, Croce MA, et al. Is resection and primary anastomosis following destructive colon wounds always safe? *Am J Surg*. 1994;168(4):316–9.
20. Murray JA, Demetriades D, Colson M, et al. Colonic resection in trauma: colostomy vs. anastomosis. *J Trauma*. 1999;46(2):250–4.
21. Demetriades D, Murray JA, Chan L, et al. Penetrating colon injuries requiring resection: diversion or anastomosis? An AAST prospective multicenter study. *J Trauma*. 2001;50(5):765–75.
22. Sharpe JP, Magnotti LJ, Weinberg JA, et al. Adherence to a simplified management algorithm reduces morbidity and mortality after penetrating colon injuries: a 15-year experience. *J Am Coll*

Surg. 2012;214(4):591–7.

23. Crookes B. An evidence-based approach to damage control laparotomy for trauma. In: Cohn SM, editor. *Acute care surgery and trauma: evidence based practice*. 1st ed. London: Informa; 2009.
24. Miller PR, Chang MC, Hoth JJ. Colonic resection in the setting of damage control laparotomy: is delayed anastomosis safe? *Am Surg*. 2007;73(6):606–9.
25. Georgoff P, Perales P, Laguna B, et al. Colonic injuries and the damage control abdomen: does management strategy matter? *J Surg Res*. 2013;181(2):293–9.
26. Kashuk JL, Cothren CC, Moore EE, et al. Primary repair of civilian colon injuries is safe in the damage control scenario. *Surgery*. 2009;146(6):663–70.
27. Weinberg JA, Griffin RL, Vandromme MJ, et al. Management of colon wounds in the setting of damage control laparotomy: a cautionary tale. *J Trauma*. 2009;67(4):929–35.
28. Fischer PE, Nunn AM, Wormer BA, et al. Vasopressor use after initial damage control laparotomy increases risk for anastomotic disruption in the management of destructive colon injuries. *Am J Surg*. 2013;206(6):900–3.
29. Sharpe JP, Magnotti LJ, Weinberg JA, et al. Adherence to an established management algorithm for destructive colon injuries after abbreviated laparotomy: a 17-year experience. *J Am Coll Surg*. 2014;218(4):636–43.
30. Ciesla DJ, Burch JM. Colon and rectal injuries. In: Asensio JA, Trunkey DD, editors. *Current therapy of trauma and surgical critical care*. 1st ed. Philadelphia: Mosby Elsevier; 2008.
31. Law WL, Bailey HR, Max E, et al. Single layer continuous colon and rectal anastomosis using monofilament absorbable suture (Maxon): study of 500 cases. *Dis Colon Rectum*. 1999;42(6):736–40.
32. Demetriades D, Murray JA, Chan LS, et al. Hand sewn versus stapled anastomosis in penetrating colon injuries requiring resection: a multicenter study. *J Trauma*. 2002;52(1):117–21.
33. Morken JJ, Kraatz JJ, Balcos EG, et al. Civilian rectal trauma: a changing perspective. *Surgery*. 1999;126(4):693–8.
34. Velmahos GC, Gomez H, Falabella A, et al. Operative management of civilian rectal gunshot wounds: simpler is better. *World J Surg*. 2000;24(1):114–8.
35. Ivatury RR, Licata J, Gunduz Y, et al. Management options in penetrating rectal injuries. *Am Surg*. 1991;57(1):50–5.
36. Anderson SW, Soto JA. Anorectal trauma: the use of computed tomography in diagnosis. *Semin Ultrasound CT MR*. 2008;29(6):472–82.
37. Lavenson GS, Cohen A. Management of rectal injuries. *Am J Surg*. 1971;122(2):226–30.
38. Siler VE, Bebb K. Trauma to the perineum, anus, rectum, and colon. *Am J Surg*. 1950;80(4):652–62.
39. McCune WS. War wounds of the rectum and anal sphincter. *Surgery*. 1948;23(4):653–64.
40. Mossadegh S, Tai N, Midwinter M, et al. Improvised explosive device related pelvi-perineal trauma: anatomic injuries and surgical management. *J Trauma Acute Care Surg*. 2012;73(2 Suppl 1):S24–31.
41. Glasgow SC, Heafner TA, Watson JDB, et al. Initial management and outcome of modern battlefield anal trauma. *Dis Colon Rectum*. 2014;57(8):1012–8.
42. Levine JH, Longo WE, Pruitt C, et al. Management of selected rectal injuries by primary repair. *Am J Surg*. 1996;172(5):575–8.
43. Navsaria PH, Shaw JM, Zellweger R, et al. Diagnostic laparoscopy and diverting sigmoid loop



colostomy in the management of civilian extraperitoneal rectal gunshot injuries. *Br J Surg*. 2004;91(4):460–4.

44. Davit FE, Schafer GP, Po RP, et al. Open pelvic fracture and rectal injury managed with abdominoperineal resection. *Am Surg*. 2010;76:E15–6.

45. Gonzalez RP, Falimirski ME, Holevar MR. The role of presacral drainage in the management of penetrating rectal injuries. *J Trauma*. 1998;45(4):656–61.

## 第 44 章

1. Wilks S. Morbid appearances in the intestines of Miss Bankes. *Med Times Gazette*. 1859;2:264–5.

2. Crohn BB, Ginzburg L, Oppenheimer GD. Landmark article Oct 15, 1932. Regional ileitis. A pathological and clinical entity. By Burril B. Crohn, Leon Ginzburg, and Gordon D. Oppenheimer. *JAMA*. 1984;251(1):73–9.

3. Koltun WA. IBD: diagnosis and evaluation. In: Beck DE, Roberts PL, Saclarides TJ, editors. *The ASCRS textbook of colon and rectal surgery*. 2nd ed. New York: Springer; 2011. p. 449–62.

4. Cho JH, Brant SR. Recent insights into the genetics of inflammatory bowel disease. *Gastroenterology*. 2011;140(6):1704–12.

5. Ponder A, Long MD. A clinical review of recent findings in the epidemiology of inflammatory bowel disease. *Clin Epidemiol*. 2013;5:237–47.

6. Mahmud N, Weir DG. The urban diet and Crohn's disease: is there a relationship? *Eur J Gastroenterol Hepatol*. 2001;13(2):93–5.

7. Hou JK, El-Serag H, Thirumurthi S. Distribution and manifestations of inflammatory bowel disease in Asians, Hispanics, and African Americans: a systematic review. *Am J Gastroenterol*. 2009;104(8):2100–9.

8. Ahmad T, Satsangi J, McGovern D, Bunce M, Jewell DP. Review article: the genetics of inflammatory bowel disease. *Aliment Pharmacol Ther*. 2001;15(6):731–48.

9. Soon IS, Molodecky NA, Rabi DM, Ghali WA, Barkema HW, Kaplan GG. The relationship between urban environment and the inflammatory bowel diseases: a systematic review and meta-analysis. *BMC Gastroenterol*. 2012;12:51.

10. Economou M, Pappas G. New global map of Crohn's disease: Genetic, environmental, and socioeconomic correlations. *Inflamm Bowel Dis*. 2008;14(5):709–20.

11. Bernstein CN, Shanahan F. Disorders of a modern lifestyle: reconciling the epidemiology of inflammatory bowel diseases. *Gut*. 2008;57(9):1185–91.

12. Prideaux L, Kamm MA, De Cruz PP, Chan FK, Ng SC. Inflammatory bowel disease in Asia: a systematic review. *J Gastroenterol Hepatol*. 2012;27(8):1266–80.

13. Molodecky NA, Soon IS, Rabi DM, et al. Increasing incidence and prevalence of the inflammatory bowel diseases with time, based on systematic review. *Gastroenterology*. 2012;142(1):46–54. e42; quiz e30.

14. Roth MP, Petersen GM, McElree C, Feldman E, Rotter JI. Geographic origins of Jewish patients with inflammatory bowel disease. *Gastroenterology*. 1989;97(4):900–4.

15. Greenstein RJ. Is Crohn's disease caused by a mycobacterium? Comparisons with leprosy, tuberculosis, and Johne's disease. *Lancet Infect Dis*. 2003;3(8):507–14.

16. Wagner J, Sim WH, Lee KJ, Kirkwood CD. Current knowledge and systematic review of viruses associated with Crohn's disease. *Rev Med Virol.* 2013;23(3):145–71.
17. Strober W. Adherent-invasive *E. coli* in Crohn disease: bacterial “agent provocateur”. *J Clin Invest.* 2011;121(3):841–4.
18. Rutgeerts P, Goobes K, Peeters M, et al. Effect of faecal stream diversion on recurrence of Crohn's disease in the neoterminal ileum. *Lancet.* 1991;338(8770):771–4.
19. Marks DJ, Rahman FZ, Sewell GW, Segal AW. Crohn's disease: an immune deficiency state. *Clin Rev Allergy Immunol.* 2010;38(1):20–31.
20. Danese S, Fiocchi C. Ulcerative colitis. *N Engl J Med.* 2011;365(18):1713–25.
21. Targan SR. The utility of ANCA and ASCA in inflammatory bowel disease. *Inflamm Bowel Dis.* 1999;5(1):61–3. discussion 66–67.
22. Bernstein CN, Rawsthorne P, Cheang M, Blanchard JF. A population-based case control study of potential risk factors for IBD. *Am J Gastroenterol.* 2006;101(5):993–1002.
23. Cottone M, Rosselli M, Orlando A, et al. Smoking habits and recurrence in Crohn's disease. *Gastroenterology.* 1994;106(3):643–8.
24. Sutherland LR, Ramcharan S, Bryant H, Fick G. Effect of cigarette smoking on recurrence of Crohn's disease. *Gastroenterology.* 1990;98(5 Pt 1):1123–8.
25. Reese GE, Nanidis T, Borysiewicz C, Yamamoto T, Orchard T, Tekkis PP. The effect of smoking after surgery for Crohn's disease: a meta-analysis of observational studies. *Int J Colorectal Dis.* 2008;23(12):1213–21.
26. Birrenbach T, Bocker U. Inflammatory bowel disease and smoking: a review of epidemiology, pathophysiology, and therapeutic implications. *Inflamm Bowel Dis.* 2004;10(6):848–59.
27. Abraham C, Cho JH. Inflammatory bowel disease. *N Engl J Med.* 2009;361(21):2066–78.
28. Calkins BM. A meta-analysis of the role of smoking in inflammatory bowel disease. *Dig Dis Sci.* 1989;34(12):1841–54.
29. Mahid SS, Minor KS, Soto RE, Hornung CA, Galandiuk S. Smoking and inflammatory bowel disease: a meta-analysis. *Mayo Clin Proc.* 2006;81(11):1462–71.
30. Ananthakrishnan AN, Higuchi LM, Huang ES, et al. Aspirin, nonsteroidal anti-inflammatory drug use, and risk for Crohn disease and ulcerative colitis: a cohort study. *Ann Intern Med.* 2012;156(5):350–9.
31. Felder JB, Korelitz BI, Rajapakse R, Schwarz S, Horatagis AP, Gleim G. Effects of nonsteroidal antiinflammatory drugs on inflammatory bowel disease: a case-control study. *Am J Gastroenterol.* 2000;95(8):1949–54.
32. O'Brien J. Nonsteroidal anti-inflammatory drugs in patients with inflammatory bowel disease. *Am J Gastroenterol.* 2000;95(8):1859–61.
33. Morgan XC, Tickle TL, Sokol H, et al. Dysfunction of the intestinal microbiome in inflammatory bowel disease and treatment. *Genome Biol.* 2012;13(9):R79.
34. Takeuchi K, Smale S, Premchand P, et al. Prevalence and mechanism of nonsteroidal anti-inflammatory drug-induced clinical relapse in patients with inflammatory bowel disease. *Clin Gastroenterol Hepatol.* 2006;4(2):196–202.
35. Bernstein CN, Singh S, Graff LA, Walker JR, Miller N, Cheang M. A prospective population-based study of triggers of symptomatic flares in IBD. *Am J Gastroenterol.* 2010;105(9):1994–2002.
36. Bonner GF, Walczak M, Kitchen L, Bayona M. Tolerance of nonsteroidal antiinflammatory drugs in patients with inflammatory bowel disease. *Am J Gastroenterol.* 2000;95(8):1946–8.

37. Olszak T, An D, Zeissig S, et al. Microbial exposure during early life has persistent effects on natural killer T cell function. *Science*. 2012;336(6080):489–93.
38. Summers RW, Elliott DE, Urban Jr JF, Thompson R, Weinstock JV. *Trichuris suis* therapy in Crohn's disease. *Gut*. 2005;54(1):87–90.
39. Garg SK, Croft AM, Bager P. Helminth therapy (worms) for induction of remission in inflammatory bowel disease. *Cochrane Database Syst Rev*. 2014;1:CD009400.
40. Binder V. Genetic epidemiology in inflammatory bowel disease. *Dig Dis*. 1998;16(6):351–5.
41. Probert CS, Jayanthi V, Pinder D, Wicks AC, Mayberry JF. Epidemiological study of ulcerative proctocolitis in Indian migrants and the indigenous population of Leicestershire. *Gut*. 1992;33(5):687–93.
42. Montgomery SM, Morris DL, Pounder RE, Wakefield AJ. Asian ethnic origin and the risk of inflammatory bowel disease. *Eur J Gastroenterol Hepatol*. 1999;11(5):543–6.
43. Frank DN, St Amand AL, Feldman RA, Boedeker EC, Harpaz N, Pace NR. Molecular-phylogenetic characterization of microbial community imbalances in human inflammatory bowel diseases. *Proc Natl Acad Sci U S A*. 2007;104(34):13780–5.
44. Manichanh C, Rigottier-Gois L, Bonnaud E, et al. Reduced diversity of faecal microbiota in Crohn's disease revealed by a metagenomic approach. *Gut*. 2006;55(2):205–11.
45. Sokol H, Seksik P, Furet JP, et al. Low counts of *Faecalibacterium prausnitzii* in colitis microbiota. *Inflamm Bowel Dis*. 2009;15(8):1183–9.
46. Hviid A, Svanstrom H, Frisch M. Antibiotic use and inflammatory bowel diseases in childhood. *Gut*. 2011;60(1):49–54.
47. Kronman MP, Zaoutis TE, Haynes K, Feng R, Coffin SE. Antibiotic exposure and IBD development among children: a population-based cohort study. *Pediatrics*. 2012;130(4):e794–803.
48. Shaw SY, Blanchard JF, Bernstein CN. Association between the use of antibiotics in the first year of life and pediatric inflammatory bowel disease. *Am J Gastroenterol*. 2010;105(12):2687–92.
49. Virta L, Auvinen A, Helenius H, Huovinen P, Kolho KL. Association of repeated exposure to antibiotics with the development of pediatric Crohn's disease—a nationwide, register-based finnish case-control study. *Am J Epidemiol*. 2012;175(8):775–84.
50. Ghouri YA, Richards DM, Rahimi EF, Krill JT, Jelinek KA, DuPont AW. Systematic review of randomized controlled trials of probiotics, prebiotics, and synbiotics in inflammatory bowel disease. *Clin Exp Gastroenterol*. 2014;7:473–87.
51. Colman RJ, Rubin DT. Fecal microbiota transplantation as therapy for inflammatory bowel disease: a systematic review and meta-analysis. *J Crohn's Colitis*. 2014;8(12):1569–81.
52. Rehman A, Rausch P, Wang J, et al. Geographical patterns of the standing and active human gut microbiome in health and IBD. *Gut*. Jan 7 2015; pii: gutjnl-2014-308341. doi: 10.1136/gutjnl-2014-308341.
53. Knights D, Silverberg MS, Weersma RK, et al. Complex host genetics influence the microbiome in inflammatory bowel disease. *Genome Med*. 2014;6(12):107.
54. Kaplan GG, Jackson T, Sands BE, Frisch M, Andersson RE, Korzenik J. The risk of developing Crohn's disease after an appendectomy: a meta-analysis. *Am J Gastroenterol*. 2008;103(11):2925–31.
55. Russel MG, Dorant E, Brummer RJ, et al. Appendectomy and the risk of developing ulcerative colitis or Crohn's disease: results of a large case-control study. *South Limburg Inflammatory Bowel Disease Study Group. Gastroenterology*. 1997;113(2):377–82.

56. Koutroubakis IE, Vlachonikolis IG. Appendectomy and the development of ulcerative colitis: results of a metaanalysis of published case-control studies. *Am J Gastroenterol*. 2000;95(1):171–6.
57. Frisch M, Pedersen BV, Andersson RE. Appendicitis, mesenteric lymphadenitis, and subsequent risk of ulcerative colitis: cohort studies in Sweden and Denmark. *BMJ*. 2009;338:b716.
58. Farmer RG, Michener WM, Mortimer EA. Studies of family history among patients with inflammatory bowel disease. *Clin Gastroenterol*. 1980;9(2):271–7.
59. Peeters M, Nevens H, Baert F, et al. Familial aggregation in Crohn's disease: increased age-adjusted risk and concordance in clinical characteristics. *Gastroenterology*. 1996;111(3):597–603.
60. Colombel JF, Grandbastien B, Gower-Rousseau C, et al. Clinical characteristics of Crohn's disease in 72 families. *Gastroenterology*. 1996;111(3):604–7.
61. Satsangi J, Grootsholten C, Holt H, Jewell DP. Clinical patterns of familial inflammatory bowel disease. *Gut*. 1996;38(5):738–41.
62. Bayless TM, Tokayer AZ, Polito II JM, Quaskey SA, Mellits ED, Harris ML. Crohn's disease: concordance for site and clinical type in affected family members—potential hereditary influences. *Gastroenterology*. 1996;111(3):573–9.
63. Russell RK, Satsangi J. Does IBD run in families? *Inflamm Bowel Dis*. 2008;14 Suppl 2:S20–1.
64. Halme L, Paavola-Sakki P, Turunen U, Lappalainen M, Farkkila M, Kontula K. Family and twin studies in inflammatory bowel disease. *World J Gastroenterol*. 2006;12(23):3668–72.
65. Parkes M, Jewell D. Ulcerative colitis and Crohns disease: molecular genetics and clinical implications. *Expert Rev Mol Med*. 2001;2001:1–18.
66. Cho JH, Abraham C. Inflammatory bowel disease genetics: Nod2. *Ann Rev Med*. 2007;58:401–16.
67. Dawn Teare M, Barrett JH. Genetic linkage studies. *Lancet*. 2005;366(9490):1036–44.
68. Bentley DR. The human genome project—an overview. *Med Res Rev*. 2000;20(3):189–96.
69. The International Hapmap Project. 2014; [http://hapmap.ncbi.nlm.nih.gov/cgi-perl/gbrowse/hapmap27\\_B36/#search](http://hapmap.ncbi.nlm.nih.gov/cgi-perl/gbrowse/hapmap27_B36/#search). Accessed 1 June 2014.
70. Budarf ML, Labbe C, David G, Rioux JD. GWA studies: rewriting the story of IBD. *Trends Genet*. 2009;25(3):137–46.
71. Ishihara S, Aziz MM, Yuki T, Kazumori H, Kinoshita Y. Inflammatory bowel disease: review from the aspect of genetics. *J Gastroenterol*. 2009;44(11):1097–108.
72. Xavier RJ, Rioux JD. Genome-wide association studies: a new window into immune-mediated diseases. *Nat Rev Immunol*. 2008;8(8):631–43.
73. National Human Genome Research Institute NIOH. <http://www.genome.gov/sequencingcosts/>. Accessed 1 June 2014.
74. Mardis ER. A decade's perspective on DNA sequencing technology. *Nature*. 2011;470(7333):198–203.
75. Lee JC, Parkes M. 100 genes for IBD... whatever next!? *Inflamm Bowel Dis*. 2011;11(3):103–11.
76. Jostins L, Ripke S, Weersma RK, et al. Host-microbe interactions have shaped the genetic architecture of inflammatory bowel disease. *Nature*. 2012;491(7422):119–24.
77. Santaolalla R, Abreu MT. Innate immunity in the small intestine. *Curr Opin Gastroenterol*. 2012;28(2):124–9.
78. Cader MZ, Kaser A. Recent advances in inflammatory bowel disease: mucosal immune cells in

intestinal inflammation. *Gut*. 2013;62(11):1653–64.

79. Petersen HJ, Smith AM. The role of the innate immune system in granulomatous disorders. *Front Immunol*. 2013;4:120.

80. Wehkamp J, Stange EF. Paneth's disease. *J Crohn's Colitis*. 2010;4(5):523–31.

81. Hering NA, Fromm M, Schulzke JD. Determinants of colonic barrier function in inflammatory bowel disease and potential therapeutics. *J Physiol*. 2012;590(Pt 5):1035–44.

82. Schreiber S, Rosenstiel P, Albrecht M, Hampe J, Krawczak M. Genetics of Crohn disease, an archetypal inflammatory barrier disease. *Nat Rev Genet*. 2005;6(5):376–88.

83. Lucas K, Maes M. Role of the Toll like receptor (TLR) radical cycle in chronic inflammation: possible treatments targeting the TLR4 pathway. *Mol Neurobiol*. 2013;48(1):190–204.

84. Cario E. Toll-like receptors in inflammatory bowel diseases: a decade later. *Inflamm Bowel Dis*. 2010;16(9):1583–97.

85. Nys K, Agostinis P, Vermeire S. Autophagy: a new target or an old strategy for the treatment of Crohn's disease? *Nat Rev Gastroenterol Hepatol*. 2013;10(7):395–401.

86. Stappenbeck TS, Rioux JD, Mizoguchi A, et al. Crohn disease: a current perspective on genetics, autophagy and immunity. *Autophagy*. 2011;7(4):355–74.

87. Eksteen B, Liaskou E, Adams DH. Lymphocyte homing and its role in the pathogenesis of IBD. *Inflamm Bowel Dis*. 2008;14(9):1298–312.

88. Mann ER, McCarthy NE, Peake ST, et al. Skin- and gut-homing molecules on human circulating gammadelta T cells and their dysregulation in inflammatory bowel disease. *Clin Exp Immunol*. 2012;170(2):122–30.

89. Koizumi M, King N, Lobb R, Benjamin C, Podolsky DK. Expression of vascular adhesion molecules in inflammatory bowel disease. *Gastroenterology*. 1992;103(3):840–7.

90. Janse M, Lamberts LE, Franke L, et al. Three ulcerative colitis susceptibility loci are associated with primary sclerosing cholangitis and indicate a role for IL2, REL, and CARD9. *Hepatology*. 2011;53(6):1977–85.

91. Farache J, Zigmond E, Shakhar G, Jung S. Contributions of dendritic cells and macrophages to intestinal homeostasis and immune defense. *Immunol Cell Biol*. 2013;91(3):232–9.

92. Cho JH. The genetics and immunopathogenesis of inflammatory bowel disease. *Nat Rev Immunol*. 2008;8(6):458–66.

93. Bouma G, Strober W. The immunological and genetic basis of inflammatory bowel disease. *Nat Rev Immunol*. 2003;3(7):521–33.

94. Plevy SE, Targan SR. Future therapeutic approaches for inflammatory bowel diseases. *Gastroenterology*. 2011;140(6):1838–46.

95. Brand S. Crohn's disease: Th1, Th17 or both? The change of a paradigm: new immunological and genetic insights implicate Th17 cells in the pathogenesis of Crohn's disease. *Gut*. 2009;58(8):1152–67.

96. Poritz LS, Harris III LR, Kelly AA, Koltun WA. Increase in the tight junction protein claudin-1 in intestinal inflammation. *Dig Dis Sci*. 2011;56(10):2802–9. doi: 10.1007/s10620-011-1688-9. Epub 2011 Jul 12.

97. McCole DF. IBD candidate genes and intestinal barrier regulation. *Inflamm Bowel Dis*. 2014;20(10):1829–49.

98. Vivinus-Nebot M, Frin-Mathy G, Bziouche H, et al. Functional bowel symptoms in quiescent inflammatory bowel diseases: role of epithelial barrier disruption and low-grade inflammation. *Gut*.

2014;63(5):744–52.

99. Waterman M, Xu W, Stempak JM, et al. Distinct and overlapping genetic loci in Crohn's disease and ulcerative colitis: correlations with pathogenesis. *Inflamm Bowel Dis*. 2011;17(9):1936–42.

100. Biancheri P, Di Sabatino A, Rovedatti L, et al. Effect of tumor necrosis factor- $\alpha$  blockade on mucosal addressin cell-adhesion molecule-1 in Crohn's disease. *Inflamm Bowel Dis*. 2013;19(2):259–64.

101. Niess JH. Role of mucosal dendritic cells in inflammatory bowel disease. *World J Gastroenterol*. 2008;14(33):5138–48.

102. Ueno A, Jijon H, Traves S, et al. Opposing effects of smoking in ulcerative colitis and Crohn's disease may be explained by differential effects on dendritic cells. *Inflamm Bowel Dis*. 2014;20(5):800–10.

103. Wenzel UA, Magnusson MK, Rydstrom A, et al. Spontaneous colitis in muc2-deficient mice reflects clinical and cellular features of active ulcerative colitis. *PloS one*. 2014;9(6), e100217.

104. Dorofeyev AE, Vasilenko IV, Rassokhina OA, Kondratiuk RB. Mucosal barrier in ulcerative colitis and Crohn's disease. *Gastroenterol Res Pract*. 2013;2013:431231.

105. Van Limbergen J, Wilson DC, Satsangi J. The genetics of Crohn's disease. *Annu Rev Genomics Hum Genet*. 2009;10:89–116.

106. Fanning AS, Jameson BJ, Jesaitis LA, Anderson JM. The tight junction protein ZO-1 establishes a link between the transmembrane protein occludin and the actin cytoskeleton. *J Biol Chem*. 1998;273(45):29745–53.

107. Poritz LS, Garver KI, Green C, Fitzpatrick L, Ruggiero F, Koltun WA. Loss of the tight junction protein ZO-1 in dextran sulfate sodium induced colitis. *J Surg Res*. 2007;140(1):12–9.

108. Weber CR, Nalle SC, Tretiakova M, Rubin DT, Turner JR. Claudin-1 and claudin-2 expression is elevated in inflammatory bowel disease and may contribute to early neoplastic transformation. *Lab Invest*. 2008;88(10):1110–20.

109. Reuter BK, Pizarro TT. Mechanisms of tight junction dysregulation in the SAMP1/YitFc model of Crohn's disease-like ileitis. *Ann N Y Acad Sci*. 2009;1165:301–7.

110. Kucharzik T, Walsh SV, Chen J, Parkos CA, Nusrat A. Neutrophil transmigration in inflammatory bowel disease is associated with differential expression of epithelial intercellular junction proteins. *Am J Pathol*. 2001;159(6):2001–9.

111. Piazza F, Valens J, Lagasse E, Schindler C. Myeloid differentiation of FdCP1 cells is dependent on Stat5 processing. *Blood*. 2000;96(4):1358–65.

112. Snow JW, Abraham N, Ma MC, Herndier BG, Pastuszak AW, Goldsmith MA. Loss of tolerance and autoimmunity affecting multiple organs in STAT5A/5B-deficient mice. *J Immunol*. 2003;171(10):5042–50.

113. Shuai K, Liu B. Regulation of JAK-STAT signalling in the immune system. *Nat Rev Immunol*. 2003;3(11):900–11.

114. Neufert C, Pickert G, Zheng Y, et al. Activation of epithelial STAT3 regulates intestinal homeostasis. *Cell Cycle*. 2010;9(4):652–5.

115. Barrett JC, Hansoul S, Nicolae DL, et al. Genome-wide association defines more than 30 distinct susceptibility loci for Crohn's disease. *Nat Genet*. 2008;40(8):955–62.

116. Stoll M, Corneliussen B, Costello CM, et al. Genetic variation in DLG5 is associated with inflammatory bowel disease. *Nat Genet*. 2004;36(5):476–80.

117. Lin Z, Poritz L, Franke A, et al. Genetic association of DLG5 R30Q with familial and sporadic

- inflammatory bowel disease in men. *Dis Markers*. 2009;27(5):193–201.
118. Yamamoto-Furusho JK, Mendivil-Rangel EJ, Fonseca-Camarillo G, Villeda-Espinoza MA, Barreto-Zuniga R. Increased expression of discs large homolog 5 gene (DLG5) in ulcerative colitis patients compared to healthy individuals. *Inflamm Bowel Dis*. 2011;17(7):1639.
119. Genin E, Schumacher M, Roujeau JC, et al. Genome-wide association study of Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis in Europe. *Orphanet J Rare Dis*. 2011;6:52.
120. Zhu KJ, Lv YM, Yin XY, et al. Psoriasis regression analysis of MHC loci identifies shared genetic variants with vitiligo. *PloS one*. 2011;6(11), e23089.
121. Edwards TL, Shrubsole MJ, Cai Q, et al. Genome-wide association study identifies possible genetic risk factors for colorectal adenomas. *Cancer Epidemiol Biomarkers Prev*. 2013;22(7):1219–26.
122. Steingart RA, Heldenberg E, Pinhasov A, Brennehan DE, Fridkin M, Gozes I. A vasoactive intestinal peptide receptor analog alters the expression of homeobox genes. *Life Sci*. 2002;71(21):2543–52.
123. Yasuda H, Tanaka K, Okita Y, et al. CD133, OCT4, and NANOG in ulcerative colitis-associated colorectal cancer. *Oncol Lett*. 2011;2(6):1065–71.
124. Hochedlinger K, Yamada Y, Beard C, Jaenisch R. Ectopic expression of Oct-4 blocks progenitor-cell differentiation and causes dysplasia in epithelial tissues. *Cell*. 2005;121(3):465–77.
125. Connelly T, Sanders B, Berg A, Harris III L, Tinsley A, Williams E, Koltun W. Genetic predictors of quality of life post ileal anal pouch anastomosis for ulcerative colitis (abstract). *Inflamm Bowel Dis*. 2013;19 Suppl 1:S1–132.
126. Barrett JC, Lee JC, Lees CW, et al. Genome-wide association study of ulcerative colitis identifies three new susceptibility loci, including the HNF4A region. *Nat Genet*. 2009;41(12):1330–4.
127. Schmehl K, Florian S, Jacobasch G, Salomon A, Korber J. Deficiency of epithelial basement membrane laminin in ulcerative colitis affected human colonic mucosa. *Int J Colorectal Dis*. 2000;15(1):39–48.
128. Fisher SA, Tremelling M, Anderson CA, et al. Genetic determinants of ulcerative colitis include the ECM1 locus and five loci implicated in Crohn's disease. *Nat Genet*. 2008;40(6):710–2.
129. Wellcome Trust Case Control Consortium, et al. Genome-wide association study of 14,000 cases of seven common diseases and 3,000 shared controls. *Nature*. 2007;447(7145):661–78.
130. Cario E, Podolsky DK. Differential alteration in intestinal epithelial cell expression of toll-like receptor 3 (TLR3) and TLR4 in inflammatory bowel disease. *Infect Immun*. 2000;68(12):7010–7.
131. Hugot JP, Chamaillard M, Zouali H, et al. Association of NOD2 leucine-rich repeat variants with susceptibility to Crohn's disease. *Nature*. 2001;411(6837):599–603.
132. McCauley JL, Abreu MT. Genetics in diagnosing and managing inflammatory bowel disease. *Gastroenterol Clin North Am*. 2012;41(2):513–22.
133. Broom OJ, Widjaya B, Troelsen J, Olsen J, Nielsen OH. Mitogen activated protein kinases: a role in inflammatory bowel disease? *Clin Exp Immunol*. 2009;158(3):272–80.
134. Kosovac K, Brenmoehl J, Holler E, et al. Association of the NOD2 genotype with bacterial translocation via altered cell-cell contacts in Crohn's disease patients. *Inflamm Bowel Dis*. 2010;16(8):1311–21.
135. Bonen DK, Ogura Y, Nicolae DL, et al. Crohn's disease-associated NOD2 variants share a signaling defect in response to lipopolysaccharide and peptidoglycan. *Gastroenterology*.

2003;124(1):140–6.

136. Palomino-Morales RJ, Oliver J, Gomez-Garcia M, et al. Association of ATG16L1 and IRGM genes polymorphisms with inflammatory bowel disease: a meta-analysis approach. *Genes Immun.* 2009;10(4):356–64.

137. Massey DC, Parkes M. Genome-wide association scanning highlights two autophagy genes, ATG16L1 and IRGM, as being significantly associated with Crohn's disease. *Autophagy.* 2007;3(6):649–51.

138. Singh SB, Davis AS, Taylor GA, Deretic V. Human IRGM induces autophagy to eliminate intracellular mycobacteria. *Science.* 2006;313(5792):1438–41.

139. Lu XC, Tao Y, Wu C, et al. Association between variants of the autophagy related gene—IRGM and susceptibility to Crohn's disease and ulcerative colitis: a meta-analysis. *PloS one.* 2013;8(11), e80602.

140. Sehgal R, Berg A, Polinski JI, et al. Mutations in IRGM are associated with more frequent need for surgery in patients with ileocolonic Crohn's disease. *Dis Colon Rectum.* 2012;55(2):115–21.

141. Ahmad T, Marshall SE, Jewell D. Genetics of inflammatory bowel disease: the role of the HLA complex. *World J Gastroenterol.* 2006;12(23):3628–35.

142. Stokkers PC, Reitsma PH, Tytgat GN, van Deventer SJ. HLA-DR and -DQ phenotypes in inflammatory bowel disease: a meta-analysis. *Gut.* 1999;45(3):395–401.

143. Silverberg MS, Mirea L, Bull SB, et al. A population- and family-based study of Canadian families reveals association of HLA DRB1\*0103 with colonic involvement in inflammatory bowel disease. *Inflamm Bowel Dis.* 2003;9(1):1–9.

144. Hancock L, Beckly J, Geremia A, et al. Clinical and molecular characteristics of isolated colonic Crohn's disease. *Inflamm Bowel Dis.* 2008;14(12):1667–77.

145. Bamias G, Martin III C, Marini M, et al. Expression, localization, and functional activity of TL1A, a novel Th1-polarizing cytokine in inflammatory bowel disease. *J Immunol.* 2003;171(9):4868–74.

146. Yang CR, Hsieh SL, Teng CM, Ho FM, Su WL, Lin WW. Soluble decoy receptor 3 induces angiogenesis by neutralization of TL1A, a cytokine belonging to tumor necrosis factor superfamily and exhibiting angiostatic action. *Cancer Res.* 2004;64(3):1122–9.

147. Meylan F, Song YJ, Fuss I, et al. The TNF-family cytokine TL1A drives IL-13-dependent small intestinal inflammation. *Mucosal Immunol.* 2011;4(2):172–85.

148. Young HA, Tovey MG. TL1A: a mediator of gut inflammation. *Proc Natl Acad Sci U S A.* 2006;103(22):8303–4.

149. Michelsen KS, Thomas LS, Taylor KD, et al. IBD-associated TL1A gene (TNFSF15) haplotypes determine increased expression of TL1A protein. *PloS one.* 2009;4(3), e4719.

150. Jones GW, Stumhofer JS, Foster T, et al. Naive and activated T cells display differential responsiveness to TL1A that affects Th17 generation, maintenance, and proliferation. *Faseb J.* 2011;25(1):409–19.

151. Cavallini C, Lovato O, Bertolaso A, et al. The TNF-family cytokine TL1A inhibits proliferation of human activated B cells. *PloS one.* 2013;8(4), e60136.

152. Kang YJ, Kim WJ, Bae HU, et al. Involvement of TL1A and DR3 in induction of pro-inflammatory cytokines and matrix metalloproteinase-9 in atherogenesis. *Cytokine.* 2005;29(5):229–35.

153. Connelly TM, Berg AS, Hegarty JP, et al. The TNFSF15 gene single nucleotide polymorphism



- rs7848647 is associated with surgical diverticulitis. *Ann Surg.* 2014;259(6):1132–7.
154. Liao W, Lin JX, Wang L, Li P, Leonard WJ. Modulation of cytokine receptors by IL-2 broadly regulates differentiation into helper T cell lineages. *Nat Immunol.* 2011;12(6):551–9.
155. O'Shea JJ, Lahesmaa R, Vahedi G, Laurence A, Kanno Y. Genomic views of STAT function in CD4<sup>+</sup> T helper cell differentiation. *Nat Rev Immunol.* 2011;11(4):239–50.
156. Budagian V, Bulanova E, Paus R, Bulfone-Paus S. IL-15/IL-15 receptor biology: a guided tour through an expanding universe. *Cytokine Growth Factor Rev.* 2006;17(4):259–80.
157. Laurence A, Tato CM, Davidson TS, et al. Interleukin-2 signaling via STAT5 constrains T helper 17 cell generation. *Immunity.* 2007;26(3):371–81.
158. Gilbert S, Zhang R, Denson L, et al. Enterocyte STAT5 promotes mucosal wound healing via suppression of myosin light chain kinase-mediated loss of barrier function and inflammation. *EMBO Mol Med.* 2012;4(2):109–24.
159. Pandiyan P, Yang XP, Saravanamuthu SS, et al. The role of IL-15 in activating STAT5 and fine-tuning IL-17A production in CD4 T lymphocytes. *J Immunol.* 2012;189(9):4237–46.
160. Mao M, Biery MC, Kobayashi SV, et al. T lymphocyte activation gene identification by coregulated expression on DNA microarrays. *Genomics.* 2004;83(6):989–99.
161. Eyre S, Hinks A, Bowes J, et al. Overlapping genetic susceptibility variants between three autoimmune disorders: rheumatoid arthritis, type 1 diabetes and coeliac disease. *Arthritis Res Ther.* 2010;12(5):R175.
162. Franke A, McGovern DP, Barrett JC, et al. Genome-wide meta-analysis increases to 71 the number of confirmed Crohn's disease susceptibility loci. *Nat Genet.* 2010;42(12):1118–25.
163. Festen EA, Goyette P, Green T, et al. A meta-analysis of genome-wide association scans identifies IL18RAP, PTPN2, TAGAP, and PUS10 as shared risk loci for Crohn's disease and celiac disease. *PLoS Genet.* 2011;7(1), e1001283.
164. Toedter G, Li K, Marano C, et al. Gene expression profiling and response signatures associated with differential responses to infliximab treatment in ulcerative colitis. *Am J Gastroenterol.* 2011;106(7):1272–80.
165. Cernuda-Morollon E, Ridley AJ. Rho GTPases and leukocyte adhesion receptor expression and function in endothelial cells. *Circ Res.* 2006;98(6):757–67.
166. Ligeti E, Welti S, Scheffzek K. Inhibition and termination of physiological responses by GTPase activating proteins. *Physiol Rev.* 2012;92(1):237–72.
167. Moon SY, Zheng Y. Rho GTPase-activating proteins in cell regulation. *Trends Cell Biol.* 2003;13(1):13–22.
168. Connelly TM, Sehgal R, Berg AS, et al. Mutation in TAGAP is protective of anal sepsis in ileocolic Crohn's disease. *Dis Colon Rectum.* 2012;55(11):1145–52.
169. Connelly TM, Berg AS, Harris III LR, et al. T-cell activation Rho GTPase-activating protein expression varies with inflammation location and severity in Crohn's disease. *J Surg Res.* 2014;190(2):457–64.
170. Begue B, Verdier J, Rieux-Laucat F, et al. Defective IL10 signaling defining a subgroup of patients with inflammatory bowel disease. *Am J Gastroenterol.* 2011;106(8):1544–55.
171. Glocker EO, Kotlarz D, Boztug K, et al. Inflammatory bowel disease and mutations affecting the interleukin-10 receptor. *N Engl J Med.* 2009;361(21):2033–45.
172. Shih DQ, Targan SR, McGovern D. Recent advances in IBD pathogenesis: genetics and immunobiology. *Curr Gastroenterol Rep.* 2008;10(6):568–75.

173. Lees CW, Barrett JC, Parkes M, Satsangi J. New IBD genetics: common pathways with other diseases. *Gut*. 2011;60(12):1739–53.
174. Cravo ML, Ferreira PA, Sousa P, et al. IL23R polymorphisms influence phenotype and response to therapy in patients with ulcerative colitis. *Eur J Gastroenterol Hepatol*. 2014;26(1):26–32.
175. Averboukh F, Ziv Y, Kariv Y, et al. Colorectal carcinoma in inflammatory bowel disease: a comparison between Crohn's and ulcerative colitis. *Colorectal Dis*. 2011;13(11):1230–5.
176. Goldstone R, Itzkowitz S, Harpaz N, Ullman T. Progression of low-grade dysplasia in ulcerative colitis: effect of colonic location. *Gastrointest Endosc*. 2011;74(5):1087–93.
177. Bergeron V, Vienne A, Sokol H, et al. Risk factors for neoplasia in inflammatory bowel disease patients with pancolitis. *Am J Gastroenterol*. 2010;105(11):2405–11.
178. Gillen CD, Andrews HA, Prior P, Allan RN. Crohn's disease and colorectal cancer. *Gut*. 1994;35(5):651–5.
179. Svrcek M, Cosnes J, Beaugerie L, et al. Colorectal neoplasia in Crohn's colitis: a retrospective comparative study with ulcerative colitis. *Histopathology*. 2007;50(5):574–83.
180. Ullman T, Croog V, Harpaz N, Sachar D, Itzkowitz S. Progression of flat low-grade dysplasia to advanced neoplasia in patients with ulcerative colitis. *Gastroenterology*. 2003;125(5):1311–9.
181. Befrits R, Ljung T, Jaramillo E, Rubio C. Low-grade dysplasia in extensive, long-standing inflammatory bowel disease: a follow-up study. *Dis Colon Rectum*. 2002;45(5):615–20.
182. Blackstone MO, Riddell RH, Rogers BHG, Levin B. Dysplasia-associated lesion or mass (dalm) detected by colonoscopy in long-standing ulcerative-colitis—an indication for colectomy. *Gastroenterology*. 1981;80(2):366–74.
183. Thomas T, Abrams KA, Robinson RJ, Mayberry JF. Meta-analysis: cancer risk of low-grade dysplasia in chronic ulcerative colitis. *Aliment Pharmacol Ther*. 2007;25(6):657–68.
184. Itzkowitz SH, Yio XY. Inflammation and cancer—IV. Colorectal cancer in inflammatory bowel disease: the role of inflammation. *Am J Physiol*. 2004;287(1):G7–17.
185. Goel GA, Kandiel A, Achkar JP, Lashner B. Molecular pathways underlying IBD-associated colorectal neoplasia: therapeutic implications. *Am J Gastroenterol*. 2011;106(4):719–30.
186. Tarmin L, Yin J, Harpaz N, et al. Adenomatous polyposis coli gene mutations in ulcerative colitis-associated dysplasias and cancers versus sporadic colon neoplasms. *Cancer Res*. 1995;55(10):2035–8.
187. Connelly TM, Koltun WA. The cancer “fear” in IBD patients: is it still REAL? *J Gastrointest Surg*. 2014;18(1):213–8.
188. Fukata M, Shang L, Santaolalla R, et al. Constitutive activation of epithelial TLR4 augments inflammatory responses to mucosal injury and drives colitis-associated tumorigenesis. *Inflamm Bowel Dis*. 2011;17(7):1464–73.
189. Hartnett L, Egan LJ. Inflammation, DNA methylation and colitis-associated cancer. *Carcinogenesis*. 2012;33(4):723–31.
190. Martini M, Ferrara AM, Giachelia M, et al. Association of the OCTN1/1672T variant with increased risk for colorectal cancer in young individuals and ulcerative colitis patients. *Inflamm Bowel Dis*. 2012;18(3):439–48.
191. Connelly TM, Berg AS, Harris III LR, et al. Ulcerative colitis neoplasia is not associated with common inflammatory bowel disease single-nucleotide polymorphisms. *Surgery*. 2014;156:253–62.
192. Wheeler JM, Kim HC, Efsthathiou JA, Ilyas M, Mortensen NJ, Bodmer WF. Hypermethylation

of the promoter region of the E-cadherin gene (CDH1) in sporadic and ulcerative colitis associated colorectal cancer. *Gut*. 2001;48(3):367–71.

193. Houlston RS, Webb E, Broderick P, et al. Meta-analysis of genome-wide association data identifies four new susceptibility loci for colorectal cancer. *Nat Genet*. 2008;40(12):1426–35.

194. Pekow J, Dougherty U, Huang Y, et al. Gene signature distinguishes patients with chronic ulcerative colitis harboring remote neoplastic lesions. *Inflamm Bowel Dis*. 2013;19(3):461–70.

195. Kim TO, Park J, Kang MJ, et al. DNA hypermethylation of a selective gene panel as a risk marker for colon cancer in patients with ulcerative colitis. *Int J Mol Med*. 2013;31(5):1255–61.

196. Greten FR, Eckmann L, Greten TF, et al. IKK $\beta$  links inflammation and tumorigenesis in a mouse model of colitis-associated cancer. *Cell*. 2004;118(3):285–96.

197. Koltun W, Connelly T, Tinsley A. Inflammatory bowel disease: general conditions, approaches to medical management, and the future of surgery in gastrointestinal tract and abdomen. Scientific. In: Ashley SW, editor. *American surgery*. Hamilton: Decker Intellectual Properties; 2014.

198. Farrell RJ, Murphy A, Long A, et al. High multidrug resistance (P-glycoprotein 170) expression in inflammatory bowel disease patients who fail medical therapy. *Gastroenterology*. 2000;118(2):279–88.

199. Cucchiara S, Latiano A, Palmieri O, et al. Polymorphisms of tumor necrosis factor- $\alpha$  but not MDR1 influence response to medical therapy in pediatric-onset inflammatory bowel disease. *J Pediatr Gastroenterol Nutr*. 2007;44(2):171–9.

200. Dubinsky MC, Kugathasan S, Kwon S, et al. Multidimensional prognostic risk assessment identifies association between IL12B variation and surgery in Crohn's disease. *Inflamm Bowel Dis*. 2013;19(8):1662–70.

201. Seiderer J, Brand S, Herrmann KA, et al. Predictive value of the CARD15 variant 1007fs for the diagnosis of intestinal stenoses and the need for surgery in Crohn's disease in clinical practice: results of a prospective study. *Inflamm Bowel Dis*. 2006;12(12):1114–21.

202. Tyler AD, Milgrom R, Stempak JM, et al. The NOD2<sup>insC</sup> polymorphism is associated with worse outcome following ileal pouch-anal anastomosis for ulcerative colitis. *Gut*. 2013;62(10):1433–9.

203. Sehgal R, Berg A, Hegarty JP, et al. NOD2/CARD15 mutations correlate with severe pouchitis after ileal pouch-anal anastomosis. *Dis Colon Rectum*. 2010;53(11):1487–94.

204. Sehgal R, Berg A, Polinski JJ, et al. Genetic risk profiling and gene signature modeling to predict risk of complications after IPAA. *Dis Colon Rectum*. 2012;55(3):239–48.

205. Nissen LH, Nagtegaal ID, de Jong DJ, et al. Epstein-Barr virus in inflammatory bowel disease: the spectrum of intestinal lymphoproliferations. *J Crohn's Colitis*. 2015;9(5):398–403.

206. Wright EK, Kamm MA, Teo SM, Inouye M, Wagner J, Kirkwood CD. Recent advances in characterizing the gastrointestinal microbiome in Crohn's disease: a systematic review. *Inflamm Bowel Dis*. 2015;21(6):1219–28.

207. Mukhopadhyay I, Hansen R, Meharg C, et al. The fungal microbiota of de-novo paediatric inflammatory bowel disease. *Microbes Infect*. 2015;17(4):304–10.

208. Li Q, Wang C, Tang C, He Q, Li N, Li J. Dysbiosis of gut fungal microbiota is associated with mucosal inflammation in Crohn's disease. *J Clin Gastroenterol*. 2014;48(6):513–23.

209. Hoarau G, Colombel JF, Poulain D, Sendid B. Fungal intestinal flora in the development of Crohn's disease. *Med Sci*. 2013;29(8–9):691–3.

210. Hubbard VM, Cadwell K. Viruses, autophagy genes, and Crohn's disease. *Viruses*. 2011;3(7):1281–311.
211. Missaghi B, Barkema HW, Madsen KL, Ghosh S. Perturbation of the human microbiome as a contributor to inflammatory bowel disease. *Pathogens*. 2014;3(3):510–27.
212. Bringiotti R, Ierardi E, Lovero R, Losurdo G, Di Leo A, Principi M. Intestinal microbiota: The explosive mixture at the origin of inflammatory bowel disease? *World J Gastrointest Pathophysiol*. 2014;5(4):550–9.
213. Wallace KL, Zheng LB, Kanazawa Y, Shih DQ. Immunopathology of inflammatory bowel disease. *World J Gastroenterol*. 2014;20(1):6–21.

## 第 45 章

1. Baron JH. Inflammatory bowel disease up to 1932. *Mt Sinai J Med N Y*. 2000;67(3):174–89.
2. Hale-White W. On simple ulcerative colitis and other rare incidental ulcers. *Guys Hosp Rep*. 1888;30:131–62. 3rd series.
3. Mummery PL. Remarks on the value of the Sigmoidoscope in the diagnosis between primary and secondary colitis. *Br Med J*. 1905;2(2347):1630–1.
4. Crohn BB, Ginzburg L, Oppenheimer GD. Regional ileitis: a pathologic and clinical entity. *J Am Med Assoc*. 1932;99(16):1323–9.
5. Walmsley RS, Ayres RCS, Pounder RE, Allan RN. A simple clinical colitis activity index. *Gut*. 1998;43(1):29–32.
6. Huang B, Kwan YL, Shih QD. Extraintestinal manifestations of ulcerative colitis. In: O'Connor M (ed). *Ulcerative Colitis—epidemiology, pathogenesis and complications* [Internet]. InTech; 2011 [cited 2015 Apr 28]. Available from: <http://www.intechopen.com/books/ulcerative-colitis-epidemiology-pathogenesis-and-complications/extraintestinal-manifestations-of-ulcerative-colitis>
7. Dendrinos K, Cerda S, Farraye FA. The “cecal patch” in patients with ulcerative colitis. *Gastrointest Endosc*. 2008;68(5):1006–7.
8. Fahmy M, Shabaik A, Sandborn WJ. Cecal patch manifest as an inflammatory pseudopolyp and characterized by chromoendoscopy. *Inflamm Bowel Dis*. 2013;19(4):E57–8.
9. Goldstein N, Dulai M. Contemporary morphologic definition of backwash ileitis in ulcerative colitis and features that distinguish it from Crohn Disease. *Am J Clin Pathol*. 2006;126(3):365–76.
10. Bernstein CN, Shanahan F, Anton PA, Weinstein WM. Patchiness of mucosal inflammation in treated ulcerative colitis: a prospective study. *Gastrointest Endosc*. 1995;42(3):232–7.
11. Jenkins D, Balsitis M, Gallivan S, Dixon MF, Gilmour HM, Shepherd NA, et al. Guidelines for the initial biopsy diagnosis of suspected chronic idiopathic inflammatory bowel disease. The British Society of Gastroenterology Initiative. *J Clin Pathol*. 1997;50(2):93–105.
12. McCormick DA, Horton LW, Mee AS. Mucin depletion in inflammatory bowel disease. *J Clin Pathol*. 1990;43(2):143–6.
13. Magro F, Langner C, Driessen A, Ensari A, Geboes K, Mantzaris GJ, et al. European consensus on the histopathology of inflammatory bowel disease. *J Crohns Colitis*. 2013;7(10):827–51.
14. Goldstein NS, Leon-Armin C, Mani A. Crohn's colitis-like changes in sigmoid diverticulitis specimens is usually an idiosyncratic inflammatory response to the diverticulosis rather than Crohn's colitis. *Am J Surg Pathol*. 2000;24(5):668–75.

15. Kent TH, Ammon RK, DenBesten L. Differentiation of ulcerative colitis and regional enteritis of colon. *Arch Pathol.* 1970;89(1):20–9.
16. Price AB. Overlap in the spectrum of non-specific inflammatory bowel disease--‘colitis indeterminate’. *J Clin Pathol.* 1978;31(6):567–77.
17. Satsangi J, Silverberg MS, Vermeire S, Colombel J. The Montreal classification of inflammatory bowel disease: controversies, consensus, and implications. *Gut.* 2006;55(6):749–53.
18. Yu CS, Pemberton DJH, Larson D. Ileal pouch-anal anastomosis in patients with indeterminate colitis. *Dis Colon Rectum.* 2000;43(11):1487–96.
19. Delaney CP, Remzi FH, Gramlich T, Dadvand B, Fazio VW. Equivalent function, quality of life and pouch survival rates after ileal pouch-anal anastomosis for indeterminate and ulcerative colitis. *Ann Surg.* 2002;236(1):43–8.
20. Odze RD. A contemporary and critical appraisal of “indeterminate colitis.”. *Mod Pathol.* 2015;28(S1):S30–46.
21. Turina M, Remzi FH. The J-pouch for patients with Crohn’s Disease and indeterminate colitis: (When) Is it an option? *J Gastrointest Surg.* 2014;18(7):1343–4.
22. Cioffi M, Rosa AD, Serao R, Picone I, Vietri MT. Laboratory markers in ulcerative colitis: current insights and future advances. *World J Gastrointest Pathophysiol.* 2015;6(1):13–22.
23. Joossens S, Reinisch W, Vermeire S, Sendid B, Poulain D, Peeters M, et al. The value of serologic markers in indeterminate colitis: a prospective follow-up study. *Gastroenterology.* 2002;122(5):1242–7.
24. Dendrinos KG, Becker JM, Stucchi AF, Saubermann LJ, LaMorte W, Farraye FA. Anti-*Saccharomyces cerevisiae* antibodies are associated with the development of postoperative fistulas following ileal pouch-anal anastomosis. *J Gastrointest Surg Off J Soc Surg Aliment Tract.* 2006;10(7):1060–4.
25. Fleshner P, Vasiliauskas E, Kam L, Fleshner N, Gaiennie J, Abreu-Martin M, et al. High level perinuclear antineutrophil cytoplasmic antibody (pANCA) in ulcerative colitis patients before colectomy predicts the development of chronic pouchitis after ileal pouch-anal anastomosis. *Gut.* 2001;49(5):671–7.
26. Lehmann FS, Burri E, Beglinger C. The role and utility of faecal markers in inflammatory bowel disease. *Therap Adv Gastroenterol.* 2015;8(1):23–36.
27. Abraham BP, Kane S. Faecal markers: calprotectin and Lactoferrin. *Gastroenterol Clin North Am.* 2012;41(2):483–95.
28. Meuwis M-A, Vernier-Massouille G, Grimaud JC, Bouhnik Y, Laharie D, Piver E, et al. Serum calprotectin as a biomarker for Crohn’s disease. *J Crohns Colitis.* 2013;7(12):e678–83.
29. Van Rhee PF, Van de Vijver E, Fidler V. Faecal calprotectin for screening of patients with suspected inflammatory bowel disease: diagnostic meta-analysis. *BMJ [Internet].* 2010 [cited 2015 Apr 20];341. Available from: <http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2904879/>
30. Pineton de Chambrun G, Peyrin-Biroulet L, Lémann M, Colombel J-F. Clinical implications of mucosal healing for the management of IBD. *Nat Rev Gastroenterol Hepatol.* 2010;7(1):15–29.
31. Røseth AG, Aadland E, Grzyb K. Normalization of faecal calprotectin: a predictor of mucosal healing in patients with inflammatory bowel disease. *Scand J Gastroenterol.* 2004;39(10):1017–20.
32. Louis E, Mary J-Y, Vernier-Massouille G, Grimaud J-C, Bouhnik Y, Laharie D, et al. Maintenance of remission among patients with Crohn’s disease on antimetabolite therapy after infliximab therapy is stopped. *Gastroenterology.* 2012;142(1):63–70. e5.quiz e31.

33. Ho GT, Lee HM, Brydon G, Ting T, Hare N, Drummond H, et al. Fecal calprotectin predicts the clinical course of acute severe ulcerative colitis. *Am J Gastroenterol*. 2009;104(3):673–8.
34. Orlando A, Modesto I, Castiglione F, Scala L, Scimeca D, Rispo A, et al. The role of calprotectin in predicting endoscopic post-surgical recurrence in asymptomatic Crohn's disease: a comparison with ultrasound. *Eur Rev Med Pharmacol Sci*. 2006;10(1):17–22.
35. Wright EK, Kamm MA, De Cruz P, Hamilton AL, Ritchie KJ, Krejany EO, et al. Measurement of fecal calprotectin improves monitoring and detection of recurrence of crohn's disease after surgery. *Gastroenterology* [Internet]. [cited 2015 Apr 5]; Available from: <http://www.sciencedirect.com/science/article/pii/S0016508515001110>
36. Vermeire S, Van Assche G, Rutgeerts P. Laboratory markers in IBD: useful, magic, or unnecessary toys? *Gut*. 2006;55(3):426–31.
37. Saverymuttu SH, Hodgson HJ, Chadwick VS, Pepys MB. Differing acute phase responses in Crohn's disease and ulcerative colitis. *Gut*. 1986;27(7):809–13.
38. Gabay C, Kushner I. Acute-phase proteins and other systemic responses to inflammation. *N Engl J Med*. 1999;340(6):448–54.
39. Shine B, Berghouse L, Jones JE, Landon J. C-reactive protein as an aid in the differentiation of functional and inflammatory bowel disorders. *Clin Chim Acta Int J Clin Chem*. 1985;148(2):105–9.
40. Poullis AP, Zar S, Sundaram KK, Moodie SJ, Risley P, Theodossi A, et al. A new, highly sensitive assay for C-reactive protein can aid the differentiation of inflammatory bowel disorders from constipation- and diarrhoea-predominant functional bowel disorders. *Eur J Gastroenterol Hepatol*. 2002;14(4):409–12.
41. Schoepfer AM, Beglinger C, Straumann A, Trummeler M, Vavricka SR, Bruegger LE, et al. Fecal calprotectin correlates more closely with the simple endoscopic score for Crohn's Disease (SES-CD) than CRP, blood leukocytes, and the CDAI. *Am J Gastroenterol*. 2009;105(1):162–9.
42. Ogura Y, Bonen DK, Inohara N, Nicolae DL, Chen FF, Ramos R, et al. A frameshift mutation in NOD2 associated with susceptibility to Crohn's disease. *Nature*. 2001;411(6837):603–6.
43. Hugot JP, Chamaillard M, Zouali H, Lesage S, Cézard JP, Belaiche J, et al. Association of NOD2 leucine-rich repeat variants with susceptibility to Crohn's disease. *Nature*. 2001;411(6837):599–603.
44. Chen H, Lee A, Bowcock A, Zhu W, Li E, Ciorba M, et al. Influence of Crohn's disease risk alleles and smoking on disease location. *Dis Colon Rectum*. 2011;54(8):1020–5.
45. Sehgal R, Berg A, Hegarty JP, Kelly AA, Lin Z, Poritz LS, et al. NOD2/CARD15 mutations correlate with severe pouchitis after ileal pouch-anal anastomosis. *Dis Colon Rectum*. 2010;53(11):1487–94.
46. Hugot J-P, Zaccaria I, Cavanaugh J, Yang H, Vermeire S, Lappalainen M, et al. Prevalence of CARD15/NOD2 mutations in Caucasian Healthy People. *Am J Gastroenterol*. 2007;102(6):1259–67.
47. Kostic AD, Xavier RJ, Gevers D. The microbiome in inflammatory bowel disease: current status and the future ahead. *Gastroenterology*. 2014;146(6):1489–99.
48. Gumaste V, Sachar DB, Greenstein AJ. Benign and malignant colorectal strictures in ulcerative colitis. *Gut*. 1992;33(7):938–41.
49. Yamazaki Y, Ribeiro MB, Sachar DB, Aufses AH, Greenstein AJ. Malignant colorectal strictures in Crohn's disease. *Am J Gastroenterol*. 1991;86(7):882–5.
50. Navaneethan U, Parasa S, Venkatesh PGK, Trikudanathan G, Shen B. Prevalence and risk

factors for colonic perforation during colonoscopy in hospitalized inflammatory bowel disease patients. *J Crohns Colitis*. 2011;5(3):189–95.

51. Tong JL, Feng Q, Shen J, Qiao YQ, Zheng Q, Gu Y, et al. Computed tomography enterography versus balloon-assisted enteroscopy for evaluation of small bowel lesions in Crohn's disease. *J Gastroenterol Hepatol*. 2013;28(7):1180–6.

52. Rondonotti E, Sunada K, Yano T, Paggi S, Yamamoto H. Double-balloon endoscopy in clinical practice: where are we now? *Dig Endosc*. 2012;24(4):209–19.

53. Makipour K, Modiri AN, Ehrlich A, Friedenberg FK, Maranki J, Enestvedt BK, et al. Double balloon enteroscopy: effective and minimally invasive method for removal of retained video capsules. *Dig Endosc Off J Jpn Gastroenterol Endosc Soc*. 2014;26(5):646–9.

54. Rahman A, Ross A, Leighton JA, Schembre D, Gerson L, Lo SK, et al. Double-balloon enteroscopy in Crohn's disease: findings and impact on management in a multicenter retrospective study. *Gastrointest Endosc* [Internet]. [cited 2015 Apr 12]; Available from: <http://www.sciencedirect.com/science/article/pii/S0016510714026108>

55. Papay P, Ignjatovic A, Karmiris K, Amarante H, Miheller P, Feagan B, et al. Optimising monitoring in the management of Crohn's disease: a physician's perspective. *J Crohns Colitis*. 2013;7(8):653–69.

56. De Cruz P, Kamm MA, Hamilton AL, Ritchie KJ, Krejany EO, Gorelik A, et al. Crohn's disease management after intestinal resection: a randomised trial. *Lancet*. 2015;385(9976):1406–17.

57. Mary JY, Modigliani R. Development and validation of an endoscopic index of the severity for Crohn's disease: a prospective multicentre study. *Groupe d'Etudes Thérapeutiques des Affections Inflammatoires du Tube Digestif (GETAID)*. *Gut*. 1989;30(7):983–9.

58. Daperno M, D'Haens G, Van Assche G, Baert F, Bulois P, Maunoury V, et al. Development and validation of a new, simplified endoscopic activity score for Crohn's disease: the SES-CD. *Gastrointest Endosc*. 2004;60(4):505–12.

59. Rutgeerts P, Geboes K, Vantrappen G, Beyls J, Kerremans R, Hiele M. Predictability of the postoperative course of Crohn's disease. *Gastroenterology*. 1990;99(4):956–63.

60. Blum E, Katz JA. Postoperative therapy for Crohn's Disease. *Inflamm Bowel Dis*. 2009;15(3):463–72.

61. Baron JH, Connell AM, Lennard-Jones JE. Variation between observers in describing mucosal appearances in proctocolitis. *Br Med J*. 1964;1(5375):89–92.

62. Schroeder KW, Tremaine WJ, Ilstrup DM. Coated oral 5-aminosalicylic acid therapy for mildly to moderately active ulcerative colitis. A randomized study. *N Engl J Med*. 1987;317(26):1625–9.

63. Eaden JA, Abrams KR, Mayberry JF. The risk of colorectal cancer in ulcerative colitis: a meta-analysis. *Gut*. 2001;48(4):526–35.

64. Ross H, Steele SR, Varma M, Dykes S, Cima R, Buie WD, et al. Practice parameters for the surgical treatment of ulcerative colitis. *Dis Colon Rectum*. 2014;57(1):5–22.

65. Connelly TM, Koltun WA. The cancer “Fear” in IBD patients: is it still real? *J Gastrointest Surg*. 2013;18(1):213–8.

66. Itzkowitz SH, Present DH. Crohn's and Colitis Foundation of America Colon Cancer in IBD Study Group. Consensus conference: colorectal cancer screening and surveillance in inflammatory bowel disease. *Inflamm Bowel Dis*. 2005;11(3):314–21.

67. Kornbluth A, Sachar DB. Practice Parameters Committee of the American College of Gastroenterology. Ulcerative colitis practice guidelines in adults: American College Of

Gastroenterology, Practice Parameters Committee. *Am J Gastroenterol*. 2010;105(3):501–23. quiz 524.

68. Jayaram H, Satsangi J, Chapman R. Increased colorectal neoplasia in chronic ulcerative colitis complicated by primary sclerosing cholangitis: fact or fiction? *Gut*. 2001;48(3):430–4.

69. Itzkowitz SH, Harpaz N. Diagnosis and management of dysplasia in patients with inflammatory bowel diseases. *Gastroenterology*. 2004;126(6):1634–48.

70. Rubin CE, Haggitt RC, Burner GC, Brentnall TA, Stevens AC, Levine DS, et al. DNA aneuploidy in colonic biopsies predicts future development of dysplasia in ulcerative colitis. *Gastroenterology*. 1992;103(5):1611–20.

71. Laine L, Kaltenbach T, Barkun A, McQuaid KR, Subramanian V, Soetikno R, et al. SCENIC international consensus statement on surveillance and management of dysplasia in inflammatory bowel disease. *Gastrointest Endosc*. 2015;81(3):489–501.e26.

72. Subramanian V, Ramappa V, Telakis E, Mannath J, Jawhari AU, Hawkey CJ, et al. Comparison of high definition with standard white light endoscopy for detection of dysplastic lesions during surveillance colonoscopy in patients with colonic inflammatory bowel disease. *Inflamm Bowel Dis*. 2013;19(2):350–5.

73. Rutter MD, Saunders BP, Schofield G, Forbes A, Price AB, Talbot IC. Pancolonoscopic indigo carmine dye spraying for the detection of dysplasia in ulcerative colitis. *Gut*. 2004;53(2):256–60.

74. Marion JF, Waye JD, Present DH, Israel Y, Bodian C, Harpaz N, et al. Chromoendoscopy-targeted biopsies are superior to standard colonoscopic surveillance for detecting dysplasia in inflammatory bowel disease patients: a prospective endoscopic trial. *Am J Gastroenterol*. 2008;103(9):2342–9.

75. Choi C-HR, Rutter MD, Askari A, Lee GH, Warusavitarne J, Moorghen M, et al. Forty-Year Analysis of Colonoscopic Surveillance Program for Neoplasia in Ulcerative Colitis: an updated overview. *Am J Gastroenterol*. 2015;110:1022–34.

76. Dekker E, van den Broek FJ, Reitsma JB, Hardwick JC, Offerhaus GJ, van Deventer SJ, et al. Narrow-band imaging compared with conventional colonoscopy for the detection of dysplasia in patients with longstanding ulcerative colitis. *Endoscopy*. 2007;39(3):216–21.

77. De Palma GD, Rispo A. Confocal laser endomicroscopy in inflammatory bowel diseases: dream or reality? *World J Gastroenterol WJG*. 2013;19(34):5593–7.

78. Kiesslich R, Goetz M, Lammersdorf K, Schneider C, Burg J, Stolte M, et al. Chromoscopy-guided endomicroscopy increases the diagnostic yield of intraepithelial neoplasia in ulcerative colitis. *Gastroenterology*. 2007;132(3):874–82.

79. Van de Bruaene C, De Looze D, Hindryckx P. Small bowel capsule endoscopy: where are we after almost 15 years of use? *World J Gastrointest Endosc*. 2015;7(1):13–36.

80. Kotwal VS, Attar BM, Gupta S, Agarwal R. Should bowel preparation, antifoaming agents, or prokinetics be used before video capsule endoscopy? A systematic review and meta-analysis. *Eur J Gastroenterol Hepatol*. 2014;26(2):137–45.

81. Park S-K, Ye BD, Kim KO, Park CH, Lee W-S, Jang BI, et al. Guidelines for video capsule endoscopy: emphasis on Crohn's disease. *Clin Endosc*. 2015;48(2):128–35.

82. Dionisio PM, Gurudu SR, Leighton JA, Leontiadis GI, Fleischer DE, Hara AK, et al. Capsule endoscopy has a significantly higher diagnostic yield in patients with suspected and established small-bowel Crohn's disease: a meta-analysis. *Am J Gastroenterol*. 2010;105(6):1240–8.

83. Pennazio M, Spada C, Eliakim R, Keuchel M, May A, Mulder C, et al. Small-bowel capsule



endoscopy and device-assisted enteroscopy for diagnosis and treatment of small-bowel disorders: European Society of Gastrointestinal Endoscopy (ESGE) Clinical Guideline. *Endoscopy*. 2015;47(04):352–86.

84. Höög CM, Bark L-Å, Arkani J, Gorsetman J, Broström O, Sjöqvist U. Capsule retentions and incomplete capsule endoscopy examinations: an analysis of 2300 examinations. *Gastroenterol Res Pract*. 2012;2012, e518718.

85. Dambha F, Tanner J, Carroll N. Diagnostic imaging in Crohn's disease: what is the new gold standard? *Best Pract Res Clin Gastroenterol*. 2014;28(3):421–36.

86. Gianluca G, Graziella DG, Veronica DM, Cinzia L, Luigi M, Ilario DS, et al. Crohn's Disease imaging: a review. *Gastroenterol Res Pract* [Internet]. 2012 [cited 2015 Apr 9];2012. Available from: <http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3270553/>

87. Gore R, Marn C, Kirby D, Vogelzang R, Neiman H. CT findings in ulcerative, granulomatous, and indeterminate colitis. *Am J Roentgenol*. 1984;143(2):279–84.

88. Ananthakrishnan AN, McGinley EL. Treatment of intra-abdominal abscesses in Crohn's Disease—A nationwide analysis of patterns and outcomes of care. *Dig Dis Sci*. 2013;58(7):2013–8.

89. Minordi LM, Vecchioli A, Guidi L, Mirk P, Fiorentini L, Bonomo L. Multidetector CT enteroclysis versus barium enteroclysis with methylcellulose in patients with suspected small bowel disease. *Eur Radiol*. 2006;16(7):1527–36.

90. Bruining DH, Siddiki HA, Fletcher JG, Sandborn WJ, Fidler JL, Huprich JE, et al. Benefit of computed tomography enterography in Crohn's disease: effects on patient management and physician level of confidence. *Inflamm Bowel Dis*. 2012;18(2):219–25.

91. Higgins PDR, Caoili E, Zimmermann M, Bhuket TP, Sonda PL, Manoogian B, et al. Computed tomographic enterography adds information to clinical management in small bowel Crohn's disease. *Inflamm Bowel Dis*. 2007;13(3):262–8.

92. Minordi LM, Vecchioli A, Poloni G, Guidi L, De Vitis I, Bonomo L. Enteroclysis CT and PEG-CT in patients with previous small-bowel surgical resection for Crohn's disease: CT findings and correlation with endoscopy. *Eur Radiol*. 2009;19(10):2432–40.

93. Mao R, Gao X, Zhu Z, Feng S, Chen B, He Y, et al. CT enterography in evaluating postoperative recurrence of Crohn's disease after ileocolic resection: complementary role to endoscopy. *Inflamm Bowel Dis*. 2013;19(5):977–82.

94. Rodriguez P, Mendez R, Matute F, Hernandez P, Mendoza JL. Imaging Crohn disease: MR enterography. *J Comput Assist Tomogr*. 2014;38(2):219–27.

95. Grand DJ, Guglielmo FF, Al-Hawary MM. MR enterography in Crohn's disease: current consensus on optimal imaging technique and future advances from the SAR Crohn's disease-focused panel. *Abdom Imaging*. 2015;10:1–12.

96. Siddiki HA, Fidler JL, Fletcher JG, Burton SS, Huprich JE, Hough DM, et al. Prospective comparison of state-of-the-Art MR Enterography and CT Enterography in Small-Bowel Crohn's Disease. *Am J Roentgenol*. 2009;193(1):113–21.

97. Bruining DH, Bhatnagar G, Rimola J, Taylor S, Zimmermann EM, Fletcher JG. CT and MR enterography in Crohn's disease: current and future applications. *Abdom Imaging* [Internet]. 2015 Jan 31 [cited 2015 Mar 4]; Available from: 10.1007/s00261-015-0360-9

98. Kralik R, Trnovsky P, Kopáčová M. Transabdominal ultrasonography of the small bowel. *Gastroenterol Res Pract*. 2013;2013:1–11.

99. Ercole E. Role of bowel ultrasound in the management of postoperative Crohn's disease. *World J Gastrointest Pathophysiol.* 2014;5(4):457.
100. Cammarota T, Ribaldone DG, Resegotti A, Repici A, Danese S, Fiorino G, et al. Role of bowel ultrasound as a predictor of surgical recurrence of Crohn's disease. *Scand J Gastroenterol.* 2013;48(5):552–5.
101. Jacene HA, Ginsburg P, Kwon J, Nguyen GC, Montgomery EA, Bayless TM, et al. Prediction of the need for surgical intervention in obstructive Crohn's Disease by 18F-FDG PET/CT. *J Nucl Med.* 2009;50(11):1751–9.
102. Shyn PB, Morteale KJ, Britz-Cunningham SH, Friedman S, Odze RD, Burakoff R, et al. Low-dose 18F-FDG PET/CT enterography: improving on CT enterography assessment of patients with Crohn Disease. *J Nucl Med.* 2010;51(12):1841–8.
103. Brenner DJ, Hall EJ. Computed Tomography—An increasing source of radiation exposure. *N Engl J Med.* 2007;357(22):2277–84.
104. Sauer CG, Kugathasan S, Martin DR, Applegate KE. Medical radiation exposure in children with inflammatory bowel disease estimates high cumulative doses. *Inflamm Bowel Dis.* 2011;17(11):2326–32.

## 第 46 章

1. Kappelman MD, Moore KR, Allen JK, Cook SF. Recent trends in the prevalence of Crohn's disease and ulcerative colitis in a commercially insured US population. *Dig Dis Sci.* 2012;58(2): 519–25.
2. Israeli E, Ying S, Henderson B, Mottola J, Strome T, Bernstein CN. The impact of abdominal computed tomography in a tertiary referral centre emergency department on the management of patients with inflammatory bowel disease. *Aliment Pharmacol Ther.* 2013;38(5):513–21.
3. Takashima S, Kato J, Hiraoka S, Nakarai A, Takei D, Inokuchi T, et al. Evaluation of mucosal healing in ulcerative colitis by fecal calprotectin Vs. fecal immunochemical test. *The American Journal of Gastroenterology.* 2015;110:873–80.
4. Joossens S, Reinisch W, Vermeire S, Sendid B, Poulain D, Peeters M, et al. The value of serologic markers in indeterminate colitis: A prospective follow-up study. *Gastroenterology.* 2002;122(5):1242–7.
5. Loftus CG, Loftus Jr EV, Harmsen SW, Zinsmeister AR, Tremaine WJ, Melton III JL, et al. Update on the incidence and prevalence of Crohn's disease and ulcerative colitis in Olmsted County, Minnesota, 1940–2000. *Inflamm Bowel Dis.* 2007; 13(3):254–61.
6. Samuel S, Ingle SB, Dhillon S, Yadav S, Harmsen WS, Zinsmeister AR, et al. Cumulative incidence and risk factors for hospitalization and surgery in a population-based cohort of ulcerative colitis. *Inflamm Bowel Dis.* 2013;19(9):1858–66.
7. Bach J-F. The effect of infections on susceptibility to autoimmune and allergic diseases. *N Engl J Med.* 2002;347(12):911–20.
8. Bernstein CN, Shanahan F. Disorders of a modern lifestyle: reconciling the epidemiology of inflammatory bowel diseases. *Gut.* 2008;57(9):1185–91.
9. Kornbluth A, Sachar DB, ATPCOTACO Gastroenterology. Ulcerative colitis practice guidelines in adults: American College of Gastroenterology, Practice Parameters Committee. *Am J*

Gastroenterol. 2010;105(3):501–23.

10. Lutgens M, Vleggaar F, Schipper M, Stokkers P, van der Woude C, Hommes D, et al. High frequency of early colorectal cancer in inflammatory bowel disease. *Gut*. 2008;57(9):1246–51.

11. Yashiro M. Ulcerative colitis-associated colorectal cancer. *World J Gastroenterol*. 2014;20(44):16389–97.

12. Choi C-HR, Rutter MD, Askari A, Lee GH, Warusavitarne J, Moorghen M, et al. Forty-year Analysis of Colonoscopic Surveillance Program for Neoplasia in Ulcerative Colitis: An updated overview. *Am J Gastroenterol*. 2015;110:1022–34.

13. Omata F, Ohde S, Deshpande GA, Kobayashi D, Masuda K, Fukui T. Image-enhanced, chromo, and cap-assisted colonoscopy for improving adenoma/neoplasia detection rate: a systematic review and meta-analysis. *Scand J Gastroenterol*. 2014;49(2):222–37.

14. Ullman TA. Patients with low-grade dysplasia should be advised to undergo colectomy. *Inflamm Bowel Dis*. 2003;9(4):267–9. Discussion 273–5.

15. Truelove SC, Witts LJ. Cortisone in ulcerative colitis; final report on a therapeutic trial. *Br Med J*. 1955;2(4947):1041–8.

16. Silverberg MS, Satsangi J, Ahmad T, Ahmad T, Arnott I, Bernstein CN, Brant SR, et al. Toward an integrated clinical, molecular and serological classification of inflammatory bowel disease: report of a Working Party of the 2005 Montreal World Congress of Gastroenterology. *Can J Gastroenterol*. 2005;19(Suppl A):5A–36A.

17. Schroeder KW, Tremaine WJ, Ilstrup DM. Coated oral 5-aminosalicylic acid therapy for mildly to moderately active ulcerative colitis. A randomized study. *N Engl J Med*. 1987;317(26):1625–9.

18. Walmsley RS, Ayres RC, Pounder RE, Allan RN. A simple clinical colitis activity index. *Gut*. 1998;43(1):29–32.

19. Holubar SD, Long KH, Loftus Jr EV, Wolff BG, Pemberton JH, Cima RR. Long-term direct costs before and after proctocolectomy for ulcerative colitis: A population-based study in Olmsted County, Minnesota. *Dis Colon Rectum*. 2009;52(11):1815–23.

20. Holubar SD, Pendlimari R, Loftus Jr EV, Moriarty JP, Larson D, O’Byrne M, et al. Drivers of cost after surgical and medical therapy for chronic ulcerative colitis. *Dis Colon Rectum*. 2012;55(12):1258–65.

21. Park KT, Tsai R, Perez F, Cipriano LE, Bass D, Garber AM. Cost-effectiveness of early colectomy with ileal pouch-anal anastomosis versus standard medical therapy in severe ulcerative colitis. *Ann Surg*. 2012;256(1):117–24.

22. Holubar SD, Piazik B, Xu K, Dulai P, Tosteson A, Siegel C, Finlayson S. Cost - effectiveness of infliximab versus colectomy for severe ulcerative colitis: a Markov analysis: P - 108. *Inflamm Bowel Dis*. 2012;18:S57–8.

23. Feagan BG, Macdonald JK. Oral 5-aminosalicylic acid for maintenance of remission in ulcerative colitis (Review). *Cochrane Database Syst Rev*. 2012;10, CD000544.

24. Nguyen GC, Gulamhusein A, Bernstein CN. 5-aminosalicylic acid is not protective against colorectal cancer in inflammatory bowel disease: a meta-analysis of non-referral populations. *Am J Gastroenterol*. 2012;107(9):1298–304. quiz 1297–1305.

25. Osterman MT, Kundu R, Lichtenstein GR, Lewis JD. Association of 6-thioguanine nucleotide levels and inflammatory bowel disease activity: a meta-analysis. *Gastroenterology*. 2006;130(4):1047–53.

26. Dassopoulos T, Dubinsky MC, Bentsen JL, Martin CF, Galanko JA, Seidman EG, et al.

Randomised clinical trial: individualised vs. weight-based dosing of azathioprine in Crohn's disease. *Aliment Pharmacol Ther.* 2014;39(2):163–75.

27. Siegel CA, Marden SM, Persing SM, Larson RJ, Sands BE. Risk of lymphoma associated with combination anti-tumor necrosis factor and immunomodulator therapy for the treatment of Crohn's disease: a meta-analysis. *Clin Gastroenterol Hepatol.* 2009;7(8):874–81.

28. Drobne D, Bossuyt P, Breynaert C, Cattaert T, Vande Casteele N, Compernelle G, et al. Withdrawal of immunomodulators after co-treatment does not reduce trough level of infliximab in patients with Crohn's disease. *Clin Gastroenterol Hepatol.* 2015;13(3):514–4.

29. Colombel J-F, Sandborn WJ, Reinisch W, Mantzaris GJ, Kornbluth A, Rachmilewitz D, et al. Infliximab, azathioprine, or combination therapy for Crohn's disease. *N Engl J Med.* 2010;362(15):1383–95.

30. Rutgeerts P, Sandborn WJ, Feagan BG, Reinisch W, Olson A, Johanns J, et al. Infliximab for induction and maintenance therapy for ulcerative colitis. *N Engl J Med.* 2005;353(23): 2462–76.

31. Panaccione R, Ghosh S, Middleton S, Márquez JR, Scott BB, Flint L, et al. Combination therapy with infliximab and azathioprine is superior to monotherapy with either agent in ulcerative colitis. *Gastroenterology.* 2014;146(2):392–3.

32. Singh JA, Wells GA, Christensen R, Tanjong Ghogomu E, Maxwell L, Macdonald JK, et al. Adverse effects of biologics: a network meta-analysis and Cochrane overview. *Cochrane Database Syst Rev.* 2011;2, CD008794.

33. Mariette X, Tubach F, Bagheri H, Bardet M, Berthelot JM, Gaudin P, et al. Lymphoma in patients treated with anti-TNF: results of the 3-year prospective French RATIO registry. *Ann Rheum Dis.* 2010;69(2):400–8.

34. Selvasekar C, Cima R, Larson D, Dozois E, Harrington J, Harmsen W, et al. Effect of infliximab on short-term complications in patients undergoing operation for chronic ulcerative colitis. *J Am Coll Surg.* 2007;204(5):956–62.

35. Gu J, Remzi FH, Shen B, Vogel JD, Kiran RP. Operative strategy modifies risk of pouch-related outcomes in patients with ulcerative colitis on preoperative anti-tumor necrosis factor- $\alpha$  therapy. *Dis Colon Rectum.* 2013;56(11):1243–52.

36. Holubar SD, Holder-Murray J, Flasar M, Lazarev M. Anti-tumor necrosis factor- $\alpha$  antibody therapy management before and after intestinal surgery for inflammatory bowel disease. *Inflamm Bowel Dis.* 2015;21(11):2658–72.

37. Sandborn WJ, Feagan BG, Marano C, Zhang H, Strauss R, Johanns J, et al. Subcutaneous golimumab induces clinical response and remission in patients with moderate-to-severe ulcerative colitis. *Gastroenterology.* 2014;146(1):85–95. quiz 14–5.

38. Sandborn WJ, Feagan BG, Marano C, Zhang H, Strauss R, Johanns J, et al. Subcutaneous golimumab maintains clinical response in patients with moderate-to-severe ulcerative colitis. *Gastroenterology.* 2014;146(1):96–109e.1.

39. Fedyk ER, Wyant T, Yang L-L, Csizmadia V, Burke K, Yang H, et al. Exclusive antagonism of the  $\alpha 4 \beta 7$  integrin by vedolizumab confirms the gut-selectivity of this pathway in primates. *Inflamm Bowel Dis.* 2012;18(11):2107–19.

40. Feagan BG, Rutgeerts P, Sands BE, Hanauer S, Colombel J-F, Sandborn WJ, et al. Vedolizumab as induction and maintenance therapy for ulcerative colitis. *N Engl J Med.* 2013;369(8): 699–710.

41. Targan SR, Feagan BG, Fedorak RN, Lashner BA, Panaccione R, Present DH, et al. Natalizumab for the treatment of active crohn's disease: Results of the ENCORE Trial. *Gastroenterology.*

2007;132(5):1672–83.

42. Rhen T, Cidlowski JA. Antiinflammatory action of glucocorticoids—new mechanisms for old drugs. *N Engl J Med*. 2005;353(16):1711–23.
43. Sandborn WJ, Travis S, Moro L, Jones R, Gaultier T, Bagin R, et al. Once-daily budesonide MMX® extended-release tablets induce remission in patients with mild to moderate ulcerative colitis: results from the CORE I study. *Gastroenterology*. 2012;143(5):1218–26e1–2.
44. Sandborn WJ, Bosworth B, Zakko S, Gordon GL, Clemmons DR, Golden PL, et al. Budesonide foam induces remission in patients with mild to moderate ulcerative proctitis and ulcerative proctosigmoiditis. *Gastroenterology*. 2015;148(4):740–2.
45. Schoon EJ, Bollani S, Mills PR, Israeli E, Felsenberg D, Ljunghall S, et al. Bone mineral density in relation to efficacy and side effects of budesonide and prednisolone in Crohn's disease. *Clin Gastroenterol Hepatol*. 2005;3(2):113–21.
46. Faubion Jr WA, Loftus Jr EV, Harmsen WS, Zinsmeister AR, Sandborn WJ. The natural history of corticosteroid therapy for inflammatory bowel disease: a population-based study. *Gastroenterology*. 2001;121(2):255–60.
47. Farrell RJ, Alsahli M, Jeen Y-T, Falchuk KR, Peppercorn MA, Michetti P. Intravenous hydrocortisone premedication reduces antibodies to infliximab in Crohn's disease: a randomized controlled trial. *Gastroenterology*. 2003;124(4):917–24.
48. Marik PE, Varon J. Requirement of perioperative stress doses of corticosteroids: a systematic review of the literature. *Arch Surg*. 2008;143(12):1222–6.
49. Zaghiyan K, Melmed GY, Berel D, Ovsepyan G, Murrell Z, Fleshner P. A prospective, randomized, noninferiority trial of steroid dosing after major colorectal surgery. *Ann Surg*. 2014;259(1):32–7.
50. Narula N, Fine M, Colombel J-F, Marshall JK, Reinisch W. Systematic review: sequential rescue therapy in severe ulcerative colitis: do the benefits outweigh the risks? *Inflamm Bowel Dis*. 2015;21:1683–92.
51. El-Matary W, Vandermeer B, Griffiths AM. Methotrexate for maintenance of remission in ulcerative colitis. *Cochrane Database Syst Rev*. 2009;3, CD007560.
52. Chande N, Wang Y, Macdonald JK, McDonald JWD. Methotrexate for induction of remission in ulcerative colitis. *Cochrane Database Syst Rev*. 2014;8, CD006618.
53. Regueiro M, Loftus EV, Steinhart AH, Cohen RD, Inflammatory Bowel Disease Center. Clinical guidelines for the medical management of left-sided ulcerative colitis and ulcerative proctitis: summary statement. *Inflamm Bowel Dis*. 2006;12(10):972–8.
54. Safdi M, DeMicca M, Snisky C, Banks P, Wruble L, Deren J, et al. A double-blind comparison of oral versus rectal mesalamine versus combination therapy in the treatment of distal ulcerative colitis. *Am J Gastroenterol*. 1997;92(10):1867–71.
55. Feagan BG, Macdonald JK. Oral 5-aminosalicylic acid for induction of remission in ulcerative colitis. *Cochrane Database Syst Rev*. 2012;10, CD000543.
56. Timmer A, McDonald JWD, Tsoulis DJ, Macdonald JK. Azathioprine and 6-mercaptopurine for maintenance of remission in ulcerative colitis. *Cochrane Database Syst Rev*. 2012;9, CD000478.
57. Lawlor G, Moss AC. Cytomegalovirus in inflammatory bowel disease: pathogen or innocent bystander? *Inflamm Bowel Dis*. 2010;16(9):1620–7.
58. Palmer KR, Duerden BI, Holdsworth CD. Bacteriological and endotoxin studies in cases of ulcerative colitis submitted to surgery. *Gut*. 1980;21(10):851–4.

59. Lichtiger S, Present DH, Kornbluth A, Gelernt I, Bauer J, Galler G, et al. Cyclosporine in severe ulcerative colitis refractory to steroid therapy. *N Engl J Med*. 1994;330(26):1841–5.
60. Moskovitz DN, Van Assche G, Maenhout B, Arts J, Ferrante M, Vermeire S, et al. Incidence of colectomy during long-term follow-up after cyclosporine-induced remission of severe ulcerative colitis. *Clin Gastroenterol Hepatol*. 2006;4(6):760–5.
61. Gustavsson A, Järnerot G, Hertervig E, Friis-Liby I, Blomquist L, Karlen P, et al. Clinical trial: colectomy after rescue therapy in ulcerative colitis—3-year follow-up of the Swedish-Danish controlled infliximab study. *Aliment Pharmacol Ther*. 2010; 32(8):984–9.
62. Sands BE, Tremaine WJ, Sandborn WJ, Rutgeerts PJ, Hanauer SB, Mayer L, et al. Infliximab in the treatment of severe, steroid-refractory ulcerative colitis: a pilot study. *Inflamm Bowel Dis*. 2001;7(2):83–8.
63. Laharie D, Bourreille A, Branche J, Allez M, Bouhnik Y, Filippi J, et al. Ciclosporin versus infliximab in patients with severe ulcerative colitis refractory to intravenous steroids: a parallel, open-label randomised controlled trial. *Lancet*. 2012; 380(9857):1909–15.
64. Leblanc S, Allez M, Seksik P, Eacute BF, Peeters H, Dupas JL, et al. Successive treatment with cyclosporine and infliximab in steroid-refractory ulcerative colitis. *Am J Gastroenterol*. 2011;106(4):771–7.
65. Holubar SD, Privitera A, Cima RR, Dozois EJ, Pemberton JH, Larson DW. Minimally invasive total proctocolectomy with Brooke ileostomy for ulcerative colitis. *Inflamm Bowel Dis*. 2009;15(9):1337–42.
66. Roberts SE, Williams JG, Yeates D, Goldacre MJ. Mortality in patients with and without colectomy admitted to hospital for ulcerative colitis and Crohn's disease: record linkage studies. *BMJ*. 2007;335(7628):1033–3.
67. Randall J, Singh B, Warren BF, Travis SPL, Mortensen NJ, George BD. Delayed surgery for acute severe colitis is associated with increased risk of postoperative complications. *Br J Surg*. 2010;97(3):404–9.
68. Gross ME, Vogler SA, Mone MC, Sheng X, Sklow B. The importance of extended postoperative venous thromboembolism prophylaxis in IBD. *Dis Colon Rectum*. 2014;57(4): 482–9.
69. Group ES. Efficacy and safety of enoxaparin versus unfractionated heparin for prevention of deep vein thrombosis in elective cancer surgery: a double-blind randomized multicentre trial with venographic assessment. *Br J Surg*. 1997;84(8): 1099–103.
70. Bergqvist D, Agnelli G, Cohen A, Eldor A, Nilsson P, Le Moigne-Amrani A, et al. Duration of prophylaxis against venous thromboembolism with enoxaparin after surgery for cancer. *N Engl J Med*. 2002;346(13):975–80.
71. Greaves SW, Holubar SD. Preoperative hospitalization is independently associated with increased risk for venous thromboembolism in patients undergoing colorectal surgery: A National Surgical Quality Improvement Program Database Study. *Dis Colon Rectum*. 2015;58(8):782–91.
72. Paquette IM, Solan P, Rafferty JF, Ferguson MA, Davis BR. Readmission for dehydration or renal failure after ileostomy creation. *Dis Colon Rectum*. 2013;56(8):974–9.
73. Nagle D, Pare T, Keenan E, Marcet K, Tizio S, Poylin V. Ileostomy pathway virtually eliminates readmissions for dehydration in new ostomates. *Dis Colon Rectum*. 2012;55(12):1266–72.
74. Holubar SD, Cima RR, Sandborn WJ, Pardi DS. Treatment and prevention of pouchitis after ileal pouch-anal anastomosis for chronic ulcerative colitis. *Cochrane Database Syst Rev*. 2010;6:1–37.

75. Mahadevan U. Medical treatment of ulcerative colitis. *Clin Colon Rectal Surg.* 2004;17(1):7–19.
76. Loftus EV. Epidemiology of inflammatory bowel disease. In: Talley NJ, editor. *GI epidemiology*. 2nd ed. Hoboken, NJ: Wiley Blackwell; 2014. p. 273–84.

## 第 47 章

1. Gasche C, Scholmerich J, Brynskov J, D’Haens G, Hanauer SB, Irvine EJ, Jewell DP, Rachmilewitz D, Sachar DB, Sandborn WJ, Sutherland LR. A simple classification of Crohn’s disease: report of the Working Party for the World Congresses of Gastroenterology, Vienna 1998. *Inflamm Bowel Dis.* 2000;6:8–15.
2. Silverberg MS, Satsangi J, Ahmad T, Arnott ID, Bernstein CN, Brant SR, Caprilli R, Colombel JF, Gasche C, Geboes K, Jewell DP, Karban A, Loftus Jr EV, Peña AS, Riddell RH, Sachar DB, Schreiber S, Steinhart AH, Targan SR, Vermeire S, Warren BF. Toward an integrated clinical, molecular and serological classification of inflammatory bowel disease: report of a Working Party of the 2005 Montreal World Congress of Gastroenterology. *Can J Gastroenterol.* 2005;19(Suppl A):5–36.
3. Satsangi J, Silverberg MS, Vermeire S, Colombel J-F. The Montreal classification of inflammatory bowel disease: controversies, consensus, and implications. *Gut.* 2006;55(6):749–53.
4. Fedorak RN. Is it time to re-classify Crohn’s disease? *Best Pract Res Clin Gastroenterol.* 2004;18 Suppl:99–106.
5. Louis E, Collard A, Oger AF, Degroote E, Aboul Nasr El Yafi FA, Belaiche J. Behaviour of Crohn’s disease according to the Vienna classification: changing pattern over the course of the disease. *Gut.* 2001;49:777–82.
6. Freeman HJ. Application of the Vienna Classification for Crohn’s disease to a single clinician database of 877 patients. *Can J Gastroenterol.* 2001;15:89–93.
7. Papi C, Festa V, Fagnani C, Stazi A, Antonelli G, Moretti A, Koch M, Capurso L. Evolution of clinical behaviour in Crohn’s disease: predictive factors of penetrating complications. *Dig Liver Dis.* 2005;37:247–53.
8. Lovasz BD, Lakatos L, Horvath A, Szita I, Pandur T, Mandel M, Vegh Z, Golovics PA, Mester G, Balogh M, Molnar C, Komaromi E, Kiss LS, Lakatos PL. Evolution of disease phenotype in adult and pediatric onset Crohn’s disease in a population-based cohort. *World J Gastroenterol.* 2013;19:2217–26.
9. Krishnaprasad K, Andrews JM, Lawrance IC, Florin T, Gearry RB, Leong RW, Mahy G, Bampton P, Prosser R, Leach P, Chitti L, Cock C, Grafton R, Croft AR, Cooke S, Doecke JD, Radford-Smith GL. Inter-observer agreement for Crohn’s disease sub-phenotypes using the Montreal Classification: how good are we? A multi-centre Australasian study. *J Crohns Colitis.* 2012;6:287–93.
10. Spekhorst LM, Visschedijk MC, Alberts R, Festen EA, van der Wouden EJ, Dijkstra G, Weersma RK, Dutch Initiative on Crohn and Colitis. Performance of the Montreal classification for inflammatory bowel diseases. *World J Gastroenterol.* 2014;20:15374–81.
11. Leiman DA, Lichtenstein GR. Therapy of inflammatory bowel disease: what to expect in the next decade. *Curr Opin Gastroenterol.* 2014;30:385–90.
12. Best WR, Becktel JM, Singleton JW, Kern Jr F. Development of a Crohn’s disease activity index.

- National Cooperative Crohn's Disease Study. *Gastroenterology*. 1976;70:439–44.
13. Sandler RS, Jordan MC, Kupper LL. Development of a Crohn's index for survey research. *J Clin Epidemiol*. 1988;41:451–8.
  14. Thia K, Faubion Jr WA, Loftus Jr EV, Persson T, Persson A, Sandborn WJ. Short CDAI: development and validation of a shortened and simplified Crohn's disease activity index. *Inflamm Bowel Dis*. 2011;17:105–11.
  15. Harvey RF, Bradshaw JM. A simple index of Crohn's-disease activity. *Lancet*. 1980;1:514.
  16. Vermeire S, Schreiber S, Sandborn WJ, Dubois C, Rutgeerts P. Correlation between the Crohn's disease activity and Harvey-Bradshaw indices in assessing Crohn's disease severity. *Clin Gastroenterol Hepatol*. 2010;8:357–63.
  17. Mary JY, Modigliani R. Development and validation of an endoscopic index of the severity for Crohn's disease: a prospective multicentre study. Groupe d'Etudes Thérapeutiques des Affections Inflammatoires du Tube Digestif (GETAID). *Gut*. 1989;30:983–9.
  18. Khanna R, Bouguen G, Feagan BG, D'Haens G, Sandborn WJ, Dubcenco E, Baker KA, Levesque BG. A systematic review of measurement of endoscopic disease activity and mucosal healing in Crohn's disease: recommendations for clinical trial design. *Inflamm Bowel Dis*. 2014;20:1850–61.
  19. Mary JY, Modigliani R. Development and validation of an endoscopic index of the severity for Crohn's disease: a prospective multicentre study. Groupe d'Etudes Thérapeutiques des Affections Inflammatoires du Tube Digestif (GETAID). *Gut*. 1989;30(7):983–9.
  20. Daperno M, D'Haens G, Van Assche G, Baert F, Bulois P, Maunoury V, Sostegni R, Rocca R, Pera A, Gevers A, Mary JY, Colombel JF, Rutgeerts P. Development and validation of a new, simplified endoscopic activity score for Crohn's disease: the SES-CD. *Gastrointest Endosc*. 2004;60:505–12.
  21. Cellier C, Sahmoud T, Froguel E, Adenis A, Belaiche J, Bretagne JF, Florent C, Bouvry M, Mary JY, Modigliani R. Correlations between clinical activity, endoscopic severity, and biological parameters in colonic or ileocolonic Crohn's disease. A prospective multicentre study of 121 cases. The Groupe d'Etudes Thérapeutiques des Affections Inflammatoires Digestives. *Gut*. 1994;35:231–5.
  22. Schoepfer AM, Beglinger C, Straumann A, Trummel M, Vavricka SR, Bruegger LE, Seibold F. Fecal calprotectin correlates more closely with the Simple Endoscopic Score for Crohn's disease (SES-CD) than CRP, blood leukocytes, and the CDAI. *Am J Gastroenterol*. 2010;105:162–9.
  23. Levesque BG, Sandborn WJ, Ruel J, Feagan BG, Sands BE, Colombel JF. Converging goals of treatment of inflammatory bowel disease from clinical trials and practice. *Gastroenterology*. 2015;148:37–51.
  24. Byrne CM, Solomon MJ, Young JM, Selby W, Harrison JD. Patient preferences between surgical and medical treatment in Crohn's disease. *Dis Colon Rectum*. 2007;50:586–97.
  25. Rolfe VE, Fortun PJ, Hawkey CJ, Bath-Hextall F. Probiotics for maintenance of remission in Crohn's disease. *Cochrane Database Syst Rev*. 2006;(4):CD004826.
  26. Butterworth AD, Thomas AG, Akobeng AK. Probiotics for induction of remission in Crohn's disease. *Cochrane Database Syst Rev*. 2008;(3):CD006634.
  27. Jonkers D, Penders J, Masclee A, Pierik M. Probiotics in the management of inflammatory bowel disease: a systematic review of intervention studies in adult patients. *Drugs*. 2012;72:803–23.



28. Kale-Pradhan PB, Zhao JJ, Palmer JR, Wilhelm SM. The role of antimicrobials in Crohn's disease. *Expert Rev Gastroenterol Hepatol*. 2013;7:281–8.
29. Scribano ML, Prantera C. Use of antibiotics in the treatment of Crohn's disease. *World J Gastroenterol*. 2013;19:648–53.
30. Feller M, Huwiler K, Schoepfer A, Shang A, Furrer H, Egger M. Long-term antibiotic treatment for Crohn's disease: systematic review and meta-analysis of placebo-controlled trials. *Clin Infect Dis*. 2010;50:473–80.
31. Khan KJ, Ullman TA, Ford AC, Abreu MT, Abadir A, Marshall JK, Talley NJ, Moayyedi P. Antibiotic therapy in inflammatory bowel disease: a systematic review and meta-analysis. *Am J Gastroenterol*. 2011;106:661–73.
32. Lichtenstein GR, Hanauer SB, Sandborn WJ, Practice Parameters Committee of American College of Gastroenterology. Management of Crohn's disease in adults. *Am J Gastroenterol*. 2009;104:465–83.
33. Cheifetz AS. Management of active Crohn disease. *JAMA*. 2013;309:2150–8.
34. Ford AC, Kane SV, Khan KJ, Achkar JP, Talley NJ, Marshall JK, Moayyedi P. Efficacy of 5-aminosalicylates in Crohn's disease: systematic review and meta-analysis. *Am J Gastroenterol*. 2011;106:617–29.
35. Criscuoli V, Modesto I, Orlando A, Cottone M. Mesalazine for the treatment of inflammatory bowel disease. *Expert Opin Pharmacother*. 2013;14:1669–78.
36. Munkholm P, Langholz E, Davidsen M, Binder V. Frequency of glucocorticoid resistance and dependency in Crohn's disease. *Gut*. 1994;35:360–2.
37. Faubion Jr WA, Loftus Jr EV, Harmsen WS, Zinsmeister AR, Sandborn WJ. The natural history of corticosteroid therapy for inflammatory bowel disease: a population-based study. *Gastroenterology*. 2001;121:255–60.
38. Franchimont DP, Louis E, Croes F, Belaiche J. Clinical pattern of corticosteroid dependent Crohn's disease. *Eur J Gastroenterol Hepatol*. 1998;10:821–5.
39. Ford AC, Bernstein CN, Khan KJ, Abreu MT, Marshall JK, Talley NJ, Moayyedi P. Glucocorticosteroid therapy in inflammatory bowel disease: systematic review and meta-analysis. *Am J Gastroenterol*. 2011;106:590–9.
40. Kuenzig ME, Rezaie A, Seow CH, Otley AR, Steinhart AH, Griffiths AM, Kaplan GG, Benchimol EI. Budesonide for maintenance of remission in Crohn's disease. *Cochrane Database Syst Rev*. 2014;(8):CD002913.
41. Beaugerie L, Brousse N, Bouvier AM, Colombel JF, Lémann M, Cosnes J, Hébuterne X, Cortot A, Bouhnik Y, Gendre JP, Simon T, Maynadié M, Hermine O, Faivre J, Carrat F, CESAME Study Group. Lymphoproliferative disorders in patients receiving thiopurines for inflammatory bowel disease: a prospective observational cohort study. *Lancet*. 2009;374:1617–25.
42. Chaparro M, Ordás I, Cabré E, Garcia-Sanchez V, Bastida G, Peñalva M, Gomollón F, García-Planella E, Merino O, Gutiérrez A, Esteve M, Márquez L, Garcia-Sepulcre M, Hinojosa J, Vera I, Muñoz F, Mendoza JL, Cabriada JL, Montoro MA, Barreiro-de Acosta M, Ceña G, Saro C, Aldeguer X, Barrio J, Maté J, Gisbert JP. Safety of thiopurine therapy in inflammatory bowel disease: long-term follow-up study of 3931 patients. *Inflamm Bowel Dis*. 2013;19:1404–10.
43. Dassopoulos T, Sultan S, Falck-Ytter YT, Inadomi JM, Hanauer SB. American Gastroenterological Association Institute technical review on the use of thiopurines, methotrexate, and anti-TNF- $\alpha$  biologic drugs for the induction and maintenance of remission in inflammatory

Crohn's disease. *Gastroenterology*. 2013;145:1464–78.

44. Khan KJ, Dubinsky MC, Ford AC, Ullman TA, Talley NJ, Moayyedi P. Efficacy of immunosuppressive therapy for inflammatory bowel disease: a systematic review and meta-analysis. *Am J Gastroenterol*. 2011;106:630–42.

45. Lichtenstein GR, Feagan BG, Cohen RD, Salzberg BA, Diamond RH, Price S, Langholff W, Londhe A, Sandborn WJ. Serious infection and mortality in patients with Crohn's disease: more than 5 years of follow-up in the TREAT™ registry. *Am J Gastroenterol*. 2012;107:1409–22.

46. McDonald JW, Tsoulis DJ, Macdonald JK, Feagan BG. Methotrexate for induction of remission in refractory Crohn's disease. *Cochrane Database Syst Rev*. 2012;12:CD003459.

47. Patel V, Wang Y, MacDonald JK, McDonald JW, Chande N. Methotrexate for maintenance of remission in Crohn's disease. *Cochrane Database Syst Rev*. 2014;(8):CD006884.

48. Singh S, Garg SK, Pardi DS, Wang Z, Murad MH, Loftus Jr EV. Comparative efficacy of biologic therapy in biologic-naïve patients with Crohn disease: a systematic review and network meta-analysis. *Mayo Clin Proc*. 2014;89:1621–35.

49. Dignass A, Van Assche G, Lindsay JO, Lémann M, Söderholm J, Colombel JF, Danese S, D'Hoore A, Gassull M, Gomollón F, Hommes DW, Michetti P, O'Morain C, Oresland T, Windsor A, Stange EF, Travis SP, European Crohn's and Colitis Organisation (ECCO). The second European evidence-based Consensus on the diagnosis and management of Crohn's disease: current management. *J Crohns Colitis*. 2010;4:28–62.

50. Orlando A, Armuzzi A, Papi C, Annese V, Ardizzone S, Biancone L, Bortoli A, Castiglione F, D'Inca R, Gionchetti P, Kohn A, Poggioli G, Rizzello F, Vecchi M, Cottone M, Italian Society of Gastroenterology; Italian Group for the study of Inflammatory Bowel Disease. The Italian Society of Gastroenterology (SIGE) and the Italian Group for the study of Inflammatory Bowel Disease (IG-IBD) Clinical Practice Guidelines: the use of tumor necrosis factor-alpha antagonist therapy in inflammatory bowel disease. *Dig Liver Dis*. 2011;43:1–20.

51. Ueno F, Matsui T, Matsumoto T, Matsuoka K, Watanabe M, Hibi T, Guidelines Project Group of the Research Group of Intractable Inflammatory Bowel Disease subsidized by the Ministry of Health, Labour and Welfare of Japan and the Guidelines Committee of the Japanese Society of Gastroenterology. Evidence-based clinical practice guidelines for Crohn's disease, integrated with formal consensus of experts in Japan. *J Gastroenterol*. 2013;48:31–72.

52. Terdiman JP, Gruss CB, Heidelbaugh JJ, Sultan S, Falck-Ytter YT, AGA Institute Clinical Practice and Quality Management Committee. American Gastroenterological Association Institute guideline on the use of thiopurines, methotrexate, and anti-TNF- $\alpha$  biologic drugs for the induction and maintenance of remission in inflammatory Crohn's disease. *Gastroenterology*. 2013;145:1459–63.

53. Hazlewood GS, Rezaie A, Borman M, Panaccione R, Ghosh S, Seow CH, Kuenzig E, Tomlinson G, Siegel CA, Melmed GY, Kaplan GG. Comparative effectiveness of immunosuppressants and biologics for inducing and maintaining remission in Crohn's disease: a network meta-analysis. *Gastroenterology*. 2015;148:344–54.

54. Pariente B, Laharie D. Review article: why, when and how to de-escalate therapy in inflammatory bowel diseases. *Aliment Pharmacol Ther*. 2014;40:338–53.

55. Frolkis AD, Dykeman J, Negrón ME, Debruyn J, Jette N, Fiest KM, Frolkis T, Barkema HW, Rioux KP, Panaccione R, Ghosh S, Wiebe S, Kaplan GG. Risk of surgery for inflammatory bowel diseases has decreased over time: a systematic review and meta-analysis of population based studies.

Gastroenterology. 2013;145:996–1006.

56. Buisson A, Chevaux JB, Allen PB, Bommelaer G, Peyrin-Biroulet L. Review article: the natural history of postoperative Crohn's disease recurrence. *Aliment Pharmacol Ther.* 2012;35:625–33.

57. Singh S, Garg SK, Pardi DS, Wang Z, Murad MH, Loftus Jr EV. Comparative efficacy of pharmacologic interventions in preventing relapse of Crohn's disease after surgery: a systematic review and network meta-analysis. *Gastroenterology.* 2015;148:64–76.

## 第 48 章

1. Lazarev M, Huang C, Bitton A, et al. Relationship between proximal Crohn's disease location and disease behavior and surgery: a cross-sectional study of the IBD Genetics Consortium. *Am J Gastroenterol.* 2013;108(1):106–12.

2. Crohn BB, Ginzburg L, Oppenheimer GD. Regional Ileitis. A pathologic and clinical entity. *JAMA.* 1932;99(16):1323–9.

3. Bissell AD. Localized chronic ulcerative ileitis. *Ann Surg.* 1934;99(6):957–66.

4. Penner A, Crohn BB. Perianal fistulae as a complication of regional ileitis. *Ann Surg.* 1938;108(5):867–73.

5. Ingle SB, Loftus Jr EV. The natural history of perianal Crohn's disease. *Dig Liver Dis.* 2007;39(10):963–9.

6. Kanaan Z, Ahmad S, Bilchuk N, Vahrenhold C, Pan J, Galandiuk S. Perianal Crohn's disease: predictive factors and genotype-phenotype correlations. *Dig Surg.* 2012;29(2):107–14.

7. Eglinton TW, Barclay ML, Gearry RB, Frizelle FA. The spectrum of perianal Crohn's disease in a population-based cohort. *Dis Colon Rectum.* 2012;55(7):773–7.

8. Hellers G, Bergstrand O, Ewerth S, Holmstrom B. Occurrence and outcome after primary treatment of anal fistulae in Crohn's disease. *Gut.* 1980;21(6):525–7.

9. Keljo DJ, Markowitz J, Langton C, et al. Course and treatment of perianal disease in children newly diagnosed with Crohn's disease. *Inflamm Bowel Dis.* 2009;15(3):383–7.

10. Gray BK, Lockhart-Mummery HE, Morson BC. Crohn's disease of the anal region. *Gut.* 1965;6(6):515–24.

11. Beaugerie L, Seksik P, Nion-Larmurier I, Gendre JP, Cosnes J. Predictors of Crohn's disease. *Gastroenterology.* 2006;130(3):650–6.

12. Rankin GB, Watts HD, Melnyk CS, Kelley Jr ML. National Cooperative Crohn's Disease Study: extraintestinal manifestations and perianal complications. *Gastroenterology.* 1979;77(4 Pt 2):914–20.

13. Gelbmann CM, Rogler G, Gross V, et al. Prior bowel resections, perianal disease, and a high initial Crohn's disease activity index are associated with corticosteroid resistance in active Crohn's disease. *Am J Gastroenterol.* 2002;97(6):1438–45.

14. Vermeire S, Pierik M, Hlavaty T, et al. Association of organic cation transporter risk haplotype with perianal penetrating Crohn's disease but not with susceptibility to IBD. *Gastroenterology.* 2005;129(6):1845–53.

15. Armuzzi A, Ahmad T, Ling KL, et al. Genotype-phenotype analysis of the Crohn's disease susceptibility haplotype on chromosome 5q31. *Gut.* 2003;52(8):1133–9.

16. Latiano A, Palmieri O, Cucchiara S, et al. Polymorphism of the IRGM gene might predispose

- to fistulizing behavior in Crohn's disease. *Am J Gastroenterol*. 2009;104(1):110–6.
17. Brant SR, Picco MF, Achkar JP, et al. Defining complex contributions of NOD2/CARD15 gene mutations, age at onset, and tobacco use on Crohn's disease phenotypes. *Inflamm Bowel Dis*. 2003;9(5):281–9.
  18. Hughes LE. Surgical pathology and management of anorectal Crohn's disease. *J R Soc Med*. 1978;71(9):644–51.
  19. Parks AG. Pathogenesis and treatment of fistula-in-ano. *Br Med J*. 1961;1(5224):463–9.
  20. Schwartz DA, Wiersema MJ, Dudiak KM, et al. A comparison of endoscopic ultrasound, magnetic resonance imaging, and exam under anesthesia for evaluation of Crohn's perianal fistulas. *Gastroenterology*. 2001;121(5):1064–72.
  21. Hughes LE. Clinical classification of perianal Crohn's disease. *Dis Colon Rectum*. 1992;35(10):928–32.
  22. Pikarsky AJ, Gervaz P, Wexner SD. Perianal Crohn disease: a new scoring system to evaluate and predict outcome of surgical intervention. *Arch Surg*. 2002;137(7):774–7.
  23. Francois Y, Vignal J, Descos L. Outcome of perianal fistulae in Crohn's disease—value of Hughes' pathogenic classification. *Int J Colorectal Dis*. 1993;8(1):39–41.
  24. American Gastroenterological Association medical position statement: perianal Crohn's disease. *Gastroenterology* 2003; 125(5):1503–1507.
  25. Sandborn WJ, Fazio VW, Feagan BG, Hanauer SB. AGA technical review on perianal Crohn's disease. *Gastroenterology*. 2003;125(5):1508–30.
  26. Bonheur JL, Braunstein J, Korelitz BI, Panagopoulos G. Anal skin tags in inflammatory bowel disease: new observations and a clinical review. *Inflamm Bowel Dis*. 2008;14(9):1236–9.
  27. Peyrin-Biroulet L, Loftus Jr EV, Tremaine WJ, Harmsen WS, Zinsmeister AR, Sandborn WJ. Perianal Crohn's disease findings other than fistulas in a population-based cohort. *Inflamm Bowel Dis*. 2012;18(1):43–8.
  28. Taylor BA, Williams GT, Hughes LE, Rhodes J. The histology of anal skin tags in Crohn's disease: an aid to confirmation of the diagnosis. *Int J Colorectal Dis*. 1989;4(3):197–9.
  29. Jeffery PJ, Parks AG, Ritchie JK. Treatment of haemorrhoids in patients with inflammatory bowel disease. *Lancet*. 1977;1(8021):1084–5.
  30. Wolkomir AF, Luchtefeld MA. Surgery for symptomatic hemorrhoids and anal fissures in Crohn's disease. *Dis Colon Rectum*. 1993;36(6):545–7.
  31. Cracco N, Zinicola R. Is haemorrhoidectomy in inflammatory bowel disease harmful? An old dogma re-examined. *Colorectal Dis*. 2014;16(7):516–9.
  32. Klosterhalfen B, Vogel P, Rixen H, Mittermayer C. Topography of the inferior rectal artery: a possible cause of chronic, primary anal fissure. *Dis Colon Rectum*. 1989;32(1):43–52.
  33. Schouten WR, Briel JW, Auwerda JJ. Relationship between anal pressure and anodermal blood flow. The vascular pathogenesis of anal fissures. *Dis Colon Rectum*. 1994;37(7):664–9.
  34. Fleshner PR, Schoetz Jr DJ, Roberts PL, Murray JJ, Collier JA, Veidenheimer MC. Anal fissure in Crohn's disease: a plea for aggressive management. *Dis Colon Rectum*. 1995;38(11):1137–43.
  35. Sweeney JL, Ritchie JK, Nicholls RJ. Anal fissure in Crohn's disease. *Br J Surg*. 1988;75(1):56–7.
  36. Figg RE, Church JM. Perineal Crohn's disease: an indicator of poor prognosis and potential proctectomy. *Dis Colon Rectum*. 2009;52(4):646–50.
  37. Pfenninger JL, Zainea GG. Common anorectal conditions. *Obstet Gynecol*. 2001;98(6):1130–9.

38. American Gastroenterological Association medical position statement. Diagnosis and care of patients with anal fissure. *Gastroenterology*. 2003;124(1):233–4.
39. Perry WB, Dykes SL, Buie WD, Rafferty JF. Practice parameters for the management of anal fissures (3rd revision). *Dis Colon Rectum*. 2010;53(8):1110–5.
40. Asim M, Lowrie N, Stewart J, Lolohea S, Van DR. Botulinum toxin versus botulinum toxin with low-dose glyceryltrinitrate for healing of chronic anal fissure: a prospective, randomised trial. *N Z Med J*. 2014;127(1393):80–6.
41. Bailey HR, Beck DE, Billingham RP, et al. A study to determine the nitroglycerin ointment dose and dosing interval that best promote the healing of chronic anal fissures. *Dis Colon Rectum*. 2002;45(9):1192–9.
42. Gandomkar H, Zeinoddini A, Heidari R, Amoli HA. Partial lateral internal sphincterotomy versus combined botulinum toxin A injection and topical diltiazem in the treatment of chronic anal fissure: a randomized clinical trial. *Dis Colon Rectum*. 2015;58(2):228–34.
43. Nelson R. A systematic review of medical therapy for anal fissure. *Dis Colon Rectum*. 2004;47(4):422–31.
44. Pardhan A, Azami R, Mazahir S, Murtaza G. Diltiazem vs. glyceryl tri-nitrate for symptomatic relief in anal fissure: a randomised clinical study. *J Pak Med Assoc*. 2014;64(5):510–3.
45. Valizadeh N, Jalaly NY, Hassanzadeh M, et al. Botulinum toxin injection versus lateral internal sphincterotomy for the treatment of chronic anal fissure: randomized prospective controlled trial. *Langenbecks Arch Surg*. 2012;397(7):1093–8.
46. Richard CS, Gregoire R, Plewes EA, et al. Internal sphincterotomy is superior to topical nitroglycerin in the treatment of chronic anal fissure: results of a randomized, controlled trial by the Canadian Colorectal Surgical Trials Group. *Dis Colon Rectum*. 2000;43(8):1048–57.
47. Stringer EE, Nicholson TJ, Armstrong D. Efficacy of topical metronidazole (10%) in the treatment of anorectal Crohn's disease. *Dis Colon Rectum*. 2005;48(5):970–4.
48. Hart AL, Plamondon S, Kamm MA. Topical tacrolimus in the treatment of perianal Crohn's disease: exploratory randomized controlled trial. *Inflamm Bowel Dis*. 2007;13(3):245–53.
49. Buchmann P, Keighley MR, Allan RN, Thompson H, exander-Williams J. Natural history of perianal Crohn's disease. Ten year follow-up: a plea for conservatism. *Am J Surg*. 1980;140(5):642–4.
50. Kruis W, Katalinic A, Klugmann T, et al. Predictive factors for an uncomplicated long-term course of Crohn's disease: a retrospective analysis. *J Crohns Colitis*. 2013;7(7):e263–70.
51. Siproudhis L, Mortaji A, Mary JY, Juguet F, Bretagne JF, Gosselin M. Anal lesions: any significant prognosis in Crohn's disease? *Eur J Gastroenterol Hepatol*. 1997;9(3):239–43.
52. Pearson DC, May GR, Fick GH, Sutherland LR. Azathioprine and 6-mercaptopurine in Crohn disease. A meta-analysis. *Ann Intern Med*. 1995;123(2):132–42.
53. Plamondon S, Ng SC, Kamm MA. Thalidomide in luminal and fistulizing Crohn's disease resistant to standard therapies. *Aliment Pharmacol Ther*. 2007;25(5):557–67.
54. Cat H, Sophani I, Lemann M, Modigliani R, Solue JC. Cyclosporin treatment of anal and perianal lesions associated with Crohn's disease. *Turk J Gastroenterol*. 2003;14(2):121–7.
55. Colombel JF, Mathieu D, Bouault JM, et al. Hyperbaric oxygenation in severe perineal Crohn's disease. *Dis Colon Rectum*. 1995;38(6):609–14.
56. Poggioli G, Laureti S, Pierangeli F, et al. Local injection of Infliximab for the treatment of perianal Crohn's disease. *Dis Colon Rectum*. 2005;48(4):768–74.

57. Korzenik JR, Dieckgraefe BK. An open-labelled study of granulocyte colony-stimulating factor in the treatment of active Crohn's disease. *Aliment Pharmacol Ther.* 2005;21(4):391–400.
58. Bouguen G, Trouilloud I, Siproudhis L, et al. Long-term outcome of non-fistulizing (ulcers, stricture) perianal Crohn's disease in patients treated with infliximab. *Aliment Pharmacol Ther.* 2009;30(7):749–56.
59. Keighley MR, Allan RN. Current status and influence of operation on perianal Crohn's disease. *Int J Colorectal Dis.* 1986;1(2):104–7.
60. Makowiec F, Jehle EC, Becker HD, Starlinger M. Perianal abscess in Crohn's disease. *Dis Colon Rectum.* 1997;40(4):443–50.
61. Laniado M, Makowiec F, Dammann F, Jehle EC, Claussen CD, Starlinger M. Perianal complications of Crohn disease: MR imaging findings. *Eur Radiol.* 1997;7(7):1035–42.
62. Caliste X, Nazir S, Goode T, et al. Sensitivity of computed tomography in detection of perirectal abscess. *Am Surg.* 2011;77(2):166–8.
63. Giovannini M, Bories E, Moutardier V, et al. Drainage of deep pelvic abscesses using therapeutic echo endoscopy. *Endoscopy.* 2003;35(6):511–4.
64. Brook I, Frazier EH. The aerobic and anaerobic bacteriology of perirectal abscesses. *J Clin Microbiol.* 1997;35(11):2974–6.
65. Garcia-Granero A, Granero-Castro P, Frasson M, et al. Management of cryptoglandular supralelevator abscesses in the magnetic resonance imaging era: a case series. *Int J Colorectal Dis.* 2014;29(12):1557–64.
66. Schwartz DA, Loftus Jr EV, Tremaine WJ, et al. The natural history of fistulizing Crohn's disease in Olmsted County. *Minnesota Gastroenterol.* 2002;122(4):875–80.
67. Parks AG, Gordon PH, Hardcastle JD. A classification of fistula-in-ano. *Br J Surg.* 1976;63(1):1–12.
68. Bell SJ, Williams AB, Wiesel P, Wilkinson K, Cohen RC, Kamm MA. The clinical course of fistulating Crohn's disease. *Aliment Pharmacol Ther.* 2003;17(9):1145–51.
69. Spinelli A, De CC, Sacchi M, et al. Imaging modalities for perianal Crohn's disease. *Curr Drug Targets.* 2012;13(10):1287–93.
70. Fishman EK, Wolf EJ, Jones B, Bayless TM, Siegelman SS. CT evaluation of Crohn's disease: effect on patient management. *AJR Am J Roentgenol.* 1987;148(3):537–40.
71. Kuijpers HC, Schulpen T. Fistulography for fistula-in-ano. Is it useful? *Dis Colon Rectum.* 1985;28(2):103–4.
72. Person B, Wexner SD. Management of perianal Crohn's Disease. *Curr Treat Options Gastroenterol.* 2005;8(3):197–209.
73. Malchow H, Ewe K, Brandes JW, et al. European Cooperative Crohn's Disease Study (ECCDS): results of drug treatment. *Gastroenterology.* 1984;86(2):249–66.
74. Summers RW, Switz DM, Sessions Jr JT, et al. National Cooperative Crohn's Disease Study: results of drug treatment. *Gastroenterology.* 1979;77(4 Pt 2):847–69.
75. Bernstein LH, Frank MS, Brandt LJ, Boley SJ. Healing of perineal Crohn's disease with metronidazole. *Gastroenterology.* 1980;79(2):357–65.
76. Jakobovits J, Schuster MM. Metronidazole therapy for Crohn's disease and associated fistulae. *Am J Gastroenterol.* 1984;79(7):533–40.
77. Thia KT, Mahadevan U, Feagan BG, et al. Ciprofloxacin or metronidazole for the treatment of perianal fistulas in patients with Crohn's disease: a randomized, double-blind, placebo-controlled

pilot study. *Inflamm Bowel Dis*. 2009;15(1):17–24.

78. Su JW, Ma JJ, Zhang HJ. Use of antibiotics in patients with Crohn's disease: a systematic review and meta-analysis. *J Dig Dis*. 2015;16(2):58–66.

79. Dejaco C, Harrer M, Waldhoer T, Miehsler W, Vogelsang H, Reinisch W. Antibiotics and azathioprine for the treatment of perianal fistulas in Crohn's disease. *Aliment Pharmacol Ther*. 2003;18(11–12):1113–20.

80. Renna S, Orlando A, Cottone M. Comparing medical treatments for Crohn's disease. *J Comp Eff Res*. 2013;2(2):135–49.

81. Sandborn WJ, Present DH, Isaacs KL, et al. Tacrolimus for the treatment of fistulas in patients with Crohn's disease: a randomized, placebo-controlled trial. *Gastroenterology*. 2003;125(2):380–8.

82. Present DH, Lichtiger S. Efficacy of cyclosporine in treatment of fistula of Crohn's disease. *Dig Dis Sci*. 1994;39(2):374–80.

83. Hanauer SB, Smith MB. Rapid closure of Crohn's disease fistulas with continuous intravenous cyclosporin A. *Am J Gastroenterol*. 1993;88(5):646–9.

84. Ehrenpreis ED, Kane SV, Cohen LB, Cohen RD, Hanauer SB. Thalidomide therapy for patients with refractory Crohn's disease: an open-label trial. *Gastroenterology*. 1999;117(6):1271–7.

85. Vasiliauskas EA, Kam LY, breu-Martin MT, et al. An open-label pilot study of low-dose thalidomide in chronically active, steroid-dependent Crohn's disease. *Gastroenterology*. 1999;117(6):1278–87.

86. Present DH, Rutgeerts P, Targan S, et al. Infliximab for the treatment of fistulas in patients with Crohn's disease. *N Engl J Med*. 1999;340(18):1398–405.

87. Sands BE, Anderson FH, Bernstein CN, et al. Infliximab maintenance therapy for fistulizing Crohn's disease. *N Engl J Med*. 2004;350(9):876–85.

88. Regueiro M, Mardini H. Treatment of perianal fistulizing Crohn's disease with infliximab alone or as an adjunct to exam under anesthesia with seton placement. *Inflamm Bowel Dis*. 2003;9(2):98–103.

89. Topstad DR, Panaccione R, Heine JA, Johnson DR, MacLean AR, Buie WD. Combined seton placement, infliximab infusion, and maintenance immunosuppressives improve healing rate in fistulizing anorectal Crohn's disease: a single center experience. *Dis Colon Rectum*. 2003;46(5):577–83.

90. Sands BE, Blank MA, Patel K, Van Deventer SJ. Long-term treatment of rectovaginal fistulas in Crohn's disease: response to infliximab in the ACCENT II Study. *Clin Gastroenterol Hepatol*. 2004;2(10):912–20.

91. Rasul I, Wilson SR, MacRae H, Irwin S, Greenberg GR. Clinical and radiological responses after infliximab treatment for perianal fistulizing Crohn's disease. *Am J Gastroenterol*. 2004;99(1):82–8.

92. Alessandrini L, Kohn A, Cosentino R, et al. Local injection of infliximab in severe fistulating perianal Crohn's disease: an open uncontrolled study. *Tech Coloproctol*. 2011;15(4):407–12.

93. Colombel JF, Sandborn WJ, Rutgeerts P, et al. Adalimumab for maintenance of clinical response and remission in patients with Crohn's disease: the CHARM trial. *Gastroenterology*. 2007;132(1):52–65.

94. Colombel JF, Schwartz DA, Sandborn WJ, et al. Adalimumab for the treatment of fistulas in patients with Crohn's disease. *Gut*. 2009;58(7):940–8.

95. Lichtiger S, Binion DG, Wolf DC, et al. The CHOICE trial: adalimumab demonstrates safety, fistula healing, improved quality of life and increased work productivity in patients with Crohn's disease who failed prior infliximab therapy. *Aliment Pharmacol Ther.* 2010;32(10):1228–39.
96. Lichtenstein GR, Thomsen OO, Schreiber S, et al. Continuous therapy with certolizumab pegol maintains remission of patients with Crohn's disease for up to 18 months. *Clin Gastroenterol Hepatol.* 2010;8(7):600–9.
97. Sandborn WJ, Feagan BG, Stoinov S, et al. Certolizumab pegol for the treatment of Crohn's disease. *N Engl J Med.* 2007;357(3):228–38.
98. Sandborn WJ, Schreiber S, Hanauer SB, Colombel JF, Bloomfield R, Lichtenstein GR. Reinduction with certolizumab pegol in patients with relapsed Crohn's disease: results from the PRECiSE 4 Study. *Clin Gastroenterol Hepatol.* 2010;8(8):696–702.
99. Schreiber S, Khaliq-Kareemi M, Lawrance IC, et al. Maintenance therapy with certolizumab pegol for Crohn's disease. *N Engl J Med.* 2007;357(3):239–50.
100. Schreiber S, Lawrance IC, Thomsen OO, Hanauer SB, Bloomfield R, Sandborn WJ. Randomised clinical trial: certolizumab pegol for fistulas in Crohn's disease—subgroup results from a placebo-controlled study. *Aliment Pharmacol Ther.* 2011;33(2):185–93.
101. Ghosh S, Goldin E, Gordon FH, et al. Natalizumab for active Crohn's disease. *N Engl J Med.* 2003;348(1):24–32.
102. Juillerat P, Wasan SK, Fowler SA, et al. Efficacy and safety of natalizumab in Crohn's disease patients treated at 6 Boston academic hospitals. *Inflamm Bowel Dis.* 2013;19(11):2457–63.
103. Soler D, Chapman T, Yang LL, Wyant T, Egan R, Fedyk ER. The binding specificity and selective antagonism of vedolizumab, an anti- $\alpha 4\beta 7$  integrin therapeutic antibody in development for inflammatory bowel diseases. *J Pharmacol Exp Ther.* 2009;330(3):864–75.
104. Sandborn WJ, Feagan BG, Rutgeerts P, et al. Vedolizumab as induction and maintenance therapy for Crohn's disease. *N Engl J Med.* 2013;369(8):711–21.
105. Smith MA, Mohammad RA. Vedolizumab: an  $\alpha 4\beta 7$  integrin inhibitor for inflammatory bowel diseases. *Ann Pharmacother.* 2014;48(12):1629–35.
106. White RA, Eisenstat TE, Rubin RJ, Salvati EP. Seton management of complex anorectal fistulas in patients with Crohn's disease. *Dis Colon Rectum.* 1990;33(7):587–9.
107. Ritchie RD, Sackier JM, Hodde JP. Incontinence rates after cutting seton treatment for anal fistula. *Colorectal Dis.* 2009;11(6):564–71.
108. Faucheron JL, Saint-Marc O, Guibert L, Parc R. Long-term seton drainage for high anal fistulas in Crohn's disease—a sphincter-saving operation? *Dis Colon Rectum.* 1996;39(2):208–11.
109. Galis-Rozen E, Tulchinsky H, Rosen A, et al. Long-term outcome of loose seton for complex anal fistula: a two-centre study of patients with and without Crohn's disease. *Colorectal Dis.* 2010;12(4):358–62.
110. Nordgren S, Fasth S, Hulten L. Anal fistulas in Crohn's disease: incidence and outcome of surgical treatment. *Int J Colorectal Dis.* 1992;7(4):214–8.
111. Williams JG, MacLeod CA, Rothenberger DA, Goldberg SM. Seton treatment of high anal fistulae. *Br J Surg.* 1991;78(10):1159–61.
112. Cintron JR, Park JJ, Orsay CP, et al. Repair of fistulas-in-ano using fibrin adhesive: long-term follow-up. *Dis Colon Rectum.* 2000;43(7):944–9.
113. Grimaud JC, Munoz-Bongrand N, Siproudhis L, et al. Fibrin glue is effective healing perianal fistulas in patients with Crohn's disease. *Gastroenterology.* 2010;138(7):2275–81.



114. Singer M, Cintron J, Nelson R, et al. Treatment of fistulas-in-ano with fibrin sealant in combination with intra-adhesive antibiotics and/or surgical closure of the internal fistula opening. *Dis Colon Rectum*. 2005;48(4):799–808.
115. Ellis CN, Clark S. Fibrin glue as an adjunct to flap repair of anal fistulas: a randomized, controlled study. *Dis Colon Rectum*. 2006;49(11):1736–40.
116. Garg P, Song J, Bhatia A, Kalia H, Menon GR. The efficacy of anal fistula plug in fistula-in-ano: a systematic review. *Colorectal Dis*. 2010;12(10):965–70.
117. Ommer A, Herold A, Joos A, Schmidt C, Weyand G, Bussen D. Gore BioA Fistula Plug in the treatment of high anal fistulas—initial results from a German multicenter-study. *Ger Med Sci* 2012; 10:Doc13.
118. Ratto C, Litta F, Parello A, Donisi L, Zacccone G, De Simone V. Gore Bio-A® Fistula plug: a new sphincter-sparing procedure for complex anal fistula. *Colorectal Dis*. 2012;14(5):e264–9.
119. Garcia-Olmo D, Garcia-Arranz M, Garcia LG, et al. Autologous stem cell transplantation for treatment of rectovaginal fistula in perianal Crohn's disease: a new cell-based therapy. *Int J Colorectal Dis*. 2003;18(5):451–4.
120. De la Portilla F, Alba F, Garcia-Olmo D, Herrerias JM, Gonzalez FX, Galindo A. Expanded allogeneic adipose-derived stem cells (eASCs) for the treatment of complex perianal fistula in Crohn's disease: results from a multicenter phase I/IIa clinical trial. *Int J Colorectal Dis*. 2013;28(3):313–23.
121. Garcia-Olmo D, Herreros D, Pascual I, et al. Expanded adipose-derived stem cells for the treatment of complex perianal fistula: a phase II clinical trial. *Dis Colon Rectum*. 2009;52(1):79–86.
122. Lee WY, Park KJ, Cho YB, et al. Autologous adipose tissue-derived stem cells treatment demonstrated favorable and sustainable therapeutic effect for Crohn's fistula. *Stem Cells*. 2013;31(11):2575–81.
123. DelaRosa O, Dalemans W, Lombardo E. Mesenchymal stem cells as therapeutic agents of inflammatory and autoimmune diseases. *Curr Opin Biotechnol*. 2012;23(6):978–83.
124. Lombardo E, van der Poll T, DelaRosa O, Dalemans W. Mesenchymal stem cells as a therapeutic tool to treat sepsis. *World J Stem Cells*. 2015;7(2):368–79.
125. Guadalajara H, Herreros D, De-La-Quintana P, Trebol J, Garcia-Arranz M, Garcia-Olmo D. Long-term follow-up of patients undergoing adipose-derived adult stem cell administration to treat complex perianal fistulas. *Int J Colorectal Dis*. 2012;27(5):595–600.
126. Rojanasakul A, Pattanaarun J, Sahakitrungruang C, Tantiphlachiva K. Total anal sphincter saving technique for fistula-in-ano; the ligation of intersphincteric fistula tract. *J Med Assoc Thai*. 2007;90(3):581–6.
127. Bleier JI, Moloo H, Goldberg SM. Ligation of the intersphincteric fistula tract: an effective new technique for complex fistulas. *Dis Colon Rectum*. 2010;53(1):43–6.
128. Shanwani A, Nor AM, Amri N. Ligation of the intersphincteric fistula tract (LIFT): a sphincter-saving technique for fistula-in-ano. *Dis Colon Rectum*. 2010;53(1):39–42.
129. Zirak-Schmidt S, Perdawood SK. Management of anal fistula by ligation of the intersphincteric fistula tract—a systematic review. *Dan Med J*. 2014;61(12):A4977.
130. Tan KK, Tan IJ, Lim FS, Koh DC, Tsang CB. The anatomy of failures following the ligation of intersphincteric tract technique for anal fistula: a review of 93 patients over 4 years. *Dis Colon Rectum*. 2011;54(11):1368–72.

131. Ellis CN. Outcomes with the use of bioprosthetic grafts to reinforce the ligation of the intersphincteric fistula tract (BioLIFT procedure) for the management of complex anal fistulas. *Dis Colon Rectum*. 2010;53(10):1361–4.
132. Tan KK, Lee PJ. Early experience of reinforcing the ligation of the intersphincteric fistula tract procedure with a bioprosthetic graft (BioLIFT) for anal fistula. *ANZ J Surg*. 2014;84(4):280–3.
133. Gingold DS, Murrell ZA, Fleshner PR. A prospective evaluation of the ligation of the intersphincteric tract procedure for complex anal fistula in patients with Crohn's disease. *Ann Surg*. 2014;260(6):1057–61.
134. Jarrar A, Church J. Advancement flap repair: a good option for complex anorectal fistulas. *Dis Colon Rectum*. 2011;54(12):1537–41.
135. Soltani A, Kaiser AM. Endorectal advancement flap for cryptoglandular or Crohn's fistula-in-ano. *Dis Colon Rectum*. 2010;53(4):486–95.
136. Halverson AL, Hull TL, Fazio VW, Church J, Hammel J, Floruta C. Repair of recurrent rectovaginal fistulas. *Surgery*. 2001;130(4):753–7.
137. Hull TL, Fazio VW. Surgical approaches to low anovaginal fistula in Crohn's disease. *Am J Surg*. 1997;173(2):95–8.
138. Mizrahi N, Wexner SD, Zmora O, et al. Endorectal advancement flap: are there predictors of failure? *Dis Colon Rectum*. 2002;45(12):1616–21.
139. Ozuner G, Hull TL, Cartmill J, Fazio VW. Long-term analysis of the use of transanal rectal advancement flaps for complicated anorectal/vaginal fistulas. *Dis Colon Rectum*. 1996;39(1):10–4.
140. Penninckx F, Moneghini D, D'Hoore A, Wyndaele J, Coremans G, Rutgeerts P. Success and failure after repair of rectovaginal fistula in Crohn's disease: analysis of prognostic factors. *Colorectal Dis*. 2001;3(6):406–11.
141. Loffler T, Welsch T, Muhl S, Hinz U, Schmidt J, Kienle P. Long-term success rate after surgical treatment of anorectal and rectovaginal fistulas in Crohn's disease. *Int J Colorectal Dis*. 2009;24(5):521–6.
142. Devesa JM, Devesa M, Velasco GR, et al. Benign rectovaginal fistulas: management and results of a personal series. *Tech Coloproctol*. 2007;11(2):128–34.
143. Nosti PA, Stahl TJ, Sokol AI. Surgical repair of rectovaginal fistulas in patients with Crohn's disease. *Eur J Obstet Gynecol Reprod Biol*. 2013;171(1):166–70.
144. Sher ME, Bauer JJ, Gelernt I. Surgical repair of rectovaginal fistulas in patients with Crohn's disease: transvaginal approach. *Dis Colon Rectum*. 1991;34(8):641–8.
145. Tan KK, Alsuwaigh R, Tan AM, et al. To LIFT or to flap? Which surgery to perform following seton insertion for high anal fistula? *Dis Colon Rectum*. 2012;55(12):1273–7.
146. Van Koperen PJ, Bemelman WA, Gerhards MF, et al. The anal fistula plug treatment compared with the mucosal advancement flap for cryptoglandular high transsphincteric perianal fistula: a double-blinded multicenter randomized trial. *Dis Colon Rectum*. 2011;54(4):387–93.
147. Van Koperen PJ, Safiruddin F, Bemelman WA, Slors JF. Outcome of surgical treatment for fistula in ano in Crohn's disease. *Br J Surg*. 2009;96(6):675–9.
148. Fry RD, Shemesh EI, Kodner IJ, Timmcke A. Techniques and results in the management of anal and perianal Crohn's disease. *Surg Gynecol Obstet*. 1989;168(1):42–8.
149. Singh B, George BD, Mortensen NJ. Surgical therapy of perianal Crohn's disease. *Dig Liver Dis*. 2007;39(10):988–92.
150. Grant DR, Cohen Z, McLeod RS. Loop ileostomy for anorectal Crohn's disease. *Can J Surg*.

- 1986;29(1):32–5.
151. Rehg KL, Sanchez JE, Krieger BR, Marcet JE. Fecal diversion in perirectal fistulizing Crohn's disease is an underutilized and potentially temporary means of successful treatment. *Am Surg.* 2009;75(8):715–8.
152. Gu J, Valente MA, Remzi FH, Stocchi L. Factors affecting the fate of faecal diversion in patients with perianal Crohn's disease. *Colorectal Dis.* 2015;17(1):66–72.
153. Hong MK, Craig LA, Bell S, et al. Faecal diversion in the management of perianal Crohn's disease. *Colorectal Dis.* 2011;13(2):171–6.
154. Cirincione E, Gorfine SR, Bauer JJ. Is Hartmann's procedure safe in Crohn's disease? Report of three cases. *Dis Colon Rectum.* 2000;43(4):544–7.
155. Singh B, McC Mortensen NJ, Jewell DP, George B. Perianal Crohn's disease. *Br J Surg.* 2004;91(7):801–14.
156. Galandiuk S, Kimberling J, Al-Mishlab TG, Stromberg AJ. Perianal Crohn disease: predictors of need for permanent diversion. *Ann Surg.* 2005;241(5):796–801.
157. Bauer JJ, Gelernt IM, Salk BA, Kreel I. Proctectomy for inflammatory bowel disease. *Am J Surg.* 1986;151(1):157–62.
158. Elliot MS, Todd IP. Primary suture of the perineal wound using constant suction and irrigation, following rectal excision for inflammatory bowel disease. *Ann R Coll Surg Engl.* 1985;67(1):6–7.
159. Hartz RS, Poticha SM, Shields TW. Healing of the perineal wound. *Arch Surg.* 1980;115(4):471–4.
160. Yamamoto T, Allan RN, Keighley MR. Audit of single-stage proctocolectomy for Crohn's disease: postoperative complications and recurrence. *Dis Colon Rectum.* 2000;43(2):249–56.
161. Anderson R, Turnbull Jr RB. Grafting the unhealed perineal wound after coloproctectomy for Crohn disease. *Arch Surg.* 1976;111(4):335–8.
162. Rius J, Nessim A, Nogueras JJ, Wexner SD. Gracilis transposition in complicated perianal fistula and unhealed perineal wounds in Crohn's disease. *Eur J Surg.* 2000;166(3):218–22.
163. Schaden D, Schauer G, Haas F, Berger A. Myocutaneous flaps and proctocolectomy in severe perianal Crohn's disease—a single stage procedure. *Int J Colorectal Dis.* 2007;22(12):1453–7.
164. Sher ME, Bauer JJ, Gorphine S, Gelernt I. Low Hartmann's procedure for severe anorectal Crohn's disease. *Dis Colon Rectum.* 1992;35(10):975–80.
165. Linares L, Moreira LF, Andrews H, Allan RN, exander-Williams J, Keighley MR. Natural history and treatment of anorectal strictures complicating Crohn's disease. *Br J Surg.* 1988;75(7):653–5.
166. Simmang CL, Lacey SW, Huber Jr PJ. Rectal sleeve advancement: repair of rectovaginal fistula associated with anorectal stricture in Crohn's disease. *Dis Colon Rectum.* 1998;41(6):787–9.
167. Sjodahl RI, Myrelid P, Soderholm JD. Anal and rectal cancer in Crohn's disease. *Colorectal Dis.* 2003;5(5):490–5.
168. Slessor AA, Bhangu A, Bower M, Goldin R, Tekkis PP. A systematic review of anal squamous cell carcinoma in inflammatory bowel disease. *Surg Oncol.* 2013;22(4):230–7.
169. Ky A, Sohn N, Weinstein MA, Korelitz BI. Carcinoma arising in anorectal fistulas of Crohn's disease. *Dis Colon Rectum.* 1998;41(8):992–6.
170. Vermeire S, Van AG, Rutgeerts P. Perianal Crohn's disease: classification and clinical evaluation. *Dig Liver Dis.* 2007;39(10):959–62.

## 第 49 章

1. Leowardi C, Heuschen G, Kienle P, Heuschen U, Schmidt J. Surgical treatment of severe inflammatory bowel diseases. *Dig Dis*. 2003;21(1):54–62.
2. Hovde Ø, Moum BA. Epidemiology and clinical course of Crohn's disease: results from observational studies. *World J Gastroenterol*. 2012;18(15):1723–31.
3. Cosnes J, Gower-Rousseau C, Seksik P, Cortot A. Epidemiology and natural history of inflammatory bowel diseases. *Gastroenterology*. 2011;140(6):1785–94.
4. Loftus Jr EV, Silverstein MD, Sandborn WJ, Tremaine WJ, Harmsen WS, Zinsmeister AR. Crohn's disease in Olmsted County, Minnesota, 1940–1993: incidence, prevalence, and survival. *Gastroenterology*. 1998;114(6):1161–8. Erratum in: *Gastroenterology* 1999 Jun;116(6):1507.
5. Loftus CG, Loftus Jr EV, Harmsen WS, Zinsmeister AR, Tremaine WJ, Melton 3rd LJ, et al. Update on the incidence and prevalence of Crohn's disease and ulcerative colitis in Olmsted County, Minnesota, 1940–2000. *Inflamm Bowel Dis*. 2007;13(3):254–61.
6. Jacobsen BA, Fallingborg J, Rasmussen HH, Nielsen KR, Drewes AM, Puho E, et al. Increase in incidence and prevalence of inflammatory bowel disease in northern Denmark: a population-based study, 1978–2002. *Eur J Gastroenterol Hepatol*. 2006;18(6):601–6.
7. Loftus Jr EV, Schoenfeld P, Sandborn WJ. The epidemiology and natural history of Crohn's disease in population-based patient cohorts from North America: a systematic review. *Aliment Pharmacol Ther*. 2002;16(1):51–60.
8. Agrez MV, Valente RM, Pierce W, Melton 3rd LJ, van Heerden JA, Beart Jr RW. Surgical history of Crohn's disease in a well-defined population. *Mayo Clin Proc*. 1982;57(12):747–52.
9. Bernell O, Lapidus A, Hellers G. Risk factors for surgery and postoperative recurrence in Crohn's disease. *Ann Surg*. 2000;231(1):38–45.
10. Basilisco G, Campanini M, Cesana B, Ranzi T, Bianchi P. Risk factors for first operation in Crohn's disease. *Am J Gastroenterol*. 1989;84(7):749–52.
11. Munkholm P, Langholz E, Davidsen M, Binder V. Intestinal cancer risk and mortality in patients with Crohn's disease. *Gastroenterology*. 1993;105(6):1716–23.
12. Farmer RG, Whelan G, Fazio VW. Long-term follow-up of patients with Crohn's disease. Relationship between the clinical pattern and prognosis. *Gastroenterology*. 1985;88(6):1818–25.
13. Truelove SC, Pena AS. Course and prognosis of Crohn's disease. *Gut*. 1976;17(3):192–201.
14. Michelassi F, Balestracci T, Chappell R, Block GE. Primary and recurrent Crohn's disease. Experience with 1379 patients. *Ann Surg*. 1991;214(3):230–8. discussion 238–40.
15. Ramadas AV, Gunesh S, Thomas GA, Williams GT, Hawthorne AB. Natural history of Crohn's disease in a population-based cohort from Cardiff (1986–2003): a study of changes in medical treatment and surgical resection rates. *Gut*. 2010;59(9):1200–6.
16. Jess T, Riis L, Vind I, Winther KV, Borg S, Binder V, et al. Changes in clinical characteristics, course, and prognosis of inflammatory bowel disease during the last 5 decades: a population-based study from Copenhagen. *Denmark Inflamm Bowel Dis*. 2007;13(4):481–9.
17. Rungoe C, Langholz E, Andersson M, Basit S, Nielsen NM, Wohlfahrt J, et al. Changes in medical treatment and surgery rates in inflammatory bowel disease: a nationwide cohort study 1979–2011. *Gut*. 2014;63(10):1607–16.
18. Vester-Andersen MK, Prosberg MV, Jess T, Andersson M, Bengtsson BG, Blixt T, et al. Disease

course and surgery rates in inflammatory bowel disease: a population-based, 7-year follow-up study in the era of immunomodulating therapy. *Am J Gastroenterol*. 2014;109(5):705–14.

19. Peyrin-Biroulet L, Oussalah A, Williet N, Pillot C, Bresler L, Bigard MA. Impact of azathioprine and tumour necrosis factor antagonists on the need for surgery in newly diagnosed Crohn's disease. *Gut*. 2011;60(7):930–6.

20. Solberg IC, Vatn MH, Høie O, Stray N, Sauar J, Jahnsen J, IBSEN Study Group, et al. Clinical course in Crohn's disease: results of a Norwegian population-based ten-year follow-up study. *Clin Gastroenterol Hepatol*. 2007;5(12):1430–8.

21. Sands BE, Arsenault JE, Rosen MJ, Alsahli M, Bailen L, Banks P, et al. Risk of early surgery for Crohn's disease: implications for early treatment strategies. *Am J Gastroenterol*. 2003;98(12):2712–8.

22. Picco MF, Zubiaurre I, Adluni M, Cangemi JR, Shelton D. Immunomodulators are associated with a lower risk of first surgery among patients with non-penetrating non-stricturing Crohn's disease. *Am J Gastroenterol*. 2009;104(11):2754–9.

23. D'Haens G, Baert F, van Assche G, Caenepeel P, Vergauwe P, Tuynman H, Belgian Inflammatory Bowel Disease Research Group, North-Holland Gut Club, et al. Early combined immunosuppression or conventional management in patients with newly diagnosed Crohn's disease: an open randomised trial. *Lancet*. 2008;371(9613):660–7.

24. Peyrin-Biroulet L, Lepage C, Jooste V, Guéant JL, Faivre J, Bouvier AM. Colorectal cancer in inflammatory bowel diseases: a population-based study (1976–2008). *Inflamm Bowel Dis*. 2012;18(12):2247–51.

25. Burke JP, Velupillai Y, O'Connell PR, Coffey JC. National trends in intestinal resection for Crohn's disease in the post-biologic era. *Int J Colorectal Dis*. 2013;28(10):1401–6.

26. Bouguen G, Peyrin-Biroulet L. Surgery for adult Crohn's disease: what is the actual risk? *Gut*. 2011;60(9):1178–81.

27. Hurst RD, Molinari M, Chung TP, Rubin M, Michelassi F. Prospective study of the features, indications, and surgical treatment in 513 consecutive patients affected by Crohn's disease. *Surgery*. 1997;122(4):661–7.

28. Fichera A, Michelassi F. Surgical treatment of Crohn's disease. *J Gastrointest Surg*. 2007;11(6):791–803.

29. Faubion Jr WA, Loftus Jr EV, Harmsen WS, Zinsmeister AR, Sandborn WJ. The natural history of corticosteroid therapy for inflammatory bowel disease: a population-based study. *Gastroenterology*. 2001;121(2):255–60.

30. Scott NA, Hughes LE. Timing of ileocolonic resection for symptomatic Crohn's disease—the patient's view. *Gut*. 1994;35(5):656–7.

31. Alós R, Hinojosa J. Timing of surgery in Crohn's disease: a key issue in the management. *World J Gastroenterol*. 2008;14(36):5532–9.

32. Ajlouni Y, Iser JH, Gibson PR. Endoscopic balloon dilatation of intestinal strictures in Crohn's disease: safe alternative to surgery. *J Gastroenterol Hepatol*. 2007;22(4):486–90.

33. Ferlitsch A, Reinisch W, Püspök A, Dejaco C, Schillinger M, Schöfl R, et al. Safety and efficacy of endoscopic balloon dilation for treatment of Crohn's disease strictures. *Endoscopy*. 2006;38(5):483–7.

34. Homan WP, Tang CK, Thorbjarnarson B. Acute massive hemorrhage from intestinal Crohn disease. Report of seven cases and review of the literature. *Arch Surg*. 1976;111(8):901–5.

35. Robert JR, Sachar DB, Greenstein AJ. Severe gastrointestinal hemorrhage in Crohn's disease. *Ann Surg.* 1991;213(3):207–11.
36. Driver CP, Anderson DN, Keenan RA. Massive intestinal bleeding in association with Crohn's disease. *J R Coll Surg Edinb.* 1996;41(3):152–4.
37. Cirocco WC, Reilly JC, Rusin LC. Life-threatening hemorrhage and exsanguination from Crohn's disease. Report of four cases. *Dis Colon Rectum.* 1995;38(1):85–95.
38. Kostka R, Lukás M. Massive, life-threatening bleeding in Crohn's disease. *Acta Chir Belg.* 2005;105(2):168–74.
39. Remzi FH, Dietz DW, Unal E, Levitin A, Sands MJ, Fazio VW. Combined use of preoperative provocative angiography and highly selective methylene blue injection to localize an occult small-bowel bleeding site in a patient with Crohn's disease: report of a case. *Dis Colon Rectum.* 2003;46(2):260–3.
40. Nagler SM, Poticha SM. Intraabdominal abscess in regional enteritis. *Am J Surg.* 1979;137(3):350–4.
41. Steinberg DM, Cooke WT, Alexander-Williams J. Abscess and fistulae in Crohn's disease. *Gut.* 1973;14(11):865–69.
42. Edwards H. Crohn's disease. An inquiry into its nature and consequences. *Ann R Coll Surg Engl.* 1969;44(3):121–39.
43. Greenstein AJ, Sachar DB, Greenstein RJ, Janowitz HD, Aufses Jr AH. Intraabdominal abscess in Crohn's (ileo) colitis. *Am J Surg.* 1982;143(6):727–30.
44. Keighley MR, Eastwood D, Ambrose NS, Allan RN, Burdon DW. Incidence and microbiology of abdominal and pelvic abscess in Crohn's disease. *Gastroenterology.* 1982;83(6):1271–5.
45. Garcia JC, Persky SE, Bonis PA, Topazian M. Abscesses in Crohn's disease: outcome of medical versus surgical treatment. *J Clin Gastroenterol.* 2001;32(5):409–12.
46. Gervais DA, Hahn PF, O'Neill MJ, Mueller PR. Percutaneous abscess drainage in Crohn disease: technical success and short- and long-term outcomes during 14 years. *Radiology.* 2002;222(3):645–51.
47. Van Patter WN, Barga JA, Dockerty MB, Feldman WH, Mayo CW, Waugh JM. Regional enteritis. *Gastroenterology.* 1954;26(3):347–450.
48. Banks BM, Zetzel L, Richter HS. Morbidity and mortality in regional enteritis. Report of 168 cases. *Am J Dig Dis.* 1969;14(6):369–79.
49. Tassiopoulos AK, Baum G, Halverson JD. Small bowel fistulas. *Surg Clin North Am.* 1996;76(5):1175–81.
50. Berry SM, Fischer JE. Enterocutaneous fistulas. *Curr Probl Surg.* 1994;31(6):469–566.
51. Poritz LS, Gagliano GA, McLeod RS, MacRae H, Cohen Z. Surgical management of entero and colocutaneous fistulae in Crohn's disease: 17 year's experience. *Int J Colorectal Dis.* 2004;19(5):481–5.
52. Laukoetter MG, Mennigen R, Hannig CM, Osada N, Rijcken E, Vowinkel T, et al. Intestinal cancer risk in Crohn's disease: a meta-analysis. *J Gastrointest Surg.* 2011;15(4):576–83.
53. Canavan C, Abrams KR, Mayberry J. Meta-analysis: colorectal and small bowel cancer risk in patients with Crohn's disease. *Aliment Pharmacol Ther.* 2006;23(8):1097–104.
54. Von Roon AC, Reese G, Teare J, Constantinides V, Darzi AW, Tekkis PP. The risk of cancer in patients with Crohn's disease. *Dis Colon Rectum.* 2007;50(6):839–55.
55. Ribeiro MB, Greenstein AJ, Sachar DB, Barth J, Balasubramanian S, Harpaz N, et al. Colorectal

- adenocarcinoma in Crohn's disease. *Ann Surg.* 1996;223(2):186–93.
56. Michelassi F, Testa G, Pomidor WJ, Lashner BA, Block GE. Adenocarcinoma complicating Crohn's disease. *Dis Colon Rectum.* 1993;36(7):654–61.
  57. Richards ME, Rickert RR, Nance FC. Crohn's disease-associated carcinoma. A poorly recognized complication of inflammatory bowel disease. *Ann Surg.* 1989;209(6):764–73.
  58. Lovasz BD, Lakatos L, Golovics PA, David G, Pandur T, Erdelyi Z, et al. Risk of colorectal cancer in Crohn's disease patients with colonic involvement and stenosing disease in a population-based cohort from Hungary. *J Gastrointest Liver Dis.* 2013;22(3):265–8.
  59. Kiran RP, Nisar PJ, Goldblum JR, Fazio VW, Remzi FH, Shen B, et al. Dysplasia associated with Crohn's colitis: segmental colectomy or more extended resection? *Ann Surg.* 2012;256(2):221–6.
  60. Simpson S, Traube J, Riddell RH. The histologic appearance of dysplasia (precarcinomatous change) in Crohn's disease of the small and large intestine. *Gastroenterology.* 1981;81(3):492–501.
  61. Riddell RH, Goldman H, Ransohoff DF, Appelman HD, Fenoglio CM, Haggitt RC, et al. Dysplasia in inflammatory bowel disease: standardized classification with provisional clinical applications. *Hum Pathol.* 1983;14(11):931–68.
  62. SC T, LJ W. Cortisone in ulcerative colitis; final report on a therapeutic trial. *Br Med J.* 1955;2(4947):1041–8.
  63. Jalan KN, Sircus W, Card WI, Falconer CW, Bruce CB, Crean GP, et al. An experience of ulcerative colitis. I. Toxic dilation in 55 cases. *Gastroenterology.* 1969;57(1):68–82.
  64. Gulliford SR, Limdi JK. Acute severe ulcerative colitis: timing is everything. *Postgrad Med J.* 2011;87(1025):215–22.
  65. McIntyre PB, Powell-Tuck J, Wood SR, Lennard-Jones JE, Lerebours E, Heeketsweiler P, et al. Controlled trial of bowel rest in the treatment of severe acute colitis. *Gut.* 1986;27(5):481–5.
  66. Dickinson RJ, Ashton MG, Axon AT, Smith RC, Yeung CK, Hill GL. Controlled trial of intravenous hyperalimentation and total bowel rest as an adjunct to the routine therapy of acute colitis. *Gastroenterology.* 1980;79(6):1199–204.
  67. Chapman RW, Selby WS, Jewell DP. Controlled trial of intravenous metronidazole as an adjunct to corticosteroids in severe ulcerative colitis. *Gut.* 1986;27(10):1210–2.
  68. Mantzaris GJ, Petraki K, Archavlis E, Amberiadis P, Kourteas D, Christidou A, et al. A prospective randomized controlled trial of intravenous ciprofloxacin as an adjunct to corticosteroids in acute, severe ulcerative colitis. *Scand J Gastroenterol.* 2001;36(9):971–4.
  69. Kornbluth A, Sachar DB, Practice Parameters Committee of the American College of Gastroenterology. Ulcerative colitis practice guidelines in adults: American college of gastroenterology, practice parameters committee. *Am J Gastroenterol.* 2010;105(3):501–23.
  70. Lees CW, Heys D, Ho GT, Noble CL, Shand AG, Mowat C, Scottish Society of Gastroenterology Influximab Group, et al. A retrospective analysis of the efficacy and safety of infliximab as rescue therapy in acute severe ulcerative colitis. *Aliment Pharmacol Ther.* 2007;26(3):411–9.
  71. Järnerot G, Hertervig E, Friis-Liby I, Blomquist L, Karlén P, Grännö C, et al. Infliximab as rescue therapy in severe to moderately severe ulcerative colitis: a randomized, placebo-controlled study. *Gastroenterology.* 2005;128(7):1805–11.
  72. Kohn A, Daperno M, Armuzzi A, Cappello M, Biancone L, Orlando A, et al. Infliximab in severe ulcerative colitis: short-term results of different infusion regimens and long-term follow-up.

Aliment Pharmacol Ther. 2007;26(5):747–56.

73. Bartels SA, Gardenbroek TJ, Bos L, Ponsioen CY, D’Haens GR, Tanis PJ, et al. Prolonged preoperative hospital stay is a risk factor for complications after emergency colectomy for severe colitis. *Colorectal Dis*. 2013;15(11):1392–8.

74. Sheth SG, LaMont JT. Toxic megacolon. *Lancet*. 1998;351(9101):509–13.

75. Heppell J, Farkouh E, Dubé S, Péloquin A, Morgan S, Bernard D. Toxic megacolon. An analysis of 70 cases. *Dis Colon Rectum*. 1986;29(12):789–92.

76. Harling H, Hegnhøj J, Rasmussen TN, Jarnum S. Fate of the rectum after colectomy and ileostomy for Crohn’s colitis. *Dis Colon Rectum*. 1991;34(10):931–5.

77. Park MJ, Lim JS. Computed tomography enterography for evaluation of inflammatory bowel disease. *Clin Endosc*. 2013;46(4):327–66.

78. Booya F, Fletcher JG, Huprich JE, Barlow JM, Johnson CD, Fidler JL, et al. Active Crohn disease: CT findings and interobserver agreement for enteric phase CT enterography. *Radiology*. 2006;241(3):787–95.

79. Lee SS, Kim AY, Yang SK, Chung JW, Kim SY, Park SH, Ha HK. Crohn disease of the small bowel: comparison of CT enterography, MR enterography, and small-bowel follow-through as diagnostic techniques. *Radiology*. 2009;251(3):751–61.

80. Masselli G, Gualdi G. CT and MR enterography in evaluating small bowel diseases: when to use which modality? *Abdom Imaging*. 2013;38(2):249–59. doi: 10.1007/s00261-012-9961-8.

81. Jensen MD, Kjeldsen J, Rafaelsen SR, Nathan T. Diagnostic accuracies of MR enterography and CT enterography in symptomatic Crohn’s disease. *Scand J Gastroenterol*. 2011;46(12):1449–57.

82. Seastedt KP, Trencheva K, Michelassi F, Alsaleh D, Milsom JW, Sonoda T, et al. Accuracy of CT enterography and magnetic resonance enterography imaging to detect lesions preoperatively in patients undergoing surgery for Crohn’s disease. *Dis Colon Rectum*. 2014;57(12):1364–70.

83. Windsor JA, Hill GL. Protein depletion and surgical risk. *Aust N Z J Surg*. 1988;58(9):711–5.

84. Parekh NR, Steiger E. Percentage of weight loss as a predictor of surgical risk: from the time of Hiram Studley to today. *Nutr Clin Pract*. 2004;19(5):471–6.

85. Rombeau JL, Barot LR, Williamson CE, Mullen JL. Preoperative total parenteral nutrition and surgical outcome in patients with inflammatory bowel disease. *Am J Surg*. 1982;143(1):139–43.

86. Studley HO. Percentage of weight loss: a basic indicator of surgical risk in patients with chronic peptic ulcer. 1936. *Nutr Hosp*. 2001;16(4):141–3.

87. Seltzer MH, Slocum BA, Cataldi-Betcher EL, Fileti C, Gerson N. Instant nutritional assessment: absolute weight loss and surgical mortality. *JPEN J Parenter Enteral Nutr*. 1982;6(3):218–21.

88. Gibbs J, Cull W, Henderson W, Daley J, Hur K, Khuri SF. Preoperative serum albumin level as a predictor of operative mortality and morbidity: results from the National VA Surgical Risk Study. *Arch Surg*. 1999;134(1):36–42.

89. Lindor KD, Fleming CR, Ilstrup DM. Preoperative nutritional status and other factors that influence surgical outcome in patients with Crohn’s disease. *Mayo Clin Proc*. 1985;60(6):393–6.

90. Triantafillidis JK, Papalois AE. The role of total parenteral nutrition in inflammatory bowel disease: current aspects. *Scand J Gastroenterol*. 2014;49(1):3–14.

91. Shiloni E, Coronado E, Freund HR. Role of total parenteral nutrition in the treatment of Crohn’s disease. *Am J Surg*. 1989;157(1):180–5.

92. Lerebours E, Messing B, Chevalier B, Bories C, Colin R, Bernier JJ. An evaluation of total



parenteral nutrition in the management of steroid-dependent and steroid-resistant patients with Crohn's disease. *JPEN J Parenter Enteral Nutr.* 1986;10(3):274–8.

93. Müller JM, Keller HW, Erasmi H, Pichlmaier H. Total parenteral nutrition as the sole therapy in Crohn's disease—a prospective study. *Br J Surg.* 1983;70(1):40–3.

94. Greenberg GR, Fleming CR, Jeejeebhoy KN, Rosenberg IH, Sales D, Tremaine WJ. Controlled trial of bowel rest and nutritional support in the management of Crohn's disease. *Gut.* 1988;29(10):1309–15.

95. Jacobson S. Early postoperative complications in patients with Crohn's disease given and not given preoperative total parenteral nutrition. *Scand J Gastroenterol.* 2012;47(2):170–7.

96. Lashner BA, Evans AA, Hanauer SB. Preoperative total parenteral nutrition for bowel resection in Crohn's disease. *Dig Dis Sci.* 1989;34(5):741–6.

97. No Authors Listed. Perioperative total parenteral nutrition in surgical patients. The Veterans Affairs Total Parenteral Nutrition Cooperative Study Group. *N Engl J Med.* 1991;325(8):525–32.

98. Pettigrew RA, Hill GL. Indicators of surgical risk and clinical judgement. *Br J Surg.* 1986;73(1):47–51.

99. Candy S, Wright J, Gerber M, Adams G, Gerig M, Goodman R. A controlled double blind study of azathioprine in the management of Crohn's disease. *Gut.* 1995;37(5):674–8.

100. Markowitz J, Grancher K, Kohn N, Lesser M, Daum F. A multicenter trial of 6-mercaptopurine and prednisone in children with newly diagnosed Crohn's disease. *Gastroenterology.* 2000;119(4):895–902.

101. Targan SR, Hanauer SB, van Deventer SJ, Mayer L, Present DH, Braakman T, et al. A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn's disease. Crohn's Disease cA2 Study Group. *N Engl J Med.* 1997;337(15):1029–35.

102. Aszodi A, Ponsky JL. Effects of corticosteroid on the healing bowel anastomosis. *Am Surg.* 1984;50(10):546–8.

103. Furst MB, Stromberg BV, Blatchford GJ, Christensen MA, Thorson AG. Colonic anastomoses: bursting strength after corticosteroid treatment. *Dis Colon Rectum.* 1994;37(1):12–5.

104. Ehrlich HP, Hunt TK. Effects of cortisone and vitamin A on wound healing. *Ann Surg.* 1968;167(3):324–8.

105. Stuck AE, Minder CE, Frey FJ. Risk of infectious complications in patients taking glucocorticosteroids. *Rev Infect Dis.* 1989;11(6):954–63.

106. Subramanian V, Saxena S, Kang JY, Pollok RC. Preoperative steroid use and risk of postoperative complications in patients with inflammatory bowel disease undergoing abdominal surgery. *Am J Gastroenterol.* 2008;103(9):2373–81.

107. Aberra FN, Lewis JD, Hass D, Rombeau JL, Osborne B, Lichtenstein GR. Corticosteroids and immunomodulators: postoperative infectious complication risk in inflammatory bowel disease patients. *Gastroenterology.* 2003;125(2):320–7.

108. Bruewer M, Utech M, Rijcken EJ, Anthoni C, Laukoetter MG, Kersting S, et al. Preoperative steroid administration: effect on morbidity among patients undergoing intestinal bowel resection for Crohn's disease. *World J Surg.* 2003;27(12):1306–10.

109. Mascarenhas C, Nunoo R, Asgeirsson T, Rivera R, Kim D, Hoedema R, et al. Outcomes of ileocolic resection and right hemicolectomies for Crohn's patients in comparison with non-Crohn's patients and the impact of perioperative immunosuppressive therapy with biologics and steroids on inpatient complications. *Am J Surg.* 2012;203(3):375–8.

110. Kunitake H, Hodin R, Shellito PC, Sands BE, Korzenik J, Bordeianou L. Perioperative treatment with infliximab in patients with Crohn's disease and ulcerative colitis is not associated with an increased rate of postoperative complications. *J Gastrointest Surg.* 2008;12(10):1730–6. discussion 1736–7.
111. Colombel JF, Loftus Jr EV, Tremaine WJ, Pemberton JH, Wolff BG, Young-Fadok T, et al. Early postoperative complications are not increased in patients with Crohn's disease treated perioperatively with infliximab or immunosuppressive therapy. *Am J Gastroenterol.* 2004;99(5):878–83.
112. Bafford AC, Powers S, Ha C, Kruse D, Gorfine SR, Chessin DB, et al. Immunosuppressive therapy does not increase operative morbidity in patients with Crohn's disease. *J Clin Gastroenterol.* 2013;47(6):491–5.
113. Marchal L, D'Haens G, Van Assche G, Vermeire S, Noman M, Ferrante M, et al. The risk of post-operative complications associated with infliximab therapy for Crohn's disease: a controlled cohort study. *Aliment Pharmacol Ther.* 2004;19(7):749–54.
114. Appau KA, Fazio VW, Shen B, Church JM, Lashner B, Remzi F, et al. Use of infliximab within 3 months of ileocolonic resection is associated with adverse postoperative outcomes in Crohn's patients. *J Gastrointest Surg.* 2008;12(10):1738–44.
115. Ahmed Ali U, Martin ST, Rao AD, Kiran RP. Impact of preoperative immunosuppressive agents on postoperative outcomes in Crohn's disease. *Dis Colon Rectum.* 2014;57(5):663–74.
116. Choy PY, Bissett IP, Docherty JG, Parry BR, Merrie A, Fitzgerald A. Stapled versus handsewn methods for ileocolic anastomoses. *Cochrane Database Syst Rev.* 2011;9, CD004320.
117. He X, Chen Z, Huang J, Lian L, Rouniyar S, Wu X, Lan P. Stapled side-to-side anastomosis might be better than handsewn end-to-end anastomosis in ileocolic resection for Crohn's disease: a meta-analysis. *Dig Dis Sci.* 2014;59(7):1544–51.
118. Yamamoto T, Bain IM, Mylonakis E, Allan RN, Keighley MR. Stapled functional end-to-end anastomosis versus sutured end-to-end anastomosis after ileocolonic resection in Crohn disease. *Scand J Gastroenterol.* 1999;34(7):708–13.
119. Resegotti A, Astegiano M, Farina EC, Ciccone G, Avagnina G, Giustetto A, et al. Side-to-side stapled anastomosis strongly reduces anastomotic leak rates in Crohn's disease surgery. *Dis Colon Rectum.* 2005;48(3):464–8.
120. Ikeuchi H, Kusunoki M, Yamamura T. Long-term results of stapled and hand-sewn anastomoses in patients with Crohn's disease. *Dig Surg.* 2000;17(5):493–6.
121. Simillis C, Purkayastha S, Yamamoto T, Strong SA, Darzi AW, Tekkis PP. A meta-analysis comparing conventional end-to-end anastomosis vs. other anastomotic configurations after resection in Crohn's disease. *Dis Colon Rectum.* 2007;50(10):1674–87.
122. McLeod RS, Wolff BG, Ross S, Parkes R, McKenzie M, Investigators of the CAST Trial. Recurrence of Crohn's disease after ileocolic resection is not affected by anastomotic type: results of a multicenter, randomized, controlled trial. *Dis Colon Rectum.* 2009;52(5):919–27.
123. Vangeenberghe N, De Vogelaere K, Haentjens P, Delvaux G. Laparoscopically assisted ileocelectomy in patients with Crohn's disease: a study of 50 consecutive patients. *Surg Endosc.* 2009;23(8):1797–801.
124. Soop M, Larson DW, Malireddy K, Cima RR, Young-Fadok TM, Dozois EJ. Safety, feasibility, and short-term outcomes of laparoscopically assisted primary ileocolic resection for Crohn's disease. *Surg Endosc.* 2009;23(8):1876–81.

125. Reissman P, Salky BA, Pfeifer J, Edye M, Jagelman DG, Wexner SD. Laparoscopic surgery in the management of inflammatory bowel disease. *Am J Surg.* 1996;171(1):47–50.
126. Reissman P, Salky BA, Edye M, Wexner SD. Laparoscopic surgery in Crohn's disease. Indications and results. *Surg Endosc.* 1996;10(12):1201–3.
127. Tabet J, Hong D, Kim CW, Wong J, Goodacre R, Anvari M. Laparoscopic versus open bowel resection for Crohn's disease. *Can J Gastroenterol.* 2001;15(4):237–42.
128. Duepre HJ, Senagore AJ, Delaney CP, Brady KM, Fazio VW. Advantages of laparoscopic resection for ileocecal Crohn's disease. *Dis Colon Rectum.* 2002;45(5):605–10.
129. Bergamaschi R, Pessaux P, Arnaud JP. Comparison of conventional and laparoscopic ileocolic resection for Crohn's disease. *Dis Colon Rectum.* 2003;46(8):1129–33.
130. Luan X, Gross E. Laparoscopic assisted surgery for Crohn's disease an initial experience and results. *J Tongji Med Univ.* 2000;20(4):332–5.
131. Umanskiy K, Malhotra G, Chase A, Rubin MA, Hurst RD, Fichera A. Laparoscopic colectomy for Crohn's colitis. A large prospective comparative study. *J Gastrointest Surg.* 2010;14(4):658–63.
132. Rosman AS, Melis M, Fichera A. Metaanalysis of trials comparing laparoscopic and open surgery for Crohn's disease. *Surg Endosc.* 2005;19(12):1549–55.
133. Tan JJ, Tjandra JJ. Laparoscopic surgery for Crohn's disease: a meta-analysis. *Dis Colon Rectum.* 2007;50(5):576–85.
134. Milsom JW, Hammerhofer KA, Böhm B, Marcello P, Elson P, Fazio VW. Prospective, randomized trial comparing laparoscopic vs. conventional surgery for refractory ileocolic Crohn's disease. *Dis Colon Rectum.* 2001;44(1):1–8.
135. Maartense S, Dunker MS, Slors JF, Cuesta MA, Pierik EG, Gouma DJ, et al. Laparoscopic-assisted versus open ileocolic resection for Crohn's disease: a randomized trial. *Ann Surg.* 2006;243(2):143–9.
136. Goyer P, Alves A, Bretagnol F, Bouhnik Y, Valleur P, Panis Y. Impact of complex Crohn's disease on the outcome of laparoscopic ileocecal resection: a comparative clinical study in 124 patients. *Dis Colon Rectum.* 2009;52(2):205–10.
137. Schmidt CM, Talamini MA, Kaufman HS, Lilliemoe KD, Learn P, Bayless T. Laparoscopic surgery for Crohn's disease: reasons for conversion. *Ann Surg.* 2001;233(6):733–9.
138. Drenick EJ, Ament ME, Finegold SM, Corrodi P, Passaro E. Bypass enteropathy. Intestinal and systemic manifestations following small-bowel bypass. *JAMA.* 1976;236(3):269–72.
139. Frank JD, Shorey BA. Adenocarcinoma of the small bowel as a complication of Crohn's disease. *Gut.* 1973;14(2):120–4.
140. Hawker PC, Gyde SN, Thompson H, Allan RN. Adenocarcinoma of the small intestine complicating Crohn's disease. *Gut.* 1982;23(3):188–93.
141. Fazio VW, Marchetti F, Church M, Goldblum JR, Lavery C, Hull TL, et al. Effect of resection margins on the recurrence of Crohn's disease in the small bowel. A randomized controlled trial. *Ann Surg.* 1996;224(4):563–71.
142. Tichansky D, Cagir B, Yoo E, Marcus SM, Fry RD. Strictureplasty for Crohn's disease: meta-analysis. *Dis Colon Rectum.* 2000;43(7):911–9.
143. Ambe R, Campbell L, Cagir B. A comprehensive review of strictureplasty techniques in Crohn's disease: types, indications, comparisons, and safety. *J Gastrointest Surg.* 2012;16(1):209–17.
144. Michelassi F. Side-to-side isoperistaltic strictureplasty for multiple Crohn's strictures. *Dis*

Colon Rectum. 1996;39(3):345–9.

145. Poggioli G, Stocchi L, Laureti S, Selleri S, Marra C, Magalotti C, et al. Conservative surgical management of terminal ileitis: side-to-side enterocolic anastomosis. *Dis Colon Rectum*. 1997;40(2):234–7.

146. Poggioli G, Laureti S, Pierangeli F, Ugolini F. A new model of strictureplasty for multiple and long stenoses in Crohn's ileitis: side-to-side diseased to disease-free anastomosis. *Dis Colon Rectum*. 2003;46(1):127–30.

147. Roy P, Kumar D. Strictureplasty for active Crohn's disease. *Int J Colorectal Dis*. 2006;21(5):427–32.

148. Ozuner G, Fazio VW, Lavery IC, Milsom JW, Strong SA. Reoperative rates for Crohn's disease following strictureplasty. Long-term analysis. *Dis Colon Rectum*. 1996;39(11):1199–203.

149. Tonelli F, Fedi M, Paroli GM, Fazi M. Indications and results of side-to-side isoperistaltic strictureplasty in Crohn's disease. *Dis Colon Rectum*. 2004;47(4):494–501.

150. Stebbing JF, Jewell DP, Kettlewell MG, Mortensen NJ. Recurrence and reoperation after strictureplasty for obstructive Crohn's disease: long-term results [corrected]. *Br J Surg*. 1995;82(11):1471–4.

151. Dietz DW, Fazio VW, Laureti S, Strong SA, Hull TL, Church J, et al. Strictureplasty in diffuse Crohn's jejunoileitis: safe and durable. *Dis Colon Rectum*. 2002;45(6):764–70.

152. Yamamoto T, Fazio VW, Tekkis PP. Safety and efficacy of strictureplasty for Crohn's disease: a systematic review and meta-analysis. *Dis Colon Rectum*. 2007;50(11):1968–86.

153. Hurst RD, Michelassi F. Strictureplasty for Crohn's disease: techniques and long-term results. *World J Surg*. 1998;22(4):359–63.

154. Sampietro GM, Cristaldi M, Maconi G, Parente F, Sartani A, Ardizzone S, et al. A prospective, longitudinal study of nonconventional strictureplasty in Crohn's disease. *J Am Coll Surg*. 2004;199(1):8–20.

155. Chardavoyne R, Flint GW, Pollack S, Wise L. Factors affecting recurrence following resection for Crohn's disease. *Dis Colon Rectum*. 1986;29(8):495–502.

156. Whelan G, Farmer RG, Fazio VW, Goormastic M. Recurrence after surgery in Crohn's disease. Relationship to location of disease (clinical pattern) and surgical indication. *Gastroenterology*. 1985;88(6):1826–33.

157. Tjandra JJ, Fazio VW, Lavery IC. Results of multiple strictureplasties in diffuse Crohn's disease of the small bowel. *Aust N Z J Surg*. 1993;63(2):95–9.

158. Yamamoto T, Keighley MR. Proctocolectomy is associated with a higher complication rate but carries a lower recurrence rate than total colectomy and ileorectal anastomosis in Crohn colitis. *Scand J Gastroenterol*. 1999;34(12):1212–5.

159. Longo WE, Oakley JR, Lavery IC, Church JM, Fazio VW. Outcome of ileorectal anastomosis for Crohn's colitis. *Dis Colon Rectum*. 1992;35(11):1066–71.

160. Steinberg DM, Allan RN, Cooke WT, Alexander-Williams J. The place of ileorectal anastomosis in Crohn's disease. *Aust N Z J Surg*. 1976;46(1):49–54.

161. Ambrose NS, Keighley MR, Alexander-Williams J, Allan RN. Clinical impact of colectomy and ileorectal anastomosis in the management of Crohn's disease. *Gut*. 1984;25(3):223–7.

162. Cooper JC, Jones D, Williams NS. Outcome of colectomy and ileorectal anastomosis in Crohn's disease. *Ann R Coll Surg Engl*. 1986;68(5):279–82.

163. O'Riordan JM, O'Connor BI, Huang H, Victor JC, Gryfe R, MacRae HM, et al. Long-term

outcome of colectomy and ileorectal anastomosis for Crohn's colitis. *Dis Colon Rectum*. 2011;54(11):1347–54.

164. Cattan P, Bonhomme N, Panis Y, Lémann M, Coffin B, Bouhnik Y, et al. Fate of the rectum in patients undergoing total colectomy for Crohn's disease. *Br J Surg*. 2002;89(4):454–9.

165. Chevalier JM, Jones DJ, Ratelle R, Frileux P, Tiret E, Parc R. Colectomy and ileorectal anastomosis in patients with Crohn's disease. *Br J Surg*. 1994;81(9):1379–81.

166. Buchmann P, Weterman IT, Keighley MR, Peña SA, Allan RN, Alexander-Williams J. The prognosis of ileorectal anastomosis in Crohn's disease. *Br J Surg*. 1981;68(1):7–10.

167. Lock MR, Fazio VW, Farmer RG, Jagelman DG, Lavery IC, Weakley FL. Proximal recurrence and the fate of the rectum following excisional surgery for Crohn's disease of the large bowel. *Ann Surg*. 1981;194(6):754–60.

168. Polle SW, Slors JF, Weverling GJ, Gouma DJ, Hommes DW, Bemelman WA. Recurrence after segmental resection for colonic Crohn's disease. *Br J Surg*. 2005;92(9):1143–9.

169. Andersson P, Olaison G, Hallböök O, Sjö Dahl R. Segmental resection or subtotal colectomy in Crohn's colitis? *Dis Colon Rectum*. 2002;45(1):47–53.

170. Prabhakar LP, Laramée C, Nelson H, Dozois RR. Avoiding a stoma: role for segmental or abdominal colectomy in Crohn's colitis. *Dis Colon Rectum*. 1997;40(1):71–8.

171. Korelitz BI, Taunk R, Kesar V. Segmental sigmoid polypoidosis as a colonoscopic indicator of an ileosigmoid fistula in Crohn's ileitis. *J Crohn's Colitis*. 2015;9(4):339–41.

172. Yamamoto T, Bain IM, Allan RN, Keighley MR. Persistent perineal sinus after proctocolectomy for Crohn's disease. *Dis Colon Rectum*. 1999;42(1):96–101.

173. Keighley MR, Allan RN. Current status and influence of operation on perianal Crohn's disease. *Int J Colorectal Dis*. 1986;1(2):104–7.

174. Corman ML, Veidenheimer MC, Collier JA, Ross VH. Perineal wound healing after proctectomy for inflammatory bowel disease. *Dis Colon Rectum*. 1978;21(3):155–9.

175. Hurst RD, Gottlieb LJ, Crucitti P, Melis M, Rubin M, Michelassi F. Primary closure of complicated perineal wounds with myocutaneous and fasciocutaneous flaps after proctectomy for Crohn's disease. *Surgery*. 2001;130(4):767–72.

176. Genua JC, Vivas DA. Management of nonhealing perineal wounds. *Clin Colon Rectal Surg*. 2007;20(4):322–8.

177. Rutgeerts P, Geboes K, Vantrappen G, Beyls J, Kerremans R, Hiele M. Predictability of the postoperative course of Crohn's disease. *Gastroenterology*. 1990;99(4):956–63.

178. Olaison G, Smedh K, Sjö Dahl R. Natural course of Crohn's disease after ileocolic resection: endoscopically visualised ileal ulcers preceding symptoms. *Gut*. 1992;33(3):331–5.

179. Frolkis AD, Lipton DS, Fiest KM, Negrón ME, Dykeman J, deBruyn J, et al. Cumulative incidence of second intestinal resection in Crohn's disease: a systematic review and meta-analysis of population-based studies. *Am J Gastroenterol*. 2014;109(11):1739–48.

180. Lennard-Jones JE, Stalder GA. Prognosis after resection of chronic regional ileitis. *Gut*. 1967;8(4):332–6.

181. Riss S, Schuster I, Papay P, Mittlböck M, Stift A. Repeat intestinal resections increase the risk of recurrence of Crohn's disease. *Dis Colon Rectum*. 2013;56(7):881–7.

182. Avidan B, Sakhnini E, Lahat A, Lang A, Koler M, Zmora O, et al. Risk factors regarding the need for a second operation in patients with Crohn's disease. *Digestion*. 2005;72(4):248–53.

183. Reese GE, Nanidis T, Borysiewicz C, Yamamoto T, Orchard T, Tekkis PP. The effect of

smoking after surgery for Crohn's disease: a meta-analysis of observational studies. *Int J Colorectal Dis.* 2008;23(12):1213–21.

184. Yamamoto T, Watanabe T. Strategies for the prevention of postoperative recurrence of Crohn's disease. *Colorectal Dis.* 2013;15(12):1471–80.

185. Simillis C, Yamamoto T, Reese GE, Umegae S, Matsumoto K, Darzi AW, et al. A meta-analysis comparing incidence of recurrence and indication for reoperation after surgery for perforating versus nonperforating Crohn's disease. *Am J Gastroenterol.* 2008;103(1):196–205.

186. Lautenbach E, Berlin JA, Lichtenstein GR. Risk factors for early postoperative recurrence of Crohn's disease. *Gastroenterology.* 1998;115(2):259–67.

187. Buisson A, Chevaux JB, Bommelaer G, Peyrin-Biroulet L. Diagnosis, prevention and treatment of postoperative Crohn's disease recurrence. *Dig Liver Dis.* 2012;44(6):453–60.

188. El-Hachem S, Regueiro M. Postoperative Crohn's disease: prevention and treatment. *Expert Rev Gastroenterol Hepatol.* 2009;3(3):249–56.

189. Brignola C, Cottone M, Pera A, Ardizzone S, Scribano ML, De Franchis R, et al. Mesalamine in the prevention of endoscopic recurrence after intestinal resection for Crohn's disease. Italian Cooperative Study Group. *Gastroenterology.* 1995;108(2):345–9.

190. Singh S, Garg SK, Pardi DS, Wang Z, Murad MH, Loftus Jr EV. Comparative efficacy of pharmacologic interventions in preventing relapse of Crohn's disease after surgery: a systematic review and network meta-analysis. *Gastroenterology.* 2015;148(1):64–76.

191. Doherty G, Bennett G, Patil S, Cheifetz A, Moss AC. Interventions for prevention of postoperative recurrence of Crohn's disease. *Cochrane Database Syst Rev.* 2009;4, CD006873.

192. Cottone M, Cammà C. Mesalamine and relapse prevention in Crohn's disease. *Gastroenterology.* 2000;119(2):597.

193. Lochs H, Mayer M, Fleig WE, Mortensen PB, Bauer P, Genser D, et al. Prophylaxis of postoperative relapse in Crohn's disease with mesalamine: European Cooperative Crohn's Disease Study VI. *Gastroenterology.* 2000;118(2):264–73.

194. Rutgeerts P, Hiele M, Geboes K, Peeters M, Penninckx F, Aerts R, et al. Controlled trial of metronidazole treatment for prevention of Crohn's recurrence after ileal resection. *Gastroenterology.* 1995;108(6):1617–21.

195. Rutgeerts P, Van Assche G, Vermeire S, D'Haens G, Baert F, Noman M, et al. Ornidazole for prophylaxis of postoperative Crohn's disease recurrence: a randomized, double-blind, placebo-controlled trial. *Gastroenterology.* 2005;128(4):856–61.

196. Markowitz J. Can we change the natural history of Crohn's disease with early immunomodulation? *Dig Dis.* 2014;32(4):345–50.

197. Van Loo ES, Vosseberg NW, van der Heide F, Pierie JP, van der Linde K, Ploeg RJ, et al. Thiopurines are associated with a reduction in surgical re-resections in patients with Crohn's disease: a long-term follow-up study in a regional and academic cohort. *Inflamm Bowel Dis.* 2013;19(13):2801–8.

198. Domènech E, Mañosa M, Bernal I, Garcia-Planella E, Cabré E, Piñol M, et al. Impact of azathioprine on the prevention of postoperative Crohn's disease recurrence: results of a prospective, observational, long-term follow-up study. *Inflamm Bowel Dis.* 2008;14(4):508–13.

199. Hanauer SB, Feagan BG, Lichtenstein GR, Mayer LF, Schreiber S, Colombel JF, ACCENT I Study Group, et al. Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial. *Lancet.* 2002;359(9317):1541–9.

200. Savarino E, Bodini G, Dulbecco P, Assandri L, Bruzzzone L, Mazza F, Frigo AC, et al. Adalimumab is more effective than azathioprine and mesalamine at preventing postoperative recurrence of Crohn's disease: a randomized controlled trial. *Am J Gastroenterol*. 2013;108(11):1731–42.
201. Regueiro M, Schraut W, Baidoo L, Kip KE, Sepulveda AR, Pesci M, et al. Infliximab prevents Crohn's disease recurrence after ileal resection. *Gastroenterology*. 2009;136(2):441–50.
202. Yoshida K, Fukunaga K, Ikeuchi H, Kamikozuru K, Hida N, Ohda Y, Yokoyama Y, et al. Scheduled infliximab monotherapy to prevent recurrence of Crohn's disease following ileocolic or ileal resection: a 3-year prospective randomized open trial. *Inflamm Bowel Dis*. 2012;18(9):1617–23.
203. Yamamoto T, Umegae S, Matsumoto K. Impact of infliximab therapy after early endoscopic recurrence following ileocolonic resection of Crohn's disease: a prospective pilot study. *Inflamm Bowel Dis*. 2009;15(10):1460–6.

## 第 50 章

1. Andersson P, Soderholm JD. Surgery in ulcerative colitis: indication and timing. *Dig Dis*. 2009;27(3):335–40.
2. Biancone L et al. European evidence-based consensus on the management of ulcerative colitis: special situations. *J Crohns Colitis*. 2008;2(1):63–92.
3. Eaden JA, Abrams KR, Mayberry JF. The risk of colorectal cancer in ulcerative colitis: a meta-analysis. *Gut*. 2001;48(4):526–35.
4. Kiran RP et al. Colorectal cancer complicating inflammatory bowel disease: similarities and differences between Crohn's and ulcerative colitis based on three decades of experience. *Ann Surg*. 2010;252(2):330–5.
5. Connell WR et al. Long-term neoplasia risk after azathioprine treatment in inflammatory bowel disease. *Lancet*. 1994;343(8908):1249–52.
6. Ullman TA et al. The fate of low grade dysplasia in ulcerative colitis. *Am J Gastroenterol*. 2002;97(4):922–7.
7. Hurlstone DP et al. Endoscopic mucosal resection for flat neoplasia in chronic ulcerative colitis: can we change the endoscopic management paradigm? *Gut*. 2007;56(6):838–46.
8. Smith LA et al. Endoscopic resection of adenoma-like mass in chronic ulcerative colitis using a combined endoscopic mucosal resection and cap assisted submucosal dissection technique. *Inflamm Bowel Dis*. 2008;14(10):1380–6.
9. Dayan B, Turner D. Role of surgery in severe ulcerative colitis in the era of medical rescue therapy. *World J Gastroenterol*. 2012;18(29):3833–8.
10. Truelove SC, Witts LJ. Cortisone in ulcerative colitis; final report on a therapeutic trial. *Br Med J*. 1955;2(4947):1041–8.
11. Travis SP et al. European evidence-based consensus on the management of ulcerative colitis: current management. *J Crohns Colitis*. 2008;2(1):24–62.
12. Randall J et al. Delayed surgery for acute severe colitis is associated with increased risk of postoperative complications. *Br J Surg*. 2010;97(3):404–9.
13. Roberts SE et al. Mortality in patients with and without colectomy admitted to hospital for

- ulcerative colitis and Crohn's disease: record linkage studies. *BMJ*. 2007;335(7628):1033.
14. Teeuwen PH et al. Colectomy in patients with acute colitis: a systematic review. *J Gastrointest Surg*. 2009;13(4):676–86.
  15. Geltzeiler CB et al. Initial surgical management of ulcerative colitis in the biologic era. *Dis Colon Rectum*. 2014;57(12):1358–63.
  16. Heuschen UA et al. Outcome after septic complications in J pouch procedures. *Br J Surg*. 2002;89(2):194–200.
  17. Gorfine SR et al. Long-term results of salvage surgery for septic complications after restorative proctocolectomy: does fecal diversion improve outcome? *Dis Colon Rectum*. 2003;46(10):1339–44.
  18. Alves A et al. Subtotal colectomy for severe acute colitis: a 20-year experience of a tertiary care center with an aggressive and early surgical policy. *J Am Coll Surg*. 2003;197(3):379–85.
  19. Heuschen UA et al. Risk factors for ileoanal J pouch-related septic complications in ulcerative colitis and familial adenomatous polyposis. *Ann Surg*. 2002;235(2):207–16.
  20. Lim WC, Hanauer SB. Emerging biologic therapies in inflammatory bowel disease. *Rev Gastroenterol Disord*. 2004;4(2):66–85.
  21. Ferrante M et al. Corticosteroids but not infliximab increase short-term postoperative infectious complications in patients with ulcerative colitis. *Inflamm Bowel Dis*. 2009;15(7):1062–70.
  22. Schluender SJ et al. Does infliximab influence surgical morbidity of ileal pouch-anal anastomosis in patients with ulcerative colitis? *Dis Colon Rectum*. 2007;50(11):1747–53.
  23. Selvasekar CR et al. Effect of infliximab on short-term complications in patients undergoing operation for chronic ulcerative colitis. *J Am Coll Surg*. 2007;204(5):956–62. discussion 962–3.
  24. Mor IJ et al. Infliximab in ulcerative colitis is associated with an increased risk of postoperative complications after restorative proctocolectomy. *Dis Colon Rectum*. 2008;51(8):1202–7. discussion 1207–10.
  25. Waterman M et al. Preoperative biological therapy and short-term outcomes of abdominal surgery in patients with inflammatory bowel disease. *Gut*. 2013;62(3):387–94.
  26. Kunitake H et al. Perioperative treatment with infliximab in patients with Crohn's disease and ulcerative colitis is not associated with an increased rate of postoperative complications. *J Gastrointest Surg*. 2008;12(10):1730–6. discussion 1736–7.
  27. Krane MK et al. Preoperative infliximab therapy does not increase morbidity and mortality after laparoscopic resection for inflammatory bowel disease. *Dis Colon Rectum*. 2013;56(4):449–57.
  28. Ehteshami-Afshar S et al. A systematic review and meta-analysis of the effects of infliximab on the rate of colectomy and post-operative complications in patients with inflammatory bowel disease. *Arch Med Sci*. 2011;7(6):1000–12.
  29. Bordeianou L et al. Preoperative infliximab treatment in patients with ulcerative and indeterminate colitis does not increase rate of conversion to emergent and multistep abdominal surgery. *Int J Colorectal Dis*. 2009;25:401–4.
  30. Gorfine SR et al. Restorative proctocolectomy without diverting ileostomy. *Dis Colon Rectum*. 1995;38(2):188–94.
  31. Rutgeerts P et al. Infliximab for induction and maintenance therapy for ulcerative colitis. *N Engl J Med*. 2005;353(23):2462–76.
  32. Yang Z et al. Meta-analysis: pre-operative infliximab treatment and short-term post-operative complications in patients with ulcerative colitis. *Aliment Pharmacol Ther*. 2010;31(4):486–92.



33. Bordeianou L. In flux on infliximab: conflicting studies on surgical outcomes. *Inflamm Bowel Dis.* 2009;15(10):1605–6.
34. Hicks CW, Hodin RA, Bordeianou L. Possible overuse of 3-stage procedures for active ulcerative colitis. *JAMA Surg.* 2013;148(7):658–64.
35. Pandey S et al. Minimally invasive pouch surgery for ulcerative colitis: is there a benefit in staging? *Dis Colon Rectum.* 2011;54(3):306–10.
36. Brooke BN. Ileostomy. *Surgery.* 1968;64(3):678–80.
37. Daly DW, Brooke BN. Ileostomy and excision of the large intestine for ulcerative colitis. *Lancet.* 1967;2(7506):62–4.
38. Hendren S et al. Clinical practice guidelines for ostomy surgery. *Dis Colon Rectum.* 2015;58(4):375–87.
39. Leenen LP, Kuypers JH. Some factors influencing the outcome of stoma surgery. *Dis Colon Rectum.* 1989;32(6):500–4.
40. Camilleri-Brennan J, Steele RJ. Objective assessment of quality of life following panproctocolectomy and ileostomy for ulcerative colitis. *Ann R Coll Surg Engl.* 2001;83(5):321–4.
41. Ware Jr JE, Sherbourne CD. The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection. *Med Care.* 1992;30(6):473–83.
42. Kock NG. Intra-abdominal “reservoir” in patients with permanent ileostomy. Preliminary observations on a procedure resulting in fecal “continence” in five ileostomy patients. *Arch Surg.* 1969;99(2):223–31.
43. Ecker KW, Haberer M, Feifel G. Conversion of the failing ileoanal pouch to reservoir-ileostomy rather than to ileostomy alone. *Dis Colon Rectum.* 1996;39(9):977–80.
44. Gelernt IM, Bauer JJ, Kreel I. The continent ileostomy in the pediatric patient. *Hosp Pract.* 1977;12(4):64–74.
45. Gelernt IM, Bauer JJ, Kreel I. Continent ileostomy in the pediatric patient. *J Pediatr Surg.* 1976;11(5):773–9.
46. Beahrs OH et al. Ileostomy with ileal reservoir rather than ileostomy alone. *Ann Surg.* 1974;179(5):634–8.
47. Beart Jr RW et al. The continent ileostomy: a viable alternative. *Mayo Clin Proc.* 1979;54(10):643–5.
48. Gelernt IM, Bauer JJ, Kreel I. The reservoir ileostomy: early experience with 54 patients. *Ann Surg.* 1977;185(2):179–84.
49. Aytac E, Ashburn J, Dietz DW. Is there still a role for continent ileostomy in the surgical treatment of inflammatory bowel disease? *Inflamm Bowel Dis.* 2014;20(12):2519–25.
50. Nessar G et al. Long-term outcome and quality of life after continent ileostomy. *Dis Colon Rectum.* 2006;49(3):336–44.
51. Kohler LW et al. Quality of life after proctocolectomy. A comparison of Brooke ileostomy, Kock pouch, and ileal pouch-anal anastomosis. *Gastroenterology.* 1991;101(3):679–84.
52. Baker WN. The results of ileorectal anastomosis at St Mark’s Hospital from 1953 to 1968. *Gut.* 1970;11(3):235–9.
53. Aylett S. Results following total colectomy and ileorectal anastomosis. *Proc R Soc Med.* 1959;52(Suppl):24–5.
54. Hueting WE, Gooszen HG, van Laarhoven CJ. Sexual function and continence after ileo pouch anal anastomosis: a comparison between a meta-analysis and a questionnaire survey. *Int J Colorectal*

Dis. 2004;19(3):215–8.

55. Parks AG, Nicholls RJ. Proctocolectomy without ileostomy for ulcerative colitis. *Br Med J*. 1978;2(6130):85–8.

56. Utsunomiya J et al. Total colectomy, mucosal proctectomy, and ileoanal anastomosis. *Dis Colon Rectum*. 1980;23(7):459–66.

57. Fichera A et al. Preservation of the anal transition zone in ulcerative colitis. Long-term effects on defecatory function. *J Gastrointest Surg*. 2007;11(12):1647–52. discussion 1652–3.

58. Silvestri MT et al. Chronic inflammatory changes in the anal transition zone after stapled ileal pouch-anal anastomosis: is mucosectomy a superior alternative? *Surgery*. 2008;144(4):533–7. discussion 537–9.

59. Das P et al. Risk of dysplasia and adenocarcinoma following restorative proctocolectomy for ulcerative colitis. *Colorectal Dis*. 2007;9(1):15–27.

60. Da Luz Moreira A, Kiran RP, Lavery I. Clinical outcomes of ileorectal anastomosis for ulcerative colitis. *Br J Surg*. 2010;97(1):65–9.

61. Oakley JR et al. Complications and quality of life after ileorectal anastomosis for ulcerative colitis. *Am J Surg*. 1985;149(1):23–30.

62. Leijonmarck CE et al. Long-term results of ileorectal anastomosis in ulcerative colitis in Stockholm County. *Dis Colon Rectum*. 1990;33(3):195–200.

63. Pastore RL, Wolff BG, Hodge D. Total abdominal colectomy and ileorectal anastomosis for inflammatory bowel disease. *Dis Colon Rectum*. 1997;40(12):1455–64.

64. Da Luz Moreira A, Lavery IC. Ileorectal anastomosis and proctocolectomy with end ileostomy for ulcerative colitis. *Clin Colon Rectal Surg*. 2010;23(4):269–73.

65. Lepisto A, Jarvinen HJ. Fate of the rectum after colectomy with ileorectal anastomosis in ulcerative colitis. *Scand J Surg*. 2005;94(1):40–2.

66. Johnson WR et al. The risk of rectal carcinoma following colectomy in ulcerative colitis. *Dis Colon Rectum*. 1983;26(1):44–6.

67. Kiran RP et al. Risk and location of cancer in patients with preoperative colitis-associated dysplasia undergoing proctocolectomy. *Ann Surg*. 2014;259(2):302–9.

68. Wexner SD et al. Practice parameters for the treatment of mucosal ulcerative colitis—supporting documentation. The Standards Practice Task Force. The American Society of Colon and Rectal Surgeons. *Dis Colon Rectum*. 1997;40(11):1277–85.

69. Ross H et al. Practice parameters for the surgical treatment of ulcerative colitis. *Dis Colon Rectum*. 2014;57(1):5–22.

70. Holder-Murray J et al. Totally laparoscopic total proctocolectomy: a safe alternative to open surgery in inflammatory bowel disease. *Inflamm Bowel Dis*. 2012;18(5):863–8.

71. Gearhart SL et al. Sphincter defects are not associated with long-term incontinence following ileal pouch-anal anastomosis. *Dis Colon Rectum*. 2005;48(7):1410–5.

72. Sauer R et al. Adjuvant vs. neoadjuvant radiochemotherapy for locally advanced rectal cancer: the German trial CAO/ARO/AIO-94. *Colorectal Dis*. 2003;5(5):406–15.

73. Kapiteijn E et al. Total mesorectal excision (TME) with or without preoperative radiotherapy in the treatment of primary rectal cancer. Prospective randomised trial with standard operative and histopathological techniques. Dutch ColoRectal Cancer Group. *Eur J Surg*. 1999;165(5):410–20.

74. Wu XR et al. Preoperative pelvic radiation increases the risk for ileal pouch failure in patients with colitis-associated colorectal cancer. *J Crohns Colitis*. 2013;7(10):e419–26.

75. Radice E et al. Ileal pouch-anal anastomosis in patients with colorectal cancer: long-term functional and oncologic outcomes. *Dis Colon Rectum*. 1998;41(1):11–7.
76. Remzi FH, Preen M. Rectal cancer and ulcerative colitis: does it change the therapeutic approach? *Colorectal Dis*. 2003;5(5):483–5.
77. Ogden CL et al. Prevalence of childhood and adult obesity in the united states, 2011–2012. *JAMA*. 2014;311(8):806–14.
78. Canedo JA et al. Restorative proctectomy with ileal pouch-anal anastomosis in obese patients. *Dis Colon Rectum*. 2010;53(7):1030–4.
79. Krane MK et al. Does morbid obesity change outcomes after laparoscopic surgery for inflammatory bowel disease? Review of 626 consecutive cases. *J Am Coll Surg*. 2013;216(5):986–96.
80. Klos CL et al. Obesity increases risk for pouch-related complications following restorative proctocolectomy with ileal pouch-anal anastomosis (IPAA). *J Gastrointest Surg*. 2014;18(3):573–9.
81. Sturm R. Increases in morbid obesity in the USA: 2000–2005. *Public Health*. 2007;121(7):492–6.
82. Delaney CP et al. Prospective, age-related analysis of surgical results, functional outcome, and quality of life after ileal pouch-anal anastomosis. *Ann Surg*. 2003;238(2):221–8.
83. Pellino G et al. Complications and functional outcomes of restorative proctocolectomy for ulcerative colitis in the elderly. *BMC Surg*. 2013;13 Suppl 2:S9.
84. Rothenberger DA et al. The Parks S ileal pouch and anal anastomosis after colectomy and mucosal proctectomy. *Am J Surg*. 1985;149(3):390–4.
85. Harms BA, Andersen AB, Starling JR. The W ileal reservoir: long-term assessment after proctocolectomy for ulcerative colitis and familial polyposis. *Surgery*. 1992;112(4):638–46.
86. Nicholls RJ, Lubowski DZ. Restorative proctocolectomy: the four loop (W) reservoir. *Br J Surg*. 1987;74(7):564–6.
87. Stone MM, Lewin K, Fonkalsrud EW. Late obstruction of the lateral ileal reservoir after colectomy and endorectal ileal pullthrough procedures. *Surg Gynecol Obstet*. 1986;162(5):411–7.
88. Michelassi F, Block GE. A simplified technique for ileal J-pouch construction. *Surg Gynecol Obstet*. 1993;176(3):290–4.
89. Michelassi F, Hurst R. Restorative proctocolectomy with J-pouch ileoanal anastomosis. *Arch Surg*. 2000;135(3):347–53.
90. Sagar PM et al. Comparison of triplicated (S) and quadruplicated (W) pelvic ileal reservoirs. Studies on manovolumetry, fecal bacteriology, fecal volatile fatty acids, mucosal morphology, and functional results. *Gastroenterology*. 1992;102(2):520–8.
91. Hewett PJ, Stitz R, Hewett MK, Harry E, Bacon Oration. Comparison of the functional results of restorative proctocolectomy for ulcerative colitis between the J and W configuration ileal pouches with sutured ileoanal anastomosis. *Dis Colon Rectum*. 1995;38(6):567–72.
92. Selvaggi F et al. Randomized, controlled trial to compare the J-pouch and W-pouch configurations for ulcerative colitis in the maturation period. *Dis Colon Rectum*. 2000;43(5):615–20.
93. Johnston D et al. Prospective controlled trial of duplicated (J) versus quadruplicated (W) pelvic ileal reservoirs in restorative proctocolectomy for ulcerative colitis. *Gut*. 1996;39(2):242–7.
94. Keighley MR, Yoshioka K, Kmiet W. Prospective randomized trial to compare the stapled double lumen pouch and the sutured quadruple pouch for restorative proctocolectomy. *Br J Surg*.

1988;75(10):1008–11.

95. Parks AG, Nicholls RJ, Belliveau P. Proctocolectomy with ileal reservoir and anal anastomosis. *Br J Surg.* 1980;67(8):533–8.

96. Tuckson WB et al. Impact of anal manipulation and pouch design on ileal pouch function. *J Natl Med Assoc.* 1991;83(12):1089–92.

97. Miller AS et al. Does eversion of the anorectum during restorative proctocolectomy influence functional outcome? *Dis Colon Rectum.* 1996;39(5):489–93.

98. Williamson ME et al. Clinical and physiological evaluation of anorectal eversion during restorative proctocolectomy. *Br J Surg.* 1995;82(10):1391–4.

99. Miller R et al. Improvement of anal sensation with preservation of the anal transition zone after ileoanal anastomosis for ulcerative colitis. *Dis Colon Rectum.* 1990;33(5):414–8.

100. Gemlo BT et al. Functional assessment of ileal pouch-anal anastomotic techniques. *Am J Surg.* 1995;169(1):137–41.

101. Gullberg K, Lindquist K, Lijeqvist L. Pelvic pouch-anal anastomoses: pros and cons about omission of mucosectomy and loop ileostomy. A study of 60 patients. *Ann Chir.* 1995;49(6):527–33.

102. Landi E et al. Proctocolectomy and stapled ileo-anal anastomosis without mucosal proctectomy. *Int J Colorectal Dis.* 1990;5(3):151–4.

103. Lewis WG et al. Preservation of complete anal sphincteric proprioception in restorative proctocolectomy: the inhibitory reflex and fine control of continence need not be impaired. *Gut.* 1995;36(6):902–6.

104. Sagar PM, Holdsworth PJ, Johnston D. Correlation between laboratory findings and clinical outcome after restorative proctocolectomy: serial studies in 20 patients with end-to-end pouch-anal anastomosis. *Br J Surg.* 1991;78(1):67–70.

105. Choen S, Tsunoda A, Nicholls RJ. Prospective randomized trial comparing anal function after hand sewn ileoanal anastomosis with mucosectomy versus stapled ileoanal anastomosis without mucosectomy in restorative proctocolectomy. *Br J Surg.* 1991;78(4):430–4.

106. Luukkonen P, Jarvinen H. Stapled vs hand-sutured ileoanal anastomosis in restorative proctocolectomy. A prospective, randomized study. *Arch Surg.* 1993;128(4):437–40.

107. Reilly WT et al. Randomized prospective trial comparing ileal pouch-anal anastomosis performed by excising the anal mucosa to ileal pouch-anal anastomosis performed by preserving the anal mucosa. *Ann Surg.* 1997;225(6):666–76.

108. Ziv Y et al. Stapled ileal pouch anal anastomoses are safer than handsewn anastomoses in patients with ulcerative colitis. *Am J Surg.* 1996;171(3):320–3.

109. Fazio VW, Tjandra JJ. Transanal mucosectomy. Ileal pouch advancement for anorectal dysplasia or inflammation after restorative proctocolectomy. *Dis Colon Rectum.* 1994;37(10):1008–11.

110. Lavery IC et al. Anal canal inflammation after ileal pouch-anal anastomosis. The need for treatment. *Dis Colon Rectum.* 1995;38(8):803–6.

111. Fenger C. The anal transitional zone. Location and extent. *Acta Pathol Microbiol Scand.* 1979;87(5):379–86.

112. Thompson-Fawcett MW, Warren BF, Mortensen NJ. A new look at the anal transitional zone with reference to restorative proctocolectomy and the columnar cuff. *Br J Surg.* 1998;85(11):1517–21.

113. O'Connell PR et al. Does rectal mucosa regenerate after ileoanal anastomosis? *Dis Colon Rectum*. 1987;30(1):1–5.
114. O'Riordain MG et al. Incidence and natural history of dysplasia of the anal transitional zone after ileal pouch-anal anastomosis: results of a five-year to ten- year follow-up. *Dis Colon Rectum*. 2000;43(12):1660–5.
115. Dolgin SE et al. Restorative proctocolectomy in children with ulcerative colitis utilizing rectal mucosectomy with or without diverting ileostomy. *J Pediatr Surg*. 1999;34(5):837–9.
116. Marchesa P et al. The risk of cancer and dysplasia among ulcerative colitis patients with primary sclerosing cholangitis. *Am J Gastroenterol*. 1997;92(8):1285–8.
117. McMullen K et al. Complications associated with ileal pouch-anal anastomosis. *World J Surg*. 1991;15(6):763–6. discussion 766–7.
118. Burnstein MJ et al. Technique of mesenteric lengthening in ileal reservoir-anal anastomosis. *Dis Colon Rectum*. 1987;30(11):863–6.
119. Goes RN et al. Lengthening of the mesentery using the marginal vascular arcade of the right colon as the blood supply to the ileal pouch. *Dis Colon Rectum*. 1995;38(8):893–5.
120. Edwards CM, Warren BF, Shepherd NA. Ileal pouch-anal anastomosis for Crohn's disease. *Gut*. 1999;44(6):896.
121. Keighley MR, Allan RN, Sanders DS. Ileal pouch-anal anastomosis for Crohn's disease. *Gut*. 1999;44(3):440–1.
122. Sagar PM, Dozois RR, Wolff BG. Long-term results of ileal pouch-anal anastomosis in patients with Crohn's disease. *Dis Colon Rectum*. 1996;39(8):893–8.
123. Deutsch AA et al. Results of the pelvic-pouch procedure in patients with Crohn's disease. *Dis Colon Rectum*. 1991;34(6):475–7.
124. Hyman NH et al. Consequences of ileal pouch-anal anastomosis for Crohn's colitis. *Dis Colon Rectum*. 1991;34(8):653–7.
125. Panis Y et al. Ileal pouch/anal anastomosis for Crohn's disease. *Lancet*. 1996;347(9005):854–7.

## 第 51 章

1. Kiely JM, Fazio VW, Remzi FH, Shen B, Kiran RP. Pelvic sepsis after IPAA adversely affects function of the pouch and quality of life. *Dis Colon Rectum*. 2012;55:387–92.
2. Fazio VW, Kiran RP, Remzi FH, Coffey JC, Heneghan HM, Kirat HT, Manilich E, Shen B, Martin ST. Ileal pouch anal anastomosis—analysis of outcome and quality of life in 3707 patients. *Ann Surg*. 2013;257(4):679–85.
3. Manilich E, Remzi FH, Fazio VW, Church JM, Kiran RP. Prognostic modeling of preoperative risk factors of pouch failure. *Dis Colon Rectum*. 2012;55:393–9.
4. Kiran RP, Moreira A, Remzi FH, Church JM, Lavery I, Hammel J, Fazio VW. Factors associated with septic complications after restorative proctocolectomy. *Ann Surg*. 2010;251:436–40.
5. Gu J, Remzi FH, Shen B, Vogel JD, Kiran RP. Operative strategy modifies risk of pouch-related outcomes in patients with ulcerative colitis on preoperative anti-tumor necrosis factor- $\alpha$  therapy. *Dis Colon Rectum*. 2013;56:1243–52.
6. Selvaggi F, Pellino G, Canonico S, Sciaudone G. Effect of preoperative biologic drugs on

complications and function after restorative proctocolectomy with primary ileal pouch formation: systematic review and meta-analysis. *Inflamm Bowel Dis*. 2015;21:79–92.

7. Wu X, Kiran RP, Remzi FH, Katz S, Mukewar S, Shen B. Preoperative pelvic radiation increases the risk for ileal pouch failure in patients with colitis-associated colorectal cancer. *J Crohns Colitis*. 2013;7:419–26.

8. Wu X, Zhu H, Kiran RP, Remzi FH, Shen B. Excessive weight gain is associated with an increased risk for pouch failure in patients with restorative proctocolectomy. *Inflamm Bowel Dis*. 2013;19:2173–81.

9. Kirat HT, Remzi FH, Kiran RP, Fazio VW. Comparison of outcomes after hand-sewn versus stapled ileal pouch-anal anastomosis in 3,109 patients. *Surgery*. 2009;146:723–30.

10. Wu X, Kirat HT, Kalady MF, Church JM. Restorative proctocolectomy with a hand-sewn IPAA: S-pouch or J-pouch? *Dis Colon Rectum*. 2015;58:205–13.

11. Offodile AC, Feingold DL, Nasar A, Whelan RL, Arnell TD. High incidence of technical errors involving the EEA circular stapler: a single institution experience. *J Am Coll Surg*. 2010;210:331–5.

12. Lian L, Serclova Z, Fazio VW, Kiran RP, Remzi FH, Shen B. Clinical features and management of postoperative pouch bleeding after ileal pouch-anal anastomosis. *J Gastrointest Surg*. 2008;12:1991–4.

13. Mallick IH, Hull TL, Remzi FH, Kiran RP. Management and outcome of pouch-vaginal fistulas after IPAA surgery. *Dis Colon Rectum*. 2014;57:490–6.

14. Nisar PJ, Kiran RP, Shen B, Remzi FH, Fazio VW. Factors associated with ileoanal pouch failure in patients developing early or late pouch-related fistula. *Dis Colon Rectum*. 2011;54:446–53.

15. Shah NS, Remzi FH, Massmann A, Baixauli J, Fazio VW. Management and treatment outcome of pouch-vaginal fistulas following restorative proctocolectomy. *Dis Colon Rectum*. 2003;46:910–7.

16. Heriot AG, Tekkis PP, Smith JJ, Bona R, Cohen RG, Nicholls RJ. Management and outcome of pouch-vaginal fistulas following restorative proctocolectomy. *Dis Colon Rectum*. 2005;48:451–8.

17. Gajsek U, McArthur DR, Sagar PM. Long-term efficacy of the button fistula plug in the treatment of ileal pouch-vaginal and Crohn's-related rectovaginal fistulas. *Dis Colon Rectum*. 2011;54:999–1002.

18. Loungnarath R, Dietz DW, Mutch MG, Birnbaum EH, Kodner IJ, Fleshman JW. Fibrin glue treatment of complex anal fistulas has low success rate. *Dis Colon Rectum*. 2004;47:432–6.

19. Wexner SD, Ruiz DE, Genua J, Nogueras JJ, Weiss EG, Zmora O. Gracilis muscle interposition for the treatment of rectourethral, rectovaginal and pouch-vaginal fistulas—results in 53 patients. *Ann Surg*. 2008;248:39–43.

20. Ogunbiyi OA, Korsgen S, Keighley MR. Pouch salvage—long-term outcome. *Dis Colon Rectum*. 1997;40:548–52.

21. Dehni N, Remacle G, Dozois RR, Banchini F, Tiset E, Parc R. Salvage reoperation for complications after ileal pouch-anal anastomosis. *Br J Surg*. 2005;92:748–53.

22. MacLean AR, O'Connor B, Parkes R, Cohen Z, McLeod RS. Reconstructive surgery for failed ileal pouch-anal anastomosis. *Dis Colon Rectum*. 2002;45:880–6.

23. Baixauli J, Delaney CP, Wu JS, Remzi FH, Lavery IC, Fazio VW. Functional outcome and quality of life after repeat ileal pouch-anal anastomosis for complications of ileoanal surgery. *Dis Colon Rectum*. 2004;47:2–11.

24. Sagar PM, Dozois RR, Wolff BG, Kelly KA. Disconnection, pouch revision and reconnection of the ileal pouch-anal anastomosis. *Br J Surg.* 1996;83:1401–5.
25. Tekkis PP, Heriot AG, Smith JJ, Das P, Canero A, Nicholls RJ. Long-term results of abdominal salvage surgery following restorative proctocolectomy. *Br J Surg.* 2006;93:231–7.
26. Fazio VW, Wu JS, Lavery IC. Repeat ileal pouch-anal anastomosis to salvage septic complications of pelvic pouches: clinical outcome and quality of life assessment. *Ann Surg.* 1998;228:588–97.
27. Remzi FH, Fazio VW, Kirat HT, Wu JS, Lavery IC, Kiran RP. Repeat pouch surgery by the abdominal approach safely salvages failed ileal pelvic pouch. *Dis Colon Rectum.* 2009;52:198–204.
28. Theodoropoulos GE, Choman EN, Wexner SD. Salvage procedures after restorative proctocolectomy: a systematic review and meta-analysis. *J Am Coll Surg.* 2015;220:225–42.
29. Lian L, Fazio VW, Remzi FH, Shen B, Dietz D, Kiran RP. Outcomes for patients undergoing continent ileostomy after a failed ileal pouch-anal anastomosis. *Dis Colon Rectum.* 2009;52:1409–16.
30. Kiran RP, Kirat HT, Rottoli M, Zhaja X, Remzi FH, Fazio VW. Permanent ostomy after ileoanal pouch failure: pouch in situ or pouch excision? *Dis Colon Rectum.* 2012;55:4–9.
31. Akbari RP, Madoff RD, Parker SC, Hagerman G, Minami S, Dunn KM, Mellgren AF. Anastomotic sinuses after ileoanal pouch construction: incidence, management and outcome. *Dis Colon Rectum.* 2009;52:452–5.
32. Nyam DC, Wolff BG, Dozois RR, Pemberton JH, Mathison SM. Does the presence of a pre-ileostomy closure asymptomatic pouch-anastomotic sinus tract affect the success of ileal pouch-anal anastomosis? *J Gastrointest Surg.* 1997;1:274–7.
33. Swain BT, Ellis CN. Fibrin glue treatment of low rectal and pouch-anal anastomotic sinuses. *Dis Colon Rectum.* 2004;47:253–5.
34. Ali UA, Shen B, Remzi FH, Kiran RP. The management of anastomotic pouch sinus after IPAA. *Dis Colon Rectum.* 2012;55:541–8.
35. Sherman J, Greenstein AJ, Greenstein AJ. Ileal pouch complications and surgical solutions: a review. *Inflamm Bowel Dis.* 2014;20:1678–85.
36. Melton GB, Fazio VW, Kiran RP, He J, Lavery IC, Shen B, Achkar J, Church JM, Remzi FH. Long-term outcomes with ileal pouch-anal anastomosis and Crohn's disease. *Ann Surg.* 2008;248:608–16.
37. Turina M, Remzi FH. The J-pouch for patients with Crohn's disease and indeterminate colitis: (When) is it an option? *J Gastrointest Surg.* 2014;18:1343–4.
38. Shen B, Fazio VW, Remzi FH, Bennett AE, Lavery IC, Lopez R, Brezinski A, Sherman KK, Bambrick ML, Lashner BA. Clinical features and quality of life in patients with different phenotypes of Crohn's disease of the ileal pouch. *Dis Colon Rectum.* 2007;50:1450–9.
39. Beliard A, Prudhomme M. Ileal reservoir with ileo-anal anastomosis: long-term complications. *J Visc Surg.* 2010;147:137–44.
40. Ozdemir Y, Kiran RP, Erem HH, Aytac E, Gorgun E, Magnuson D, Remzi FH. Functional outcomes and complications after restorative proctocolectomy and ileal pouch-anal anastomosis in the pediatric population. *J Am Coll Surg.* 2014;218:328–35.
41. Farouk R, Pemberton JH, Wolff BG, Dozois RR, Browning S, Larson D. Functional outcomes after ileal pouch-anal anastomosis for chronic ulcerative colitis. *Ann Surg.* 2000;231:919–26.
42. Lovegrove RE, Constantinides VA, Heriot AG, Athanasiou T, Darzi A, Remzi FH, Nicholls RJ,

- Fazio VW, Tekkis PP. A comparison of hand-sewn versus stapled ileal pouch anal anastomosis (IPAA) following proctocolectomy—a meta-analysis of 4183 patients. *Ann Surg.* 2006;244:18–26.
43. Silva-Velazco J, Hull TL, Stocchi L, Gorgun E. Is it really small bowel obstruction in patients with paradox after IPAA? *Dis Colon Rectum.* 2015;58:328–32.
44. Lovegrove RE, Tilney HS, Heriot AG, Roon AC, Athanasiou T, Church J, Fazio VW, Tekkis PP. A comparison of adverse effects and functional outcomes after restorative proctocolectomy for familial adenomatous polyposis and ulcerative colitis. *Dis Colon Rectum.* 2006;49:1293–306.
45. Ehsan M, Isler JT, Kimmins MH, Billingham RP. Prevalence and management of prolapse of the ileoanal pouch. *Dis Colon Rectum.* 2004;47:885–8.
46. Joyce MR, Fazio VW, Hull TL, Church J, Kiran RP, Mor I, Lian L, Shen B, Remzi FH. Ileal pouch prolapse: prevalence, management and outcomes. *J Gastrointest Surg.* 2010;14:993–7.
47. Kirat HT, Kiran RP, Oncel M, Shen B, Fazio VW, Remzi FH. Management of leak from the tip of the “J” in ileal pouch-anal anastomosis. *Dis Colon Rectum.* 2011;54:454–9.
48. Selvaggi F, Pellino G, Canonico S, Sciaudone G. Systematic review of cuff and pouch cancer in patients with ileal pelvic pouch for ulcerative colitis. *Inflamm Bowel Dis.* 2014;20:1296–308.
49. Ross H, Steele SR, Varma M, Dykes S, Cima R, Buie WD, Rafferty J. Practice parameters for the surgical treatment of ulcerative colitis. *Dis Colon Rectum.* 2014;57:5–22.
50. Derikx LA, Kievit W, Drenth JP, Jong DJ, Ponsioen CY, Oldenburg B, Meulen AE, Dijkstra G, Grubben MJ, Laarhoven CJ, Nagtegaal ID, Hoentjen F. Prior colorectal neoplasia is associated with increased risk of ileoanal pouch neoplasia in patients with inflammatory bowel disease. *Gastroenterology.* 2014;146:119–28.
51. Boostrom SY, Mathis KL, Pendlimari R, Cima RR, Larson DW, Dozois EJ. Risk of neoplastic change in ileal pouches in familial adenomatous polyposis. *J Gastrointest Surg.* 2013;17:1804–8.
52. Åberg H, Pählman L, Karlbom U. Small bowel obstruction after restorative proctocolectomy in patients with ulcerative colitis. *Int J Colorectal Dis.* 2007;22:637–42.
53. Fichera A, Silvestri MT, Hurst RD, Rubin MA, Michelassi F. Laparoscopic restorative proctocolectomy with ileal pouch anal anastomosis: a comparative observational study on long-term functional results. *J Gastrointest Surg.* 2009;13:526–32.
54. Benlice C, Stocchi L, Costedio M, Gorgun E, Hull T, Kessler H, Remzi FH. Laparoscopic IPAA is not associated with decreased rates of incisional hernia and small bowel obstruction when compared with open technique: long-term follow-up of a case-matched study. *Dis Colon Rectum.* 2015;58:314–20.
55. Fazio VW, Cohen Z, Fleshman JW, et al. Reduction in adhesive small bowel obstruction by Seprafilm adhesion barrier after intestinal resection. *Dis Colon Rectum.* 2005;49:1–11.
56. Chapman JR, Larson DW, Wolff BG, Dozois EJ, Cima RR, Pemberton JH, Crownhart BS, Larson DR. Ileal pouch-anal anastomosis—does age at the time of surgery affect outcome? *Arch Surg.* 2005;140:534–40.
57. Hueting WE, Gooszen HG, Laarhoven CJ. Sexual function and continence after ileo pouch-anal anastomosis: a comparison between a meta-analysis and a questionnaire survey. *Int J Colorectal Dis.* 2004;19:215–8.
58. Bharadwaj S, Philpott JR, Barber MD, Graff LA, Shen B. Women’s health issues after ileal pouch surgery. *Inflamm Bowel Dis.* 2014;20:2470–82.
59. Lindsey I, George BD, Kettlewell MG, Mortensen NJ. Impotence after mesorectal and close



- rectal dissection for inflammatory bowel disease. *Dis Colon Rectum*. 2001;44:831–5.
60. Ahmed AU, Keus F, Heikens JT, Bemelman WA, Berdah SV, Gooszen HG, Laarhoven CJ. Open versus laparoscopic (assisted) ileo pouch-anal anastomosis for ulcerative colitis and familial adenomatous polyposis. *Cochrane Database Syst Rev*. 2009;(1):CD006267.
61. Larson DW, Davies MM, Dozois EJ, Cima RR, Piotrowicz K, Anderson K, Barnes SA, Harmsen WS, Young-Fadok TM, Wolff BG, Pemberton JH. Sexual function, body image, and quality of life after laparoscopic and open ileal pouch-anal anastomosis. *Dis Colon Rectum*. 2008;51:392–6.
62. Waljee A, Waljee J, Morris AM, Higgins PD. Threefold increased risk of infertility: a meta-analysis of infertility after ileal pouch anal anastomosis in ulcerative colitis. *Gut*. 2006;55:1575–80.
63. Hull TL, Joyce MR, Geisler DP, Coffey JC. Adhesions after laparoscopic and open ileal pouch-anal anastomosis surgery for ulcerative colitis. *Br J Surg*. 2012;99:270–5.
64. Bartels SA, D’Hoore A, Cuesta MA, Bensdorp AJ, Lucas C, Bemelman WA. Significantly increased pregnancy rates after laparoscopic restorative proctocolectomy. *Ann Surg*. 2012;256:1045–8.

## 第 52 章

1. Navaneethan U, Giannella RA. Infectious colitis. *Curr Opin Gastroenterol*. 2011;27:66–71.
2. Crim SM, Iwamoto M, Huang JY, Griffin PM, Gilliss D, Cronquist AB, Cartter M, Tobin-D’Angelo M, Blythe D, Smith K, Lathrop S, Zansky S, Cieslak PR, Dunn J, Holt KG, Lance S, Tauxe R, Henao OL. Incidence and trends of infection with pathogens transmitted commonly through food - Foodborne Diseases Active Surveillance Network, 10 U.S. sites, 2006-2013. *MMWR Morb Mortal Wkly Rep*. 2014;63(15):328–32.
3. Stuart TL, Sandhu J, Stirling R, Corder J, Ellis A, Misa P, Goh S, Wong B, Martiquet P, Hoang L, Galanis E. Campylobacteriosis outbreak associated with ingestion of mud during a mountain bike race. *Epidemiol Infect*. 2010; 138(12):1695–703.
4. Papaconstantinou HT, Thomas JS. Bacterial colitis. *Clin Colon Rectal Surg*. 2007;20:18–27.
5. Loss RW, Mangla JC, Pereira M. Campylobacter colitis presenting as inflammatory bowel disease with segmental colonic ulcerations. *Gastroenterology*. 1980;79(1):138–40.
6. Smith KE, Besser JM, Hedberg CW, Leano FT, Bender JB, Wicklund JH, Johnson BP, Moore KA, Osterholm MT. Quinolone-resistant Campylobacter jejuni infections in Minnesota, 1992-1998. Investigation team. *N Engl J Med*. 1999;340(20):1525–32.
7. Wieczorek K, Osek J. Antimicrobial resistance mechanisms among Campylobacter. *Biomed Res Int*. 2013;2013:340605.
8. Aboutaleb N, Kuijper EJ, van Dissel JT. Emerging infectious colitis. *Curr Opin Gastroenterol*. 2014;30:106–15.
9. Lee JH, Kim JJ, Jung JH, Lee SY, Bae MH, Kim YH, Son HJ, Rhee PL, Rhee JC. Colonoscopic manifestations of typhoid fever with lower gastrointestinal bleeding. *Dig Liver Dis*. 2004;36(2):141–6.
10. DuPont HL. Approach to the patient with infectious colitis. *Curr Opin Gastroenterol*. 2012;28:39–46.
11. Butler T. Treatment of typhoid fever in the 21st century: promises and shortcomings. *Clin Microbiol Infect*. 2011;17(7):959–63.

12. Speelman P, Kabir I, Islam M. Distribution and spread of colonic lesions in Shigellosis: a colonoscopic study. *J Infect Dis.* 1984;150(6):899–903.
13. Khuroo MS, Mahajan R, Zargar SA, Panhotra BR, Bhat RL, Javid G, Mahajan B. The colon in shigellosis: serial colonoscopic appearances in *Shigella dysenteriae* I. *Endoscopy.* 1990;22(1):35–8.
14. Pons MJ, Gomes C, Martinez-Puchol S, Ruiz L, Mensa L, Vila J, Gascon J, Ruiz J. Antimicrobial resistance in *Shigella* spp. causing traveller's diarrhoea (1995-2010): a retrospective analysis. *Travel Med Infect Dis.* 2013;11(5):315–9.
15. Shah N, DuPont HL, Ramsey DJ. Global etiology of travelers' diarrhea: systematic review from 1973 to the present. *Am J Trop Med Hyg.* 2009;80(4):609–14.
16. Riley LW, Remis RS, Helgerson SD, McGee HB, Wells JG, Davis BR, Hebert RJ, Olcott ES, Johnson LM, Hargrett NT, Blake PA, Cohen ML. Hemorrhagic colitis associated with a rare *Escherichia coli* serotype. *N Engl J Med.* 1983; 308(12):681–5.
17. Mead PS, Stutsker L, Dietz V, McCaig LF, Bresee JS, Shapiro C, Griffin PM, Tauxe RV. Food-related illness and death in the United States. *Emerg Infect Dis.* 1999;5(5):607–25.
18. Lim JY, Yoon J, Hovde CJ. A brief overview of *Escherichia coli* O157:H7 and its plasmid O157. *J Microbiol Biotechnol.* 2010;20(1):5–14.
19. Frank C, Faber MS, Askar M, Bernard H, Fruth A, Gilsdorf A, Hohle M, Karch H, Krause G, Prager R, Spode A, Stark K, Werber D. Large and ongoing outbreak of haemolytic uraemic syndrome, Germany, May 2011. *Euro Surveill.* 2011;16(21): pii=19878.
20. Oh KH, Kim SB, Park MS, Cho SH. Development of a one-step PCR assay with nine primer pairs for the detection of five diarrheagenic *Escherichia coli* types. *J Microbiol Biotechnol.* 2014;24(6):862–8.
21. Shigeno T, Akamatsu T, Fujimori K, Nakatsuji Y, Nagata A. The clinical significance of colonoscopy in hemorrhagic colitis due to enterohemorrhagic *Escherichia coli* O157:H7 infection. *Endoscopy.* 2002;24(4):311–4.
22. Behrens RH, Cramer JP, Jelinek T, Shaw H, von Sonnenburg F, Wilbraham D, Weinke T, Bell DJ, Asturias E, Pauwells HL, Maxwell R, Paredes-Paredes M, Glenn GM, Dewasthaly S, Stablein DM, Jiang ZD, DuPont HL. Efficacy and safety of a patch vaccine containing heat-labile toxin from *Escherichia coli* against travellers' diarrhoea: a phase 3, randomised, double-blind, placebo-controlled field trial in travellers from Europe to Mexico and Guatemala. *Lancet Infect Dis.* 2014;142:197–204.
23. Mantzaris GJ. Endoscopic diagnosis of infectious colitis. *Ann Gastroenterol.* 2007;20(1):71–4.
24. Newton A, Kendall M, Vugia DJ, Henao OL, Mahon BE. Increasing rates of Vibriosis in the United States, 1996-2010: review of surveillance data from 2 systems. *Clin Infect Dis.* 2012;54(S5):S391–5.
25. Daniels NA, MacKinnon L, Bishop R, Altekruze S, Ray B, Hammond RM, Thompson S, Wilson S, Bean NH, Griffin PM, Slutsker L. *Vibrio parahaemolyticus* infections in the United States 1973-1998. *J Infect Dis.* 2000;181:1661–6.
26. Ali M, Lopez AL, You YA, Kim YE, Sah B, Maskery B, Clemens J. The global burden of cholera. *Bull World Health Organ.* 2012;90:209–18A.
27. Daniels NA, Shafaie A. A review of pathogenic *Vibrio* infections for clinicians. *Infect Med.* 2000;17(10):665–85.
28. Fillion K, Mileno MD. Cholera in travelers: shifting tides in epidemiology, management, and

- prevention. *Curr Infect Dis Rep*. 2015;17(1):455.
29. Pastor M, Pedraz JL, Esquisabel A. The state-of-the-art of approved and under-development cholera vaccines. *Vaccine*. 2013;31(38):4069–78.
30. Breiter JR, Hajjar JJ. Segmental tuberculosis of the colon diagnosed by colonoscopy. *Am J Gastroenterol*. 1981;76(4): 369–73.
31. Sharma MP, Bhatia V. Abdominal tuberculosis. *Indian J Med Res*. 2004;120(4):305–15.
32. Igbinosa IH, Igumbor EU, Aghdasi F, Tom M, Okoh AI. Emerging *Aeromonas* species and their significance in public health. *ScientificWorldJournal*. 2012;2012:625023.
33. Jiang Z, DuPont HL, Brown EL, Nandy RK, Ramamurthy T, Sinha A, Ghosh S, Guin S, Gurleen K, Rodrigues S, Chen JJ, McKenzie R, Steffen R. Microbial etiology of travelers' diarrhea in Mexico, Guatemala, and India: importance of enterotoxigenic *Bacteroides fragilis* and *Arcobacter* species. *J Clin Microbiol*. 2010;48(4):1417–9.
34. McCollum JT, Cronquist AB, Silk BJ, Jackson KA, O'Connor KA, Cosgrove S, Gossack JP, Parachini SS, Jain NS, Ettestad P, Ibraheem M, Cantu V, Joshi M, DuVernoy T, Fogg Jr NW, Gorny JR, Mogen KM, Spires C, Teitell P, Joseph LA, Tarr CL, Imanishi M, Neil KP, Tauxe RV, Mahon BE. Multistate outbreak of listeriosis associated with cantaloupe. *N Engl J Med*. 2013;369(10):944–53.
35. Lorber B. *Listeria monocytogenes*. In: Mandell GL, Bennett JE, Dolin R, editors. *Principles and practice of infectious diseases*. 6th ed. Philadelphia: Elsevier; 2005.
36. Ooi ST, Lorber B. Gastroenteritis due to *Listeria monocytogenes*. *Clin Infect Dis*. 2005;40(9):1327–32.
37. Singh D, Marrazzo JM. Screening and management of genital chlamydial infections. *Infect Dis Clin North Am*. 2013;27: 739–53.
38. Schwebke JR, Whittington W, Rice RJ, Handsfield HH, Hale J, Holmes KK. Trends in susceptibility of *Neisseria gonorrhoeae* to ceftriaxone from 1985-1991. *Antimicrob Agents Chemother*. 1995;39(4):917–20.
39. Koo DT, Dean AG, Slade RW, Knowles CM, Adams DA, Fortune WK, Hall PA, Fagan RF, Panter-Connah B, Holden HR, Jones GF, Maddox CL. MMWR summary of notifiable diseases, United States, 1993. *MMWR Morb Mortal Wkly Rep*. 1994;42(53):1–73.
40. Powell SJ, MacLeod I, Wilmot AJ, Elsdon-Dew R. Metronidazole in amoebic dysentery and amoebic liver abscess. *Lancet*. 1966;2(7477):1329–31.
41. Cohen HG, Reynolds TB. Comparison of metronidazole and chloroquine for the treatment of amoebic liver abscess. A controlled trial. *Gastroenterology*. 1975;69(1):35–41.
42. Hochberg NS, Hamer DH. Anisakidosis: perils of the deep. *Clin Infect Dis*. 2010;51(7):806–12.
43. Pinkus GS, Coolidge C, Little MD. Intestinal anisakiasis. First case report from North America. *Am J Med*. 1975;59(1): 114–20.
44. Couture C, Measures L, Gagnon J, Desbiens C. Human intestinal anisakidosis due to consumption of raw salmon. *Am J Surg Pathol*. 2003;27(8):1167–72.
45. McKerrow JH, Sakanari J, Deardorff TL. Anisakiasis: revenge of the sushi parasite. *N Engl J Med*. 1988;319(18):1228–9.
46. Bouree P, Paugam A, Petithory JC. Anisakidosis: report of 25 cases and review of the literature. *Comp Immunol Microbiol Infect Dis*. 1995;18(2):75–84.
47. Pacios E, Arias-Diaz J, Zuloaga J, Gonzalez-Armengol J, Villarroel P, Balibrea JL. Albendazole for the treatment of anisakiasis ileus. *Clin Infect Dis*. 2005;41(12):1825–6.

48. De Silva NR, Brooker S, Hotez PJ, Montresor A, Engels D, Savioli L. Soil-transmitted helminth infections: updating the global picture. *Trends Parasitol.* 2003;19(12):547–51.
49. De Silva NR, Guyatt HL, Bundy DA. Worm burden in intestinal obstruction caused by *Ascaris lumbricoides*. *Trop Med Int Health.* 1997;2(2):189–90.
50. Keiser J, Utzinger J. Efficacy of current drugs against soil-transmitted helminth infections: systematic review and meta-analysis. *JAMA.* 2008;299(16):1937–48.
51. Liu LX, Weller PF. Strongyloidiasis and other intestinal nematode infections. *Infect Dis Clin North Am.* 1993;7(3):655–82.
52. Vadlamudi RS, Chi DS, Krishnaswamy G. Intestinal strongyloidiasis and hyperinfection syndrome. *Clin Mol Allergy.* 2006;4:8.
53. Minematsu H, Hokama A, Makishi T, Arakaki K, Kinjo F, Fujita J. Colonoscopic findings and pathologic characteristics of Strongyloides colitis: a case series. *Digestion.* 2011;83(3): 210–4.
54. Drugs for parasitic infections. *Med Lett.* 2007;5(S):e1–15.
55. Bethony J, Brooker S, Albonico M, Geiger SM, Loukas A, Diemert D, Hotez PJ. Soil-transmitted helminth infections: ascariasis, trichuriasis, and hookworm. *Lancet.* 2006;367(9521): 1521–32.
56. Steinmann P, Utzinger J, Du Z, Jiang J, Chen J, Hattendorf J, Zhou H, Zhou X. Efficacy of single dose and triple-dose albendazole and mebendazole against soil-transmitted helminth infections and *Taenia* spp.: a randomized controlled trial. *PLoS One.* 2011;6(9):e25003.
57. Wang LC, Hwang KP, Chen ER. Enterobius vermicularis infection in schoolchildren: a large-scale survey 6 years after a population-based control. *Epidemiol Infect.* 2010;138(1):28–36.
58. White Jr AC. Cryptosporidiosis and the ears of the hippopotamus. *Clin Infect Dis.* 2010;50(10):1373–4.
59. Dillingham RA, Lima AA, Guerrant RL. Cryptosporidiosis: epidemiology and impact. *Microbes Infect.* 2002;4(10): 1059–66.
60. Karanis P, Thekisoe O, Kiouptsi K, Ongerth J, Igarashi I, Inoue N. Development and preliminary evaluation of a loop-mediated isothermal amplification procedure for sensitive detection of cryptosporidium oocysts in fecal and water samples. *Appl Environ Microbiol.* 2007;73(17):5660–2.
61. Rossignol JF. Cryptosporidium and Giardia: treatment options and prospects for new drugs. *Exp Parasitol.* 2010;124(1): 45–53.
62. Pantenburg B, Cabada MM, White Jr AC. Treatment of cryptosporidiosis. *Expert Rev Anti Infect Ther.* 2009;7(4):385–91.
63. Checkley W, White Jr AC, Jaganath D, Arrowood MJ, Chalmers RM, Chen XM, Fayer R, Griffiths JK, Guerrant RL, Hedstrom L, Huston CD, Kotloff KL, Kang G, Mead JR, Miller M, Petri Jr WA, Priest JW, Roos DS, Stripen B, Thompson RC, Ward HD, VanVoorhis WA, Xiao L, Zhu G, Houpt ER. A review of the global burden, novel diagnostics, therapeutics, and vaccine targets for cryptosporidium. *Lancet Infect Dis.* 2015;15(1):85–94.
64. Mintz ED, Hudson-Wragg M, Mshar P, Cartter ML, Hadler JL. Foodborne giardiasis in a corporate office setting. *J Infect Dis.* 1993;167(1):250–3.
65. Gardner TB, Hill DR. Treatment of giardiasis. *Clin Microbiol Rev.* 2001;14(1):114–28.
66. Chitsulo L, Engels D, Montresor A, Savioli L. The global status of schistosomiasis and its control. *Acta Trop.* 2000;77(1):41–51.
67. Ross AG, Bartley PB, Sleight AC, Olds GR, Li Y, Williams GM, McManus DP. Schistosomiasis.

N Engl J Med. 2002;346(16):1212–20.

68. Craig P, Ito A. Intestinal cestodes. *Curr Opin Infect Dis*. 2007;20(5):524–32.

69. Bocchi EA, Guimaraes G, Tarasoutshi F, Spina G, Mangini S, Bacal F. Cardiomyopathy, adult valve disease and heart failure in South America. *Heart*. 2009;95(3):181–9.

70. Koberle F. Chagas' disease and Chagas' syndromes: the pathology of American trypanosomiasis. *Adv Parasitol*. 1968;6:63–116.

71. Zhang LJ, Hanff P, Rutherford C, Churchill WH, Crumpacker CS. Detection of human cytomegalovirus DNA, RNA, and antibody in normal donor blood. *J Infect Dis*. 1995;171(4): 1002–6.

72. Sager K, Alam S, Bond A, Chinnappan L, Probert CS. Review article: cytomegalovirus and inflammatory bowel disease. *Aliment Pharmacol Ther*. 2015;41(8):725–33.

73. Quinn TC, Corey L, Chaffee RG, Schuffler MD, Brancato FP, Holmes KK. The etiology of anorectal infections in homosexual men. *Am J Med*. 1981;71(3):395–406.

74. Yan Z, Nguyen S, Poles M, Melamed J, Scholes JV. Adenovirus colitis in human immunodeficiency virus infection: an underdiagnosed entity. *Am J Surg Pathol*. 1998;22(9):1101–6.

75. Grohmann GS, Glass RI, Pereira HG, Monroe SS, Hightower AW, Weber R, Bryant RT. Enteric viruses and diarrhea in HIV-infected patients. Enteric Opportunistic Infections Working Group. *N Engl J Med*. 1993;329(1):14–20.

76. Kendall RE, Gosser RA, Schulz LT, Trapskin PJ, Caponi B, Safdar N. Anti-diarrheal medication use in the treatment of Ebola virus-induced diarrhea. *Travel Med Infect Dis*. 2015;13(2):205–6.

77. Gonzalez Keelan CG, Imbert M. Colonic histoplasmosis simulating Crohn's disease in a patient with AIDS: case report and review of the literature. *Bol Asoc Med P R*. 1988;80(7): 248–50.

78. Lee JT, Dixon MR, Murrell Z, Konyalian V, Agbunag R, Rostami S, French S, Kumar RR. Colonic histoplasmosis presenting as colon cancer in the nonimmunocompromised patient: report of a case and review of the literature. *Am Surg*. 2004;70(11):959–63.

79. Jayagopal S, Cervia JS. Colitis due to *Candida albicans* in a patient with AIDS. *Clin Infect Dis*. 1992;15(3):555.

80. Stevens DA, Kan VL, Judson MA, Morrison VA, Dummer S, Denning DW, Bennett JE, Walsh TJ, Patterson TF, Pankey GA. Practice guidelines for diseases caused by *Aspergillus*. Infectious Diseases Society of America. *Clin Infect Dis*. 2000;30(4):696–709.

81. Washington K, Gottfried MR, Wilson ML. Gastrointestinal cryptococcosis. *Mod Pathol*. 1991;4(6):707–11.

82. Greenwood Z, Black J, Weld L, O'Brien D, Leder K, Von Sonnenburg F, Pandey P, Schwartz E, Connor BA, Brown G, Freedman DO, Torresi J, GeoSentinel Surveillance Network. Gastrointestinal infection among international travelers globally. *J Travel Med*. 2008;15(4):221–8.

83. Steffen R, Hill DR, DuPont HL. Traveler's diarrhea a clinical review. *JAMA*. 2015;313(1):71–80.

84. Soonawala D, Vlot JA, Visser LG. Inconvenience due to travelers' diarrhea: a prospective follow-up study. *BMC Infect Dis*. 2011;11:322.

85. Goldsmid JM. The returned traveller with diarrhoea. *Aust Fam Physician*. 2007;36(5):322–7.

86. Swaminathan A, Torresi J, Schlagenhauf P, Thursky K, Wilder-Smith A, Connor BA, Schwartz D, von Sonnenberg F, Keystone J, O'Brien DP. A global study of pathogens and host risk factors associated with infectious gastrointestinal disease in returned international travellers. *J Infect*.

2009;59(1):19–27.

87. Gradel KO, Nielsen HL, Schonheyder HC, Ejlersen T, Kristensen B, Nielsen H. Increased short- and long-term risk of inflammatory bowel disease after salmonella or campylobacter gastroenteritis. *Gastroenterology*. 2009;137(2):495–501.

88. Kanazawa M, Fukudo S. Relationship between infectious gastroenteritis and irritable bowel syndrome. *Clin J Gastroenterol*. 2014;7:14–8.

89. Wright SG. Persistent diarrhea in the returned traveler. In: Magill AJ, Ryan ET, Hill D, Solomon T, editors. *Hunter's tropical medicine and emerging infectious diseases*. 9th ed. Philadelphia: Elsevier; 2012.

90. DuPont HL, Ericsson CD, Johnson PC, Bitsura JA, DuPont MW, de la Cabada FJ. Prevention of travelers' diarrhea by the tablet formulation of bismuth subsalicylate. *JAMA*. 1987;257(10):1347–50.

91. Hu Y, Ren J, Zhan M, Li W, Dai H. Efficacy of rifaximin in prevention of travelers' diarrhea: a meta-analysis of randomized, double-blind, placebo-controlled trials. *J Travel Med*. 2012;19(6):352–6.

92. Hill DR, Ericsson CD, Pearson RD, Keystone JS, Freedman DO, Kozarsky PE, DuPont HL, Bia FJ, Fischer PR, Ryan ET. The practice of travel medicine: guidelines by the Infectious Diseases Society of America. *Clin Infect Dis*. 2006;43(12):1499–539.

93. Mylonaki M, Langmead L, Pantes A, Johnson F, Rampton DS. Enteric infection in relapse of inflammatory bowel disease: importance of microbiological examination of stool. *Eur J Gastroenterol Hepatol*. 2004;16(8):775–8.

94. Meyer AM, Ramzan NN, Loftus Jr EV, Heigh RI, Leighton JA. The diagnostic yield of stool pathogen studies during relapses of inflammatory bowel disease. *J Clin Gastroenterol*. 2004;38(9):772–5.

95. Issa M, Vijayapal A, Graham MB, Otterson MF, Lundeen S, Skaros S, Weber LR, Komorowski RA, Knox JF, Emmons J, Bajaj JS, Binion DG. Impact of *Clostridium difficile* on inflammatory bowel disease. *Clin Gastroenterol Hepatol*. 2007;5(3): 345–51.

96. Sinh P, Barrett TA, Yun L. *Clostridium difficile* infection and inflammatory bowel disease: a review. *Gastroenterol Res Prac*. 2011;2011:136064.

97. Epple H. Therapy- and non-therapy-dependent infectious complications in inflammatory bowel disease. *Dig Dis*. 2009;27:555–9.

98. Kandiel A, Lashner B. Cytomegalovirus colitis complicating inflammatory bowel disease. *Am J Gastroenterol*. 2006;101: 2857–65.

99. Hansen R, Thomson JM, El-Omar EM, Hold GL. The role of infection in the aetiology of inflammatory bowel disease. *J Gastroenterol*. 2010;45:266–76.

100. Feasey NA, Healey P, Gordon MA. Review article: the aetiology, investigation and management of diarrhoea in the HIV-positive patient. *Aliment Pharmacol Ther*. 2011;34(6):587–603.

101. Knox TA, Spiegelman D, Skinner SC, Gorbach S. Diarrhea and abnormalities of gastrointestinal function in a cohort of men and women with HIV infection. *Am J Gastroenterol*. 2000;95(12):3482–9.

102. Cello JP, Day LW. Idiopathic AIDS enteropathy and treatment of gastrointestinal opportunistic pathogens. *Gastroenterology*. 2009;136(6):1952–65.

103. Kearney DJ, Steuerwald M, Koch J, Cello JP. A prospective study of endoscopy in HIV-

- associated diarrhea. *Am J Gastroenterol*. 1999;94(3):596–602.
104. Monkemuller KE, Call SA, Lazenby AJ, Wilcox CM. Declining prevalence of opportunistic gastrointestinal disease in the era of combination antiretroviral therapy. *Am J Gastroenterol*. 2000;95(2):457–62.
105. Garcia Compean D, Ramos Jimenez J, Guzman de la Garza F, Saenz C, Maldonado H, Barragan RF, Michel H. Octreotide therapy of large-volume refractory AIDS-associated diarrhea: a randomized controlled trial. *AIDS*. 1994;8(11):1563–7.
106. Maes B, Hadaya K, de Moor B, Cambier P, Peeters P, de Meester J, et al. Severe diarrhea in renal transplant patients: results of the DIDACT study. *Am J Transplant*. 2006;6(6): 1466–72.
107. Herrero JI, Benlloch S, Bernardos A, Bilbao I, Castells L, Castroagudin JF, et al. Gastrointestinal complications in liver transplant recipients: MITOS study. *Transplant Proc*. 2007; 39(7):2311–3.
108. Ginsburg PM, Thuluvath PJ. Diarrhea in liver transplant recipients: etiology and management. *Liver Transpl*. 2005;11(8): 881–90.
109. Echenique IA, Penugonda S, Stosor V, Ison MG, Angarone MP. Diagnostic yields in solid organ transplant recipients admitted with diarrhea. *Clin Infect Dis*. 2015;60(5):729–37.
110. Montes M, DuPont HL. Chapter 43, Enteritis, enterocolitis and infectious diarrhea syndromes. In: Cohen J, Powderly WG, Berkley SF, et al., editors. *Infectious diseases*. 2nd ed. Philadelphia: Mosby Elsevier; 2004. p. 477–90.
111. Farthing M, Salam MA, Lindberg G, Dite P, Khalif I, Salazar-Lindo E, Ramakrishna BS, Goh K, Thomaon A, Khan A, Krabshuis J, LeMair A. Acute diarrhea in adults and children: a global perspective. *J Clin Gastroenterol*. 2013;47(1):12–20.
112. ASGE Standards of Practice Committee. The role of endoscopy in the management of patients with diarrhea. *Gastrointest Endosc*. 2010;71(6):887–92.
113. Bennett J, Dolin R, Blaser MJ. *Mandell, Douglas, and Bennett's principles and practice of infectious diseases*. 8th ed. Philadelphia: Saunders Elsevier; 2015.
114. Trichuriasis [Internet]. Atlanta, GA: Centers for Disease Control and Prevention [cited 25 Apr 2015] [Figure]. This image depicts a condition known as rectal prolapse in a female child due to a parasitic *Trichuris trichiura* infestation. Available from <http://phil.cdc.gov/Phil/details.asp>
115. Enterobiasis [Internet]. Atlanta, GA: Centers for Disease Control and Prevention; 29 Nov 2013 [cited 25 Apr 2015] [Figure]. Figure B: Eggs of *E. vermicularis* in a wet mount. Available from <http://www.cdc.gov/dpdx/enterobiasis/gallery.html#eggs>
116. Taeniasis [Internet]. Atlanta, GA: Centers for Disease Control and Prevention; 29 Nov 2013 [cited 25 Apr 2015] [Figure], ID; 5260. This is an adult *Taenia saginata* tapeworm. Available from <http://phil.cdc.gov/Phil/details.asp>

## 第 53 章

1. Kuijper EJ, Coignard B, Tull P, ESCMID Study Group for *Clostridium difficile*; EU Member States; European Centre for Disease Prevention and Control. Emergence of *Clostridium difficile*-associated disease in North American and Europe. *Clin Microbiol Infect*. 2006;12 Suppl 6:2–18.
2. Freeman J, Bauer MP, Baines SD, Corver J, Fawley WN, Goorhuis B, Kuijper EJ, Wilcox MH. The changing epidemiology of *Clostridium difficile* infections. *Clin Microbiol Rev*.

2010;23(3):529–49.

3. Gravel D, Miller M, Simor A, Taylor G, Gardam M, McGeer A, Hutchinson J, Moore D, Kelly S, Boyd D, Mulvey M, Canadian Nosocomial Infection Surveillance Program. Health care-associated *Clostridium difficile* infection in adults admitted to acute care hospitals in Canada: a Canadian Nosocomial Infection Surveillance Program Study. *Clin Infect Dis*. 2009;48(5):568–76.
4. *Clostridium difficile* ribotyping network (CDRN) service [Internet] [updated 8 Aug 2014; cited 15 Jan 2015]. Available from <https://www.gov.uk/government/collections/clostridium-difficile-ribotyping-network-cdrn-service>
5. Bartlett JG, Gerding D. Clinical recognition and diagnosis of *Clostridium difficile* infection. *Clin Infect Dis*. 2008;46(S1):S12–8.
6. Pépin J, Valiquette L, Alary ME, Villemure P, Pelletier A, Forget K, Pépin K, Chouinard D. *Clostridium difficile*-associated diarrhea in a region of Quebec from 1991 to 2003: a changing pattern of disease severity. *CMAJ*. 2004;171(5):466–72.
7. Lucado J, Gould C, Elixhauser A. *Clostridium difficile* infections (CDI) in hospital stays, 2009. HCUP Statistical Brief X124. Rockville, MD: Agency for Healthcare Research and Quality; 2012. p. 1–12.
8. Centers for Disease Control. Rates of *Clostridium difficile* infection among hospitalized patients aged >65 years, by Age Group-National Hospital Discharge Survey United States, 1996-2009. *MMWR Morb Mortal Wkly Rep*. 2011;60(3):1171–85.
9. Gupta SB, Dubberke ER. Overview and changing epidemiology of *Clostridium difficile* infection. *Semin Colon Rectal Surg*. 2014;25:118–23.
10. Kuijper EJ, Coignard B, Brazier JS, Suetens C, Drudy D, Wiuff C, Pituch H, Reichert P, Schneider F, Widmer AF, Olsen KE, Allerberger F, Notermans DW, Barbut F, Delmée M, Wilcox M, Pearson A, Patel BC, Brown DJ, Frei R, Akerlund T, Poxton IR, Tüll P. Update of *Clostridium difficile*-associated disease due to PCR ribotype 027 in Europe. *Euro Surveill*. 2007;12:E1–2.
11. Surawicz CM, Brandt LJ, Binion DG, Ananthakrishnan AN, Curry SR, Gilligan PH, McFarland LV, Mellow M, Zuckerbraun BS. Guidelines for diagnosis, treatment, and prevention of *Clostridium difficile* infections. *Am J Gastroenterol*. 2013;108:478–98.
12. US Institute of Peace. Roadmap to eliminate HAI: 2013 Action Plan Conference, Washington, DC, 25–26 Sept 2013.
13. Gould CV, Edwards JR, Cohen J, Bamberg WM, Clark LA, Farley MM, Johnston H, Nadle J, Winston L, Gerding DN, McDonald LC, Lessa FC, *Clostridium difficile* Infection Surveillance Investigators, Centers for Disease Control and Prevention. Effect of nucleic acid amplification testing on population-based incidence rates of *Clostridium difficile* infection. *Clin Infect Dis*. 2013;57(9):1304–7.
14. Loo VG, Poirier L, Miller MA, Oughton M, Libman MD, Michaud S, Bourgault AM, Nguyen T, Frenette C, Kelly M, Vibien A, Brassard P, Fenn S, Dewar K, Hudson TJ, Horn R, René P, Monczak Y, Dascal A. A predominantly clonal multi-institutional outbreak of *Clostridium difficile*-associated diarrhea with high morbidity and mortality. *N Engl J Med*. 2005;353(23):2442–9.
15. Warny M, Pepin J, Fang A, Killgore G, Thompson A, Brazier J, Frost E, McDonald LC. Toxin production by an emerging strain of *Clostridium difficile* associated with outbreaks of severe disease in North America and Europe. *Lancet*. 2005;366(9491):1079–84.
16. Muto CA, Pokrywka M, Shutt K, Mendelsohn AB, Nouri K, Posey K, Roberts T, Croyle K, Krystofiak S, Patel-Brown S, Pasculle AW, Paterson DL, Saul M, Harrison LH. A large outbreak of



*Clostridium difficile*-associated disease with an unexpected proportion of deaths and colectomies at a teaching hospital following increased fluoroquinolone use. *Infect Control Hosp Epidemiol*. 2005;26(3):273–80.

17. McDonald LC, Killgore GE, Thompson A, Owens Jr RC, Kazakova SV, Sambol SP, Johnson S, Gerding DN. An epidemic, toxin gene-variant strain of *Clostridium difficile*. *N Engl J Med*. 2005;353(23):2433–41.

18. Cohen SH, Gerding DN, Johnson S, Kelly CP, Loo VG, McDonald LC, Pepin J, Wilcox MH, Society for Healthcare Epidemiology of America; Infectious Diseases Society of America. Clinical practice guidelines for *Clostridium difficile* infection in adults: 2010 update by the Society for Healthcare Epidemiology of America (SHEA) and the infectious diseases society of America (IDSA). *Infect Control Hosp Epidemiol*. 2010;31(5):431–55.

19. Centers of Disease Control and Prevention (CDC). Severe *Clostridium difficile*-associated disease in populations previously at low risk—four states. *Morb Mortal Wkly Rep*. 2005;54(17):1201–5.

20. Collins CE, Ayturk MD, Flahive JM, Emhoff TA, Anderson Jr FA, Santry HP. Epidemiology and outcomes of community-acquired *Clostridium difficile* infections in Medicare beneficiaries. *J Am Coll Surg*. 2014;218(6):1141–7.

21. Esfandiari Z, Weese S, Ezzatpanah H, Jalali M, Chamani M. Occurrence of *Clostridium difficile* in seasoned hamburgers and seven processing plants in Iran. *BMC Microbiol*. 2014;14(1):283.

22. Hensgens MP, Keessen EC, Squire MM, Riley TV, Koene MG, de Boer E, Lipman LJ, Kuijper EJ, European Society of Clinical Microbiology and Infectious Diseases Study Group for *Clostridium difficile* (ESGCD). *Clostridium difficile* infection in the community: a zoonotic disease? *Clin Microbiol Infect*. 2012;18(7):635–45.

23. Janezic S, Ocepek M, Zidaric V, Rupnik M. *Clostridium difficile* genotypes other than ribotype 078 that are prevalent among human, animal and environmental isolates. *BMC Microbiol*. 2012;12:48.

24. Chitnis AS, Holzbauer SM, Belflower RM, Winston LG, Bamberg WM, Lyons C, Farley MM, Dumyati GK, Wilson LE, Beldavs ZG, Dunn JR, Gould LH, MacCannell DR, Gerding DN, McDonald LC, Lessa FC. Epidemiology of community-associated *Clostridium difficile* infection, 2009 through 2011. *JAMA Intern Med*. 2013;173(14):1359–67.

25. Rodriguez C, Korsak N, Taminiau B, Avesani V, Van Broeck J, Delmée M, Daube G. *Clostridium difficile* infection in elderly nursing home residents. *Anaerobe*. 2014;30:184–7.

26. Simor AE, Bradley SF, Strausbaugh LJ, Crossley K, Nicolle LE, SHEA Long-Term-Care Committee. *Clostridium difficile* in long-term-care facilities for the elderly. *Infect Control Hosp Epidemiol*. 2002;23(11):696–703.

27. Keller JM, Surawicz CM. *Clostridium difficile* infection in the elderly. *Clin Geriatr Med*. 2014;30(1):79–93.

28. McFarland LV, Mulligan ME, Kwok RY, Stamm WE. Nosocomial acquisition of *Clostridium difficile* infection. *N Engl J Med*. 1989;320:204–10.

29. Samore MH, DeGirolami PC, Tlucko A, Lichtenberg DA, Melvin ZA, Karchmer AW. *Clostridium difficile* colonization and diarrhea at a tertiary care hospital. *Clin Infect Dis*. 1994;18:181–7.

30. Walker KJ, Gilliland SS, Vance-Bryan K, Moody JA, Larsson AJ, Rotschafer JC, Guay DR. *Clostridium difficile* colonization in residents of long-term care facilities: prevalence and risk

factors. *J Am Geriatr Soc.* 1993;41:940–6.

31. Stevens V, Dumyati G, Fine LS, Fisher SG, van Wijngaarden E. Cumulative antibiotic exposures over time and the risk of *Clostridium difficile* infection. *Clin Infect Dis.* 2011;53(1):42–8.

32. Marufu O, Desai N, Aldred D, Brown T, Eltringham I. Analysis of interventions to reduce the incidence of *Clostridium difficile* infection at a London teaching hospital trust, 2003–2011. *J Hosp Infect.* 2015;89(1):38–45.

33. Slimings C, Riley TV. Antibiotics and hospital-acquired *Clostridium difficile* infection: update of systematic review and meta-analysis. *J Antimicrob Chemother.* 2014;69(4):881–91.

34. Britton RA, Young VB. Role of the intestinal microbiota in resistance to colonization by *Clostridium difficile*. *Gastroenterology.* 2014;146:1547–53.

35. Zalg S, Rupnik M. *Clostridium difficile* infection and gut microbiota. *Semin Colon Rectal Surg.* 2014;25:124–7.

36. Andersson AF, Lindberg M, Jakobsson H, Bäckhed F, Nyrén P, Engstrand L. Comparative analysis of human gut microbiota by barcoded pyrosequencing. *PLoS One.* 2008;3(7):e2836.

37. Lozupone CA, Stombaugh JL, Gordon JL, Jansson JK, Knight R. Diversity, stability and resilience of the human gut microbiota. *Nature.* 2012;489(7415):220–30.

38. Reeves AE, Koenigsnecht MJ, Bergin IL, Young VB. Suppression of *Clostridium difficile* in the gastrointestinal tracts of germfree mice inoculated with a murine isolate from the family Lachnospiraceae. *Infect Immun.* 2012;80:3786–94.

39. Sorg JA, Sonenshein AL. Bile salts and glycine as cogerminants for *Clostridium difficile* spores. *J Bacteriol.* 2008;190(7):2505–12.

40. Sorg JA, Sonenshein AL. Chenodeoxycholate is an inhibitor of *Clostridium difficile* spore germination. *J Bacteriol.* 2009;191(3):1115–7.

41. Krapohl GL, Phillips LR, Campbell Jr DA, Hendren S, Banerjee M, Metzger B, Morris AM. Bowel preparation for colectomy and risk of *Clostridium difficile* infection. *Dis Colon Rectum.* 2011;54(7):810–7.

42. Kim EK, Sheetz KH, Bonn J, DeRoo S, Lee C, Stein I, Zarinsefat A, Cai S, Campbell Jr DA, Englesbe MJ. A statewide colectomy experience: the role of full bowel preparation in preventing surgical site infection. *Ann Surg.* 2014;259(2):310–4.

43. Bartlett JG. Historical perspectives on studies of *Clostridium difficile* and *C. difficile* infection. *Clin Infect Dis.* 2008;46 Suppl 1:S4–11.

44. Morris AM, Jobe BA, Stoney M, Sheppard BC, Deveney CW, Deveney KE. *Clostridium difficile* colitis: an increasingly aggressive iatrogenic disease? *Arch Surg.* 2002;137(10):1096–100.

45. Hansen D, Pollan LD, Fernando H. Fulminant *Clostridium difficile* colitis: a complication of perioperative antibiotic prophylaxis. *J Oral Maxillofac Surg.* 2013;71(11):1880–5.

46. Haines CF, Moore RD, Bartlett JG, Sears CL, Cosgrove SE, Carroll K, Gebo KA. *Clostridium difficile* in a HIV-infected cohort: incidence, risk factors, and clinical outcomes. *AIDS.* 2013;27(17):2799–807.

47. Arango JJ, Restrepo A, Schneider DL, Callander NS, Ochoa-Bayona JL, Restrepo MI, Bradshaw P, Patterson J, Freytes CO. Incidence of *Clostridium difficile*-associated diarrhea before and after autologous peripheral blood stem cell transplantation for lymphoma and multiple myeloma. *Bone Marrow Transplant.* 2006;37(5):517–21.

48. Nitzan O, Elias M, Chazan B, Raz R, Saliba W. *Clostridium difficile* and inflammatory bowel disease: role in pathogenesis and implications in treatment. *World J Gastroenterol.*

2013;19(43):7577–85.

49. Meyer AM, Ramzan NN, Loftus Jr EV, Heigh RI, Leighton JA. The diagnostic yield of stool pathogen studies during relapses of inflammatory bowel disease. *J Clin Gastroenterol*. 2004;38(9):772–5.

50. Connelly TM, Koltun WA, Sangster W, Berg AS, Hegarty JP, Harris 3rd L, Deiling S, Stewart DB. An interleukin-4 polymorphism is associated with susceptibility to *Clostridium difficile* infection in patients with inflammatory bowel disease: results of a retrospective cohort study. *Surgery*. 2014;156(4):769–74.

51. Peterson CT, Sharma V, Elmén L, Peterson SN. Immune homeostasis, dysbiosis and therapeutic modulation of the gut microbiota. *Clin Exp Immunol*. 2015;179(3):363–77. doi: 10.1111/cei.12474 [Epub ahead of print].

52. Schneeweiss S, Korzenik J, Solomon DH, Canning C, Lee J, Bressler B. Infliximab and other immunomodulating drugs in patients with inflammatory bowel disease and the risk of serious bacterial infections. *Aliment Pharmacol Ther*. 2009;30(3):253–64.

53. Ben-Horin S, Margalit M, Bossuyt P, Maul J, Shapira Y, Bojic D, Chermesh I, Al-Rifai A, Schoepfer A, Bosani M, Allez M, Lakatos PL, Bossa F, Eser A, Stefanelli T, Carbonnel F, Katsanos K, Checchin D, Miera IS, Chowers Y, Moran GW, European Crohn's and Colitis Organization (ECCO). Combination immunomodulator and antibiotic treatment in patients with inflammatory bowel disease and *Clostridium difficile* infection. *Clin Gastroenterol Hepatol*. 2009;7(9):981–7.

54. Ananthakrishnan AN, McGinley EL, Binion DG. Excess hospitalisation burden associated with *Clostridium difficile* in patients with inflammatory bowel disease. *Gut*. 2008;57:205–10.

55. Issa M, Vijayapal A, Graham MB, Beaulieu DB, Otterson MF, Lundeen S, Skaros S, Weber LR, Komorowski RA, Knox JF, Emmons J, Bajaj JS, Binion DG. Impact of *Clostridium difficile* on inflammatory bowel disease. *Clin Gastroenterol Hepatol*. 2007;5:345–51.

56. Ricciardi R, Ogilvie JW, Roberts PL, Marcello PW, Concan TW, Baxter NN. Epidemiology of *Clostridium difficile* colitis in hospitalized patients with inflammatory bowel diseases. *Dis Colon Rectum*. 2009;52:40–5.

57. FDA U. S. Food and Drug Administration, U. S. Department of Health and Human Services [Internet] [updated 8 Aug 2012; cited 20 Jan 2015]. Proton pump inhibitors (PPIs)—drug safety communication: *Clostridium difficile*-associated diarrhea (CDAD) can be associated with stomach acid drugs. Available from <http://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm290838.htm>

58. Stewart DB, Hegarty JP. Correlation between virulence gene expression and proton pump inhibitors and ambient pH in *Clostridium difficile*: results of an in vitro study. *J Med Microbiol*. 2013;62(Pt 10):1517–23.

59. Seto CT, Jeraldo P, Orenstein R, Chia N, DiBaise JK. Prolonged use of a proton pump inhibitor reduces microbial diversity: implications for *Clostridium difficile* susceptibility. *Microbiome*. 2014;2:42.

60. Hegarty JP, Sangster W, Harris 3rd LR, Stewart DB. Proton pump inhibitors induce changes in colonocyte gene expression that may affect *Clostridium difficile* infection. *Surgery*. 2014;156(4):972–8.

61. Kwok CS, Arthur AK, Anibueze CI, Singh S, Cavallazzi R, Loke YK. Risk of *Clostridium difficile* infection with acid suppressing drugs and antibiotics: meta-analysis. *Am J Gastroenterol*.

2012;107(7):1011–9.

62. Tleyjeh IM, Bin Abdulhak AA, Riaz M, Alasmari FA, Garbati MA, AlGhamdi M, Khan AR, Al Tannir M, Erwin PJ, Ibrahim T, Allehibi A, Baddour LM, Sutton AJ. Association between proton pump inhibitor therapy and clostridium difficile infection: a contemporary systematic review and meta-analysis. *PLoS One*. 2012;7(12):e50836.

63. Stone SP, Fuller C, Savage J, Cookson B, Hayward A, Cooper B, Duckworth G, Michie S, Murray M, Jeanes A, Roberts J, Teare L, Charlett A. Evaluation of the national Cleanyourhands campaign to reduce *Staphylococcus aureus* bacteraemia and *Clostridium difficile* infection in hospitals in England and Wales by improved hand hygiene: four year, prospective, ecological, interrupted time series study. *BMJ*. 2012;344:e3005.

64. Edmonds SL, Zapka C, Kasper D, Gerber R, McCormack R, Macinga D, Johnson S, Sambol S, Fricker C, Arbogast J, Gerding DN. Effectiveness of hand hygiene for removal of *Clostridium difficile* spores from hands. *Infect Control Hosp Epidemiol*. 2013;34(3):302–5.

65. Oughton MT, Loo VG, Dendukuri N, Fenn S, Libman MD. Hand hygiene with soap and water is superior to alcohol rub and antiseptic wipes for removal of *Clostridium difficile*. *Infect Control Hosp Epidemiol*. 2009;30(10):939–44.

66. Loo VG, Libman MD, Miller MA, Bourgault AM, Frenette CH, Kelly M, Michaud S, Nguyen T, Poirier L, Vibien A, Horn R, Laflamme PJ, René P. *Clostridium difficile*: a formidable foe. *CMAJ*. 2004;71:47–8.

67. Manian FA, Griesnauer S, Bryant A. Implementation of hospital-wide enhanced terminal cleaning of targeted patient rooms and its impact on endemic *Clostridium difficile* infection rates. *Am J Infect Control*. 2013;41(6):537–41.

68. Rupnik M, Dupuy B, Fairweather NF, Gerding DN, Johnson S, Just I, Lysterly DM, Popoff MR, Rood JI, Sonenshein AL, Thelestam M, Wren BW, Wilkins TD, von Eichel-Streiber C. Revised nomenclature of *Clostridium difficile* toxins and associated genes. *J Med Microbiol*. 2005;54:113–7.

69. Mani N, Dupuy B. Regulation of toxin synthesis in *Clostridium difficile* by an alternative RNA polymerase sigma factor. *Proc Natl Acad Sci U S A*. 2001;98:5844–9.

70. Mani N, Lyras D, Barroso L, Howarth P, Wilkins T, Rood JI, Sonenshein AL, Dupuy B. Environmental response and autoregulation of *Clostridium difficile* TcdR, a sigma factor for toxin gene expression. *J Bacteriol*. 2002;184(21):5971–8.

71. Dupuy B, Govind R, Antunes A, Matamouros S. *Clostridium difficile* toxin synthesis is negatively regulated by TcdC. *J Med Microbiol*. 2008;57(Part 6):685–9.

72. Govind R, VEDIYAPPAN G, Rolfe RD, Fralick JA. Evidence that *Clostridium difficile* TcdC is a membrane-associated protein. *J Bacteriol*. 2006;188(10):3716–20.

73. Helmann JD. Anti-sigma factors. *Curr Opin Microbiol*. 1999;2(2):135–41.

74. Stewart DB, Berg A, Hegarty J. Predicting recurrence of *C. difficile* colitis using bacterial virulence factors: binary toxin is the key. *J Gastrointest Surg*. 2013;17(1):118–24. Discussion 124–5.

75. Stewart DB, Berg AS, Hegarty JP. Single nucleotide polymorphisms of the *tcdC* gene and presence of the binary toxin gene predict recurrent episodes of *Clostridium difficile* infection. *Ann Surg*. 2014;260(2):299–304.

76. Goldenberg SD, French GL. Lack of association of *tcdC* type and binary toxin status with disease severity and outcome in toxigenic *Clostridium difficile*. *J Infect*. 2011;62(5):355–62.

77. Cartman ST, Kelly ML, Heeg D, Heap JT, Minton NP. Precise manipulation of the *Clostridium difficile* chromosome reveals a lack of association between the *tcdC* genotype and toxin production. *Appl Environ Microbiol.* 2012;78(13):4683–90.
78. Davies AH, Roberts AK, Shone CS, Acharya KR. Super toxins from a super bug: structure and function of *Clostridium difficile* toxins. *Biochem J.* 2011;436(3):517–26.
79. Kuehne SA, Cartman ST, Heap JT, Kelly ML, Cockayne A, Minton NP. The role of toxin A and toxin B in *Clostridium difficile* infection. *Nature.* 2010;467(7316):711–3.
80. Jank T, Aktories K. Structure and mode of action of clostridial glucosylating toxins: the ABCD model. *Trends Microbiol.* 2008;16(5):222–9.
81. Jank T, Giesemann T, Aktories K. Rho-glucosylating *Clostridium difficile* Toxins A and B: new insights into structure and function. *Glycobiology.* 2007;17(4):15R–22.
82. Just I, Wilm M, Selzer J, Rex G, von Eichel-Streiber C, Mann M, Aktories K. The enterotoxin from *Clostridium difficile* (ToxA) monoglucosylates the Rho proteins. *J Biol Chem.* 1995;270(23):13932–6.
83. Holbourn KP, Shone CC, Acharya KR. A family of killer toxins. Exploring the mechanism of ADP-ribosylating toxins. *FEBS J.* 2006;273(20):4579–93.
84. Geric B, Johnson S, Gerding DN, Grabnar M, Johnson S. Frequency of binary toxin genes among *Clostridium difficile* strains that do not produce large clostridial toxins. *J Clin Microbiol.* 2003;41(Pt 9):5227–32.
85. Barth H. Uptake of binary actin ADP-ribosylating toxins. *Rev Physiol Biochem Pharmacol.* 2004;152:165–82.
86. Schwan C, Stecher B, Tzivelekidis T, van Ham M, Rohde M, Hardt WD, Wehland J, Aktories K. *Clostridium difficile* toxin CDT induces formation of microtubule-based protrusions and increases adherence of bacteria. *PLoS Pathog.* 2009;5(10):e1000626.
87. Rupnik M, Avesani V, Janc M, von Eichel-Streiber C, Delmée M. A novel toxinotyping scheme and correlation of toxinotypes with serogroups of *Clostridium difficile* isolates. *J Clin Microbiol.* 1998;36(8):2240–7.
88. Van de Berg RJ, Claas EC, Oyib DH, Klaassen CH, Dijkshoorn L, Brazier JS, Kuijper EJ. Characterization of a toxin A-negative, toxin B-positive *Clostridium difficile* isolates from outbreaks in different countries by amplified fragment length polymorphism and PCR ribotyping. *J Clin Microbiol.* 2004;42(3):1035–41.
89. Von Eichel-Streiber C, Sauerborn M. *Clostridium difficile* toxin A carries a C-terminal repetitive structure homologous to the carbohydrate binding region of streptococcal glycosyltransferases. *Gene.* 1990;96(1):107–13.
90. Gurtler V, Wilson VA, Mayall BC. Classification of medically important clostridia using restriction endonuclease site differences of PCR-amplified 16S rDNA. *J Gen Microbiol.* 1991;137(11):2673–9.
91. See I, Mu Y, Cohen J, Beldavs ZG, Winston LG, Dumyati G, Holzbauer S, Dunn J, Farley MM, Lyons C, Johnston H, Phipps E, Perlmutter R, Anderson L, Gerding DN, Lessa FC. NAP1 strain type predicts outcomes from *Clostridium difficile* infection. *Clin Infect Dis.* 2014;58(10):1394–400.
92. Cartwright CP, Stock F, Beekmann SE, Williams EC, Gill VJ. PCR amplification of rRNA intergenic spacer regions as a method for epidemiologic typing of *Clostridium difficile*. *J Clin Microbiol.* 1995;33(1):184–7.
93. Bidet P, Barbut F, Lalande V, Burghoffer B, Petit JC. Development of a new PCR-ribotyping

method for *Clostridium difficile* based on ribosomal RNA gene sequencing. *FEMS Microbiol Lett.* 1999;175(2):261–6.

94. Griffiths D, Fawley W, Kachrimanidou M, Bowden R, Crook DW, Fung R, Golubchik T, Harding RM, Jeffery KJ, Jolley KA, Kirton R, Peto TE, Rees G, Stoesser N, Vaughan A, Walker AS, Young BC, Wilcox M, Dingle KE. Multilocus sequence typing of *Clostridium difficile*. *J Clin Microbiol.* 2010;48(3):770–8.

95. Marsh JW, O’Leary MM, Shutt KA, Sambol SP, Johnson S, Gerding DN, Harrison LH. Multilocus variable-number tandem-repeat analysis and multilocus sequence typing reveal genetic relationships among *Clostridium difficile* isolates genotyped by restriction endonuclease analysis. *J Clin Microbiol.* 2010;48(2):412–8.

96. Eyre DW, Fawley WN, Best EL, Griffiths D, Stoesser NE, Crook DW, Peto TE, Walker AS, Wilcox MH. Comparison of multilocus variable-number tandem-repeat analysis and whole-genome sequencing for investigation of *Clostridium difficile* transmission. *J Clin Microbiol.* 2013;51(12):4141–9.

97. Goorhuis A, Bakker D, Corver J, Debast SB, Harmanus C, Notermans DW, Bergwerff AA, Dekker FW, Kuijper EJ. Emergence of *Clostridium difficile* infection due to a new hypervirulent strain, polymerase chain reaction ribotype 078. *Clin Infect Dis.* 2008;47(9):1162–70.

98. Walk ST, Micic D, Jain R, Lo ES, Trivedi I, Liu EW, Almassalha LM, Ewing SA, Ring C, Galecki AT, Rogers MA, Washer L, Newton DW, Malani PN, Young VB, Aronoff DM. *Clostridium difficile* ribotype does not predict severe infection. *Clin Infect Dis.* 2012;55(12):1661–8.

99. Archbald-Pannone LR, Boone JH, Carman RJ, Lyerly DM, Guerrant RL. *Clostridium difficile* ribotype 027 is most prevalent among inpatients admitted from long-term care facilities. *J Hosp Infect.* 2014;88(4):218–21.

100. Labbé AC, Poirier L, Maccannell D, Louie T, Savoie M, Béliveau C, Laverdière M, Pépin J. *Clostridium difficile* infections in a Canadian tertiary care hospital before and during a regional epidemic associated with the BI/NAP1/027 strain. *Antimicrob Agents Chemother.* 2008;52(9):3180–7.

101. Pettit LJ, Browne HP, Yu L, Smits WK, Fagan RP, Barquist L, Martin MJ, Goulding D, Duncan SH, Flint HJ, Dougan G, Choudhary JS, Lawley TD. Functional genomics reveals that *Clostridium difficile* Spo0A coordinates sporulation, virulence and metabolism. *BMC Genomics.* 2014;15:160.

102. Merrigan M, Venugopal A, Malozzi M, Roxas B, Viswanathan VK, Johnson S, Gerding DN, Vedantam G. Human hypervirulent *Clostridium difficile* strains exhibit increased sporulation as well as robust toxin production. *J Bacteriol.* 2010;192(19):4904–11.

103. Smits WK. Hype or hypervirulence. A reflection on problematic *C. difficile* strains. *Virulence.* 2013;4(7):592–6.

104. Heeg D, Burns DA, Cartman ST, Minton NP. Spores of *Clostridium difficile* clinical isolates display a diverse germination response to bile salts. *PLoS One.* 2012;7:e32381.

105. Akerlund T, Svenungsson B, Lagergren A, Burman LG. Correlation of disease severity with fecal toxin levels in patients with *Clostridium difficile*-associated diarrhea and distribution of PCR ribotypes and toxin yields in vitro of corresponding isolates. *J Clin Microbiol.* 2006;44(2):353–8.

106. Kim J, Seo MR, Kang JO, Choi TY, Pai H. Clinical and microbiologic characteristics of *Clostridium difficile* infection caused by binary toxin producing strain in Korea. *Infect Chemother.* 2013;45(2):175–83.

107. Blossom DB, McDonald LC. The challenges posed by re-emerging *Clostridium difficile*

infection. *Clin Infect Dis*. 2007;45(2):222–7.

108. Nale JY, Shan J, Hickenbotham PT, Fawley WN, Wilcox MH, Clokie MRJ. Diverse temperate bacteriophage carriage in *Clostridium difficile* 027 strains. *PLoS One*. 2012;7(5):e37263.

109. Sekulovic O, Meessen-Pinard M, Fortier LC. Prophage-stimulated toxin production in *Clostridium difficile* NAP1/027 lysogens. *J Bacteriol*. 2011;193(11):2726–34.

110. Stabler RA, He M, Dawson L, Martin M, Valiente E, Corton C, Lawley TD, Sebaihia M, Quail MA, Rose G, Gerding DN, Gibert M, Popoff MR, Parkhill J, Dougan G, Wren BW. Comparative genome and phenotypic analysis of *Clostridium difficile* 027 strains provides insight into the evolution of a hypervirulent bacterium. *Genome Biol*. 2009;10(9):R102.

111. Janezic S, Zidaric V, Pardon B, Indra A, Kokotovic B, Blanco JL, Seyboldt C, Diaz CR, Poxton IR, Perreten V, Drigo I, Jiraskova A, Ocepek M, Weese JS, Songer JG, Wilcox MH, Rupnik M. International *Clostridium difficile* animal strain collection and large diversity of animal associated strains. *BMC Microbiol*. 2014;14:173.

112. Sangster W, Hegarty JP, Stewart Sr DB. Phage tail-like particles kill *Clostridium difficile* and represent an alternative to conventional antibiotics. *Surgery*. 2015;157(1):96–103.

113. Heinrichs JH, Therien AG. Prevention of *Clostridium difficile* infections—the role of vaccines and therapeutic immunoglobulins. *Semin Colon Rectal Surg*. 2014;25:153–7.

114. Kyne L, Warny M, Qamar A, Kelly CP. Asymptomatic carriage of *Clostridium difficile* and serum levels of IgG antibody against toxin A. *N Engl J Med*. 2000;342(6):390–7.

115. Kyne L, Warny M, Qamar A, Kelly CP. Association between antibody response to toxin A and protection against recurrent *Clostridium difficile* diarrhea. *Lancet*. 2001;357(9251):189–93.

116. Leav BA, Blair B, Leney M, Knauber M, Reilly C, Lowy I, Gerding DN, Kelly CP, Katchar K, Baxter R, Ambrosino D, Molrine D. Serum anti-toxin B antibody correlates with protection from recurrent *Clostridium difficile* infection (CDI). *Vaccine*. 2010;28(4):965–9.

117. Chang TW, Lin PS, Gorbach SL, Bartlett JG. Ultrastructural changes of cultured human amnion cells by *Clostridium difficile* toxin. *Infect Immun*. 1979;22(3):795–8.

118. Gilligan PH. Contemporary approaches for the laboratory diagnosis of *Clostridium difficile* infections. *Semin Colon Rectal Surg*. 2014;25:137–42.

119. Lyrerly DM, Barroso LA, Wilkins TD. Identification of the latex test-reactive protein of *Clostridium difficile* as glutamate dehydrogenase. *J Clin Microbiol*. 1991;29(11):2639–42.

120. Turgeon DK, Novicki TJ, Quick J, Carlson L, Miller P, Ulness B, Cent A, Ashley R, Larson A, Coyle M, Limaye AP, Cookson BT, Fritsche TR. Six rapid tests for direct detection of *Clostridium difficile* and its toxins in fecal samples compared with the fibroblast cytotoxicity assay. *J Clin Microbiol*. 2003;41(2):667–70.

121. Debast SB, van Kregten E, Oskam KM, van den Berg T, Van den Berg RJ, Kuijper EJ. Effect on diagnostic yield of repeated stool testing during outbreaks of *Clostridium difficile*-associated disease. *Clin Microbiol Infect*. 2008;14(6):622–4.

122. Katzman M. Antibiotic therapy for *Clostridium difficile* infection. *Semin Colon Rectal Surg*. 2014;25:143–9.

123. Stewart DB, Yacoub E, Zhu J. Chemotherapy patients with *C. difficile* colitis have outcomes similar to immunocompetent *C. difficile* patients. *J Gastrointest Surg*. 2012;16(8):1566–72.

124. Jafari NV, Kuehne SA, Bryant CE, Elawad M, Wren BW, Minton NP, Allan E, Bajaj-Elliott M. *Clostridium difficile* modulates host innate immunity via toxin-independent and dependent mechanism(s). *PLoS One*. 2013;8(7):e69846.

125. Venugopal AA, Johnson S. Current state of *Clostridium difficile* treatment options. *Clin Infect Dis*. 2012;55(S2):S71–6.
126. Bassetti M, Villa G, Percori D, Arzese A, Wilcox M. Epidemiology, diagnosis and treatment of *Clostridium difficile* infection. *Expert Rev Anti Infect Ther*. 2012;10(12):1405–23.
127. No authors. Recommendations for preventing the spread of vancomycin resistance. Recommendations of the Hospital Infection Control Practices Advisory Committee (HICPAC). *MMWR Recomm Rep*. 1995;44(RR-12):1–13.
128. Teasley DG, Gerding DN, Olson MM, Peterson LR, Gebhard RL, Schwartz MJ, Lee Jr JT. Prospective randomized trial of metronidazole versus vancomycin for *Clostridium difficile*-associated diarrhea and colitis. *Lancet*. 1983;2(8358):1043–6.
129. Wenisch C, Parschalk B, Hasenhündl M, Hirschl AM, Graninger W. Comparison of vancomycin, teicoplanin, metronidazole, and fusidic acid for the treatment of *Clostridium difficile*-associated diarrhea. *Clin Infect Dis*. 1996;22(5):813–8.
130. Zar FA, Bakkanagari SR, Moorthi KM, Davis MB. A comparison of vancomycin and metronidazole for the treatment of *Clostridium difficile*-associated diarrhea, stratified by disease severity. *Clin Infect Dis*. 2007;45(3):302–7.
131. Johnson S, Homann SR, Bettin KM, Quick JN, Clabots CR, Peterson LR, Gerding DN. Treatment of asymptomatic *Clostridium difficile* carriers (fecal excretors) with vancomycin or metronidazole. A randomized, placebo-controlled trial. *Ann Intern Med*. 1992;117:297–302.
132. Kim PK, Huh HC, Cohen HW, Feinberg EJ, Ahmad S, Coyle C, Teperman S, Boothe H. Intracolonic vancomycin for severe *Clostridium difficile* colitis. *Surg Infect (Larchmt)*. 2013;14(6):532–9.
133. Keller JJ, Kuijper EJ. Treatment of recurrent and severe *Clostridium Difficile* infection. *Annu Rev Med*. 2015;66:373–86.
134. Hashash JG, Binion DG. Managing *Clostridium difficile* in inflammatory bowel disease (IBD). *Curr Gastroenterol Rep*. 2014;16(7):393.
135. Sullivan KM, Spooner LM. Fidaxomicin: a macrocyclic antibiotic for the management of *Clostridium difficile* infection. *Ann Pharmacother*. 2010;44:352–9.
136. Whitman CB, Czosnowski QA. Fidaxomicin for the treatment of *Clostridium difficile* infections. *Ann Pharmacother*. 2012;46:219–28.
137. Louie TJ, Miller MA, Mullane KM, Weiss K, Lentnek A, Golan Y, Gorbach S, Sears P, Shue YK, OPT-80-003 Clinical Study Group. Fidaxomicin versus vancomycin for *Clostridium difficile* infection. *N Engl J Med*. 2011;364(5):422–31.
138. Babakhani F, Gomez A, Robert N, Sears P. Postantibiotic effect of fidaxomicin and its major metabolite, OP-1118, against *Clostridium difficile*. *Antimicrob Agents Chemother*. 2011;55(9):4427–9.
139. Mullane KM, Miller MA, Weiss K, Lentnek A, Golan Y, Sears PS, Shue YK, Louie TJ, Gorbach SL. Efficacy of fidaxomicin versus vancomycin as therapy for *Clostridium difficile* infection in individuals taking concomitant antibiotics for other concurrent infections. *Clin Infect Dis*. 2011;53(5):440–7.
140. Babakhani F, Bouillaut L, Sears P, Sims C, Gomez A, Sonenshein AL. Fidaxomicin inhibits toxin production in *Clostridium difficile*. *J Antimicrob Chemother*. 2013;68(3):515–22.
141. Cornely OA, Nathwani D, Ivanescu C, Odufowora-Sita O, Retsa P, Odeyemi IA. Clinical efficacy of fidaxomicin compared with vancomycin and metronidazole in *Clostridium difficile*



infections: a meta-analysis and indirect treatment comparison. *J Antimicrob Chemother.* 2014;69(11):2892–900.

142. Nathwani D, Cornely OA, Van Engen AK, Odufowora-Sita O, Retsa P, Odeyemi IA. Cost-effectiveness analysis of fidaxomicin versus vancomycin in *Clostridium difficile* infection. *J Antimicrob Chemother.* 2014;69(11):2901–12.

143. Neal MD, Alverdy JC, Hall DE, Simmons RL, Zuckerbraun BS. Diverting loop ileostomy and colonic lavage: an alternative to total abdominal colectomy for the treatment of severe, complicated *Clostridium difficile* associated disease. *Ann Surg.* 2011;254(3):423–7. Discussion 427–9.

144. Dallal RM, Harbrecht BG, Boujoukas AJ, Sirio CA, Farkas LM, Lee KK, Simmons RL. Fulminant *Clostridium difficile*: an underappreciated and increasing cause of death and complications. *Ann Surg.* 2002;235(3):363–72.

145. Sailhammer EA, Carson K, Chang Y, Zacharias N, Spaniolas K, Tabbara M, Alam HB, DeMoya MA, Velmahos GC. Fulminant *Clostridium difficile* colitis: patterns of care and predictors of mortality. *Arch Surg.* 2009;144(5):433–9.

146. Byrn JC, Maun DC, Ginglode DS, Baril DT, Ozao JJ, Divino CM. Predictors of mortality after colectomy for fulminant *Clostridium difficile* colitis. *Arch Surg.* 2008;43(2):150–4. Discussion 155.

147. Hall JF, Berger D. Outcome of colectomy for *Clostridium difficile* colitis: a plea for early surgical management. *Am J Surg.* 2008;196:384–8.

148. Bhangu A, Nepogodiev D, Gupta A, Torrance A, Singh P, West Midlands Research Collaborative. Systematic review and meta-analysis of outcomes following emergency surgery for *Clostridium difficile* colitis. *Br J Surg.* 2012;99(11):1501–13.

149. Stewart DB, Hollenbeak CS, Wilson MZ. Is colectomy for fulminant *Clostridium difficile* colitis life saving? A systematic review. *Colorectal Dis.* 2013;15(7):798–804.

150. Borody TJ, Finlayson S. Fecal microbiota transplantation for *Clostridium difficile* infection: a surgeon's perspective. *Semin Colon Rectal Surg.* 2014;25(3):163–6.

151. Song Y, Garg S, Girotra M, Maddox C, von Rosenvinge EC, Dutta A, Dutta S, Fricke WF. Microbiota dynamics in patients treated with fecal microbiota transplantation for recurrent *Clostridium difficile* infection. *PLoS One.* 2013;8(11):e81330.

152. Khoruts A, Dicksved J, Jansson JK, Sadowsky MJ. Changes in the composition of the human fecal microbiome after bacteriotherapy for recurrent *Clostridium difficile*-associated diarrhea. *J Clin Gastroenterol.* 2010;44(5):354–60.

153. Yu S, Abdelkarim A, Nawras A, Hinch BT, Mbaso C, Valavoor S, Safi F, Hammersley J, Tang J, Assaly R. Fecal transplant for treatment of toxic megacolon associated with *Clostridium difficile* colitis in a patient with duchenne muscular dystrophy. *Am J Ther.* 2014 [Epub ahead of print]

154. Neemann K, Eichele DD, Smith PW, Bociek R, Akhtari M, Freifeld A. Fecal microbiota transplantation for fulminant *Clostridium difficile* infection in an allogeneic stem cell transplant patient. *Transpl Infect Dis.* 2012;14(6):E161–5.

155. Lee M, Shelton AA, Concepcion WL, Bonham CA, Daugherty TJ. Fulminant *Clostridium difficile* colitis in a post-liver transplant patient. *Dig Dis Sci.* 2010;55(9):2459–62.

## 第 54 章

1. Ballas LK, Elkin EB, Schrag D, Minsky BD, Bach PB. Radiation therapy facilities in the United States. *Int J Radiat Oncol Biol Phys.* 2006;66:1204–11.
2. West CM, Barnett GC. Genetics and genomics of radiotherapy toxicity; towards protection. *Genome Med.* 2011;3(8):52.
3. Hauer-Jensen M, Denham JW, Andreyev HJ. Radiation enteropathy—pathogenesis, treatment and prevention. *Nat Rev Gastroenterol Hepatol.* 2014;11(8):470–9. PubMed Central PMCID: 4346191.
4. Eifel PJ, Jhingran A, Bodurka DC, Levenback C, Thames H. Correlation of smoking history and other patient characteristics with major complications of pelvic radiation therapy for cervical cancer. *J Clin Oncol.* 2002;20:3651–7.
5. Herold DM, Hanlon AL, Hanks GE. Diabetes mellitus: a predictor for late radiation morbidity. *Int J Radiat Oncol Biol Phys.* 1999;43:475–9.
6. Willett CG, et al. Acute and late toxicity of patients with inflammatory bowel disease undergoing irradiation for abdominal and pelvic neoplasms. *Int J Radiat Oncol Biol Phys.* 2000;46:995–8.
7. Eifel PJ, Levenback C, Wharton JT, et al. Time course and incidence of late complications in patients treated with radiation therapy for FIGO stage IB carcinoma of the uterine cervix. *Int J Radiat Oncol Biol Phys.* 1995;32(5):1289–300.
8. Kennedy GD, Heise CP. Radiation colitis and proctitis. *Clin Colon Rectal Surg.* 2007;20(1):64–72.
9. Dorr W, Hendry JH. Consequential late effects in normal tissues. *Radiother Oncol.* 2001;61:223–31.
10. Showalter TN, Wages NA, Ohri N. Strategic evaluation of interventions to prevent consequential late proctitis after prostate radiation therapy: new clinical trial designs should be considered. *Cancer Biol Ther.* 2014;15(4):361–4.
11. Shadad AK, Sullivan FJ, Martin JD, Egan LJ. Gastrointestinal radiation injury: prevention and treatment. *World J Gastroenterol.* 2013;19(2):199–208.
12. Nutting CM, Convery DJ, Cosgrove VP, Rowbottom C, Padhani AR, Webb S, Dearnaley DP. Reduction of small and large bowel irradiation using an optimized intensity-modulated pelvic radiotherapy technique in patients with prostate cancer. *Int J Radiat Oncol Biol Phys.* 2000;48:649–56.
13. Marchand V, Bourdin S, Charbonnel C, Rio E, Munos C, Campion L, Bonnaud-Antignac A, Lisbona A, Mahe MA, Supiot S. No impairment of quality of life 18 months after high dose intensity modulated radiotherapy for localized prostate cancer: a prospective study. *Int J Radiat Oncol Biol Phys.* 2010;2010(77):1053–9.
14. Lips IM, Dehnad H, van Gils CH, Boeken Kruger AE, van der Heide UA, van Vulpen M. High dose intensity modulated radiotherapy for prostate cancer using daily fiducial marker based position verification: acute and late toxicity in 331 patients. *Int J Radiat Oncol.* 2008;3:15.
15. Peters CA, Cesaretti JA, Stone NN, Stock RG. Low dose rate prostate brachytherapy is well tolerated in patients with a history of inflammatory bowel disease. *Int J Radiat Oncol Biol Phys.* 2006;66:424–9.
16. Lee WR, Bae K, Lawton C, Gillin M, Morton G, Firat S, Baikadi M, Kuettel M, Greven K, Sandler H. Late toxicity and biochemical recurrence after external beam radiotherapy combined with permanent source prostate brachytherapy: analysis of Radiation Therapy Oncology Group study 0019. *Cancer.* 2007;109:1506–12.

17. Sugahara S, Oshiro Y, Fukuda K, Mizumoto M, Abei M, Shoda J, Matsuzaki Y, Thono E, Tokita M. Proton beam therapy for large hepatocellular carcinoma. *Int J Radiat Oncol Biol Phys.* 2010;76:460–6.
18. Bayley AJ, Catton CN, Haycocks T, Kelly V, Alasti H, Bristow R, Catton P, Crook J, Gospodarowicz MK, Mclean M. A randomized trial of supine vs prone positioning in patients undergoing escalated dose conformal radiotherapy for prostate cancer. *Radiat Oncol.* 2004;70:37–44.
19. Shanahan TG, Mehta MP, Bertelrud KL, Buchler DA, Frank LE, Gehring MA, Kubsad SS, Utrie PC, Kinsella TJ. Minimization of small bowel volume within treatment fields utilizing customized belly boards. *Int J Radiat Oncol Biol Phys.* 1990;19:469–76.
20. Lalla RV, Bowen J, Barasch A, Elting L, Epstein J, Keefe DM, McGuire DB, Migliorati C, Nicolatou-Galitis O, Peterson DE, Raber-Durlacher JE, Sonis ST, Elad S. MASCC/ISOO clinical practice guidelines for the management of mucositis secondary to cancer therapy. *Cancer.* 2014;120(10):1453–61.
21. Quastler H. Cell renewal and acute radiation damage. *Radiology.* 1959;73:161–5.
22. Otterson MF, Sarna SK, Leming SC, Moulder JE, Fink JG. Effects of fractionated doses of ionizing radiation on colonic motor activity. *Am J Physiol.* 1992;263:G518–26.
23. Kountouras J, Zavos C. Recent advances in the management of radiation colitis. *World J Gastroenterol.* 2008;14(48):7289–301.
24. Vernia P, Fracasso PL, Casale V, Villotti G, Marcheggiano A, Stigliano V, Pinnaro P, Bagnardi V, Caprilli R. Topical butyrate for acute radiation proctitis: randomised, crossover trial. *Lancet.* 2000;356(9237):1232–5.
25. Cox JD, Stetz J, Pajak TF. Toxicity criteria of the Radiation Therapy Oncology Group (RTOG) and the European Organization for Research and Treatment of Cancer (EORTC). *Int J Radiat Oncol Biol Phys.* 1995;31(5):1341–6.
26. Chen SW, Liang JA, Yang SN, Hung YC, Yeh LS, Shiau AC, et al. Radiation injury to intestine following hysterectomy and adjuvant radiotherapy for cervical cancer. *Gynecol Oncol.* 2004;95(1):208–14.
27. Theodorescu D, Gillenwater JY, Koutrouvelis PG. Prostatourethral-rectal fistula after prostate brachytherapy. *Cancer.* 2000;89(10):2085–91.
28. Kochhar R, Patel F, Dhar A, Sharma SC, Ayyagari S, Aggarwal R, Goenka MK, Gupta BD, Mehta SK. Radiation-induced proctosigmoiditis. Prospective, randomized, double-blind controlled trial of oral sulfasalazine plus rectal steroids versus rectal sucralfate. *Dig Dis Sci.* 1991;36(1):103–7.
29. Kochhar R, Sriram PV, Sharma SC, Goel RC, Patel F. Natural history of late radiation proctosigmoiditis treated with topical sucralfate suspension. *Dig Dis Sci.* 1999;44(5):973–8.
30. Henriksson R, Franzén L, Littbrand B. Prevention and therapy of radiation-induced bowel discomfort. *Scand J Gastroenterol Suppl.* 1992;191:7–11.
31. Baum CA, Biddle WL, Miner Jr PB. Failure of 5-aminosalicylic acid enemas to improve chronic radiation proctitis. *Dig Dis Sci.* 1989;34(5):758–60.
32. Goldstein F, Khoury J, Thornton JJ. Treatment of chronic radiation enteritis and colitis with salicylazosulfapyridine and systemic corticosteroids. A pilot study. *Am J Gastroenterol.* 1976;65(3):201–8.
33. Martenson Jr JA, Hyland G, Moertel CG, Mailliard JA, O’Fallon JR, Collins RT, Morton RF,

Tewfik HH, Moore RL, Frank AR, Urias RE, Deming RL. Olsalazine is contraindicated during pelvic radiation therapy: results of a double-blind, randomized clinical trial. *Int J Radiat Oncol Biol Phys.* 1996;35:299–303.

34. Cook SI, Sellin JH. Review article: short chain fatty acids in health and disease. *Aliment Pharmacol Ther.* 1998;12:499–507.

35. Cavčić J, Turčić J, Martinac P, Jelincić Z, Zupancić B, Panijan-Pezerović R, Unusić J. Metronidazole in the treatment of chronic radiation proctitis: clinical trial. *Croat Med J.* 2000;41(3):314–8.

36. Sarin A, Safar B. Management of radiation proctitis. *Gastroenterol Clin North Am.* 2013;42(4):913–25.

37. Haas EM, Bailey HR, Farragher I. Application of 10 percent formalin for the treatment of radiation-induced hemorrhagic proctitis. *Dis Colon Rectum.* 2007;50:213–7.

38. Ma TH, Yuan ZX, Zhong QH, Wang HM, Qin QY, Chen XX, Wang JP, Wang L. Formalin irrigation for hemorrhagic chronic radiation proctitis. *World J Gastroenterol.* 2015;21(12):3593–8.

39. Luna-Pérez P, Rodríguez-Ramírez SE. Formalin instillation for refractory radiation-induced hemorrhagic proctitis. *J Surg Oncol.* 2002;80(1):41–4.

40. De Parades V, Etienney I, Bauer P, Bourguignon J, Meary N, Mory B, Sultan S, Taouk M, Thomas C, Atienza P. Formalin application in the treatment of chronic radiation-induced hemorrhagic proctitis—an effective but not risk-free procedure: a prospective study of 33 patients. *Dis Colon Rectum.* 2005;48(8):1535–41.

41. Kennedy M, Bruninga K, Mutlu EA, Losurdo J, Choudhary S, Keshavarzian A. Successful and sustained treatment of chronic radiation proctitis with antioxidant vitamins E and C. *Am J Gastroenterol.* 2001;96(4):1090–4.

42. Yeoh EK, Horowitz M, Russo A, Muecke T, Robb T, Chatterton BE. Gastrointestinal function in chronic radiation enteritis—effects of loperamide-N-oxide. *Gut.* 1993;34:476–82.

43. Oscarsson N, Arnell P, Lodding P, Ricksten SE, Seeman-Lodding H. Hyperbaric oxygen treatment in radiation-induced cystitis and proctitis: a prospective cohort study on patient-perceived quality of recovery. *Int J Radiat Oncol Biol Phys.* 2013;87(4):670–5.

44. Hoggan BL, Cameron AL. Systematic review of hyperbaric oxygen therapy for the treatment of non-neurological soft tissue radiation-related injuries. *Support Care Cancer.* 2014;22(6):1715–26.

45. Karamanolis G, Triantafyllou K, Tsiamoulos Z, Polymeros D, Kalli T, Misailidis N, Ladas SD. Argon plasma coagulation has a long-lasting therapeutic effect in patients with chronic radiation proctitis. *Endoscopy.* 2009;41(6):529–31.

46. Tam W, Moore J, Schoeman M. Treatment of radiation proctitis with argon plasma coagulation. *Endoscopy.* 2000;32:667–72.

47. De la Serna Higuera C, Martín Arribas M, Rodríguez Gómez S, Pérez Villoria A, Martínez Moreno J, Betancourt González A. Efficacy and safety of argon plasma coagulation for the treatment of hemorrhagic radiation proctitis. *Rev Esp Enferm Dig.* 2004;96:758–64.

48. Yeoh E, Tam W, Schoeman M, Moore J, Thomas M, Botten R, Di Matteo A. Argon plasma coagulation therapy versus topical formalin for intractable rectal bleeding and anorectal dysfunction after radiation therapy for prostate carcinoma. *Int J Radiat Oncol Biol Phys.* 2013;87(5):954–9.

49. Chruscielewska-Kiliszek MR, Regula J, Polkowski M, Rupinski M, Kraszewska E, Pachlewski J, Czaczowska-Kurek E, Butruk E. Sucralfate or placebo following argon plasma coagulation for chronic radiation proctitis: a randomized double blind trial. *Colorectal Dis.* 2013;15(1):e48–55.

50. Viggiano TR, Zigelboim J, Ahlquist DA, Gostout CJ, Wang KK, Larson MV. Endoscopic Nd:YAG laser coagulation of bleeding from radiation proctopathy. *Gastrointest Endosc.* 1993;39:513–7.
51. Zhou C, Adler DC, Becker L, Chen Y, Tsai TH, Figueiredo M, Schmitt JM, Fujimoto JG, Mashimo H. Effective treatment of chronic radiation proctitis using radiofrequency ablation. *Therap Adv Gastroenterol.* 2009;2(3):149–56.
52. Jao SW, Beart Jr RW, Gunderson LL. Surgical treatment of radiation injuries of the colon and rectum. *Am J Surg.* 1986;151(2):272–7.
53. Galland RB, Spencer J. Surgical management of radiation enteritis. *Surgery.* 1986;99:133–9.
54. Pricolo VE, Shellito PC. Surgery for radiation injury to the large intestine. Variables influencing outcome. *Dis Colon Rectum.* 1994;37(7):675–84.
55. Ayerdi J, Moinuddeen K, Loving A, Wiseman J, Deshmukh N. Diverting loop colostomy for the treatment of refractory gastrointestinal bleeding secondary to radiation proctitis. *Mil Med.* 2001;166(12):1091–3.
56. Lindstrom C. ‘Collagenous colitic’ with watery diarrhoea—a new entity? *Pathol Eur.* 1976;11(1):87–9.
57. Freeman H, Weinstein W, Shnitka T, Wensel R, Sartor V. Watery diarrhea syndrome associated with a lesion of the colonic basement membrane-lamina propria interface. *Ann R Coll Phys Surg Can.* 1976;9:A45.
58. Bohr J, Wickbom A, Hegedus A, Nyhlin N, Hultgren Hornquist E, Tysk C. Diagnosis and management of microscopic colitis: current perspectives. *Clin Exp Gastroenterol.* 2014;7:273–84. PubMed Central PMCID: 4144984.
59. Nyhlin N, Wickbom A, Montgomery SM, Tysk C, Bohr J. Long-term prognosis of clinical symptoms and health-related quality of life in microscopic colitis: a case-control study. *Aliment Pharmacol Ther.* 2014;39(9):963–72.
60. Hjortswang H, Tysk C, Bohr J, Benoni C, Vigren L, Kilander A, et al. Health-related quality of life is impaired in active collagenous colitis. *Dig Liver Dis.* 2011;43(2):102–9.
61. Williams JJ, Beck P, Andrews C, Hogan D, Storr MA. Microscopic colitis—a common cause of diarrhoea in older adults. *Age Ageing.* 2010;39:162–8.
62. Munch A, Aust D, Bohr J, Bonderup O, Fernandez Banares F, Hjortswang H, et al. Microscopic colitis: current status, present and future challenges: statements of the European Microscopic Colitis Group. *J Crohns Colitis.* 2012;6(9):932–45.
63. Pardi DS, Loftus Jr EV, Smyrk TC, Kammer PP, Tremaine WJ, Schleck CD, et al. The epidemiology of microscopic colitis: a population based study in Olmsted County, Minnesota. *Gut.* 2007;56(4):504–8. PubMed Central PMCID: 1856874.
64. Olesen M, Eriksson S, Bohr J, Järnerot G, Tysk C. Lymphocytic colitis: a retrospective clinical study of 199 Swedish patients. *Gut.* 2004;53(4):536–41.
65. Tysk C, Wickbom A, Nyhlin N, Eriksson S, Bohr J. Recent advances in diagnosis and treatment of microscopic colitis. *Ann Gastroenterol.* 2011;24(4):253–62.
66. Abdo AA, Zetler PJ, Halparin L. Familial microscopic colitis. *Can J Gastroenterol.* 2001;15(5):341–3.
67. Fernández-Bañares F, Esteve M, Farré C, Salas A, Alsina M, Casalots J, et al. Predisposing HLA-DQ2 and HLA-DQ8 haplotypes of coeliac disease and associated enteropathy in microscopic colitis. *Eur J Gastroenterol Hepatol.* 2005;17:1333–8.

68. Koskela RM, Karttunen TJ, Niemelä SE, Lehtola JK, Ilonen J, Karttunen RA. Human leucocyte antigen and TNF $\alpha$  polymorphism association in microscopic colitis. *Eur J Gastroenterol Hepatol*. 2008;20:276–82.
69. Madisch A, Hellmig S, Schreiber S, Bethke B, Stolte M, Miehke S. NOD2/CARD15 gene polymorphisms are not associated with collagenous colitis. *Int J Colorectal Dis*. 2007;22(4):425–8.
70. Madisch A, Hellmig S, Schreiber S, Bethke B, Stolte M, Miehke S. Allelic variation of the matrix metalloproteinase-9 gene is associated with collagenous colitis. *Inflamm Bowel Dis*. 2011;17(11):2295–8.
71. Yen EF, Pokhrel B, Du H, Nwe S, Bianchi L, Witt B, et al. Current and past cigarette smoking significantly increase risk for microscopic colitis. *Inflamm Bowel Dis*. 2012;18(10):1835–41.
72. Fernandez-Banares F, de Sousa MR, Salas A, Beltran B, Piqueras M, Iglesias E, et al. Impact of current smoking on the clinical course of microscopic colitis. *Inflamm Bowel Dis*. 2013;19(7):1470–6.
73. Pascua MF, Kedia P, Weiner MG, Holmes J, Ellenberg J, Lewis JD. Microscopic colitis and medication use. *Clin Med Insights Gastroenterol*. 2010;18(3):11–9.
74. Keszthelyi D, Penders J, Masclee A, Pierik M. Is microscopic colitis a drug-induced disease? *J Clin Gastroenterol*. 2012;46:811–22.
75. Vigren L, Tysk C, Strom M, Kilander AF, Hjortswang H, Bohr J, et al. Celiac disease and other autoimmune diseases in patients with collagenous colitis. *Scand J Gastroenterol*. 2013;48(8):944–50.
76. Pardi DS, Ramnath VR, Loftus EV, Tremaine WJ, Sandborn WJ. Lymphocytic colitis: clinical features, treatment, and outcomes. *Am J Gastroenterol*. 2002;97(11):2829–33.
77. Tysk C, Bohr J, Nyhlin N, Wickbom A, Eriksson S. Diagnosis and management of microscopic colitis. *World J Gastroenterol*. 2008;28(14):7280–8.
78. Freeman HJ, James D, Mahoney CJ. Spontaneous peritonitis from perforation of the colon in collagenous colitis. *Can J Gastroenterol*. 2001;15:265–7.
79. Bohr J, Larsson LG, Eriksson S, Jarnerot G, Tysk C. Colonic perforation in collagenous colitis: an unusual complication. *Eur J Gastroenterol Hepatol*. 2005;17:121.
80. Allende DS, Taylor SL, Bronner MP. Colonic perforation as a complication of collagenous colitis in a series of 12 patients. *Am J Gastroenterol*. 2008;103(10):2598–604.
81. Sherman A, Ackert JJ, Rajapaksa R, West B, Oweity T. “Fractured colon” an endoscopically distinctive lesion associated with colonic perforation following colonoscopy in patients with collagenous colitis. *J Clin Gastroenterol*. 2004;38(4):341–5.
82. Kao K, Pedraza B, McClune A, Rios D, Mao Y-Q, Zuch R, et al. Microscopic colitis: a large retrospective analysis from a health maintenance organization experience. *World J Gastroenterol*. 2009;15(25):3122–7.
83. Yen EF, Pokhrel B, Bianchi LK, Roy HK, Du H, Patel A, et al. Decreased colorectal cancer and adenoma risk in patients with microscopic colitis. *Dig Dis Sci*. 2012;57(1):161–9.
84. Langner C, Aust D, Ensari A, Villanacci V, Becheanu G, Miehke S, et al. Histology of microscopic colitis-review with a practical approach for pathologists. *Histopathology*. 2015;66(5):613–26.
85. Yantiss RK, Odze RD. Optimal approach to obtaining mucosal biopsies for assessment of inflammatory disorders of the gastrointestinal tract. *Am J Gastroenterol*. 2009;104(3):774–83.
86. Warren BF, Edwards CM, Travis SPL. ‘Microscopic colitis’: classification and terminology.

Histopathology. 2002;40:374–6.

87. Koulaouzidis A, Saeed AA. Distinct colonoscopy findings of microscopic colitis: not so microscopic after all? *World J Gastroenterol*. 2011;17(37):4157–65. PubMed Central PMCID: 3209563.

88. Shaz BH, Reddy SI, Ayata G, Brien T, Farraye FA, Antonioli DA, et al. Sequential clinical and histopathological changes in collagenous and lymphocytic colitis over time. *Mod Pathol*. 2004;17(4):395–401.

89. Fiehn AM, Bjornbak C, Warnecke M, Engel PJ, Munck LK. Observer variability in the histopathologic diagnosis of microscopic colitis and subgroups. *Hum Pathol*. 2013;44(11):2461–6.

90. Wildta S, Nordgaard-Lassena I, Bendtsen F, Rumessen J. Metabolic and inflammatory faecal markers in collagenous colitis. *Eur J Gastroenterol Hepatol*. 2007;19:567–74.

91. Hjortswang H, Tysk C, Bohr J, Benoni C, Kilander A, Larsson L, et al. Defining clinical criteria for clinical remission and disease activity in collagenous colitis. *Inflamm Bowel Dis*. 2009;15(12):1875–81.

92. Stewart MJ, Seow CH, Storr MA. Prednisolone and budesonide for short- and long-term treatment of microscopic colitis: systematic review and meta-analysis. *Clin Gastroenterol Hepatol*. 2011;9(10):881–90.

93. Chande N, McDonald JW, Macdonald JK. Interventions for treating lymphocytic colitis. *Cochrane Database Syst Rev*. 2008; (2):CD006096.

94. Chande N, McDonald JW, Macdonald JK. Interventions for treating collagenous colitis. *Cochrane Database Syst Rev*. 2008; (2):CD003575.

95. Miehke S, Hansen JB, Madisch A, Schwarz F, Kuhlisch E, Morgner A, et al. Risk factors for symptom relapse in collagenous colitis after withdrawal of short-term budesonide therapy. *Inflamm Bowel Dis*. 2013;19(13):2763–7.

96. Miehke S, Madisch A, Kupcinkas L, Petruskas D, Bohm G, Marks HJ, et al. Budesonide is more effective than mesalamine or placebo in short-term treatment of collagenous colitis. *Gastroenterology*. 2014;146(5):1222–30 e1–2.

97. Calabrese C, Fabbri A, Areni A, Zahlane D, Scialpi C, Di Febo G. Mesalazine with or without cholestyramine in the treatment of microscopic colitis: randomized controlled trial. *J Gastroenterol Hepatol*. 2007;22(6):809–14.

98. Munch A, Fernandez-Banares F, Munck LK. Azathioprine and mercaptopurine in the management of patients with chronic, active microscopic colitis. *Aliment Pharmacol Ther*. 2013;37(8):795–8.

99. Munch A, Bohr J, Vigren L, Tysk C, Strom M. Lack of effect of methotrexate in budesonide-refractory collagenous colitis. *Clin Exp Gastroenterol*. 2013;6:149–52. PubMed Central PMCID: 3770495.

100. Riddell J, Hillman L, Chiragakis L, Clarke A. Collagenous colitis: oral low-dose methotrexate for patients with difficult symptoms: long-term outcomes. *J Gastroenterol Hepatol*. 2007;22(10):1589–93.

101. Pola S, Fahmy M, Evans E, Tipps A, Sandborn WJ. Successful use of infliximab in the treatment of cortico-steroid dependent collagenous colitis. *Am J Gastroenterol*. 2013;108:857–8.

102. Munch A, Ignavota S, Strom M. Adalimumab in budesonide and methotrexate refractory collagenous colitis. *Scand J Gastroenterol*. 2012;47(1):59–63.

103. Esteve M, Mahadevan U, Sainz E, Rodriguez E, Salas A, Fernandez Banares F. Efficacy of

- anti-TNF therapies in refractory severe microscopic colitis. *J Crohns Colitis*. 2011;5(6):612–8.
104. Aram G, Bayless TM, Chen ZM, Montgomery EA, Donowitz M, Giardiello FM. Refractory lymphocytic enterocolitis and tumor necrosis factor antagonist therapy. *Clin Gastroenterol Hepatol*. 2010;8(4):391–4. PubMed Central PMCID: 2846972.
105. Fine K, Ogunji F, Lee E, Lafon G, Tanzi M. Randomized, double-blind, placebo-controlled trial of bismuth subsalicylate for microscopic colitis. *Gastroenterology*. 1999;116(4):A880.
106. Fine KD, Lee EL. Efficacy of open-label bismuth subsalicylate for the treatment of microscopic colitis. *Gastroenterology*. 1998;114(1):29.
107. Thazhath SS, Haque M, Florin TH. Oral bismuth for chronic intractable diarrheal conditions? *Clin Exp Gastroenterol*. 2013;6:19–25.
108. Munch A, Soderholm JD, Wallon C, Ost A, Olaison G, Strom M. Dynamics of mucosal permeability and inflammation in collagenous colitis before, during, and after loop ileostomy. *Gut*. 2005;54(8):1126–8. PubMed Central PMCID: 1774864.
109. Varghese L, Galandiuk S, Tremaine WJ, Burgart LJ. Lymphocytic colitis treated with proctocolectomy and ileal J-pouch-anal anastomosis report of a case. *Dis Colon Rectum*. 2002;45:123–6.
110. Martson A, Pheils MT, Thomas L, Morson BC. Ischemic colitis. *Gut*. 1966;7:1–15.
111. Brandt LJ, Feuerstadt P, Longstreth GF, Boley SJ, American College of Gastroenterology. ACG clinical guideline: epidemiology, risk factors, patterns of presentation, diagnosis, and management of colon ischemia (CI). *Am J Gastroenterol*. 2015;110(1):18–44. Quiz 5,
112. Rosenblum J, Boyle C, Schwartz L. The mesenteric circulation—anatomy and physiology. *Surg Clin North Am*. 1997;77:289–306.
113. Gandhi SK, Morin MH, Vernava AM, Kaminski DL, Longo WE. Ischemic colitis. *Dis Colon Rectum*. 1996;39(1):88–100.
114. Higgins PD, Davis KJ, Laine L. Systematic review: the epidemiology of ischaemic colitis. *Aliment Pharmacol Ther*. 2004;19(7):729–38.
115. Washington C, Carmichael JC. Management of ischemic colitis. *Clin Colon Rectal Surg*. 2012;25(4):228–35. PubMed Central PMCID: 3577613.
116. Hass DJ, Kozuch P, Brandt LJ. Pharmacologically mediated colon ischemia. *Am J Gastroenterol*. 2007;102(8):1765–80.
117. Perry RJ, Martin MJ, Eckert MJ, Sohn VY, Steele SR. Colonic ischemia complicating open vs endovascular abdominal aortic aneurysm repair. *J Vasc Surg*. 2008;48(2):272–7.
118. Senekowitsch C, Assadian A, Assadian O, Hartleb H, Ptakovsky H, Hagmuller GW. Replanting the inferior mesentery artery during infrarenal aortic aneurysm repair: influence on postoperative colon ischemia. *J Vasc Surg*. 2006;43(4):689–94.
119. Champagne BJ, Lee EC, Valerian B, Mulhotra N, Mehta M. Incidence of colonic ischemia after repair of ruptured abdominal aortic aneurysm with endograft. *J Am Coll Surg*. 2007;204(4):597–602.
120. Grubel P, Lamont JT, Nandakumar G, Collins. Ischemic colitis 2015 [updated 13 Feb 2015; cited 8 Apr 2015].
121. Samel S, Keese M, Kleczka M, Lanig S, Gretz N, Hafner M, Sturm J, Post S. Microscopy of bacterial translocation during small bowel obstruction and ischemia in vivo—a new animal model. *BMC Surg*. 2002;2:6.
122. Haglund U, Bulkley G, Granger D. On the pathophysiology of intestinal ischemic injury.



Clinical review. *Acta Chir Scand*. 1987;153(5–6):321.

123. Hourmand-Olivier I, Bouin M, Saloux E, Morello R, Rousselot P, Piquet M, et al. Cardiac sources of embolism should be routinely screened in ischemic colitis. *Am J Gastroenterol*. 2003;98(7):1573–7.

124. Iwashita A, Yao T, Schlemper R, Kuwano Y, Yao T, Iida M, et al. Mesenteric phleboscrosis. A new disease entity causing ischemic colitis. *Dis Colon Rectum*. 2003;46:209–20.

125. Longstreth GF, Yao JF. Epidemiology, clinical features, high-risk factors, and outcome of acute large bowel ischemia. *Clin Gastroenterol Hepatol*. 2009;7(10):1075–80 e1–2. Quiz 23.

126. Feuerstadt P, Brandt LJ. Colon ischemia : recent insights and advances. *Curr Gastroenterol Rep*. 2010;12(5):383–90.

127. Montoro MA, Brandt LJ, Santolaria S, Gomollon F, Sanchez Puertolas B, Vera J, et al. Clinical patterns and outcomes of ischaemic colitis: results of the Working Group for the Study of Ischaemic Colitis in Spain (CIE study). *Scand J Gastroenterol*. 2011;46(2):236–46.

128. Beaugerie L, Metz M, Barbut F, Bellaiche G, Bouhnik Y, Raskine L, et al. *Klebsiella oxytoca* as an agent of antibiotic-associated hemorrhagic colitis. *Clin Gastroenterol Hepatol*. 2003;1(5):370–6.

129. Hogenauer C, Langner C, Beubler E, Lippe I, Schicho R, Gorkiewicz G, et al. *Klebsiella oxytoca* as a causative organism of antibiotic-associated hemorrhagic colitis. *N Engl J Med*. 2006;355(23):2418–26.

130. Blachar A, Barnes S, Adam S, Levy G, Weinstein I, Precel R, et al. Radiologists' performance in the diagnosis of acute intestinal ischemia, using MDCT and specific CT findings, using a variety of CT protocol. *Emerg Radiol*. 2011;18(5):385–94.

131. Iacobellis F, Berritto D, Fleischmann D, Gagliardi G, Brilliantino A, Mazzei MA, et al. CT findings in acute, subacute, and chronic ischemic colitis: suggestions for diagnosis. *BioMed Res Int*. 2014;2014:895248. PubMed Central PMCID: 4163450.

132. Lassandro F, Valente T, Rea G, Lassandro G, Golia E, Brunese L, et al. Imaging assessment and clinical significance of pneumatosis in adult patients. *Radiol Med*. 2015;120(1):96–104.

133. Sherid M, Samo S, Sulaiman S, Husein H, Sethuraman SN, Vainder JA. Is CT angiogram of the abdominal vessels needed following the diagnosis of ischemic colitis? A multicenter community study. *ISRN Gastroenterol*. 2014;2014:756926. PubMed Central PMCID: 3947673.

134. Beppu K, Osada T, Nagahara A, Mastumoto K, Shibuya T, Sakamoto N, et al. Relationship between endoscopic findings and clinical severity in ischemic colitis. *Intern Med*. 2011;50:2263–7.

135. Ripollés T, Simo L, Martinez-Perez M, Pastor M, Igual A, Lopez A. Sonographic findings in ischemic colitis in 58 patients. *AJR Am J Roentgenol*. 2005;184(3):777–85.

136. Diaz Nieto R, Varcada M, Ogunbiyi OA, Winslet MC. Systematic review on the treatment of ischaemic colitis. *Colorectal Dis*. 2011;13(7):744–7.

137. Beck DE. Endoscopic colonic stents and dilatation. *Clin Colon Rectal Surg*. 2010;23(1):37–41. PubMed Central PMCID: 2850165.

138. Park CH, Yoon JY, Park SJ, Cheon JH, Kim TI, Lee SK, et al. Clinical efficacy of endoscopic treatment for benign colorectal stricture: balloon dilatation versus stenting. *Gut Liver*. 2015;9(1):73–9. PubMed Central PMCID: 4282860.

139. Huguier M, Barrier A, Boelle PY, Houry S, Lacaine F. Ischemic colitis. *Am J Surg*. 2006;192(5):679–84.

140. O'Neill S, Yalamarthy S. Systematic review of the management of ischaemic colitis. *Colorectal*

Dis. 2012;14(11):e751–63.

141. Chung JW, Cheon JH, Park JJ, Jung ES, Choi EH, Kim H. Development and validation of a novel prognostic scoring model for ischemic colitis. *Dis Colon Rectum*. 2010;53(9):1287–94.

## 第 55 章

1. Turnbull GB. Ostomy statistics: the \$64,000 question. *Ostomy Wound Manage*. 2003;49(6):22–3.

2. Rombeau J. Physiologic and metabolic effects of intestinal stomas. In: Fazio VW, Church JM, Wu JS, editors. *Atlas of intestinal stomas*. New York: Springer; 2012.

3. Parekh N, Seidner DL. Medical management of the high output enterostomy and enterocutaneous fistula. In: Fazio VW, Church JM, Wu JS, editors. *Atlas of intestinal stomas*. New York: Springer; 2012.

4. Kent DJ, Arnold Long M, Bauer C. Revisiting colostomy irrigation: a viable option for persons with permanent descending and sigmoid colostomies. *J Wound Ostomy Continence Nurs*. 2015;42(2):162–4.

5. Nightingale J, Woodward JM, Small B, Nutrition Committee of the British Society of Gastroenterology. Guidelines for management of patients with a short bowel. *Gut*. 2006;55 Suppl 4:iv1–12.

6. Teitelbaum EN, Vaziri K, Zettervall S, Amdur RL, Orkin BA. Intraoperative small bowel length measurements and analysis of demographic predictors of increased length. *Clin Anat*. 2013;26(7):827–32.

7. Hendren S, et al. Clinical practice guidelines for ostomy surgery. *Dis Colon Rectum*. 2015;58(4):375–87.

8. Salvadalena G, et al. WOCN Society and ASCRS position statement on preoperative stoma site marking for patients undergoing colostomy or ileostomy surgery. *J Wound Ostomy Continence Nurs*. 2015;42(3):249–52.

9. Bass EM, et al. Does preoperative stoma marking and education by the enterostomal therapist affect outcome? *Dis Colon Rectum*. 1997;40(4):440–2.

10. Parmar KL, et al. A prospective audit of early stoma complications in colorectal cancer treatment throughout the Greater Manchester and Cheshire colorectal cancer network. *Colorectal Dis*. 2011;13(8):935–8.

11. Person B, et al. The impact of preoperative stoma site marking on the incidence of complications, quality of life, and patient's independence. *Dis Colon Rectum*. 2012;55(7):783–7.

12. Whitehead A, Seah A, Cataldo P. Technical tips for difficult stomas. In: Steele S et al., editors. *Complexities in colorectal surgery: decision-making and management*. New York: Springer; 2014.

13. Erwin-Toth P, Hocevar B, Stricker LJ. Wound, ostomy, and continence/enterostomal therapy (WOC/ET) nursing. In: Fazio VW, Church JM, Wu JS, editors. *Atlas of intestinal stomas*. New York: Springer; 2012.

14. Sjudahl R, Anderberg B, Bolin T. Parastomal hernia in relation to site of the abdominal stoma. *Br J Surg*. 1988;75(4):339–41.

15. Hardt J, et al. Lateral pararectal versus transrectal stoma placement for prevention of parastomal herniation. *Cochrane Database Syst Rev*. 2013;11:CD009487.

16. Chaudhri S, Brown L, Hassan I, Horgan AF. Preoperative intensive, community-based vs. traditional stoma education: a randomized, controlled trial. *Dis Colon Rectum*. 2005;48(3):504–9.
17. Younis J, et al. Focused preoperative patient stoma education, prior to ileostomy formation after anterior resection, contributes to a reduction in delayed discharge within the enhanced recovery programme. *Int J Colorectal Dis*. 2012;27(1):43–7.
18. Stocchi L. Ileostomy. In: Fazio VW, Church JM, Wu JS, editors. *Atlas of intestinal stomas*. New York: Springer; 2012.
19. Cottam J, Richards K, Hasted A, Blackman A. Results of a nationwide prospective audit of stoma complications within 3 weeks of surgery. *Colorectal Dis*. 2007;9(9):834–8.
20. Speirs M, et al. Ileostomy rod—is it a bridge too far? *Colorectal Dis*. 2006;8(6):484–7.
21. Salum M, et al. Does sodium hyaluronate- and carboxymethylcellulose-based bioresorbable membrane (Seprafilm) decrease operative time for loop ileostomy closure? *Tech Coloproctol*. 2006;10(3):187–90. Discussion 190–1.
22. Tang CL, Seow-Choen F, Fook-Chong S, Eu KW. Bioresorbable adhesion barrier facilitates early closure of the defunctioning ileostomy after rectal excision: a prospective, randomized trial. *Dis Colon Rectum*. 2003;46(9):1200–7.
23. Tjandra JJ, Chan MK. A sprayable hydrogel adhesion barrier facilitates closure of defunctioning loop ileostomy: a randomized trial. *Dis Colon Rectum*. 2008;51(6):956–60.
24. Hayden DM, et al. Hospital readmission for fluid and electrolyte abnormalities following ileostomy construction: preventable or unpredictable? *J Gastrointest Surg*. 2013;17(2):298–303.
25. Hignett S, Parmar CD, Lewis W, Makin CA, Walsh CJ. Ileostomy formation does not prolong hospital length of stay after open anterior resection when performed within an enhanced recovery programme. *Colorectal Dis*. 2011;13(10):1180–3.
26. Erwin-Toth P, Thompson SJ, Davis JS. Factors impacting the quality of life of people with an ostomy in North America: results from the Dialogue Study. *J Wound Ostomy Continence Nurs*. 2012;39(4):417–22. Quiz 423–4.
27. Altuntas YE, et al. The role of group education on quality of life in patients with a stoma. *Eur J Cancer Care (Engl)*. 2012;21(6):776–81.
28. UOAA. Available from <http://www.ostomy.org/Home.html#>
29. Ostomy Guidelines Task Force, et al. Management of the patient with a fecal ostomy: best practice guideline for clinicians. *J Wound Ostomy Continence Nurs*. 2010;37(6):596–8.
30. Sheetz KH, et al. Complication rates of ostomy surgery are high and vary significantly between hospitals. *Dis Colon Rectum*. 2014;57(5):632–7.
31. Salvadalena G. Incidence of complications of the stoma and peristomal skin among individuals with colostomy, ileostomy, and urostomy: a systematic review. *J Wound Ostomy Continence Nurs*. 2008;35(6):596–607. Quiz 608–9.
32. Herlufsen P, et al. Study of peristomal skin disorders in patients with permanent stomas. *Br J Nurs*. 2006;15(16):854–62.
33. Alvey B, Beck DE. Peristomal dermatology. *Clin Colon Rectal Surg*. 2008;21(1):41–4.
34. Nybaek H, Bang Knudsen D, Norgaard Laursen T, Karlsmark T, Jemec GB. Skin problems in ostomy patients: a case-control study of risk factors. *Acta Derm Venereol*. 2009;89(1):64–7.
35. Lyon CC, Smith AJ, Beck MH, Wong GA, Griffiths CE. Parastomal pyoderma gangrenosum: clinical features and management. *J Am Acad Dermatol*. 2000;42(6):992–1002.

36. Poritz LS, Lebo MA, Bobb AD, Ardell CM, Koltun WA. Management of peristomal pyoderma gangrenosum. *J Am Coll Surg*. 2008;206(2):311–5.
37. Weizman AV, et al. Pyoderma gangrenosum among patients with inflammatory bowel disease: a descriptive cohort study. *J Cutan Med Surg*. 2015;19(2):125–31.
38. Wu XR, et al. Risk factors for peristomal pyoderma gangrenosum complicating inflammatory bowel disease. *J Crohns Colitis*. 2013;7(5):e171–7.
39. Miller J, Yentzer BA, Clark A, Jorizzo JL, Feldman SR. Pyoderma gangrenosum: a review and update on new therapies. *J Am Acad Dermatol*. 2010;62(4):646–54.
40. Hanley J. Effective management of peristomal pyoderma gangrenosum. *Br J Nurs*. 2011;20(7):S12, S14–7.
41. Ratnagobal S, Sinha S. Pyoderma gangrenosum: guideline for wound practitioners. *J Wound Care*. 2013;22(2):68–73.
42. Kiran RP, O'Brien-Ermlich B, Achkar JP, Fazio VW, Delaney CP. Management of peristomal pyoderma gangrenosum. *Dis Colon Rectum*. 2005;48(7):1397–403.
43. Pennick MO, Artioukh DY. Management of parastomal varices: who re-bleeds and who does not? A systematic review of the literature. *Tech Coloproctol*. 2013;17(2):163–70.
44. Pabon-Ramos WM, Niemeyer MM, Dasika NL. Alternative treatment for bleeding peristomal varices: percutaneous parastomal embolization. *Cardiovasc Intervent Radiol*. 2013;36(5):1399–404.
45. Gordon P, Nivatvongs S, editors. Principles and practices of surgery of colon, rectum, and anus. St Louis: Quality Medical; 2006.
46. Beck DE, Fazio VW, Grundfest-Broniatowski S. Surgical management of bleeding stomal varices. *Dis Colon Rectum*. 1988;31(5):343–6.
47. Morris CS, Najarian KE. Transjugular intrahepatic portosystemic shunt for bleeding stomal varices associated with chronic portal vein occlusion: long-term angiographic, hemodynamic, and clinical follow-up. *Am J Gastroenterol*. 2000;95(10):2966–8.
48. Ryu RK, et al. Treatment of stomal variceal hemorrhage with TIPS: case report and review of the literature. *Cardiovasc Intervent Radiol*. 2000;23(4):301–3.
49. Samaraweera RN, et al. Stomal varices: percutaneous transhepatic embolization. *Radiology*. 1989;170(3 Pt 1):779–82.
50. Wolfsen HC, Kozarek RA, Bredfeldt JE, Fenster LF, Brubacher LL. The role of endoscopic injection sclerotherapy in the management of bleeding peristomal varices. *Gastrointest Endosc*. 1990;36(5):472–4.
51. Selby D, Jackson LD. Octreotide for control of bleeding peristomal varices in palliative care. *J Pain Symptom Manage*. 2015;49(3):e2–4.
52. De Ocampo ML. WOC nurse consult: peristomal varices. *J Wound Ostomy Continence Nurs*. 2012;39(2):178–9.
53. Wiesner RH, LaRusso NF, Dozois RR, Beaver SJ. Peristomal varices after proctocolectomy in patients with primary sclerosing cholangitis. *Gastroenterology*. 1986;90(2):316–22.
54. Poritz LS, Koltun WA. Surgical management of ulcerative colitis in the presence of primary sclerosing cholangitis. *Dis Colon Rectum*. 2003;46(2):173–8.
55. Kartheuser AH, et al. Complications and risk factors after ileal pouch-anal anastomosis for ulcerative colitis associated with primary sclerosing cholangitis. *Ann Surg*. 1993;217(4):314–20.
56. Kartheuser AH, et al. Comparison of surgical treatment of ulcerative colitis associated with primary sclerosing cholangitis: ileal pouch-anal anastomosis versus Brooke ileostomy. *Mayo Clin*

Proc. 1996;71(8):748–56.

57. Grucela AL, Steinhagen RM. Restorative proctocolectomy and ileal pouch-anal anastomosis for ulcerative colitis after liver transplant for primary sclerosing cholangitis: case report and review of literature. *Am Surg.* 2005;71(4):362–5.

58. Lian L, Menon KV, Shen B, Remzi F, Kiran RP. Inflammatory bowel disease complicated by primary sclerosing cholangitis and cirrhosis: is restorative proctocolectomy safe? *Dis Colon Rectum.* 2012;55(1):79–84.

59. Szmulowicz U, Hull T. Stoma prolapse. In: Fazio VW, Church JM, Wu JS, editors. *Atlas of intestinal stomas.* New York: Springer; 2012.

60. Wu JS, Fazio VW. Difficult stomas. In: Schrock TR, editor. *Perspectives in colon and rectal surgery.* St. Louis: Quality Medical; 1998.

61. Sanders DL, Kingsnorth AN. The modern management of incisional hernias. *BMJ.* 2012;344:e2843.

62. Kalady MF, Lavery IC. Parastomal hernias. In: Fazio VW, Church JM, Wu JS, editors. *Atlas of intestinal stomas.* New York: Springer; 2012.

63. De Raet J, Delvaux G, Haentjens P, Van Nieuwenhove Y. Waist circumference is an independent risk factor for the development of parastomal hernia after permanent colostomy. *Dis Colon Rectum.* 2008;51(12):1806–9.

64. Pilgrim CH, McIntyre R, Bailey M. Prospective audit of parastomal hernia: prevalence and associated comorbidities. *Dis Colon Rectum.* 2010;53(1):71–6.

65. Albino FP, et al. Does mesh location matter in abdominal wall reconstruction? A systematic review of the literature and a summary of recommendations. *Plast Reconstr Surg.* 2013;132(5):1295–304.

66. Rubin MS, Schoetz Jr DJ, Matthews JB. Parastomal hernia. Is stoma relocation superior to fascial repair? *Arch Surg.* 1994;129(4):413–8. Discussion 418–9.

67. Sugarbaker PH. Prosthetic mesh repair of large hernias at the site of colonic stomas. *Surg Gynecol Obstet.* 1980;150(4):576–8.

68. Ellis CN. Short-term outcomes with the use of bioprosthesis for the management of parastomal hernias. *Dis Colon Rectum.* 2010;53(3):279–83.

69. Souza JM, Dumanian GA. Routine use of bioprosthesis mesh is not necessary: a retrospective review of 100 consecutive cases of intra-abdominal midweight polypropylene mesh for ventral hernia repair. *Surgery.* 2013;153(3):393–9.

70. Primus FE, Harris HW. A critical review of biologic mesh use in ventral hernia repairs under contaminated conditions. *Hernia.* 2013;17(1):21–30.

71. Carbonell AM, Cobb WS. Safety of prosthetic mesh hernia repair in contaminated fields. *Surg Clin North Am.* 2013;93(5):1227–39.

72. Carbonell AM, Criss CN, Cobb WS, Novitsky YW, Rosen MJ. Outcomes of synthetic mesh in contaminated ventral hernia repairs. *J Am Coll Surg.* 2013;217(6):991–8.

73. Hansson BM, et al. Surgical techniques for parastomal hernia repair: a systematic review of the literature. *Ann Surg.* 2012;255(4):685–95.

74. Raigani S, et al. Single-center experience with parastomal hernia repair using retromuscular mesh placement. *J Gastrointest Surg.* 2014;18(9):1673–7.

75. Janes A, Cengiz Y, Israelsson LA. Randomized clinical trial of the use of a prosthetic mesh to prevent parastomal hernia. *Br J Surg.* 2004;91(3):280–2.

76. Janes A, Cengiz Y, Israelsson LA. Preventing parastomal hernia with a prosthetic mesh: a 5-year follow-up of a randomized study. *World J Surg.* 2009;33(1):118–21. Discussion 122–3.
77. Serra-Aracil X, et al. Randomized, controlled, prospective trial of the use of a mesh to prevent parastomal hernia. *Ann Surg.* 2009;249(4):583–7.
78. Lopez-Cano M, et al. Use of a prosthetic mesh to prevent parastomal hernia during laparoscopic abdominoperineal resection: a randomized controlled trial. *Hernia.* 2012;16(6):661–7.
79. Shabbir J, Chaudhary BN, Dawson R. A systematic review on the use of prophylactic mesh during primary stoma formation to prevent parastomal hernia formation. *Colorectal Dis.* 2012;14(8):931–6.
80. Fleshman JW, et al. A prospective, multicenter, randomized, controlled study of non-cross-linked porcine acellular dermal matrix fascial sublay for parastomal reinforcement in patients undergoing surgery for permanent abdominal wall ostomies. *Dis Colon Rectum.* 2014;57(5):623–31.
81. Baker ML, Williams RN, Nightingale JM. Causes and management of a high-output stoma. *Colorectal Dis.* 2011;13(2):191–7.
82. Avery ME, Snyder JD. Oral therapy for acute diarrhea. The underused simple solution. *N Engl J Med.* 1990;323(13):891–4.
83. Nightingale JM, Lennard-Jones JE, Walker ER, Farthing MJ. Oral salt supplements to compensate for jejunostomy losses: comparison of sodium chloride capsules, glucose electrolyte solution, and glucose polymer electrolyte solution. *Gut.* 1992;33(6):759–61.
84. Nightingale JM, Walker ER, Burnham WR, Farthing MJ, Lennard-Jones JE. Octreotide (a somatostatin analogue) improves the quality of life in some patients with a short intestine. *Aliment Pharmacol Ther.* 1989;3(4):367–73.
85. Jeppesen PB. Pharmacologic options for intestinal rehabilitation in patients with short bowel syndrome. *JPEN J Parenter Enteral Nutr.* 2014;38(1 Suppl):45S–52.
86. Geraghty JM, Talbot IC. Diversion colitis: histological features in the colon and rectum after defunctioning colostomy. *Gut.* 1991;32(9):1020–3.
87. Hong SY, Kim do Y, Oh SY, Suh KW. Routine barium enema prior to closure of defunctioning ileostomy is not necessary. *J Korean Surg Soc.* 2012;83(2):88–91.
88. Kalady MF, Mantyh CR, Petrofski J, Ludwig KA. Routine contrast imaging of low pelvic anastomosis prior to closure of defunctioning ileostomy: is it necessary? *J Gastrointest Surg.* 2008;12(7):1227–31.
89. Khair G, et al. Routine use of gastrograffin enema prior to the reversal of a loop ileostomy. *Dig Surg.* 2007;24(5):338–41.
90. Da Silva GM, et al. Is routine pouchogram prior to ileostomy closure in colonic J-pouch really necessary? *Colorectal Dis.* 2004;6(2):117–20.
91. Selvaggi F, Pellino G, Canonico S, Sciaudone G. Is omitting pouchography before ileostomy takedown safe after negative clinical examination in asymptomatic patients with pelvic ileal pouch? An observational study. *Tech Coloproctol.* 2012;16(6):415–20.
92. Perez RO, et al. Loop ileostomy morbidity: timing of closure matters. *Dis Colon Rectum.* 2006;49(10):1539–45.
93. Krand O, Yalti T, Berber I, Tellioglu G. Early vs. delayed closure of temporary covering ileostomy: a prospective study. *Hepatogastroenterology.* 2008;55(81):142–5.
94. Omundsen M, et al. Early ileostomy closure: is there a downside? *ANZ J Surg.* 2012;82(5):352–

4.

95. Worni M, et al. Early closure of ileostomy is associated with less postoperative nausea and vomiting. *Dig Surg*. 2011;28(5-6):417–23.
96. Danielsen AK, et al. Early closure of temporary ileostomy—the EASY trial: protocol for a randomised controlled trial. *BMJ Open*. 2011;1(1):e000162.
97. Phatak UR, et al. Impact of ileostomy-related complications on the multidisciplinary treatment of rectal cancer. *Ann Surg Oncol*. 2014;21(2):507–12.
98. Tulchinsky H, Shacham-Shmueli E, Klausner JM, Inbar M, Geva R. Should a loop ileostomy closure in rectal cancer patients be done during or after adjuvant chemotherapy? *J Surg Oncol*. 2014;109(3):266–9.
99. Fleming FJ, Gillen P. Reversal of Hartmann’s procedure following acute diverticulitis: is timing everything? *Int J Colorectal Dis*. 2009;24(10):1219–25.
100. Keck JO, et al. Reversal of Hartmann’s procedure: effect of timing and technique on ease and safety. *Dis Colon Rectum*. 1994;37(3):243–8.
101. Pearce NW, Scott SD, Karran SJ. Timing and method of reversal of Hartmann’s procedure. *Br J Surg*. 1992;79(8):839–41.
102. Roe AM, Prabhu S, Ali A, Brown C, Brodribb AJ. Reversal of Hartmann’s procedure: timing and operative technique. *Br J Surg*. 1991;78(10):1167–70.
103. Gong J, et al. Stapled vs hand suture closure of loop ileostomy: a meta-analysis. *Colorectal Dis*. 2013;15(10):e561–8.
104. Hull TL, Kobe I, Fazio VW. Comparison of handsewn with stapled loop ileostomy closures. *Dis Colon Rectum*. 1996;39(10):1086–9.
105. Leung TT, MacLean AR, Buie WD, Dixon E. Comparison of stapled versus handsewn loop ileostomy closure: a meta-analysis. *J Gastrointest Surg*. 2008;12(5):939–44.
106. Hasegawa H, Radley S, Morton DG, Keighley MR. Stapled versus sutured closure of loop ileostomy: a randomized controlled trial. *Ann Surg*. 2000;231(2):202–4.
107. Markides GA, Wijetunga IU, Brown SR, Anwar S. Meta-analysis of handsewn versus stapled reversal of loop ileostomy. *ANZ J Surg*. 2015;85(4):217–24.
108. Loffler T, et al. HAnd Suture Versus STAppling for Closure of Loop Ileostomy (HASTA Trial): results of a multicenter randomized trial (DRKS00000040). *Ann Surg*. 2012;256(5):828–35. Discussion 835–6.
109. Camacho-Mauries D, Rodriguez-Diaz JL, Salgado-Nesme N, Gonzalez QH, Vergara-Fernandez O. Randomized clinical trial of intestinal ostomy takedown comparing pursestring wound closure vs conventional closure to eliminate the risk of wound infection. *Dis Colon Rectum*. 2013;56(2):205–11.
110. Reid K, Pockney P, Pollitt T, Draganic B, Smith SR. Randomized clinical trial of short-term outcomes following purse-string versus conventional closure of ileostomy wounds. *Br J Surg*. 2010;97(10):1511–7.
111. Mazeh H, et al. Laparoscopic and open reversal of Hartmann’s procedure—a comparative retrospective analysis. *Surg Endosc*. 2009;23(3):496–502.
112. Haughn C, et al. Complication rates after Hartmann’s reversal: open vs. laparoscopic approach. *Dis Colon Rectum*. 2008; 51(8):1232–6.
113. Guenaga KF, Lustosa SA, Saad SS, Saconato H, Matos D. Ileostomy or colostomy for temporary decompression of colorectal anastomosis. *Cochrane Database Syst Rev*. 2007;

1:CD004647.

114. Gooszen AW, Geelkerken RH, Hermans J, Lagaay MB, Gooszen HG. Quality of life with a temporary stoma: ileostomy vs. colostomy. *Dis Colon Rectum*. 2000;43(5): 650–5.
115. Sakai Y, et al. Temporary transverse colostomy vs loop ileostomy in diversion: a case-matched study. *Arch Surg*. 2001;136(3):338–42.
116. Edwards DP, Leppington-Clarke A, Sexton R, Heald RJ, Moran BJ. Stoma-related complications are more frequent after transverse colostomy than loop ileostomy: a prospective randomized clinical trial. *Br J Surg*. 2001;88(3):360–3.
117. Klink CD, et al. Diversion stoma after colorectal surgery: loop colostomy or ileostomy? *Int J Colorectal Dis*. 2011;26(4): 431–6.
118. Rullier E, et al. Loop ileostomy versus loop colostomy for defunctioning low anastomoses during rectal cancer surgery. *World J Surg*. 2001;25(3):274–7. Discussion 277–8.
119. Colombo R, Naspro R. Ileal conduit as the standard for urinary diversion after radical cystectomy for bladder cancer. *Eur Urol Suppl*. 2010;9(10):736–44.
120. Gakis G, Stenzl A. Ileal neobladder and its variants. *Eur Urol Suppl*. 2010;9(10):745–53.
121. Rowland RG, Mitchell ME, Bihrlé R, Kahnoski RJ, Piser JE. Indiana continent urinary reservoir. *J Urol*. 1987;137(6):1136–9.
122. Harris CF, Cooper CS, Hutcheson JC, Snyder 3rd HM. Appendicovesicostomy: the mitrofanoff procedure—a 15-year perspective. *J Urol*. 2000;163(6):1922–6.
123. Cain MP, Casale AJ, Rink RC. Initial experience using a catheterizable ileovesicostomy (Monti procedure) in children. *Urology*. 1998;52(5):870–3.
124. Ooi BS, Remzi FH, Fazio VW. Turnbull-Blowhole colostomy for toxic ulcerative colitis in pregnancy: report of two cases. *Dis Colon Rectum*. 2003;46(1):111–5.
125. Bhangu A, Nepogodiev D, Futaba K, West Midlands Research Collaborative. Systematic review and meta-analysis of the incidence of incisional hernia at the site of stoma closure. *World J Surg*. 2012;36(5):973–83.
126. Aydin HN, Remzi FH, Tekkis PP, Fazio VW. Hartmann’s reversal is associated with high postoperative adverse events. *Dis Colon Rectum*. 2005;48(11):2117–26.
127. Law WL, Chu KW, Choi HK. Randomized clinical trial comparing loop ileostomy and loop transverse colostomy for faecal diversion following total mesorectal excision. *Br J Surg*. 2002;89(6):704–8.

## 第 56 章

1. Howlader N, Noone AM, Krapcho M, et al. SEER cancer statistics review, 1975-2012. Bethesda, MD: National Cancer Institute; 2013. [http://seer.cancer.gov/csr/1975\\_2012/](http://seer.cancer.gov/csr/1975_2012/), based on November 2014 SEER data submission, posted to the SEER web site, April 2015.
2. Ziv Y, Zbar A, Bar-Shavit Y, et al. Low anterior resection syndrome (LARS): cause and effect and reconstructive considerations. *Tech Coloproctol*. 2012;17:151–62.
3. Bregendahl S, Emmertsen KJ, Lous J, et al. Bowel dysfunction after low anterior resection with and without neoadjuvant therapy for rectal cancer: a population-based cross-sectional study. *Colorectal Dis*. 2013;15:1130–9.
4. Bryant CL, Lunniss PJ, Knowles CH, et al. Anterior resection syndrome. *Lancet Oncol*.



2012;13:e403–8.

5. Juul T, Ahlberg M, Biondo S, et al. Low anterior resection syndrome and quality of life: an international multicenter study. *Dis Colon Rectum*. 2014;57:585–91.
6. Visser WS, teRiele WW, Boerma D, et al. Pelvic floor rehabilitation to improve functional outcome after a low anterior resection: a systematic review. *Ann Coloproctol*. 2014;30:109–14.
7. Chen TY, Emmertsen KJ, Lauberg S. Bowel dysfunction after rectal resection cancer treatment: a study comparing the specialist's versus patient's perspective. *BMJ Open*. 2014;4:e003374.
8. Emmertsen KJ, Bregendahl S, Fassov J. A hyperactive postprandial response in the neorectum—the clue to low anterior resection syndrome after total mesorectal excision surgery? *Colorectal Dis*. 2013;15:e599–606.
9. Kakodkar R, Gupta S, Nundy S. Low anterior resection with total mesorectal excision for rectal cancer: functional assessment and factors affecting outcome. *Colorectal Dis*. 2005;8:650–6.
10. Efthimiadis C, Basdanis G, Zatagias A, et al. Manometric and clinical evaluation of patients after low anterior resection for rectal cancer. *Tech Coloproctol*. 2004;8:S205–7.
11. Ramage L, Qiu S, Kontovounisios C, et al. A systematic review of sacral nerve stimulation for low anterior resection syndrome. *Colorectal Dis*. 2015. doi: 10.1111/codi.12968.
12. Parc Y, Zutshi M, Zalinski S, et al. Preoperative radiotherapy is associated with worse functional results after coloanal anastomosis for rectal cancer. *Dis Colon Rectum*. 2009;52:2004–15.
13. Koch SM, Rietveld MP, Govaert B, et al. Retrograde colonic irrigation for faecal incontinence after low anterior resection. *Int J Colorectal Dis*. 2009;24:1019–22.
14. Dietz D. Chapter 10: Postoperative complications. In: Beck D, Roberts P, Saclarides T, et al., editors. *The ASCRS textbook of colon and rectal surgery*. 2nd ed. New York: Springer; 2011. p. 157–73.
15. Heriot AG, Tekkis PP, Constantinides V, et al. Meta-analysis of colonic reservoirs versus straight coloanal anastomoses after anterior resection. *Br J Surg*. 2006;93:19–32.
16. Hida J, Yasutomi M, Fujimoto K, et al. Functional outcome after low anterior resection with low anastomosis for rectal cancer using the colonic J-pouch. Prospective randomized study for the determination of optimum pouch size. *Dis Colon Rectum*. 1996;39:986–91.
17. Rubin F, Douard R, Wind F. The functional outcomes of coloanal and low colorectal anastomoses with reservoirs after low rectal cancer resections. *Am Surg*. 2014;80:1222–9.
18. Fazio VW, Zutshi M, Remzi FH, et al. A randomized multicenter trial to compare long-term functional outcome, quality of life and complications of surgical procedures for low rectal cancers. *Ann Surg*. 2007;246:481–8.
19. Ho YH, Brown S, Heah SM, et al. Comparison of J-pouch and coloplasty pouch for low rectal cancers: a randomized, controlled trial investigating functional results and comparative anastomotic leak rates. *Ann Surg*. 2002;236:49–55.
20. Siddiqui MR, Sajid MS, Woods WG, et al. A meta-analysis comparing side to end with colonic J-pouch formation after anterior resection for rectal cancer. *Tech Coloproctol*. 2010;14:113–23.
21. Slieker J, Damms F, Mulder I, et al. Systematic review of the technique of colorectal anastomosis. *JAMA Surg*. 2013;148:190–201.
22. Fletcher TF, Bradley WE. Neuroanatomy of the bladder urethra [Review]. *J Urol*. 1978;119:153–60.
23. Havenga K, Maas CP, deRuiter MC, Welvaart K, Trimbos JB. Avoiding long-term disturbance to bladder and sexual function in pelvic surgery, particularly with rectal cancer. *Semin Surg Oncol*.

2000;18:235–43.

24. Levin RJ. The physiology of sexual function in women [Review]. *Clin Obstet Gynaecol*. 1980;7:213–52.
25. Wein AJ, Van Arsdalen K, Hanno PM, Levin RM. Anatomy of male sexual function. In: Jonas U, Thon WF, Stief CG, et al., editors. *Erectile dysfunction*. New York: Springer; 1991.
26. Moszkowicz D, Alsaid B, Bessede T, et al. Where does pelvic nerve injury occur during rectal surgery for cancer? *Colorectal Dis*. 2011;13:1326–34.
27. Hendren S, O'Connor B, Liu M, et al. Prevalence of male and female sexual dysfunction is high following surgery for rectal cancer. *Ann Surg*. 2005;242:212–23.
28. Lange M, Marijnen C, Maas C, et al. Risk factors for sexual dysfunction after rectal cancer treatment. *Eur J Cancer*. 2009;45:1578–88.
29. Donovan KA, Thompson LM, Hoffe SE. Sexual function in colorectal cancer survivors. *Cancer Control*. 2010;17(1):44–51.
30. Liang JT, Lai HS, Lee PH. Laparoscopic pelvic autonomic nerve-preserving surgery for patients with lower rectal cancer after chemoradiation therapy. *Ann Surg Oncol*. 2007;14(4):1285–7.
31. Arafa M, El Tabie O. Medical treatment of retrograde ejaculation in diabetic patients: a hope for spontaneous pregnancy. *J Sex Med*. 2008;5(1):194–8.
32. Liu CH, Chen CH, Lee JC. Rehabilitation exercise on the quality of life in anal sphincter-preserving surgery. *Hepatogastroenterology*. 2011;58:1461–5.
33. Hanson PA. Perianal skin care for persons with an ileoanal reservoir. *Ostomy Wound Manage*. 1990;27:16–20.
34. Verma SK, Baltarowich OH, Lev-Toaff AS, Mitchell DG, Verma M, Batzer F. Hematocolpos secondary to acquired vaginal scarring after radiation therapy for colorectal carcinoma. *J Ultrasound Med*. 2009;28(7):949–53.
35. Andersen PH, Buch AP, Saeed I, Lee PC, Davis JA, Maibach HI. Faecal enzymes: en vivo human skin irritation. *Contact Dermatitis*. 1994;30(3):152–8.

## 第 57 章

1. Nygaard I, Barber MD, Burgio KL, et al. Prevalence of symptomatic pelvic floor disorders in US women. *JAMA*. 2008;300:1311–6.
2. Brown HW, Wexner SD, Segall MM, Brezoczky KL, Lukacz ES. Accidental bowel leakage in the mature women's health study: prevalence and predictors. *Int J Clin Pract*. 2012;66:1101–8.
3. Pare P, Ferrazzi S, Thompson WG, et al. An epidemiological survey of constipation in Canada: definitions, rates, demographics, and predictors of health care seeking. *Am J Gastroenterol*. 2001;96:3130–7.
4. Stewart WF, Liberman JN, Sandler RS, et al. Epidemiology of constipation (EPOC) study in the United States: relation of clinical subtypes to sociodemographic features. *Am J Gastroenterol*. 1999;94:3530–40.
5. Everhart JE, Go VL, Johannes RS, Fitzsimmons SC, Roth HP, White LR. A longitudinal survey of self-reported bowel habits in the United States. *Dig Dis Sci*. 1989;34:1153–62.
6. Sung VW, Washington B, Raker CA. Costs of ambulatory care related to female pelvic floor disorders in the United States. *Am J Obstet Gynecol*. 2010;202:483.e1–4.

7. Maeda Y, Parés D, Norton C, Vaizey CJ, Kamm MA. Does the St. Mark's incontinence score reflect patients' perceptions? A review of 390 patients. *Dis Colon Rectum*. 2008;51:436–42.
8. Jorge JM, Wexner SD. Etiology and management of fecal incontinence. *Dis Colon Rectum*. 1993;36:77–97.
9. Vaizey CJ, Carapeti E, Cahill JA, Kamm MA. Prospective comparison of faecal incontinence grading systems. *Gut*. 1999;44:77–80.
10. Maeda Y, Pares D, Norton C. Comparison between patients' subjective perception of bowel control and Vaizey's score in fecal incontinence: is there a correlation? Review of 423 patients. *Dis Colon Rectum*. 2007;50:787–8.
11. Rockwood TH, Church JM, Fleshman JW, et al. Patient and surgeon ranking of the severity of symptoms associated with fecal incontinence: the fecal incontinence severity index. *Dis Colon Rectum*. 1999;42:1525–32.
12. Rockwood TH, Church JM, Fleshman JW, et al. Fecal Incontinence Quality of Life Scale: quality of life instrument for patients with fecal incontinence. *Dis Colon Rectum*. 2000;43:9–16. discussion 16–7.
13. Bordeianou L, Rockwood T, Baxter N, Lowry A, Mellgren A, Parker S. Does incontinence severity correlate with quality of life? Prospective analysis of 502 consecutive patients. *Colorectal Dis*. 2008;10:273–9.
14. Agachan F, Chen T, Pfeifer J, Reissman P, Wexner SD. A constipation scoring system to simplify evaluation and management of constipated patients. *Dis Colon Rectum*. 1996;39:681–5.
15. Frank L, Kleinman L, Farup C, Taylor L, Miner Jr P. Psychometric validation of a constipation symptom assessment questionnaire. *Scand J Gastroenterol*. 1999;34:870–7.
16. Marquis P, De La Loge C, Dubois D, Mcdermott A, Chassany O. Development and validation of the Patient Assessment of Constipation Quality of Life questionnaire. *Scand J Gastroenterol*. 2005;40:540–1.
17. Law PJ, Kamm MA, Bartram CI. A comparison between electromyography and anal endosonography in mapping external anal sphincter defects. *Dis Colon Rectum*. 1990;33:370–3.
18. Law PJ, Kamm MA, Bartram CI. Anal endosonography in the investigation of faecal incontinence. *Br J Surg*. 1991;78:312–4.
19. Burnett SJ, Speakman CT, Kamm MA, Bartram CI. Confirmation of endosonographic detection of external anal sphincter defects by simultaneous electromyographic mapping. *Br J Surg*. 1991;78:448–50.
20. Dobben AC, Terra MP, Deutekom M, Slors JFM, Janssen LWM, Bossuyt PMM, Stoker J. The role of endoluminal imaging in clinical outcome of overlapping anterior anal sphincter repair in patients with fecal incontinence. *AJR Am J Roentgenol*. 2007;189:W70–7.
21. Christiansen J, Lorentzen M. Implantation of artificial sphincter for anal incontinence. *Lancet*. 1987;2:244–5.
22. Parker SC, Spencer MP, Madoff RD, Jensen LL, Wong WD, Rothenberger DA. Artificial bowel sphincter: long-term experience at a single institution. *Dis Colon Rectum*. 2003;46:722–9.
23. Matzel KE, Kamm MA, Stosser M, et al. Sacral spinal nerve stimulation for faecal incontinence: multicentre study. *Lancet*. 2004;363:1270–6.
24. Matzel KE, Stadelmaier U, Hohenfellner M, Gall FP. Electrical stimulation of sacral spinal nerves for treatment of faecal incontinence.[see comment]. *Lancet*. 1995;346:1124–7.
25. Melenhorst J, Koch SM, Uludag O, van Gemert WG, Baeten CG. Sacral neuromodulation in

patients with faecal incontinence: results of the first 100 permanent implantations. *Colorectal Dis.* 2007;9:725–30.

26. Maeda Y, Vaizey CJ, Kamm MA. Pilot study of two new injectable bulking agents for the treatment of faecal incontinence. *Colorectal Dis.* 2008;10:268–72.

27. Tjandra JJ, Lim JF, Hiscock R, Rajendra P. Injectable silicone biomaterial for fecal incontinence caused by internal anal sphincter dysfunction is effective. *Dis Colon Rectum.* 2004;47:2138–46.

28. Vaizey CJ, Kamm MA. Injectable bulking agents for treating faecal incontinence. *Br J Surg.* 2005;92:521–7.

29. Starck M, Bohe M, Valentin L. The extent of endosonographic anal sphincter defects after primary repair of obstetric sphincter tears increases over time and is related to anal incontinence. *Ultrasound Obstet Gynecol.* 2006;27:188–97.

30. Savoye-Collet C, Savoye G, Koning E, et al. Anal endosonography after sphincter repair: specific patterns related to clinical outcome. *Abdom Imaging.* 1999;24:569–73.

31. De la Portilla F, Vega J, Rada R, et al. Evaluation by three-dimensional anal endosonography of injectable silicone biomaterial (PTQ) implants to treat fecal incontinence: long-term localization and relation with the deterioration of the continence. *Tech Coloproctol.* 2009;13:195–9.

32. Tsang CMR, Wong W, Rothenberger D, Finne C, Singer D, Lowry A. Anal sphincter integrity and function influences outcome in rectovaginal fistula repair. *Dis Colon Rectum.* 1998;41:1141–6.

33. Yee LBE, Read T, Kodner I, Fleshman J. Use of endoanal ultrasound in patients with rectovaginal fistulas. *Dis Colon Rectum.* 1999;42:1057–64.

34. Lindsey I, Humphreys MM, George B, Mortensen N. . The role of anal ultrasound in the management of anal fistulas. *Colorectal Dis.* 2002;4:118–22.

35. Deen KLWJ, Hutchinson R, et al. Fistulas in ano: endoanal ultrasonographic assessment assists decision making for surgery. *Gut.* 1994;35:391.

36. Soew-Choen FBS, Bartram CL, Nicholls RJ. Comparison between anal endosonography and digital examination in the evaluation of anal fistulas. *Br J Surg.* 1991;78:445.

37. Ratto CGE, Parello A, et al. Endoanal ultrasound-guided surgery for anal fistula. *Endoscopy.* 2005;37:722.

38. Cho D. Endosonographic criteria for an internal opening of fistula-in-ano. *Dis Colon Rectum.* 1999;42:515–8.

39. Zbar AHN, Bucholtz V, Zmora O, Beer-Gabel M, Carter D. Are there specific endosonographic features in Crohn's patients with perianal fistulae? *J Crohns Colitis.* 2013;7:490–6.

40. Blom JNP, Gunnarson U, Strigard K. Endoanal ultrasonography may distinguish Crohn's anal fistulae from cryptoglandular fistulae in patients with Crohn's disease: a cross-sectional study. *Tech Coloproctol.* 2011;15:327–30.

41. Schwartz DA, White CM, Wise P, Herline A. Use of endoscopic ultrasound to guide combination medical and surgical therapy for patients with Crohn's perianal fistulas. *Inflamm Bowel Dis.* 2005;11:727–32.

42. Zetterstrom JP, Mellgren A, Madoff RD, Kim DG, Wong WD. Perineal body measurement improves evaluation of anterior sphincter lesions during endoanal ultrasonography. *Dis Colon Rectum.* 1998;41:705–13.

43. Emblem R, Dhaenens G, Stien R, Morkrid L, Aasen AO, Bergan A. The importance of anal endosonography in the evaluation of idiopathic fecal incontinence. *Dis Colon Rectum.* 1994;37:42–8.

44. Sentovich SM, Wong WD, Blatchford G. Accuracy and reliability of transanal ultrasound for anterior anal sphincter injury. *Dis Colon Rectum*. 1998;41:1000–4.
45. Cazemier M, Terra MP, Stoker J, et al. Atrophy and defects detection of the external anal sphincter: comparison between three-dimensional anal endosonography and endoanal magnetic resonance imaging. *Dis Colon Rectum*. 2006;49:20–7.
46. Christensen AF, Nyhuus B, Nielsen MB, Christensen H. Three-dimensional anal endosonography may improve diagnostic confidence of detecting damage to the anal sphincter complex. *Br J Radiol*. 2005;78:308–11.
47. Santoro GA, Fortling B. The advantages of volume rendering in three-dimensional endosonography of the anorectum. *Dis Colon Rectum*. 2007;50:359–68.
48. Williams AB, Bartram CI, Halligan S, et al. Alteration of anal sphincter morphology following vaginal delivery revealed by multiplanar anal endosonography. *BJOG*. 2002;109:942–6.
49. West RL, Felt-Bersma RJ, Hansen BE, Schouten WR, Kuipers EJ. Volume measurements of the anal sphincter complex in healthy controls and fecal-incontinent patients with a three-dimensional reconstruction of endoanal ultrasonography images. *Dis Colon Rectum*. 2005;48:540–8.
50. Santoro GA, Wiczorek AP, Dietz HP, Mellgren A, Sultan AH, Shobeiri SA, Stankiewicz A, Bartram C. State of the art: an integrated approach to pelvic floor ultrasonography. *Ultrasound Obstet Gynecol*. 2011;37:381–96.
51. Santoro GA, Wiczorek AP, Stankiewicz A, Wozniak MM, Bogusiewicz M, Rechbereger T. High-resolution three-dimensional endovaginal ultrasonography in the assessment of pelvic floor anatomy: a preliminary study. *Int Urogynecol J Pelvic Floor Dysfunct*. 2009;20:1213–22.
52. DeLancey JO, Morgan DM, Fenner DE, Kearney R, Guire K, Miller JM, Hussain H, Umek W, Hsu Y, Ashton-Miller JA. Comparison of levator ani muscle defects and function in women with and without pelvic organ prolapse. *Obstet Gynecol*. 2007;109:295–302.
53. Dietz HP, Shek C. Levator avulsion and grading of pelvic floor muscle strength. *Int Urogynecol J Pelvic Floor Dysfunct*. 2008;19:633–6.
54. Beer-Gabel M, Teshler M, Schechtman E, Zbar A. Dynamic transperineal ultrasound vs. defecography in patients with evacuatory difficulty: a pilot study. *Int J Colorectal Dis*. 2004;19:60–7.
55. Perniola G, Shek C, Chong CC, et al. Defecation proctography and translabial ultrasound in the investigation of defecatory disorders. *Ultrasound Obstet Gynecol*. 2008;31:567–71.
56. Bruscianno L, Limongelli P, Pescatori M, Napolitano V, Gagliardi G, Maffettone V, Rossetti G, del Genio G, Russo G, Pizza F, del Genio A. Ultrasonographic patterns in patients with obstructed defaecation. *Int J Colorectal Dis*. 2007;22:969–77.
57. Murad-Regadas SM, Regadas FS, Rodrigues LV, et al. A novel procedure to assess anismus using three-dimensional dynamic anal ultrasonography. *Colorectal Dis*. 2007;9:159–65.
58. Murad-Regadas SM, Regadas FS, Rodrigues LV, et al. A novel three-dimensional dynamic anorectal ultrasonography technique (echodefecography) to assess obstructed defecation, a comparison with defecography. *Surg Endosc*. 2008;22:974–9.
59. Regadas FS, Haas EM, Abbas M, Jorge JM, Habr-Gama A, Sands D, Wexner S, Melo-Amaral I, Sardiñas C, Lima D, Sagae E, Murad-Regadas SM. Prospective multicenter trial comparing echodefecography with defecography in the assessment of anorectal dysfunction in patients with obstructed defecation. *Dis Colon Rectum*. 2011;54:686–92.
60. Vitton V, Vignally P, Barthet M, Cohen V, Durieux O, Bouvier M, Grimaud JC. Dynamic anal

endosonography and MRI defecography in diagnosis of pelvic floor disorders: comparison with conventional defecography. *Dis Colon Rectum*. 2011;54:1398–404.

61. Hussain SM, Stoker J, Lameris JS. Anal sphincter complex: endoanal MR imaging of normal anatomy. *Radiology*. 1995;197:671–7.

62. DeSouza NM, Puni R, Kmiot WA, Bartram CI, Hall AS, Bydder GM. MRI of the anal sphincter. *J Comput Assist Tomogr*. 1995;19:745–51.

63. Williams AB, Malouf AJ, Bartram CI, Halligan S, Kamm MA, Kmiot WA. Assessment of external anal sphincter morphology in idiopathic fecal incontinence with endocoil magnetic resonance imaging. *Dig Dis Sci*. 2001;46:1466–71.

64. Malouf AJ, Williams AB, Halligan S, Bartram CI, Dhillon S, Kamm MA. Prospective assessment of accuracy of endoanal MR imaging and endosonography in patients with fecal incontinence. *Am J Roentgenol*. 2000;175:741–5.

65. Williams AB, Bartram CI, Halligan S, Marshall MM, Nicholls RJ, Kmiot WA. Endosonographic anatomy of the normal anal canal compared with endocoil magnetic resonance imaging. *Dis Colon Rectum*. 2002;45:176–83.

66. Briel JW, Stoker J, Rociu E, Lameris JS, Hop WC, Schouten WR. External anal sphincter atrophy on endoanal magnetic resonance imaging adversely affects continence after sphincteroplasty. *Br J Surg*. 1999;86:1322–7.

67. West RL, Dwarkasing S, Briel JW, Hansen BE, Hussain SM, Schouten WR, Kuipers EJ. Can three-dimensional endoanal ultrasonography detect external anal sphincter atrophy? A comparison with endoanal magnetic resonance imaging. *Int J Colorectal Dis*. 2005;20:328–33.

68. Gowers WR. The automatic action of the sphincter ani. *Proc R Soc Lond B Biol Sci*. 1877;26:77–84.

69. Duthie HL, Watts JM. Contribution of the external anal sphincter to the pressure zone in the anal canal. *Gut*. 1965;6:64–8.

70. Olson CH. Diagnostic testing for fecal incontinence. *Clin Colon Rectal Surg*. 2014;27:85–90.

71. Liu TT, Chen CL, Yi CH. Anorectal manometry in patients with chronic constipation. *Hepatogastroenterology*. 2008;55:426–9.

72. Xu C, Zhao R, Conklin JL, et al. Three-dimensional high-resolution anorectal manometry in the diagnosis of paradoxical puborectalis syndrome compared with healthy adults: a retrospective study in 79 cases. *Eur J Gastroenterol Hepatol*. 2014;26:621–9.

73. Eckardt VF, Dodt O, Kanzler G, et al. Anorectal function and morphology in patients with sporadic proctalgia fugax. *Dis Colon Rectum*. 1996;39:755–62.

74. Opazo A, Aguirre E, Saldana E, et al. Patterns of impaired internal anal sphincter activity in patients with anal fissure. *Colorectal Dis*. 2013;15:492–9.

75. Tang YF, Chen JG, An HL, et al. High-resolution anorectal manometry in newborns: normative values and diagnostic utility in Hirschsprung disease. *Neurogastroenterol Motil*. 2014;26:1565–72.

76. Lee HR, Lim SB, Park JY. Anorectal manometric parameters are influenced by gender and age in subjects with normal bowel function. *Int J Colorectal Dis*. 2014;29:1393–9.

77. Rao SS, Azpiroz F, Diamant N, et al. Minimum standards of anorectal manometry. *Neurogastroenterol Motil*. 2002;14:553–9.

78. Sun WM, Rao SS. Manometric assessment of anorectal function. *Gastroenterol Clin North Am*. 2001;30:15–32.

79. Clouse RE, Staiano A, et al. Application of topographical methods to clinical esophageal

- manometry. *Am J Gastroenterol*. 2000;95:2720–30.
80. Lee YY, Erdogan A, Rao SSC. High resolution and high definition anorectal manometry and pressure topography: diagnostic advance or a new kid on the block? *Curr Gastroenterol Rep*. 2013;15(12):360.
81. Kang HRLJ, Lee JS, et al. Comparison of high-resolution anorectal manometry with water-perfused anorectal manometry. *J Neurogastroenterol Motil*. 2015;21:126–32.
82. Vitton V, Ben Hadj Amor W, Baumstarck K, et al. Water-perfused manometry vs three-dimensional high-resolution manometry: a comparative study on a large patient population with anorectal disorders. *Colorectal Dis*. 2013;15:726–31.
83. Eckardt VF, Schmitt T, Bernhard G. Anal ultra slow waves: a smooth muscle phenomenon associated with dyschezia. *Dig Dis Sci*. 1997;42:2439–45.
84. Hermann D. *Elements of human physiology*. London: Smith, Elder; 1875.
85. Lestar B, Penninckx F, Kerremans R. The composition of anal basal pressure. An in vivo and in vitro study in man. *Int J Colorectal Dis*. 1989;4:118–22.
86. Lestar B, Penninckx F, Rigauts H, et al. The internal anal sphincter can not close the anal canal completely. *Int J Colorectal Dis*. 1992;7:159–61.
87. Jorge JM, Wexner SD. Anorectal manometry: techniques and clinical applications. *South Med J*. 1993;86:924–31.
88. Gundling F, Seidl H, Scalerico N, et al. Influence of gender and age on anorectal function: normal values from anorectal manometry in a large Caucasian population. *Digestion*. 2010;81:207–13.
89. Poos RJ, Bittner R, Frank J, et al. Results of anorectal manometry for the determination of age- and sex-dependent pressure differences. *Z Gastroenterol*. 1984;22:592–7.
90. Scott SM, Gladman MA. Manometric, sensorimotor, and neurophysiologic evaluation of anorectal function. *Gastroenterol Clin North Am*. 2008;37:511–38.
91. Telford KJ, Ali AS, Lymer K, et al. Fatigability of the external anal sphincter in anal incontinence. *Dis Colon Rectum*. 2004;47:746–52.
92. Nockolds CL, Hosker GL, Kiff ES. Fatigue rate of the external anal sphincter. *Colorectal Dis*. 2012;14:1095–100.
93. Chan CL, Ponsford S, Swash M. The anal reflex elicited by cough and sniff: validation of a neglected clinical sign. *J Neurol Neurosurg Psychiatry*. 2004;75:1449–51.
94. Parkman HP, McCallum RW, Rao SSC. *GI motility testing: a laboratory and office handbook*. Thorofare, NJ: SLACK; 2011.
95. Vorderholzer WA, Neuhaus DA, Klauser AG, et al. Paradoxical sphincter contraction is rarely indicative of anismus. *Gut*. 1997;41:258–62.
96. Duthie GS, Bartolo DC. Anismus: the cause of constipation? Results of investigation and treatment. *World J Surg*. 1992;16:831–5.
97. Remes-Troche JM, De-Ocampo S, Valestin BS, et al. Rectoanal reflexes and sensorimotor response in rectal hyposensitivity. *Dis Colon Rectum*. 2010;53:1047–54.
98. Miller R, Bartolo DC, Cervero F, et al. Anorectal sampling: a comparison of normal and incontinent patients. *Br J Surg*. 1988;75:44–7.
99. Azpiroz F, Enck P, Whitehead W. Anorectal functional testing: review of collective experience. *Am J Gastroenterol*. 2002;97:232–40.
100. Sangwan YP, Collier JA, Schoetz DJ, et al. Spectrum of abnormal rectoanal reflex patterns in

- patients with fecal incontinence. *Dis Colon Rectum*. 1996;39:59–65.
101. Kaur G, Gardiner A, Duthie GS. Rectoanal reflex parameters in incontinence and constipation. *Dis Colon Rectum*. 2002;45:928–33.
  102. Rogers J. Testing for and the role of anal and rectal sensation. *Baillieres Clin Gastroenterol*. 1992;6:179–91.
  103. Minguez M, Herreros B, Sanchiz V, et al. Predictive value of the balloon expulsion test for excluding the diagnosis of pelvic floor dyssynergia in constipation. *Gastroenterology*. 2004;126:57–62.
  104. Lee BE, Kim GH. How perform and interpret balloon expulsion test. *J Neurogastroenterol Motil*. 2014;20:407–9.
  105. Beck A. Electromyographische untersuchungen am sphinkter ani. *Arch Physiol*. 1930;224:278–92.
  106. Enck P, von Giesen H, Schafer A, et al. Comparison of anal sonography with conventional needle electromyography in the evaluation of anal sphincter defects. *Am J Gastroenterol*. 1996;91:2539–43.
  107. Podnar S, Zalewska E, Hausmanowa-Petrusewicz I. Evaluation of the complexity of motor unit potentials in anal sphincter electromyography. *Clin Neurophysiol*. 2005;116:948–56.
  108. Podnar S. Electrodiagnosis of the anorectum: a review of techniques and clinical applications. *Tech Coloproctol*. 2003;7:71–6.
  109. Lefaucher JP. Neurophysiologic testing in anorectal disorders. *Muscle Nerve*. 2006;33:324–33.
  110. Pfeifer J, Teoh TA, Salanga VD, Agachan F, Wexner SD. Comparative study between intra-anal sponge and needle electrode for electromyographic evaluation of constipated patients. *Dis Colon Rectum*. 1998;41:1153–7.
  111. Axelson HW, Edebol Eeg-Olofsson K. Simplified evaluation of the paradoxical puborectalis contraction with surface electrodes. *Dis Colon Rectum*. 2010;53:928–31.
  112. Kiff ES, Swash M. Slowed conduction in the pudendal nerves in idiopathic (neurogenic) faecal incontinence. *Br J Surg*. 1984;71:614–6.
  113. Kiff ES, Swash M. Normal proximal and delayed distal conduction in the pudendal nerves of patients with idiopathic (neurogenic) faecal incontinence. *J Neurol Neurosurg Psychiatry*. 1984;47:820–3.
  114. Rogers J, Henry MM, Miesewicz JJ. Disposable pudendal nerve stimulator: evaluation of the standard instrument and new device. *Gut*. 1988;29:1131–3.
  115. Tetzschner T, Sørensen M, Rasmussen OO, et al. Reliability of pudendal nerve terminal motor latency. *Int J Colorectal Dis*. 1997;12:280–4.
  116. Wexner SD, Marchetti F, Salanga VD, et al. Neurophysiologic assessment of the anal sphincters. *Dis Colon Rectum*. 1991;34:606–12.
  117. Yip B, Barrett RC, Collier JA, et al. Pudendal nerve terminal motor latency testing: assessing the educational learning curve: can we teach our own? *Dis Colon Rectum*. 2002;45:184–7.
  118. Ricciardi R, Mellgren AF, Madoff RD, et al. The utility of pudendal nerve terminal motor latencies in idiopathic incontinence. *Dis Colon Rectum*. 2006;49:852–7.
  119. Loganathan A, Schlothe AC, Hakendorf P, et al. Prolonged pudendal nerve terminal motor latency is associated with decreased resting and squeeze pressures in the intact anal sphincter. *Colorectal Dis*. 2013;15:1410–5.
  120. Hinton JM, Lennard-Jones JE, Young AC. A new method for studying gut transit times using



radiopaque markers. *Gut*. 1969;10:842–7.

121. Arhan P, Devroede G, Jehannu B, et al. Segmental colonic transit time. *Dis Colon Rectum*. 1981;24:625–9.

122. Metcalf AM, Phillips SF, Zinsmeister AR, et al. Simplified assessment of segmental colonic transit. *Gastroenterology*. 1987;92:40–7.

123. Sadik R, Abrahamsson H, Stotzer PO. Gender differences in gut transit shown with a newly developed radiological procedure. *Scand J Gastroenterol*. 2003;38:36–42.

124. Szarka LA, Sweetser S. Breath testing for gastric emptying. In: *GI motility testing*. NJ: SLACK; 2011. p. 131–2.

125. D'Angelo G, Di Rienzo TA, Scaldaferri F, et al. Tricks for interpreting and making a good report on hydrogen and <sup>13</sup>C breath tests. *Eur Rev Med Pharmacol Sci*. 2013;17:90–8.

126. Sciarretta G, Furno A, Mazzoni M, et al. Lactulose hydrogen breath test in orocecal transit assessment. Critical evaluation by means of scintigraphic method. *Dig Dis Sci*. 1994;39:1505–10.

127. Miller MA, Parkman HP, Urbain JL, et al. Comparison of scintigraphy and lactulose breath hydrogen test for assessment of orocecal transit: lactulose accelerates small bowel transit. *Dig Dis Sci*. 1997;42:10–8.

128. Jones T, Clark JC. Measurement of gastric emptying using the scintillation camera and <sup>129</sup>Cs. *Br J Radiol*. 1970;43:537–41.

129. Tougas G, Eaker EY, Abell TL, et al. Assessment of gastric emptying using a low fat meal: Establishment of international control values. *Am J Gastroenterol*. 2000;95:1456–62.

130. Antoniou AJ, Raja S, El-Khouli R, et al. Comprehensive radionuclide esophagogastrintestinal transit study: methodology, reference values, and initial clinical experience. *J Nucl Med*. 2015;56:721–7.

131. Rao SS, Camilleri M, Hasler WL, et al. Evaluation of gastrointestinal transit in clinical practice: position paper of the American and European Neurogastroenterology and Motility Societies. *Neurogastroenterol Motil*. 2011;23:8–23.

132. Lundin E, Graf W, Garske U, Nilsson S, Maripuu E, Karlbom U. Segmental colonic transit studies: comparison of a radiological and a scintigraphic method. *Colorectal Dis*. 2007;9:344–51.

133. Zarate N, Mohammed SD, O'Shaughnessy E, et al. Accurate localization of a fall in pH within the ileocecal region: validation using a dual-scintigraphic technique. *Am J Physiol Gastrointest Liver Physiol*. 2010;299:1276–86.

134. Saad RJ, Hasler WL. A technical review and clinical assessment of the wireless motility capsule. *Gastroenterol Hepatol*. 2011;7:795–804.

135. Lee YY, Erdogan A, Rao SS. How to assess regional and whole gut transit time with wireless motility capsule. *J Neurogastroenterol Motil*. 2014;20:265–70.

136. Lim M, Sagar PM, Gonsalves S, Thekkinkattil D, Landon C. Surgical management of pelvic organ prolapse in females: functional outcome of mesh sacrocolpopexy and rectopexy as a combined procedure. *Dis Colon Rectum*. 2007;50:1412–21.

137. Watadani Y, Vogler SA, Warshaw JS, et al. Sacrocolpopexy with rectopexy for pelvic floor prolapse improves bowel function and quality of life. *Dis Colon Rectum*. 2013;56:1415–22.

138. Collinson R, Wijffels N, Cunningham C, Lindsey I. Laparoscopic ventral rectopexy for internal rectal prolapse: short-term functional results. *Colorectal Dis*. 2010;12:97–104.

139. Prapasrivokakul S, Gosselink MP, Gorissen K, Fourie S, Hompes R, Jones O, Cunningham C, Lindsey I. Sacral neuromodulation for faecal incontinence: is the outcome compromised in patients

- with high-grade internal rectal prolapse? *Int J Colorectal Dis.* 2015;30:229–34.
140. Ekberg O, Nylander G, Fork F. Defecography. *Radiology.* 1985;155:45–8.
  141. Lunniss PJ, Gladman MA, Benninga M, Rao S. Pathophysiology of evacuation disorders. *Neurogastroenterol Motil.* 2009;21:31–40.
  142. Kelvin FM, Maglinte DD, Benson T, Brubaker L, Smith C. Dynamic cystoproctography: a technique for assessing disorders of the pelvic floor in women. *Am J Roentgenol.* 1994;163:368–70.
  143. Bremmer S, Mellgren A, Holmstrom B, Uden R. Peritoneocele and enterocele. Formation and transformation during rectal evacuation as studied by means of defaeco-peritoneography. *Acta Radiol.* 1998;39:167–75.
  144. Bremmer S, Mellgren A, Holmstrom B, Lopez A, Uden R. Peritoneocele: visualization with defecography and peritoneography performed simultaneously. *Radiology.* 1997;202:373–7.
  145. Chan CL, Scott SM, Knowles CH, Lunniss PJ. Exaggerated rectal adaptation – another cause of outlet obstruction. *Colorectal Dis.* 2001;3:141–2.
  146. Palit S, Bhan C, Lunniss P, Boyle D, Gladman M, Knowles C, Scott S. Evacuation proctography: a reappraisal of normal variability. *Colorectal Dis.* 2014;16:538–46.
  147. Goei R, Kemerink G. Radiation dose in defecography. *Radiology.* 1990;176:137–9.
  148. Healy JC, Halligan S, Reznick RH, et al. Dynamic MR imaging compared with evacuation proctography when evaluating anorectal configuration and pelvic floor movement. *AJR Am J Roentgenol.* 1997;169:775–9.
  149. Karasick S, Karasick D, Karasick SR. Functional disorders of the anus and rectum: findings on defecography. *AJR Am J Roentgenol.* 1993;160:777–82.
  150. Halligan S, Bartram CI, Park H, Kamm M. Proctographic features of anismus. *Radiology.* 1995;197:679–82.
  151. Ferrante SL, Perry RE, Schreiman J, Cheng S, Frick M. The reproducibility of measuring the anorectal angle in defecography. *Dis Colon Rectum.* 1991;34:51–5.
  152. Penninckx F, Debruyne C, Lestar B, Kerremans R. Observer variation in the radiological measurement of the anorectal angle. *Int J Colorectal Dis.* 1990;5:94–7.
  153. Kelvin FM, Maglinte DD, Benson JT. Evacuation proctography (defecography): an aid to the investigation of pelvic floor disorders. *Obstet Gynecol.* 1994;83:307–14.
  154. Bartolo DCC, Bartram CI, Eckberg O, Fork FT, Kodner I, Kuijpers JH, et al. Proctography symposium. *Int J Colorectal Dis.* 1988;3:67–89.
  155. Shorvon PJ, McHugh S, Diamant NE, Somers S. Defecography in normal volunteers: results and implications. *Gut.* 1989;30:1737–49.
  156. Jones H, Swift RI, Blake H. A prospective audit of the usefulness of evacuating proctography. *Ann R Coll Surg Engl.* 1998;80:40–5.
  157. Halligan S, Bartram C, Hall C, Wingate J. Enterocele revealed by simultaneous evacuation proctography and peritoneography: does “defecation block” exist? *Am J Roentgenol.* 1996;167:461–6.
  158. Oettle GJ, Roe AM, Bartolo DC, Mortensen NJ. What is the best way of measuring perineal descent? A comparison of radiographic and clinical methods. *Br J Surg.* 1985;72:999–1001.
  159. Choi JS, Wexner SD, Nam YS, et al. Intraobserver and interobserver measurements of the anorectal angle and perineal descent in defecography. *Dis Colon Rectum.* 2000;43:1121–6.
  160. Boulay C, Prudhomme M, Prat-Pradal D, Pouderoux P, Duval-Beaupere G, Pelissier J. Perineal

descent predicted by a pelvic bone factor: the pelvic incidence angle. *Dis Colon Rectum*. 2009;52:119–26.

161. Alves-Ferreira PC, Gurland B, Zutshi M, Hull T. Perineal descent does not imply a more severe clinical disorder. *Colorectal Dis*. 2012;14:1372–9.

162. Flusberg M, Sahni VA, Erturk SM, Morteale KJ. Dynamic MR defecography: assessment of the usefulness of the defecation phase. *AJR Am J Roentgenol*. 2011;196:W394–9.

163. Hetzer FH, Andreisek G, Tsagari C, Sahrbacher U, Weishaupt D. MR defecography in patients with fecal incontinence: imaging findings and their effect on surgical management. *Radiology*. 2006;240:449–57.

164. Law YM, Fielding JR. MRI of pelvic floor dysfunction: review. *AJR Am J Roentgenol*. 2008;191:S45–53.

165. Woodfield CA, Hampton BS, Sung V, Brody JM. Magnetic resonance imaging of pelvic organ prolapse: comparing pubococcygeal and midpubic lines with clinical staging. *Int Urogynecol J Pelvic Floor Dysfunct*. 2009;20:695–701.

166. Kelvin FM, Maglinte DD, Hale D, Benson JT. Female pelvic organ prolapse: a comparison of triphasic dynamic MR imaging and triphasic fluoroscopic cystocolpoproctography. *AJR Am J Roentgenol*. 2000;174:81–8.

167. Maglinte DD, Hale DS, Sandrasegaran K. Comparison between dynamic cystocolpoproctography and dynamic pelvic floor MRI: pros and cons: Which is the “functional” examination for anorectal and pelvic floor dysfunction? *Abdom Imaging*. 2013;38:952–73.

## 第 58 章

1. Higgins PD, Johanson JF. Epidemiology of constipation in North America: a systematic review. *Am J Gastroenterol*. 2004;99(4):750–9.

2. Sonnenberg A, Koch TR. Physician visits in the United States for constipation: 1958 to 1986. *Dig Dis Sci*. 1989;34(4):606–11.

3. Ribas Y, et al. Prevalence and pathophysiology of functional constipation among women in Catalonia, Spain. *Dis Colon Rectum*. 2011;54(12):1560–9.

4. Knowles CH, et al. Idiopathic slow-transit constipation: an almost exclusively female disorder. *Dis Colon Rectum*. 2003;46(12):1716–7.

5. Harari D, Gurwitz JH, Minaker KL. Constipation in the elderly. *J Am Geriatr Soc*. 1993;41(10):1130–40.

6. Sandler RS, Jordan MC, Shelton BJ. Demographic and dietary determinants of constipation in the US population. *Am J Public Health*. 1990;80(2):185–9.

7. Johanson JF, Sonnenberg A, Koch TR. Clinical epidemiology of chronic constipation. *J Clin Gastroenterol*. 1989;11(5):525–36.

8. Talley NJ, et al. Constipation in an elderly community: a study of prevalence and potential risk factors. *Am J Gastroenterol*. 1996;91(1):19–25.

9. Drossman DA. The functional gastrointestinal disorders and the Rome III process. *Gastroenterology*. 2006;130(5):1377–90.

10. Longstreth GF, et al. Functional bowel disorders. *Gastroenterology*. 2006;130(5):1480–91.

11. Rao SS, et al. Dyssynergic defecation: demographics, symptoms, stool patterns, and quality of

- life. *J Clin Gastroenterol*. 2004;38(8):680–5.
12. Hinton JM, Lennard-Jones JE, Young AC. A new method for studying gut transit times using radioopaque markers. *Gut*. 1969;10(10):842–7.
13. Metcalf AM, et al. Simplified assessment of segmental colonic transit. *Gastroenterology*. 1987;92(1):40–7.
14. Cowlam S, et al. Validity of segmental transit studies used in routine clinical practice, to characterize defaecatory disorder in patients with functional constipation. *Colorectal Dis*. 2008;10(8):818–22.
15. Nam YS, et al. Reproducibility of colonic transit study in patients with chronic constipation. *Dis Colon Rectum*. 2001;44(1):86–92.
16. Eising EG, von der Ohe MR. Differentiation of prolonged colonic transit using scintigraphy with indium-111-labeled polystyrene pellets. *J Nucl Med*. 1998;39(6):1062–6.
17. Manabe N, et al. Lower functional gastrointestinal disorders: evidence of abnormal colonic transit in a 287 patient cohort. *Neurogastroenterol Motil*. 2010;22(3):293–e82.
18. Rao SS, et al. Investigation of colonic and whole-gut transit with wireless motility capsule and radiopaque markers in constipation. *Clin Gastroenterol Hepatol*. 2009;7(5):537–44.
19. Camilleri M, et al. Wireless pH-motility capsule for colonic transit: prospective comparison with radiopaque markers in chronic constipation. *Neurogastroenterol Motil*. 2010;22(8):874–82. e233.
20. Tobon F, et al. Nonsurgical test for the diagnosis of Hirschsprung's disease. *N Engl J Med*. 1968;278(4):188–93.
21. Harari D, et al. Bowel habit in relation to age and gender. Findings from the National Health Interview Survey and clinical implications. *Arch Intern Med*. 1996;156(3):315–20.
22. Longstreth GF. Bowel patterns and anxiety. Demographic factors. *J Clin Gastroenterol*. 1993;17(2):128–32.
23. De Schryver AM, et al. Effects of regular physical activity on defecation pattern in middle-aged patients complaining of chronic constipation. *Scand J Gastroenterol*. 2005;40(4):422–9.
24. Rao SS, et al. Effects of acute graded exercise on human colonic motility. *Am J Physiol*. 1999;276(5 Pt 1):G1221–6.
25. Tuteja AK, et al. Is constipation associated with decreased physical activity in normally active subjects? *Am J Gastroenterol*. 2005;100(1):124–9.
26. Muller-Lissner SA, et al. Myths and misconceptions about chronic constipation. *Am J Gastroenterol*. 2005;100(1):232–42.
27. Anti M, et al. Water supplementation enhances the effect of high-fiber diet on stool frequency and laxative consumption in adult patients with functional constipation. *Hepatogastroenterology*. 1998;45(21):727–32.
28. Ashraf W, et al. Effects of psyllium therapy on stool characteristics, colon transit and anorectal function in chronic idiopathic constipation. *Aliment Pharmacol Ther*. 1995;9(6):639–47.
29. Castle SC, et al. Constipation prevention: empiric use of stool softeners questioned. *Geriatrics*. 1991;46(11):84–6.
30. Johanson JF, et al. Multicenter, 4-week, double-blind, randomized, placebo-controlled trial of lubiprostone, a locally-acting type-2 chloride channel activator, in patients with chronic constipation. *Am J Gastroenterol*. 2008;103(1):170–7.
31. Johanson JF, Ueno R. Lubiprostone, a locally acting chloride channel activator, in adult patients with chronic constipation: a double-blind, placebo-controlled, dose-ranging study to evaluate

- efficacy and safety. *Aliment Pharmacol Ther.* 2007;25(11):1351–61.
32. Johnston JM, et al. Pilot study on the effect of linaclotide in patients with chronic constipation. *Am J Gastroenterol.* 2009;104(1):125–32.
33. Lembo AJ, et al. Efficacy of linaclotide for patients with chronic constipation. *Gastroenterology.* 2010;138(3):886–95. e1.
34. Yuan CS, et al. Effects of subcutaneous methylnaltrexone on morphine-induced peripherally mediated side effects: a double-blind randomized placebo-controlled trial. *J Pharmacol Exp Ther.* 2002;300(1):118–23.
35. Thomas J, et al. Methylnaltrexone for opioid-induced constipation in advanced illness. *N Engl J Med.* 2008;358(22):2332–43.
36. Webster L, et al. Alvimopan, a peripherally acting mu-opioid receptor (PAM-OR) antagonist for the treatment of opioid-induced bowel dysfunction: results from a randomized, double-blind, placebo-controlled, dose-finding study in subjects taking opioids for chronic non-cancer pain. *Pain.* 2008;137(2):428–40.
37. Foxx-Orenstein AE, et al. Does co-administration of a non-selective opiate antagonist enhance acceleration of transit by a 5-HT4 agonist in constipation-predominant irritable bowel syndrome? a randomized controlled trial. *Neurogastroenterol Motil.* 2007;19(10):821–30.
38. Sloots CE, et al. Effects of prucalopride on colonic transit, anorectal function and bowel habits in patients with chronic constipation. *Aliment Pharmacol Ther.* 2002;16(4):759–67.
39. Emmanuel AV, et al. Prucalopride, a systemic enterokinetic, for the treatment of constipation. *Aliment Pharmacol Ther.* 2002;16(7):1347–56.
40. Redmond JM, et al. Physiological tests to predict long-term outcome of total abdominal colectomy for intractable constipation. *Am J Gastroenterol.* 1995;90(5):748–53.
41. Ho YH, et al. Laparoscopic-assisted compared with open total colectomy in treating slow transit constipation. *Aust N Z J Surg.* 1997;67(8):562–5.
42. Athanasakis H, et al. Laparoscopically assisted subtotal colectomy for slow-transit constipation. *Surg Endosc.* 2001;15(10):1090–2.
43. Webster C, Dayton M. Results after colectomy for colonic inertia: a sixteen-year experience. *Am J Surg.* 2001;182(6):639–44.
44. Pikarsky AJ, et al. Long-term follow-up of patients undergoing colectomy for colonic inertia. *Dis Colon Rectum.* 2001;44(2):179–83.
45. Sarli L, et al. The rationale for cecorectal anastomosis for slow transit constipation. *Acta Biomed.* 2003;74 Suppl 2:74–9.
46. Marchesi F, et al. Subtotal colectomy with antiperistaltic cecorectal anastomosis in the treatment of slow-transit constipation: long-term impact on quality of life. *World J Surg.* 2007;31(8):1658–64.
47. Feng Y, Jianjiang L. Functional outcomes of two types of subtotal colectomy for slow-transit constipation: ileosigmoidal anastomosis and cecorectal anastomosis. *Am J Surg.* 2008;195(1):73–7.
48. Knowles CH, Scott M, Lunniss PJ. Outcome of colectomy for slow transit constipation. *Ann Surg.* 1999;230(5):627–38.
49. FitzHarris GP, et al. Quality of life after subtotal colectomy for slow-transit constipation: both quality and quantity count. *Dis Colon Rectum.* 2003;46(4):433–40.
50. Thaler K, et al. Quality of life after colectomy for colonic inertia. *Tech Coloproctol.* 2005;9(2):133–7.
51. Zutshi M, et al. Surgery for slow transit constipation: are we helping patients? *Int J Colorectal*

Dis. 2007;22(3):265–9.

52. Bernini A, et al. Should patients with combined colonic inertia and nonrelaxing pelvic floor undergo subtotal colectomy? *Dis Colon Rectum*. 1998;41(11):1363–6.

53. Reshef A, et al. Colectomy for slow transit constipation: effective for patients with coexistent obstructed defecation. *Int J Colorectal Dis*. 2013;28(6):841–7.

54. Zmora O, et al. Small bowel transit does not correlate with outcome of surgery in patients with colonic inertia. *Surg Innov*. 2005;12(3):215–8.

55. Mollen RM, Kuijpers HC, Claassen AT. Colectomy for slow-transit constipation: preoperative functional evaluation is important but not a guarantee for a successful outcome. *Dis Colon Rectum*. 2001;44(4):577–80.

56. Glia A, Akerlund JE, Lindberg G. Outcome of colectomy for slow-transit constipation in relation to presence of small-bowel dysmotility. *Dis Colon Rectum*. 2004;47(1):96–102.

57. O'Brien S, et al. Sexual abuse: a strong predictor of outcomes after colectomy for slow-transit constipation. *Dis Colon Rectum*. 2009;52(11):1844–7.

58. Kamm MA, et al. Left hemicolectomy with rectal excision for severe idiopathic constipation. *Int J Colorectal Dis*. 1991;6(1):49–51.

59. De Graaf EJ, Gilberts EC, Schouten WR. Role of segmental colonic transit time studies to select patients with slow transit constipation for partial left-sided or subtotal colectomy. *Br J Surg*. 1996;83(5):648–51.

60. You YT, et al. Segmental colectomy in the management of colonic inertia. *Am Surg*. 1998;64(8):775–7.

61. Lundin E, et al. Outcome of segmental colonic resection for slow-transit constipation. *Br J Surg*. 2002;89(10):1270–4.

62. Ripetti V, et al. Is total colectomy the right choice in intractable slow-transit constipation? *Surgery*. 2006;140(3):435–40.

63. Keighley MR, Grobler S, Bain I. An audit of restorative proctocolectomy. *Gut*. 1993;34(5):680–4.

64. Kalbassi MR, Winter DC, Deasy JM. Quality-of-life assessment of patients after ileal pouch-anal anastomosis for slow-transit constipation with rectal inertia. *Dis Colon Rectum*. 2003;46(11):1508–12.

65. El-Tawil AM. Reasons for creation of permanent ileostomy for the management of idiopathic chronic constipation. *J Gastroenterol Hepatol*. 2004;19(8):844–6.

66. Scarpa M, Barollo M, Keighley MR. Ileostomy for constipation: long-term postoperative outcome. *Colorectal Dis*. 2005;7(3):224–7.

67. Malone PS, Ransley PG, Kiely EM. Preliminary report: the antegrade continence enema. *Lancet*. 1990;336(8725):1217–8.

68. Squire R, et al. The clinical application of the Malone antegrade colonic enema. *J Pediatr Surg*. 1993;28(8):1012–5.

69. Kim SM, Han SW, Choi SH. Left colonic antegrade continence enema: experience gained from 19 cases. *J Pediatr Surg*. 2006;41(10):1750–4.

70. Patton V, Lubowski DZ. Clinical outcome and efficacy of antegrade colonic enemas administered via an indwelling cecostomy catheter in adults with defecatory disorders. *Dis Colon Rectum*. 2015;58(4):457–62.

71. Gerharz EW, et al. The value of the MACE (Malone antegrade colonic enema) procedure in

- adult patients. *J Am Coll Surg*. 1997;185(6):544–7.
72. Rongen MJ, van der Hoop AG, Baeten CG. Cecal access for antegrade colon enemas in medically refractory slow-transit constipation: a prospective study. *Dis Colon Rectum*. 2001;44(11):1644–9.
73. Poirier M, Abcarian H, Nelson R. Malone antegrade continent enema: an alternative to resection in severe defecation disorders. *Dis Colon Rectum*. 2007;50(1):22–8.
74. Lees NP, et al. Long-term results of the antegrade continent enema procedure for constipation in adults. *Colorectal Dis*. 2004;6(5):362–8.
75. Worsoe J, et al. Long-term results of antegrade colonic enema in adult patients: assessment of functional results. *Dis Colon Rectum*. 2008;51(10):1523–8.
76. Dinning PG, et al. Sacral nerve stimulation induces pan-colonic propagating pressure waves and increases defecation frequency in patients with slow-transit constipation. *Colorectal Dis*. 2007;9(2):123–32.
77. Kenefick NJ, et al. Double-blind placebo-controlled crossover study of sacral nerve stimulation for idiopathic constipation. *Br J Surg*. 2002;89(12):1570–1.
78. Dinning PG, et al. Pancolonic motor response to subsensory and suprasensory sacral nerve stimulation in patients with slow-transit constipation. *Br J Surg*. 2012;99(7):1002–10.
79. Govaert B, et al. Medium-term outcome of sacral nerve modulation for constipation. *Dis Colon Rectum*. 2012;55(1):26–31.
80. Kamm MA, et al. Sacral nerve stimulation for intractable constipation. *Gut*. 2010;59(3):333–40.
81. Ortiz H, et al. Functional outcome of sacral nerve stimulation in patients with severe constipation. *Dis Colon Rectum*. 2012;55(8):876–80.
82. Graf W, et al. Results after sacral nerve stimulation for chronic constipation. *Neurogastroenterol Motil*. 2015;27(5):734–9.
83. Lewis SJ, Heaton KW. Stool form scale as a useful guide to intestinal transit time. *Scand J Gastroenterol*. 1997;32(9):920–4.

## 第 59 章

1. Handa VL, Cundiff G, Chang HH, et al. Female sexual function and pelvic floor disorders. *Obstet Gynecol*. 2008;111(5):1045–52.
2. Nygaard I, Barber MD, Burgio KL, et al. Pelvic floor disorders network. Prevalence of symptomatic pelvic floor disorders in US women. *JAMA*. 2008;300(11):1311–6.
3. MacLennan AH, Taylor AW, Wilson DH, et al. The prevalence of pelvic floor disorders and their relationship to gender, age, parity and mode of delivery. *BJOG*. 2000;107(12):1460–70.
4. Walters MD. Pelvic floor disorders in women: an overview. *Rev Med Univ Navarra*. 2004;48(4):9–12. 15–7.
5. Andromanakos NP, Pinis SI, Kostakis AI. Chronic severe constipation: current pathophysiological aspects, new diagnostic approaches and therapeutic options. *Eur J Gastroenterol Hepatol*. 2015;27(3):204–10.
6. Higgins PD, Johnason JF. Epidemiology of constipation in North America: a systematic review. *Am J Gastroenterol*. 2004;99(4):750–9.
7. Varma MG, Hart SL, Brown JS, Creasman JM, Van Den Eeden SK, Thom DH. Obstructed

- defecation in middle aged women. *Dig Dis Sci*. 2008;53(10):2702–9.
8. Talley NJ, Fleming KC, Evans JM, Okeefe EA, Weaver AL, Zinsmeister AR. Constipation in an elderly community: a study of prevalence and risk factors. *Am J Gastroenterol*. 1996;91(1):19–25.
  9. Soligo M, Salvatore S, Emmanuel AV, et al. Patterns of constipation in urogynecology: clinical importance and pathophysiologic insights. *Am J Obstet Gynecol*. 2006;195(1):50–5.
  10. Jelovsek JE, Barber MD, Paraiso MF, et al. Functional bowel and anorectal disorders in patients with pelvic organ prolapse. *Am J Obstet Gynecol*. 2005;193(6):2105–11.
  11. Meschia M, Buonaguidi A, Pifarotti P, et al. Prevalence of anal incontinence in women with symptoms of urinary incontinence and genital prolapse. *Obstet Gynecol*. 2002;100(4):719–23.
  12. Nichols CM, Ramakrishnan V, Gill EJ, et al. Anal incontinence in women with and those without pelvic floor disorders. *Obstet Gynecol*. 2005;106(6):1266–71.
  13. Costilla VC, Foss-Orenstein AE. Constipation in adults: diagnosis and management. *Curr Treat Options Gastroenterol*. 2014;12(3):310–21.
  14. Kahyap AS, Kohli DR, Raizon A, Olden KW. A prospective study evaluating emotional disturbance in subjects undergoing defecating proctography. *World J Gastroenterol*. 2013;19(25):3990–5.
  15. Cosentino M, Beati C, Fornari S, Capalbo E, Peli M, Lovisatti M, Cariati M, Cornalba G. Defaecography and colonic transit time for the evaluation of female patients with obstructed defecation. *Radiol Med*. 2014;119(11):813–9.
  16. Metcalf AM, Phillips SF, Zinsmeister AR, MacCarty RL, Beart RW, Wolff BG. Simplified assessment of segmental colonic transit. *Gastroenterology*. 1987;92(1):40–7.
  17. Chiaroni G, Kim SM, Vantini, Whitehead WE. Validation of the balloon evacuation test: reproducibility and agreement with findings from anorectal manometry and electromyography. *Clin Gastroenterol Hepatol*. 2014;12(12):2049–54.
  18. Van Koughnett JA, da Silva G. Anorectal physiology and testing. *Gastroenterol Clin North Am*. 2013;42(4):713–28.
  19. Pucciani F, Ringressi MN. Obstructed defecation: the role of anorectal manometry. *Tech Coloproctol*. 2012;16(1):67–72.
  20. Solan P, Davis B. Anorectal anatomy and imaging techniques. *Gastroenterol Clin North Am*. 2013;42(4):701–12.
  21. Faggian A, Alabiso ME, Serra N, Pizza NL, Iasiello F, Tecame M, Somma F, Rossi C, Di Grezia G, Feragalli B, Iacomino A, Grassi R. Entero-colpo-defecography vs supine entero-MRI: which one is the best tool in the differentiation of enterocele, elythrocele and edrocele? *J Biol Regul Homeost Agents*. 2013;27(3):861–8.
  22. Khatri G. Magnetic resonance imaging of pelvic floor disorders. *Top Magn Reson Imaging*. 2014;23(4):259–73.
  23. Lalwani N, Moshiri M, Lee JH, Bhargava P, Dighe MK. Magnetic resonance imaging of pelvic floor dysfunction. *Radiol Clin North Am*. 2013;51(6):1127–39.
  24. De la Portilla F, Rubio Manzanares Dorado M, Pino Diaz V, Vazquez Monchul JM, Palacios C, Diaz Pavon JM, Sanchez Gil JM, Garcia Cabrera AM. The role of tridimensional dynamic ultrasound as a complimentary diagnostic tool in a pelvic floor unit. *Cir Esp*. 2015;93(8):530–5.
  25. Murad-Regades SM, Regadas Filho FS, Regadas FS, Rodrigues LV, de J R Pereira J, da S Fernandes GO, Dealcanfreitas ID, Mendonca Filho JJ. Use of dynamic 3-dimensional transvaginal and transrectal ultrasonography to assess posterior pelvic floor dysfunction related to obstructed



defecation. *Dis Colon Rectum*. 2014;57(2):228–36.

26. Benezech A, Bouvier M, Grimaud JC, Baunstarck K, Vitton V. Three-dimensional high-resolution anorectal manometry and diagnosis of excessive perineal descent: a comparative pilot study with defaecography. *Colorectal Dis*. 2014;16(5):O170–5.

27. Palit S, Bhan C, Lunniss PJ, Boyle DJ, Gladman MA, Knowles CH, Scott SM. Evacuation proctography: a reappraisal of normal variability. *Colorectal Dis*. 2014;16(7):538–46.

28. Schreyer AG, Paetzel C, Furst A, Dendl LM, Hutzl E, Muller-Wille R, Wiggerman P, Schleder S, Stroszczynski C, Hoffstetter P. Dynamic magnetic resonance defecography in 10 asymptomatic volunteers. *World J Gastroenterol*. 2012;18(46):6836–42.

29. Starr JA, Drobnis EZ, Lenger S, Parrott J, Barrier B, Foster R. Outcomes of a comprehensive nonsurgical approach to pelvic floor rehabilitation for urinary symptoms, defecatory dysfunction and pelvic pain. *Female Pelvic Med Reconstr Surg*. 2013;19(5):260–5.

30. Prichard D, Bharucha AE. Management of pelvic floor disorders: biofeedback and more. *Curr Treat Options Gastroenterol*. 2014;12(4):456–67.

31. Podzemny V, Pescatori LC, Pescatori M. Management of obstructed defecation. *World J Gastroenterol*. 2015;21(4):1053–60.

32. Jodorkovsky D, Dunbar KB, Gearhart SL, Stein EM, Clarke JO. Biofeedback therapy for defecatory dysfunction: “real life” experience. *J Clin Gastroenterol*. 2013;47(3):252–5.

33. Chung BD, Parekh U, Sellin JH. Effect of increase fluid intake on stool output in normal healthy volunteers. *J Clin Gastroenterol*. 1999;28:29–32.

34. De Schryver AM, Keulmans YC, Peters HP, Akkermans LM, Smout AJ, De Vriess WR, van Berge-Henegouwen GP. Effects of regular physical activity on defecation pattern in middle aged patients complaining of chronic constipation. *Scand J Gastroenterol*. 2005;40:422–9.

35. Pucciani F, Raggioli M, Rigrissi MN. Usefulness of psyllium in rehabilitation of obstructed defecation. *Tech Coloproctol*. 2011;15(4):377–83.

36. Suares NC, Ford AC. Systematic review: the effects of fibre in the management of chronic idiopathic constipation. *Aliment Pharmacol Ther*. 2011;33:895–901.

37. Bharucha AE. Difficult defecation: difficult problem assessment and management: what really helps? *Gastroenterol Clin North Am*. 2011;40(4):833–44.

38. Woodward S, Norton C, Chiarelli P. Biofeedback for treatment of chronic idiopathic constipation in adults. *Cochrane Database Syst Rev*. 2014;3:CD008486.

39. Heyman S, Scarlett Y, Jones K, Ringel Y, Drossman D, Whitehead WE. Randomized, controlled trial shows biofeedback to be superior to alternative treatments for patients with pelvic floor dyssynergia type constipation. *Dis Colon Rectum*. 2007;50(4):428–41.

40. Rao S, Seaton K, Miller M, et al. Randomized, controlled trial of biofeedback, sham feedback and standard therapy for dyssynergic defecation. *Clin Gastroenterol Hepatol*. 2007;5(3):331–8.

41. Ahadi T, Madjlesi F, Mahjoubi B, Mirzaei R, Forogh B, Daliri SS, Derakhshandeh SM, Behbahani RB, Raissi GR. The effect of biofeedback therapy on dyssynergic constipation in patients with or without irritable bowel syndrome. *J Res Med Sci*. 2014;19(10):950–6.

42. Lee HJ, Boo SJ, Jung KW, Han S, Seo SY, Koo HS, Yoon IJ, Park SH, Yang DH, Kim KJ, Ye BD, Byeon JS, Yang SK, Kim JH, Myung SJ. Long term efficacy of biofeedback therapy in patients with dyssynergic defecation: results of a median 44 months follow-up. *Neurogastroenterol Motil*. 2015;27(6):787–95.

43. Hedrick TL, Friel CM. Constipation and pelvic outlet obstruction. *Gastroenterol Clin North Am*.

2013;42(4):863–76.

44. Huber SA, Northington GM, Karp DR. Bowel and bladder dysfunction following surgery within the presacral space: an overview of neuroanatomy, function and dysfunction. *Int Urogynecol J*. 2015;28(7):941–6.

45. Dyrberg DL, Nordentoft T, Rosenstock S. Laparoscopic posterior mesh rectopexy for rectal prolapse is a safe procedure in older patients: a prospective follow-up study. *Scand J Surg*. 2015;104:227–32.

46. Tsunoda A, Ohta T, Kiyasu Y, Kusanagi H. Laparoscopic ventral rectopexy for rectoanal intussusception: postoperative evaluation with proctography. *Dis Colon Rectum*. 2015;58(4):449–56.

47. Bordeianu L, Hick CW, Kaiser AM, Alavi K, Sudan R, Wise PE. Rectal prolapse: an overview of clinical features, diagnosis and patient specific management strategies. *J Gastrointest Surg*. 2014;18(5):1059–69.

48. Wijffels NA, Jones OM, Cunningham C, Bemelman WA, Lindsey I. What are the symptoms of internal rectal prolapse? *Colorectal Dis*. 2013;15(3):368–73.

49. Hatch Q, Steele SR. Rectal prolapse and intussusception. *Gastroenterol Clin North Am*. 2013;42(4):837–61.

50. Franceschilli L, Varvaras D, Capuano I, Ciangola CI, Giorgi F, Boehm G, Gaspari AL, Sileri P. Laparoscopic ventral rectopexy using biologic mesh for the treatment of obstructed defecation syndrome and/or fecal incontinence in patients with internal rectal prolapse: a critical appraisal of the first 100 cases. *Tech Coloproctol*. 2015;19(4):209–19.

51. Borie F, Bigourdan JM, Pissas MH, Guillon F. Laparoscopic ventral rectopexy for the treatment of outlet obstruction associated with rectoanal intussusception and rectocele: a valid alternative to STARR procedure in patients with anal sphincter weakness. *Clin Res Hepatol Gastroenterol*. 2014;38(4):528–34.

52. Cullen J, Rosselli JM, Gurland BH. Ventral rectopexy for rectal prolapse and obstructed defecation. *Clin Colon Rectal Surg*. 2012;25(1):34–6.

53. Boenicke L, Jayne DG, Kim M, Reibetanz J, Bolte R, Kenn W, Germer CT, Isbert C. What happens in stapled transanal rectum resection? *Dis Colon Rectum*. 2011;54(5):593–600.

54. Kohler K, Stelzner S, Helmichh G, Lehmann D, Jackisch T, Fankhanel B, Witzigmann H. Results in the long term course after stapled transanal rectal resection (STARR). *Langenbecks Arch Surg*. 2012;397(5):771–8.

55. Meurette G, Wong M, Frampas E, Regenet N, Lehur PA. Anatomical and functional results after stapled transanal rectal resection (STARR) for obstructed defecation. *Colorectal Dis*. 2011;13(1):e6–11.

56. Schwandner O, Furst A, German STARR Registry Group. Assessing the safety, effectiveness and quality of life after the STARR procedure for obstructed defecation: results of the German STARR registry. *Langenbecks Arch Surg*. 2010;395(5):505–13.

57. Jayne DG, Schwandner O, Stuto A. Stapled transanal rectal resection for obstructed defecation syndrome: one year results of the European STARR Registry. *Dis Colon Rectum*. 2009;52(7):1205–12.

58. Gagliardi G, Pescatori M, Altomare DF, Binda GA, Bottini C, Dodi G, Filingeri V, Milito G, Rinaldi G, Spazzafumo L, Trompetto M. Results, outcome predictors and complications after stapled transanal rectal resection for obstructed defecation. *Dis Colon Rectum*. 2008;51(2):186–95.

59. Pilzek AL, Raker CA, Sung VW. Are patients personal goals achieved after pelvic reconstructive surgery? *Int Urogynecol J*. 2014;25(3):347–50.
60. Polin MR, Gleason JL, Szychowski JM, Holley RL, Richter HE. Effects of transvaginal repair of symptomatic rectocele on symptom specific distress and impact on quality of life. *Int J Gynaecol Obstet*. 2012;117(3):224–7.
61. Karram M, Maher C. Surgery for posterior vaginal wall prolapse. *Int Urogynecol J*. 2013;24(11):1835–41.
62. Richardson ML, Elliot CS, Sokol ER. Posterior compartment prolapse: a urogynecology perspective. *Urol Clin North Am*. 2012;39(3):361–9.
63. Baessler K. Do we need meshes in pelvic floor reconstruction? *World J Urol*. 2012;30(4):479–86.
64. Brown RA, Ellis CN. The role of synthetic and biologic material in the treatment of pelvic organ prolapse. *Clin Colon Rectal Surg*. 2014;27(4):182–90.
65. Hick CW, Weinstein M, Wakamatsu M, Savitt L, Pulliam S, Bordeianu L. In patients with rectoceles and obstructed defecation syndrome, surgery should be the option of last resort. *Surgery*. 2014;155(4):659–67.
66. Hall GM, Shanmugan S, Nobel T, Paspulati R, Delaney CP, Reynolds HL, Stein SL, Champagne BJ. Symptomatic rectocele: what are the indications for repair? *Am J Surg*. 2014;207(3):375–9.
67. Beck DE, Allen NL. Rectocele. *Clin Colon Rectal Surg*. 2010;23(2):90–8.
68. Maher C, Feiner B, Baessler K, Schmid C. Surgical management of pelvic organ prolapse in women. *Cochrane Database Syst Rev*. 2013;4.
69. Miklos JR, Moore RD. The 26 minute laparoscopic sacral colpopexy do we really need robotic technology. *J Minim Invasive Gynecol*. 2015;22(5):712.
70. Flack CK, Monn MF, Patel NB, Gardner TA, Powell CR. National trends in the performance of robot-assisted sacral colpopexy. *J Endourol*. 2015;29(7):777–83.
71. VanderPas Lamb S, Massengill J, Sheridan MJ, Stern LE, von Pechmann W. Safety of combined abdominal sacral colpopexy and sigmoid resection with suture rectopexy: a retrospective cohort study. *Female Pelvic Med Reconstr Surg*. 2015;21(1):18–24.
72. Uzoma A, Faraq KA. Vaginal vault prolapse. *Obstet Gynecol Int*. 2009;2009:275621.
73. Mueller MG, Ellimootil C, Abernethy MG, Mueller ER, Hohmann S, Kenton K. Colpocleisis: a safe, minimally invasive option for pelvic organ prolapse. *Female Pelvic Med Reconstr Surg*. 2015;21(1):30–3.
74. Harewood GC, Coulie B, Camelleri M, et al. Descending perineum syndrome: audit of clinical and laboratory features and outcome of pelvic floor retraining. *Am J Gastroenterol*. 1999;94(1):126–30.
75. Patcharatrakul T, Gonlachanvit S. Outcome of biofeedback therapy in dyssynergic defecation patients with and without irritable bowel syndrome. *J Clin Gastroenterol*. 2011;45(7):593–8.
76. Rao SS, Valestin J, Brown CK, Zimmerman B, Schulze K. Long term efficacy of biofeedback therapy for dyssynergic defecation: randomized controlled trial. *Am J Gastroenterol*. 2010;105(4):890–6.
77. Thomas GP, Dudding TC, Rahbour G, Nicholls RJ, Vaizey CJ. Sacral nerve stimulation for constipation. *Br J Surg*. 2013;100(2):174–81.
78. Ortiz H, De Miguel M, Rinaldi M, Oteiza F, Altomare DF. Functional outcome of sacral nerve stimulation in patients with severe constipation. *Dis Colon Rectum*. 2012;55(8):876–80.

79. Govaert B, Maeda Y, Alberga J, Buntzen S, Laurberg S, Baeten CG. Medium term outcome of sacral nerve modulation for constipation. *Dis Colon Rectum*. 2012;55(1):26–31.

## 第 60 章

1. Peters 3rd WA, Smith MR, Drescher CW. Rectal prolapse in women with other defects of pelvic floor support. *Am J Obstet Gynecol*. 2001;184(7):1488–94. discussion 1494–5.
2. Kairaluoma MV, Kellokumpu IH. Epidemiologic aspects of complete rectal prolapse. *Scand J Surg*. 2005;94(3):207–10.
3. Marceau C, Parc Y, Debroux E, Tired E, Parc R. Complete rectal prolapse in young patients: psychiatric disease a risk factor of poor outcome. *Colorectal Dis*. 2005;7(4):360–5.
4. Mitchell N, Norris ML. Rectal prolapse associated with anorexia nervosa: a case report and review of the literature. *Int J Eat Disord*. 2013;1:39.
5. Kim DS, Tsang CB, Wong WD, Lowry AC, Goldberg SM, Madoff RD. Complete rectal prolapse: evolution of management and results. *Dis Colon Rectum*. 1999;42(4):460–6. discussion 466–9.
6. Glasgow SC, Birnbaum EH, Kodner IJ, Fleshman JW, Dietz DW. Preoperative anal manometry predicts continence after perineal proctectomy for rectal prolapse. *Dis Colon Rectum*. 2006;49(7):1052–8.
7. Snooks SJ, Henry MM, Swash M. Anorectal incontinence and rectal prolapse: differential assessment of the innervation to puborectalis and external anal sphincter muscles. *Gut*. 1985;26(5):470–6.
8. Madoff RD, Mellgren A. One hundred years of rectal prolapse surgery. *Dis Colon Rectum*. 1999;42(4):441–50.
9. Varma M, Rafferty J, Buie WD, Standards Practice Task Force of American Society of Colon and Rectal Surgeons. Practice parameters for the management of rectal prolapse. *Dis Colon Rectum*. 2011;54(11):1339–46.
10. Pescatori M, Spyrou M, Pulvirenti d’Urso A. A prospective evaluation of occult disorders in obstructed defecation using the ‘iceberg diagram’. *Colorectal Dis*. 2007;9(5):452–6.
11. Renzi A, Izzo D, Di Sarno G, De Iuri A, Bucci L, Izzo G, et al. Cinedefecographic findings in patients with obstructed defecation syndrome. A study in 420 cases. *Minerva Chir*. 2006;61(6):493–9.
12. Myers JO, Rothenberger DA. Sugar in the reduction of incarcerated prolapsed bowel. Report of two cases. *Dis Colon Rectum*. 1991;34(5):416–8.
13. Hamalainen KJ, Raivio P, Antila S, Palmu A, Mecklin JP. Biofeedback therapy in rectal prolapse patients. *Dis Colon Rectum*. 1996;39(3):262–5.
14. Gourgiotis S, Baratsis S. Rectal prolapse. *Int J Colorectal Dis*. 2007;22(3):231–43.
15. Deen KI, Grant E, Billingham C, Keighley MR. Abdominal resection rectopexy with pelvic floor repair versus perineal rectosigmoidectomy and pelvic floor repair for full-thickness rectal prolapse. *Br J Surg*. 1994;81(2):302–4.
16. Senapati A, Gray RG, Middleton LJ, Harding J, Hills RK, Armitage NC, et al. PROSPER: a randomised comparison of surgical treatments for rectal prolapse. *Colorectal Dis*. 2013;15(7):858–68.
17. Kuijpers HC. Treatment of complete rectal prolapse: to narrow, to wrap, to suspend, to fix, to

- encircle, to plicate or to resect? *World J Surg.* 1992;16(5):826–30.
18. Lieberth M, Kondylis LA, Reilly JC, Kondylis PD. The Delorme repair for full-thickness rectal prolapse: a retrospective review. *Am J Surg.* 2009;197(3):418–23.
19. Tsunoda A, Yasuda N, Yokoyama N, Kamiyama G, Kusano M. Delorme's procedure for rectal prolapse: clinical and physiological analysis. *Dis Colon Rectum.* 2003;46(9):1260–5.
20. Liberman H, Hughes C, Dippolito A. Evaluation and outcome of the Delorme procedure in the treatment of rectal outlet obstruction. *Dis Colon Rectum.* 2000;43(2):188–92.
21. Chun SW, Pikarsky AJ, You SY, Gervaz P, Efron J, Weiss E, et al. Perineal rectosigmoidectomy for rectal prolapse: role of levatorplasty. *Tech Coloproctol.* 2004;8(1):3–8. discussion 8–9.
22. Altomare DF, Binda G, Ganio E, De Nardi P, Giamundo P, Pescatori M, et al. Long-term outcome of Altemeier's procedure for rectal prolapse. *Dis Colon Rectum.* 2009;52(4):698–703.
23. Graf W, Karlhom U, Pahlman L, Nilsson S, Ejerblad S. Functional results after abdominal suture rectopexy for rectal prolapse or intussusception. *Eur J Surg.* 1996;162(11):905–11.
24. Khanna AK, Misra MK, Kumar K. Simplified sutured sacral rectopexy for complete rectal prolapse in adults. *Eur J Surg.* 1996;162(2):143–6.
25. Novell JR, Osborne MJ, Winslet MC, Lewis AA. Prospective randomized trial of Ivalon sponge versus sutured rectopexy for full-thickness rectal prolapse. *Br J Surg.* 1994;81(6):904–6.
26. Bachoo P, Brazzelli M, Grant A. Surgery for complete rectal prolapse in adults. *Cochrane Database Syst Rev.* 2000;(2)(2):CD001758.
27. Aitola PT, Hiltunen KM, Matikainen MJ. Functional results of operative treatment of rectal prolapse over an 11-year period: emphasis on transabdominal approach. *Dis Colon Rectum.* 1999;42(5):655–60.
28. Frykman HM, Goldberg SM. The surgical treatment of rectal procidentia. *Surg Gynecol Obstet.* 1969;129(6):1225–30.
29. Sayfan J, Pinho M, Alexander-Williams J, Keighley MR. Sutured posterior abdominal rectopexy with sigmoidectomy compared with Marlex rectopexy for rectal prolapse. *Br J Surg.* 1990;77(2):143–5.
30. Luukkonen P, Mikkonen U, Jarvinen H. Abdominal rectopexy with sigmoidectomy vs. rectopexy alone for rectal prolapse: a prospective, randomized study. *Int J Colorectal Dis.* 1992;7(4):219–22.
31. Tou S, Brown SR, Malik AI, Nelson RL. Surgery for complete rectal prolapse in adults. *Cochrane Database Syst Rev.* 2008;(4)(4):CD001758.
32. Hsu A, Brand MI, Saclarides TJ. Laparoscopic rectopexy without resection: a worthwhile treatment for rectal prolapse in patients without prior constipation. *Am Surg.* 2007;73(9):858–61.
33. El Muhtaseb MS, Bartolo DC, Zayia D, Salem T. Colonic transit before and after resection rectopexy for full-thickness rectal prolapse. *Tech Coloproctol.* 2014;18(3):273–6.
34. Formijne Jonkers HA, Draaisma WA, Wexner SD, Broeders IA, Bemelman WA, Lindsey I, et al. Evaluation and surgical treatment of rectal prolapse: an international survey. *Colorectal Dis.* 2013;15(1):115–9.
35. Gurland B. Ventral mesh rectopexy: is this the new standard for surgical treatment of pelvic organ prolapse? *Dis Colon Rectum.* 2014;57(12):1446–7.
36. Ripstein CB, Lanter B. Etiology and surgical therapy of massive prolapse of the rectum. *Ann Surg.* 1963;157:259–64.
37. Winde G, Reers B, Nottberg H, Berns T, Meyer J, Bunte H. Clinical and functional results of

abdominal rectopexy with absorbable mesh-graft for treatment of complete rectal prolapse. *Eur J Surg.* 1993;159(5):301–5.

38. Tjandra JJ, Fazio VW, Church JM, Milsom JW, Oakley JR, Lavery IC. Ripstein procedure is an effective treatment for rectal prolapse without constipation. *Dis Colon Rectum.* 1993;36(5):501–7.

39. McMahan JD, Ripstein CB. Rectal prolapse. An update on the rectal sling procedure. *Am Surg.* 1987;53(1):37–40.

40. Roberts PL, Schoetz Jr DJ, Collier JA, Veidenheimer MC. Ripstein procedure. Lahey Clinic experience: 1963–1985. *Arch Surg.* 1988;123(5):554–7.

41. D’Hoore A, Cadoni R, Penninckx F. Long-term outcome of laparoscopic ventral rectopexy for total rectal prolapse. *Br J Surg.* 2004;91(11):1500–5.

42. Samaranayake CB, Luo C, Plank AW, Merrie AE, Plank LD, Bissett IP. Systematic review on ventral rectopexy for rectal prolapse and intussusception. *Colorectal Dis.* 2010;12(6):504–12.

43. Mackenzie H, Dixon AR. Proficiency gain curve and predictors of outcome for laparoscopic ventral mesh rectopexy. *Surgery.* 2014;156(1):158–67.

44. Van Geluwe B, Wolthuis A, Penninckx F, D’Hoore A. Lessons learned after more than 400 laparoscopic ventral rectopexies. *Acta Chir Belg.* 2013;113(2):103–6.

45. Badrek-Al Amoudi AH, Greenslade GL, Dixon AR. How to deal with complications after laparoscopic ventral mesh rectopexy: lessons learnt from a tertiary referral centre. *Colorectal Dis.* 2013;15(6):707–12.

46. Rajamaheswari N, Agarwal S, Seethalakshmi K. Lumbosacral spondylodiscitis: an unusual complication of abdominal sacrocolpopexy. *Int Urogynecol J.* 2012;23(3):375–7.

47. Draaisma WA, van Eijck MM, Vos J, Consten EC. Lumbar discitis after laparoscopic ventral rectopexy for rectal prolapse. *Int J Colorectal Dis.* 2011;26(2):255–6.

48. Formijne Jonkers HA, Maya A, Draaisma WA, Bemelman WA, Broeders IA, Consten EC, et al. Laparoscopic resection rectopexy versus laparoscopic ventral rectopexy for complete rectal prolapse. *Tech Coloproctol.* 2014;18(7):641–6.

49. Panis Y. Laparoscopic ventral rectopexy: resection or no resection? That is the question.... *Tech Coloproctol.* 2014;18(7):611–2.

50. Mehmood RK, Parker J, Bhuvimanian L, Qasem E, Mohammed AA, Zeeshan M, et al. Short-term outcome of laparoscopic versus robotic ventral mesh rectopexy for full-thickness rectal prolapse. Is robotic superior? *Int J Colorectal Dis.* 2014;29(9):1113–8.

51. Rondelli F, Bugiantella W, Villa F, Sanguinetti A, Boni M, Mariani E, et al. Robot-assisted or conventional laparoscopic rectopexy for rectal prolapse? Systematic review and meta-analysis. *Int J Surg.* 2014;12 Suppl 2:S153–9.

52. Heemskerk J, de Hoog DE, van Gemert WG, Baeten CG, Greve JW, Bouvy ND. Robot-assisted vs. conventional laparoscopic rectopexy for rectal prolapse: a comparative study on costs and time. *Dis Colon Rectum.* 2007;50(11):1825–30.

53. Fang SH, Cromwell JW, Wilkins KB, Eisenstat TE, Notaro JR, Alva S, et al. Is the abdominal repair of rectal prolapse safer than perineal repair in the highest risk patients? An NSQIP analysis. *Dis Colon Rectum.* 2012;55(11):1167–72.

54. Magruder JT, Efron JE, Wick EC, Gearhart SL. Laparoscopic rectopexy for rectal prolapse to reduce surgical-site infections and length of stay. *World J Surg.* 2013;37(5):1110–4.

55. Wijffels N, Cunningham C, Dixon A, Greenslade G, Lindsey I. Laparoscopic ventral rectopexy for external rectal prolapse is safe and effective in the elderly. Does this make perineal procedures

obsolete? *Colorectal Dis.* 2011;13(5):561–6.

56. Germain A, Perrenot C, Scherrer ML, Ayav C, Brunaud L, Ayav A, et al. Long-term outcome of robotic-assisted laparoscopic rectopexy for full-thickness rectal prolapse in elderly patients. *Colorectal Dis.* 2014;16(3):198–202.

57. Hotouras A, Ribas Y, Zakeri S, Bhan C, Wexner SD, Chan CL, et al. A systematic review of the literature on the surgical management of recurrent rectal prolapse. *Colorectal Dis.* 2015. doi: 10.1111/codi.12946.

58. Steele SR, Goetz LH, Minami S, Madoff RD, Mellgren AF, Parker SC. Management of recurrent rectal prolapse: surgical approach influences outcome. *Dis Colon Rectum.* 2006;49(4):440–5.

59. Hool GR, Hull TL, Fazio VW. Surgical treatment of recurrent complete rectal prolapse: a thirty-year experience. *Dis Colon Rectum.* 1997;40(3):270–2.

60. Ding JH, Canedo J, Lee SH, Kalaskar SN, Rosen L, Wexner SD. Perineal rectosigmoidectomy for primary and recurrent rectal prolapse: are the results comparable the second time? *Dis Colon Rectum.* 2012;55(6):666–70.

61. Jackson SL, Weber AM, Hull TL, Mitchinson AR, Walters MD. Fecal incontinence in women with urinary incontinence and pelvic organ prolapse. *Obstet Gynecol.* 1997;89(3):423–7.

62. Riansuwan W, Hull TL, Bast J, Hammel JP. Combined surgery in pelvic organ prolapse is safe and effective. *Colorectal Dis.* 2010;12(3):188–92.

63. Watadani Y, Vogler SA, Warshaw JS, Sueda T, Lowry AC, Madoff RD, et al. Sacrocolpopexy with rectopexy for pelvic floor prolapse improves bowel function and quality of life. *Dis Colon Rectum.* 2013;56(12):1415–22.

64. Ayav A, Bresler L, Brunaud L, Zarnegar R, Boissel P. Surgical management of combined rectal and genital prolapse in young patients: transabdominal approach. *Int J Colorectal Dis.* 2005;20(2):173–9.

65. VanderPas Lamb S, Massengill J, Sheridan MJ, Stern LE, von Pechmann W. Safety of combined abdominal sacral colpopexy and sigmoid resection with suture rectopexy: a retrospective cohort study. *Female Pelvic Med Reconstr Surg.* 2015;21(1):18–24.

66. Ortega AE, Klipfel N, Kelso R, Petrone P, Roman I, et al. Changing concepts in the pathogenesis, evaluation, and management of solitary rectal ulcer syndrome. *Am Surg.* 2008;74(10):967–72.

67. Lee TH, Hong SJ, Lee JS. Thickened internal anal sphincter has been reported to be a typical finding in solitary rectal ulcer syndrome. *J Neurogastroenterol Motil.* 2015;21(1):140–1.

68. Rao SS, Benninga MA, Bharucha AE, Chiarioni G, Di Lorenzo C, et al. ANMS-ESNM position paper and consensus guidelines on biofeedback therapy for anorectal disorders. *Neurogastroenterol Motil.* 2015;27(5):594–609.

69. Vaizey CJ, van den Bogaerde JB, Emmanuel AV, Talbot IC, Nicholls RJ, et al. Solitary rectal ulcer syndrome. *Br J Surg.* 1998;85(12):1617–23.

70. Waniczek D, Rdes J, Rudzki MK, Piecuch J, Rubicz N, et al. Effective treatment of solitary rectal ulcer syndrome using argon plasma coagulation. *Prz Gastroenterol.* 2014;9(4):249–53.

71. Evans C, Ong E, Jones OM, Cunningham C, Lindsey I. Laparoscopic ventral rectopexy is effective for solitary rectal ulcer syndrome when associated with rectal prolapse. *Colorectal Dis.* 2014;16(3):O112–6.

72. Badrek-Amoudi AH, Roe T, Mabey K, Carter H, Mills A, et al. Laparoscopic ventral mesh rectopexy in the management of solitary rectal ulcer syndrome: a cause for optimism? *Colorectal Dis.* 2013;15(5):575–81.

73. Beck DE. Surgical therapy for colitis cystica profunda and solitary rectal ulcer syndrome. *Curr Treat Options Gastroenterol*. 2002;5(3):231–7.

## 第 61 章

1. Rao SS. Diagnosis and management of fecal incontinence. American College of Gastroenterology Practice Parameters Committee. *Am J Gastroenterol*. 2004;99(8):1585–604.
2. Wald A. Clinical practice. Fecal incontinence in adults. *N Engl J Med*. 2007;356(16):1648–55.
3. Tjandra JJ, Dykes SL, Kumar RR, et al. Practice parameters for the treatment of fecal incontinence. *Dis Colon Rectum*. 2007;50(10):1497–507.
4. Madoff RD, Parker SC, Varma MG, Lowry AC. Faecal incontinence in adults. *Lancet*. 2004;364(9434):621–32.
5. Ditah I, Devaki P, Luma HN, et al. Prevalence, trends, and risk factors for fecal incontinence in United States adults, 2005–2010. *Clin Gastroenterol Hepatol*. 2014;12(4):636–43. e2.
6. Goode PS, Burgio KL, Halli AD, et al. Prevalence and correlates of fecal incontinence in community-dwelling older adults. *J Am Geriatr Soc*. 2005;53(4):629–35.
7. Markland AD, Goode PS, Burgio KL, et al. Incidence and risk factors for fecal incontinence in black and white older adults: a population-based study. *J Am Geriatr Soc*. 2010;58(7):1341–6.
8. Brown HW, Wexner SD, Segall MM, Brezoczky KL, Lukacz ES. Accidental bowel leakage in the mature women’s health study: prevalence and predictors. *Int J Clin Pract*. 2012;66(11):1101–8.
9. Brown HW, Wexner SD, Segall MM, Brezoczky KL, Lukacz ES. Quality of life impact in women with accidental bowel leakage. *Int J Clin Pract*. 2012;66(11):1109–16.
10. Mellgren A. Fecal incontinence. *Surg Clin North Am*. 2010;90(1):185–94. Table of Contents.
11. Jorge JM, Wexner SD. Etiology and management of fecal incontinence. *Dis Colon Rectum*. 1993;36(1):77–97.
12. Vaizey CJ, Carapeti E, Cahill JA, Kamm MA. Prospective comparison of faecal incontinence grading systems. *Gut*. 1999;44(1):77–80.
13. Rockwood TH. Incontinence severity and QOL scales for fecal incontinence. *Gastroenterology*. 2004;126(1 Suppl 1):S106–13.
14. Rockwood TH, Church JM, Fleshman JW, et al. Fecal Incontinence Quality of Life Scale: quality of life instrument for patients with fecal incontinence. *Dis Colon Rectum*. 2000;43(1):9–16. discussion 16–7.
15. Paquette IM, Abodeely A, Johnson 3rd BL, Rafferty JF. Quantifying patient improvement following sacral neuromodulation: is it time for a new scoring system for fecal incontinence? *Dis Colon Rectum*. 2014;57(10):1209–12.
16. Lee JT, Madoff RD, Rockwood TH. Quality-of-life measures in fecal incontinence: is validation valid? *Dis Colon Rectum*. 2015;58(3):352–7.
17. Omar MI, Alexander CE. Drug treatment for faecal incontinence in adults. *Cochrane Database Syst Rev*. 2013;6, CD002116.
18. Walker J, Webster P. Successful management of faecal incontinence using the enema continence catheter. *Z Kinderchir*. 1989;44 Suppl 1:44–5.
19. Chiarioni G, Ferri B, Morelli A, Iantorno G, Bassotti G. Bio-feedback treatment of fecal incontinence: where are we, and where are we going? *World J Gastroenterol*. 2005;11(31):4771–5.



20. Lacima G, Pera M, Amador A, Escaramis G, Pique JM. Long-term results of biofeedback treatment for faecal incontinence: a comparative study with untreated controls. *Colorectal Dis.* 2010;12(8):742–9.
21. Norton C. Fecal incontinence and biofeedback therapy. *Gastroenterol Clin North Am.* 2008;37(3):587–604. viii.
22. Norton C, Chelvanayagam S, Wilson-Barnett J, Redfern S, Kamm MA. Randomized controlled trial of biofeedback for fecal incontinence. *Gastroenterology.* 2003;125(5):1320–9.
23. Norton C, Cody JD, Hosker G. Biofeedback and/or sphincter exercises for the treatment of faecal incontinence in adults. *Cochrane Database Syst Rev.* 2006;3, CD002111.
24. Bharucha AE. Update of tests of colon and rectal structure and function. *J Clin Gastroenterol.* 2006;40(2):96–103.
25. Bharucha AE. Pro: anorectal testing is useful in fecal incontinence. *Am J Gastroenterol.* 2006;101(12):2679–81.
26. Zutshi M, Salcedo L, Hammel J, Hull T. Anal physiology testing in fecal incontinence: is it of any value? *Int J Colorectal Dis.* 2010;25(2):277–82.
27. Bharucha AE, Fletcher JG, Melton 3rd LJ, Zinsmeister AR. Obstetric trauma, pelvic floor injury and fecal incontinence: a population-based case–control study. *Am J Gastroenterol.* 2012;107(6):902–11.
28. Brouwer R, Duthie G. Sacral nerve neuromodulation is effective treatment for fecal incontinence in the presence of a sphincter defect, pudendal neuropathy, or previous sphincter repair. *Dis Colon Rectum.* 2010;53(3):273–8.
29. Sangwan YP, Collier JA, Barrett RC, et al. Unilateral pudendal neuropathy. Impact on outcome of anal sphincter repair. *Dis Colon Rectum.* 1996;39(6):686–9.
30. Gilliland R, Altomare DF, Moreira Jr H, Oliveira L, Gilliland JE, Wexner SD. Pudendal neuropathy is predictive of failure following anterior overlapping sphincteroplasty. *Dis Colon Rectum.* 1998;41(12):1516–22.
31. Chen AS, Luchtefeld MA, Senagore AJ, Mackeigan JM, Hoyt C. Pudendal nerve latency. Does it predict outcome of anal sphincter repair? *Dis Colon Rectum.* 1998;41(8):1005–9.
32. Gronewold M, Kroencke T, Hagedorn A, Tunn R, Gauruder-Burmester A. External anal sphincter repair using the overlapping technique in patients with anal incontinence and concomitant pudendal nerve damage. *Zentralbl Chir.* 2008;133(2):129–34.
33. Bordeianou L, Lee KY, Rockwood T, et al. Anal resting pressures at manometry correlate with the Fecal Incontinence Severity Index and with presence of sphincter defects on ultrasound. *Dis Colon Rectum.* 2008;51(7):1010–4.
34. Roos AM, Abdool Z, Sultan AH, Thakar R. The diagnostic accuracy of endovaginal and transperineal ultrasound for detecting anal sphincter defects: the PREDICT study. *Clin Radiol.* 2011;66(7):597–604.
35. Johnson 3rd BL, Abodeely A, Ferguson MA, Davis BR, Rafferty JF, Paquette IM. Is sacral neuromodulation here to stay? Clinical outcomes of a new treatment for fecal incontinence. *J Gastrointest Surg.* 2015;19(1):15–9. discussion 9–20.
36. Danielson J, Karlbom U, Sonesson AC, Wester T, Graf W. Submucosal injection of stabilized nonanimal hyaluronic acid with dextranomer: a new treatment option for fecal incontinence. *Dis Colon Rectum.* 2009;52(6):1101–6.
37. Graf W, Mellgren A, Matzel KE, Hull T, Johansson C, Bernstein M. Efficacy of dextranomer in

stabilised hyaluronic acid for treatment of faecal incontinence: a randomised, sham-controlled trial. *Lancet*. 2011;377(9770):997–1003.

38. Peterli R, Ackermann C, Herzog U, Schuppisser JP, Tondelli P. Results of anal sphincteroplasty in fecal incontinence—significance of intra-anal ultrasound imaging. *Swiss Surg*. 1997;3(3):112–6.

39. Goetz LH, Lowry AC. Overlapping sphincteroplasty: is it the standard of care? *Clin Colon Rectal Surg*. 2005;18(1):22–31.

40. Mik M, Rosniak K, Narbutt P, et al. Anterior overlapping sphincteroplasty—who benefits from the surgery? *Pol Przegl Chir*. 2014;86(1):33–8.

41. Glasgow SC, Lowry AC. Long-term outcomes of anal sphincter repair for fecal incontinence: a systematic review. *Dis Colon Rectum*. 2012;55(4):482–90.

42. Bravo Gutierrez A, Madoff RD, Lowry AC, Parker SC, Buie WD, Baxter NN. Long-term results of anterior sphincteroplasty. *Dis Colon Rectum*. 2004;47(5):727–31. discussion 31–2.

43. Halverson AL, Hull TL. Long-term outcome of overlapping anal sphincter repair. *Dis Colon Rectum*. 2002;45(3):345–8.

44. Lamblin G, Bouvier P, Damon H, et al. Long-term outcome after overlapping anterior anal sphincter repair for fecal incontinence. *Int J Colorectal Dis*. 2014;29(11):1377–83.

45. Jensen LL, Lowry AC. Biofeedback improves functional outcome after sphincteroplasty. *Dis Colon Rectum*. 1997;40(2):197–200.

46. Moscovitz I, Rotholtz NA, Baig MK, et al. Overlapping sphincteroplasty: does preservation of the scar influence immediate outcome? *Colorectal Dis*. 2002;4(4):275–9.

47. Parnell BA, Whitehead WE, Geller EJ, Jannelli ML, Connolly A. Overlapping anal sphincteroplasty: impact of suture selection on bowel symptoms. *J Reprod Med*. 2011;56(5–6):187–91.

48. Giordano P, Renzi A, Efron J, et al. Previous sphincter repair does not affect the outcome of repeat repair. *Dis Colon Rectum*. 2002;45(5):635–40.

49. Thin NN, Horrocks EJ, Hotouras A, et al. Systematic review of the clinical effectiveness of neuromodulation in the treatment of faecal incontinence. *Br J Surg*. 2013;100(11):1430–47.

50. Carrington EV, Knowles CH. The influence of sacral nerve stimulation on anorectal dysfunction. *Colorectal Dis*. 2011;13 Suppl 2:5–9.

51. Lundby L, Moller A, Buntzen S, et al. Relief of fecal incontinence by sacral nerve stimulation linked to focal brain activation. *Dis Colon Rectum*. 2011;54(3):318–23.

52. Michelsen HB, Christensen P, Krogh K, et al. Sacral nerve stimulation for faecal incontinence alters colorectal transport. *Br J Surg*. 2008;95(6):779–84.

53. Hull T, Giese C, Wexner SD, et al. Long-term durability of sacral nerve stimulation therapy for chronic fecal incontinence. *Dis Colon Rectum*. 2013;56(2):234–45.

54. Matzel KE, Lux P, Heuer S, Besendorfer M, Zhang W. Sacral nerve stimulation for faecal incontinence: long-term outcome. *Colorectal Dis*. 2009;11(6):636–41.

55. Wexner SD, Collier JA, Devroede G, et al. Sacral nerve stimulation for fecal incontinence: results of a 120-patient prospective multicenter study. *Ann Surg*. 2010;251(3):441–9.

56. Zbar AP. Sacral neuromodulation and peripheral nerve stimulation in patients with anal incontinence: an overview of techniques, complications and troubleshooting. *Gastroenterol Rep*. 2014;2(2):112–20.

57. Dudding TC, Hollingshead JR, Nicholls RJ, Vaizey CJ. Sacral nerve stimulation for faecal incontinence: optimizing outcome and managing complications. *Colorectal Dis*. 2011;13(8):e196–

58. Efron JE. The SECCA procedure: a new therapy for treatment of fecal incontinence. *Surg Technol Int*. 2004;13:107–10.
59. Efron JE, Corman ML, Fleshman J, et al. Safety and effectiveness of temperature-controlled radio-frequency energy delivery to the anal canal (Secca procedure) for the treatment of fecal incontinence. *Dis Colon Rectum*. 2003;46(12):1606–16. discussion 16–8.
60. Lam TJ, Visscher AP, Meurs-Szojda MM, Felt-Bersma RJ. Clinical response and sustainability of treatment with temperature-controlled radiofrequency energy (Secca) in patients with faecal incontinence: 3 years follow-up. *Int J Colorectal Dis*. 2014;29(6):755–61.
61. Felt-Bersma RJ. Temperature-controlled radiofrequency energy in patients with anal incontinence: an interim analysis of worldwide data. *Gastroenterol Rep*. 2014;2(2):121–5.
62. Felt-Bersma RJ, Szojda MM, Mulder CJ. Temperature-controlled radiofrequency energy (SECCA) to the anal canal for the treatment of faecal incontinence offers moderate improvement. *Eur J Gastroenterol Hepatol*. 2007;19(7):575–80.
63. Frascio M, Mandolino F, Imperatore M, et al. The SECCA procedure for faecal incontinence: a review. *Colorectal Dis*. 2014;16(3):167–72.
64. Herman RM, Berho M, Murawski M, et al. Defining the histopathological changes induced by non-ablative radiofrequency (RF) treatment of faecal incontinence—a blinded assessment in an animal model. *Colorectal Dis*. 2015;17:433–40.
65. Danielson J, Karlbom U, Wester T, Graf W. Efficacy and quality of life 2 years after treatment for faecal incontinence with injectable bulking agents. *Tech Coloproctol*. 2013;17(4):389–95.
66. Maeda Y, Laurberg S, Norton C. Perianal injectable bulking agents as treatment for faecal incontinence in adults. *Cochrane Database Syst Rev*. 2013;2, CD007959.
67. Parker SC, Spencer MP, Madoff RD, Jensen LL, Wong WD, Rothenberger DA. Artificial bowel sphincter: long-term experience at a single institution. *Dis Colon Rectum*. 2003;46(6):722–9.
68. O'Brien PE, Skinner S. Restoring control: the Acticon Neosphincter artificial bowel sphincter in the treatment of anal incontinence. *Dis Colon Rectum*. 2000;43(9):1213–6.
69. Wexner SD, Jin HY, Weiss EG, Nogueras JJ, Li VK. Factors associated with failure of the artificial bowel sphincter: a study of over 50 cases from Cleveland Clinic Florida. *Dis Colon Rectum*. 2009;52(9):1550–7.
70. Wong WD, Congliosi SM, Spencer MP, et al. The safety and efficacy of the artificial bowel sphincter for fecal incontinence: results from a multicenter cohort study. *Dis Colon Rectum*. 2002;45(9):1139–53.
71. Ruiz Carmona MD, Alos Company R, Roig Vila JV, Solana Bueno A, Pla MV. Long-term results of artificial bowel sphincter for the treatment of severe faecal incontinence. are they what we hoped for? *Colorectal Dis*. 2009;11(8):831–7.
72. O'Brien PE, Dixon JB, Skinner S, Laurie C, Khera A, Fonda D. A prospective, randomized, controlled clinical trial of placement of the artificial bowel sphincter (Acticon Neosphincter) for the control of fecal incontinence. *Dis Colon Rectum*. 2004;47(11):1852–60.
73. Gallas S, Leroi AM, Bridoux V, Lefebure B, Tuech JJ, Michot F. Constipation in 44 patients implanted with an artificial bowel sphincter. *Int J Colorectal Dis*. 2009;24(8):969–74.
74. Devesa JM, Rey A, Hervas PL, et al. Artificial anal sphincter: complications and functional results of a large personal series. *Dis Colon Rectum*. 2002;45(9):1154–63.
75. Pakravan F, Helmes C. Magnetic anal sphincter augmentation in patients with severe fecal

incontinence. *Dis Colon Rectum*. 2015;58(1):109–14.

76. Lehur PA, McNevin S, Buntzen S, Mellgren AF, Laurberg S, Madoff RD. Magnetic anal sphincter augmentation for the treatment of fecal incontinence: a preliminary report from a feasibility study. *Dis Colon Rectum*. 2010;53(12):1604–10.

77. Wong MT, Meurette G, Stangherlin P, Lehur PA. The magnetic anal sphincter versus the artificial bowel sphincter: a comparison of 2 treatments for fecal incontinence. *Dis Colon Rectum*. 2011;54(7):773–9.

78. Barussaud ML, Mantoo S, Wyart V, Meurette G, Lehur PA. The magnetic anal sphincter in faecal incontinence: is initial success sustained over time? *Colorectal Dis*. 2013;15(12):1499–503.

79. Norton C, Burch J, Kamm MA. Patients' views of a colostomy for fecal incontinence. *Dis Colon Rectum*. 2005;48(5):1062–9.

80. Colquhoun P, Kaiser Jr R, Efron J, et al. Is the quality of life better in patients with colostomy than patients with fecal incontinence? *World J Surg*. 2006;30(10):1925–8.

81. Malone PS, Ransley PG, Kiely EM. Preliminary report: the antegrade continence enema. *Lancet*. 1990;336(8725):1217–8.

82. Abbes Orabi N, Paterson HM, Goncette L, Danse E, Saey JP, Kartheuser A. Malone appendicostomy: an unexpected complication. *Tech Coloproctol*. 2011;15(1):81–3.

83. Ahn SM, Han SW, Choi SH. The results of antegrade continence enema using a retubularized sigmoidostomy. *Pediatr Surg Int*. 2004;20(7):488–91.

84. Aigner F, Conrad F, Margreiter R, Oberwalder M, Coloproctology Working Group. Anal submucosal carbon bead injection for treatment of idiopathic fecal incontinence: a preliminary report. *Dis Colon Rectum*. 2009;52(2):293–8.

85. Altomare DF, La Torre F, Rinaldi M, Binda GA, Pescatori M. Carbon-coated microbeads anal injection in outpatient treatment of minor fecal incontinence. *Dis Colon Rectum*. 2008;51(4):432–

86. Bartlett L, Ho YH. PTQ anal implants for the treatment of faecal incontinence. *Br J Surg*. 2009;96(12):1468–75.

87. Beggs AD, Irukulla S, Sultan AH, Ness W, Abulafi AM. A pilot study of ultrasound guided Durasphere injection in the treatment of faecal incontinence. *Colorectal Dis*. 2010;12(9):935–40.

88. Chan MK, Tjandra JJ. Injectable silicone biomaterial (PTQ) to treat fecal incontinence after hemorrhoidectomy. *Dis Colon Rectum*. 2006;49(4):433–9.

89. De la Portilla F, Fernandez A, Leon E, et al. Evaluation of the use of PTQ implants for the treatment of incontinent patients due to internal anal sphincter dysfunction. *Colorectal Dis*. 2008;10(1):89–94.

90. Hachiro Y, Kunimoto M, Abe T, Kitada M, Ebisawa Y. Aluminum potassium sulfate and tannic acid injection in the treatment of total rectal prolapse: early outcomes. *Dis Colon Rectum*. 2007;50(11):1996–2000.

91. Hussain ZI, Lim M, Mussa H, Abbas K, Stojkovic S. The use of Permacol(R) injections for the treatment of faecal incontinence. *Updates Surg*. 2012;64(4):289–95.

92. Kang SB, Lee HS, Lim JY, et al. Injection of porous polycaprolactone beads containing autologous myoblasts in a dog model of fecal incontinence. *J Korean Surg Soc*. 2013;84(4):216–24.

93. Kenefick NJ, Vaizey CJ, Malouf AJ, Norton CS, Marshall M, Kamm MA. Injectable silicone biomaterial for faecal incontinence due to internal anal sphincter dysfunction. *Gut*. 2002;51(2):225–8.

94. Maslekar S, Smith K, Harji D, Griffiths B, Sagar PM. Injectable collagen for the treatment of

- fecal incontinence: long-term results. *Dis Colon Rectum*. 2013;56(3):354–9.
95. Shafik A. Polytetrafluoroethylene injection for the treatment of partial fecal incontinence. *Int Surg*. 1993;78(2):159–61.
96. Siproudhis L, Morcet J, Laine F. Elastomer implants in faecal incontinence: a blind, randomized placebo-controlled study. *Aliment Pharmacol Ther*. 2007;25(9):1125–32.
97. Smith S, Callear J. Intra-anal collagen injection for the treatment of faecal incontinence (*Br J Surg* 2006; 93: 1514–1518). *Br J Surg*. 2007;94(5):643. author reply -4.
98. Soerensen MM, Lundby L, Buntzen S, Laurberg S. Intersphincteric injected silicone biomaterial implants: a treatment for faecal incontinence. *Colorectal Dis*. 2009;11(1):73–6.
99. Stojkovic SG, Lim M, Burke D, Finan PJ, Sagar PM. Intra-anal collagen injection for the treatment of faecal incontinence. *Br J Surg*. 2006;93(12):1514–8.
100. Tjandra JJ, Chan MK, Yeh HC. Injectable silicone biomaterial (PTQ) is more effective than carbon-coated beads (Durasphere) in treating passive faecal incontinence—a randomized trial. *Colorectal Dis*. 2009;11(4):382–9.
101. Tjandra JJ, Lim JF, Hiscock R, Rajendra P. Injectable silicone biomaterial for fecal incontinence caused by internal anal sphincter dysfunction is effective. *Dis Colon Rectum*. 2004;47(12):2138–46.
102. Ullah S, Tayyab M, Arsalani-Zadeh R, Duthie GS. Injectable anal bulking agent for the management of faecal incontinence. *J Coll Physicians Surg Pak*. 2011;21(4):227–9.
103. Vaizey CJ, Kamm MA. Injectable bulking agents for treating faecal incontinence. *Br J Surg*. 2005;92(5):521–7.
104. Vergara-Fernandez O, Valdovinos-Diaz MA, Hagerman-Ruiz Galindo G, Salinas-Aragon LE, Ruiz-Campos M, Castillo-Machado W. Improvement of fecal incontinence with silicone implants in patients with internal anal sphincter injury: first report in North America. *Rev Gastroenterol Mex*. 2011;76(4):384–8.
105. Watson NF, Koshy A, Sagar PM. Anal bulking agents for faecal incontinence. *Colorectal Dis*. 2012;14 Suppl 3:29–33.
106. Rosato G, Piccinini P, Oliveira L, Habr-Gamma A, Chwat C. Initial results of a new bulking agent for fecal incontinence: a multicenter study. *Dis Colon Rectum*. 2015;58(2):241–6.
107. Baeten CG, Konsten J, Spaans F, et al. Dynamic graciloplasty for treatment of faecal incontinence. *Lancet*. 1991;338(8776):1163–5.
108. Christiansen J, Sorensen M, Rasmussen OO. Gracilis muscle transposition for faecal incontinence. *Br J Surg*. 1990;77(9):1039–40.
109. Faucheron JL, Hannoun L, Thome C, Parc R. Is fecal continence improved by nonstimulated gracilis muscle transposition? *Dis Colon Rectum*. 1994;37(10):979–83.
110. Hassan MZ, Rathnayaka MM, Deen KI. Modified dynamic gracilis neosphincter for fecal incontinence: an analysis of functional outcome at a single institution. *World J Surg*. 2010;34(7):1641–7.
111. Korsgen S, Keighley MR. Stimulated gracilis neosphincter—not as good as previously thought. Report of four cases. *Dis Colon Rectum*. 1995;38(12):1331–3.
112. Rosen HR, Ausch C, Novi G, Zoch G, Feil W, Schiessel R. Anal sphincter restoration using dynamic graciloplasty—results of 50 patients. *Chirurg*. 1999;70(4):469–75.
113. Seccia M, Banti P, Zocco G, Viacava P. Restoration of fecal continence with chronic electrostimulation of gracilis muscle 17 years after a Pickrell's operation. *Int J Colorectal Dis*.

2001;16(6):391–4.

114. Shatari T, Fujita M, Kodaira S. Dynamic graciloplasty resulting fecal continence without electrical stimulation: report of a case. *Surg Today*. 2004;34(5):463–5.

115. Zailani MH, Azmi MN, Deen KI. Gracilis muscle as neoanal sphincter for faecal incontinence. *Med J Malaysia*. 2010;65(1):66–7.

116. Bock S, Folie P, Wolff K, Marti L, Engeler DS, Hetzer FH. First experiences with pudendal nerve stimulation in fecal incontinence: a technical report. *Tech Coloproctol*. 2010;14(1):41–4.

117. George AT, Dudding TC, Nicholls RJ, Vaizey CJ. A new minimally invasive technique for pudendal nerve stimulation. *Colorectal Dis*. 2012;14(1):98–103.

118. Kaiser AM, Orangio GR, Zutshi M, et al. Current status: new technologies for the treatment of patients with fecal incontinence. *Surg Endosc*. 2014;28(8):2277–301.

## 第 62 章

1. Lovell RM, Ford AC. Global prevalence of and risk factors for irritable bowel syndrome: a meta-analysis. *Clin Gastroenterol Hepatol*. 2012;10(7):712–21.

2. Rey E, Talley NJ. Irritable bowel syndrome: novel views on the epidemiology and potential risk factors. *Dig Liver Dis*. 2009;41(11):772–80.

3. Choung RS, Locke 3rd GR. Epidemiology of IBS. *Gastroenterol Clin North Am*. 2011;40(1):1–10.

4. Lovell RM, Ford AC. Effect of gender on prevalence of irritable bowel syndrome in the community: systematic review and meta-analysis. *Am J Gastroenterol*. 2012;107(7):991–1000.

5. Chey WD, Kurlander J, Eswaran S. Irritable bowel syndrome: a clinical review. *JAMA*. 2015;313(9):949–58.

6. Bye W, Ishaq N, Bolin TD, Duncombe VM, Riordan SM. Overgrowth of the indigenous gut microbiome and irritable bowel syndrome. *World J Gastroenterol*. 2014;20(10):2449–55.

7. Thabane M, Simunovic M, Akhtar-Danesh N, Garg AX, Clark WF, Collins SM, Salvadori M, Marshall JK. An outbreak of acute bacterial gastroenteritis is associated with an increased incidence of irritable bowel syndrome in children. *Am J Gastroenterol*. 2010;105(4):933–9.

8. Manning AP, Thompson WG, Heaton KW, Morris AF. Towards positive diagnosis of the irritable bowel. *Br Med J*. 1978;2(6138):653–4.

9. Longstreth GF, Thompson WG, Chey WD, Houghton LA, Mearin F, Spiller RC. Functional bowel disorders. *Gastroenterology*. 2006;130(5):1480–91.

10. American College of Gastroenterology Task Force on Irritable Bowel Syndrome, Brandt LJ, Chey WD, Foxx-Orenstein AE, Schiller LR, Schoenfeld PS, Spiegel BM, Talley NJ, Quigley EM. An evidence-based position statement on the management of irritable bowel syndrome. *Am J Gastroenterol*. 2009;104 Suppl 1:S1–35.

11. Sainsbury A, Sanders DS, Ford AC. Prevalence of irritable bowel syndrome-type symptoms in patients with celiac disease: a meta-analysis. *Clin Gastroenterol Hepatol*. 2013;11(4):359–65.

12. Furman DL, Cash BD. The role of diagnostic testing in irritable bowel syndrome. *Gastroenterol Clin North Am*. 2011;40(1):105–19.

13. Lewis SJ, Heaton KW. Stool form scale as a useful guide to intestinal transit time. *Scand J Gastroenterol*. 1997;32(9):920–4.

14. Rona RJ, Keil T, Summers C, Gislason D, Zuidmeer L, Sodergren E, Sigurdardottir ST, Lindner T, Goldhahn K, Dahlstrom J, McBride D, Madsen C. The prevalence of food allergy: a meta-analysis. *J Allergy Clin Immunol*. 2007;120(3):638–46.
15. Simrén M, Månsson A, Langkilde AM, Svedlund J, Abrahamsson H, Bengtsson U, Björnsson ES. Food-related gastrointestinal symptoms in the irritable bowel syndrome. *Digestion*. 2001;63(2):108–15.
16. Hayes P, Corish C, O'Mahony E, Quigley EM. A dietary survey of patients with irritable bowel syndrome. *J Hum Nutr Diet*. 2014;27 Suppl 2:36–47.
17. Biesiekierski JR, Newnham ED, Irving PM, Barrett JS, Haines M, Doecke JD, Shepherd SJ, Muir JG, Gibson PR. Gluten causes gastrointestinal symptoms in subjects without celiac disease: a double-blind randomized placebo-controlled trial. *Am J Gastroenterol*. 2011;106(3):508–14.
18. Vazquez-Roque MI, Camilleri M, Smyrk T, Murray JA, Marietta E, O'Neill J, Carlson P, Lamsam J, Janzow D, Eckert D, Burton D, Zinsmeister AR. A controlled trial of gluten-free diet in patients with irritable bowel syndrome-diarrhea: effects on bowel frequency and intestinal function. *Gastroenterology*. 2013;144(5):903–11.
19. Biesiekierski JR, Peters SL, Newnham ED, Rosella O, Muir JG, Gibson PR. No effects of gluten in patients with self-reported non-celiac gluten sensitivity after dietary reduction of fermentable, poorly absorbed, short-chain carbohydrates. *Gastroenterology*. 2013;145(2):320–8.
20. Halmos EP, Power VA, Shepherd SJ, Gibson PR, Muir JG. A diet low in FODMAPs reduces symptoms of irritable bowel syndrome. *Gastroenterology*. 2014;146(1):67–75.
21. Staudacher HM, Lomer MC, Anderson JL, Barrett JS, Muir JG, Irving PM, Whelan K. Fermentable carbohydrate restriction reduces luminal bifidobacteria and gastrointestinal symptoms in patients with irritable bowel syndrome. *J Nutr*. 2012;142(8):1510–8.
22. Bijkerk CJ, de Wit NJ, Muris JW, Whorwell PJ, Kottnerus JA, Hoes AW. Soluble or insoluble fibre in irritable bowel syndrome in primary care? Randomised placebo controlled trial. *BMJ*. 2009;339:b3154.
23. Moayyedi P, Quigley EM, Lacy BE, Lembo AJ, Saito YA, Schiller LR, Soffer EE, Spiegel BM, Ford AC. The effect of fiber supplementation on irritable bowel syndrome: a systematic review and meta-analysis. *Am J Gastroenterol*. 2014;109(9):1367–74.
24. Ford AC, Moayyedi P, Lacy BE, Lembo AJ, Saito YA, Schiller LR, Soffer EE, Spiegel BM, Quigley EM, Task Force on the Management of Functional Bowel Disorders. American College of Gastroenterology monograph on the management of irritable bowel syndrome and chronic idiopathic constipation. *Am J Gastroenterol*. 2014;109 Suppl 1:S226.
25. Halvorson HA, Schlett CD, Riddle MS. Postinfectious irritable bowel syndrome--a meta-analysis. *Am J Gastroenterol*. 2006;101(8):1894–9.
26. Abbasi MH, Zahedi M, Darvish Moghadam S, Shafieipour S, HayatBakhsh Abbasi M. Small bowel bacterial overgrowth in patients with irritable bowel syndrome: the first study in Iran. *Middle East J Dig Dis*. 2015;7(1):36–40.
27. Moraru IG, Moraru AG, Andrei M, Lordache T, Drug V, Diculescu M, Portincasa P, Dumitrascu DL. Small intestinal bacterial overgrowth is associated to symptoms in irritable bowel syndrome. Evidence from a multicentre study in Romania. *Rom J Intern Med*. 2014;52(3):143–50.
28. Ford AC, Spiegel BM, Talley NJ, Moayyedi P. Small intestinal bacterial overgrowth in irritable bowel syndrome: systematic review and meta-analysis. *Clin Gastroenterol Hepatol*. 2009;7(12):1279–86.

29. Spiegel BM. Questioning the bacterial overgrowth hypothesis of irritable bowel syndrome: an epidemiologic and evolutionary perspective. *Clin Gastroenterol Hepatol*. 2011;9(6):461–9.
30. Menees SB, Maneerattannaporn M, Kim HM, Chey WD. The efficacy and safety of rifaximin for the irritable bowel syndrome: a systematic review and meta-analysis. *Am J Gastroenterol*. 2012;107(1):28–35.
31. Johannesson E, Simrén M, Strid H, Bajor A, Sadik R. Physical activity improves symptoms in irritable bowel syndrome: a randomized controlled trial. *Am J Gastroenterol*. 2011;106(5):915–22.
32. Ford AC, Quigley EM, Lacy BE, Lembo AJ, Saito YA, Schiller LR, Soffer EE, Spiegel BM, Moayyedi P. Effect of antidepressants and psychological therapies, including hypnotherapy, in irritable bowel syndrome: systematic review and meta-analysis. *Am J Gastroenterol*. 2014;109(9):1350–65.
33. Manheimer E, Wieland LS, Cheng K, Li SM, Shen X, Berman BM, Lao L. Acupuncture for irritable bowel syndrome: systematic review and meta-analysis. *Am J Gastroenterol*. 2012;107(6):835–47.
34. Ruepert L, Quartero AO, de Wit NJ, van der Heijden GJ, Rubin G, Muris JW. Bulking agents, antispasmodics and antidepressants for the treatment of irritable bowel syndrome. *Cochrane Database Syst Rev*. 2011;(8).
35. Khanna R, MacDonald JK, Levesque BG. Peppermint oil for the treatment of irritable bowel syndrome: a systematic review and meta-analysis. *J Clin Gastroenterol*. 2014;48(6):505–12.
36. Goldberg PA, Kamm MA, Setti-Carraro P, van der Sijp JR, Roth C. Modification of visceral sensitivity and pain in irritable bowel syndrome by 5-HT<sub>3</sub> antagonism (ondansetron). *Digestion*. 1996;57(6):478–83.
37. Houghton LA, Foster JM, Whorwell PJ. Alosetron, a 5-HT<sub>3</sub> receptor antagonist, delays colonic transit in patients with irritable bowel syndrome and healthy volunteers. *Aliment Pharmacol Ther*. 2000;14(6):775–82.
38. Garsed K, Chernova J, Hastings M, Lam C, Marciani L, Singh G, Henry A, Hall I, Whorwell P, Spiller R. A randomised trial of ondansetron for the treatment of irritable bowel syndrome with diarrhoea. *Gut*. 2014;63(10):1617–25.
39. Prather CM, Camilleri M, Zinsmeister AR, McKinzie S, Thomforde G. Tegaserod accelerates orocecal transit in patients with constipation-predominant irritable bowel syndrome. *Gastroenterology*. 2000;118(3):463–8.
40. Forte LR. Guanylin regulatory peptides: structures, biological activities mediated by cyclic GMP and pathobiology. *Regul Pept*. 1999;81(1–3):25–39.
41. Videlock EJ, Cheng V, Cremonini F. Effects of linaclotide in patients with irritable bowel syndrome with constipation or chronic constipation: a meta-analysis. *Clin Gastroenterol Hepatol*. 2013;11(9):1084–92.
42. Drossman DA, Chey WD, Johanson JF, Fass R, Scott C, Panas R, Ueno R. Clinical trial: lubiprostone in patients with constipation-associated irritable bowel syndrome--results of two randomized, placebo-controlled studies. *Aliment Pharmacol Ther*. 2009;29(3):329–41.
43. Chapman RW, Stanghellini V, Geraint M, Halphen M. Randomized clinical trial: macrogol/PEG 3350 plus electrolytes for treatment of patients with constipation associated with irritable bowel syndrome. *Am J Gastroenterol*. 2013;108(9):1508–15.
44. Park DH, Yoon SG, Kim KU, Hwang DY, Kim HS, Lee JK, Kim KY. Comparison study between electrogalvanic stimulation and local injection therapy in levator ani syndrome. *Int J Colorectal Dis*.



2005;20:272–6.

45. Ger GC, Wexner SD, Jorge JM, Lee E, Amaranath LA, Heymen S, Nogueras JJ, Jagelman DG. Evaluation and treatment of chronic intractable rectal pain--a frustrating endeavor. *Dis Colon Rectum*. 1993;36:139–45.
46. Chiarioni G, Nardo A, Vantini I, Romito A, Whitehead WE. Biofeedback is superior to electrogalvanic stimulation and massage for treatment of levator ani syndrome. *Gastroenterology*. 2010;138:1321–9.
47. Rao SS, Paulson J, Mata M, Zimmerman B. Clinical trial: effects of botulinum toxin on Levator ani syndrome--a double-blind, placebo-controlled study. *Aliment Pharmacol Ther*. 2009;29:985–91.
48. Salvati EP. The levator syndrome and its variant. *Gastroenterol Clin North Am*. 1987;16:71–8.
49. Grant SR, Salvati EP, Rubin RJ. Levator syndrome: an analysis of 316 cases. *Dis Colon Rectum*. 1975;18:161–3.
50. Simpson JY. Coccygodynia and discuss and deformities of the coccyx. *Med Times Gaz*. 1859;1:1–7.
51. Maigne JY, Lagauche D, Doursounian L. Instability of the coccyx in coccydynia. *J Bone Joint Surg (Br)*. 2000;82:1038–41.
52. Maigne JY, Doursounian L, Chatellier G. Causes and mechanisms of common coccydynia: role of body mass index and coccygeal trauma. *Spine (Phila Pa 1976)*. 2000;25:3072–9.
53. Traycoff RB, Crayton H, Dodson R. Sacrococcygeal pain syndromes: diagnosis and treatment. *Orthopedics*. 1989;12:1373–7.
54. Mazza L, Formento E, Fonda G. Anorectal and perineal pain: new pathophysiological hypothesis. *Tech Coloproctol*. 2004;8:77–83.
55. Maigne JY, Chatellier G, Faou ML, Archambeau M. The treatment of chronic coccydynia with intrarectal manipulation: a randomized controlled study. *Spine (Phila Pa 1976)*. 2006;31:E621–7.
56. Cebesoy O, Guclu B, Kose KC, Basarir K, Guner D, Us AK. Coccygectomy for coccygodynia: do we really have to wait? *Injury*. 2007;38:1183–8.
57. Wray C, Esom S, Hoskinson J. Coccydynia: etiology and treatment. *J Bone Joint Surg Am*. 1991;73B(2):335–8.
58. Robert R, Prat-Pradal D, Labat JJ, Bensignor M, Raoul S, Rebai R, Leborgne J. Anatomic basis of chronic perineal pain: role of the pudendal nerve. *Surg Radiol Anat*. 1998;20:93–8.
59. Labat JJ, Riant T, Robert R, Amarenco G, Lefaucheur JP, Rigaud J. Diagnostic criteria for pudendal neuralgia by pudendal nerve entrapment (Nantes criteria). *Neurourol Urodyn*. 2008;27:306–10.
60. Vancaillie T, Eggermont J, Armstrong G, Jarvis S, Liu J, Beg N. Response to pudendal nerve block in women with pudendal neuralgia. *Pain Med*. 2012;13(4):596–603.
61. Mamlouk MD, vanSonnenberg E, Dehkharghani S. CT-guided nerve block for pudendal neuralgia: diagnostic and therapeutic implications. *AJR Am J Roentgenol*. 2014;203(1):196–200.
62. Schelhorn J, Habenicht U, Malessa R, Dannenberg C. Magnetic resonance imaging-guided perineural therapy as a treatment option in young adults with pudendal nerve entrapment syndrome. *Clin Neuroradiol*. 2013;23(2):161–3.
63. Rigoard P, Delmotte A, Moles A, Hervochon R, Vrignaud T, Misbert L, Lafay N, D'houtaud S, Frasca D, Guenot C, Giot JP, Diallo B, Bataille B. Successful treatment of pudendal neuralgia with tricolumn spinal cord stimulation: case report. *Neurosurgery*. 2012;71(3):E757–62.
64. Valovska A, Peccora CD, Philip CN, Kaye AD, Urman RD. Sacral neuromodulation as a

treatment for pudendal neuralgia. *Pain Physician*. 2014;17(5):E645–50.

65. Prologo JD, Lin RC, Williams R, Corn D. Percutaneous CT-guided cryoablation for the treatment of refractory pudendal neuralgia. *Skeletal Radiol*. 2015;44(5):709–14.

66. Hibner M, Castellanos ME, Drachman D, Balducci J. Repeat operation for treatment of persistent pudendal nerve entrapment after pudendal neurolysis. *J Minim Invasive Gynecol*. 2012;19(3):325–30.

67. Erdogru T, Avci E, Akand M. Laparoscopic pudendal nerve decompression and transposition combined with omental flap protection of the nerve (Istanbul technique): technical description and feasibility analysis. *Surg Endosc*. 2014;28(3):925–32.

68. Venturi M, Boccasanta P, Lombardi B, Brambilla M, Contessini Avesani E, Vergani C. Pudendal neuralgia: a new option for treatment? Preliminary results on feasibility and efficacy. *Pain Med*. 2015;16:1475–81.

## 第 63 章

1. Lim M, Sagar PM, Gonsalves S, Thekkinkattil D, Landon C. Surgical management of pelvic organ prolapse in females: functional outcome of mesh sacrocolpopexy and rectopexy as a combined procedure. *Dis Colon Rectum*. 2007;50:1412–21.

2. Amico JC, Marino AWM. Prolapse of the vagina in association with rectal procidentia. *Dis Colon Rectum*. 1968;11:115–9.

3. Kirkley WH, Gilbert JC, McDaniel GC, Pickel GL. Rectal prolapse. *Am J Obstet Gynecol*. 1970;108:20–1.

4. Azpuru CE. Total rectal prolapse and total genital prolapse: a series of 17 cases. *Dis Colon Rectum*. 1974;17:528–31.

5. Johansson C, Ihre T, Ahlback SO. Disturbances in the defecation mechanism with special reference to intussusception of the rectum (internal procidentia). *Dis Colon Rectum*. 1985;28:920–4.

6. Tancer ML, Fleischer M, Berkowitz BJ. Simultaneous colpo-recto-sacropepy. *Obstet Gynecol*. 1987;70:951–5.

7. Baker KR, Drutz HP, Sterm HS, Deutsch A. Combining coloposacropepy and Ripstein procedure for combined vaginal vault and rectal prolapse: with and without retropubic colpourethropepy for stress urinary incontinence. *Int Urogynecol J*. 1990;1(4):228–32.

8. Barham K, Collopy BT. Post-hysterectomy rectal and vaginal prolapse: a commonly overlooked problem. *Aust N Z J Obstet Gynaecol*. 1993;33:300–3.

9. Dekel A, Rabinerson D, Rafael ZB, Kaplan B, Mislovaty B, et al. Concurrent genital and rectal prolapse: two pathologies—one joint operation. *BJOG*. 2000;107:125–9.

10. Nager CW, Kumar D, Kahn MA, Stanton SL. Management of pelvic floor dysfunction. *Lancet*. 1997;350(9093):1751.

11. Spence-Jones C, Kamm MA, Henry MM, Hudson CN. Bowel dysfunction: a pathogenetic factor in uterovaginal prolapse and stress urinary incontinence. *Br J Obstet Gynaecol*. 1994;101:147–52.

12. Kahn MA, Stanton SL. Posterior colporrhaphy: it's effects on bowel and sexual function. *Br J Obstet Gynaecol*. 1997;104:82–6.

13. Mellgren A, Bremner S, Johansson C, Dolk A, Uden R, Ahlback SO, Holmstrom B.

Defecography. Results of investigations in 2,816 patients. *Dis Colon Rectum*. 1994;37(11):1133–41.

14. Hausammann R, Steffen T, Wishaupt D, Beutner U, Hetzer FH. Rectocele and intussusception: is there any coherence in symptoms or additional pelvic floor disorders? *Tech Coloproctol*. 2009;13:17–26.

15. Peters WA, Smith MR, Drescher CW. Rectal prolapse in women with other defects of pelvic floor support. *Am J Obstet Gynecol*. 2000;184(7):1488–95.

16. Thompson JR, Chen AH, Pettit PDM, Bridges MD. Incidence of occult rectal prolapse in patients with clinical rectoceles and defecatory dysfunction. *Am J Obstet Gynecol*. 2002;187:1494–500.

17. Kapoor DS, Sultan AH, Thakar R, Abulafi MA, Swift RI, Ness W. Management of complex pelvic floor disorders in a multidisciplinary pelvic floor clinic. *Colorectal Dis*. 2007;10:118–23.

18. Federative Committee on Anatomical Terminology. *Terminologia anatomica*. New York: Thieme; 1998. Stuttgart (Germany).

19. Singh K, Reid WM, Berger LA. Magnetic resonance imaging of normal levator ani anatomy and function. *Obstet Gynecol*. 2002;99:433–8.

20. Berglas B, Rubin IC. The study of the supportive structures of the uterus by levator myography. *Surg Gynecol Obstet*. 1953;97:677–92.

21. Lawson JON. Pelvic anatomy I. Pelvic floor muscles. *Ann R Coll Surg Engl*. 1974;54:244–52.

22. DeLancey JOL, Starr RA. Histology of the connection between the vagina and levator ani muscles: implications for the urinary function. *J Reprod Med*. 1990;35:765–71.

23. Corton MM. Anatomy of the pelvis: how the pelvis is built for support. *Clin Obstet Gynecol*. 2005;48(3):611–26.

24. Stein TA, DeLancey JO. Structure of the perineal membrane in females: gross and microscopic anatomy. *Obstet Gynecol*. 2008;111:686–93.

25. DeLancey JOL. The anatomy of the pelvic floor. *Curr Opin Obstet Gynecol*. 1994;6:313–6.

26. Uhlenhuth E, Day E, Smith RD, Middleton EB. The visceral endopelvic fascia and the hypogastric sheath. *Surg Gynecol Obstet*. 1948;86:9–28.

27. DeLancey JOL. Anatomy and biomechanics of genital prolapse. *Clin Obstet Gynecol*. 1993;36:897–909.

28. DeLancey JO. Structural anatomy of the posterior pelvic compartment as it relates to rectocele. *Am J Obstet Gynecol*. 1994;180(4):815–23.

29. Norton PA. Pelvic floor disorders: the role of fascia and ligaments. *Clin Obstet Gynecol*. 1993;36:926–38.

30. Kuhn RJP, Hollyock VE. Observations of the anatomy of the rectovaginal pouch and rectovaginal septum. *Obstet Gynecol*. 1982;59:445–7.

31. Leffler KS, Thompson JR, Cundiff GW, et al. Attachment of the rectovaginal septum to the pelvic sidewall. *Am J Obstet Gynecol*. 2001;185:41–3.

32. Kleeman SD, Westermann C, Karram MM. Rectoceles and the anatomy of the posterior vaginal wall: revisited. *Am J Obstet Gynecol*. 2005;193(6):2050–5.

33. DeLancey JOL. Anatomic aspects of vaginal eversion after hysterectomy. *Am J Obstet Gynecol*. 1992;166:1724–8.

34. DeLancey JOL, Kearney R, Chou Q, et al. The appearance of levator ani muscle abnormalities in magnetic resonance images after vaginal deliveries. *Obstet Gynecol*. 2003;101:46–53.

35. Hsu Y, Summers A, Hussain HK, et al. Levator plate angle in women with pelvic organ prolapse compared to women with normal support using dynamic MR imaging. *Am J Obstet Gynecol.* 2006;194:1427–33.
36. Wong MY, Harmanli OH, Agar M, et al. Collagen content of nonsupport tissue in pelvic organ prolapse and stress urinary incontinence. *Am J Obstet Gynecol.* 2003;189:1597–9.
37. Bump RC, Mattiasson A, Bø K, Brubaker LP, DeLancey JO, Klarskov P, et al. The standardization of terminology of female pelvic organ prolapse and pelvic floor dysfunction. *Am J Obstet Gynecol.* 1996;175(1):10–7.
38. Walters MD, Ridgeway B. Surgical treatment of vaginal apex prolapse. *Obstet Gynecol.* 2013;121(2):354–74.
39. Brubaker L, Cundiff GW, Fine P, Nygaard I, Richter HE, Visco AG, et al; Pelvic Floor Disorders Network. Abdominal sacrocolpopexy with Burch colposuspension to reduce urinary stress incontinence. *N Engl J Med.* 2006;354:1557–1566.
40. Wei JT, Nygaard I, Richter HE, Nager CW, Barber MD, Kenton K, et al; Pelvic Floor Disorders Network. A midurethral sling to reduce incontinence after vaginal prolapse repair. *N Engl J Med.* 2012;366:2358–2367.
41. Abrams P, Cardoza L, Khoury S, Wein A, eds. *Incontinence*, 5th ed. Paris; 2013.
42. Culligan PJ. Nonsurgical management of pelvic organ prolapse. *Obstet Gynecol.* 2012;119(4):852–60.
43. Wong V, Shek KL, Goh J, Krause H, Martin A, Dietz HP. Cystocele recurrence after anterior colporrhaphy with and without mesh use. *Eur J Obstet Gynecol Reprod Biol.* 2014;172:131–5.
44. Maher C, Feiner B, Baessler K, Schmid C. Surgical management of pelvic organ prolapse in women. *Cochrane Database Syst Rev.* 2013;(4):CD004014. doi: 10.1002/14651858.CD004014.pub5.
45. Margulies RU, Rogers MA, Morgan DM. Outcomes of transvaginal uterosacral ligament suspension: systematic review and metaanalysis. *Am J Obstet Gynecol.* 2010;202(2):124–34.
46. Whiteside JL, Weber AM, Meyn LA, Walters MD. Risk factors for prolapse recurrence after vaginal repair. *Am J Obstet Gynecol.* 2004;191(5):1533–8.
47. Paraiso MF, Ballard LA, Walters MD, Lee JC, Mitchinson AR. Pelvic support defects and visceral and sexual function in women treated with sacrospinous ligament suspension and pelvic reconstruction. *Am J Obstet Gynecol.* 1996;175(6):1423–30.
48. Abbasy S, Kenton K. Obliterative procedures for pelvic organ prolapse. *Clin Obstet Gynecol.* 2010;53(1):86–98.
49. Culligan PJ, Blackwell L, Goldsmith LJ, Graham CA, Rogers A, Heit MH. A randomized controlled trial comparing fascia lata and synthetic mesh for sacral colpopexy. *Obstet Gynecol.* 2005;106(1):29–37.
50. Tate SB, Blackwell L, Lorenz DJ, Steptoe MM, Culligan PJ. Randomized trial of fascia lata and polypropylene mesh for abdominal sacrocolpopexy: 5-year follow-up. *Int Urogynecol J.* 2011;22(2):137–43.
51. Ayav A, Bresler L, Brunaud L, Zarnegar R, Boissel P. Surgical management of combined rectal and genital prolapse in young patients: transabdominal approach. *Int J Colorectal Dis.* 2005;20(2):173–9.
52. Collopy BT, Barham K. Abdominal colpoproctopexy with pelvic cul-de-sac closure. *Dis Colon Rectum.* 2002;45(4):522–9.

53. Greene KA, Sanchez JE, Campbell ML, Marcet JE. Robot-assisted recopexy and colpopexy for rectal prolapse. *Int Urogynecol J*. 2014;25(4):553–5.
54. Lauretta A, Bellomo RE, Galanti F, Tonizzo CA, Infantino A. Laparoscopic low ventral rectocolpopexy (LLVR) for rectal and rectogenital prolapse: surgical technique and functional results. *Tech Coloproctol*. 2012;16(6):477–83.
55. Sagar PM, Thekkinkattil DK, Heath RM, Woodfield J, Gonsalves S, Landon CR. Feasibility and functional outcome of laparoscopic sacrocolporectopexy for combined vaginal and rectal prolapse. *Dis Colon Rectum*. 2008;51(9):1414–20.
56. Lim M, Sagar PM, Gonsalves S, Thekkinkattil D, Landon C. Prolapse in females: functional outcome of mesh sacrocolpopexy and rectopexy as a combined procedure. *Dis Colon Rectum*. 2007;50(9):1–10.
57. Watadani Y, Vogler SA, Warshaw JS, Sueda T, Lowry AC, Madoff RD, Mellgren A. Sacrocolpopexy with rectopexy for pelvic floor prolapse improves bowel function and quality of life. *Dis Colon Rectum*. 2013;56(12):1415–22.
58. Slawik S, Soulsby R, Carter H, Payne H, Dixon AR. Laparoscopic ventral rectopexy, posterior colporrhaphy and vaginal sacrocolpopexy for the treatment of recto-genital prolapse and mechanical outlet obstruction. *Colorectal Dis*. 2008;10(2):138–43.
59. VanderPas LS, Massengill J, Sheriden MJ, Stern LE, von Pechmann W. Safety of combined abdominal sacral colpopexy and sigmoid resection with suture rectopexy: a retrospective cohort study. *Female Pelvic Med Reconstr Surg*. 2015;21(1):18–24.
60. Cottle L, Riordan T. Infectious spondylodiscitis. *J Infect*. 2008;56(6):401–12.
61. Apostolis CA, Heiselman C. Sacral osteomyelitis after laparoscopic sacral colpopexy performed after a recent dental extraction: a case report. *Female Pelvic Med Reconstr Surg*. 2014;20(6):e5–7.
62. Downing KT. Vertebral osteomyelitis and epidural abscess after laparoscopic uterus-preserving cervicosacropepy. *J Minim Invasive Gynecol*. 2008;15(3):370–2.
63. Unger CA, Paraiso MF, Jelovsek JE, Barber MD, Ridgeway B. Perioperative adverse events after minimally invasive abdominal sacrocolpopexy. *Am J Obstet Gynecol*. 2014;211(5):547. e1–8.
64. Propst K, Tunitsky-Biton E, Schimpf MO, Ridgeway B. Pyogenic spondylodiscitis associated with sacral colpopexy and rectopexy: report of two cases and evaluation of the literature. *Int Urogynecol J*. 2014;25(1):21–31.
65. Puigdollers A, Fernandez-Fraga X, Azpiroz F. Persistent symptoms of functional outlet obstruction after rectocele repair. *Colorectal Dis*. 2007;9(3):262–5.
66. Weber AM, Walters MD, Ballard LA, et al. Posterior vaginal prolapse and bowel function. *Am J Obstet Gynecol*. 1998;179:1446–9.
67. Paraiso MFR, Weber AM, Walters MD, Ballard LA, Piedmonte MR, Skibinski C. Anatomic and functional outcome after posterior colporrhaphy. *J Pelvic Surg*. 2001;7(6):335–9.
68. Altman D, Zetterstrom J, Mellgren A, Gustafsson C, Anzen B, Lopez A. A 3-year prospective assessment of rectocele repair using porcine xenograft. *Obstet Gynecol*. 2006;107(1):59–65.
69. Sand PK, Koduri S, Lobel RW, et al. Prospective randomized trial of polyglactin 910 mesh to prevent recurrence of cystoceles and rectoceles. *Am J Obstet Gynecol*. 2001;184(7):1357–62.
70. Karram M, Maher C. Surgery for posterior vaginal wall prolapse. *Int Urogynecol J*. 2013;24(11):1835–41.
71. Abramov Y, Gandhi S, Goldberg RP, Botros SM, Kwon C, Sand PK. Site-specific rectocele repair compared with standard posterior colporrhaphy. *Obstet Gynecol*. 2005;105(2):314–8.

72. Paraiso MFR, Barber MD, Muir TW, Walters MD. Rectocele repair: a randomized trial of three surgical techniques including graft augmentation. *Am J Obstet Gynecol.* 2006;195(6):1762–71.
73. Sung VW, Rardin CR, Raker CA, Lasala CA, Myers DL. Porcine subintestinal submucosal graft augmentation for rectocele repair: a randomized controlled trial. *Obstet Gynecol.* 2012;119(1):125–33.
74. Marks MM. The rectal side of the rectocele. *Dis Colon Rectum.* 1967;10(5):387–8.
75. Kahn MA, Stanton SL, Kumar D, Fox SD. Posterior colporrhaphy is superior to the transanal repair for treatment of posterior vaginal wall prolapse. *Neurourol Urodyn.* 1999;18(4):70–1.
76. Nieminen K, Hiltunen KM, Laitinen J, Oksala J, Heinonen PK. Transanal or vaginal approach to rectocele repair: a prospective, randomized pilot study. *Dis Colon Rectum.* 2004;47(10):1636–42.

## 第 64 章

1. Winkler NS, Kennedy AM, Woodward PJ. Cloacal malformation: embryology, anatomy, and prenatal imaging features. *J. Ultrasound Med.* 2012; 31(11): 1843–55.
2. Pena A, Bischoff A, Breech L, Loudon E, Levitt MA. Posterior cloaca: further experience and guidelines for the treatment of an unusual anorectal malformation. *J Pediatr Surg.* 2010; 45: 1234–40.
3. Selfert AW, Harfe BD, Cohn MJ. Cell lineage analysis demonstrates an endodermal origin of the distal urethra and perineum. *Dev Biol.* 2008; 318(1): 143–52.
4. Paidas CN, Morreale RF, Holoski KM, Lund RE, Hutchins GM. Septation and differentiation of the embryonic human cloaca. *J Pediatr Surg.* 1999; 34: 877–84.
5. DeUgarte CM, Bast J. Embryology of the urogenital system and congenital anomalies of the female genital tract. In Nathan L, DeCherney AH, editors. *Current diagnosis and treatment: obstetrics and gynecology.* New York: McGraw-Hill Medical; 2006. p. 38–66.
6. Bien-Willner GA, Stankiewicz P, Lupski JR. SOX9<sup>cre1</sup>, a cis-acting regulatory element located 1.1 Mb upstream of SOX9, mediates its enhancement through the SHH pathway. *Hum Mol Genet.* 2007; 16(10): 1143–56.
7. Bischoff A, Levitt M, Breech L, Loudon E, Pena A. Hydrocolpos in cloacal malformations. *J Pediatr Surg.* 2010; 45(6): 1241–5.
8. Speck KE et al. Cloaca and hydrocolpos: laparoscopic-, cystoscopic- and colposcopic-assisted vaginostomy tube placement. *J Pediatr Surg.* 2014;49(12):1867–9.
9. Jarboe MD, Teitelbaum DH, Dillman JR. Combined 3D rotational fluoroscopic-MRI cloacagram procedure defines luminal and extraluminal pelvic anatomy prior to surgical reconstruction of cloacal and other complex pelvic malformations. *Pediatr Surg Int.* 2012;28(8):757–63.
10. Herman RS, Teitelbaum D. Anorectal Malformations. *Clin Perinatol.* 2012; 39(2): 403–22.
11. Pena A. Total urogenital mobilization-an easier way to repair cloacas. *J Pediatr Surg.* 1997;32:263–8.
12. Sawaya D, Goldstein S, Seethara R, Suson K, Nabaweesi R, Colombani P, Gearhart J. Gastrointestinal ramifications of the cloacal exstrophy complex: a 44-year experience. *J Pediatr Surg.* 2010; 45: 171–6.
13. Holschneider AM, Hutson JM. Anorectal malformations in children. Berlin: Springer; 2006. p.

49–55.

14. Sadler TW. Langman's Medical Embryology. 8th ed. (Eds. Sadler & Langman) LW&W Publishing. 2000;297–301.
15. Nichol PF, Reeder A, Botham R. Humans, mice, and mechanisms of intestinal atresias: a window into understanding early intestinal development. *J Gastrointest Surg.* 2011; 15: 694–700.
16. Ornitz DM, Itoh N. Fibroblast growth factors. *Genome Biol.* 2001; 2(3)(3005): 1–9.
17. Fairbanks TJ, De Langhe S, Sala FG, Warburton D, Anderson KD, Bellusci S, Burns RC. Fibroblast growth factor 10 (Fgf10) invalidation results in anorectal malformation in mice. *J Pediatr Surg.* 2004; 39(3): 360–5.
18. Fairbanks TJ, Sala FG, Kanard R, et al. The fibroblast growth factor pathway serves a regulatory role in proliferation and apoptosis in the pathogenesis of intestinal atresia. *J Pediatr Surg.* 2006; 41(1): 132–6.
19. Zhang J, Zhang ZB, Gao H, Zhang D, Wang WL. Down-regulation of SHH/BMP4 signalling in human anorectal malformations. *J Int Med Res.* 2009; 37: 1842–50.
20. Tai CC, Sala FG, Ford HR, et al. Wnt5a knock-out mouse as a new model of anorectal malformation. *J Surg Res.* 2009; 156: 278–82.
21. Gao N, White P, Kaestner KH. Establishment of intestinal identity and epithelial-mesenchymal signaling by Cdx2. *Dev Cell.* 2009; 16(4): 588–99.
22. Mundt E, Bates M. Genetics of Hirschsprung disease and anorectal malformations. *Semin Pediatr Surg.* 2010; 19: 107–17.
23. Solomon BD. VACTERL/VATER Association. *Orphanet J Rare Dis.* 2011; 6(56): 1–12.
24. Hong AR, Acuna MF, Pena A, et al. Urologic injuries associated with repair of anorectal malformation in male patients. *J Ped Surg.* 2002; 37(3): 339–44.
25. Peña A. Anorectal malformations. *Semin Pediatr Surg.* 1995;5:35–41.
26. Georgeson KE, Inge TH, Albanese CT. Laparoscopically assisted anorectal pull-through for high imperforate anus--a new technique. *J Pediatr Surg.* 2000;35(6):927–30. discussion 930–1.
27. Mullholland M. Greenfield's surgery: scientific principles and practice. 5th ed. Philadelphia, PA: Wolters Kluwer/Lippincott Williams & Wilkins; 2011.
28. Amiel J et al. Hirschsprung disease, associated syndromes and genetics: a review. *J Med Genet.* 2008;45(1):1–14.
29. Webster W. Embryogenesis of the enteric ganglia in normal mice and in mice that develop congenital aganglionic megacolon. *J Embryol Exp Morphol.* 1973;30(3):573–85.
30. Pagon R, Bird TD, Dolan CR, et al. 2011. Hirschsprung disease overview. In GeneReviews. Seattle: NCBI Bookshelf: A service of the National Library of Medicine, National Institutes of Health.
31. Vanderwinden JM et al. Nitric oxide synthase distribution in the enteric nervous system of Hirschsprung's disease. *Gastroenterology.* 1993;105(4):969–73.
32. Swenson O, Bill AH Jr. Resection of rectum and rectosigmoid with preservation of the sphincter for benign spastic lesions producing megacolon; an experimental study. *Surgery.* 1948. 24(2): 212–20.
33. Georgeson KE et al. Primary laparoscopic-assisted endorectal colon pull-through for Hirschsprung's disease: a new gold standard. *Ann Surg.* 1999;229(5):678–82. discussion 682–3.
34. Minford JL et al. Comparison of functional outcomes of Duhamel and transanal endorectal coloanal anastomosis for Hirschsprung's disease. *J Pediatr Surg.* 2004;39(2):161–5.

35. Saleh W et al. Management of Hirschsprung's disease: a comparison of Soave's and Duhamel's pull-through methods. *Pediatr Surg Int.* 2004;20(8):590–3.
36. Craigie RJ et al. Primary pull-through for Hirschsprung's disease: comparison of open and laparoscopic-assisted procedures. *J Laparoendosc Adv Surg Tech A.* 2007;17(6):809–12.
37. Engum SA, Grosfeld JL. Long-term results of treatment of Hirschsprung's disease. *Semin Pediatr Surg.* 2004; 13(4): 273–85.
38. Fortuna RS et al. Critical analysis of the operative treatment of Hirschsprung's disease. *Arch Surg.* 1996;131(5):520–4.
39. Zhang SC et al. Long-term outcome, colonic motility, and sphincter performance after Swenson's procedure for Hirschsprung's disease: a single-center 2-decade experience with 346 cases. *Am J Surg.* 2007;194(1):40–7.
40. Demehri FR et al. Hirschsprung-associated enterocolitis: pathogenesis, treatment and prevention. *Pediatr Surg Int.* 2013;29(9):873–81.
41. Teitelbaum DH, Coran AG. Enterocolitis. [Review] [59 refs]. *Semin Pediatr Surg.* 1998;7(3):162–9.
42. Ralls MW, Coran AG, Teitelbaum DH. Reoperative surgery for Hirschsprung disease. *Semin Pediatr Surg.* 2012; 21(4): 354–63.
43. Coe A, Collins MH, Lawal T, et al. Reoperation for Hirschsprung disease: pathology of the resected problematic distal pull-through. *Pediatr Dev Pathol.* 2012;15:30–38.
44. Teitelbaum DH et al. Long-term stooling patterns in infants undergoing primary endorectal pull-through for Hirschsprung's disease. *J Pediatr Surg.* 1997;32(7):1049–52. discussion 1052–3.
45. Wildhaber B et al. Posterior myotomy/myectomy for persistent stooling problems in Hirschsprung's disease. *J Pediatr Surg.* 2004;39(6):920–6.
46. Ralls MW, Coran AG, Teitelbaum DH. Reoperative surgery for Hirschsprung disease. *Semin Pediatr Surg.* 2012;21(4):354–63.
47. Sylvester KG, Liu GY, Albanese CT. Necrotizing enterocolitis. In Coran AG, editor. *Pediatric surgery.* Philadelphia: Elsevier Saunders; 2012.
48. Palmer C, Bik EM, DiGiulio DB, et al. Development of the human infant intestinal microbiota. *PLoS Biol.* 2007; 5: e177.
49. Yazji I, Sodhi CP, Lee EK, Good M, Egan CE, Afrazi A, Neal MD, Jia H, Lin J, Ma C, Branca MF, Prindle T, Richardson WM, Ozolek J, Billiar TR, Binion DG, Gladwin MT, Hackam DJ. Endothelial TLR4 activation impairs intestinal microcirculatory perfusion in necrotizing enterocolitis via eNOS-NO-nitrate signaling. *Proc Natl Acad Sci USA.* 2013; 110(23): 9451–6.
50. Giuliani F, Prandi G, Coscia A, Cresi F, Di Nicola P, Raia M, Sabatino G, Occhi L, Bertino E. Donor human milk versus mother's own milk in preterm VLBWIs: a case control study. *J Biol Regul Homeost Agents.* 2012; 26(3 Suppl): 19–24.
51. Read LC, Francis GL, Wallace JC, Ballard FJ. Growth factor concentrations and growth-promoting activity in human milk following premature birth. *J Dev Physiol.* 1985; 7:135–45.
52. LoCascio RG, Ninonuevo MR, Freeman SL, Sela DA, Grimm R, Lebrilla CB, Mills DA, German JB. Glycoprofiling of bifidobacterial consumption of human milk Oligosaccharides demonstrates strain specific, preferential consumption of small chain flycans secreted in early human lactation. *J Food Chem.* 2007; 55: 8914–9.
53. Moss RL et al. Laparotomy versus peritoneal drainage for necrotizing enterocolitis and perforation. *N Engl J Med.* 2006;354(21):2225–34.



54. Van den Berg MM, Benninga MA, Di Lorenzo C. Epidemiology of childhood constipation: a systematic review. *Am J Gastroenterol*. 2006;101(10):2401–9.
55. Clark D. Times of first void and first stool in 500 newborns. *Pediatrics*. 1977;60(4):457–9.
56. Tabbers MM et al. Evaluation and treatment of functional constipation in infants and children: evidence-based recommendations from ESPGHAN and NASPGHAN. *J Pediatr Gastroenterol Nutr*. 2014;58(2):258–74.
57. Hyman PE et al. Childhood functional gastrointestinal disorders: neonate/toddler. *Gastroenterology*. 2006;130(5):1519–26.
58. Rasquin-Weber A et al. Childhood functional gastrointestinal disorders. *Gut*. 1999;45 Suppl 2:II60–8.
59. Brazzelli M et al. Behavioural and cognitive interventions with or without other treatments for the management of faecal incontinence in children. *Cochrane Database Syst Rev*. 2011;12, CD002240.
60. Van Dijk M, et al. Behavioral therapy for childhood constipation: a randomized, controlled trial. *Pediatrics*. 2008; 121(5):e1334–41.
61. Keuzenkamp-Jansen CW et al. Diagnostic dilemmas and results of treatment for chronic constipation. *Arch Dis Child*. 1996;75(1):36–41.
62. Staiano A et al. Long-term follow-up of children with chronic idiopathic constipation. *Dig Dis Sci*. 1994;39(3):561–4.
63. Chase J et al. Pilot study using transcutaneous electrical stimulation (interferential current) to treat chronic treatment-resistant constipation and soiling in children. *J Gastroenterol Hepatol*. 2005;20(7):1054–61.
64. Yik YI et al. The impact of transcutaneous electrical stimulation therapy on appendicostomy operation rates for children with chronic constipation--a single-institution experience. *J Pediatr Surg*. 2012;47(7):1421–6.
65. Corbett P, et al. Peristeen integrated transanal irrigation system successfully treats faecal incontinence in children. *J Pediatr Urol*. 2014; 10(2): 219–22.
66. Kokoska ER, Keller MS, Weber TR. Outcome of the antegrade colonic enema procedure in children with chronic constipation. *Am J Surg*. 2001;182(6):625–9.
67. Malone PS, Ransley PG, Kiely EM. Preliminary report: the antegrade continence enema. *Lancet*. 1990;336(8725):1217–8.
68. Youssef NN, et al. Management of intractable constipation with antegrade enemas in neurologically intact children. *J Pediatr Gastroenterol Nutr*. 2002; 34: 402–5.
69. Chait PG et al. Percutaneous cecostomy: updates in technique and patient care. *Radiology*. 2003;227(1):246–50.
70. Khan WU et al. The percutaneous cecostomy tube in the management of fecal incontinence in children. *J Vasc Interv Radiol*. 2015;26(2):189–95.
71. Woodward MN, Foley P, Cusick EL. Colostomy for treatment of functional constipation in children: a preliminary report. *J Pediatr Gastroenterol Nutr*. 2004;38(1):75–8.
72. Roth TJ et al. Sacral neuromodulation for the dysfunctional elimination syndrome: a single center experience with 20 children. *J Urol*. 2008;180(1):306–11.
73. Sulkowski JP, et al. Sacral nerve stimulator for dysfunctional elimination syndrome in children. Presentation at the American Pediatric Surgical Association Annual Meeting. 2014, Phoenix, AZ.
74. Sulkowski JP, et al. Sacral nerve stimulation: a promising therapy for fecal and urinary

- incontinence and constipation in children. *J Pediatr Surg.* 2015; 50:1644–7.
75. Thomas GP, Dudding TC, Rahbour G. Sacral nerve stimulation for constipation. *Br J Surg.* 2013; 100: 174–81.
76. Yanchar NL, Soucy P. Long-term outcome after Hirschsprung's disease: patients' perspectives. *J Pediatr Surg.* 1999;34(7):1152–60.
77. Hashish MS et al. Long-term functional outcome and quality of life in patients with high imperforate anus. *J Pediatr Surg.* 2010;45(1):224–30.
78. Neuvonen MI, et al. A population-based, complete follow-up of 146 consecutive patients after transanal mucosectomy for Hirschsprung disease. *J Pediatr Surg.* 2015; 50:1653–8.
79. Teitelbaum DH, Caniano DA, Qualman SJ. The pathophysiology of Hirschsprung's-associated enterocolitis: importance of histologic correlates. *J Pediatr Surg.* 1989;24(12):1271–7.
80. Ralls MW et al. Redo pullthrough for Hirschsprung disease: a single surgical group's experience. *J Pediatr Surg.* 2014;49(9):1394–9.
81. Kyrklund K et al. Long-term bowel functional outcomes in rectourethral fistula treated with PSARP: controlled results after 4-29 years of follow-up: a single-institution, cross-sectional study. *J Pediatr Surg.* 2014;49(11):1635–42.
82. Kyrklund K et al. Bowel functional outcomes in females with perineal or vestibular fistula treated with anterior sagittal anorectoplasty: controlled results into adulthood. *Dis Colon Rectum.* 2015;58(1):97–103.
83. Kyrklund K, et al. Bowel function and lower urinary tract symptoms in males with low anorectal malformations: an update of controlled, long-term outcomes. *Int J Colorectal Dis.* 2015; 30(2): 221–8.
84. Freeman JJ et al. Antegrade continent enema procedures performed prior to starting school may improve functional stooling and quality of life. *Pediatr Surg Int.* 2014;30(7):715–22.
85. Russell KW, et al. Effectiveness of an organized bowel management program in the management of severe chronic constipation in children. *J Pediatr Surg.* 2015; 50(3): 444–7.
86. Han-Geurts IJ et al. Outcome after anal intrasphincteric Botox injection in children with surgically treated Hirschsprung disease. *J Pediatr Gastroenterol Nutr.* 2014;59(5):604–7.
87. Koivusalo AI, Pakarinen MP, Rintala RJ. Botox injection treatment for anal outlet obstruction in patients with internal anal sphincter achalasia and Hirschsprung's disease. *Pediatr Surg Int.* 2009;25(10):873–6.
88. Griffiths A. Specificities of inflammatory bowel disease in childhood. *Best Pract Res Clin Gastroenterol.* 2004;18(3):509–23.
89. Sandberg KC et al. Increasing hospitalizations in inflammatory bowel disease among children in the United States, 1988-2011. *Inflamm Bowel Dis.* 2014;20(10):1754–60.
90. Billiet T, Vermeire S. Differences between adults and children: genetics and beyond. *Expert Rev Gastroenterol Hepatol.* 2015; 9(2): 191–6.
91. Mollard BJ, Smith EA, Dillman JR. Pediatric MR enterography: technique and approach to interpretation-how we do it. *Radiology.* 2015;274(1):29–43.
92. Hammer MR, et al. Magnetic resonance imaging of perianal and perineal Crohn disease in children and adolescents. *Magn Reson Imaging Clin N Am.* 2013; 21(4): 813–28.
93. Hyams J et al. Safety and efficacy of maintenance infliximab therapy for moderate-to-severe Crohn's disease in children: REACH open-label extension. *Curr Med Res Opin.* 2011;27(3):651–62.

94. Topf-Olivestone C, Turner D. How effective is the use of long-term anti-TNF for paediatric IBD? Clues from real-life surveillance cohorts. *Arch Dis Child*. 2015;100(4):391–2.
95. Cameron FL et al. Anti-TNF therapy for paediatric IBD: the Scottish national experience. *Arch Dis Child*. 2015;100(4):399–405.
96. Hyams J et al. Evaluation of the pediatric Crohn disease activity index: a prospective multicenter experience. *J Pediatr Gastroenterol Nutr*. 2005;41(4):416–21.
97. Hyams J et al. Induction and maintenance infliximab therapy for the treatment of moderate-to-severe Crohn's disease in children. *Gastroenterology*. 2007;132(3):863–73.
98. Wu XR et al. Comparable pouch retention rate between pediatric and adult patients after restorative proctocolectomy and ileal pouches. *Clin Gastroenterol Hepatol*. 2014;12(8):1295–302.
99. Seetharamaiah R et al. Outcomes in pediatric patients undergoing straight vs J pouch ileoanal anastomosis: a multicenter analysis. *J Pediatr Surg*. 2009;44(7):1410–7.

## 第 65 章

1. Reuben DB, Rubenstein LV, Hirsch SH, Hays RD. Value of functional status as a predictor of mortality: results of a prospective study. *Am J Med*. 1992;93(6):663–9.
2. Etzioni DA, Liu JH, O'Connell JB, Maggard MA, Ko CY. Elderly patients in surgical workloads: a population-based analysis. *Am Surg*. 2003;69(11):961–5.
3. Lewis JH, Kilgore ML, Goldman DP, et al. Participation of patients 65 years of age or older in cancer clinical trials. *J Clin Oncol*. 2003;21(7):1383–9.
4. Farrow DC, Hunt WC, Samet JM. Temporal and regional variability in the surgical treatment of cancer among older people. *J Am Geriatr Soc*. 1996;44(5):559–64.
5. Ellis PM, Butow PN, Tattersall MH, Dunn SM, Houssami N. Randomized clinical trials in oncology: understanding and attitudes predict willingness to participate. *J Clin Oncol*. 2001;19(15):3554–61.
6. Turrentine FE, Wang H, Simpson VB, Jones RS. Surgical risk factors, morbidity, and mortality in elderly patients. *J Am Coll Surg*. 2006;203(6):865–77.
7. Kristjansson SR, Nesbakken A, Jordhoy MS, et al. Comprehensive geriatric assessment can predict complications in elderly patients after elective surgery for colorectal cancer: a prospective observational cohort study. *Crit Rev Oncol Hematol*. 2010;76(3):208–17.
8. Hamel MB, Henderson WG, Khuri SF, Daley J. Surgical outcomes for patients aged 80 and older: morbidity and mortality from major noncardiac surgery. *J Am Geriatr Soc*. 2005;53(3):424–9.
9. Audisio RA, Pope D, Ramesh HS, et al. Shall we operate? Preoperative assessment in elderly cancer patients (PACE) can help. A SIOG surgical task force prospective study. *Crit Rev Oncol Hematol*. 2008;65(2):156–63.
10. Makary MA, Segev DL, Pronovost PJ, et al. Frailty as a predictor of surgical outcomes in older patients. *J Am Coll Surg*. 2010;210(6):901–8.
11. Leung JM, Dzankic S. Relative importance of preoperative health status versus intraoperative factors in predicting postoperative adverse outcomes in geriatric surgical patients. *J Am Geriatr Soc*. 2001;49(8):1080–5.
12. Tekkis PP, Prytherch DR, Kocher HM, et al. Development of a dedicated risk-adjustment scoring system for colorectal surgery (colorectal POSSUM). *Br J Surg*. 2004;91(9):1174–82.

13. Bromage SJ, Cunliffe WJ. Validation of the CR-POSSUM risk-adjusted scoring system for major colorectal cancer surgery in a single center. *Dis Colon Rectum*. 2007;50(2):192–6.
14. Cohen ME, Bilimoria KY, Ko CY, Hall BL. Development of an American college of surgeons national surgery quality improvement program: morbidity and mortality risk calculator for colorectal surgery. *J Am Coll Surg*. 2009;208(6):1009–16.
15. Neuman HB, Weiss JM, Levenson G, et al. Predictors of short-term postoperative survival after elective colectomy in colon cancer patients  $\geq 80$  years of age. *Ann Surg Oncol*. 2013;20(5):1427–35.
16. Cheema FN, Abraham NS, Berger DH, Albo D, Taffet GE, Naik AD. Novel approaches to perioperative assessment and intervention may improve long-term outcomes after colorectal cancer resection in older adults. *Ann Surg*. 2011;253(5):867–74.
17. Louis DJ, Hsu A, Brand MI, Saclarides TJ. Morbidity and mortality in octogenarians and older undergoing major intestinal surgery. *Dis Colon Rectum*. 2009;52(1):59–63.
18. Tan KY, Tan P, Tan L. A collaborative transdisciplinary “geriatric surgery service” ensures consistent successful outcomes in elderly colorectal surgery patients. *World J Surg*. 2011;35(7):1608–14.
19. Kurian A, Suryadevara S, Ramaraju D, et al. In-hospital and 6-month mortality rates after open elective vs open emergent colectomy in patients older than 80 years. *Dis Colon Rectum*. 2011;54(4):467–71.
20. Mamidanna R, Eid-Arimoku L, Almoudaris AM, et al. Poor 1-year survival in elderly patients undergoing nonelective colorectal resection. *Dis Colon Rectum*. 2012;55(7):788–96.
21. Speicher PJ, Lagoo-Deenadayalan SA, Galanos AN, Pappas TN, Scarborough JE. Expectations and outcomes in geriatric patients with do-not-resuscitate orders undergoing emergency surgical management of bowel obstruction. *JAMA Surg*. 2013;148(1):23–8.
22. Janssen-Heijnen ML, Maas HA, Housterman S, Lemmens VE, Rutten HJ, Coebergh JW. Comorbidity in older surgical cancer patients: influence on patient care and outcome. *Eur J Cancer*. 2007;43(15):2179–93.
23. McGillicuddy EA, Schuster KM, Davis KA, Longo WE. Factors predicting morbidity and mortality in emergency colorectal procedures in elderly patients. *Arch Surg*. 2009;144(12):1157–62.
24. Lawrence VA, Hazuda HP, Cornell JE, et al. Functional independence after major abdominal surgery in the elderly. *J Am Coll Surg*. 2004;199(5):762–72.
25. Bosshardt TL. Outcomes of ostomy procedures in patients aged 70 years and older. *Arch Surg*. 2003;138(10):1077–82.
26. Wong RW, Rappaport WD, Witzke DB, Putnam CW, Hunter GC. Factors influencing the safety of colostomy closure in the elderly. *J Surg Res*. 1994;57(2):289–92.
27. Payne JE, Chapuis PH, Pheils MT. Surgery for large bowel cancer in people aged 75 years and older. *Dis Colon Rectum*. 1986;29(11):733–7.
28. Ma N, Harvey J, Stewart J, Andrews L, Hill AG. The effect of age on the quality of life of patients living with stomas: a pilot study. *ANZ J Surg*. 2007;77(10):883–5.
29. Saghir JH, McKenzie FD, Leckie DM, et al. Factors that predict complications after construction of a stoma: a retrospective study. *Eur J Surg*. 2001;167(7):531–4.
30. Tariq SH. Fecal incontinence in older adults. *Clin Geriatr Med*. 2007;23(4):857–69. vii.
31. Schiller LR. Constipation and fecal incontinence in the elderly. *Gastroenterol Clin North Am*.

2001;30(2):497–515.

32. Bliss DZ, Fischer LR, Savik K, Avery M, Mark P. Severity of fecal incontinence in community-living elderly in a health maintenance organization. *Res Nurs Health*. 2004;27(3):162–73.
33. Tariq SH. Geriatric fecal incontinence. *Clin Geriatr Med*. 2004;20(3):571–87. ix.
34. Whitehead WE, Burgio KL, Engel BT. Biofeedback treatment of fecal incontinence in geriatric patients. *J Am Geriatr Soc*. 1985;33(5):320–4.
35. Mäkelä JT, Kiviniemi H, Laitinen S. Prognostic factors of perforated sigmoid diverticulitis in the elderly. *Dig Surg*. 2005;22(1–2):100–6.
36. Moran-Atkin E, Stem M, Lidor AO. Surgery for diverticulitis is associated with high risk of in-hospital mortality and morbidity in older patients with end-stage renal disease. *Surgery*. 2014;156(2):361–70.
37. Etzioni DA, Mack TM, Beart RW, Kaiser AM. Diverticulitis in the United States: 1998-2005: changing patterns of disease and treatment. *Ann Surg*. 2009;249(2):210–7.
38. Broderick-Villa G, Burchette RJ, Collins JC, Abbas MA, Haigh PI. Hospitalization for acute diverticulitis does not mandate routine elective colectomy. *Arch Surg*. 2005;140(6):576–81. discussion 581–573.
39. Lidor AO, Schneider E, Segal J, Yu Q, Feinberg R, Wu AW. Elective surgery for diverticulitis is associated with high risk of intestinal diversion and hospital readmission in older adults. *J Gastrointest Surg*. 2010;14(12):1867–73. discussion 1873–1864.
40. Lidsky ME, Thacker JK, Lagoo-Deenadayalan SA, Scarborough JE. Advanced age is an independent predictor for increased morbidity and mortality after emergent surgery for diverticulitis. *Surgery*. 2012;152(3):465–72.
41. Anaya DA, Flum DR. Risk of emergency colectomy and colostomy in patients with diverticular disease. *Arch Surg*. 2005;140(7):681–5.
42. Tiengthanthum R, Jensen CC, Goldberg SM, Mellgren A. Clinical outcomes of perineal proctectomy among patients of advanced age. *Dis Colon Rectum*. 2014;57(11):1298–303.
43. Clark CE, Jupiter DC, Thomas JS, Papaconstantinou HT. Rectal prolapse in the elderly: trends in surgical management and outcomes from the American College of Surgeons National Surgical Quality Improvement Program database. *J Am Coll Surg*. 2012;215(5):709–14.
44. Germain A, Perrenot C, Scherrer ML, et al. Long-term outcome of robotic-assisted laparoscopic rectopexy for full-thickness rectal prolapse in elderly patients. *Colorectal Dis*. 2014;16(3):198–202.
45. Ballantyne GH, Brandner MD, Beart RW, Ilstrup DM. Volvulus of the colon. Incidence and mortality. *Ann Surg*. 1985;202(1):83–92.
46. JECK HS. Volvulus of the cecum; with a review of the recent literature and report of a case occurring as a postoperative complication. *Am J Surg*. 1958;96(3):411–4.
47. Ballantyne GH. Review of sigmoid volvulus: history and results of treatment. *Dis Colon Rectum*. 1982;25(5):494–501.
48. Raveenthiran V, Madiba TE, Atamanalp SS, De U. Volvulus of the sigmoid colon. *Colorectal Dis*. 2010;12(7 Online):e1–17.
49. Madiba TE, Thomson SR. The management of sigmoid volvulus. *J R Coll Surg Edinb*. 2000;45(2):74–80.
50. Page MJ, Poritz LS, Kunselman SJ, Koltun WA. Factors affecting surgical risk in elderly patients with inflammatory bowel disease. *J Gastrointest Surg*. 2002;6(4):606–13.
51. Pinto RA, Canedo J, Murad-Regadas S, Regadas SF, Weiss EG, Wexner SD. Ileal pouch-anal

anastomosis in elderly patients: is there a difference in morbidity compared with younger patients? *Colorectal Dis.* 2011;13(2):177–83.

52. Heuschen UA, Hinz U, Allemeyer EH, et al. Risk factors for ileoanal J pouch-related septic complications in ulcerative colitis and familial adenomatous polyposis. *Ann Surg.* 2002;235(2):207–16.

53. Delaney CP, Dadvand B, Remzi FH, Church JM, Fazio VW. Functional outcome, quality of life, and complications after ileal pouch-anal anastomosis in selected septuagenarians. *Dis Colon Rectum.* 2002;45(7):890–4. discussion 894.

54. Pellino G, Sciaudone G, Candilio G, et al. Complications and functional outcomes of restorative proctocolectomy for ulcerative colitis in the elderly. *BMC Surg.* 2013;13 Suppl 2:S9.

55. Pellino G, Sciaudone G, Candilio G, et al. Restorative proctocolectomy with ileal pouch-anal anastomosis is safe and effective in selected very elderly patients suffering from ulcerative colitis. *Int J Surg.* 2014;12 Suppl 2:S56–9.

56. Chapman JR, Larson DW, Wolff BG, et al. Ileal pouch-anal anastomosis: does age at the time of surgery affect outcome? *Arch Surg.* 2005;140(6):534–9. discussion 539–540.

57. Shung DL, Abraham B, Sellin J, Hou JK. Medical and surgical complications of inflammatory bowel disease in the elderly: a systematic review. *Dig Dis Sci.* 2015;60(5):1132–40.

58. Database S. <http://seer.cancer.gov/statfacts/html/colorect.html>

59. Kahi CJ, Rex DK, Imperiale TF. Screening, surveillance, and primary prevention for colorectal cancer: a review of the recent literature. *Gastroenterology.* 2008;135(2):380–99.

60. Marusch F, Koch A, Schmidt U, et al. The impact of the risk factor “age” on the early postoperative results of surgery for colorectal carcinoma and its significance for perioperative management. *World J Surg.* 2005;29(8):1013–21. discussion 1021–1012.

61. Bouassida M, Chtourou MF, Hamzaoui L, et al. Clinico-pathological characteristics, therapeutic features and post-operative course of colorectal cancer in elderly patients. *J Clin Diagn Res.* 2014;8(1):77–9.

62. Surgery for colorectal cancer in elderly patients: a systematic review. *Colorectal Cancer Collaborative Group. Lancet.* 2000;356(9234):968–74.

63. Davila JA, Rabeneck L, Berger DH, El-Serag HB. Postoperative 30-day mortality following surgical resection for colorectal cancer in veterans: changes in the right direction. *Dig Dis Sci.* 2005;50(9):1722–8.

64. Ong ES, Alassas M, Dunn KB, Rajput A. Colorectal cancer surgery in the elderly: acceptable morbidity? *Am J Surg.* 2008;195(3):344–8. discussion 348.

65. Haller DG, O’Connell MJ, Cartwright TH, et al. Impact of age and medical comorbidity on adjuvant treatment outcomes for stage III colon cancer: a pooled analysis of individual patient data from four randomized, controlled trials. *Ann Oncol.* 2015;26(4):715–24.

66. Devon KM, Vergara-Fernandez O, Victor JC, McLeod RS. Colorectal cancer surgery in elderly patients: presentation, treatment, and outcomes. *Dis Colon Rectum.* 2009;52(7):1272–7.

67. Sargent DJ, Goldberg RM, Jacobson SD, et al. A pooled analysis of adjuvant chemotherapy for resected colon cancer in elderly patients. *N Eng J Med.* 2001;345(15):1091–7.

68. Goldberg RM, Tabah-Fisch I, Bleiberg H, et al. Pooled analysis of safety and efficacy of oxaliplatin plus fluorouracil/leucovorin administered bimonthly in elderly patients with colorectal cancer. *J Clin Oncol.* 2006;24(25):4085–91.

69. André T, Boni C, Navarro M, et al. Improved overall survival with oxaliplatin, fluorouracil, and

leucovorin as adjuvant treatment in stage II or III colon cancer in the MOSAIC trial. *J Clin Oncol*. 2009;27(19):3109–16.

70. Pallis AG, Papamichael D, Audisio R, et al. EORTC elderly task force experts' opinion for the treatment of colon cancer in older patients. *Cancer Treat Rev*. 2010;36(1):83–90.

71. Golfinopoulos V, Pentheroudakis G, Pavlidis N. Treatment of colorectal cancer in the elderly: a review of the literature. *Cancer Treat Rev*. 2006;32(1):1–8.

72. Stec R, Bodnar L, Smoter M, Mączewski M, Szczylik C. Metastatic colorectal cancer in the elderly: an overview of the systemic treatment modalities (Review). *Oncol Lett*. 2011;2(1):3–11.

73. Puig-La Calle J, Quayle J, Thaler HT, et al. Favorable short-term and long-term outcome after elective radical rectal cancer resection in patients 75 years of age or older. *Dis Colon Rectum*. 2000;43(12):1704–9.

74. Steele SR, Park GE, Johnson EK, et al. The impact of age on colorectal cancer incidence, treatment, and outcomes in an equal-access health care system. *Dis Colon Rectum*. 2014;57(3):303–10.

75. Finlayson E, Zhao S, Varma MG. Outcomes after rectal cancer surgery in elderly nursing home residents. *Dis Colon Rectum*. 2012;55(12):1229–35.

76. Phillips PS, Farquharson SM, Sexton R, Heald RJ, Moran BJ. Rectal cancer in the elderly: patients' perception of bowel control after restorative surgery. *Dis Colon Rectum*. 2004;47(3):287–90.

77. Hida J, Yoshifuji T, Okuno K, et al. Long-term functional outcome of colonic J-pouch reconstruction after low anterior resection for rectal cancer. *Surg Today*. 2006;36(5):441–9.

78. Rutten H, den Dulk M, Lemmens V, et al. Survival of elderly rectal cancer patients not improved: analysis of population based data on the impact of TME surgery. *Eur J Cancer*. 2007;43(15):2295–300.

79. Tougeron D, Roullet B, Paillot B, et al. Safety and outcome of chemoradiotherapy in elderly patients with rectal cancer: results from two French tertiary centres. *Dig Liver Dis*. 2012;44(4):350–4.

80. Bosset JF, Collette L, Calais G, et al. Chemotherapy with preoperative radiotherapy in rectal cancer. *N Eng J Med*. 2006;355(11):1114–23.

81. Gérard JP, Conroy T, Bonnetain F, et al. Preoperative radiotherapy with or without concurrent fluorouracil and leucovorin in T3-4 rectal cancers: results of FFCD 9203. *J Clin Oncol*. 2006;24(28):4620–5.

82. Braendengen M, Tveit KM, Berglund A, et al. Randomized phase III study comparing preoperative radiotherapy with chemoradiotherapy in nonresectable rectal cancer. *J Clin Oncol*. 2008;26(22):3687–94.

83. Cai X, Wu H, Peng J, et al. Tolerability and outcomes of radiotherapy or chemoradiotherapy for rectal cancer in elderly patients aged 70 years and older. *Radiat Oncol*. 2013;8:86.

84. Neuman HB, Elkin EB, Guillem JG, et al. Treatment for patients with rectal cancer and a clinical complete response to neoadjuvant therapy: a decision analysis. *Dis Colon Rectum*. 2009;52(5):863–71.

85. Frasson M, Braga M, Vignali A, Zuliani W, Di Carlo V. Benefits of laparoscopic colorectal resection are more pronounced in elderly patients. *Dis Colon Rectum*. 2008;51(3):296–300.

86. Stocchi L, Nelson H, Young-Fadok TM, Larson DR, Ilstrup DM. Safety and advantages of laparoscopic vs. open colectomy in the elderly: matched-control study. *Dis Colon Rectum*.

2000;43(3):326–32.

87. Kurian AA, Wang L, Grunkemeier G, Bhayani NH, Swanström LL. Defining “the elderly” undergoing major gastrointestinal resections: receiver operating characteristic analysis of a large ACS-NSQIP cohort. *Ann Surg.* 2013;258(3):483–9.
88. Poldermans D, Bax JJ, Boersma E, et al. Guidelines for pre-operative cardiac risk assessment and perioperative cardiac management in non-cardiac surgery: the task force for preoperative cardiac risk assessment and perioperative cardiac management in non-cardiac surgery of the European Society of Cardiology (ESC) and endorsed by the European Society of Anaesthesiology (ESA). *Eur J Anaesthesiol.* 2010;27(2):92–137.
89. Audisio RA, Ramesh H, Longo WE, Zbar AP, Pope D. Preoperative assessment of surgical risk in oncogeriatric patients. *Oncologist.* 2005;10(4):262–8.
90. Tan KY, Konishi F, Tan L, Chin WK, Ong HY, Tan P. Optimizing the management of elderly colorectal surgery patients. *Surg Today.* 2010;40(11):999–1010.
91. Livhits M, Ko CY, Leonardi MJ, Zingmond DS, Gibbons MM, de Virgilio C. Risk of surgery following recent myocardial infarction. *Ann Surg.* 2011;253(5):857–64.
92. Goldman L, Caldera DL, Nussbaum SR, et al. Multifactorial index of cardiac risk in noncardiac surgical procedures. *N Eng J Med.* 1977;297(16):845–50.
93. Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. *J Chronic Dis.* 1987;40(5):373–83.
94. Smetana GW. Preoperative pulmonary assessment of the older adult. *Clin Geriatr Med.* 2003;19(1):35–55.
95. Ljungqvist O, Nygren J, Thorell A. Modulation of post-operative insulin resistance by pre-operative carbohydrate loading. *Proc Nutr Soc.* 2002;61(3):329–36.
96. Kiran RP, Turina M, Hammel J, Fazio V. The clinical significance of an elevated postoperative glucose value in nondiabetic patients after colorectal surgery: evidence for the need for tight glucose control? *Ann Surg.* 2013;258(4):599–604. discussion 604–595.
97. Lee P, Min L, Mody L. Perioperative glucose control and infection risk in older surgical patients. *Curr Geriatr Rep.* 2014;3(1):48–55.
98. Ganai S, Lee KF, Merrill A, et al. Adverse outcomes of geriatric patients undergoing abdominal surgery who are at high risk for delirium. *Arch Surg.* 2007;142(11):1072–8.
99. Dellinger RP, Levy MM, Rhodes A, et al. Surviving sepsis campaign: international guidelines for management of severe sepsis and septic shock, 2012. *Intensive Care Med.* 2013;39(2):165–228.
100. Pirlich M, Lochs H. Nutrition in the elderly. *Best Pract Res Clin Gastroenterol.* 2001;15(6):869–84.
101. Jin F, Chung F. Minimizing perioperative adverse events in the elderly. *Br J Anaesth.* 2001;87(4):608–24.
102. Guralnik JM, Eisenstaedt RS, Ferrucci L, Klein HG, Woodman RC. Prevalence of anemia in persons 65 years and older in the United States: evidence for a high rate of unexplained anemia. *Blood.* 2004;104(8):2263–8.
103. Wu WC, Schiffner TL, Henderson WG, et al. Preoperative hematocrit levels and postoperative outcomes in older patients undergoing noncardiac surgery. *JAMA.* 2007;297(22):2481–8.
104. Wu WC, Smith TS, Henderson WG, et al. Operative blood loss, blood transfusion, and 30-day mortality in older patients after major noncardiac surgery. *Ann Surg.* 2010;252(1):11–7.



105. Dzankic S, Pastor D, Gonzalez C, Leung JM. The prevalence and predictive value of abnormal preoperative laboratory tests in elderly surgical patients. *Anesth Analg*. 2001;93(2):301–8, 302nd contents page.
106. Monk TG, Weldon BC, Garvan CW, et al. Predictors of cognitive dysfunction after major noncardiac surgery. *Anesthesiology*. 2008;108(1):18–30.
107. Fried LP, Tangen CM, Walston J, et al. Frailty in older adults: evidence for a phenotype. *J Gerontol A Biol Sci Med Sci*. 2001;56(3):M146–56.
108. Extermann M, Hurria A. Comprehensive geriatric assessment for older patients with cancer. *J Clin Oncol*. 2007;25(14):1824–31.
109. Extermann M, Aapro M, Bernabei R, et al. Use of comprehensive geriatric assessment in older cancer patients: recommendations from the task force on CGA of the International Society of Geriatric Oncology (SIOG). *Crit Rev Oncol Hematol*. 2005;55(3):241–52.
110. Alessi CA, Stuck AE, Aronow HU, et al. The process of care in preventive in-home comprehensive geriatric assessment. *J Am Geriatr Soc*. 1997;45(9):1044–50.
111. Inouye SK, Peduzzi PN, Robison JT, Hughes JS, Horwitz RI, Concato J. Importance of functional measures in predicting mortality among older hospitalized patients. *JAMA*. 1998;279(15):1187–93.
112. Siu AL, Morishita L, Blaustein J. Comprehensive geriatric assessment in a day hospital. *J Am Geriatr Soc*. 1994;42(10):1094–9.
113. Tinetti ME, Baker DI, McAvay G, et al. A multifactorial intervention to reduce the risk of falling among elderly people living in the community. *N Eng J Med*. 1994;331(13):821–7.
114. Inouye SK, Bogardus Jr ST, Charpentier PA, et al. A multicomponent intervention to prevent delirium in hospitalized older patients. *N Eng J Med*. 1999;340(9):669–76.
115. Stuck AE, Siu AL, Wieland GD, Adams J, Rubenstein LZ. Comprehensive geriatric assessment: a meta-analysis of controlled trials. *Lancet*. 1993;342(8878):1032–6.
116. Extermann M, Overcash J, Lyman GH, Parr J, Balducci L. Comorbidity and functional status are independent in older cancer patients. *J Clin Oncol*. 1998;16(4):1582–7.
117. Robinson TN, Eiseman B, Wallace JI, et al. Redefining geriatric preoperative assessment using frailty, disability and co-morbidity. *Ann Surg*. 2009;250(3):449–55.
118. Chow WB, Rosenthal RA, Merkow RP, et al. Optimal preoperative assessment of the geriatric surgical patient: a best practices guideline from the American College of Surgeons National Surgical Quality Improvement Program and the American Geriatrics Society. *J Am Coll Surg*. 2012;215(4):453–66.
119. Stewart AL, Greenfield S, Hays RD, et al. Functional status and well-being of patients with chronic conditions. Results from the medical outcomes study. *JAMA*. 1989;262(7):907–13.
120. Fillenbaum GG, Smyer MA. The development, validity, and reliability of the OARS multidimensional functional assessment questionnaire. *J Gerontol*. 1981;36(4):428–34.
121. Yates JW, Chalmer B, McKegney FP. Evaluation of patients with advanced cancer using the Karnofsky performance status. *Cancer*. 1980;45(8):2220–4.
122. Podsiadlo D, Richardson S. The timed “Up & Go”: a test of basic functional mobility for frail elderly persons. *J Am Geriatr Soc*. 1991;39(2):142–8.
123. Naeim A, Reuben D. Geriatric syndromes and assessment in older cancer patients. *Oncology (Williston Park)*. 2001;15(12):1567–77, 80; discussion 1581, 1586, 1591.
124. Kawas C, Karagiozis H, Resau L, Corrada M, Brookmeyer R. Reliability of the blessed

- telephone information-memory-concentration test. *J Geriatr Psychiatry Neurol.* 1995;8(4):238–42.
125. Zigmond AS, Snaith RP. The hospital anxiety and depression scale. *Acta Psychiatr Scand.* 1983;67(6):361–70.
126. Carroll BT, Kathol RG, Noyes Jr R, Wald TG, Clamon GH. Screening for depression and anxiety in cancer patients using the hospital anxiety and depression scale. *Gen Hosp Psychiatry.* 1993;15(2):69–74.
127. Hopwood P, Howell A, Maguire P. Screening for psychiatric morbidity in patients with advanced breast cancer: validation of two self-report questionnaires. *Br J Cancer.* 1991;64(2):353–6.
128. Landi F, Zuccala G, Gambassi G, et al. Body mass index and mortality among older people living in the community. *J Am Geriatr Soc.* 1999;47(9):1072–6.
129. Dewys WD, Begg C, Lavin PT, et al. Prognostic effect of weight loss prior to chemotherapy in cancer patients. Eastern Cooperative Oncology Group. *Am J Med.* 1980;69(4):491–7.
130. Newman AB, Yanez D, Harris T, Duxbury A, Enright PL, Fried LP. Weight change in old age and its association with mortality. *J Am Geriatr Soc.* 2001;49(10):1309–18.
131. Walter LC, Kovinsk KE. Cancer screening in elderly patients: a framework for individualized decision making. *JAMA.* 2001;285(21):2750–6.

## 第 66 章

### References

1. Achenbaum A. Social security visions and revisions. New York: Cambridge Press; 1986. p. 25–6.
2. LaTour K. Health information management: concepts, principles, and practice. 4th ed. Chicago: AHIMA Press; 2013.
3. Social Security Aments of 1965 Public Law 89–87 pkisupport@gpo.gov.
4. Annual U.S. Healthcare spending Hits \$3.8 Trillion Munro D, Pharma & Healthcare 2/20/2014 released Forbes Website.
5. Executive Office of the President, Council of Economic Advisers, The Economic Case for Health Care Reform, June 2009 <https://www.whitehouse.gov/assets/documents/CEA-Health-Care-Report>.
6. Ginsberg P. Fee-for-service will remain a feature of major payment reforms requiring more changes in Medicare physician payment. *Health Aff.* 2012;31(9):1977–83.
7. Glaser WA. The politics of paying American physicians. *Health Aff.* 1989;8(3):129–46.
8. Showstack JA, et al. “Fee-for-Service Physician Payment,” *Inquiry* (Fall 1979) 233–7; and Physician Reimbursement Under Medicare: Options for Change (Washington: Congressional Budget Office, 1986), Chapter 2.
9. Hsiao WC, Stason WB. Toward developing a relative value scale for medical and surgical services. *Health Care Financ Rev.* 1979;1(2):23–38.
10. Hsiao WC, et al. A National Study of Resource-Based relative Value Scales for Physician Services: Final Report to the Health Care Financing Administration publication 17-C-98795/1-30. Boston, Harvard University School of Public Health, 1988.
11. Hsiao WC, Braun P, et al. The resource-based relative value scale: toward development of an alternative physician payment system. *JAMA.* 1987;258(6):799–802.

12. American Medical Association Web site: [ama-assn.org /history of the RBRVS](http://ama-assn.org/history-of-the-RBRVS).
13. Roper WL, Hackbarth GM. HCFA's agenda for promoting high-quality care. *Health Aff.* 1988;7(1):91–8.
14. Marquis SM, Kominski GF. Alternative Volume Performance Standards for Medicare Physicians' Services: Strengths and Limitations Rand Publication 1992. R-4154\_HCFA. [www.rand.org/content/dam/rand/pubs/reports/2009/R4154-pdf](http://www.rand.org/content/dam/rand/pubs/reports/2009/R4154-pdf).
15. Balanced Budget Act of 1997 PL 105–33 H.R. 2015. [www.gpo.gov/fdsys/pkg/Bills-105/hr2015/enr/pdf](http://www.gpo.gov/fdsys/pkg/Bills-105/hr2015/enr/pdf).
16. Reschovsky JD, Converse L, Rich EC. Solving the Sustainable Growth Rate formula conundrum continues steps toward cost savings and care improvements. *Health Aff.* 2015;34(4):1–8.
17. Hahn J, Mulvey J. Medicare physician payment updates the Sustainable Growth Rate (SGR) System CRS Report for Congress 7-5700. [www.crs.gov R40907](http://www.crs.gov/R40907).
18. Congressional Budget Office. Medicare's payment to physicians: the budgetary effects of alternative policies relative to CBO's January 2015 baseline. [www.cbo.gov/sites/default/files/cbofiles/attachments/49923-SGR\\_Options.pdf](http://www.cbo.gov/sites/default/files/cbofiles/attachments/49923-SGR_Options.pdf).
19. Health Reform: Summary of the Affordable Care Act; April 25, 2013 [kkf.org](http://www.kkf.org).
20. How Much Money Is Lost to Medicare Fraud Annually? April 8, 2015 [medicarenewsgroup.com](http://medicarenewsgroup.com).
21. Wilensky GR. Developing a viable alternative to Medicare's physician payment strategy. *Health Aff.* 2014;33(1):153–60.
22. Merrell K, Berenson R. Structuring payment for medical homes. *Health Aff.* 2010;29(5):852–8.
23. Share DA, Mason MH. Michigan's Physician Group Incentive Program offers a regional model for incremental "fee for value" payments reform. *Health Aff (Millwood)*. 2012;31(9):1993–2000.
24. Lemark CH, Nahra TA, Cohen GR, et al. Michigan's fee-for-value physician incentive program reduces spending and improves quality in primary care. *Health Aff.* 2015;34(4):645–52.
25. Cole ES, Campbell C, Diana ML, et al. Patient-centered medical homes in Louisiana had minimal impact on Medicaid population's use of acute care and costs. *Health Aff.* 2015;34(1):87–94.
26. Hussey PS, Ridgely SM, Rosenthal MB. The PROMETHEUS bundled payment experiments: slow start shows problems in implementing new payment models. *Health Aff.* 2011;30(11):2116–24.
27. Tsai TC, Joynt KE, Wild RC, et al. Medicare's Bundled Payment initiative: most hospitals are focused on a few high-volume conditions. *Health Aff.* 2015;34(3):371–80.
28. Institute of Medicine, Medicare: A Strategy for Quality Assurances 1990; 21.
29. 2011 Report to Congress: National Strategy for Quality Improvement in Health Care Submitted by the U.S. Department of Health and Human Services: Agency for Healthcare Research and Quality. [www.ahrq.gov/workingforquality/nqs/nqs2011annlpt.htm](http://www.ahrq.gov/workingforquality/nqs/nqs2011annlpt.htm).
30. Lee TH, Bothe A, Glenn DS. How Geisinger structures its physicians' compensation to support improvements in quality, efficiency, and volume. *Health Aff.* 2012;31(9):2068–73.
31. Agency for Healthcare Research and Quality; 208 Aug {cited 2013 Aug 20}. [http://www.ncbi.nlm.nih.gov/books/n/aps2v3/advances-meyer\\_41/](http://www.ncbi.nlm.nih.gov/books/n/aps2v3/advances-meyer_41/).
32. Torchiana DF, Colton DG, Rao SK, et al. Massachusetts General Physicians Organization's quality incentive program produces encouraging results. *Health Aff.* 2013;32(10):1748–56.

## 第 67 章

1. DeBolt D. Jahi McMath: Oakland girl's family sues hospital, surgeon. San Jose Mercury News. 3/3/2015.
2. Beauchamp TL, Childress JF. Principles of biomedical ethics. 6th ed. New York: Oxford University Press; 2008.
3. Emanuel LL, Emanuel EJ, Stoeckle JD, Hummel LR, Barry MJ. Advance directives. Stability of patients' treatment choices. Arch Intern Med. 1994;154(2):209–17.
4. Burns JP, Truog RD. Futility: a concept in evolution. Chest. 2007;132(6):1987–93.
5. Plows CW, Tenery Jr RM, Hartford A, et al. Medical futility in end-of-life care - report of the Council on Ethical and Judicial Affairs. JAMA. 1999;281:937–41.
6. Muramoto O. Bioethical aspects of the recent changes in the policy of refusal of blood by Jehovah's witnesses. BMJ. 2001;322(7277):37–9.
7. Prince V. Massachusetts, 321 U.S. 158 (1944).
8. Statement on healthcare disparities. The American College of Surgeons. November 16, 2010. Accessed online on April 27, 2015 at <https://www.facs.org/about-ac/s/statements/67-health-care-disparities>.
9. Esnaola NF, Stewart AK, Feig BW, Skibber JM, Rodriguez-Bigas MA. Age-, race-, and ethnicity-related differences in the treatment of nonmetastatic rectal cancer: a patterns of care study from the national cancer data base. Ann Surg Oncol. 2008;15(11):3036–47.
10. Esnaola NF, Gebregziabher M, Finney C, Ford ME. Underuse of surgical resection in black patients with nonmetastatic colorectal cancer: location, location, location. Ann Surg. 2009;250(4):549–57.
11. Tabrizian P, Overbey J, Carrasco-Avino G, Bagiella E, Labow DM, Sarpel U. Escalation of socioeconomic disparities among patients with colorectal cancer receiving advanced surgical treatment. Ann Surg Oncol. 2015;22(5):1746–50.
12. Aizer AA, Wilhite TJ, Chen MH, Graham PL, Choueiri TK, Hoffman KE, Martin NE, Trinh QD, Hu JC, Nguyen PL. Lack of reduction in racial disparities in cancer-specific mortality over a 20-year period. Cancer. 2014;120(10):1532–9.
13. Liu CJ, Chou YJ, Teng CJ, Lin CC, Lee YT, Hu YW, Yeh CM, Chen TJ, Huang N. Association of surgeon volume and hospital volume with the outcome of patients receiving definitive surgery for colorectal cancer: a nationwide population-based study. Cancer. 2015;17.
14. Haider AH, Sexton J, Sriram N, Cooper LA, Efron DT, Swoboda S, Villegas CV, Haut ER, Bonds M, Pronovost PJ, Lipsett PA, Freischlag JA, Cornwell 3rd EE. Association of unconscious race and social class bias with vignette-based clinical assessments by medical students. JAMA. 2011;306(9):942–51.
15. Haider AH, Schneider EB, Sriram N, Dossick DS, Scott VK, Swoboda SM, Losonczy L, Haut ER, Efron DT, Pronovost PJ, Lipsett PA, Cornwell 3rd EE, MacKenzie EJ, Cooper LA, Freischlag JA. Unconscious race and social class bias among acute care surgical clinicians and clinical treatment decisions. JAMA Surg. 2015;150:457–64.
16. Hong L, Page SE. Groups of diverse problem solvers can outperform groups of high-ability problem solvers. Proc Natl Acad Sci U S A. 2004;101(46):16385–9.
17. Bollinger LC. The need for diversity in higher education. Acad Med. 2003;78(5):431–6.

18. Population, Race – Hispanic Origin. The 2012 Statistical Abstract: USA Statistics in Brief. United States Census Bureau. Accessed online on 1 April 2012 at <http://www.census.gov/compendia/statab/brief.html>.
19. Derek Smart R. Physician characteristics and distribution in the US. Chicago: American Medical Association; 2010.
20. Committee on Diversity Issues. Committees of the American College of Surgeons. Accessed online on 28 April 2015 at <http://www.facs.org/about/committees/index.html#diversity>.
21. Keune JD, Vig S, Hall BL, Matthews BD, Klingensmith ME. Taking disclosure seriously: disclosing financial conflicts of interest at the American College of Surgeons. *J Am Coll Surg*. 2011;212(2):215–24.
22. Brandeis, Louis. “What Publicity Can Do” *Harper’s Weekly* December 20, 1913.
23. The Patient Protection and Affordable Care Act (PPACA). Public Law 111–148. March 23, 2010.
24. Rothman DJ. Here comes the sun. *Milbank Q*. 2014;92(3):471–4.

## 第 68 章

1. Jena AB, Seabury S, Lakdawalla D, Chandra A. Malpractice risk according to physician specialty. *N Engl J Med*. 2011;365: 629–36.
2. This is not a law review article. It is intended to be of general application to clinicians. Citations to relevant laws are kept to a minimum, as the letter of the law varies from jurisdiction to jurisdiction. I practice in California. The citations included are to California legal authorities, and may not be specifically applicable in your jurisdiction. Consult your attorney for a more detailed discussion of the law as it applies to your case.
3. See, e.g., Cal. Evid. Code section 1157, et seq.
4. See, e.g., Cal. Code of Civ. Proc. section 2030.220 (c).
5. Judicial Council of California, Civil Jury Instructions, Instruction 208.
6. Judicial Council of California, Civil Jury Instructions, Instruction 200.
7. Judicial Council of California, Civil Jury Instructions, Instruction 501.
8. Judicial Council of California, Civil Jury Instructions, Instruction 505.
9. Judicial Council of California, Civil Jury Instructions, Instruction 506.
10. *Clemens v. Regents of Univ. of Cal.* (1970) 8 Cal.App.3d 1, 13.
11. *Barton v. Owen* (1977) 71 Cal.App.3d 484, 501–502.
12. Judicial Council of California, Civil Jury Instructions, Instruction 219.
13. Judicial Council of California, Civil Jury Instructions, Instruction 221.

## 第 69 章

1. Nasca TJ, Philibert I, Brigham T, Flynn TC. The next GME accreditation system—rationale and benefits. *N Engl J Med*. 2012;366(11):1051–6.
2.  
“Competence by Design: Reshaping Canadian Medical Education. Royal College of Physicians and Surgeons of Canada.” March 2014. Available at

[http://www.royalcollege.ca/portal/page/portal/rc/common/documents/educational\\_initiatives/rc\\_competency-by-design\\_ebook\\_e.pdf](http://www.royalcollege.ca/portal/page/portal/rc/common/documents/educational_initiatives/rc_competency-by-design_ebook_e.pdf). Accessed 13 May 2015.

3. Committee on the Health Professions Educational Summit; Board on Health Care Services. Institute of Medicine. Health professions education: a bridge to quality. In: Greiner AC, Knebel E, editors. Washington: National Academies Press; 2003. Available at [http://books.nap.edu/openbook.php?record\\_id=10681](http://books.nap.edu/openbook.php?record_id=10681). Accessed 13 May 2015.
4. Center for Total Health. Synopsis of roundtable on physician readiness for a reformed delivery system. Washington, DC: Health Affairs and Kaiser Permanente Institution for Health Policy, Center for Total Health; 7–8 Dec 2011.
5. Makary MA, Sexton JB, Freischlag JA, Millman EA, et al. Patient safety in surgery. *Ann Surg*. 2006;243:628–32.
6. Lewis FR, Klingensmith ME. Issues in general surgery residency training – 2012. *Ann Surg*. 2012;256:553–9.
7. Palter V, Grantcharov T, Harvey A, MacRae HM. Ex vivo technical skills training transfers to the operating room and enhances cognitive learning: a randomized controlled trial. *Ann Surg*. 2011;253(5):886–9.
8. Snyder RA, Tarpley MJ, Tarpley JL, Davidson M, Brophy C, Dattilo JB. Teaching in the operating room: results of a national survey. *J Surg Educ*. 2012;69(5):643.
9. Frank JR, Mungroo R, Ahmad Y, Wang M, De Rossi S, Horsley T. Toward a definition of competency-based education in medicine: as systematic review of published definitions. *Med Teach*. 2010;32:631–7.
10. Ten Cate O. Nuts and bolts of entrustable professional activities. *J Grad Med Educ*. 2013;5(1):157–8.
11. American Board of Surgeons Resident Review Committee. Mandatory requirements for surgical training programs. Available at [http://www.acgme.org/acgmeweb/Portals/0/PFAssets/ProgramRequirements/440\\_general\\_surgery\\_07012014.pdf](http://www.acgme.org/acgmeweb/Portals/0/PFAssets/ProgramRequirements/440_general_surgery_07012014.pdf) Accessed 8 May 2015.
12. Crochet P, Aggarwal R, Dubb SS, et al. Deliberate practice on a virtual reality laparoscopic simulator enhances the quality of surgical technical. *Ann Surg*. 2011;253(6):1216–22.
13. Grantcharov TP, Kristiansen VB, Bendix J, et al. Randomized clinical trial of virtual reality simulation for laparoscopic skills training. *Br J Surg*. 2004;91(2):146–50.
14. Beyer L, Troyer JD, Mancini J, Bladou F, Berdah SV, Karsenty G. Impact of laparoscopy simulator training on the technical skills of future surgeons in the operating room: a prospective study. *Am J Surg*. 2011;202(3):265–72.
15. McDougall EM, Corica FA, Boker JR, et al. Construct validity testing of a laparoscopic surgical simulator. *J Am Coll Surg*. 2006;202:779–87.
16. Zhang A, Hünerbein M, Dai Y, Schlag PM, Beller S. Construct validity testing of a laparoscopic surgery simulator (Lap Mentor): evaluation of surgical skill with a virtual laparoscopic training simulator. *Surg Endosc*. 2008;22:1440–4.
17. Shanmugan S, Leblanc F, Senagore AJ, et al. Virtual reality simulator training for laparoscopic colectomy: what metrics have construct validity. *Dis Colon Rectum*. 2014;57(2):210–4.
18. Calatayud MD, Arora S. Warm-up in a virtual reality environment improves performance in the operating room. *Ann Surg*. 2010;251:1181–5.
19. Palter VN, Grantcharov TP. Development and validation of a comprehensive curriculum to teach

an advanced minimally invasive procedure: a randomized controlled trial. *Ann Surg.* 2012;256(1):25–32.

20. Singh P, Aggarwal R, Tahir M, Pucher PH, Darzi A. A randomized controlled study to evaluate the role of video-based coaching in training laparoscopic skills. *Ann Surg.* 2015;261(5):862–9.

21. Iordache F, Bucobo J, Devlin D, You K, Bergamaschi R. Simulated training in colonoscopic stenting of colonic strictures: validation of a cadaver model. *Colorectal Dis.* 2014. doi: 10.1111/codi.12887. [Epub ahead of print].

22. Williams MR, Crossett JR, Cleveland EM, et al. Equivalence in colonoscopy results between gastroenterologists and general surgery residents following an endoscopy simulation curriculum. *J Surg Educ.* 2015. doi: 10.1016/j.jsurg.2015.01.018. [Epub ahead of print].

23. Kim MJ, Boehler ML. Skills coaches as part of the educational team: a randomized controlled trial of teaching of a basic surgical skill in the laboratory setting. *Am J Surg.* 2010;199:94–8.

24. Carraccio C, Wolfsthal SD, Englander R, Ferentz K, Martin C. Shifting paradigms: from Flexner to competencies. *Acad Med.* 2002;77:361–7.

25. Weinberger SE, Pereira AG, Iobst WF, Mechaber AJ, Bronze MS. Competency-based education and training in internal medicine. *Ann Intern Med.* 2010;153:751–6.

26. Sachdeva AK, Flynn TC, Brigham TP, et al. Interventions to address challenges associated with the transition from residency training to independent surgical practice. *Surgery.* 2014;155:867–82.

27. Accreditation Council for Graduate Medical Education. Clinical Competency Committees: a guidebook for programs. In: Andolsek K, Padmore J, Hauer KE, Holmboe E., editors. January 2015. Available at <http://www.acgme.org/acgmeweb/Portals/0/ACGMEClinicalCompetencyCommitteeGuidebook.pdf> Accessed 8 May 2015.

28. Ginsburg S, Eva K, Regehr G. Do in-training evaluation reports deserve their bad reputations? A study of the reliability and predictive ability of ITER scores and narrative comments. *Acad Med.* 2013;88(10):1539–44.

29. Watling CJ, Kenyon CF, Schulz V, Goldszmidt MA, Zibrowski E, Lingard L. An exploration of faculty perspectives on the in-training evaluation of residents. *Acad Med.* 2010;85(7): 1157–62.

30. Kogan JR, Bellini LM, Shea JA. Feasibility, reliability, and validity of the mini-clinical evaluation exercise (mCEX) in a medicine core clerkship. *Acad Med.* 2003;78(10 Suppl):S33–5.

31. Gofton WT, Dudek NL, Wood TJ, Balaa F, Hamstra SJ. The Ottawa Surgical Competency Operating Room Evaluation (O-SCORE): a tool to assess surgical competence. *Acad Med.* 2012;87:1401–7.

32. Wood J, Collins J, Burnside ES, et al. Patient, faculty, and self-assessment of radiology resident performance: a 360-degree method of measuring professionalism and interpersonal/communication skills. *Acad Radiol.* 2004;11(8):931–9.

33. Challis M. AMEE medical education guide No. 11 (revised): portfolio-based learning and assessment in medical education. *Med Teacher.* 1999;21(4):370–86.

34. Maruthappu M, Gilbert BJ, El-Harasis MA, et al. The influence of volume and experience on individual surgical performance: a systematic review. *Ann Surg.* 2015;261(4):42–7.

35. Beard J, Rowley D, Bussey M, Pitts D. Workplace-based assessment: assessing technical skill throughout the continuum of surgical training. *ANZ J Surg.* 2009;79:148–53.

36. Iramaneerat C. Instruction and assessment of professionalism for surgery residents. *J Surg Educ.* 2009;66(3):158–62.

37. Sevdalis N, Davis R, Koutantji M, Undre S, Darzi A, Vincent CA. Reliability of a revised NOTECHS scale for use in surgical teams. *Am J Surg.* 2008;196(2):184–90.
38. Falcone JL, Claxton RN, Marshall GT. Communication skills training in surgical residency: a needs assessment and metacognition analysis of a difficult conversation objective structured clinical examination. *J Surg Educ.* 2014;71(3):309–15.
39. Martin JA, Regehr G, Reznick R, et al. Objective structured assessment of technical skill (OSATS) for surgical residents. *Br J Surg.* 1997;84:273–8.
40. Fried GM, Feldman LS, Vassiliou MC, et al. Proving the value of simulation in laparoscopic surgery. *Ann Surg.* 2004;240(3): 518–25.
41. Nagendran M, Gurusamy KS, Aggarwal R, Loizidou M, Davidson BR. Virtual reality training for surgical trainees in laparoscopic surgery. *Cochrane Database Syst Rev.* 2013;8, CD006575.
42. Miskovic D, Wyles SM, Carter F, Coleman MG, Hanna GB. Development, validation and implementation of a monitoring tool for training in laparoscopic colorectal surgery in the English National Training Program. *Surg Endosc.* 2011;25: 1136–42.
43. Miskovic D, Ni M, Wyles SM, et al. Is competency assessment at the specialist level achievable? A study for the national training programme in laparoscopic colorectal surgery in England. *Ann Surg.* 2013;257:476–82.
44. De Montbrun SL, Roberts PL, Lowry AC, et al. A novel approach to assessing technical competence of colorectal surgery residents: the development and evaluation of the Colorectal Objective Structured Assessment of Technical Skill (COSATS). *Ann Surg.* 2013;258:1001–6.
45. Vassiliou MC, Feldman LS, Andrew CG, et al. A global assessment tool for intraoperative evaluation of laparoscopic skills. *Am J Surg.* 2005;190(1):107–13.
46. Vassiliou MC, Kaneva PA, Poulou BK, et al. Global Assessment of Gastrointestinal Endoscopic Skills (GAGES): a valid measurement tool for technical skills in flexible endoscopy. *Surg Endosc.* 2010;24(8):1834–41.
47. Birkmeyer JD, Finks JF, O'Reilly A, Oerline M, Carlin AM, Nunn AR, Dimick J, Banerjee M, Birkmeyer NJ; Michigan Bariatric Surgery Collaborative. Surgical skill and complication rates after bariatric surgery. *N Engl J Med.* 2013;369(15):1434–42.
48. The 21 Irrefutable Laws of Leadership. Septemebr 2007: John C. Maxwell. Thomas Nelson

## 第 70 章

1. Kohn LT, Corrigan JM, Donaldson MS, editors. To err is human: building a safer health system. Washington: National Academies Press; 2000.
2. Lynch DC, Swing SR, Horowitz SD, Holt K, Messer JV. Assessing practice based learning and improvement. *Teach Learn Med.* 2004;16:85–92.
3. Hawkins RE, Lipner RS, Ham HP, Wagner R, Holmboe ES. American Board of Medical Specialties Maintenance Of Certification: theory and evidence regarding the current framework. *J Contin Educ Health Prof.* 2013;33(S1):S7–19.
4. Levinson W, Holmboe E. Maintenance of certification: 20 years later. *Am J Med.* 2011;124:180–5.
5. Williams BW. The prevalence and special educational requirements of dyscompetent physicians. *J Contin Educ Health Prof.* 2006;26:173–91.



6. Choudhry NK, Fletcher RH, Soumerai SB. Systematic review: the relationship between clinical experience and quality of health care. *Ann Intern Med.* 2005;142:260–73.
7. McGlynn EA, Asch SM, Adams J, Keesey J, Hicks J, DeCristofaro A, et al. The quality of health care delivered to adults in the United States. *NEJM.* 2003;348:2635–45.
8. Kohatsu ND, Gould D, Ross LK, Fox PJ. Characteristics associated with physician discipline: a case–control study. *Arch Intern Med.* 2004;164:653–8.
9. Leape LL, Fromson JA. Problem doctors: is there a system-level solution? *Ann Intern Med.* 2006;144:107–15.
10. Khaliq AA, Dimassi H, Huang CY, Narine L, Smego Jr RA. Disciplinary action against physicians: who is likely to get disciplined? *Am J Med.* 2005;118:773–7.
11. Hawkins R, Roenheld-Hamm B, Ciccone A, Mee J, Tallia A. A multimethod study of needs for physician assessment: implications for education and regulation. *J Contin Educ Health Prof.* 2009;29:220–34.
12. Eva KW, Regehr G. “I’ll never play professional football” and other fallacies of self-assessment. *J Contin Educ Health Prof.* 2008;28:14–9.
13. Davis DA, Mazmanian PE, Fordis M, Van Harrison R, Thorpe KE, Perrier L. Accuracy of physician self-assessment compared with observed measures of competence: a systematic review. *JAMA.* 2006;296:1094–102.
14. Gray B, Reschovsky J, Holmboe E, Lipner R. Do early career indicators of clinical skill predict subsequent career outcomes and practice characteristics for general internists? *Health Serv Res.* 2013;48:1096–115.
15. Freed GL, Dunham KM, Lamarand KE. Permanent pediatric diplomate awareness of and perspectives on maintenance of certification. *J Pediatr.* 2009;155:919–23.
16. Engstrom S, Madion-Kay DJ. Choosing a family physician. What do patients want to know? *Minn Med.* 1998;81:22–6.
17. Freed GL, Dunham KM, Clark SJ, Davis MM. Perspectives and preferences among the general public regarding physician selection and board certification. *J Pediatr.* 2010;156:841–5.
18. Brennan TA, Horwitz RI, Duffy FD, Cassel CK, Goode LD, Lipner RS. The role of physician specialty board certification status in the quality movement. *JAMA.* 2004;292:1038–43.
19. Hall PB. What is a physician health program? The West Virginia medical professionals health program mission. *W V Med J.* 2007;103:32–4.
20. DuPont RL, McLellan AT, Carr G, Gendel M, Skipper GE. How are addicted physicians treated? A national survey of physician health programs. *J Subst Abuse Treat.* 2009;37:1–7.
21. Hayes J, Jackson JL, McNutt GM, Hertz BJ, Ryan JJ, Pawlikowski SA. Association between physician time-unlimited vs time-limited internal medicine board certification and ambulatory patient care quality. *JAMA.* 2014;312:2358–63.
22. Gray BM, Vandergrift JL, Johnston MM, Reschovsky JD, Lynn LA, Holmboe ES, et al. Association between imposition of a Maintenance of Certification requirement and ambulatory care-sensitive hospitalizations and health care costs. *JAMA.* 2014; 312:2348–57.
23. Peterson LE, Blackburn B, Puffer JC, Phillips RL. Family physicians’ quality interventions and performance improvement for hypertension through maintenance of certification. *J Healthcare Qual.* 2014. doi: 10.1111/jhq.12082. [Epub ahead of print].
24. Peterson LE, Blackburn B, Phillips RL, Puffer JC. Improving quality of care for diabetes through a maintenance of certification activity: family physicians’ use of the chronic care model. *J Contin*

Educ Health Prof. 2014;34:47–55.

25. Galliher JM, Manning BK, Petterson SM, Dickinson LM, Brandt EC, Staton EW, et al. Do professional development programs for maintenance of certification (MOC) affect quality of patient care? *J Am Board Fam Med.* 2014;27:19–25.
26. Centor RM, Fleming DA, Moyer DV. Maintenance of certification: beauty is in the eyes of the beholder. *Ann Intern Med.* 2014;161:226–7.
27. Holmboe ES, Wang Y, Meehan TP, Tate JP, Ho SY, Starkey KS, et al. Association between maintenance of certification examination scores and quality of care for medicare beneficiaries. *Arch Intern Med.* 2008;168:1396–403.
28. Lipner R, Song H, Biester T, Rhodes R. Factors that influence general internists' and surgeons' performance on maintenance of certification exams. *Acad Med.* 2011;86:53–8.
29. O'Neill TR, Puffer JC. Maintenance of certification and its association with the clinical knowledge of family physicians. *Acad Med.* 2013;88:780–7.
30. Iglehart JK, Baron RB. Ensuring physicians' competence – is maintenance of certification the answer? *NEJM.* 2012;367:2543–9.
31. Bower EA, Choi D, Becker TM, Girard DE. Awareness of and participation in maintenance of professional certification: a prospective study. *J Contin Educ Health Prof.* 2007;27:164–72.
32. Lipner RS, Brossman BG. Characteristics of internal medicine physicians and their practices that have differential impacts on their maintenance of certification. *Acad Med.* 2015;90(1):82–7.
33. Valentine MA, Barsade S, Edmondson AC, Gal A, Rhodes R. Informal peer interaction and practice type as predictors of physician performance on maintenance of certification examinations. *JAMA Surg.* 2014;149(6):597–603. doi: 10.1001/jamasurg.2014.183.
34. Reed DA, West CP, Holmboe ES, Halvorsen AJ, Lipner RS, Jacobs C, et al. Relationship of electronic medical knowledge resource use and practice characteristics with internal medicine maintenance of certification examination scores. *J Gen Intern Med.* 2012;27:917–23.
35. Culley DJ, Sun H, Harman AE, Warner DO. Perceived value of board certification and the maintenance of certification in anesthesiology program (MOCA). *J Clin Anesth.* 2013;25:12–9.
36. Weiss K. Future of board certification in a new era of public accountability. *J Am Board Fam Med.* 2010;23:S32–9.
37. Cook DA, Holmboe ES, Sorensen KJ. Getting maintenance of certification to work; a grounded theory of physicians' perceptions. *JAMA Intern Med.* 2015;175(1):35–42. doi: 10.1001/jamainternmed.2014.5437.
38. Caffarini K. Board certification process for doctors to be examined. *AMA House of Delegates.* 2013:21–4.
39. Norcini JJ, Lipner RS, Downing SM. How meaningful are scores on a take-home recertification examination? *Acad Med.* 1996;71:S71–3.
40. Campbell CM, Parboosingh J. The Royal College experience and plans for the maintenance of certification program. *J Contin Educ Health Prof.* 2013;33(S1):S36–47.
41. Archer J, de Regan Bere S. The United Kingdom's experience with and future plans for revalidation. *J Contin Educ Health Prof.* 2013;33(S1):S48–53.

## 第 71 章

1. Wang Y, Eldridge N, Metersky ML, et al. National trends in patient safety for four common conditions, 2005–2011. *N Engl J Med*. 2014;370(4):341–51.
2. Kohn KT, Corrigan JM, Donaldson MS. *To err is human: building a safer health system*. Washington: National Academy Press; 1999.
3. Committee on Quality of Health Care in America and Institute of Medicine. *Crossing the Quality Chasm: A New Health System for the 21st Century*.
4. McWilliams JM, Chernew ME, Landon BE, Schwartz AL. Performance differences in Year 1 of pioneer accountable care organizations. *N Engl J Med*. 2015;372:1927–36.
5. VanLare JM, Conway PH. Value-based purchasing--national programs to move from volume to value. *N Engl J Med*. 2012;367(4):292–5.
6. Donabedian A. Evaluating the quality of medical care. *Milbank Mem Fund Q*. 1966;44(3 Suppl):166–206.
7. Berenholtz SM, Pronovost PJ. Monitoring patient safety. *Crit Care Clin*. 2007;23(3):659–73.
8. Liu CJ, Chou YJ, Teng CJ, et al. Association of surgeon volume and hospital volume with the outcome of patients receiving definitive surgery for colorectal cancer: a nationwide population-based study. *Cancer*. 2015;121:2782–90.
9. Gietelink L, Henneman D, van Leersum NJ, et al. The influence of hospital volume on circumferential resection margin involvement: results of the Dutch surgical colorectal audit. *Ann Surg*. 2014.
10. Monson JR, Probst CP, Wexner SD, et al. Failure of evidence-based cancer care in the United States: the association between rectal cancer treatment, cancer center volume, and geography. *Ann Surg*. 2014;260(4):625–31. discussion 631–2.
11. Read TE, Myerson RJ, Fleshman JW, et al. Surgeon specialty is associated with outcome in rectal cancer treatment. *Dis Colon Rectum*. 2002;45(7):904–14.
12. Ricciardi R, Roberts PL, Read TE, Baxter NN, Marcello PW, Schoetz DJ. Who performs proctectomy for rectal cancer in the United States? *Dis Colon Rectum*. 2011;54(10):1210–5.
13. Kennedy ED, Rothwell DM, Cohen Z, McLeod RS. Increased experience and surgical technique lead to improved outcome after ileal pouch-anal anastomosis: a population-based study. *Dis Colon Rectum*. 2006;49(7):958–65.
14. El Chaar M, Claros L, Ezeji GC, Miletics M, Stoltzfus J. Improving outcome of bariatric surgery: best practices in an accredited surgical center. *Obes Surg*. 2014;24(7):1057–63.
15. Morton JM, Garg T, Nguyen N. Does hospital accreditation impact bariatric surgery safety? *Ann Surg*. 2014;260(3):504–8. discussion 508–9.
16. Young MT, Jafari MD, Gebhart A, Phelan MJ, Nguyen NT. A decade analysis of trends and outcomes of bariatric surgery in Medicare beneficiaries. *J Am Coll Surg*. 2014;219(3):480–8.
17. Dimick JB, Nicholas LH, Ryan AM, Thumma JR, Birkmeyer JD. Bariatric surgery complications before vs after implementation of a national policy restricting coverage to centers of excellence. *JAMA*. 2013;309(8):792–9.
18. Dietz DW, Consortium for Optimizing Surgical Treatment of Rectal Cancer (OSTRiCh). Multidisciplinary management of rectal cancer: the OSTRiCh. *J Gastrointest Surg*. 2013;17(10):1863–68.
19. Fry DE. Surgical site infections and the surgical care improvement project (SCIP): evolution of national quality measures. *Surg Infect (Larchmt)*. 2008;9(6):579–84.
20. Munday GS, Deveaux P, Roberts H, Fry DE, Polk HC. Impact of implementation of the Surgical

Care Improvement Project and future strategies for improving quality in surgery. *Am J Surg*. 2014;208(5):835–40.

21. Stulberg JJ, Delaney CP, Neuhauser DV, Aron DC, Fu P, Koroukian SM. Adherence to surgical care improvement project measures and the association with postoperative infections. *JAMA*. 2010;303(24):2479–85.

22. Hawn MT, Vick CC, Richman J, et al. Surgical site infection prevention: time to move beyond the surgical care improvement program. *Ann Surg*. 2011;254(3):494–9. discussion 499–501.

23. [Http://www.qualityforum.org/measures\\_reports\\_tools.aspx](http://www.qualityforum.org/measures_reports_tools.aspx).

24. Lawson EH, Louie R, Zingmond DS, et al. A comparison of clinical registry versus administrative claims data for reporting of 30-day surgical complications. *Ann Surg*. 2012;256(6):973–81.

25. Khuri SF, Daley J, Henderson W, et al. The Department of Veterans Affairs' NSQIP: the first national, validated, outcome-based, risk-adjusted, and peer-controlled program for the measurement and enhancement of the quality of surgical care. National VA Surgical Quality Improvement Program. *Ann Surg*. 1998;228(4):491–507.

26. Dimick JB, Chen SL, Taheri PA, Henderson WG, Khuri SF, Campbell Jr DA. Hospital costs associated with surgical complications: a report from the private-sector National Surgical Quality Improvement Program. *J Am Coll Surg*. 2004;199(4):531–7.

27. Khuri SF, Henderson WG, Daley J, et al. Successful implementation of the Department of Veterans Affairs' National Surgical Quality Improvement Program in the private sector: the Patient Safety in Surgery study. *Ann Surg*. 2008;248(2):329–36.

28. Itani KM. Fifteen years of the National Surgical Quality Improvement Program in review. *Am J Surg*. 2009;198(5 Suppl):S9–18.

29. [Http://www.qualityforum.org/eisenberg\\_award/](http://www.qualityforum.org/eisenberg_award/).

30. Ju MH, Ko CY, Hall BL, Bosk CL, Bilimoria KY, Wick EC. A comparison of 2 surgical site infection monitoring systems. *JAMA Surg*. 2015;150(1):51–7.

31. [Http://www.ahrq.gov/qual/medteam/medteam4.htm](http://www.ahrq.gov/qual/medteam/medteam4.htm): Medical team training, in Baker DP, Gustafson S, Beaubien J, et al: Medical Teamwork and Patient Safety: The Evidence-Based Relation. Literature Review. AHRQ Publication No. 05–0053, Rockville, MD: Agency for Healthcare Research and Quality, April 2005.

32. Pronovost PJ, Goeschel CA, Olsen KL, et al. Reducing health care hazards: lessons from the commercial aviation safety team. *Health Aff (Millwood)*. 2009;28(3):w479–89.

33. Chassin MR, Loeb JM. High-reliability health care: getting there from here. *Milbank Q*. 2013;91(3):459–90.

34. Ruchlin HS, Dubbs NL, Callahan MA. The role of leadership in instilling a culture of safety: lessons from the literature. *J Healthc Manag*. 2004;49(1):47–58. discussion 58–9.

35. Sutcliffe KM. High reliability organizations (HROs). *Best Pract Res Clin Anaesthesiol*. 2011;25(2):133–44.

36. [Http://www.ahrq.gov/clinic/ptsafety/chap40.htm](http://www.ahrq.gov/clinic/ptsafety/chap40.htm): Pizzi LT, Goldfarb NI, Nash DB: Promoting a culture of safety, in Making Health Care Safer: A Critical Analysis of Patient Safety Practices. Evidence Report/Technology Assessment: Number 43. AHRQ Publication No. 01-E058, July 2001. Rockville, MD: Agency for Healthcare Research and Quality.

37. Sexton JB, Thomas EJ, Helmreich RL. Error, stress, and teamwork in medicine and aviation: cross sectional surveys. *BMJ*. 2000;320(7237):745–9.

38. Amalberti R, Auroy Y, Berwick D, Barach P. Five system barriers to achieving ultrasafe health care. *Ann Intern Med.* 2005; 142(9):756–64.
39. Makary MA, Sexton JB, Freischlag JA, et al. Patient safety in surgery. *Ann Surg.* 2006;243(5):628–32. discussion 632–5.
40. [Http://www.jointcommission.org/SentinelEvents/Statistics](http://www.jointcommission.org/SentinelEvents/Statistics): Sentinel Event Statistics. Joint Commission website.
41. Lingard L, Espin S, Whyte S, et al. Communication failures in the operating room: an observational classification of recurrent types and effects. *Qual Saf Health Care.* 2004;13(5):330–4.
42. Christian CK, Gustafson ML, Roth EM, et al. A prospective study of patient safety in the operating room. *Surgery.* 2006;139(2):159–73.
43. Makary MA, Sexton JB, Freischlag JA, et al. Operating room teamwork among physicians and nurses: teamwork in the eye of the beholder. *J Am Coll Surg.* 2006;202(5):746–52.
44. Makary MA, Mukherjee A, Sexton JB, et al. Operating room briefings and wrong-site surgery. *J Am Coll Surg.* 2007;204(2): 236–43.
45. Pronovost PJ, Berenholtz SM, Goeschel CA, et al. Creating high reliability in health care organizations. *Health Serv Res.* 2006;41(4 Pt 2):1599–617.
46. Nundy S, Mukherjee A, Sexton JB, et al. Impact of preoperative briefings on operating room delays: a preliminary report. *Arch Surg.* 2008;143(11):1068–72.
47. Hicks CW, Rosen M, Hobson DB, Ko C, Wick EC. Improving safety and quality of care with enhanced teamwork through operating room briefings. *JAMA Surg.* 2014;149(8):863–8.
48. [Http://www.who.int/patientsafety/safesurgery/ss\\_checklist/en/](http://www.who.int/patientsafety/safesurgery/ss_checklist/en/).
49. Pronovost P, Needham D, Berenholtz S, et al. An intervention to decrease catheter-related bloodstream infections in the ICU. *N Engl J Med.* 2006;355(26):2725–32.
50. Wick EC, Hobson DB, Bennett JL, et al. Implementation of a surgical comprehensive unit-based safety program to reduce surgical site infections. *J Am Coll Surg.* 2012;215(2):193–200.
51. [Http://www.acssurgerynews.com/index.php?id=15051&type=98&tx\\_ttnews%5Btt\\_news%5D=136093&cHash=da03e20e36](http://www.acssurgerynews.com/index.php?id=15051&type=98&tx_ttnews%5Btt_news%5D=136093&cHash=da03e20e36).
52. [Https://www.qualityforum.org/Topics/SREs/Serious\\_Reportable\\_Events.aspx](https://www.qualityforum.org/Topics/SREs/Serious_Reportable_Events.aspx).
53. Mehtsun WT, Ibrahim AM, Diener-West M, Pronovost PJ, Makary MA. Surgical never events in the United States. *Surgery.* 2013;153(4):465–72.
54. Gawande AA, Studdert DM, Orav EJ, Brennan TA, Zinner MJ. Risk factors for retained instruments and sponges after surgery. *N Engl J Med.* 2003;348(3):229–35.
55. Gibbs VC, Coakley FD, Reines HD. Preventable errors in the operating room: retained foreign bodies after surgery--Part I. *Curr Probl Surg.* 2007;44(5):281–337.
56. Pronovost PJ, Rosenstein BJ, Paine L, et al. Paying the piper: investing in infrastructure for patient safety. *Jt Comm J Qual Patient Saf.* 2008;34(6):342–8.
57. Dupree JM, Patel K, Singer SJ, West M, Wang R, Zinner MJ, Weissman JS. Attention to surgeons and surgical care is largely missing from early Medicare accountable care organizations. *Health Aff (Millwood).* 2014;33(6):972–9. doi: 10.1377/hlthaff.2013.1300.

1. Chaput B, Bertheuil N, Jacques J, et al. Professional burnout among plastic surgery residents: can it be prevented? Outcomes of a national survey. *Ann Plast Surg.* 2015;75:2–8.
2. Shanafelt TD, Balch CM, Bechamps G, et al. Burnout and medical errors among American surgeons. *Ann Surg.* 2010;251: 995–1000.
3. West CP, Huschka MM, Novotny PJ, et al. Association of perceived medical errors with resident distress and empathy: a prospective longitudinal study. *JAMA.* 2006;296:1071–8.
4. Balch CM, Shanafelt T. Combating stress and burnout in surgical practice: a review. *Thorac Surg Clin.* 2011;21:417–30.
5. Raptis DA, Schlegel A, Tschuor C, Clavien PA. Job satisfaction among young board-certified surgeons at academic centers in Europe and North America. *Ann Surg.* 2012;256:796–803. discussion 803–5.
6. McCarthy D, Mueller K, Wrenn J. Organized health care delivery system. Kaiser Permanente: bridging the quality divide with integrated practice, group accountability, and health information technology. *The Commonwealth Fund.* 2009;17.
7. Centers for Medicare and Medicaid Services. Physician Quality Reporting System. Available online at: <http://www.cms.gov/Medicare/Quality-Initiatives-Patient-Assessment-Instruments/PQRS/index.html?redirect=/PQRS/>. Last accessed December 2014.
8. Centers for Medicare and Medicaid Readmissions Reduction Program. 2012. Available online at: <http://cms.gov/Medicare/Medicare-Fee-for-Service-Payment/AcuteInpatientPPS/Readmissions-Reduction-Program.html/>. Last accessed March 2015.
9. Khuri SF, Daley J, Henderson W, et al. The Department of Veterans Affairs' NSQIP: the first national, validated, outcome-based, risk-adjusted, and peer-controlled program for the measurement and enhancement of the quality of surgical care. *National VA Surgical Quality Improvement Program.* *Ann Surg.* 1998;228:491–507.
10. Fink AS, Campbell DA, Mentzer RM, et al. The National Surgical Quality Improvement Program in non-veterans administration hospitals: initial demonstration of feasibility. *Ann Surg.* 2002;236:344–53. discussion 353–4.
11. Iannuzzi JC, Kahn SA, Zhang L, Gestring ML, Noyes K, Monson JR. Getting satisfaction: drivers of surgical Hospital Consumer Assessment of Health care Providers and Systems survey scores. *J Surg Res.* 2015;197:155–61.
12. Centers for Medicare & Medicaid Services. HCAHPS Hospital Survey. Available online at: <http://www.hcahpsonline.org>. Last accessed February 2015.
13. Scoggins CR, Crockett T, Wafford L, Cannon RM, McMasters KM. Improving clinical productivity in an academic surgical practice through transparency. *J Am Coll Surg.* 2013;217:46–51. discussion 51–5.
14. Medicare Physician Fee Schedule. Payment System Fact Sheet Series. Available online at: <http://www.cms.gov/Outreach-and-Education/Medicare-Learning-Network-MLN/MLNProducts/downloads/MedcrephysFeeSchedfctsht.pdf>. Last accessed April 2015.
15. Medical Group Management Association. Available online at: <http://www.mgma.com>. Last accessed April 2015.
16. American Medical Group Association. Available online at: <http://www.agma.com>. Last accessed April 2015.
17. Profiles- The Online Database of Graduating Physicians. 2013–2014 Physician Salary Survey. Available online at: [http://www.payscale.com/research/US/Job=Colorectal\\_Surgeon/Salary](http://www.payscale.com/research/US/Job=Colorectal_Surgeon/Salary).

18. PayScale Human Capital. Colorectal Surgeon Salary (United States). Available online at: [http://www.payscale.com/research/US/Job=Colorectal\\_Surgeon/Salary](http://www.payscale.com/research/US/Job=Colorectal_Surgeon/Salary).
19. AGMA Research and Benchmarking. Physician Compensation 2012 Colorectal Surgery. Available online at: <http://cejka.force.com/physiciancompensation>. Last Accessed April 2015.
20. American College of Surgeons Practice Management CPT Coding Workshops. Available online at: <https://www.facs.org/advocacy/practmanagement/workshops#sthash.PHs5VNhi.dpuf>. Last accessed April 2015.
21. Centers for Medicare and Medicaid Services. Evaluation and Management Services Guide. Nov. 2014. Available online at: [http://www.cms.gov/Outreach-and-Education/Medicare-Learning-Network-MLN/MLNProducts/downloads/eval\\_mgmt\\_serv\\_guide-ICN006764.pdf](http://www.cms.gov/Outreach-and-Education/Medicare-Learning-Network-MLN/MLNProducts/downloads/eval_mgmt_serv_guide-ICN006764.pdf). Last accessed June 2015.
22. American College of Medical Practice Executives Professional Paper. The Impact of Physician Practice Acquisition on Practice Managers. 2013. Available online at: <http://www.mgma.com/Libraries/Assets/Practice%20Resources/Publications/Fellow%20Papers/2013/The-Impact-of-Physician-Practice-Acquisition-on-Practice-Managers-manuscript-1.pdf?ext=.pdf>. Last accessed April 2015.